assay_tax_id,confidence_score,src_assay_id,assay_type,assay_category,variant_id,tissue_id,chembl_id,assay_strain,bao_format,assay_cell_type,tid,assay_test_type,assay_subcellular_fraction,relationship_type,assay_id,doc_id,src_id,cell_id,curated_by,assay_organism,description,assay_tissue
,8.0,,B,,,,CHEMBL615117,,BAO_0000019,,12052.0,,,H,1.0,11087.0,1.0,,Autocuration,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,
,0.0,,F,,,,CHEMBL615118,,BAO_0000219,,22226.0,,,U,2.0,684.0,1.0,,Autocuration,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,
,0.0,,B,,,,CHEMBL615119,,BAO_0000019,,22226.0,,,U,3.0,15453.0,1.0,,Autocuration,,,
9913.0,4.0,,B,,,,CHEMBL615120,,BAO_0000249,,104729.0,,,H,4.0,17841.0,1.0,,Autocuration,Bos taurus,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,
9606.0,1.0,,F,,,,CHEMBL615121,,BAO_0000219,143B,80001.0,,,N,5.0,17430.0,1.0,163.0,Intermediate,Homo sapiens,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),
9606.0,1.0,,F,,,,CHEMBL615122,,BAO_0000219,143B,80001.0,,,N,6.0,17430.0,1.0,163.0,Intermediate,Homo sapiens,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),
10090.0,1.0,,F,,,,CHEMBL615123,,BAO_0000219,143B,80001.0,,,N,7.0,13799.0,1.0,163.0,Intermediate,Mus musculus,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,
9606.0,1.0,,F,,,,CHEMBL615124,,BAO_0000219,143B,80001.0,,,N,8.0,17774.0,1.0,163.0,Expert,Homo sapiens,In vitro cell cytotoxicity was determined against 143B cell line,
9606.0,1.0,,F,,,,CHEMBL615125,,BAO_0000219,143B,80001.0,,,N,9.0,3801.0,1.0,163.0,Intermediate,Homo sapiens,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,
9606.0,1.0,,F,,,,CHEMBL615126,,BAO_0000219,143B,80001.0,,,N,10.0,17430.0,1.0,163.0,Intermediate,Homo sapiens,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,
9606.0,1.0,,F,,,,CHEMBL615127,,BAO_0000219,143B,80001.0,,,N,11.0,17430.0,1.0,163.0,Intermediate,Homo sapiens,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,
9606.0,1.0,,F,,,,CHEMBL615128,,BAO_0000219,143B,80001.0,,,N,12.0,17774.0,1.0,163.0,Expert,Homo sapiens,In vitro cell cytotoxicity was determined against 143B-LTK cell line,
1280.0,1.0,,F,,,,CHEMBL857900,,BAO_0000218,,50185.0,,,N,13.0,11324.0,1.0,,Intermediate,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",
1280.0,1.0,,F,,,,CHEMBL615129,,BAO_0000218,,50185.0,,,N,14.0,11324.0,1.0,,Intermediate,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",
1280.0,1.0,,F,,,,CHEMBL615130,,BAO_0000218,,50185.0,,,N,15.0,11324.0,1.0,,Intermediate,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",
1280.0,1.0,,F,,,,CHEMBL615131,,BAO_0000218,,50185.0,,,N,16.0,11324.0,1.0,,Intermediate,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",
10116.0,9.0,,A,,,,CHEMBL884521,,BAO_0000357,,100122.0,,,D,17.0,11347.0,1.0,,Expert,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,
,8.0,,B,,,,CHEMBL615132,,BAO_0000357,,12054.0,,,H,18.0,16474.0,1.0,,Autocuration,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),
,8.0,,B,,,,CHEMBL615133,,BAO_0000019,,12054.0,,,H,19.0,10091.0,1.0,,Autocuration,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,
,8.0,,B,,,,CHEMBL615134,,BAO_0000357,,12054.0,,,H,20.0,16474.0,1.0,,Autocuration,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),
,8.0,,B,,,,CHEMBL615135,,BAO_0000357,,12054.0,,,H,21.0,16474.0,1.0,,Autocuration,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),
,8.0,,B,,,,CHEMBL615136,,BAO_0000357,,12054.0,,,H,22.0,16474.0,1.0,,Autocuration,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),
,8.0,,B,,,,CHEMBL615137,,BAO_0000357,,12054.0,,,H,23.0,16474.0,1.0,,Autocuration,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,
,8.0,,B,,,,CHEMBL615138,,BAO_0000357,,12054.0,,,H,24.0,16474.0,1.0,,Autocuration,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,
,0.0,,B,,,,CHEMBL836324,,BAO_0000219,,22226.0,,,U,25.0,14352.0,1.0,,Autocuration,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",
9986.0,8.0,,B,,,,CHEMBL615139,,BAO_0000357,,12054.0,,,H,26.0,5646.0,1.0,,Autocuration,Oryctolagus cuniculus,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,
9986.0,8.0,,B,,,,CHEMBL615140,,BAO_0000357,,12054.0,,,H,27.0,5646.0,1.0,,Autocuration,Oryctolagus cuniculus,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),
,8.0,,B,,,,CHEMBL615141,,BAO_0000219,,12426.0,,,H,28.0,10997.0,1.0,,Autocuration,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,
3847.0,8.0,,B,,,,CHEMBL615142,,BAO_0000357,,12054.0,,,H,29.0,6309.0,1.0,,Autocuration,soya bean,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,
3847.0,8.0,,B,,,,CHEMBL615143,,BAO_0000357,,12054.0,,,H,30.0,167.0,1.0,,Autocuration,Glycine max,Inhibitory activity against soybean 15-lipoxygenase was evaluated,
3847.0,8.0,,B,,,,CHEMBL615144,,BAO_0000357,,12054.0,,,H,31.0,167.0,1.0,,Autocuration,Glycine max,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,
3847.0,8.0,,B,,,,CHEMBL872867,,BAO_0000357,,12054.0,,,H,32.0,11087.0,1.0,,Autocuration,Glycine max,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,
3847.0,8.0,,B,,,,CHEMBL615145,,BAO_0000357,,12054.0,,,H,33.0,11087.0,1.0,,Autocuration,Glycine max,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,
3847.0,8.0,,B,,,,CHEMBL615146,,BAO_0000357,,12054.0,,,H,34.0,13622.0,1.0,,Autocuration,Glycine max,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,
3847.0,8.0,,B,,,,CHEMBL615147,,BAO_0000357,,12054.0,,,H,35.0,13622.0,1.0,,Autocuration,Glycine max,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,
10116.0,0.0,,A,,,,CHEMBL615148,,BAO_0000019,,22226.0,,,U,36.0,11347.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,
562.0,0.0,,B,,,,CHEMBL615149,,BAO_0000019,,22226.0,,,U,37.0,5926.0,1.0,,Autocuration,Escherichia coli,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,
,0.0,,B,,,,CHEMBL615150,,BAO_0000019,,22226.0,,,U,38.0,4567.0,1.0,,Autocuration,,Dissociation constant with dimeric 16S rRNA RNA construct B,
,3.0,,B,,,,CHEMBL615151,,BAO_0000225,,22222.0,,,M,39.0,3782.0,1.0,,Intermediate,,Dissociation constant towards 16S rRNA construct A,
,3.0,,B,,,,CHEMBL615152,,BAO_0000225,,22222.0,,,M,40.0,3782.0,1.0,,Intermediate,,Dissociation constant towards 16S rRNA construct B,
562.0,3.0,,B,,,,CHEMBL615153,,BAO_0000225,,100263.0,,,M,41.0,4466.0,1.0,,Expert,Escherichia coli,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,
562.0,3.0,,B,,,,CHEMBL615154,,BAO_0000225,,100263.0,,,M,42.0,6592.0,1.0,,Expert,Escherichia coli,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,
,8.0,,B,,,,CHEMBL615155,,BAO_0000019,,13053.0,,,H,43.0,898.0,1.0,,Autocuration,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),
,8.0,,B,,,,CHEMBL615156,,BAO_0000019,,13053.0,,,H,44.0,898.0,1.0,,Autocuration,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),
9606.0,8.0,,B,,,,CHEMBL615157,,BAO_0000019,,20001.0,,,H,45.0,13163.0,1.0,,Autocuration,Homo sapiens,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,
9606.0,8.0,,B,,,,CHEMBL615158,,BAO_0000019,,20001.0,,,H,46.0,13163.0,1.0,,Autocuration,Homo sapiens,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,
10116.0,9.0,,B,,,,CHEMBL615159,,BAO_0000019,,12971.0,,,D,47.0,10691.0,1.0,,Expert,Rattus norvegicus,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",
10116.0,9.0,,B,,,,CHEMBL615172,,BAO_0000019,,12971.0,,,D,48.0,10691.0,1.0,,Expert,Rattus norvegicus,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",
10116.0,9.0,,B,,,,CHEMBL615173,,BAO_0000019,,12971.0,,,D,49.0,10691.0,1.0,,Expert,Rattus norvegicus,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",
10116.0,9.0,,B,,,,CHEMBL615174,,BAO_0000019,,12971.0,,,D,50.0,10691.0,1.0,,Expert,Rattus norvegicus,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",
,8.0,,B,,,,CHEMBL884518,,BAO_0000019,,13053.0,,,H,51.0,898.0,1.0,,Autocuration,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),
,8.0,,B,,,,CHEMBL615175,,BAO_0000357,,11512.0,,,H,52.0,912.0,1.0,,Autocuration,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),
,8.0,,B,,,,CHEMBL615176,,BAO_0000357,,11512.0,,,H,53.0,912.0,1.0,,Autocuration,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,
,8.0,,B,,,,CHEMBL615177,,BAO_0000357,,11512.0,,,H,54.0,912.0,1.0,,Autocuration,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,
10116.0,5.0,,B,,,,CHEMBL615178,,BAO_0000249,,104740.0,,Membranes,D,55.0,15103.0,1.0,,Autocuration,Rattus norvegicus,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,
9606.0,1.0,,F,,,,CHEMBL615179,,BAO_0000219,1A9,80002.0,,,N,56.0,5116.0,1.0,506.0,Intermediate,Homo sapiens,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,
10116.0,7.0,,F,,,,CHEMBL615180,,BAO_0000219,Oocytes,104835.0,,,D,57.0,14578.0,1.0,,Autocuration,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,
10116.0,7.0,,F,,,,CHEMBL615181,,BAO_0000219,Oocytes,104821.0,,,D,58.0,14578.0,1.0,,Autocuration,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,
10116.0,7.0,,F,,,,CHEMBL615182,,BAO_0000219,Oocytes,104848.0,,,D,59.0,14578.0,1.0,,Autocuration,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,
9606.0,1.0,,F,,,,CHEMBL615183,,BAO_0000219,1A9,80002.0,,,N,60.0,4787.0,1.0,506.0,Expert,Homo sapiens,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,
9606.0,1.0,,F,,,,CHEMBL615184,,BAO_0000219,1A9,80002.0,,,N,61.0,4787.0,1.0,506.0,Intermediate,Homo sapiens,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,
9606.0,1.0,,F,,,,CHEMBL615185,,BAO_0000219,1A9,80002.0,,,N,62.0,3547.0,1.0,506.0,Intermediate,Homo sapiens,Cytotoxic activity against human ovarian cancer (1A9) cell line,
9606.0,1.0,,F,,,,CHEMBL615186,,BAO_0000219,1A9,80002.0,,,N,63.0,3547.0,1.0,506.0,Intermediate,Homo sapiens,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,
9606.0,1.0,,F,,,,CHEMBL615187,,BAO_0000219,1A9,80002.0,,,N,64.0,6726.0,1.0,506.0,Intermediate,Homo sapiens,Effective dose of compound against replication of 1A9 cell line was evaluated,
9606.0,1.0,,F,,,,CHEMBL885343,,BAO_0000219,1A9,80002.0,,,N,65.0,3455.0,1.0,506.0,Expert,Homo sapiens,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,
9606.0,1.0,,F,,,,CHEMBL615188,,BAO_0000219,1A9,80002.0,,,N,66.0,5726.0,1.0,506.0,Intermediate,Homo sapiens,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),
9606.0,1.0,,F,,,,CHEMBL615189,,BAO_0000219,1A9,80002.0,,,N,67.0,5726.0,1.0,506.0,Intermediate,Homo sapiens,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,
9606.0,1.0,,F,,,,CHEMBL615190,,BAO_0000219,1A9,80002.0,,,N,68.0,5726.0,1.0,506.0,Intermediate,Homo sapiens,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,
9606.0,1.0,,F,,,,CHEMBL615191,,BAO_0000219,1A9,80002.0,,,N,69.0,3395.0,1.0,506.0,Intermediate,Homo sapiens,Inhibitory activity against Taxol resistant 1A9 cell lines,
9606.0,1.0,,F,,,,CHEMBL615192,,BAO_0000219,1A9,80002.0,,,N,70.0,3415.0,1.0,506.0,Expert,Homo sapiens,Cytotoxicity against human ovarian cancer (1A9) cell lines.,
9606.0,1.0,,F,,,,CHEMBL827083,,BAO_0000219,1A9,80002.0,,,N,71.0,3415.0,1.0,506.0,Expert,Homo sapiens,Percentage inhibition of human ovarian cancer (1A9) cell lines.,
9606.0,1.0,,F,,,,CHEMBL615193,,BAO_0000219,1A9,80002.0,,,N,72.0,17099.0,1.0,506.0,Expert,Homo sapiens,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,
9606.0,1.0,,F,,,,CHEMBL615194,,BAO_0000219,1A9,80002.0,,,N,73.0,17099.0,1.0,506.0,Intermediate,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,
9606.0,1.0,,F,,,,CHEMBL615195,,BAO_0000219,1A9,80002.0,,,N,74.0,17099.0,1.0,506.0,Intermediate,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,
9606.0,1.0,,F,,,,CHEMBL615196,,BAO_0000219,1A9,80002.0,,,N,75.0,17099.0,1.0,506.0,Intermediate,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,
9606.0,1.0,,F,,,,CHEMBL615197,,BAO_0000219,Jurkat,81072.0,,,N,76.0,17721.0,1.0,503.0,Intermediate,Homo sapiens,Inhibitory concentration against Jurkat cells,
,0.0,,F,,,,CHEMBL615198,,BAO_0000019,,22226.0,,,U,77.0,1229.0,1.0,,Intermediate,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,
10116.0,9.0,,A,,,,CHEMBL615199,,BAO_0000357,,100121.0,,,D,78.0,11347.0,1.0,,Expert,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,
,8.0,,B,,,,CHEMBL615200,,BAO_0000357,,11231.0,,,H,79.0,17117.0,1.0,,Expert,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",
,8.0,,B,,,,CHEMBL615201,,BAO_0000357,,11231.0,,,H,80.0,17117.0,1.0,,Expert,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",
,8.0,,B,,,,CHEMBL615202,,BAO_0000357,,11231.0,,,H,81.0,17117.0,1.0,,Expert,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",
5476.0,8.0,,B,,,,CHEMBL615203,,BAO_0000251,,11231.0,,Microsomes,H,82.0,11375.0,1.0,,Autocuration,Candida albicans,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",
5476.0,8.0,,B,,,,CHEMBL615204,,BAO_0000251,,11231.0,,Microsomes,H,83.0,11375.0,1.0,,Autocuration,Candida albicans,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",
4932.0,8.0,,B,,,,CHEMBL615205,,BAO_0000251,,11231.0,,Microsomes,H,84.0,11375.0,1.0,,Autocuration,Saccharomyces cerevisiae,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",
4932.0,8.0,,B,,,,CHEMBL615206,,BAO_0000251,,11231.0,,Microsomes,H,85.0,11375.0,1.0,,Autocuration,Saccharomyces cerevisiae,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",
9823.0,8.0,,B,,,2107.0,CHEMBL615207,,BAO_0000251,,12083.0,,Microsomes,H,86.0,11375.0,1.0,,Autocuration,Sus scrofa,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Liver
10116.0,8.0,,B,,,,CHEMBL827084,,BAO_0000019,,11231.0,,,H,87.0,791.0,1.0,,Autocuration,Rattus norvegicus,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",
10116.0,8.0,,B,,,,CHEMBL615208,,BAO_0000019,,11231.0,,,H,88.0,791.0,1.0,,Autocuration,Rattus norvegicus,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",
10116.0,8.0,,B,,,,CHEMBL615209,,BAO_0000019,,11231.0,,,H,89.0,791.0,1.0,,Autocuration,Rattus norvegicus,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",
10116.0,9.0,,B,,,2107.0,CHEMBL615210,,BAO_0000251,,12083.0,,Microsomes,D,90.0,11375.0,1.0,,Autocuration,Rattus norvegicus,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Liver
10116.0,9.0,,B,,,2107.0,CHEMBL615211,,BAO_0000251,,12083.0,,Microsomes,D,91.0,11375.0,1.0,,Autocuration,Rattus norvegicus,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Liver
10116.0,9.0,,B,,,2107.0,CHEMBL615212,,BAO_0000251,,12083.0,,Microsomes,D,92.0,153.0,1.0,,Autocuration,Rattus norvegicus,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Liver
,8.0,,B,,,,CHEMBL615213,,BAO_0000357,,11377.0,,,H,93.0,8269.0,1.0,,Expert,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),
,8.0,,B,,,,CHEMBL615273,,BAO_0000357,,11377.0,,,H,94.0,8269.0,1.0,,Expert,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,
9606.0,1.0,,F,,,,CHEMBL615274,,BAO_0000219,HepG2,81020.0,,,N,95.0,17653.0,1.0,726.0,Expert,Homo sapiens,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,
9606.0,1.0,,F,,,,CHEMBL615275,,BAO_0000219,HepG2,81020.0,,,N,96.0,14277.0,1.0,726.0,Intermediate,Homo sapiens,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,
9606.0,1.0,,F,,,,CHEMBL615276,,BAO_0000219,HepG2,81020.0,,,N,97.0,1717.0,1.0,726.0,Intermediate,Homo sapiens,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,
9606.0,1.0,,F,,,,CHEMBL615277,,BAO_0000219,HepG2,81020.0,,,N,98.0,14091.0,1.0,726.0,Intermediate,Homo sapiens,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,
9606.0,1.0,,F,,,,CHEMBL615326,,BAO_0000219,HepG2,81020.0,,,N,99.0,14091.0,1.0,726.0,Intermediate,Homo sapiens,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,
10407.0,1.0,,F,,,,CHEMBL883130,,BAO_0000218,,50606.0,,,N,100.0,17653.0,1.0,,Expert,Hepatitis B virus,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,
9606.0,1.0,,F,,,,CHEMBL884519,,BAO_0000219,HepG2,81020.0,,,N,101.0,13105.0,1.0,726.0,Intermediate,Homo sapiens,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,
9606.0,1.0,,F,,,,CHEMBL615327,,BAO_0000219,HepG2,81020.0,,,N,102.0,1717.0,1.0,726.0,Intermediate,Homo sapiens,Concentration required to inhibit 50% of 2.2.15 cell line,
9606.0,1.0,,A,,,,CHEMBL615328,,BAO_0000219,HepG2,81020.0,,,N,103.0,13105.0,1.0,726.0,Intermediate,Homo sapiens,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,
9606.0,1.0,,F,,,,CHEMBL615329,,BAO_0000218,2.2.15,50587.0,,,N,104.0,13600.0,1.0,,Intermediate,Homo sapiens,Cytotoxic activity of compound against uninfected 2.2.15 cells.,
9606.0,1.0,,F,,,,CHEMBL615330,,BAO_0000218,2.2.15,50587.0,,,N,105.0,13467.0,1.0,,Intermediate,Homo sapiens,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,
10407.0,1.0,,F,,,,CHEMBL615331,,BAO_0000218,2.2.15,50606.0,,,N,106.0,17477.0,1.0,,Expert,Hepatitis B virus,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",
9606.0,1.0,,F,,,,CHEMBL615332,,BAO_0000218,2.2.15,50587.0,,,N,107.0,1593.0,1.0,,Intermediate,Homo sapiens,In vitro anti-HBV activity in 2.2.15 cells,
9606.0,1.0,,F,,,,CHEMBL615333,,BAO_0000218,2.2.15,50587.0,,,N,108.0,1593.0,1.0,,Intermediate,Homo sapiens,In vitro anti-HBV activity in 2.2.15 cells; Not determined,
9606.0,1.0,,F,,,,CHEMBL615334,,BAO_0000218,2.2.15,50587.0,,,N,109.0,15089.0,1.0,,Intermediate,Homo sapiens,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,
9606.0,1.0,,F,,,,CHEMBL615335,,BAO_0000218,2.2.15,50587.0,,,N,110.0,15089.0,1.0,,Intermediate,Homo sapiens,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,
9606.0,1.0,,F,,,,CHEMBL615336,,BAO_0000218,2.2.15,50587.0,,,N,111.0,1593.0,1.0,,Intermediate,Homo sapiens,Cytotoxicity in 2.2.15 cells,
9606.0,1.0,,F,,,,CHEMBL615337,,BAO_0000218,2.2.15,50587.0,,,N,112.0,1593.0,1.0,,Intermediate,Homo sapiens,Cytotoxicity in 2.2.15 cells; Not determined,
9606.0,1.0,,F,,,,CHEMBL615338,,BAO_0000218,2.2.15,50587.0,,,N,113.0,13600.0,1.0,,Intermediate,Homo sapiens,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,
9606.0,1.0,,F,,,,CHEMBL615339,,BAO_0000218,2.2.15,50587.0,,,N,114.0,13467.0,1.0,,Intermediate,Homo sapiens,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,
9606.0,1.0,,F,,,,CHEMBL615340,,BAO_0000218,2.2.15,50587.0,,,N,115.0,13467.0,1.0,,Intermediate,Homo sapiens,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,
9606.0,1.0,,F,,,,CHEMBL615341,,BAO_0000219,HepG2,81020.0,,,N,116.0,14764.0,1.0,726.0,Intermediate,Homo sapiens,Antiviral activity against HBV was determined in 2.215 cell line,
9606.0,0.0,,B,,,,CHEMBL615342,,BAO_0000251,,22226.0,,Microsomes,U,117.0,6531.0,1.0,,Autocuration,Homo sapiens,Inhibition of 20-HETE synthesis in human renal microsomes,
,0.0,,B,,,,CHEMBL615343,,BAO_0000019,,22226.0,,,U,118.0,17322.0,1.0,,Autocuration,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,
9606.0,1.0,,F,,,,CHEMBL615344,,BAO_0000219,2008,80612.0,,,N,119.0,17072.0,1.0,388.0,Intermediate,Homo sapiens,Inhibitory concentration against 2008 (ovarian) cells,
9606.0,1.0,,F,,,,CHEMBL615345,,BAO_0000219,2008,80612.0,,,N,120.0,16936.0,1.0,388.0,Intermediate,Homo sapiens,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,
9606.0,1.0,,F,,,,CHEMBL615346,,BAO_0000219,2008,80612.0,,,N,121.0,16936.0,1.0,388.0,Intermediate,Homo sapiens,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),
9606.0,1.0,,F,,,,CHEMBL615347,,BAO_0000219,2008,80612.0,,,N,122.0,17146.0,1.0,388.0,Intermediate,Homo sapiens,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,
9606.0,1.0,,F,,,,CHEMBL615348,,BAO_0000219,2008,80612.0,,,N,123.0,17146.0,1.0,388.0,Intermediate,Homo sapiens,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,
9606.0,1.0,,F,,,,CHEMBL827085,,BAO_0000219,2008/R,80613.0,,,N,124.0,10797.0,1.0,561.0,Intermediate,Homo sapiens,In vitro inhibition of 2008/R ovarian cancer cell line,
9606.0,1.0,,F,,,,CHEMBL615349,,BAO_0000219,2008/R,80613.0,,,N,125.0,10797.0,1.0,561.0,Intermediate,Homo sapiens,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,
9606.0,1.0,,F,,,,CHEMBL615350,,BAO_0000219,2008/S,80614.0,,,N,126.0,10797.0,1.0,389.0,Intermediate,Homo sapiens,In vitro inhibition of 2008/S ovarian cancer cell line,
9606.0,1.0,,F,,,,CHEMBL615351,,BAO_0000219,2008/S,80614.0,,,N,127.0,10797.0,1.0,389.0,Intermediate,Homo sapiens,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,
9606.0,2.0,,B,,,,CHEMBL615352,,BAO_0000220,,100256.0,,,S,128.0,4823.0,1.0,,Expert,Homo sapiens,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,
9606.0,2.0,,B,,,,CHEMBL615353,,BAO_0000220,,100256.0,,,S,129.0,12912.0,1.0,,Intermediate,Homo sapiens,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,
,2.0,,B,,,,CHEMBL615354,,BAO_0000220,,100256.0,,,S,130.0,2957.0,1.0,,Expert,,Inhibition of chymotrypsin-like activity of 20S proteasome,
,2.0,,B,,,,CHEMBL615355,,BAO_0000220,,100256.0,,,S,131.0,2957.0,1.0,,Expert,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,
,2.0,,B,,,,CHEMBL615356,,BAO_0000220,,100256.0,,,S,132.0,3260.0,1.0,,Intermediate,,Inhibitory activity against 20S proteosome,
9606.0,0.0,,B,,,,CHEMBL615357,,BAO_0000019,,22226.0,,,U,133.0,3451.0,1.0,,Autocuration,Homo sapiens,Compound was tested for inhibitory activity against tryptase,
9606.0,1.0,,F,,,,CHEMBL615358,,BAO_0000219,HepG2,81020.0,,,N,134.0,13885.0,1.0,726.0,Intermediate,Homo sapiens,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,
9606.0,1.0,,F,,,,CHEMBL827086,,BAO_0000219,HepG2,81020.0,,,N,135.0,13885.0,1.0,726.0,Intermediate,Homo sapiens,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,
,0.0,,B,,,,CHEMBL615359,,BAO_0000019,,22226.0,,,U,136.0,3676.0,1.0,,Autocuration,,Compound was tested for the inhibition of Alpha-glucosidase,
,8.0,,B,,,,CHEMBL615360,,BAO_0000357,,235.0,,,H,137.0,6043.0,1.0,,Autocuration,,Inhibitory concentration against human neutrophil elastase (HNE),
10116.0,0.0,,F,,,948.0,CHEMBL615361,,BAO_0000218,,22226.0,,,U,138.0,11140.0,1.0,,Autocuration,Rattus norvegicus,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,Heart
,8.0,,F,,,,CHEMBL615362,,BAO_0000019,,19640.0,,,H,139.0,10543.0,1.0,,Autocuration,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,
,8.0,,F,,,,CHEMBL615363,,BAO_0000019,,19640.0,,,H,140.0,10543.0,1.0,,Expert,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,
,8.0,,B,,,,CHEMBL615364,,BAO_0000357,,19640.0,,,H,141.0,10543.0,1.0,,Autocuration,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,
,8.0,,F,,,,CHEMBL615365,,BAO_0000019,,19640.0,,,H,142.0,10543.0,1.0,,Expert,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,
10090.0,1.0,,F,,,,CHEMBL615366,,BAO_0000219,P338,80360.0,,,N,143.0,11365.0,1.0,524.0,Intermediate,Mus musculus,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,
10090.0,1.0,,F,,,,CHEMBL615367,,BAO_0000219,P338,80360.0,,,N,144.0,11365.0,1.0,524.0,Intermediate,Mus musculus,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,
9606.0,1.0,,F,,,,CHEMBL615368,,BAO_0000219,PBL,80384.0,,,N,145.0,11803.0,1.0,554.0,Intermediate,Homo sapiens,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,
9940.0,0.0,,F,,,,CHEMBL615369,,BAO_0000019,,22226.0,,,U,146.0,11803.0,1.0,,Autocuration,Ovis aries,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,
9940.0,0.0,,F,,,,CHEMBL615370,,BAO_0000019,,22226.0,,,U,147.0,11803.0,1.0,,Autocuration,Ovis aries,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,
,8.0,,B,,,,CHEMBL615673,,BAO_0000357,,191.0,,,H,148.0,12278.0,1.0,,Autocuration,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),
9606.0,0.0,,F,,,,CHEMBL615674,,BAO_0000019,,22226.0,,,U,149.0,8249.0,1.0,,Autocuration,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,
9606.0,0.0,,F,,,,CHEMBL615675,,BAO_0000019,,22226.0,,,U,150.0,8249.0,1.0,,Autocuration,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,
9606.0,0.0,,F,,,,CHEMBL615676,,BAO_0000219,CCRF-CEM,22226.0,,,U,151.0,8249.0,1.0,635.0,Autocuration,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,
9606.0,0.0,,F,,,,CHEMBL615677,,BAO_0000219,CCRF-CEM,22226.0,,,U,152.0,8249.0,1.0,635.0,Autocuration,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,
9606.0,0.0,,F,,,,CHEMBL615678,,BAO_0000219,CCRF-CEM,22226.0,,,U,153.0,8249.0,1.0,635.0,Autocuration,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,
9606.0,0.0,,F,,,,CHEMBL615679,,BAO_0000219,CCRF-CEM,22226.0,,,U,154.0,8249.0,1.0,635.0,Autocuration,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,
9606.0,0.0,,F,,,,CHEMBL615680,,BAO_0000019,,22226.0,,,U,155.0,8249.0,1.0,,Autocuration,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,
9606.0,0.0,,F,,,,CHEMBL615681,,BAO_0000019,,22226.0,,,U,156.0,8249.0,1.0,,Autocuration,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,
,6.0,,B,,,,CHEMBL857972,,BAO_0000249,,104290.0,,,H,157.0,16992.0,1.0,,Autocuration,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,
1314.0,1.0,,F,,,,CHEMBL857899,,BAO_0000218,,50264.0,,,N,158.0,10543.0,1.0,,Intermediate,Streptococcus pyogenes,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,
10335.0,1.0,,F,,,,CHEMBL615371,,BAO_0000218,,50527.0,,,N,159.0,17833.0,1.0,,Intermediate,Human herpesvirus 3,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),
10335.0,1.0,,F,,,,CHEMBL615372,,BAO_0000218,HEL,50527.0,,,N,160.0,17290.0,1.0,468.0,Expert,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,
10335.0,1.0,,F,,,,CHEMBL615373,,BAO_0000218,,50527.0,,,N,161.0,17290.0,1.0,,Intermediate,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV; ND: No data,
10335.0,1.0,,F,,,,CHEMBL615374,,BAO_0000218,,50527.0,,,N,162.0,17290.0,1.0,,Intermediate,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV; ND=No data,
561.0,1.0,,F,,,,CHEMBL615375,,BAO_0000218,,50145.0,,,N,163.0,10932.0,1.0,,Intermediate,escherichia cloac,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",
,0.0,,B,,,,CHEMBL615376,,BAO_0000019,,22226.0,,,U,164.0,9707.0,1.0,,Autocuration,,Ratio of Ki at A2 to Ki at A1 receptors,
5476.0,8.0,,B,,,,CHEMBL615377,,BAO_0000249,,11143.0,,,H,165.0,2346.0,1.0,,Expert,Candida albicans,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",
284593.0,8.0,,B,,,,CHEMBL615378,,BAO_0000357,,18077.0,,,H,166.0,2205.0,1.0,,Expert,Candida glabrata CBS 138,"Inhibition of 1,3-beta-glucan synthase",
9606.0,1.0,,F,,,,CHEMBL615379,,BAO_0000219,1-87 tumor cell line,80609.0,,,N,167.0,11900.0,1.0,832.0,Intermediate,Homo sapiens,Inhibition of growth of 1-87 human tumor cell line,
10116.0,9.0,,B,,,,CHEMBL615380,,BAO_0000219,,12166.0,,,D,168.0,14864.0,1.0,,Expert,Rattus norvegicus,Inhibition of 1-lipoxygenase (LOX)in RBL cells,
3847.0,9.0,,B,,,,CHEMBL615381,,BAO_0000357,,100171.0,,,D,169.0,16474.0,1.0,,Autocuration,Glycine max,Inhibitory activity against soybean 1-lipoxygenase (SLO),
3847.0,9.0,,B,,,,CHEMBL615382,,BAO_0000357,,100171.0,,,D,170.0,16474.0,1.0,,Autocuration,Glycine max,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,
3847.0,9.0,,B,,,,CHEMBL615383,,BAO_0000357,,100171.0,,,D,171.0,16474.0,1.0,,Autocuration,Glycine max,% inhibition against soybean 1-lipoxygenase (SLO),
3847.0,9.0,,B,,,,CHEMBL615384,,BAO_0000357,,100171.0,,,D,172.0,16474.0,1.0,,Autocuration,Glycine max,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,
3847.0,9.0,,B,,,,CHEMBL615385,,BAO_0000357,,100171.0,,,D,173.0,3094.0,1.0,,Autocuration,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,
3847.0,9.0,,B,,,,CHEMBL615386,,BAO_0000357,,100171.0,,,D,174.0,3094.0,1.0,,Autocuration,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,
3847.0,9.0,,B,,,,CHEMBL615387,,BAO_0000357,,100171.0,,,D,175.0,3094.0,1.0,,Autocuration,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,
3847.0,9.0,,B,,,,CHEMBL615388,,BAO_0000357,,100171.0,,,D,176.0,3094.0,1.0,,Autocuration,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,
3847.0,9.0,,B,,,,CHEMBL615214,,BAO_0000357,,100171.0,,,D,177.0,3094.0,1.0,,Autocuration,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,
3847.0,9.0,,B,,,,CHEMBL827087,,BAO_0000357,,100171.0,,,D,178.0,3094.0,1.0,,Autocuration,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,
3847.0,9.0,,B,,,,CHEMBL615215,,BAO_0000357,,100171.0,,,D,179.0,3094.0,1.0,,Autocuration,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,
3847.0,9.0,,B,,,,CHEMBL615216,,BAO_0000357,,100171.0,,,D,180.0,3094.0,1.0,,Autocuration,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,
3847.0,9.0,,B,,,,CHEMBL615217,,BAO_0000357,,100171.0,,,D,181.0,3094.0,1.0,,Autocuration,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,
3847.0,9.0,,B,,,,CHEMBL615218,,BAO_0000357,,100171.0,,,D,182.0,3094.0,1.0,,Autocuration,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,
3847.0,9.0,,B,,,,CHEMBL615219,,BAO_0000357,,100171.0,,,D,183.0,3094.0,1.0,,Autocuration,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,
10090.0,0.0,,B,,,,CHEMBL615220,,BAO_0000019,,22226.0,,,U,184.0,10413.0,1.0,,Autocuration,Mus musculus,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,
10090.0,1.0,,F,,,,CHEMBL615221,,BAO_0000219,C3H 10T1/2,80049.0,,,N,185.0,16929.0,1.0,294.0,Intermediate,Mus musculus,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),
,0.0,,F,,,,CHEMBL615222,,BAO_0000019,,22226.0,,,U,186.0,1229.0,1.0,,Intermediate,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,
,8.0,,B,,,,CHEMBL615223,,BAO_0000357,,11489.0,,,H,187.0,16587.0,1.0,,Autocuration,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),
,8.0,,B,,,,CHEMBL615224,,BAO_0000357,,11862.0,,,H,188.0,16587.0,1.0,,Autocuration,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),
,8.0,,B,,,,CHEMBL615225,,BAO_0000357,,11862.0,,,H,189.0,16587.0,1.0,,Autocuration,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,
,8.0,,B,,,,CHEMBL615226,,BAO_0000357,,11489.0,,,H,190.0,16587.0,1.0,,Autocuration,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,
,8.0,,B,,,,CHEMBL615227,,BAO_0000357,,11862.0,,,H,191.0,16587.0,1.0,,Autocuration,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,
9913.0,9.0,,F,,,,CHEMBL615228,,BAO_0000019,,12347.0,,,D,192.0,8058.0,1.0,,Expert,Bos taurus,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,
10116.0,9.0,,B,,,,CHEMBL615229,,BAO_0000357,,100120.0,,,D,193.0,9065.0,1.0,,Expert,Rattus norvegicus,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,
10116.0,9.0,,B,,,2369.0,CHEMBL615230,,BAO_0000357,,100120.0,,,D,194.0,8865.0,1.0,,Expert,Rattus norvegicus,Inhibition of 11 beta-hydroxylase from rat adrenal gland,Adrenal gland
10116.0,9.0,,B,,,,CHEMBL615231,,BAO_0000357,,100120.0,,,D,195.0,9066.0,1.0,,Expert,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase,
10116.0,9.0,,B,,,,CHEMBL884520,,BAO_0000357,,100120.0,,,D,196.0,8394.0,1.0,,Expert,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase,
10116.0,9.0,,B,,,,CHEMBL615232,,BAO_0000357,,100120.0,,,D,197.0,8394.0,1.0,,Expert,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,
,8.0,,B,,,,CHEMBL615233,,BAO_0000019,,10328.0,,,H,198.0,6431.0,1.0,,Autocuration,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,
,8.0,,B,,,,CHEMBL827088,,BAO_0000357,,11490.0,,,H,199.0,6431.0,1.0,,Autocuration,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,
,8.0,,B,,,,CHEMBL615234,,BAO_0000357,,11490.0,,,H,200.0,6431.0,1.0,,Autocuration,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,
,8.0,,F,,,,CHEMBL615235,,BAO_0000019,,11134.0,,,H,201.0,9295.0,1.0,,Autocuration,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,
,8.0,,B,,,,CHEMBL615236,,BAO_0000019,,12052.0,,,H,202.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,
,8.0,,B,,,,CHEMBL615237,,BAO_0000019,,11134.0,,,H,203.0,13622.0,1.0,,Autocuration,,Compound was tested in vitro for inhibition of 12-LO human platelet,
,8.0,,F,,,,CHEMBL615238,,BAO_0000019,,11134.0,,,H,204.0,12079.0,1.0,,Autocuration,,Inhibitory concentration against human platelet 12-lipoxygenase,
,8.0,,B,,,,CHEMBL615239,,BAO_0000019,,11134.0,,,H,205.0,13622.0,1.0,,Autocuration,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,
9606.0,9.0,,F,,,,CHEMBL615240,,BAO_0000019,,11134.0,,,D,206.0,12079.0,1.0,,Autocuration,Homo sapiens,Inhibitory concentration against human platelet 12-lipoxygenase,
,8.0,,B,,,,CHEMBL615241,,BAO_0000019,,11835.0,,,H,207.0,13500.0,1.0,,Expert,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,
,8.0,,B,,,,CHEMBL615242,,BAO_0000357,,11601.0,,,H,208.0,13723.0,1.0,,Expert,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,
,8.0,,B,,,,CHEMBL615243,,BAO_0000019,,11134.0,,,H,209.0,16474.0,1.0,,Autocuration,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),
,8.0,,B,,,,CHEMBL615244,,BAO_0000019,,11134.0,,,H,210.0,1630.0,1.0,,Autocuration,,Inhibitory activity against human platelet 12-lipoxygenase,
,8.0,,B,,,,CHEMBL615245,,BAO_0000019,,11134.0,,,H,211.0,167.0,1.0,,Autocuration,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,
,8.0,,B,,,,CHEMBL615246,,BAO_0000019,,11134.0,,,H,212.0,16474.0,1.0,,Autocuration,,% inhibition against human platelet 12-lipoxygenase (12-HLO),
,8.0,,B,,,,CHEMBL615247,,BAO_0000019,,11134.0,,,H,213.0,167.0,1.0,,Autocuration,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,
,8.0,,B,,,,CHEMBL615248,,BAO_0000019,,11134.0,,,H,214.0,16474.0,1.0,,Autocuration,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,
,8.0,,B,,,,CHEMBL615249,,BAO_0000357,,11601.0,,,H,215.0,10091.0,1.0,,Autocuration,,Inhibitory activity towards porcine 12-lipoxygenase,
,8.0,,B,,,,CHEMBL615250,,BAO_0000357,,11601.0,,,H,216.0,11966.0,1.0,,Autocuration,,Tested for inhibition against porcine 12-LO,
,8.0,,B,,,,CHEMBL615251,,BAO_0000019,,12052.0,,,H,217.0,951.0,1.0,,Autocuration,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,
,8.0,,B,,,,CHEMBL615252,,BAO_0000019,,12052.0,,,H,218.0,10997.0,1.0,,Autocuration,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,
,8.0,,B,,,,CHEMBL828340,,BAO_0000019,,12052.0,,,H,219.0,10193.0,1.0,,Expert,,In vitro inhibition of rat platelet 12-lipoxygenase,
,8.0,,B,,,,CHEMBL615253,,BAO_0000019,,12052.0,,,H,220.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,
,8.0,,B,,,,CHEMBL615254,,BAO_0000019,,12052.0,,,H,221.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,
,8.0,,B,,,,CHEMBL615255,,BAO_0000019,,12052.0,,,H,222.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,
,8.0,,B,,,,CHEMBL615256,,BAO_0000019,,12052.0,,,H,223.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,
,8.0,,B,,,,CHEMBL615257,,BAO_0000019,,12052.0,,,H,224.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,
,8.0,,B,,,,CHEMBL615258,,BAO_0000019,,12052.0,,,H,225.0,11087.0,1.0,,Autocuration,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,
9606.0,1.0,,F,,,,CHEMBL615259,,BAO_0000219,41M,80007.0,,,N,226.0,15569.0,1.0,621.0,Intermediate,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,
9606.0,1.0,,F,,,,CHEMBL615260,,BAO_0000219,41M,80007.0,,,N,227.0,12989.0,1.0,621.0,Expert,Homo sapiens,In vitro antitumor activity against 41M cell line.,
9606.0,1.0,,F,,,,CHEMBL615261,,BAO_0000219,41M,80007.0,,,N,228.0,16745.0,1.0,621.0,Intermediate,Homo sapiens,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,
9606.0,1.0,,F,,,,CHEMBL615262,,BAO_0000219,41M,80007.0,,,N,229.0,15569.0,1.0,621.0,Intermediate,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,
9606.0,1.0,,F,,,,CHEMBL615263,,BAO_0000219,41M,80007.0,,,N,230.0,12989.0,1.0,621.0,Expert,Homo sapiens,In vitro antitumor activity against 41McisR cell line.,
9606.0,1.0,,F,,,,CHEMBL838393,,BAO_0000219,41M,80007.0,,,N,231.0,12989.0,1.0,621.0,Expert,Homo sapiens,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,
9606.0,1.0,,F,,,,CHEMBL615264,,BAO_0000219,41M,80007.0,,,N,232.0,16745.0,1.0,621.0,Intermediate,Homo sapiens,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,
9606.0,9.0,,B,,,,CHEMBL615265,,BAO_0000357,,84.0,,,D,233.0,6210.0,1.0,,Expert,Homo sapiens,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),
9606.0,9.0,,B,,,,CHEMBL615266,,BAO_0000357,,68.0,,,D,234.0,6210.0,1.0,,Expert,Homo sapiens,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),
,8.0,,B,,,,CHEMBL615267,,BAO_0000357,,68.0,,,H,235.0,6226.0,1.0,,Expert,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),
,8.0,,B,,,,CHEMBL615268,,BAO_0000357,,10201.0,,,H,236.0,17855.0,1.0,,Expert,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,
,8.0,,B,,,,CHEMBL615269,,BAO_0000357,,10201.0,,,H,237.0,17855.0,1.0,,Expert,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,
,8.0,,B,,,,CHEMBL615270,,BAO_0000357,,10201.0,,,H,238.0,17855.0,1.0,,Expert,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,
,8.0,,B,,,,CHEMBL615271,,BAO_0000357,,12220.0,,,H,239.0,10413.0,1.0,,Autocuration,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",
562.0,8.0,,B,,,,CHEMBL615272,,BAO_0000357,,11303.0,,,H,240.0,10413.0,1.0,,Autocuration,Escherichia coli,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",
562.0,8.0,,B,,,,CHEMBL615103,,BAO_0000357,,11303.0,,,H,241.0,10413.0,1.0,,Autocuration,Escherichia coli,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",
562.0,8.0,,B,,,,CHEMBL615104,,BAO_0000357,,11303.0,,,H,242.0,10413.0,1.0,,Autocuration,Escherichia coli,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",
,8.0,,B,,,,CHEMBL615105,,BAO_0000357,,12220.0,,,H,243.0,10413.0,1.0,,Autocuration,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",
,8.0,,B,,,,CHEMBL872866,,BAO_0000357,,12220.0,,,H,244.0,10413.0,1.0,,Autocuration,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",
9823.0,8.0,,B,,,,CHEMBL615106,,BAO_0000357,,11303.0,,,H,245.0,7587.0,1.0,,Autocuration,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",
9823.0,8.0,,B,,,,CHEMBL615107,,BAO_0000019,,11303.0,,,H,246.0,7587.0,1.0,,Autocuration,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",
9823.0,8.0,,B,,,,CHEMBL615108,,BAO_0000357,,11303.0,,,H,247.0,7587.0,1.0,,Autocuration,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",
9823.0,8.0,,B,,,,CHEMBL615109,,BAO_0000357,,11303.0,,,H,248.0,7587.0,1.0,,Autocuration,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",
9823.0,8.0,,B,,,,CHEMBL615110,,BAO_0000357,,11303.0,,,H,249.0,7587.0,1.0,,Autocuration,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",
9823.0,8.0,,B,,,,CHEMBL840105,,BAO_0000019,,11303.0,,,H,250.0,7587.0,1.0,,Autocuration,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",
9823.0,8.0,,B,,,,CHEMBL615111,,BAO_0000019,,11303.0,,,H,251.0,7587.0,1.0,,Autocuration,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",
9823.0,8.0,,B,,,,CHEMBL615112,,BAO_0000019,,11303.0,,,H,252.0,7587.0,1.0,,Autocuration,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",
9823.0,8.0,,B,,,,CHEMBL615113,,BAO_0000019,,11303.0,,,H,253.0,7587.0,1.0,,Autocuration,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",
9823.0,8.0,,B,,,,CHEMBL615114,,BAO_0000019,,11303.0,,,H,254.0,7587.0,1.0,,Autocuration,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",
9823.0,8.0,,B,,,,CHEMBL615115,,BAO_0000357,,11303.0,,,H,255.0,7587.0,1.0,,Autocuration,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",
9823.0,8.0,,B,,,,CHEMBL615116,,BAO_0000019,,11303.0,,,H,256.0,7587.0,1.0,,Autocuration,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",
,8.0,,B,,,,CHEMBL615698,,BAO_0000357,,11303.0,,,H,257.0,7323.0,1.0,,Autocuration,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",
9823.0,0.0,,B,,,,CHEMBL615699,,BAO_0000019,,22226.0,,,U,258.0,7587.0,1.0,,Autocuration,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",
9823.0,0.0,,B,,,,CHEMBL615700,,BAO_0000019,,22226.0,,,U,259.0,7587.0,1.0,,Autocuration,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",
4932.0,8.0,,B,,,,CHEMBL615701,,BAO_0000357,,100249.0,,,H,260.0,13750.0,1.0,,Expert,Saccharomyces cerevisiae,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,
10116.0,0.0,,B,,,,CHEMBL615702,,BAO_0000019,,22226.0,,,U,261.0,7662.0,1.0,,Autocuration,Rattus norvegicus,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,
10116.0,0.0,,B,,,,CHEMBL615703,,BAO_0000019,,22226.0,,,U,262.0,7662.0,1.0,,Autocuration,Rattus norvegicus,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,
10116.0,0.0,,B,,,,CHEMBL615704,,BAO_0000019,,22226.0,,,U,263.0,7662.0,1.0,,Autocuration,Rattus norvegicus,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",
,6.0,,F,,,,CHEMBL615705,,BAO_0000019,,104698.0,,,H,264.0,12211.0,1.0,,Autocuration,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",
,6.0,,F,,,,CHEMBL615706,,BAO_0000019,,104698.0,,,H,265.0,12211.0,1.0,,Autocuration,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",
10141.0,9.0,,F,,,2116.0,CHEMBL615707,,BAO_0000221,,20033.0,,,D,266.0,12211.0,1.0,,Intermediate,Cavia porcellus,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,Ileum
,8.0,,F,,,,CHEMBL615708,,BAO_0000019,,10623.0,,,H,267.0,12211.0,1.0,,Expert,,Stimulatory activity of intragastric pressure was tested in the rat,
,8.0,,B,,,,CHEMBL615709,,BAO_0000357,,121.0,,,H,268.0,15453.0,1.0,,Autocuration,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,
10116.0,0.0,,F,,,,CHEMBL615710,,BAO_0000218,,22226.0,,,U,269.0,11884.0,1.0,,Autocuration,Rattus norvegicus,Dose to reduce neuronal firing against 5-HT cells in rats (iv),
,8.0,,F,,,,CHEMBL615711,,BAO_0000019,,12688.0,,,H,270.0,7185.0,1.0,,Autocuration,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,
9606.0,9.0,,B,,,,CHEMBL615712,,BAO_0000357,,121.0,,,D,271.0,6876.0,1.0,,Expert,Homo sapiens,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,
9606.0,9.0,,B,,,,CHEMBL836325,,BAO_0000357,,121.0,,,D,272.0,6876.0,1.0,,Expert,Homo sapiens,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,
,8.0,,F,,,,CHEMBL615713,,BAO_0000019,,12198.0,,,H,273.0,11863.0,1.0,,Autocuration,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,
,8.0,,B,,,,CHEMBL615714,,BAO_0000357,,12198.0,,,H,274.0,11863.0,1.0,,Autocuration,,Inhibition constant of high-affinity 5-HT uptake,
,8.0,,F,,,,CHEMBL615715,,BAO_0000019,,12198.0,,,H,275.0,11863.0,1.0,,Autocuration,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,
,8.0,,F,,,,CHEMBL615716,,BAO_0000019,,12198.0,,,H,276.0,11863.0,1.0,,Autocuration,,Maximum rate was determined for high affinity transport of 5-HT,
,4.0,,F,,,,CHEMBL615717,,BAO_0000019,,104714.0,,,H,277.0,4639.0,1.0,,Autocuration,,Compound was tested for agonistic activity against 5-HT uptake,
,8.0,,B,,,,CHEMBL881818,,BAO_0000019,,10577.0,,,H,278.0,15796.0,1.0,,Expert,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,
9913.0,8.0,,B,,,,CHEMBL884540,,BAO_0000357,,105.0,,,H,279.0,15796.0,1.0,,Expert,Bos taurus,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,
10116.0,5.0,,B,,,,CHEMBL615718,,BAO_0000224,,104744.0,,,D,280.0,12801.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,
,4.0,,B,,,,CHEMBL615719,,BAO_0000224,,104744.0,,,H,281.0,12801.0,1.0,,Autocuration,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,
,4.0,,B,,,,CHEMBL615720,,BAO_0000249,,104744.0,,Membranes,H,282.0,12120.0,1.0,,Autocuration,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,
,4.0,,B,,,,CHEMBL615721,,BAO_0000249,,104744.0,,Membranes,H,283.0,12120.0,1.0,,Autocuration,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,
,4.0,,B,,,,CHEMBL615722,,BAO_0000019,,104744.0,,,H,284.0,11963.0,1.0,,Autocuration,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,
,8.0,,F,,,,CHEMBL615723,,BAO_0000019,,51.0,,,H,285.0,11701.0,1.0,,Autocuration,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,
,8.0,,B,,,10000000.0,CHEMBL615724,,BAO_0000221,,51.0,,,H,286.0,9995.0,1.0,,Autocuration,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615725,,BAO_0000221,,51.0,,,H,287.0,9995.0,1.0,,Autocuration,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615726,,BAO_0000221,,51.0,,,H,288.0,9995.0,1.0,,Autocuration,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus
,8.0,,F,,,,CHEMBL615727,,BAO_0000218,,10576.0,In vivo,,H,289.0,16394.0,1.0,,Autocuration,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),
10141.0,9.0,,F,,,,CHEMBL615728,,BAO_0000019,,105570.0,,,D,290.0,11574.0,1.0,,Intermediate,Cavia porcellus,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,
,8.0,,B,,,,CHEMBL857971,,BAO_0000219,CHO,279.0,,,H,291.0,15779.0,1.0,449.0,Autocuration,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,
,8.0,,B,,,,CHEMBL615729,,BAO_0000357,,107.0,,,H,292.0,15363.0,1.0,,Autocuration,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,
10116.0,9.0,,F,,,,CHEMBL615730,,BAO_0000019,,12687.0,,,D,293.0,15363.0,1.0,,Expert,Rattus norvegicus,Efficacy against 5-hydroxytryptamine 2A receptor,
,8.0,,F,,,,CHEMBL615731,,BAO_0000019,,12687.0,,,H,294.0,15329.0,1.0,,Expert,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,
,8.0,,F,,,,CHEMBL615732,,BAO_0000019,,12687.0,,,H,295.0,15329.0,1.0,,Expert,,Relative potency towards 5-HT2A receptor of rat tail artery,
,8.0,,F,,,,CHEMBL615733,,BAO_0000019,,12687.0,,,H,296.0,15329.0,1.0,,Expert,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,
,8.0,,F,,,,CHEMBL615734,,BAO_0000019,,12687.0,,,H,297.0,15329.0,1.0,,Expert,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,
,8.0,,F,,,,CHEMBL615735,,BAO_0000019,,12687.0,,,H,298.0,15329.0,1.0,,Autocuration,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,
,8.0,,F,,,,CHEMBL615736,,BAO_0000019,,12687.0,,,H,299.0,15329.0,1.0,,Expert,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,
10141.0,9.0,,F,,,2116.0,CHEMBL615737,,BAO_0000221,,20033.0,,,D,300.0,273.0,1.0,,Intermediate,Cavia porcellus,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL615738,,BAO_0000221,,20033.0,,,D,301.0,273.0,1.0,,Intermediate,Cavia porcellus,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL615739,,BAO_0000221,,20033.0,,,D,302.0,273.0,1.0,,Intermediate,Cavia porcellus,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum
,8.0,,B,,,,CHEMBL615278,,BAO_0000357,,10623.0,,,H,303.0,12092.0,1.0,,Autocuration,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,
10116.0,9.0,,F,,,,CHEMBL615279,,BAO_0000019,,10623.0,,,D,304.0,1317.0,1.0,,Expert,Rattus norvegicus,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,
,8.0,,B,,,,CHEMBL615280,,BAO_0000357,,168.0,,,H,305.0,12409.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 4 receptor,
9031.0,0.0,,B,,,,CHEMBL615281,,BAO_0000019,,22226.0,,,U,306.0,11126.0,1.0,,Autocuration,Gallus gallus,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,
9606.0,0.0,,F,,,,CHEMBL615282,,BAO_0000019,,22226.0,,,U,307.0,11126.0,1.0,,Autocuration,Homo sapiens,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,
9606.0,0.0,,F,,,,CHEMBL615283,,BAO_0000019,,22226.0,,,U,308.0,11126.0,1.0,,Autocuration,Homo sapiens,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,
9606.0,1.0,,B,,,,CHEMBL615284,,BAO_0000219,HL-60,80156.0,,,N,309.0,11126.0,1.0,649.0,Autocuration,Homo sapiens,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,
9606.0,0.0,,B,,,,CHEMBL615285,,BAO_0000019,,22226.0,,,U,310.0,11126.0,1.0,,Autocuration,Homo sapiens,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,
9606.0,0.0,,B,,,,CHEMBL615286,,BAO_0000019,,22226.0,,,U,311.0,11126.0,1.0,,Autocuration,Homo sapiens,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,
9606.0,7.0,,B,,,,CHEMBL615287,,BAO_0000219,Oocytes,104703.0,,,D,312.0,17807.0,1.0,,Autocuration,Homo sapiens,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,
,2.0,,F,,,,CHEMBL615288,,BAO_0000220,,100256.0,,,S,313.0,16575.0,1.0,,Intermediate,,Chymotryptic inhibitory activity against 26S proteasome,
,2.0,,B,,,,CHEMBL615289,,BAO_0000220,,100256.0,,,S,314.0,15407.0,1.0,,Intermediate,,Inhibitory activity against 26S proteasome degradation of IkB,
9606.0,1.0,,F,,,,CHEMBL615290,,BAO_0000219,A2780,81034.0,,,N,315.0,10797.0,1.0,478.0,Intermediate,Homo sapiens,In vitro inhibition of 2780/DOX ovarian cancer cell line,
9606.0,1.0,,F,,,,CHEMBL884522,,BAO_0000219,A2780,81034.0,,,N,316.0,10797.0,1.0,478.0,Intermediate,Homo sapiens,In vitro inhibition of 2780/S ovarian cancer cell line,
9606.0,0.0,,F,,,,CHEMBL615291,,BAO_0000019,,22226.0,,,U,317.0,3469.0,1.0,,Autocuration,Homo sapiens,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,
,3.0,,B,,,,CHEMBL615292,,BAO_0000225,,22222.0,,,M,318.0,16037.0,1.0,,Intermediate,,Association constant for binding to AATT 28-mer AATT hairpin,
,3.0,,B,,,,CHEMBL615293,,BAO_0000225,,22222.0,,,M,319.0,16037.0,1.0,,Intermediate,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,
,3.0,,B,,,,CHEMBL615294,,BAO_0000225,,22222.0,,,M,320.0,16037.0,1.0,,Intermediate,,Reaction Rate Parameter for 28-mer AATT hairpin,
,3.0,,B,,,,CHEMBL615295,,BAO_0000225,,22222.0,,,M,321.0,16037.0,1.0,,Intermediate,,Reaction Rate Parameter for 28-mer AATT hairpin,
9606.0,0.0,,F,,,,CHEMBL825021,,BAO_0000019,,22226.0,,,U,322.0,16524.0,1.0,,Autocuration,Homo sapiens,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),
9606.0,0.0,,F,,,,CHEMBL615296,,BAO_0000019,,22226.0,,,U,323.0,16524.0,1.0,,Autocuration,Homo sapiens,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),
9606.0,0.0,,F,,,,CHEMBL615297,,BAO_0000019,,22226.0,,,U,324.0,16524.0,1.0,,Autocuration,Homo sapiens,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,
10029.0,0.0,,F,,,,CHEMBL615298,,BAO_0000019,,22226.0,,,U,325.0,16758.0,1.0,,Autocuration,Cricetulus griseus,Cytotoxicity against cell line 2SC/20 determined by MTT test,
10029.0,0.0,,F,,,,CHEMBL615299,,BAO_0000019,,22226.0,,,U,326.0,16758.0,1.0,,Autocuration,Cricetulus griseus,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,
10029.0,0.0,,F,,,,CHEMBL615300,,BAO_0000019,,22226.0,,,U,327.0,16758.0,1.0,,Autocuration,Cricetulus griseus,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,
,8.0,,B,,,,CHEMBL615301,,BAO_0000357,,241.0,,,H,328.0,14360.0,1.0,,Autocuration,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,
9606.0,9.0,,B,,,,CHEMBL615302,,BAO_0000357,,241.0,,,D,329.0,14360.0,1.0,,Expert,Homo sapiens,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,
10116.0,0.0,,B,,,,CHEMBL615303,,BAO_0000019,,22226.0,,,U,330.0,9964.0,1.0,,Autocuration,Rattus norvegicus,Selectivity ratio of ID50 in liver and heart,
,8.0,,B,,,,CHEMBL615304,,BAO_0000019,,12132.0,,,H,331.0,9964.0,1.0,,Autocuration,,"Selectivity, ratio of relative ID50 in liver and heart",
,8.0,,B,,,,CHEMBL615305,,BAO_0000019,,12132.0,,,H,332.0,9964.0,1.0,,Autocuration,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,
,8.0,,B,,,,CHEMBL615306,,BAO_0000218,,12132.0,,,H,333.0,9964.0,1.0,,Autocuration,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",
,8.0,,B,,,,CHEMBL615307,,BAO_0000218,,12132.0,,,H,334.0,9964.0,1.0,,Autocuration,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",
,8.0,,B,,,,CHEMBL615308,,BAO_0000218,,12132.0,In vivo,,H,335.0,9964.0,1.0,,Autocuration,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",
,8.0,,F,,,,CHEMBL615309,,BAO_0000218,,12132.0,In vivo,,H,336.0,9964.0,1.0,,Autocuration,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",
,0.0,,B,,,,CHEMBL615310,,BAO_0000019,,22226.0,,,U,337.0,9964.0,1.0,,Autocuration,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",
,8.0,,B,,,,CHEMBL615311,,BAO_0000019,,12132.0,,,H,338.0,9964.0,1.0,,Autocuration,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,
9606.0,0.0,,B,,,,CHEMBL615312,,BAO_0000019,,22226.0,,,U,339.0,9964.0,1.0,,Autocuration,Homo sapiens,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",
,8.0,,B,,,,CHEMBL615313,,BAO_0000019,,12132.0,,,H,340.0,9964.0,1.0,,Autocuration,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,
,8.0,,F,,,,CHEMBL615314,,BAO_0000019,,12132.0,,,H,341.0,9964.0,1.0,,Autocuration,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,
,8.0,,B,,,,CHEMBL615315,,BAO_0000019,,12132.0,,,H,342.0,9964.0,1.0,,Autocuration,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",
10116.0,0.0,,B,,,,CHEMBL615316,,BAO_0000218,,22226.0,,,U,343.0,9964.0,1.0,,Autocuration,Rattus norvegicus,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",
,8.0,,B,,,,CHEMBL615317,,BAO_0000218,,12132.0,In vivo,,H,344.0,9964.0,1.0,,Autocuration,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,
,8.0,,B,,,,CHEMBL615318,,BAO_0000218,,12132.0,,,H,345.0,9964.0,1.0,,Autocuration,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",
10116.0,0.0,,B,,,,CHEMBL615319,,BAO_0000218,,22226.0,,,U,346.0,9964.0,1.0,,Autocuration,Rattus norvegicus,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",
,8.0,,B,,,,CHEMBL615320,,BAO_0000019,,12132.0,,,H,347.0,9964.0,1.0,,Autocuration,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",
,8.0,,F,,,,CHEMBL615321,,BAO_0000019,,12132.0,,,H,348.0,9964.0,1.0,,Autocuration,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",
10116.0,0.0,,B,,,,CHEMBL615322,,BAO_0000019,,22226.0,,,U,349.0,3796.0,1.0,,Autocuration,Rattus norvegicus,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",
562.0,8.0,,B,,,,CHEMBL615323,,BAO_0000357,,19690.0,,,H,350.0,4251.0,1.0,,Autocuration,Escherichia coli,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,
562.0,8.0,,B,,,,CHEMBL615407,,BAO_0000357,,19690.0,,,H,351.0,4251.0,1.0,,Autocuration,Escherichia coli,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,
562.0,8.0,,B,,,,CHEMBL857267,,BAO_0000357,,19690.0,,,H,352.0,4251.0,1.0,,Autocuration,Escherichia coli,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,
562.0,8.0,,B,,,,CHEMBL615408,,BAO_0000357,,19690.0,,,H,353.0,4251.0,1.0,,Autocuration,Escherichia coli,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,
,8.0,,B,,,,CHEMBL615409,,BAO_0000357,,19690.0,,,H,354.0,166.0,1.0,,Autocuration,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,
,8.0,,B,,,,CHEMBL615410,,BAO_0000357,,19690.0,,,H,355.0,17861.0,1.0,,Autocuration,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,
,8.0,,B,,,,CHEMBL615411,,BAO_0000357,,19690.0,,,H,356.0,166.0,1.0,,Autocuration,,Inhibition constant against 3-dehydroquinate synthase,
,8.0,,B,,,,CHEMBL615412,,BAO_0000357,,19690.0,,,H,357.0,166.0,1.0,,Autocuration,,Association rate constant against 3-dehydroquinate synthase,
,8.0,,B,,,,CHEMBL615413,,BAO_0000357,,19690.0,,,H,358.0,166.0,1.0,,Autocuration,,Rate constant against 3-dehydroquinate synthase,
,0.0,,B,,,,CHEMBL615414,,BAO_0000019,,22226.0,,,U,359.0,3548.0,1.0,,Autocuration,,Inhibitory activity against fuc-TVII,
10116.0,9.0,,B,,,2107.0,CHEMBL615415,,BAO_0000251,,12236.0,,Microsomes,D,360.0,9877.0,1.0,,Autocuration,Rattus norvegicus,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver
10116.0,9.0,,B,,,2107.0,CHEMBL615416,,BAO_0000251,,12236.0,,Microsomes,D,361.0,9877.0,1.0,,Autocuration,Rattus norvegicus,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver
10116.0,9.0,,B,,,2107.0,CHEMBL615417,,BAO_0000251,,12236.0,,Microsomes,D,362.0,9877.0,1.0,,Autocuration,Rattus norvegicus,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver
10116.0,9.0,,B,,,2107.0,CHEMBL615418,,BAO_0000251,,12236.0,,Microsomes,D,363.0,9877.0,1.0,,Autocuration,Rattus norvegicus,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver
10116.0,9.0,,B,,,2107.0,CHEMBL615419,,BAO_0000251,,12236.0,,Microsomes,D,364.0,9877.0,1.0,,Autocuration,Rattus norvegicus,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver
10116.0,9.0,,B,,,2107.0,CHEMBL615420,,BAO_0000251,,12236.0,,Microsomes,D,365.0,9877.0,1.0,,Autocuration,Rattus norvegicus,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Liver
10116.0,9.0,,B,,,2107.0,CHEMBL615421,,BAO_0000251,,12236.0,,Microsomes,D,366.0,9877.0,1.0,,Autocuration,Rattus norvegicus,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Liver
10116.0,9.0,,B,,,2107.0,CHEMBL615422,,BAO_0000251,,12236.0,,Microsomes,D,367.0,9877.0,1.0,,Autocuration,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Liver
10116.0,9.0,,B,,,2107.0,CHEMBL615423,,BAO_0000251,,12236.0,,Microsomes,D,368.0,9877.0,1.0,,Autocuration,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Liver
10116.0,9.0,,B,,,2107.0,CHEMBL872868,,BAO_0000251,,12236.0,,Microsomes,D,369.0,9877.0,1.0,,Autocuration,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Liver
10116.0,9.0,,B,,,2107.0,CHEMBL615424,,BAO_0000251,,12236.0,,Microsomes,D,370.0,9877.0,1.0,,Autocuration,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Liver
,4.0,,B,,,,CHEMBL825022,,BAO_0000224,,104832.0,,,H,371.0,3003.0,1.0,,Autocuration,,Inhibitory activity against 3-phosphoglycerate kinase.,
,4.0,,B,,,,CHEMBL615425,,BAO_0000224,,104832.0,,,H,372.0,3003.0,1.0,,Autocuration,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,
,4.0,,B,,,,CHEMBL615426,,BAO_0000224,,104832.0,,,H,373.0,3003.0,1.0,,Autocuration,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",
9606.0,9.0,,B,,,,CHEMBL615427,,BAO_0000357,,10612.0,,,D,374.0,17185.0,1.0,,Expert,Homo sapiens,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,
9606.0,1.0,,F,,,,CHEMBL615428,,BAO_0000219,3677 melanoma cell line,80616.0,,,N,375.0,6072.0,1.0,844.0,Intermediate,Homo sapiens,Cytotoxicity on 3677 melanoma cells,
9606.0,1.0,,F,,,,CHEMBL615429,,BAO_0000219,3677 melanoma cell line,80616.0,,,N,376.0,6072.0,1.0,844.0,Intermediate,Homo sapiens,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,
10090.0,1.0,,F,,,,CHEMBL615430,,BAO_0000219,MC-38,80617.0,,,N,377.0,5018.0,1.0,700.0,Intermediate,Mus musculus,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,
9606.0,0.0,,F,,,,CHEMBL615431,,BAO_0000019,,22226.0,,,U,378.0,2852.0,1.0,,Intermediate,Homo sapiens,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,
,0.0,,F,,,,CHEMBL615432,,BAO_0000218,B16,22226.0,,,U,379.0,8663.0,1.0,798.0,Autocuration,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,
,0.0,,F,,,,CHEMBL615433,,BAO_0000218,B16,22226.0,,,U,380.0,8663.0,1.0,798.0,Autocuration,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,
12131.0,9.0,,F,,,,CHEMBL615434,,BAO_0000019,,12464.0,,,D,381.0,3245.0,1.0,,Expert,Human rhinovirus 14,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,
169066.0,1.0,,F,,,,CHEMBL615435,,BAO_0000218,,50085.0,,,N,382.0,3245.0,1.0,,Intermediate,Human rhinovirus sp.,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,
169066.0,1.0,,F,,,,CHEMBL615436,,BAO_0000218,,50679.0,,,N,383.0,3877.0,1.0,,Intermediate,human rhinovirus type 14,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,
169066.0,1.0,,F,,,,CHEMBL615437,,BAO_0000218,,50679.0,,,N,384.0,3877.0,1.0,,Intermediate,human rhinovirus type 14,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,
12131.0,9.0,,F,,,,CHEMBL615438,,BAO_0000019,,12464.0,,,D,385.0,5861.0,1.0,,Expert,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,
12131.0,9.0,,F,,,,CHEMBL615439,,BAO_0000019,,12464.0,,,D,386.0,5861.0,1.0,,Expert,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,
12131.0,9.0,,F,,,,CHEMBL615440,,BAO_0000019,,12464.0,,,D,387.0,5861.0,1.0,,Expert,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,
12131.0,9.0,,F,,,,CHEMBL615441,,BAO_0000019,,12464.0,,,D,388.0,5861.0,1.0,,Expert,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,
12059.0,1.0,,F,,,,CHEMBL615641,,BAO_0000218,,50665.0,,,N,389.0,13748.0,1.0,,Intermediate,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,
12059.0,1.0,,F,,,,CHEMBL872065,,BAO_0000218,,50665.0,,,N,390.0,13748.0,1.0,,Intermediate,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,
12059.0,1.0,,F,,,,CHEMBL825023,,BAO_0000218,,50665.0,,,N,391.0,13748.0,1.0,,Intermediate,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,
12059.0,1.0,,F,,,,CHEMBL615642,,BAO_0000218,,50665.0,,,N,392.0,13748.0,1.0,,Intermediate,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,
147712.0,8.0,,B,,,,CHEMBL615643,,BAO_0000357,,12464.0,,,H,393.0,13748.0,1.0,,Expert,Human rhinovirus B,Inhibition of human rhinovirus 3C protease,
9606.0,0.0,,B,,,,CHEMBL615644,,BAO_0000019,,22226.0,,,U,394.0,17699.0,1.0,,Autocuration,Homo sapiens,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,
10090.0,1.0,,F,,,,CHEMBL615645,,BAO_0000218,3EM 37,80619.0,,,N,395.0,7145.0,1.0,833.0,Intermediate,Mus musculus,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),
10090.0,1.0,,F,,,,CHEMBL615646,,BAO_0000218,3EM 37,80619.0,,,N,396.0,7145.0,1.0,833.0,Intermediate,Mus musculus,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),
10090.0,1.0,,F,,,,CHEMBL615647,,BAO_0000218,3EM 37,80619.0,,,N,397.0,7145.0,1.0,833.0,Intermediate,Mus musculus,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),
10090.0,1.0,,F,,,,CHEMBL615648,,BAO_0000218,3EM 37,80619.0,,,N,398.0,7145.0,1.0,833.0,Intermediate,Mus musculus,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),
10090.0,1.0,,F,,,,CHEMBL615649,,BAO_0000218,3EM 37,80619.0,,,N,399.0,7145.0,1.0,833.0,Intermediate,Mus musculus,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,
10090.0,1.0,,F,,,,CHEMBL615650,,BAO_0000218,3EM 37,80619.0,,,N,400.0,7145.0,1.0,833.0,Intermediate,Mus musculus,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,
10090.0,1.0,,F,,,,CHEMBL615651,,BAO_0000218,3LL cell line,80620.0,,,N,401.0,5325.0,1.0,847.0,Intermediate,Mus musculus,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,
10090.0,1.0,,F,,,,CHEMBL615652,,BAO_0000218,3LL cell line,80620.0,,,N,402.0,5325.0,1.0,847.0,Intermediate,Mus musculus,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,
10090.0,1.0,,F,,,,CHEMBL615653,,BAO_0000218,3LL cell line,80620.0,,,N,403.0,5325.0,1.0,847.0,Expert,Mus musculus,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,
10090.0,1.0,,F,,,,CHEMBL615654,,BAO_0000219,3LL cell line,80620.0,,,N,404.0,16169.0,1.0,847.0,Intermediate,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,
10090.0,1.0,,F,,,,CHEMBL615655,,BAO_0000219,3LL cell line,80620.0,,,N,405.0,16169.0,1.0,847.0,Intermediate,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,
10090.0,1.0,,F,,,,CHEMBL825024,,BAO_0000219,3LL cell line,80620.0,,,N,406.0,16169.0,1.0,847.0,Intermediate,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,
10090.0,1.0,,F,,,,CHEMBL615656,,BAO_0000219,3LL cell line,80620.0,,,N,407.0,16169.0,1.0,847.0,Intermediate,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,
10090.0,1.0,,F,,,,CHEMBL615657,,BAO_0000219,3LL cell line,80620.0,,,N,408.0,16169.0,1.0,847.0,Intermediate,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,
10090.0,1.0,,F,,,,CHEMBL615658,,BAO_0000219,3LL cell line,80620.0,,,N,409.0,16169.0,1.0,847.0,Intermediate,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,
10090.0,1.0,,F,,,,CHEMBL615659,,BAO_0000219,3LL cell line,80620.0,,,N,410.0,16169.0,1.0,847.0,Intermediate,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,
10090.0,1.0,,F,,,,CHEMBL615660,,BAO_0000219,3LL cell line,80620.0,,,N,411.0,16169.0,1.0,847.0,Intermediate,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,
10090.0,1.0,,F,,,,CHEMBL615661,,BAO_0000219,3LL cell line,80620.0,,,N,412.0,16169.0,1.0,847.0,Intermediate,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,
10090.0,1.0,,F,,,,CHEMBL615662,,BAO_0000219,3LL cell line,80620.0,,,N,413.0,16169.0,1.0,847.0,Intermediate,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,
10090.0,1.0,,F,,,,CHEMBL615663,,BAO_0000219,3LL cell line,80620.0,,,N,414.0,16169.0,1.0,847.0,Intermediate,Mus musculus,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,
10090.0,1.0,,F,,,,CHEMBL615664,,BAO_0000219,3LL cell line,80620.0,,,N,415.0,16169.0,1.0,847.0,Intermediate,Mus musculus,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,
10090.0,1.0,,F,,,,CHEMBL615665,,BAO_0000219,3LL cell line,80620.0,,,N,416.0,16169.0,1.0,847.0,Intermediate,Mus musculus,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,
10090.0,1.0,,F,,,,CHEMBL615666,,BAO_0000219,3LL cell line,80620.0,,,N,417.0,16169.0,1.0,847.0,Intermediate,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,
10090.0,1.0,,F,,,,CHEMBL615667,,BAO_0000219,3LL cell line,80620.0,,,N,418.0,16169.0,1.0,847.0,Intermediate,Mus musculus,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,
10090.0,1.0,,F,,,,CHEMBL615668,,BAO_0000219,3LL cell line,80620.0,,,N,419.0,16169.0,1.0,847.0,Intermediate,Mus musculus,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,
10090.0,1.0,,F,,,,CHEMBL615669,,BAO_0000219,3LL cell line,80620.0,,,N,420.0,16169.0,1.0,847.0,Intermediate,Mus musculus,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,
10090.0,1.0,,F,,,,CHEMBL615670,,BAO_0000219,3LL cell line,80620.0,,,N,421.0,16169.0,1.0,847.0,Intermediate,Mus musculus,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,
10090.0,1.0,,F,,,,CHEMBL836739,,BAO_0000219,3LL cell line,80620.0,,,N,422.0,16169.0,1.0,847.0,Intermediate,Mus musculus,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,
10090.0,1.0,,F,,,,CHEMBL615671,,BAO_0000219,3LL cell line,80620.0,,,N,423.0,16169.0,1.0,847.0,Intermediate,Mus musculus,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,
10090.0,1.0,,F,,,,CHEMBL615672,,BAO_0000219,3LL cell line,80620.0,,,N,424.0,16169.0,1.0,847.0,Intermediate,Mus musculus,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,
10090.0,1.0,,F,,,,CHEMBL615791,,BAO_0000219,3LL cell line,80620.0,,,N,425.0,16169.0,1.0,847.0,Intermediate,Mus musculus,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,
10090.0,1.0,,F,,,,CHEMBL615792,,BAO_0000219,3LL cell line,80620.0,,,N,426.0,16169.0,1.0,847.0,Intermediate,Mus musculus,spermine levels in 3LL cells after the treatment of 1 uM of Compound,
10090.0,1.0,,F,,,,CHEMBL615793,,BAO_0000219,3LL cell line,80620.0,,,N,427.0,16169.0,1.0,847.0,Intermediate,Mus musculus,spermine levels in 3LL cells after the treatment of 10 uM of Compound,
10090.0,1.0,,F,,,,CHEMBL615794,,BAO_0000219,3LL cell line,80620.0,,,N,428.0,16169.0,1.0,847.0,Intermediate,Mus musculus,spermine levels in 3LL cells after the treatment of 250 uM of Compound,
10090.0,1.0,,F,,,,CHEMBL615795,,BAO_0000219,3LL cell line,80620.0,,,N,429.0,16169.0,1.0,847.0,Intermediate,Mus musculus,spermine levels in 3LL cells after the treatment of 50 uM of Compound,
9606.0,1.0,,F,,,,CHEMBL615590,,BAO_0000219,3LLD122,80621.0,,,N,430.0,15547.0,1.0,971.0,Intermediate,Homo sapiens,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,
,0.0,,F,,,,CHEMBL615591,,BAO_0000218,,22226.0,,,U,431.0,8663.0,1.0,,Autocuration,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,
,0.0,,F,,,,CHEMBL615592,,BAO_0000218,,22226.0,,,U,432.0,8663.0,1.0,,Autocuration,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,
,0.0,,F,,,,CHEMBL615593,,BAO_0000218,,22226.0,,,U,433.0,8663.0,1.0,,Autocuration,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,
,0.0,,F,,,,CHEMBL615594,,BAO_0000218,,22226.0,,,U,434.0,8663.0,1.0,,Autocuration,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,
10090.0,1.0,,F,,,,CHEMBL615595,,BAO_0000219,NIH3T3,80951.0,,,N,435.0,4504.0,1.0,723.0,Intermediate,Mus musculus,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,
10090.0,1.0,,F,,,,CHEMBL615596,,BAO_0000219,NIH3T3,80951.0,,,N,436.0,4504.0,1.0,723.0,Intermediate,Mus musculus,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,
,8.0,,F,,,,CHEMBL615597,,BAO_0000219,NIH3T3,11169.0,,,H,437.0,12695.0,1.0,723.0,Expert,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,
10090.0,1.0,,F,,,,CHEMBL615598,,BAO_0000219,NIH3T3,80951.0,,,N,438.0,12695.0,1.0,723.0,Intermediate,Mus musculus,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,
10090.0,1.0,,F,,,,CHEMBL615599,,BAO_0000219,NIH3T3,80951.0,,,N,439.0,12695.0,1.0,723.0,Intermediate,Mus musculus,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,
10090.0,1.0,,F,,,,CHEMBL615600,,BAO_0000219,NIH3T3,80951.0,,,N,440.0,17642.0,1.0,723.0,Expert,Mus musculus,Effective dose against murine 3T3 fibroblasts cells,
10090.0,1.0,,F,,,,CHEMBL615601,,BAO_0000219,NIH3T3,80951.0,,,N,441.0,17642.0,1.0,723.0,Expert,Mus musculus,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,
10090.0,1.0,,F,,,,CHEMBL615602,,BAO_0000219,NIH3T3,80951.0,,,N,442.0,12340.0,1.0,723.0,Expert,Mus musculus,Cytotoxic effect on 3T3 cells,
10090.0,1.0,,F,,,,CHEMBL615603,,BAO_0000219,NIH3T3,80951.0,,,N,443.0,12340.0,1.0,723.0,Expert,Mus musculus,Cytotoxic effect on 3T3 cells,
10090.0,1.0,,F,,,,CHEMBL615604,,BAO_0000219,NIH3T3,80951.0,,,N,444.0,12716.0,1.0,723.0,Intermediate,Mus musculus,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,
10090.0,1.0,,F,,,,CHEMBL615605,,BAO_0000219,NIH3T3,80951.0,,,N,445.0,6277.0,1.0,723.0,Intermediate,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,
10090.0,1.0,,F,,,,CHEMBL615606,,BAO_0000219,NIH3T3,80951.0,,,N,446.0,6277.0,1.0,723.0,Intermediate,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,
10090.0,1.0,,F,,,,CHEMBL884526,,BAO_0000219,NIH3T3,80951.0,,,N,447.0,6277.0,1.0,723.0,Expert,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,
10090.0,1.0,,F,,,,CHEMBL615607,,BAO_0000219,NIH3T3,80951.0,,,N,448.0,6277.0,1.0,723.0,Expert,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,
10090.0,1.0,,F,,,,CHEMBL615608,,BAO_0000219,NIH3T3,80951.0,,,N,449.0,6277.0,1.0,723.0,Intermediate,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,
10090.0,1.0,,F,,,,CHEMBL615609,,BAO_0000219,NIH3T3,80951.0,,,N,450.0,6277.0,1.0,723.0,Expert,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,
10090.0,1.0,,F,,,,CHEMBL615682,,BAO_0000219,NIH3T3,80951.0,,,N,451.0,6277.0,1.0,723.0,Expert,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,
10090.0,1.0,,F,,,,CHEMBL615683,,BAO_0000219,NIH3T3,80951.0,,,N,452.0,6277.0,1.0,723.0,Intermediate,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,
10090.0,1.0,,F,,,,CHEMBL615684,,BAO_0000218,NIH3T3,80951.0,,,N,453.0,17780.0,1.0,723.0,Expert,Mus musculus,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,
10090.0,7.0,,F,,,,CHEMBL615685,,BAO_0000219,,104860.0,,,D,454.0,12751.0,1.0,,Autocuration,Mus musculus,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,
10090.0,1.0,,F,,,,CHEMBL615686,,BAO_0000219,NIH3T3,80951.0,,,N,455.0,12380.0,1.0,723.0,Expert,Mus musculus,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,
10090.0,1.0,,F,,,,CHEMBL615687,,BAO_0000219,NIH3T3,80951.0,,,N,456.0,14892.0,1.0,723.0,Intermediate,Mus musculus,Inhibitory activity against 3T3 cell line,
10090.0,1.0,,F,,,,CHEMBL884523,,BAO_0000219,NIH3T3,80951.0,,,N,457.0,12695.0,1.0,723.0,Intermediate,Mus musculus,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,
,8.0,,F,,,,CHEMBL615688,,BAO_0000019,,11169.0,,,H,458.0,12695.0,1.0,,Expert,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,
10090.0,1.0,,F,,,,CHEMBL615689,,BAO_0000219,NIH3T3,80951.0,,,N,459.0,12695.0,1.0,723.0,Intermediate,Mus musculus,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,
10090.0,1.0,,F,,,,CHEMBL615690,,BAO_0000219,NIH3T3,80951.0,,,N,460.0,12695.0,1.0,723.0,Intermediate,Mus musculus,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,
,8.0,,F,,,,CHEMBL615691,,BAO_0000019,,11169.0,,,H,461.0,12695.0,1.0,,Expert,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,
,8.0,,F,,,,CHEMBL615692,,BAO_0000019,,11169.0,,,H,462.0,12695.0,1.0,,Expert,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,
10090.0,1.0,,F,,,,CHEMBL615693,,BAO_0000219,NIH3T3,80951.0,,,N,463.0,6277.0,1.0,723.0,Intermediate,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,
10090.0,1.0,,F,,,,CHEMBL615324,,BAO_0000219,NIH3T3,80951.0,,,N,464.0,6277.0,1.0,723.0,Expert,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,
9606.0,9.0,,F,,,,CHEMBL615325,,BAO_0000219,NIH3T3,9.0,,,D,465.0,4959.0,1.0,723.0,Expert,Homo sapiens,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,
9606.0,9.0,,F,,,,CHEMBL615490,,BAO_0000219,NIH3T3,9.0,,,D,466.0,4959.0,1.0,723.0,Expert,Homo sapiens,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),
9606.0,9.0,,F,,,,CHEMBL615491,,BAO_0000219,NIH3T3,188.0,,,D,467.0,4959.0,1.0,723.0,Expert,Homo sapiens,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,
9606.0,9.0,,F,,,,CHEMBL615492,,BAO_0000219,NIH3T3,188.0,,,D,468.0,4959.0,1.0,723.0,Expert,Homo sapiens,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),
10090.0,1.0,,F,,,,CHEMBL615493,,BAO_0000219,NIH3T3,80951.0,,,N,469.0,12082.0,1.0,723.0,Intermediate,Mus musculus,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,
10090.0,1.0,,F,,,,CHEMBL615494,,BAO_0000219,NIH3T3,80951.0,,,N,470.0,12082.0,1.0,723.0,Intermediate,Mus musculus,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,
10090.0,1.0,,F,,,,CHEMBL615495,,BAO_0000219,NIH3T3,80951.0,,,N,471.0,12082.0,1.0,723.0,Intermediate,Mus musculus,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,
10090.0,1.0,,F,,,,CHEMBL615496,,BAO_0000219,NIH3T3,80951.0,,,N,472.0,12082.0,1.0,723.0,Intermediate,Mus musculus,Inhibitory concentration was calculated on 3T3 cells by using growth assay,
10090.0,1.0,,F,,,,CHEMBL615497,,BAO_0000219,NIH3T3,80951.0,,,N,473.0,2643.0,1.0,723.0,Intermediate,Mus musculus,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,
10090.0,1.0,,F,,,,CHEMBL615498,,BAO_0000219,NIH3T3,80951.0,,,N,474.0,11926.0,1.0,723.0,Expert,Mus musculus,Inhibition of Swiss 3T3 mouse fibroblast proliferation,
10090.0,1.0,,A,,,,CHEMBL615499,,BAO_0000219,NIH3T3,80951.0,,,N,475.0,15204.0,1.0,723.0,Intermediate,Mus musculus,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,
10090.0,1.0,,F,,,,CHEMBL835522,,BAO_0000219,NIH3T3,80951.0,,,N,476.0,15992.0,1.0,723.0,Expert,Mus musculus,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,
10090.0,1.0,,F,,,,CHEMBL615500,,BAO_0000219,NIH3T3,80951.0,,,N,477.0,16279.0,1.0,723.0,Intermediate,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,
10090.0,1.0,,F,,,,CHEMBL615501,,BAO_0000219,NIH3T3,80951.0,,,N,478.0,16279.0,1.0,723.0,Intermediate,Mus musculus,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),
10090.0,1.0,,F,,,,CHEMBL615502,,BAO_0000219,NIH3T3,80951.0,,,N,479.0,16279.0,1.0,723.0,Intermediate,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),
10090.0,1.0,,F,,,,CHEMBL615503,,BAO_0000219,NIH3T3,80951.0,,,N,480.0,16279.0,1.0,723.0,Intermediate,Mus musculus,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),
10090.0,1.0,,F,,,,CHEMBL615504,,BAO_0000219,NIH3T3,80951.0,,,N,481.0,16279.0,1.0,723.0,Intermediate,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),
10090.0,1.0,,F,,,,CHEMBL615505,,BAO_0000219,NIH3T3,80951.0,,,N,482.0,16279.0,1.0,723.0,Intermediate,Mus musculus,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),
10090.0,1.0,,F,,,,CHEMBL615506,,BAO_0000219,NIH3T3,80951.0,,,N,483.0,12831.0,1.0,723.0,Expert,Mus musculus,Inhibition of swiss 3T3 mouse fibroblast proliferation,
10090.0,1.0,,F,,,,CHEMBL615507,,BAO_0000219,NIH3T3,80951.0,,,N,484.0,13497.0,1.0,723.0,Intermediate,Mus musculus,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,
,1.0,,F,,,,CHEMBL615508,,BAO_0000218,3T3-L1,80006.0,,,N,485.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,
10090.0,1.0,,F,,,,CHEMBL615509,,BAO_0000219,3T3-L1,80006.0,,,N,486.0,13618.0,1.0,620.0,Intermediate,Mus musculus,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,
10090.0,1.0,,F,,,,CHEMBL615510,,BAO_0000219,3T3-L1,80006.0,,,N,487.0,11902.0,1.0,620.0,Intermediate,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,
10090.0,1.0,,F,,,,CHEMBL615511,,BAO_0000219,3T3-L1,80006.0,,,N,488.0,11902.0,1.0,620.0,Intermediate,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,
10090.0,1.0,,F,,,,CHEMBL615512,,BAO_0000219,3T3-L1,80006.0,,,N,489.0,11902.0,1.0,620.0,Intermediate,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,
10090.0,1.0,,F,,,,CHEMBL615513,,BAO_0000218,3T3-L1,80006.0,,,N,490.0,14840.0,1.0,620.0,Intermediate,Mus musculus,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",
10090.0,1.0,,F,,,,CHEMBL615514,,BAO_0000218,3T3-L1,80006.0,,,N,491.0,14840.0,1.0,620.0,Intermediate,Mus musculus,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",
,1.0,,F,,,,CHEMBL615515,,BAO_0000219,3T3-L1,80006.0,,,N,492.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,
,1.0,,F,,,,CHEMBL615516,,BAO_0000219,3T3-L1,80006.0,,,N,493.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,
,1.0,,F,,,,CHEMBL615517,,BAO_0000219,3T3-L1,80006.0,,,N,494.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,
,1.0,,F,,,,CHEMBL615518,,BAO_0000219,3T3-L1,80006.0,,,N,495.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,
,1.0,,F,,,,CHEMBL615519,,BAO_0000219,3T3-L1,80006.0,,,N,496.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,
,1.0,,F,,,,CHEMBL615520,,BAO_0000218,3T3-L1,80006.0,,,N,497.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,
,1.0,,F,,,,CHEMBL615521,,BAO_0000218,3T3-L1,80006.0,,,N,498.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,
,1.0,,F,,,,CHEMBL615522,,BAO_0000218,3T3-L1,80006.0,,,N,499.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,
,1.0,,F,,,,CHEMBL615523,,BAO_0000218,3T3-L1,80006.0,,,N,500.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,
,1.0,,F,,,,CHEMBL615524,,BAO_0000218,3T3-L1,80006.0,,,N,501.0,13715.0,1.0,620.0,Expert,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,
,1.0,,F,,,,CHEMBL615525,,BAO_0000218,3T3-L1,80006.0,,,N,502.0,13715.0,1.0,620.0,Expert,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,
,1.0,,F,,,,CHEMBL615526,,BAO_0000218,3T3-L1,80006.0,,,N,503.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,
,1.0,,F,,,,CHEMBL615527,,BAO_0000218,3T3-L1,80006.0,,,N,504.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,
,1.0,,F,,,,CHEMBL615528,,BAO_0000218,3T3-L1,80006.0,,,N,505.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,
,1.0,,F,,,,CHEMBL615529,,BAO_0000218,3T3-L1,80006.0,,,N,506.0,13715.0,1.0,620.0,Expert,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,
,1.0,,F,,,,CHEMBL615530,,BAO_0000218,3T3-L1,80006.0,,,N,507.0,13715.0,1.0,620.0,Expert,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,
,1.0,,F,,,,CHEMBL615531,,BAO_0000218,3T3-L1,80006.0,,,N,508.0,13715.0,1.0,620.0,Expert,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,
,1.0,,F,,,,CHEMBL615532,,BAO_0000219,3T3-L1,80006.0,,,N,509.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,
,1.0,,F,,,,CHEMBL615533,,BAO_0000219,3T3-L1,80006.0,,,N,510.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,
,1.0,,F,,,,CHEMBL615534,,BAO_0000219,3T3-L1,80006.0,,,N,511.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,
,1.0,,F,,,,CHEMBL615535,,BAO_0000218,3T3-L1,80006.0,,,N,512.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,
,1.0,,F,,,,CHEMBL615536,,BAO_0000218,3T3-L1,80006.0,,,N,513.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,
,1.0,,F,,,,CHEMBL615537,,BAO_0000218,3T3-L1,80006.0,,,N,514.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,
,1.0,,F,,,,CHEMBL615538,,BAO_0000218,3T3-L1,80006.0,,,N,515.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,
,1.0,,F,,,,CHEMBL836166,,BAO_0000218,3T3-L1,80006.0,,,N,516.0,13715.0,1.0,620.0,Intermediate,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,
,8.0,,F,,,,CHEMBL615539,,BAO_0000219,3T3-L1,11214.0,,,H,517.0,6411.0,1.0,620.0,Expert,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,
10090.0,1.0,,F,,,,CHEMBL615540,,BAO_0000219,3T3-L1,80006.0,,,N,518.0,6411.0,1.0,620.0,Intermediate,Mus musculus,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,
,8.0,,F,,,,CHEMBL615541,,BAO_0000219,3T3-L1,11214.0,,,H,519.0,6411.0,1.0,620.0,Expert,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,
10090.0,1.0,,F,,,,CHEMBL615542,,BAO_0000219,3T3-L1,80006.0,,,N,520.0,3966.0,1.0,620.0,Expert,Mus musculus,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,
10090.0,1.0,,F,,,,CHEMBL615543,,BAO_0000219,3T3-L1,80006.0,,,N,521.0,3966.0,1.0,620.0,Intermediate,Mus musculus,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,
10090.0,1.0,,F,,,,CHEMBL615544,,BAO_0000219,3T3-L1,80006.0,,,N,522.0,15556.0,1.0,620.0,Expert,Mus musculus,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,
10090.0,1.0,,F,,,,CHEMBL615545,,BAO_0000219,3T3-L1,80006.0,,,N,523.0,5845.0,1.0,620.0,Expert,Mus musculus,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,
10090.0,1.0,,F,,,,CHEMBL615546,,BAO_0000219,3T3-L1,80006.0,,,N,524.0,14422.0,1.0,620.0,Expert,Mus musculus,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,
10090.0,1.0,,F,,,,CHEMBL615547,,BAO_0000219,3T3-L1,80006.0,,,N,525.0,5845.0,1.0,620.0,Expert,Mus musculus,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,
10090.0,1.0,,F,,,,CHEMBL615548,,BAO_0000219,3T3-L1,80006.0,,,N,526.0,14508.0,1.0,620.0,Expert,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,
10090.0,1.0,,F,,,,CHEMBL615549,,BAO_0000219,3T3-L1,80006.0,,,N,527.0,14508.0,1.0,620.0,Expert,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,
10090.0,1.0,,F,,,,CHEMBL615550,,BAO_0000219,3T3-L1,80006.0,,,N,528.0,14508.0,1.0,620.0,Expert,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,
10116.0,1.0,,F,,,,CHEMBL615551,,BAO_0000219,3Y1 cell line,80622.0,,,N,529.0,6349.0,1.0,1118.0,Intermediate,Rattus norvegicus,Inhibitory activity against rat fibroblast (3Y1) cell line,
10116.0,1.0,,F,,,,CHEMBL615552,,BAO_0000219,3Y1 cell line,80622.0,,,N,530.0,15899.0,1.0,1118.0,Expert,Rattus norvegicus,Mean concentration causing inhibition of cell growth in 3Y1 cells.,
10116.0,1.0,,F,,,,CHEMBL615553,,BAO_0000219,3Y1 cell line,80622.0,,,N,531.0,15899.0,1.0,1118.0,Expert,Rattus norvegicus,Cytotoxicity in 3Y1 cells.,
10116.0,1.0,,F,,,,CHEMBL615554,,BAO_0000219,3Y1 cell line,80622.0,,,N,532.0,15899.0,1.0,1118.0,Expert,Rattus norvegicus,Cytostatic effect in 3Y1 cells.,
10116.0,1.0,,F,,,,CHEMBL615555,,BAO_0000219,3Y1 cell line,80622.0,,,N,533.0,15899.0,1.0,1118.0,Intermediate,Rattus norvegicus,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",
10116.0,1.0,,F,,,,CHEMBL615556,,BAO_0000219,3Y1 cell line,80622.0,,,N,534.0,17038.0,1.0,1118.0,Expert,Rattus norvegicus,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,
,0.0,,B,,,,CHEMBL615557,,BAO_0000019,,22226.0,,,U,535.0,12421.0,1.0,,Autocuration,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,
,0.0,,B,,,,CHEMBL615558,,BAO_0000019,,22226.0,,,U,536.0,12947.0,1.0,,Autocuration,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,
,0.0,,B,,,,CHEMBL872066,,BAO_0000019,,22226.0,,,U,537.0,12947.0,1.0,,Autocuration,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,
9823.0,9.0,,B,,,,CHEMBL615559,,BAO_0000019,,11607.0,,,D,538.0,4896.0,1.0,,Expert,Sus scrofa,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,
,8.0,,B,,,,CHEMBL615560,,BAO_0000019,,11607.0,,,H,539.0,6148.0,1.0,,Autocuration,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,
,8.0,,B,,,,CHEMBL615561,,BAO_0000019,,11607.0,,,H,540.0,16432.0,1.0,,Autocuration,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,
,8.0,,B,,,,CHEMBL857062,,BAO_0000019,,11607.0,,,H,541.0,4978.0,1.0,,Expert,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,
,8.0,,B,,,,CHEMBL615562,,BAO_0000019,,11607.0,,,H,542.0,4978.0,1.0,,Expert,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),
,8.0,,B,,,,CHEMBL615563,,BAO_0000019,,11607.0,,,H,543.0,3723.0,1.0,,Autocuration,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,
,8.0,,B,,,,CHEMBL615564,,BAO_0000357,,11607.0,,,H,544.0,3518.0,1.0,,Autocuration,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),
,8.0,,B,,,,CHEMBL615565,,BAO_0000019,,11607.0,,,H,545.0,4164.0,1.0,,Autocuration,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,
,8.0,,B,,,,CHEMBL615566,,BAO_0000019,,11607.0,,,H,546.0,3518.0,1.0,,Autocuration,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,
9823.0,9.0,,B,,,,CHEMBL615567,,BAO_0000019,,11607.0,,,D,547.0,4164.0,1.0,,Expert,Sus scrofa,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,
,8.0,,B,,,,CHEMBL615568,,BAO_0000019,,11607.0,,,H,548.0,3518.0,1.0,,Autocuration,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,
,8.0,,B,,,,CHEMBL615569,,BAO_0000357,,11607.0,,,H,549.0,3518.0,1.0,,Autocuration,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),
,8.0,,B,,,,CHEMBL615570,,BAO_0000019,,11607.0,,,H,550.0,4978.0,1.0,,Autocuration,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,
,8.0,,B,,,,CHEMBL615571,,BAO_0000019,,11607.0,,,H,551.0,4978.0,1.0,,Autocuration,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),
,4.0,,B,,,,CHEMBL615572,,BAO_0000224,,104733.0,,,H,552.0,6455.0,1.0,,Autocuration,,Binding affinity against melatonin (MT1) receptor (pC1),
,0.0,,B,,,,CHEMBL615573,,BAO_0000019,,22226.0,,,U,553.0,2222.0,1.0,,Autocuration,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,
,0.0,,B,,,,CHEMBL615574,,BAO_0000019,,22226.0,,,U,554.0,13020.0,1.0,,Autocuration,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,
,0.0,,B,,,,CHEMBL615575,,BAO_0000019,,22226.0,,,U,555.0,13021.0,1.0,,Autocuration,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,
,8.0,,B,,,,CHEMBL615576,,BAO_0000357,,10619.0,,,H,556.0,14532.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,
,8.0,,B,,,,CHEMBL615577,,BAO_0000357,,10619.0,,,H,557.0,14118.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,
,8.0,,B,,,10000000.0,CHEMBL615578,,BAO_0000221,,51.0,,,H,558.0,11884.0,1.0,,Autocuration,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,Hippocampus
,8.0,,B,,,,CHEMBL615579,,BAO_0000357,,51.0,,,H,559.0,13969.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL615580,,BAO_0000357,,51.0,,,H,560.0,13392.0,1.0,,Expert,,Binding affinity for 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL615581,,BAO_0000019,,51.0,,,H,561.0,14430.0,1.0,,Expert,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,
,8.0,,B,,,10000000.0,CHEMBL615582,,BAO_0000221,,51.0,,,H,562.0,12248.0,1.0,,Autocuration,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615583,,BAO_0000221,,51.0,,,H,563.0,12249.0,1.0,,Autocuration,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615584,,BAO_0000221,,51.0,,,H,564.0,9995.0,1.0,,Autocuration,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL833691,,BAO_0000221,,51.0,,,H,565.0,9995.0,1.0,,Autocuration,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615585,,BAO_0000221,,51.0,,,H,566.0,9995.0,1.0,,Autocuration,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615586,,BAO_0000221,,51.0,,,H,567.0,9995.0,1.0,,Autocuration,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL884524,,BAO_0000221,,51.0,,,H,568.0,9995.0,1.0,,Autocuration,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615587,,BAO_0000221,,51.0,,,H,569.0,12249.0,1.0,,Autocuration,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615588,,BAO_0000221,,51.0,,,H,570.0,11799.0,1.0,,Autocuration,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Hippocampus
10116.0,9.0,,B,,,,CHEMBL615589,,BAO_0000249,,10576.0,,Membranes,D,571.0,14331.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,
9913.0,8.0,,B,,,10000000.0,CHEMBL615442,,BAO_0000221,,51.0,,,H,572.0,11884.0,1.0,,Expert,Bos taurus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615443,,BAO_0000221,,51.0,,,H,573.0,14331.0,1.0,,Autocuration,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615444,,BAO_0000221,,51.0,,,H,574.0,11701.0,1.0,,Autocuration,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615445,,BAO_0000221,,51.0,,,H,575.0,11701.0,1.0,,Expert,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615446,,BAO_0000221,,51.0,,,H,576.0,12248.0,1.0,,Autocuration,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,Hippocampus
,8.0,,B,,,,CHEMBL615447,,BAO_0000219,CHO,51.0,,,H,577.0,12248.0,1.0,449.0,Autocuration,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,
,8.0,,B,,,10000000.0,CHEMBL615448,,BAO_0000221,,51.0,,,H,578.0,12248.0,1.0,,Expert,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615449,,BAO_0000221,,51.0,,,H,579.0,12249.0,1.0,,Expert,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus
,8.0,,B,,,,CHEMBL615450,,BAO_0000219,CHO,51.0,,,H,580.0,12248.0,1.0,449.0,Autocuration,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,
,8.0,,B,,,10000000.0,CHEMBL615451,,BAO_0000221,,51.0,,,H,581.0,11799.0,1.0,,Expert,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Hippocampus
,8.0,,B,,,,CHEMBL615452,,BAO_0000357,,51.0,,,H,582.0,634.0,1.0,,Autocuration,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,
,8.0,,B,,,10000000.0,CHEMBL615453,,BAO_0000221,,51.0,,,H,583.0,9995.0,1.0,,Autocuration,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615454,,BAO_0000221,,51.0,,,H,584.0,9995.0,1.0,,Autocuration,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615455,,BAO_0000221,,51.0,,,H,585.0,9995.0,1.0,,Autocuration,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615456,,BAO_0000221,,51.0,,,H,586.0,9995.0,1.0,,Autocuration,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615457,,BAO_0000221,,51.0,,,H,587.0,9995.0,1.0,,Autocuration,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615458,,BAO_0000218,,51.0,,,H,588.0,12210.0,1.0,,Expert,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615459,,BAO_0000221,,51.0,,,H,589.0,13311.0,1.0,,Expert,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus
9606.0,9.0,,B,,,,CHEMBL615460,,BAO_0000219,CHO,51.0,,,D,590.0,2331.0,1.0,449.0,Expert,Homo sapiens,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",
10141.0,8.0,,F,,,,CHEMBL615461,,BAO_0000019,,51.0,,,H,591.0,1375.0,1.0,,Autocuration,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,
10141.0,8.0,,F,,,,CHEMBL615462,,BAO_0000019,,51.0,,,H,592.0,1375.0,1.0,,Autocuration,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,
10141.0,8.0,,F,,,10000000.0,CHEMBL615463,,BAO_0000221,,51.0,,,H,593.0,11574.0,1.0,,Autocuration,Cavia porcellus,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,Hippocampus
10141.0,8.0,,B,,,2116.0,CHEMBL615464,,BAO_0000221,,51.0,,,H,594.0,12867.0,1.0,,Autocuration,Cavia porcellus,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Ileum
10141.0,8.0,,B,,,2116.0,CHEMBL615465,,BAO_0000221,,51.0,,,H,595.0,12867.0,1.0,,Autocuration,Cavia porcellus,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Ileum
10141.0,8.0,,B,,,2116.0,CHEMBL615466,,BAO_0000221,,51.0,,,H,596.0,12867.0,1.0,,Autocuration,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Ileum
10141.0,8.0,,B,,,2116.0,CHEMBL615467,,BAO_0000221,,51.0,,,H,597.0,12867.0,1.0,,Autocuration,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Ileum
10141.0,8.0,,B,,,2116.0,CHEMBL615468,,BAO_0000221,,51.0,,,H,598.0,12867.0,1.0,,Autocuration,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Ileum
10141.0,8.0,,B,,,2116.0,CHEMBL615469,,BAO_0000221,,51.0,,,H,599.0,12867.0,1.0,,Autocuration,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,Ileum
10141.0,8.0,,B,,,,CHEMBL615470,,BAO_0000357,,51.0,,,H,600.0,11574.0,1.0,,Autocuration,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 1A receptor,
10141.0,8.0,,B,,,,CHEMBL615471,,BAO_0000357,,51.0,,,H,601.0,13114.0,1.0,,Autocuration,Cavia porcellus,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,
10141.0,8.0,,B,,,,CHEMBL615472,,BAO_0000357,,51.0,,,H,602.0,13181.0,1.0,,Autocuration,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,
10141.0,8.0,,B,,,10000000.0,CHEMBL883242,,BAO_0000221,,106.0,,,H,603.0,10639.0,1.0,,Autocuration,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Hippocampus
10141.0,8.0,,F,,,10000000.0,CHEMBL615473,,BAO_0000221,,106.0,,,H,604.0,10639.0,1.0,,Autocuration,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Hippocampus
10029.0,8.0,,B,,,,CHEMBL615474,,BAO_0000218,CHO,11863.0,,,H,605.0,11883.0,1.0,449.0,Autocuration,Cricetulus griseus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),
,8.0,,B,,,,CHEMBL615475,,BAO_0000357,,51.0,,,H,606.0,17785.0,1.0,,Autocuration,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,
,8.0,,F,,,,CHEMBL615476,,BAO_0000219,HeLa,51.0,,,H,607.0,1558.0,1.0,308.0,Autocuration,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,
,8.0,,F,,,,CHEMBL615477,,BAO_0000219,HeLa,51.0,,,H,608.0,1558.0,1.0,308.0,Autocuration,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,
,8.0,,F,,,,CHEMBL615478,,BAO_0000019,,51.0,,,H,609.0,15740.0,1.0,,Autocuration,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,
,8.0,,F,,,,CHEMBL615160,,BAO_0000219,CHO,51.0,,,H,610.0,17624.0,1.0,449.0,Autocuration,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,
,8.0,,F,,,,CHEMBL615161,,BAO_0000219,CHO,51.0,,,H,611.0,17624.0,1.0,449.0,Expert,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,
,8.0,,F,,,,CHEMBL615162,,BAO_0000219,CHO,51.0,,,H,612.0,17624.0,1.0,449.0,Autocuration,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,
,8.0,,F,,,,CHEMBL615163,,BAO_0000219,CHO,51.0,,,H,613.0,17624.0,1.0,449.0,Autocuration,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,
,8.0,,B,,,,CHEMBL615164,,BAO_0000219,CHO,51.0,,,H,614.0,17624.0,1.0,449.0,Expert,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,
,8.0,,B,,,,CHEMBL615165,,BAO_0000219,CHO,51.0,,,H,615.0,17624.0,1.0,449.0,Expert,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,
,8.0,,B,,,,CHEMBL615166,,BAO_0000219,CHO,51.0,,,H,616.0,17624.0,1.0,449.0,Autocuration,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,
,8.0,,F,,,,CHEMBL615167,,BAO_0000219,,51.0,,,H,617.0,14256.0,1.0,,Autocuration,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,
9606.0,9.0,,B,,,,CHEMBL615168,,BAO_0000219,HeLa,51.0,,,D,618.0,3445.0,1.0,308.0,Expert,Homo sapiens,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,
9606.0,9.0,,B,,,,CHEMBL615169,,BAO_0000219,HeLa,51.0,,,D,619.0,3445.0,1.0,308.0,Expert,Homo sapiens,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,
9606.0,9.0,,B,,,,CHEMBL615170,,BAO_0000219,CHO,51.0,,,D,620.0,17200.0,1.0,449.0,Expert,Homo sapiens,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,
9606.0,9.0,,B,,,,CHEMBL615171,,BAO_0000219,CHO,51.0,,,D,621.0,17200.0,1.0,449.0,Expert,Homo sapiens,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,
,8.0,,F,,,,CHEMBL615694,,BAO_0000019,,51.0,,,H,622.0,15180.0,1.0,,Autocuration,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,
,8.0,,F,,,,CHEMBL615695,,BAO_0000019,,51.0,,,H,623.0,15180.0,1.0,,Autocuration,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,
,8.0,,F,,,,CHEMBL615696,,BAO_0000019,,51.0,,,H,624.0,16026.0,1.0,,Autocuration,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",
,8.0,,F,,,,CHEMBL615697,,BAO_0000219,CHO,51.0,,,H,625.0,2759.0,1.0,449.0,Autocuration,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,
9606.0,9.0,,F,,,,CHEMBL859410,,BAO_0000219,CHO,51.0,,,D,626.0,2759.0,1.0,449.0,Expert,Homo sapiens,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),
,8.0,,F,,,,CHEMBL615841,,BAO_0000219,CHO,51.0,,,H,627.0,2759.0,1.0,449.0,Autocuration,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),
9606.0,9.0,,F,,,,CHEMBL615842,,BAO_0000219,CHO,51.0,,,D,628.0,2759.0,1.0,449.0,Expert,Homo sapiens,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),
,8.0,,F,,,,CHEMBL835003,,BAO_0000219,CHO,51.0,,,H,629.0,2759.0,1.0,449.0,Autocuration,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,
,8.0,,F,,,,CHEMBL615843,,BAO_0000219,CHO,51.0,,,H,630.0,2759.0,1.0,449.0,Autocuration,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),
9606.0,9.0,,F,,,,CHEMBL615979,,BAO_0000219,CHO,51.0,,,D,631.0,2759.0,1.0,449.0,Expert,Homo sapiens,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),
,8.0,,F,,,,CHEMBL615980,,BAO_0000219,CHO,51.0,,,H,632.0,2759.0,1.0,449.0,Autocuration,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),
9606.0,9.0,,F,,,,CHEMBL615981,,BAO_0000219,CHO,51.0,,,D,633.0,2759.0,1.0,449.0,Expert,Homo sapiens,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),
9606.0,9.0,,F,,,,CHEMBL615982,,BAO_0000019,,51.0,,,D,634.0,3445.0,1.0,,Expert,Homo sapiens,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,
9606.0,9.0,,F,,,,CHEMBL615983,,BAO_0000019,,51.0,,,D,635.0,5272.0,1.0,,Expert,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",
9606.0,9.0,,F,,,,CHEMBL615984,,BAO_0000019,,51.0,,,D,636.0,5272.0,1.0,,Expert,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",
9606.0,9.0,,F,,,,CHEMBL615985,,BAO_0000019,,51.0,,,D,637.0,5272.0,1.0,,Expert,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",
,8.0,,F,,,,CHEMBL615986,,BAO_0000219,CHO,51.0,,,H,638.0,17624.0,1.0,449.0,Autocuration,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,
,8.0,,F,,,,CHEMBL615987,,BAO_0000219,CHO,51.0,,,H,639.0,17624.0,1.0,449.0,Autocuration,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,
,8.0,,F,,,,CHEMBL615988,,BAO_0000219,CHO,51.0,,,H,640.0,17624.0,1.0,449.0,Autocuration,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,
,8.0,,F,,,,CHEMBL615989,,BAO_0000219,CHO,51.0,,,H,641.0,17624.0,1.0,449.0,Expert,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,
,8.0,,F,,,,CHEMBL615990,,BAO_0000219,CHO,51.0,,,H,642.0,17624.0,1.0,449.0,Autocuration,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,
,8.0,,F,,,,CHEMBL615991,,BAO_0000219,CHO,51.0,,,H,643.0,17624.0,1.0,449.0,Autocuration,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,
,8.0,,F,,,,CHEMBL615992,,BAO_0000219,CHO,51.0,,,H,644.0,17624.0,1.0,449.0,Autocuration,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,
,8.0,,F,,,,CHEMBL615993,,BAO_0000219,CHO,51.0,,,H,645.0,17624.0,1.0,449.0,Autocuration,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,
,8.0,,F,,,,CHEMBL615994,,BAO_0000219,CHO,51.0,,,H,646.0,17624.0,1.0,449.0,Expert,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,
,8.0,,F,,,,CHEMBL615995,,BAO_0000219,CHO,51.0,,,H,647.0,17624.0,1.0,449.0,Autocuration,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,
,8.0,,F,,,,CHEMBL615996,,BAO_0000219,CHO,51.0,,,H,648.0,17624.0,1.0,449.0,Autocuration,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,
,8.0,,F,,,,CHEMBL615997,,BAO_0000219,CHO,51.0,,,H,649.0,17624.0,1.0,449.0,Autocuration,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,
,8.0,,F,,,,CHEMBL615998,,BAO_0000019,,51.0,,,H,650.0,6563.0,1.0,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",
,8.0,,F,,,,CHEMBL615999,,BAO_0000019,,51.0,,,H,651.0,6563.0,1.0,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",
,8.0,,F,,,,CHEMBL616000,,BAO_0000019,,51.0,,,H,652.0,6563.0,1.0,,Autocuration,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,
,8.0,,F,,,,CHEMBL616001,,BAO_0000219,HEK293,51.0,,,H,653.0,17296.0,1.0,722.0,Autocuration,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,
9606.0,9.0,,F,,,,CHEMBL616002,,BAO_0000019,,51.0,,,D,654.0,6876.0,1.0,,Expert,Homo sapiens,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",
,8.0,,F,,,,CHEMBL616003,,BAO_0000019,,51.0,,,H,655.0,6876.0,1.0,,Expert,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",
9606.0,9.0,,F,,,,CHEMBL616004,,BAO_0000019,,51.0,,,D,656.0,5272.0,1.0,,Expert,Homo sapiens,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,
9606.0,9.0,,F,,,,CHEMBL616005,,BAO_0000019,,51.0,,,D,657.0,5272.0,1.0,,Expert,Homo sapiens,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,
,8.0,,F,,,,CHEMBL616006,,BAO_0000019,,51.0,,,H,658.0,5548.0,1.0,,Autocuration,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",
,8.0,,F,,,,CHEMBL616007,,BAO_0000019,,51.0,,,H,659.0,5548.0,1.0,,Expert,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",
,8.0,,F,,,,CHEMBL616008,,BAO_0000019,,51.0,,,H,660.0,5548.0,1.0,,Autocuration,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",
,8.0,,F,,,,CHEMBL616009,,BAO_0000019,,51.0,,,H,661.0,5548.0,1.0,,Autocuration,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",
,8.0,,F,,,,CHEMBL616010,,BAO_0000019,,51.0,,,H,662.0,5929.0,1.0,,Expert,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",
9606.0,9.0,,F,,,,CHEMBL616011,,BAO_0000019,,51.0,,,D,663.0,5929.0,1.0,,Expert,Homo sapiens,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",
9606.0,9.0,,F,,,,CHEMBL615740,,BAO_0000019,,51.0,,,D,664.0,5929.0,1.0,,Expert,Homo sapiens,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",
,8.0,,F,,,,CHEMBL615741,,BAO_0000019,,51.0,,,H,665.0,16245.0,1.0,,Autocuration,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",
,8.0,,F,,,,CHEMBL615742,,BAO_0000019,,51.0,,,H,666.0,5640.0,1.0,,Expert,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",
,8.0,,F,,,,CHEMBL615743,,BAO_0000019,,51.0,,,H,667.0,5640.0,1.0,,Autocuration,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",
,8.0,,F,,,,CHEMBL615744,,BAO_0000219,CHO,51.0,,,H,668.0,14509.0,1.0,449.0,Autocuration,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,
,8.0,,F,,,,CHEMBL615745,,BAO_0000219,CHO,51.0,,,H,669.0,14509.0,1.0,449.0,Expert,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,
,8.0,,B,,,,CHEMBL615746,,BAO_0000357,,51.0,,,H,670.0,15331.0,1.0,,Autocuration,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,
,8.0,,B,,,,CHEMBL615747,,BAO_0000357,,51.0,,,H,671.0,15331.0,1.0,,Autocuration,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,
,8.0,,F,,,,CHEMBL615748,,BAO_0000019,,51.0,,,H,672.0,6563.0,1.0,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",
,8.0,,F,,,,CHEMBL615749,,BAO_0000019,,51.0,,,H,673.0,6563.0,1.0,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",
,8.0,,F,,,,CHEMBL615750,,BAO_0000019,,51.0,,,H,674.0,6563.0,1.0,,Autocuration,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,
9606.0,9.0,,F,,,,CHEMBL616259,,BAO_0000019,,51.0,,,D,675.0,6563.0,1.0,,Expert,Homo sapiens,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,
,8.0,,F,,,,CHEMBL616260,,BAO_0000019,,51.0,,,H,676.0,6563.0,1.0,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",
9606.0,9.0,,F,,,,CHEMBL616261,,BAO_0000019,,51.0,,,D,677.0,5272.0,1.0,,Expert,Homo sapiens,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,
9606.0,9.0,,F,,,,CHEMBL616262,,BAO_0000019,,51.0,,,D,678.0,5272.0,1.0,,Expert,Homo sapiens,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",
9606.0,9.0,,F,,,,CHEMBL616263,,BAO_0000019,,51.0,,,D,679.0,5272.0,1.0,,Expert,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",
9606.0,9.0,,F,,,,CHEMBL616264,,BAO_0000019,,51.0,,,D,680.0,5272.0,1.0,,Expert,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,
9606.0,9.0,,F,,,,CHEMBL616265,,BAO_0000019,,51.0,,,D,681.0,5272.0,1.0,,Expert,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,
9606.0,9.0,,F,,,,CHEMBL616266,,BAO_0000019,,51.0,,,D,682.0,5272.0,1.0,,Expert,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",
9606.0,9.0,,F,,,,CHEMBL616267,,BAO_0000019,,51.0,,,D,683.0,5272.0,1.0,,Expert,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",
9606.0,9.0,,F,,,,CHEMBL616268,,BAO_0000019,,51.0,,,D,684.0,5272.0,1.0,,Expert,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,
9606.0,9.0,,B,,,,CHEMBL616269,,BAO_0000357,,51.0,,,D,685.0,16146.0,1.0,,Expert,Homo sapiens,Inhibition of human 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL884528,,BAO_0000219,CHO,51.0,,,H,686.0,17624.0,1.0,449.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,
,9.0,,B,,,,CHEMBL616270,,BAO_0000219,HEK293,105.0,,,D,687.0,13706.0,1.0,722.0,Expert,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,
,8.0,,B,,,,CHEMBL616271,,BAO_0000219,CHO,51.0,,,H,688.0,15250.0,1.0,449.0,Autocuration,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,
,8.0,,F,,,,CHEMBL616272,,BAO_0000219,CHO,51.0,,,H,689.0,17624.0,1.0,449.0,Autocuration,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616273,,BAO_0000357,,51.0,,,H,690.0,6861.0,1.0,,Expert,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,
9606.0,9.0,,B,,,,CHEMBL616274,,BAO_0000357,,51.0,,,D,691.0,17200.0,1.0,,Expert,Homo sapiens,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616275,,BAO_0000219,CHO,51.0,,,H,692.0,17624.0,1.0,449.0,Autocuration,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,
,8.0,,B,,,,CHEMBL616276,,BAO_0000219,CHO,51.0,,,H,693.0,17624.0,1.0,449.0,Autocuration,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,
10116.0,0.0,,F,,,,CHEMBL616277,,BAO_0000218,,22226.0,In vivo,,U,694.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,
10116.0,0.0,,F,,,,CHEMBL616278,,BAO_0000218,,22226.0,In vivo,,U,695.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,
10116.0,0.0,,F,,,,CHEMBL616279,,BAO_0000218,,22226.0,In vivo,,U,696.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,
10116.0,0.0,,F,,,,CHEMBL616280,,BAO_0000218,,22226.0,In vivo,,U,697.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,
10116.0,0.0,,F,,,,CHEMBL616281,,BAO_0000218,,22226.0,In vivo,,U,698.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,
10116.0,0.0,,F,,,,CHEMBL616282,,BAO_0000218,,22226.0,In vivo,,U,699.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,
10116.0,0.0,,F,,,,CHEMBL616283,,BAO_0000218,,22226.0,In vivo,,U,700.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,
10116.0,0.0,,F,,,,CHEMBL616284,,BAO_0000218,,22226.0,In vivo,,U,701.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,
10116.0,0.0,,F,,,,CHEMBL616285,,BAO_0000218,,22226.0,In vivo,,U,702.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,
10116.0,0.0,,F,,,,CHEMBL616286,,BAO_0000218,,22226.0,In vivo,,U,703.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,
10116.0,0.0,,F,,,,CHEMBL616287,,BAO_0000218,,22226.0,In vivo,,U,704.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,
10116.0,0.0,,F,,,,CHEMBL616288,,BAO_0000218,,22226.0,In vivo,,U,705.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,
10116.0,0.0,,F,,,,CHEMBL616289,,BAO_0000218,,22226.0,In vivo,,U,706.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,
10116.0,0.0,,F,,,,CHEMBL615610,,BAO_0000218,,22226.0,In vivo,,U,707.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,
10116.0,0.0,,F,,,,CHEMBL615611,,BAO_0000218,,22226.0,In vivo,,U,708.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,
10116.0,0.0,,F,,,,CHEMBL615612,,BAO_0000218,,22226.0,In vivo,,U,709.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,
10116.0,0.0,,F,,,,CHEMBL615613,,BAO_0000218,,22226.0,In vivo,,U,710.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,
10116.0,0.0,,F,,,,CHEMBL615614,,BAO_0000218,,22226.0,In vivo,,U,711.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,
10116.0,0.0,,F,,,,CHEMBL615615,,BAO_0000218,,22226.0,In vivo,,U,712.0,12058.0,1.0,,Autocuration,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,
,4.0,,B,,,,CHEMBL615616,,BAO_0000019,,105093.0,,,H,713.0,11440.0,1.0,,Autocuration,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,
,8.0,,B,,,1898.0,CHEMBL615617,,BAO_0000249,,11923.0,,,H,714.0,6238.0,1.0,,Autocuration,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,Hypothalamus
,8.0,,B,,,,CHEMBL615618,,BAO_0000019,,10577.0,,,H,715.0,10046.0,1.0,,Autocuration,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,
,8.0,,B,,,,CHEMBL615619,,BAO_0000019,,10577.0,,,H,716.0,10046.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,
,8.0,,B,,,,CHEMBL615620,,BAO_0000019,,10577.0,,,H,717.0,10046.0,1.0,,Expert,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,
,8.0,,B,,,,CHEMBL615621,,BAO_0000357,,55.0,,,H,718.0,167.0,1.0,,Autocuration,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",
,8.0,,B,,,,CHEMBL615622,,BAO_0000357,,55.0,,,H,719.0,167.0,1.0,,Autocuration,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",
,8.0,,F,,,,CHEMBL615623,,BAO_0000019,,12166.0,,,H,720.0,11520.0,1.0,,Autocuration,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),
,8.0,,F,,,,CHEMBL615624,,BAO_0000019,,12166.0,,,H,721.0,11520.0,1.0,,Autocuration,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,
,8.0,,F,,,,CHEMBL615625,,BAO_0000019,,12166.0,,,H,722.0,11520.0,1.0,,Autocuration,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,
,8.0,,F,,,,CHEMBL767045,,BAO_0000019,,12166.0,,,H,723.0,11520.0,1.0,,Autocuration,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,
10141.0,8.0,,F,,,,CHEMBL615626,,BAO_0000019,,55.0,,,H,724.0,135.0,1.0,,Autocuration,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,
10141.0,8.0,,F,,,,CHEMBL615627,,BAO_0000019,,55.0,,,H,725.0,135.0,1.0,,Autocuration,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,
10141.0,8.0,,B,,,,CHEMBL615628,,BAO_0000019,,55.0,,,H,726.0,11311.0,1.0,,Autocuration,Cavia porcellus,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,
10141.0,8.0,,B,,,,CHEMBL615629,,BAO_0000357,,55.0,,,H,727.0,10193.0,1.0,,Autocuration,Cavia porcellus,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,
9606.0,9.0,,B,,,,CHEMBL615630,,BAO_0000357,,55.0,,,D,728.0,12281.0,1.0,,Expert,Homo sapiens,Inhibitory concentration against 5-lipoxygenase from human whole blood,
,8.0,,B,,,,CHEMBL615631,,BAO_0000219,,55.0,,,H,729.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],
,8.0,,F,,,,CHEMBL615632,,BAO_0000218,,17087.0,,,H,730.0,12576.0,1.0,,Autocuration,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,
,8.0,,B,,,,CHEMBL615633,,BAO_0000357,,17087.0,,,H,731.0,12281.0,1.0,,Autocuration,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,
,8.0,,F,,,,CHEMBL615634,,BAO_0000218,,17087.0,,,H,732.0,12576.0,1.0,,Autocuration,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,
9823.0,8.0,,B,,,,CHEMBL615635,,BAO_0000019,,55.0,,,H,733.0,11089.0,1.0,,Expert,Sus scrofa,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,
,8.0,,B,,,,CHEMBL615636,,BAO_0000357,,12166.0,,,H,734.0,11006.0,1.0,,Expert,,In vitro inhibition of rat 5-Lipoxygenase,
10116.0,9.0,,B,,,,CHEMBL615637,,BAO_0000357,,12166.0,,,D,735.0,11481.0,1.0,,Expert,Rattus norvegicus,Inhibitory activity against 5-Lipoxygenase,
,8.0,,B,,,,CHEMBL615638,,BAO_0000219,RBL-1,12166.0,,,H,736.0,10864.0,1.0,702.0,Expert,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,
,8.0,,B,,,,CHEMBL615639,,BAO_0000219,RBL-1,12166.0,,,H,737.0,3595.0,1.0,702.0,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),
,8.0,,B,,,,CHEMBL615640,,BAO_0000219,RBL-1,12166.0,,,H,738.0,11311.0,1.0,702.0,Autocuration,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,
,8.0,,B,,,,CHEMBL615796,,BAO_0000019,,12166.0,,,H,739.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,
,8.0,,B,,,,CHEMBL615845,,BAO_0000219,,12166.0,,,H,740.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],
,8.0,,B,,,,CHEMBL615846,,BAO_0000357,,12166.0,,,H,741.0,11006.0,1.0,,Autocuration,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,
,8.0,,B,,,,CHEMBL615847,,BAO_0000219,RBL-1,12166.0,,,H,742.0,3595.0,1.0,702.0,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,
,8.0,,B,,,,CHEMBL615848,,BAO_0000357,,12166.0,,,H,743.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibition of isolated 5-Lipoxygenase,
10116.0,0.0,,B,,,,CHEMBL615849,,BAO_0000019,,22226.0,,,U,744.0,11481.0,1.0,,Autocuration,Rattus norvegicus,Ratio of IC50 against 5-LO and COX,
,8.0,,B,,,,CHEMBL615850,,BAO_0000357,,12166.0,,,H,745.0,11006.0,1.0,,Autocuration,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,
,8.0,,B,,,,CHEMBL615851,,BAO_0000357,,12166.0,,,H,746.0,11006.0,1.0,,Autocuration,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,
,8.0,,B,,,,CHEMBL615852,,BAO_0000219,,12166.0,,,H,747.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,
,8.0,,F,,,,CHEMBL615853,,BAO_0000019,,12166.0,,,H,748.0,11006.0,1.0,,Autocuration,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,
,8.0,,B,,,2367.0,CHEMBL884527,,BAO_0000357,,120.0,,,H,749.0,4288.0,1.0,,Autocuration,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,Prostate gland
8932.0,0.0,,B,,,,CHEMBL872871,,BAO_0000019,,22226.0,,,U,750.0,7587.0,1.0,,Autocuration,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,
8932.0,0.0,,B,,,,CHEMBL615854,,BAO_0000019,,22226.0,,,U,751.0,7587.0,1.0,,Autocuration,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,
8932.0,0.0,,B,,,,CHEMBL767046,,BAO_0000019,,22226.0,,,U,752.0,7587.0,1.0,,Autocuration,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,
,8.0,,B,,,,CHEMBL615855,,BAO_0000357,,10732.0,,,H,753.0,11249.0,1.0,,Autocuration,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,
10116.0,9.0,,F,,,,CHEMBL615856,,BAO_0000019,,12198.0,,,D,754.0,8003.0,1.0,,Expert,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,
10116.0,9.0,,F,,,,CHEMBL615857,,BAO_0000019,,12198.0,,,D,755.0,8003.0,1.0,,Expert,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),
10116.0,9.0,,F,,,,CHEMBL615858,,BAO_0000019,,12198.0,,,D,756.0,8003.0,1.0,,Expert,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),
,8.0,,B,,,10000000.0,CHEMBL615859,,BAO_0000221,,10576.0,,,H,757.0,12416.0,1.0,,Expert,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Hippocampus
,8.0,,B,,,,CHEMBL615860,,BAO_0000357,,51.0,,,H,758.0,16293.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,
9986.0,0.0,,B,,,,CHEMBL615861,,BAO_0000019,,22226.0,,,U,759.0,13047.0,1.0,,Autocuration,Oryctolagus cuniculus,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,
9986.0,0.0,,B,,,,CHEMBL615862,,BAO_0000019,,22226.0,,,U,760.0,13047.0,1.0,,Autocuration,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,
9986.0,0.0,,B,,,,CHEMBL615863,,BAO_0000019,,22226.0,,,U,761.0,13047.0,1.0,,Autocuration,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,
9986.0,0.0,,B,,,,CHEMBL615864,,BAO_0000019,,22226.0,,,U,762.0,13047.0,1.0,,Autocuration,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,
,4.0,,B,,,10000000.0,CHEMBL615865,,BAO_0000221,,104744.0,,,H,763.0,10085.0,1.0,,Autocuration,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Hippocampus
,4.0,,B,,,10000000.0,CHEMBL615866,,BAO_0000221,,104744.0,,,H,764.0,10085.0,1.0,,Autocuration,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Hippocampus
,4.0,,B,,,10000000.0,CHEMBL615867,,BAO_0000221,,104744.0,,,H,765.0,10085.0,1.0,,Autocuration,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Hippocampus
,4.0,,B,,,,CHEMBL615868,,BAO_0000249,,104744.0,,Membranes,H,766.0,9841.0,1.0,,Autocuration,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,
10116.0,5.0,,B,,,,CHEMBL615869,,BAO_0000249,,104744.0,,,D,767.0,8822.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,
10116.0,5.0,,B,,,,CHEMBL615870,,BAO_0000019,,104744.0,,,D,768.0,9806.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,
10116.0,5.0,,B,,,,CHEMBL615871,,BAO_0000019,,104744.0,,,D,769.0,9806.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,
,4.0,,B,,,,CHEMBL615872,,BAO_0000224,,104744.0,,,H,770.0,8868.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,
,4.0,,B,,,10000000.0,CHEMBL833492,,BAO_0000221,,104744.0,,,H,771.0,9036.0,1.0,,Autocuration,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,Hippocampus
,4.0,,B,,,10000000.0,CHEMBL615873,,BAO_0000221,,104744.0,,,H,772.0,11374.0,1.0,,Autocuration,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,Hippocampus
,4.0,,B,,,,CHEMBL615479,,BAO_0000224,,104744.0,,,H,773.0,10881.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,
,4.0,,B,,,,CHEMBL615480,,BAO_0000019,,104744.0,,,H,774.0,8822.0,1.0,,Autocuration,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,
10116.0,5.0,,B,,,,CHEMBL615481,,BAO_0000249,,104744.0,,,D,775.0,9806.0,1.0,,Autocuration,Rattus norvegicus,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,
,4.0,,B,,,,CHEMBL872869,,BAO_0000019,,104744.0,,,H,776.0,15463.0,1.0,,Autocuration,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,
,4.0,,B,,,,CHEMBL615482,,BAO_0000019,,104744.0,,,H,777.0,15463.0,1.0,,Autocuration,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,
,4.0,,B,,,955.0,CHEMBL615483,,BAO_0000221,,104744.0,,,H,778.0,14542.0,1.0,,Autocuration,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Brain
,4.0,,B,,,955.0,CHEMBL615484,,BAO_0000221,,104744.0,,,H,779.0,14542.0,1.0,,Autocuration,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Brain
,4.0,,B,,,,CHEMBL615485,,BAO_0000019,,104744.0,,,H,780.0,8569.0,1.0,,Autocuration,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,
10116.0,5.0,,B,,,,CHEMBL615486,,BAO_0000224,,104744.0,,,D,781.0,10062.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,
,4.0,,B,,,,CHEMBL615487,,BAO_0000224,,104744.0,,,H,782.0,4771.0,1.0,,Autocuration,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,
,4.0,,B,,,,CHEMBL615488,,BAO_0000224,,104744.0,,,H,783.0,10062.0,1.0,,Autocuration,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,
,4.0,,B,,,,CHEMBL615489,,BAO_0000224,,104744.0,,,H,784.0,10062.0,1.0,,Autocuration,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,
,4.0,,B,,,,CHEMBL615389,,BAO_0000224,,104744.0,,,H,785.0,10062.0,1.0,,Autocuration,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,
,4.0,,B,,,,CHEMBL615390,,BAO_0000019,,104744.0,,,H,786.0,15463.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,
,4.0,,B,,,,CHEMBL615391,,BAO_0000019,,104744.0,,,H,787.0,15463.0,1.0,,Autocuration,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,
,4.0,,B,,,,CHEMBL615392,,BAO_0000224,,104744.0,,,H,788.0,9098.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,
10116.0,0.0,,B,,,,CHEMBL615393,,BAO_0000019,,22226.0,,,U,789.0,3070.0,1.0,,Autocuration,Rattus norvegicus,Affinity for 5-hydroxytryptamine 1 receptor,
,4.0,,B,,,955.0,CHEMBL615394,,BAO_0000221,,104744.0,,,H,790.0,14542.0,1.0,,Autocuration,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,Brain
,4.0,,B,,,955.0,CHEMBL615395,,BAO_0000221,,104744.0,,,H,791.0,14542.0,1.0,,Autocuration,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Brain
,4.0,,B,,,,CHEMBL615396,,BAO_0000224,,104744.0,,,H,792.0,6398.0,1.0,,Autocuration,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,
,4.0,,B,,,955.0,CHEMBL615397,,BAO_0000221,,104744.0,,,H,793.0,1344.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,Brain
,4.0,,B,,,,CHEMBL615398,,BAO_0000019,,104744.0,,,H,794.0,11963.0,1.0,,Autocuration,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,
10116.0,0.0,,B,,,,CHEMBL615399,,BAO_0000019,,22226.0,,,U,795.0,8908.0,1.0,,Autocuration,Rattus norvegicus,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,
,4.0,,B,,,,CHEMBL615400,,BAO_0000019,,104744.0,,,H,796.0,9098.0,1.0,,Autocuration,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,
10116.0,5.0,,B,,,,CHEMBL615401,,BAO_0000019,,104744.0,,,D,797.0,8841.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,
10116.0,0.0,,B,,,,CHEMBL615402,,BAO_0000019,,22226.0,,,U,798.0,8814.0,1.0,,Autocuration,Rattus norvegicus,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,
,4.0,,B,,,,CHEMBL615403,,BAO_0000019,,104744.0,,,H,799.0,11752.0,1.0,,Autocuration,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,
,4.0,,B,,,955.0,CHEMBL615404,,BAO_0000221,,104744.0,,,H,800.0,11642.0,1.0,,Autocuration,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,Brain
,4.0,,B,,,,CHEMBL615781,,BAO_0000019,,104744.0,,,H,801.0,11642.0,1.0,,Autocuration,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,
,4.0,,B,,,955.0,CHEMBL615782,,BAO_0000220,,104744.0,,,H,802.0,9231.0,1.0,,Autocuration,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,Brain
,4.0,,B,,,955.0,CHEMBL615783,,BAO_0000221,,104744.0,,,H,803.0,11351.0,1.0,,Autocuration,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,Brain
,0.0,,B,,,,CHEMBL873481,,BAO_0000019,,22226.0,,,U,804.0,4639.0,1.0,,Autocuration,,Compound was tested for binding affinity against 5-HT1 receptor,
,0.0,,B,,,,CHEMBL615784,,BAO_0000019,,22226.0,,,U,805.0,1205.0,1.0,,Autocuration,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,
,8.0,,B,,,,CHEMBL615785,,BAO_0000357,,10576.0,,,H,806.0,10025.0,1.0,,Expert,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,
,8.0,,F,,,,CHEMBL615786,,BAO_0000249,,10576.0,,,H,807.0,13241.0,1.0,,Autocuration,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",
,8.0,,F,,,,CHEMBL615787,,BAO_0000218,,10576.0,In vivo,,H,808.0,16245.0,1.0,,Autocuration,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,
,8.0,,F,,,,CHEMBL615788,,BAO_0000218,,10576.0,In vivo,,H,809.0,16245.0,1.0,,Autocuration,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,
,8.0,,F,,,,CHEMBL767044,,BAO_0000019,,10576.0,,,H,810.0,12438.0,1.0,,Autocuration,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,
,8.0,,F,,,,CHEMBL615789,,BAO_0000218,,10576.0,In vivo,,H,811.0,16245.0,1.0,,Autocuration,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,
,8.0,,F,,,,CHEMBL615790,,BAO_0000218,,10576.0,In vivo,,H,812.0,16245.0,1.0,,Autocuration,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,
,8.0,,F,,,,CHEMBL615813,,BAO_0000019,,10576.0,,,H,813.0,15740.0,1.0,,Autocuration,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,
,8.0,,F,,,,CHEMBL615814,,BAO_0000219,,10576.0,,,H,814.0,15535.0,1.0,,Autocuration,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,
,8.0,,F,,,,CHEMBL615815,,BAO_0000219,,51.0,,,H,815.0,15535.0,1.0,,Expert,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,
,8.0,,F,,,,CHEMBL615816,,BAO_0000219,,10576.0,,,H,816.0,15535.0,1.0,,Autocuration,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,
,8.0,,B,,,,CHEMBL615817,,BAO_0000249,,10576.0,,,H,817.0,9888.0,1.0,,Expert,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,
,8.0,,B,,,10000000.0,CHEMBL615818,,BAO_0000221,,10576.0,,,H,818.0,10085.0,1.0,,Autocuration,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615819,,BAO_0000221,,10576.0,,,H,819.0,10085.0,1.0,,Autocuration,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,Hippocampus
,8.0,,B,,,,CHEMBL615820,,BAO_0000249,,10576.0,,Membranes,H,820.0,17331.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,
10116.0,9.0,,B,,,10000000.0,CHEMBL615821,,BAO_0000221,,10576.0,,,D,821.0,10845.0,1.0,,Expert,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,Hippocampus
10116.0,9.0,,B,,,10000000.0,CHEMBL615822,,BAO_0000221,,10576.0,,,D,822.0,10845.0,1.0,,Expert,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615823,,BAO_0000221,,10576.0,,,H,823.0,10845.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,Hippocampus
10116.0,9.0,,B,,,10000000.0,CHEMBL615824,,BAO_0000221,,10576.0,,,D,824.0,10845.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,Hippocampus
10116.0,9.0,,B,,,10000000.0,CHEMBL615825,,BAO_0000221,,10576.0,,,D,825.0,10845.0,1.0,,Expert,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Hippocampus
,8.0,,B,,,,CHEMBL615826,,BAO_0000357,,10576.0,,,H,826.0,13730.0,1.0,,Expert,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL615827,,BAO_0000249,,10576.0,,,H,827.0,13508.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,10000000.0,CHEMBL615828,,BAO_0000249,,10576.0,,,H,828.0,13508.0,1.0,,Expert,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615829,,BAO_0000221,,10576.0,,,H,829.0,12073.0,1.0,,Expert,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615830,,BAO_0000221,,10576.0,,,H,830.0,4671.0,1.0,,Autocuration,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615831,,BAO_0000221,,10576.0,,,H,831.0,13631.0,1.0,,Expert,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,Hippocampus
,8.0,,B,,,,CHEMBL615832,,BAO_0000357,,10576.0,,,H,832.0,12438.0,1.0,,Autocuration,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL615833,,BAO_0000019,,10576.0,,,H,833.0,10483.0,1.0,,Autocuration,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,
,8.0,,B,,,10000000.0,CHEMBL615834,,BAO_0000221,,10576.0,,,H,834.0,10483.0,1.0,,Autocuration,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,Hippocampus
,8.0,,B,,,,CHEMBL615835,,BAO_0000249,,10576.0,,,H,835.0,12352.0,1.0,,Intermediate,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,
,8.0,,B,,,10000000.0,CHEMBL615836,,BAO_0000249,,10576.0,,,H,836.0,14732.0,1.0,,Autocuration,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,Hippocampus
10116.0,9.0,,B,,,,CHEMBL615837,,BAO_0000019,,10576.0,,,D,837.0,11049.0,1.0,,Expert,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,
10116.0,9.0,,B,,,,CHEMBL615838,,BAO_0000019,,10576.0,,,D,838.0,11049.0,1.0,,Expert,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,
,8.0,,B,,,,CHEMBL615839,,BAO_0000249,,10576.0,,,H,839.0,13657.0,1.0,,Expert,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",
,8.0,,B,,,,CHEMBL884525,,BAO_0000019,,10576.0,,,H,840.0,11473.0,1.0,,Autocuration,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL615840,,BAO_0000249,,10576.0,,,H,841.0,2014.0,1.0,,Autocuration,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,
,8.0,,B,,,10000000.0,CHEMBL615405,,BAO_0000221,,10576.0,,,H,842.0,3086.0,1.0,,Expert,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus
,8.0,,B,,,,CHEMBL615406,,BAO_0000019,,10576.0,,,H,843.0,15854.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,
,8.0,,B,,,10000000.0,CHEMBL615900,,BAO_0000221,,10576.0,,,H,844.0,10922.0,1.0,,Expert,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615901,,BAO_0000221,,10576.0,,,H,845.0,13346.0,1.0,,Expert,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,Hippocampus
,8.0,,B,,,,CHEMBL615902,,BAO_0000357,,10576.0,,,H,846.0,15311.0,1.0,,Expert,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,
,8.0,,B,,,10000000.0,CHEMBL615903,,BAO_0000221,,10576.0,,,H,847.0,10922.0,1.0,,Autocuration,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Hippocampus
,8.0,,B,,,,CHEMBL615904,,BAO_0000357,,10576.0,,,H,848.0,10025.0,1.0,,Autocuration,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,
,8.0,,B,,,,CHEMBL615905,,BAO_0000357,,10576.0,,,H,849.0,10025.0,1.0,,Expert,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,
,8.0,,B,,,,CHEMBL615906,,BAO_0000019,,10576.0,,,H,850.0,9742.0,1.0,,Autocuration,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,
,8.0,,F,,,,CHEMBL615907,,BAO_0000019,,10576.0,,,H,851.0,9742.0,1.0,,Autocuration,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,
,8.0,,B,,,,CHEMBL615908,,BAO_0000019,,10576.0,,,H,852.0,12304.0,1.0,,Expert,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,
,8.0,,B,,,10000000.0,CHEMBL615909,,BAO_0000221,,10576.0,,,H,853.0,15789.0,1.0,,Autocuration,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,Hippocampus
,8.0,,B,,,,CHEMBL615910,,BAO_0000019,,10576.0,,,H,854.0,9912.0,1.0,,Autocuration,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",
,8.0,,B,,,,CHEMBL615911,,BAO_0000019,,10576.0,,,H,855.0,9912.0,1.0,,Autocuration,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",
,8.0,,B,,,,CHEMBL615912,,BAO_0000019,,10576.0,,,H,856.0,9912.0,1.0,,Autocuration,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",
,8.0,,B,,,,CHEMBL615913,,BAO_0000019,,10576.0,,,H,857.0,16693.0,1.0,,Expert,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL615914,,BAO_0000357,,10576.0,,,H,858.0,13276.0,1.0,,Expert,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,
,8.0,,B,,,10000000.0,CHEMBL615915,,BAO_0000221,,10576.0,,,H,859.0,12678.0,1.0,,Autocuration,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Hippocampus
,8.0,,B,,,,CHEMBL615916,,BAO_0000357,,10576.0,,,H,860.0,11825.0,1.0,,Autocuration,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,
,8.0,,B,,,,CHEMBL615917,,BAO_0000357,,10576.0,,,H,861.0,12443.0,1.0,,Expert,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,
,8.0,,B,,,,CHEMBL615918,,BAO_0000357,,10576.0,,,H,862.0,13830.0,1.0,,Expert,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,10000000.0,CHEMBL615919,,BAO_0000249,,10576.0,,,H,863.0,14286.0,1.0,,Expert,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,Hippocampus
10116.0,9.0,,B,,,10000000.0,CHEMBL615920,,BAO_0000221,,10576.0,,,D,864.0,14356.0,1.0,,Expert,Rattus norvegicus,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Hippocampus
,8.0,,B,,,,CHEMBL615921,,BAO_0000357,,10576.0,,,H,865.0,15306.0,1.0,,Autocuration,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL615922,,BAO_0000357,,10576.0,,,H,866.0,15306.0,1.0,,Expert,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),
10116.0,9.0,,F,,,,CHEMBL881290,,BAO_0000249,,10576.0,,,D,867.0,16616.0,1.0,,Expert,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",
,8.0,,B,,,10000000.0,CHEMBL615923,,BAO_0000221,,10576.0,,,H,868.0,3651.0,1.0,,Autocuration,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",Hippocampus
,8.0,,F,,,10000000.0,CHEMBL615924,,BAO_0000221,,10576.0,,,H,869.0,14331.0,1.0,,Autocuration,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus
,8.0,,F,,,10000000.0,CHEMBL615925,,BAO_0000221,,10576.0,,,H,870.0,14331.0,1.0,,Autocuration,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus
10116.0,9.0,,B,,,,CHEMBL615926,,BAO_0000357,,10576.0,,,D,871.0,14178.0,1.0,,Expert,Rattus norvegicus,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,
10116.0,9.0,,B,,,,CHEMBL615927,,BAO_0000019,,10576.0,,,D,872.0,10639.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,10000000.0,CHEMBL615928,,BAO_0000221,,10576.0,,,H,873.0,12306.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus
10116.0,9.0,,B,,,,CHEMBL615929,,BAO_0000357,,10576.0,,,D,874.0,1348.0,1.0,,Expert,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,
,8.0,,B,,,10000000.0,CHEMBL615930,,BAO_0000221,,10576.0,,,H,875.0,13605.0,1.0,,Autocuration,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,Hippocampus
,8.0,,B,,,,CHEMBL615931,,BAO_0000219,CHO,51.0,,,H,876.0,17624.0,1.0,449.0,Autocuration,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,
,8.0,,F,,,,CHEMBL615932,,BAO_0000219,CHO,51.0,,,H,877.0,17624.0,1.0,449.0,Autocuration,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,
,8.0,,F,,,,CHEMBL615933,,BAO_0000219,CHO,51.0,,,H,878.0,17624.0,1.0,449.0,Autocuration,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL615934,,BAO_0000357,,51.0,,,H,879.0,15267.0,1.0,,Autocuration,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL615935,,BAO_0000357,,51.0,,,H,880.0,16532.0,1.0,,Autocuration,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,
,8.0,,F,,,,CHEMBL615936,,BAO_0000019,,51.0,,,H,881.0,6563.0,1.0,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",
,8.0,,B,,,,CHEMBL615937,,BAO_0000219,CHO,51.0,,,H,882.0,4751.0,1.0,449.0,Autocuration,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,
,8.0,,B,,,,CHEMBL615938,,BAO_0000357,,51.0,,,H,883.0,15463.0,1.0,,Autocuration,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL615797,,BAO_0000357,,51.0,,,H,884.0,3805.0,1.0,,Autocuration,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),
,8.0,,B,,,,CHEMBL615798,,BAO_0000357,,51.0,,,H,885.0,5640.0,1.0,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL872870,,BAO_0000357,,51.0,,,H,886.0,6563.0,1.0,,Autocuration,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,
,8.0,,B,,,,CHEMBL615799,,BAO_0000357,,51.0,,,H,887.0,5548.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,
,8.0,,B,,,,CHEMBL615800,,BAO_0000357,,51.0,,,H,888.0,6347.0,1.0,,Autocuration,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,
,8.0,,F,,,,CHEMBL615801,,BAO_0000219,HEK293,51.0,,,H,889.0,17296.0,1.0,722.0,Autocuration,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,
,8.0,,B,,,,CHEMBL615802,,BAO_0000019,,51.0,,,H,890.0,13047.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,
,8.0,,B,,,,CHEMBL615803,,BAO_0000357,,51.0,,,H,891.0,15740.0,1.0,,Autocuration,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,
,8.0,,F,,,,CHEMBL835002,,BAO_0000019,,51.0,,,H,892.0,5640.0,1.0,,Expert,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",
,8.0,,F,,,,CHEMBL615804,,BAO_0000019,,51.0,,,H,893.0,5640.0,1.0,,Autocuration,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",
,8.0,,B,,,,CHEMBL615805,,BAO_0000219,HeLa,51.0,,,H,894.0,17211.0,1.0,308.0,Expert,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL615806,,BAO_0000219,CHO,51.0,,,H,895.0,4751.0,1.0,449.0,Autocuration,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,
9606.0,9.0,,B,,,,CHEMBL615807,,BAO_0000357,,51.0,,,D,896.0,6491.0,1.0,,Expert,Homo sapiens,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,
,8.0,,B,,,,CHEMBL615808,,BAO_0000357,,51.0,,,H,897.0,4707.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,
9606.0,9.0,,B,,,,CHEMBL615809,,BAO_0000357,,51.0,,,D,898.0,13910.0,1.0,,Expert,Homo sapiens,Binding affinity against 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL615810,,BAO_0000219,HeLa,51.0,,,H,899.0,16190.0,1.0,308.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,
,8.0,,B,,,,CHEMBL615811,,BAO_0000357,,51.0,,,H,900.0,16633.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL615812,,BAO_0000219,CHO,51.0,,,H,901.0,11898.0,1.0,449.0,Autocuration,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,
,8.0,,B,,,,CHEMBL615751,,BAO_0000219,CHO,51.0,,,H,902.0,11898.0,1.0,449.0,Autocuration,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,
,8.0,,B,,,,CHEMBL615752,,BAO_0000357,,51.0,,,H,903.0,14331.0,1.0,,Autocuration,,Binding affinity against human 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL615753,,BAO_0000219,CHO,51.0,,,H,904.0,17624.0,1.0,449.0,Expert,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,
,8.0,,B,,,,CHEMBL615754,,BAO_0000219,CHO,51.0,,,H,905.0,17624.0,1.0,449.0,Autocuration,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,
,8.0,,B,,,,CHEMBL615755,,BAO_0000357,,51.0,,,H,906.0,3307.0,1.0,,Autocuration,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,
9606.0,9.0,,B,,,,CHEMBL615756,,BAO_0000219,CHO,51.0,,,D,907.0,6563.0,1.0,449.0,Expert,Homo sapiens,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,
,8.0,,B,,,,CHEMBL615757,,BAO_0000019,,51.0,,,H,908.0,14165.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL615758,,BAO_0000357,,51.0,,,H,909.0,5732.0,1.0,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,
,8.0,,B,,,,CHEMBL615759,,BAO_0000357,,51.0,,,H,910.0,13366.0,1.0,,Expert,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,
,8.0,,B,,,,CHEMBL615760,,BAO_0000357,,51.0,,,H,911.0,17626.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL615761,,BAO_0000219,HeLa,51.0,,,H,912.0,6588.0,1.0,308.0,Expert,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,
,8.0,,B,,,,CHEMBL872104,,BAO_0000357,,51.0,,,H,913.0,16209.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,
,8.0,,B,,,,CHEMBL615762,,BAO_0000357,,51.0,,,H,914.0,15463.0,1.0,,Autocuration,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL615763,,BAO_0000357,,51.0,,,H,915.0,15463.0,1.0,,Autocuration,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL615764,,BAO_0000357,,51.0,,,H,916.0,14770.0,1.0,,Autocuration,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,
,8.0,,B,,,,CHEMBL615765,,BAO_0000219,Cell line,51.0,,,H,917.0,16245.0,1.0,1167.0,Autocuration,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),
,8.0,,B,,,,CHEMBL615766,,BAO_0000019,,51.0,,,H,918.0,16245.0,1.0,,Autocuration,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),
,8.0,,B,,,,CHEMBL615767,,BAO_0000357,,51.0,,,H,919.0,5548.0,1.0,,Autocuration,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL615768,,BAO_0000357,,51.0,,,H,920.0,5548.0,1.0,,Expert,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL615769,,BAO_0000357,,51.0,,,H,921.0,5548.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL615770,,BAO_0000357,,51.0,,,H,922.0,6876.0,1.0,,Expert,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,
,8.0,,B,,,,CHEMBL615771,,BAO_0000357,,51.0,,,H,923.0,2598.0,1.0,,Autocuration,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL615772,,BAO_0000357,,51.0,,,H,924.0,17785.0,1.0,,Expert,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,
,8.0,,B,,,,CHEMBL615773,,BAO_0000357,,51.0,,,H,925.0,6013.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL615774,,BAO_0000357,,51.0,,,H,926.0,5929.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL615775,,BAO_0000357,,51.0,,,H,927.0,16633.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL615776,,BAO_0000357,,51.0,,,H,928.0,1558.0,1.0,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,
,8.0,,B,,,,CHEMBL615777,,BAO_0000357,,51.0,,,H,929.0,16026.0,1.0,,Expert,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL615778,,BAO_0000219,,51.0,,,H,930.0,12469.0,1.0,,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,
9606.0,9.0,,B,,,,CHEMBL615779,,BAO_0000357,,51.0,,,D,931.0,15874.0,1.0,,Expert,Homo sapiens,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,
,8.0,,B,,,,CHEMBL615780,,BAO_0000357,,51.0,,,H,932.0,15874.0,1.0,,Autocuration,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,
,8.0,,B,,,,CHEMBL616298,,BAO_0000357,,51.0,,,H,933.0,3935.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616299,,BAO_0000357,,51.0,,,H,934.0,15818.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616300,,BAO_0000219,CHO-K1,51.0,,,H,935.0,13706.0,1.0,485.0,Autocuration,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,
,8.0,,F,,,,CHEMBL616301,,BAO_0000219,CHO-K1,51.0,,,H,936.0,13729.0,1.0,485.0,Expert,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,
,8.0,,B,,,,CHEMBL616302,,BAO_0000019,,51.0,,,H,937.0,15413.0,1.0,,Autocuration,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616117,,BAO_0000019,,51.0,,,H,938.0,15413.0,1.0,,Autocuration,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),
,8.0,,B,,,,CHEMBL616118,,BAO_0000019,,51.0,,,H,939.0,15413.0,1.0,,Autocuration,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),
,8.0,,B,,,,CHEMBL616119,,BAO_0000019,,51.0,,,H,940.0,15413.0,1.0,,Autocuration,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,
9606.0,9.0,,B,,,,CHEMBL616120,,BAO_0000219,HeLa,51.0,,,D,941.0,3445.0,1.0,308.0,Expert,Homo sapiens,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,
,8.0,,B,,,,CHEMBL616121,,BAO_0000357,,51.0,,,H,942.0,15740.0,1.0,,Autocuration,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616122,,BAO_0000357,,51.0,,,H,943.0,15740.0,1.0,,Autocuration,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,
,8.0,,B,,,,CHEMBL616123,,BAO_0000357,,51.0,,,H,944.0,17626.0,1.0,,Autocuration,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,
9606.0,9.0,,B,,,,CHEMBL616124,,BAO_0000357,,51.0,,,D,945.0,4234.0,1.0,,Expert,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616125,,BAO_0000357,,51.0,,,H,946.0,5640.0,1.0,,Expert,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,
10116.0,8.0,,B,,,,CHEMBL616126,,BAO_0000357,,51.0,,,H,947.0,5272.0,1.0,,Expert,Rattus norvegicus,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,
,8.0,,B,,,,CHEMBL616127,,BAO_0000219,CHO,51.0,,,H,948.0,4622.0,1.0,449.0,Autocuration,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL616128,,BAO_0000019,,51.0,,,H,949.0,17085.0,1.0,,Expert,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616129,,BAO_0000357,,51.0,,,H,950.0,3025.0,1.0,,Autocuration,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,
,8.0,,B,,,,CHEMBL616130,,BAO_0000357,,51.0,,,H,951.0,15315.0,1.0,,Expert,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616131,,BAO_0000357,,51.0,,,H,952.0,15267.0,1.0,,Autocuration,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,
,8.0,,B,,,,CHEMBL616132,,BAO_0000219,HeLa,51.0,,,H,953.0,17158.0,1.0,308.0,Autocuration,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,
9606.0,9.0,,B,,,,CHEMBL616133,,BAO_0000219,HeLa,51.0,,,D,954.0,14214.0,1.0,308.0,Expert,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,
,8.0,,B,,,,CHEMBL616134,,BAO_0000357,,51.0,,,H,955.0,17133.0,1.0,,Autocuration,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL616135,,BAO_0000357,,51.0,,,H,956.0,16532.0,1.0,,Autocuration,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,
9606.0,9.0,,B,,,,CHEMBL616136,,BAO_0000357,,51.0,,,D,957.0,2391.0,1.0,,Expert,Homo sapiens,Affinity for 5-hydroxytryptamine 1A receptor subtype,
,8.0,,B,,,,CHEMBL616137,,BAO_0000019,,51.0,,,H,958.0,14447.0,1.0,,Autocuration,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,
,8.0,,B,,,,CHEMBL872105,,BAO_0000019,,51.0,,,H,959.0,14447.0,1.0,,Autocuration,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,
,8.0,,B,,,,CHEMBL616138,,BAO_0000357,,51.0,,,H,960.0,15086.0,1.0,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,
9606.0,9.0,,B,,,,CHEMBL616139,,BAO_0000357,,51.0,,,D,961.0,13051.0,1.0,,Expert,Homo sapiens,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,
,8.0,,F,,,,CHEMBL616140,,BAO_0000019,,51.0,,,H,962.0,16026.0,1.0,,Autocuration,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",
,8.0,,B,,,,CHEMBL616141,,BAO_0000019,,51.0,,,H,963.0,17085.0,1.0,,Expert,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,
,8.0,,B,,,,CHEMBL616142,,BAO_0000357,,51.0,,,H,964.0,17133.0,1.0,,Autocuration,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL616143,,BAO_0000357,,51.0,,,H,965.0,17133.0,1.0,,Autocuration,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,
,8.0,,B,,,,CHEMBL616144,,BAO_0000219,HeLa,51.0,,,H,966.0,17211.0,1.0,308.0,Autocuration,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,
,8.0,,B,,,,CHEMBL616145,,BAO_0000219,HeLa,51.0,,,H,967.0,17211.0,1.0,308.0,Autocuration,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,
,8.0,,B,,,,CHEMBL616012,,BAO_0000219,HeLa,51.0,,,H,968.0,17211.0,1.0,308.0,Autocuration,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,
,8.0,,B,,,,CHEMBL616013,,BAO_0000219,HeLa,51.0,,,H,969.0,17211.0,1.0,308.0,Autocuration,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,
,8.0,,F,,,,CHEMBL616014,,BAO_0000019,,51.0,,,H,970.0,16394.0,1.0,,Autocuration,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",
,8.0,,F,,,,CHEMBL616015,,BAO_0000019,,51.0,,,H,971.0,16394.0,1.0,,Autocuration,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",
,8.0,,F,,,,CHEMBL616016,,BAO_0000019,,51.0,,,H,972.0,16394.0,1.0,,Autocuration,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",
,8.0,,F,,,,CHEMBL616017,,BAO_0000218,,51.0,In vivo,,H,973.0,16394.0,1.0,,Autocuration,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,
,8.0,,B,,,,CHEMBL616018,,BAO_0000019,,51.0,,,H,974.0,16394.0,1.0,,Autocuration,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,
,8.0,,F,,,,CHEMBL616019,,BAO_0000019,,51.0,,,H,975.0,15740.0,1.0,,Autocuration,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,
,8.0,,F,,,,CHEMBL616020,,BAO_0000019,,51.0,,,H,976.0,15740.0,1.0,,Autocuration,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,
,8.0,,B,,,,CHEMBL858018,,BAO_0000357,,51.0,,,H,977.0,15740.0,1.0,,Autocuration,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,
,8.0,,F,,,,CHEMBL616021,,BAO_0000219,HEK293,51.0,,,H,978.0,17296.0,1.0,722.0,Autocuration,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,
,8.0,,F,,,,CHEMBL616022,,BAO_0000019,,51.0,,,H,979.0,5640.0,1.0,,Expert,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",
,8.0,,F,,,,CHEMBL616023,,BAO_0000019,,51.0,,,H,980.0,5640.0,1.0,,Autocuration,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",
,8.0,,F,,,,CHEMBL616024,,BAO_0000019,,51.0,,,H,981.0,5640.0,1.0,,Autocuration,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",
,8.0,,F,,,,CHEMBL616025,,BAO_0000019,,51.0,,,H,982.0,5640.0,1.0,,Autocuration,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",
,8.0,,F,,,,CHEMBL616026,,BAO_0000219,CHO,51.0,,,H,983.0,2759.0,1.0,449.0,Autocuration,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,
,8.0,,F,,,,CHEMBL616027,,BAO_0000019,,51.0,,,H,984.0,16394.0,1.0,,Autocuration,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",
9606.0,9.0,,F,,,,CHEMBL616028,,BAO_0000019,,51.0,,,D,985.0,16394.0,1.0,,Expert,Homo sapiens,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",
9606.0,9.0,,F,,,,CHEMBL616029,,BAO_0000019,,51.0,,,D,986.0,3445.0,1.0,,Expert,Homo sapiens,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,
,8.0,,B,,,,CHEMBL616030,,BAO_0000219,CHO,51.0,,,H,987.0,4316.0,1.0,449.0,Expert,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,
,8.0,,B,,,,CHEMBL616031,,BAO_0000019,,51.0,,,H,988.0,4316.0,1.0,,Expert,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,
9606.0,9.0,,F,,,,CHEMBL616032,,BAO_0000019,,51.0,,,D,989.0,15180.0,1.0,,Expert,Homo sapiens,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,
9606.0,9.0,,F,,,,CHEMBL616033,,BAO_0000019,,51.0,,,D,990.0,15180.0,1.0,,Expert,Homo sapiens,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,
,8.0,,F,,,,CHEMBL616034,,BAO_0000019,,51.0,,,H,991.0,15042.0,1.0,,Autocuration,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,
,8.0,,F,,,,CHEMBL616035,,BAO_0000019,,51.0,,,H,992.0,15042.0,1.0,,Autocuration,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,
,8.0,,F,,,,CHEMBL616036,,BAO_0000019,,51.0,,,H,993.0,15042.0,1.0,,Autocuration,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,
,8.0,,F,,,,CHEMBL616037,,BAO_0000019,,51.0,,,H,994.0,15042.0,1.0,,Autocuration,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,
,8.0,,F,,,,CHEMBL616038,,BAO_0000019,,51.0,,,H,995.0,15042.0,1.0,,Autocuration,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,
,8.0,,F,,,,CHEMBL616039,,BAO_0000019,,51.0,,,H,996.0,15042.0,1.0,,Autocuration,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,
,8.0,,F,,,,CHEMBL616040,,BAO_0000019,,51.0,,,H,997.0,15042.0,1.0,,Autocuration,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,
9606.0,9.0,,F,,,,CHEMBL616041,,BAO_0000219,HeLa,51.0,,,D,998.0,15180.0,1.0,308.0,Expert,Homo sapiens,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,
9606.0,9.0,,F,,,,CHEMBL616042,,BAO_0000219,HeLa,51.0,,,D,999.0,15180.0,1.0,308.0,Expert,Homo sapiens,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,
9606.0,9.0,,F,,,,CHEMBL616043,,BAO_0000219,HeLa,51.0,,,D,1000.0,15180.0,1.0,308.0,Expert,Homo sapiens,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,
,8.0,,F,,,,CHEMBL616044,,BAO_0000019,,51.0,,,H,1001.0,16245.0,1.0,,Autocuration,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",
,8.0,,F,,,,CHEMBL616045,,BAO_0000019,,51.0,,,H,1002.0,16026.0,1.0,,Autocuration,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",
,8.0,,F,,,,CHEMBL616046,,BAO_0000219,HEK293,51.0,,,H,1003.0,17296.0,1.0,722.0,Autocuration,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,
,8.0,,F,,,,CHEMBL616047,,BAO_0000219,CHO,51.0,,,H,1004.0,2759.0,1.0,449.0,Autocuration,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),
,8.0,,F,,,,CHEMBL616048,,BAO_0000219,CHO,51.0,,,H,1005.0,2759.0,1.0,449.0,Autocuration,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,
9606.0,9.0,,F,,,,CHEMBL616049,,BAO_0000219,CHO,51.0,,,D,1006.0,2759.0,1.0,449.0,Expert,Homo sapiens,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),
,8.0,,F,,,,CHEMBL616050,,BAO_0000219,CHO,51.0,,,H,1007.0,2759.0,1.0,449.0,Autocuration,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),
,8.0,,F,,,,CHEMBL616051,,BAO_0000219,,51.0,,,H,1008.0,15419.0,1.0,,Expert,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,
,8.0,,F,,,,CHEMBL616212,,BAO_0000219,,51.0,,,H,1009.0,15419.0,1.0,,Autocuration,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,
,8.0,,F,,,,CHEMBL616213,,BAO_0000019,,51.0,,,H,1010.0,16026.0,1.0,,Autocuration,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",
,8.0,,B,,,,CHEMBL616214,,BAO_0000219,,51.0,In vitro,,H,1011.0,1414.0,1.0,,Expert,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,
,8.0,,B,,,,CHEMBL616215,,BAO_0000219,,51.0,In vitro,,H,1012.0,1414.0,1.0,,Expert,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,
,8.0,,B,,,,CHEMBL616216,,BAO_0000357,,51.0,,,H,1013.0,12861.0,1.0,,Autocuration,,Binding activity radioligand.,
,8.0,,B,,,,CHEMBL616217,,BAO_0000019,,51.0,,,H,1014.0,12861.0,1.0,,Autocuration,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,
,8.0,,B,,,,CHEMBL616218,,BAO_0000357,,51.0,,,H,1015.0,5104.0,1.0,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616219,,BAO_0000357,,51.0,,,H,1016.0,5105.0,1.0,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616220,,BAO_0000357,,51.0,,,H,1017.0,16312.0,1.0,,Autocuration,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,
9606.0,9.0,,B,,,,CHEMBL833493,,BAO_0000357,,51.0,,,D,1018.0,15180.0,1.0,,Expert,Homo sapiens,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616221,,BAO_0000357,,51.0,,,H,1019.0,5033.0,1.0,,Autocuration,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,
9606.0,9.0,,B,,,,CHEMBL616222,,BAO_0000219,CHO,51.0,,,D,1020.0,16909.0,1.0,449.0,Expert,Homo sapiens,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,
,8.0,,F,,,,CHEMBL616223,,BAO_0000019,,51.0,,,H,1021.0,2590.0,1.0,,Autocuration,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,
,8.0,,F,,,,CHEMBL616224,,BAO_0000019,,51.0,,,H,1022.0,2590.0,1.0,,Autocuration,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,
,8.0,,B,,,,CHEMBL616225,,BAO_0000019,,51.0,,,H,1023.0,16394.0,1.0,,Expert,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,
9606.0,9.0,,B,,,,CHEMBL616226,,BAO_0000219,HEK293,51.0,,,D,1024.0,4540.0,1.0,722.0,Expert,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,
,8.0,,B,,,,CHEMBL616227,,BAO_0000219,HEK293,51.0,,,H,1025.0,17296.0,1.0,722.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,
,8.0,,B,,,,CHEMBL616228,,BAO_0000219,HEK293,51.0,,,H,1026.0,17296.0,1.0,722.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL616229,,BAO_0000219,HEK293,51.0,,,H,1027.0,15779.0,1.0,722.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,
,8.0,,B,,,,CHEMBL616230,,BAO_0000219,HEK293,51.0,,,H,1028.0,15779.0,1.0,722.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,
,8.0,,B,,,,CHEMBL616231,,BAO_0000219,HEK293,51.0,,,H,1029.0,15779.0,1.0,722.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,
,8.0,,B,,,,CHEMBL616232,,BAO_0000357,,51.0,,,H,1030.0,6166.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL616233,,BAO_0000219,HEK293,51.0,,,H,1031.0,15779.0,1.0,722.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,
,8.0,,B,,,,CHEMBL857973,,BAO_0000219,HEK293,51.0,,,H,1032.0,4199.0,1.0,722.0,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,
,8.0,,B,,,,CHEMBL616234,,BAO_0000219,,51.0,,,H,1033.0,15316.0,1.0,,Autocuration,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,
,8.0,,B,,,,CHEMBL616235,,BAO_0000357,,51.0,,,H,1034.0,14875.0,1.0,,Autocuration,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616236,,BAO_0000219,HeLa,51.0,,,H,1035.0,14727.0,1.0,308.0,Expert,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,
,8.0,,B,,,,CHEMBL616237,,BAO_0000019,,51.0,,,H,1036.0,14727.0,1.0,,Expert,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,
,8.0,,B,,,,CHEMBL616238,,BAO_0000219,HEK293,51.0,,,H,1037.0,15146.0,1.0,722.0,Autocuration,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,
,8.0,,B,,,,CHEMBL616239,,BAO_0000219,HEK293,51.0,,,H,1038.0,5213.0,1.0,722.0,Autocuration,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,
,8.0,,B,,,,CHEMBL616240,,BAO_0000219,,51.0,,,H,1039.0,16429.0,1.0,,Autocuration,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,
9606.0,9.0,,B,,,,CHEMBL616241,,BAO_0000219,HeLa,51.0,,,D,1040.0,15042.0,1.0,308.0,Expert,Homo sapiens,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,
,8.0,,B,,,,CHEMBL616242,,BAO_0000219,HEK293,51.0,,,H,1041.0,14818.0,1.0,722.0,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,
,8.0,,B,,,,CHEMBL616243,,BAO_0000219,HEK293,51.0,,,H,1042.0,4829.0,1.0,722.0,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",
,9.0,,B,,,,CHEMBL616244,,BAO_0000357,,51.0,,,D,1043.0,17200.0,1.0,,Expert,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,
9606.0,9.0,,B,,,,CHEMBL616245,,BAO_0000357,,51.0,,,D,1044.0,13051.0,1.0,,Autocuration,Homo sapiens,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616246,,BAO_0000357,,106.0,,,H,1045.0,5486.0,1.0,,Autocuration,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,
,8.0,,B,,,,CHEMBL616247,,BAO_0000357,,105.0,,,H,1046.0,5254.0,1.0,,Autocuration,,Binding affinity against 5-HT1D receptor,
,8.0,,B,,,,CHEMBL616248,,BAO_0000357,,105.0,,,H,1047.0,5254.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616249,,BAO_0000357,,107.0,,,H,1048.0,15331.0,1.0,,Autocuration,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,
9606.0,8.0,,B,,,,CHEMBL616250,,BAO_0000357,,10576.0,,,H,1049.0,13506.0,1.0,,Autocuration,Homo sapiens,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,
,8.0,,B,,,,CHEMBL616251,,BAO_0000357,,51.0,,,H,1050.0,15267.0,1.0,,Autocuration,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,
,8.0,,F,,,,CHEMBL616252,,BAO_0000218,,11863.0,In vivo,,H,1051.0,16616.0,1.0,,Autocuration,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,
,8.0,,F,,,,CHEMBL616253,,BAO_0000218,,11863.0,In vivo,,H,1052.0,16616.0,1.0,,Autocuration,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,
,8.0,,F,,,,CHEMBL616254,,BAO_0000218,,11863.0,In vivo,,H,1053.0,16616.0,1.0,,Autocuration,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,
10090.0,9.0,,F,,,,CHEMBL616255,,BAO_0000218,,11863.0,,,D,1054.0,16616.0,1.0,,Expert,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,
10090.0,9.0,,F,,,,CHEMBL832872,,BAO_0000218,,11863.0,,,D,1055.0,16616.0,1.0,,Expert,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,
10090.0,9.0,,F,,,,CHEMBL616256,,BAO_0000218,,11863.0,,,D,1056.0,16616.0,1.0,,Expert,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,
10090.0,9.0,,F,,,,CHEMBL616257,,BAO_0000218,,11863.0,,,D,1057.0,16616.0,1.0,,Expert,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,
10090.0,9.0,,F,,,,CHEMBL616258,,BAO_0000218,,11863.0,,,D,1058.0,16616.0,1.0,,Expert,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,
10090.0,9.0,,F,,,,CHEMBL616384,,BAO_0000218,,11863.0,,,D,1059.0,16616.0,1.0,,Expert,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,
,8.0,,B,,,10000000.0,CHEMBL616385,,BAO_0000221,,11863.0,,,H,1060.0,10297.0,1.0,,Autocuration,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Hippocampus
,8.0,,B,,,,CHEMBL616386,,BAO_0000357,,11863.0,,,H,1061.0,13704.0,1.0,,Expert,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,
10090.0,9.0,,B,,,10000000.0,CHEMBL616387,,BAO_0000221,,11863.0,,,D,1062.0,10297.0,1.0,,Expert,Mus musculus,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616388,,BAO_0000221,,11863.0,,,H,1063.0,10297.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Hippocampus
10090.0,9.0,,B,,,10000000.0,CHEMBL616389,,BAO_0000221,,11863.0,,,D,1064.0,10297.0,1.0,,Expert,Mus musculus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616390,,BAO_0000221,,11863.0,,,H,1065.0,10297.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Hippocampus
,8.0,,B,,,,CHEMBL616391,,BAO_0000357,,11863.0,,,H,1066.0,217.0,1.0,,Autocuration,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,
10090.0,9.0,,B,,,10000000.0,CHEMBL616392,,BAO_0000221,,11863.0,,,D,1067.0,10297.0,1.0,,Expert,Mus musculus,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Hippocampus
9823.0,8.0,,B,,,,CHEMBL616393,,BAO_0000357,,51.0,,,H,1068.0,4921.0,1.0,,Autocuration,Sus scrofa,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,
9823.0,8.0,,B,,,,CHEMBL616394,,BAO_0000357,,51.0,,,H,1069.0,4921.0,1.0,,Autocuration,Sus scrofa,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,
9823.0,8.0,,B,,,,CHEMBL616395,,BAO_0000019,,51.0,,,H,1070.0,4996.0,1.0,,Autocuration,Sus scrofa,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,
9823.0,8.0,,B,,,,CHEMBL616396,,BAO_0000357,,51.0,,,H,1071.0,12918.0,1.0,,Autocuration,Sus scrofa,Compound was evaluated for the binding affinity at 5- HT1A receptor,
9823.0,8.0,,B,,,,CHEMBL872907,,BAO_0000019,,51.0,,,H,1072.0,5333.0,1.0,,Autocuration,Sus scrofa,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,
9823.0,8.0,,B,,,,CHEMBL616397,,BAO_0000019,,51.0,,,H,1073.0,4437.0,1.0,,Autocuration,Sus scrofa,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,
9823.0,8.0,,B,,,,CHEMBL616398,,BAO_0000019,,51.0,,,H,1074.0,1742.0,1.0,,Autocuration,Sus scrofa,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,
9823.0,8.0,,B,,,,CHEMBL616399,,BAO_0000357,,51.0,,,H,1075.0,16688.0,1.0,,Expert,Sus scrofa,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,
9823.0,8.0,,B,,,,CHEMBL857065,,BAO_0000357,,51.0,,,H,1076.0,12861.0,1.0,,Autocuration,Sus scrofa,Binding activity radioligand.,
9823.0,8.0,,B,,,,CHEMBL616400,,BAO_0000019,,51.0,,,H,1077.0,12861.0,1.0,,Expert,Sus scrofa,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,
9823.0,8.0,,B,,,,CHEMBL616401,,BAO_0000019,,51.0,,,H,1078.0,12861.0,1.0,,Autocuration,Sus scrofa,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,
,8.0,,B,,,,CHEMBL616402,,BAO_0000019,,10624.0,,,H,1079.0,12490.0,1.0,,Expert,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,
9823.0,8.0,,B,,,,CHEMBL616403,,BAO_0000019,,51.0,,,H,1080.0,11828.0,1.0,,Expert,Sus scrofa,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,
9823.0,8.0,,B,,,10000000.0,CHEMBL616404,,BAO_0000221,,51.0,,,H,1081.0,11866.0,1.0,,Autocuration,Sus scrofa,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,Hippocampus
9823.0,8.0,,B,,,,CHEMBL616405,,BAO_0000249,,51.0,,,H,1082.0,12827.0,1.0,,Autocuration,Sus scrofa,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,
9823.0,8.0,,B,,,,CHEMBL616406,,BAO_0000019,,51.0,,,H,1083.0,12918.0,1.0,,Autocuration,Sus scrofa,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,
9823.0,8.0,,F,,,,CHEMBL616407,,BAO_0000019,,51.0,,,H,1084.0,12919.0,1.0,,Expert,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,
9986.0,8.0,,B,,,,CHEMBL616408,,BAO_0000019,,51.0,,,H,1085.0,13047.0,1.0,,Autocuration,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,
10116.0,9.0,,B,,,,CHEMBL616409,,BAO_0000249,,10576.0,,,D,1086.0,15796.0,1.0,,Expert,Rattus norvegicus,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,
10116.0,9.0,,B,,,10000000.0,CHEMBL616410,,BAO_0000221,,10576.0,,,D,1087.0,3651.0,1.0,,Expert,Rattus norvegicus,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",Hippocampus
,8.0,,B,,,,CHEMBL616411,,BAO_0000357,,10576.0,,,H,1088.0,188.0,1.0,,Autocuration,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,
10116.0,9.0,,F,,,,CHEMBL616412,,BAO_0000249,,10576.0,,Membranes,D,1089.0,16616.0,1.0,,Expert,Rattus norvegicus,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",
10116.0,9.0,,F,,,10000000.0,CHEMBL616413,,BAO_0000249,,10576.0,,Membranes,D,1090.0,16616.0,1.0,,Expert,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616414,,BAO_0000221,,10576.0,,,H,1091.0,12306.0,1.0,,Autocuration,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus
10116.0,9.0,,B,,,10000000.0,CHEMBL616415,,BAO_0000221,,10576.0,,,D,1092.0,17167.0,1.0,,Expert,Rattus norvegicus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,Hippocampus
,8.0,,B,,,,CHEMBL616416,,BAO_0000019,,10576.0,,,H,1093.0,14776.0,1.0,,Autocuration,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,
,8.0,,B,,,,CHEMBL616417,,BAO_0000357,,10576.0,,,H,1094.0,12158.0,1.0,,Expert,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,
,8.0,,B,,,,CHEMBL616418,,BAO_0000357,,10576.0,,,H,1095.0,13481.0,1.0,,Autocuration,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,
,8.0,,B,,,,CHEMBL616419,,BAO_0000219,,10576.0,In vitro,,H,1096.0,13427.0,1.0,,Autocuration,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,
,8.0,,B,,,,CHEMBL616420,,BAO_0000357,,10576.0,,,H,1097.0,10210.0,1.0,,Autocuration,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,
,8.0,,B,,,,CHEMBL616421,,BAO_0000249,,10576.0,,Membranes,H,1098.0,10205.0,1.0,,Autocuration,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,
,8.0,,B,,,,CHEMBL616422,,BAO_0000249,,10576.0,,Membranes,H,1099.0,10205.0,1.0,,Autocuration,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,
,8.0,,B,,,,CHEMBL616423,,BAO_0000249,,10576.0,,Membranes,H,1100.0,10205.0,1.0,,Expert,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,
10116.0,9.0,,B,,,,CHEMBL616424,,BAO_0000357,,10576.0,,,D,1101.0,12280.0,1.0,,Expert,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,
,8.0,,B,,,,CHEMBL616425,,BAO_0000357,,10576.0,,,H,1102.0,17386.0,1.0,,Expert,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616426,,BAO_0000357,,10576.0,,,H,1103.0,13654.0,1.0,,Expert,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,
,8.0,,B,,,10000000.0,CHEMBL616427,,BAO_0000221,,10576.0,,,H,1104.0,14423.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616428,,BAO_0000221,,10576.0,,,H,1105.0,15412.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616290,,BAO_0000221,,10576.0,,,H,1106.0,12073.0,1.0,,Autocuration,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus
10116.0,9.0,,B,,,,CHEMBL616052,,BAO_0000357,,10576.0,,,D,1107.0,4101.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616053,,BAO_0000357,,10576.0,,,H,1108.0,10062.0,1.0,,Autocuration,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616054,,BAO_0000249,,10576.0,,,H,1109.0,6238.0,1.0,,Autocuration,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL616055,,BAO_0000357,,10576.0,,,H,1110.0,16273.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616056,,BAO_0000357,,10576.0,,,H,1111.0,11139.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,
,8.0,,B,,,,CHEMBL616057,,BAO_0000019,,10576.0,,,H,1112.0,16796.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,
10116.0,9.0,,B,,,955.0,CHEMBL616058,,BAO_0000221,,10576.0,,,D,1113.0,9548.0,1.0,,Expert,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Brain
,8.0,,B,,,955.0,CHEMBL616059,,BAO_0000221,,10576.0,,,H,1114.0,10381.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Brain
,8.0,,B,,,,CHEMBL616060,,BAO_0000249,,10576.0,,,H,1115.0,13408.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,
10116.0,9.0,,B,,,10000000.0,CHEMBL616061,,BAO_0000221,,10576.0,,,D,1116.0,13825.0,1.0,,Expert,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616062,,BAO_0000221,,10576.0,,,H,1117.0,11147.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,Hippocampus
,8.0,,B,,,,CHEMBL616063,,BAO_0000249,,10576.0,,,H,1118.0,10552.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,2435.0,CHEMBL616064,,BAO_0000249,,10576.0,,,H,1119.0,10552.0,1.0,,Autocuration,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Striatum
10116.0,9.0,,B,,,,CHEMBL616065,,BAO_0000249,,10576.0,,Membranes,D,1120.0,17136.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,
10116.0,9.0,,B,,,,CHEMBL616066,,BAO_0000249,,10576.0,,Membranes,D,1121.0,5778.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,
,8.0,,B,,,10000000.0,CHEMBL616067,,BAO_0000221,,10576.0,,,H,1122.0,13481.0,1.0,,Autocuration,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616068,,BAO_0000221,,10576.0,,,H,1123.0,13481.0,1.0,,Autocuration,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616069,,BAO_0000221,,10576.0,,,H,1124.0,13630.0,1.0,,Intermediate,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,Hippocampus
,8.0,,B,,,,CHEMBL616070,,BAO_0000249,,10576.0,,,H,1125.0,16245.0,1.0,,Expert,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,
,8.0,,B,,,10000000.0,CHEMBL616071,,BAO_0000221,,10576.0,,,H,1126.0,14509.0,1.0,,Autocuration,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616072,,BAO_0000221,,10576.0,,,H,1127.0,14509.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616073,,BAO_0000221,,10576.0,,,H,1128.0,14509.0,1.0,,Autocuration,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616074,,BAO_0000221,,10576.0,,,H,1129.0,14509.0,1.0,,Autocuration,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,Hippocampus
,8.0,,B,,,,CHEMBL616075,,BAO_0000019,,10576.0,,,H,1130.0,14256.0,1.0,,Expert,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,
,8.0,,B,,,,CHEMBL616076,,BAO_0000357,,10576.0,,,H,1131.0,11139.0,1.0,,Autocuration,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,
10116.0,9.0,,B,,,,CHEMBL616077,,BAO_0000019,,10576.0,,,D,1132.0,11047.0,1.0,,Expert,Rattus norvegicus,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,
10116.0,9.0,,B,,,,CHEMBL616078,,BAO_0000019,,10576.0,,,D,1133.0,11047.0,1.0,,Expert,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,
10116.0,9.0,,B,,,,CHEMBL616079,,BAO_0000019,,10576.0,,,D,1134.0,11047.0,1.0,,Expert,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,
10116.0,9.0,,B,,,,CHEMBL616080,,BAO_0000219,CHO-K1,10576.0,,,D,1135.0,2395.0,1.0,485.0,Expert,Rattus norvegicus,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,
,8.0,,B,,,,CHEMBL616081,,BAO_0000357,,10576.0,,,H,1136.0,9699.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor,
10116.0,9.0,,B,,,10000000.0,CHEMBL616082,,BAO_0000221,,10576.0,,,D,1137.0,12028.0,1.0,,Expert,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616083,,BAO_0000221,,10576.0,,,H,1138.0,12028.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,Hippocampus
,8.0,,B,,,,CHEMBL616084,,BAO_0000019,,10576.0,,,H,1139.0,5815.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,
,8.0,,B,,,,CHEMBL616085,,BAO_0000019,,10576.0,,,H,1140.0,16616.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,
,8.0,,B,,,,CHEMBL616086,,BAO_0000019,,10576.0,,,H,1141.0,5815.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,
,8.0,,B,,,10000000.0,CHEMBL616087,,BAO_0000221,,10576.0,,,H,1142.0,2761.0,1.0,,Autocuration,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",Hippocampus
,8.0,,B,,,,CHEMBL616088,,BAO_0000357,,10576.0,,,H,1143.0,13133.0,1.0,,Expert,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,
,8.0,,B,,,,CHEMBL616089,,BAO_0000019,,10576.0,,,H,1144.0,10444.0,1.0,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,
10116.0,9.0,,B,,,,CHEMBL616090,,BAO_0000357,,10576.0,,,D,1145.0,13278.0,1.0,,Expert,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,
,8.0,,B,,,,CHEMBL616091,,BAO_0000357,,10576.0,,,H,1146.0,15874.0,1.0,,Autocuration,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,
,8.0,,B,,,2435.0,CHEMBL616092,,BAO_0000249,,10576.0,,Membranes,H,1147.0,10552.0,1.0,,Autocuration,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Striatum
,8.0,,B,,,,CHEMBL616093,,BAO_0000357,,10576.0,,,H,1148.0,11130.0,1.0,,Autocuration,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),
,8.0,,B,,,,CHEMBL616094,,BAO_0000218,,10576.0,In vivo,,H,1149.0,11130.0,1.0,,Autocuration,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),
,8.0,,B,,,955.0,CHEMBL616095,,BAO_0000221,,10576.0,,,H,1150.0,14542.0,1.0,,Autocuration,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,Brain
10116.0,9.0,,B,,,,CHEMBL616096,,BAO_0000357,,10576.0,,,D,1151.0,13670.0,1.0,,Expert,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616097,,BAO_0000249,,10576.0,,,H,1152.0,9888.0,1.0,,Expert,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,
10116.0,9.0,,B,,,,CHEMBL616098,,BAO_0000249,,10576.0,,Membranes,D,1153.0,3678.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,
,8.0,,B,,,10000000.0,CHEMBL616099,,BAO_0000221,,10576.0,,,H,1154.0,11332.0,1.0,,Autocuration,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616100,,BAO_0000221,,10576.0,,,H,1155.0,11332.0,1.0,,Autocuration,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus
,8.0,,B,,,,CHEMBL616101,,BAO_0000357,,10576.0,,,H,1156.0,1185.0,1.0,,Expert,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616102,,BAO_0000249,,10576.0,,,H,1157.0,2014.0,1.0,,Expert,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,
,8.0,,B,,,,CHEMBL616103,,BAO_0000357,,10576.0,,,H,1158.0,1185.0,1.0,,Autocuration,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616104,,BAO_0000019,,10576.0,,,H,1159.0,14429.0,1.0,,Expert,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,
,8.0,,B,,,,CHEMBL616105,,BAO_0000019,,10576.0,,,H,1160.0,16288.0,1.0,,Expert,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",
10116.0,9.0,,B,,,,CHEMBL616106,,BAO_0000019,,10576.0,,,D,1161.0,5432.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616107,,BAO_0000019,,10576.0,,,H,1162.0,14429.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,
,8.0,,B,,,,CHEMBL616108,,BAO_0000357,,10576.0,,,H,1163.0,13672.0,1.0,,Expert,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,
,8.0,,B,,,10000000.0,CHEMBL616109,,BAO_0000221,,10576.0,,,H,1164.0,11296.0,1.0,,Expert,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Hippocampus
,8.0,,B,,,,CHEMBL616110,,BAO_0000357,,10576.0,,,H,1165.0,11296.0,1.0,,Autocuration,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,
,8.0,,B,,,,CHEMBL616111,,BAO_0000219,CHO,10576.0,,,H,1166.0,14749.0,1.0,449.0,Expert,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,
,8.0,,B,,,,CHEMBL616112,,BAO_0000019,,10576.0,,,H,1167.0,15086.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,
,8.0,,B,,,10000000.0,CHEMBL616113,,BAO_0000221,,10576.0,,,H,1168.0,13462.0,1.0,,Autocuration,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,Hippocampus
,8.0,,B,,,,CHEMBL616114,,BAO_0000019,,10576.0,,,H,1169.0,15363.0,1.0,,Autocuration,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616115,,BAO_0000019,,10576.0,,,H,1170.0,15363.0,1.0,,Autocuration,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616116,,BAO_0000357,,10576.0,,,H,1171.0,10796.0,1.0,,Autocuration,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,955.0,CHEMBL615844,,BAO_0000221,,10576.0,,,H,1172.0,12816.0,1.0,,Expert,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,Brain
,8.0,,B,,,10000000.0,CHEMBL615939,,BAO_0000221,,10576.0,,,H,1173.0,13542.0,1.0,,Expert,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus
,8.0,,B,,,,CHEMBL615940,,BAO_0000019,,10576.0,,,H,1174.0,13308.0,1.0,,Expert,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,
,8.0,,B,,,10000000.0,CHEMBL615941,,BAO_0000221,,10576.0,,,H,1175.0,13541.0,1.0,,Expert,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615942,,BAO_0000221,,10576.0,,,H,1176.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615943,,BAO_0000221,,10576.0,,,H,1177.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615944,,BAO_0000221,,10576.0,,,H,1178.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615945,,BAO_0000221,,10576.0,,,H,1179.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615946,,BAO_0000221,,10576.0,,,H,1180.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615947,,BAO_0000221,,10576.0,,,H,1181.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615948,,BAO_0000221,,10576.0,,,H,1182.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615949,,BAO_0000221,,10576.0,,,H,1183.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615950,,BAO_0000221,,10576.0,,,H,1184.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615951,,BAO_0000221,,10576.0,,,H,1185.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615952,,BAO_0000221,,10576.0,,,H,1186.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615953,,BAO_0000221,,10576.0,,,H,1187.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615954,,BAO_0000221,,10576.0,,,H,1188.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,Hippocampus
10116.0,9.0,,B,,,10000000.0,CHEMBL615955,,BAO_0000221,,10576.0,,,D,1189.0,10058.0,1.0,,Expert,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615956,,BAO_0000221,,10576.0,,,H,1190.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL615957,,BAO_0000221,,10576.0,,,H,1191.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,Hippocampus
,8.0,,B,,,,CHEMBL615958,,BAO_0000019,,10576.0,,,H,1192.0,12879.0,1.0,,Expert,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,
,8.0,,B,,,,CHEMBL615959,,BAO_0000019,,10576.0,,,H,1193.0,11964.0,1.0,,Expert,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,
,8.0,,B,,,,CHEMBL615960,,BAO_0000019,,10576.0,,,H,1194.0,11964.0,1.0,,Autocuration,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),
,8.0,,B,,,,CHEMBL615961,,BAO_0000019,,10576.0,,,H,1195.0,11964.0,1.0,,Autocuration,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),
,8.0,,B,,,955.0,CHEMBL615962,,BAO_0000221,,10576.0,,,H,1196.0,9548.0,1.0,,Expert,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Brain
,8.0,,B,,,,CHEMBL615963,,BAO_0000019,,10576.0,,,H,1197.0,9098.0,1.0,,Expert,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,
,8.0,,B,,,,CHEMBL615964,,BAO_0000019,,10576.0,,,H,1198.0,9098.0,1.0,,Autocuration,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,
,8.0,,B,,,,CHEMBL615965,,BAO_0000019,,10576.0,,,H,1199.0,9098.0,1.0,,Autocuration,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,
,8.0,,B,,,,CHEMBL615966,,BAO_0000219,CHO,10576.0,,,H,1200.0,13248.0,1.0,449.0,Expert,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,
,8.0,,B,,,,CHEMBL615967,,BAO_0000249,,10576.0,,,H,1201.0,3147.0,1.0,,Expert,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,
,8.0,,B,,,,CHEMBL615968,,BAO_0000019,,10576.0,,,H,1202.0,13949.0,1.0,,Expert,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,
,8.0,,B,,,,CHEMBL615969,,BAO_0000218,CHO,10576.0,,,H,1203.0,11883.0,1.0,449.0,Autocuration,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),
,8.0,,B,,,,CHEMBL615970,,BAO_0000218,,10576.0,,,H,1204.0,11883.0,1.0,,Autocuration,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),
10116.0,9.0,,B,,,,CHEMBL615971,,BAO_0000357,,10576.0,,,D,1205.0,11883.0,1.0,,Expert,Rattus norvegicus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,
,8.0,,B,,,,CHEMBL615972,,BAO_0000249,,10576.0,,Membranes,H,1206.0,15535.0,1.0,,Expert,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,
,8.0,,B,,,,CHEMBL615973,,BAO_0000249,,10576.0,,,H,1207.0,15535.0,1.0,,Autocuration,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,
,8.0,,B,,,,CHEMBL615974,,BAO_0000249,,10576.0,,,H,1208.0,15535.0,1.0,,Autocuration,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,
9606.0,9.0,,B,,,,CHEMBL615975,,BAO_0000219,CHO,51.0,,,D,1209.0,16372.0,1.0,449.0,Expert,Homo sapiens,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,
,8.0,,B,,,,CHEMBL615976,,BAO_0000249,,10576.0,,,H,1210.0,14608.0,1.0,,Expert,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,
10116.0,9.0,,B,,,10000000.0,CHEMBL872106,,BAO_0000221,,10576.0,,,D,1211.0,4795.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,Hippocampus
,8.0,,B,,,,CHEMBL615977,,BAO_0000357,,10576.0,,,H,1212.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL615978,,BAO_0000357,,10576.0,,,H,1213.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,
,8.0,,B,,,,CHEMBL616166,,BAO_0000357,,10576.0,,,H,1214.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,
,8.0,,B,,,,CHEMBL616167,,BAO_0000357,,10576.0,,,H,1215.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,
,8.0,,B,,,,CHEMBL616168,,BAO_0000357,,10576.0,,,H,1216.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,
,8.0,,B,,,,CHEMBL616169,,BAO_0000357,,10576.0,,,H,1217.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,
,8.0,,B,,,,CHEMBL616170,,BAO_0000357,,10576.0,,,H,1218.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,
,8.0,,B,,,,CHEMBL616171,,BAO_0000357,,10576.0,,,H,1219.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,
,8.0,,B,,,,CHEMBL616172,,BAO_0000357,,10576.0,,,H,1220.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,
,8.0,,B,,,,CHEMBL616173,,BAO_0000357,,10576.0,,,H,1221.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,
,8.0,,B,,,,CHEMBL616174,,BAO_0000357,,10576.0,,,H,1222.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,
,8.0,,B,,,,CHEMBL616175,,BAO_0000357,,10576.0,,,H,1223.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,
,8.0,,B,,,,CHEMBL616176,,BAO_0000357,,10576.0,,,H,1224.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,
,8.0,,B,,,,CHEMBL616177,,BAO_0000357,,10576.0,,,H,1225.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,
,8.0,,B,,,,CHEMBL616178,,BAO_0000357,,10576.0,,,H,1226.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,
,8.0,,B,,,,CHEMBL616179,,BAO_0000019,,10576.0,,,H,1227.0,9742.0,1.0,,Autocuration,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,
,8.0,,B,,,,CHEMBL616180,,BAO_0000357,,10576.0,,,H,1228.0,12073.0,1.0,,Autocuration,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616181,,BAO_0000357,,10576.0,,,H,1229.0,4101.0,1.0,,Autocuration,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,
,8.0,,B,,,,CHEMBL616182,,BAO_0000019,,10576.0,,,H,1230.0,15360.0,1.0,,Autocuration,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,
,8.0,,B,,,10000000.0,CHEMBL616183,,BAO_0000221,,10576.0,,,H,1231.0,11576.0,1.0,,Autocuration,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus
,8.0,,B,,,,CHEMBL615874,,BAO_0000019,,10576.0,,,H,1232.0,5834.0,1.0,,Expert,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,
10116.0,9.0,,B,,,,CHEMBL615875,,BAO_0000219,CHO-K1,10576.0,,,D,1233.0,2395.0,1.0,485.0,Expert,Rattus norvegicus,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,
,8.0,,B,,,,CHEMBL615876,,BAO_0000019,,10576.0,,,H,1234.0,1375.0,1.0,,Autocuration,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,
,8.0,,B,,,,CHEMBL615877,,BAO_0000019,,10576.0,,,H,1235.0,1375.0,1.0,,Autocuration,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,
,8.0,,B,,,,CHEMBL615878,,BAO_0000357,,10576.0,,,H,1236.0,3967.0,1.0,,Autocuration,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),
,8.0,,B,,,,CHEMBL615879,,BAO_0000357,,10576.0,,,H,1237.0,12884.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,
,8.0,,B,,,,CHEMBL615880,,BAO_0000357,,10576.0,,,H,1238.0,2343.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,
,8.0,,B,,,,CHEMBL615881,,BAO_0000019,,10576.0,,,H,1239.0,11511.0,1.0,,Autocuration,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",
10116.0,9.0,,B,,,,CHEMBL615882,,BAO_0000019,,10576.0,,,D,1240.0,11511.0,1.0,,Expert,Rattus norvegicus,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",
,8.0,,F,,,,CHEMBL615883,,BAO_0000218,,10576.0,In vivo,,H,1241.0,16394.0,1.0,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,
,8.0,,F,,,,CHEMBL615884,,BAO_0000218,,10576.0,In vivo,,H,1242.0,16394.0,1.0,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),
,8.0,,F,,,,CHEMBL615885,,BAO_0000218,,10576.0,In vivo,,H,1243.0,16394.0,1.0,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),
,8.0,,F,,,,CHEMBL615886,,BAO_0000218,,10576.0,In vivo,,H,1244.0,16394.0,1.0,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),
,8.0,,F,,,,CHEMBL615887,,BAO_0000218,,10576.0,In vivo,,H,1245.0,16394.0,1.0,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),
,8.0,,F,,,,CHEMBL615888,,BAO_0000218,,10576.0,In vivo,,H,1246.0,16394.0,1.0,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),
,8.0,,F,,,,CHEMBL615889,,BAO_0000218,,10576.0,In vivo,,H,1247.0,16394.0,1.0,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),
,8.0,,F,,,,CHEMBL615890,,BAO_0000218,,10576.0,In vivo,,H,1248.0,16394.0,1.0,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),
,8.0,,F,,,,CHEMBL615891,,BAO_0000218,,10576.0,In vivo,,H,1249.0,16394.0,1.0,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),
,8.0,,F,,,,CHEMBL615892,,BAO_0000218,,10576.0,In vivo,,H,1250.0,16394.0,1.0,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),
,8.0,,F,,,,CHEMBL615893,,BAO_0000218,,10576.0,In vivo,,H,1251.0,16394.0,1.0,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),
,8.0,,F,,,,CHEMBL615894,,BAO_0000218,,10576.0,In vivo,,H,1252.0,16394.0,1.0,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),
,8.0,,F,,,,CHEMBL615895,,BAO_0000218,,10576.0,In vivo,,H,1253.0,16394.0,1.0,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),
,8.0,,F,,,,CHEMBL615896,,BAO_0000218,,10576.0,In vivo,,H,1254.0,16394.0,1.0,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),
,8.0,,F,,,,CHEMBL615897,,BAO_0000218,,10576.0,In vivo,,H,1255.0,16394.0,1.0,,Autocuration,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,
10116.0,9.0,,F,,,,CHEMBL615898,,BAO_0000249,,10576.0,,Membranes,D,1256.0,16616.0,1.0,,Expert,Rattus norvegicus,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",
,8.0,,B,,,,CHEMBL615899,,BAO_0000019,,10576.0,,,H,1257.0,16796.0,1.0,,Autocuration,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,
,8.0,,B,,,,CHEMBL616291,,BAO_0000019,,10576.0,,,H,1258.0,16796.0,1.0,,Autocuration,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,
,8.0,,B,,,,CHEMBL616292,,BAO_0000357,,10576.0,,,H,1259.0,15629.0,1.0,,Autocuration,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,
,8.0,,F,,,,CHEMBL616293,,BAO_0000249,,10576.0,,,H,1260.0,13241.0,1.0,,Autocuration,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",
,8.0,,B,,,10000000.0,CHEMBL616294,,BAO_0000221,,10576.0,,,H,1261.0,12073.0,1.0,,Expert,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616295,,BAO_0000249,,10576.0,,,H,1262.0,14286.0,1.0,,Autocuration,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,Hippocampus
,8.0,,B,,,955.0,CHEMBL616296,,BAO_0000221,,10576.0,,,H,1263.0,14542.0,1.0,,Autocuration,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,Brain
,8.0,,F,,,,CHEMBL616297,,BAO_0000019,,10576.0,,,H,1264.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,
,8.0,,F,,,,CHEMBL616605,,BAO_0000019,,10576.0,,,H,1265.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,
,8.0,,F,,,,CHEMBL616606,,BAO_0000019,,10576.0,,,H,1266.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,
,8.0,,F,,,,CHEMBL616607,,BAO_0000019,,10576.0,,,H,1267.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,
,8.0,,F,,,,CHEMBL616608,,BAO_0000019,,10576.0,,,H,1268.0,13630.0,1.0,,Expert,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,
,8.0,,F,,,,CHEMBL616609,,BAO_0000019,,10576.0,,,H,1269.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,
10116.0,9.0,,F,,,,CHEMBL616610,,BAO_0000019,,10576.0,,,D,1270.0,13630.0,1.0,,Expert,Rattus norvegicus,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,
,8.0,,F,,,,CHEMBL616611,,BAO_0000019,,10576.0,,,H,1271.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,
,8.0,,F,,,,CHEMBL616612,,BAO_0000019,,10576.0,,,H,1272.0,13630.0,1.0,,Expert,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,
,8.0,,F,,,,CHEMBL616613,,BAO_0000019,,10576.0,,,H,1273.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,
,8.0,,F,,,,CHEMBL616614,,BAO_0000019,,10576.0,,,H,1274.0,13630.0,1.0,,Expert,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,
,8.0,,F,,,,CHEMBL616615,,BAO_0000019,,10576.0,,,H,1275.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,
,8.0,,F,,,,CHEMBL616616,,BAO_0000019,,10576.0,,,H,1276.0,13630.0,1.0,,Expert,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,
,8.0,,F,,,,CHEMBL616617,,BAO_0000019,,10576.0,,,H,1277.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,
,8.0,,F,,,,CHEMBL616618,,BAO_0000019,,10576.0,,,H,1278.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,
,8.0,,F,,,,CHEMBL616619,,BAO_0000019,,10576.0,,,H,1279.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,
,8.0,,F,,,,CHEMBL616620,,BAO_0000019,,10576.0,,,H,1280.0,13630.0,1.0,,Expert,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,
,8.0,,F,,,,CHEMBL616621,,BAO_0000019,,10576.0,,,H,1281.0,13630.0,1.0,,Expert,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,
,8.0,,F,,,,CHEMBL616622,,BAO_0000019,,10576.0,,,H,1282.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,
,8.0,,F,,,,CHEMBL616146,,BAO_0000019,,10576.0,,,H,1283.0,13630.0,1.0,,Expert,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,
,8.0,,F,,,,CHEMBL832873,,BAO_0000019,,10576.0,,,H,1284.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,
,8.0,,F,,,,CHEMBL616147,,BAO_0000019,,10576.0,,,H,1285.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,
,8.0,,F,,,,CHEMBL872872,,BAO_0000019,,10576.0,,,H,1286.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,
,8.0,,F,,,,CHEMBL616148,,BAO_0000019,,10576.0,,,H,1287.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,
,8.0,,B,,,10000000.0,CHEMBL616149,,BAO_0000221,,10576.0,,,H,1288.0,9783.0,1.0,,Autocuration,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616150,,BAO_0000221,,10576.0,,,H,1289.0,9783.0,1.0,,Expert,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,Hippocampus
10116.0,9.0,,B,,,,CHEMBL616151,,BAO_0000249,,10576.0,,Membranes,D,1290.0,14331.0,1.0,,Expert,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,
,8.0,,B,,,10000000.0,CHEMBL872873,,BAO_0000221,,10576.0,,,H,1291.0,15260.0,1.0,,Expert,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616670,,BAO_0000221,,10576.0,,,H,1292.0,15260.0,1.0,,Autocuration,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616671,,BAO_0000221,,10576.0,,,H,1293.0,15260.0,1.0,,Autocuration,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,Hippocampus
10116.0,9.0,,F,,,,CHEMBL884861,,BAO_0000249,,10576.0,,,D,1294.0,16616.0,1.0,,Expert,Rattus norvegicus,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",
,8.0,,B,,,,CHEMBL616672,,BAO_0000357,,10576.0,,,H,1295.0,15629.0,1.0,,Autocuration,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,
,8.0,,B,,,,CHEMBL616673,,BAO_0000019,,10576.0,,,H,1296.0,15086.0,1.0,,Autocuration,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,
,8.0,,F,,,,CHEMBL616674,,BAO_0000019,,10576.0,,,H,1297.0,5717.0,1.0,,Expert,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,
,8.0,,B,,,,CHEMBL616675,,BAO_0000357,,10576.0,,,H,1298.0,12652.0,1.0,,Autocuration,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,
,8.0,,B,,,10000000.0,CHEMBL616676,,BAO_0000221,,10576.0,,,H,1299.0,14608.0,1.0,,Autocuration,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616677,,BAO_0000221,,10576.0,,,H,1300.0,12306.0,1.0,,Autocuration,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616678,,BAO_0000221,,10576.0,,,H,1301.0,12306.0,1.0,,Autocuration,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus
10116.0,9.0,,B,,,,CHEMBL616679,,BAO_0000357,,10576.0,,,D,1302.0,15247.0,1.0,,Expert,Rattus norvegicus,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,10000000.0,CHEMBL616680,,BAO_0000221,,10576.0,,,H,1303.0,17529.0,1.0,,Expert,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616681,,BAO_0000221,,10576.0,,,H,1304.0,14826.0,1.0,,Autocuration,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616682,,BAO_0000221,,10576.0,,,H,1305.0,14826.0,1.0,,Autocuration,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616683,,BAO_0000221,,10576.0,,,H,1306.0,13241.0,1.0,,Autocuration,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616684,,BAO_0000221,,10576.0,,,H,1307.0,14093.0,1.0,,Autocuration,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616685,,BAO_0000221,,10576.0,,,H,1308.0,14093.0,1.0,,Autocuration,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,Hippocampus
,8.0,,B,,,955.0,CHEMBL616686,,BAO_0000221,,10576.0,,,H,1309.0,14442.0,1.0,,Autocuration,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,Brain
,8.0,,B,,,,CHEMBL616687,,BAO_0000357,,10576.0,,,H,1310.0,9919.0,1.0,,Autocuration,,Affinity for 5-hydroxytryptamine 1A receptor site,
,8.0,,B,,,,CHEMBL616688,,BAO_0000357,,10576.0,,,H,1311.0,9919.0,1.0,,Autocuration,,Affinity for 5-hydroxytryptamine 1A receptor site,
,8.0,,B,,,10000000.0,CHEMBL616689,,BAO_0000221,,10576.0,,,H,1312.0,11440.0,1.0,,Autocuration,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,Hippocampus
,8.0,,B,,,,CHEMBL616690,,BAO_0000357,,10576.0,,,H,1313.0,11257.0,1.0,,Autocuration,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,
,8.0,,B,,,,CHEMBL616691,,BAO_0000357,,10576.0,,,H,1314.0,10330.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,
10116.0,9.0,,B,,,10000000.0,CHEMBL616692,,BAO_0000221,,10576.0,,,D,1315.0,17331.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,Hippocampus
,8.0,,B,,,,CHEMBL616693,,BAO_0000249,,10576.0,,,H,1316.0,16567.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,
10116.0,9.0,,B,,,,CHEMBL616694,,BAO_0000019,,10576.0,,,D,1317.0,12058.0,1.0,,Expert,Rattus norvegicus,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",
,8.0,,B,,,10000000.0,CHEMBL616695,,BAO_0000221,,10576.0,,,H,1318.0,9699.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,Hippocampus
,8.0,,B,,,,CHEMBL616696,,BAO_0000357,,10576.0,,,H,1319.0,9547.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,
,8.0,,B,,,,CHEMBL616697,,BAO_0000357,,10576.0,,,H,1320.0,10330.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,
,8.0,,B,,,,CHEMBL616698,,BAO_0000357,,10576.0,,,H,1321.0,14331.0,1.0,,Autocuration,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,
10116.0,9.0,,B,,,,CHEMBL616949,,BAO_0000019,,10576.0,,,D,1322.0,14060.0,1.0,,Expert,Rattus norvegicus,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,10000000.0,CHEMBL616950,,BAO_0000221,,10576.0,,,H,1323.0,14744.0,1.0,,Autocuration,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,Hippocampus
,8.0,,B,,,,CHEMBL832875,,BAO_0000357,,10576.0,,,H,1324.0,13506.0,1.0,,Autocuration,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,
,8.0,,B,,,955.0,CHEMBL616951,,BAO_0000221,,10576.0,,,H,1325.0,10862.0,1.0,,Expert,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Brain
,8.0,,B,,,955.0,CHEMBL616952,,BAO_0000221,,10576.0,,,H,1326.0,10862.0,1.0,,Expert,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Brain
,8.0,,B,,,,CHEMBL616953,,BAO_0000357,,10576.0,,,H,1327.0,10062.0,1.0,,Expert,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,
,8.0,,B,,,,CHEMBL616954,,BAO_0000357,,10576.0,,,H,1328.0,12073.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,
,8.0,,B,,,,CHEMBL616955,,BAO_0000357,,106.0,,,H,1329.0,14875.0,1.0,,Autocuration,,GTPgammaS radioligand binding assay,
,8.0,,B,,,,CHEMBL616956,,BAO_0000357,,106.0,,,H,1330.0,2391.0,1.0,,Autocuration,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,
,8.0,,F,,,,CHEMBL616957,,BAO_0000019,,106.0,,,H,1331.0,2391.0,1.0,,Autocuration,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,
,8.0,,F,,,,CHEMBL616958,,BAO_0000019,,106.0,,,H,1332.0,2391.0,1.0,,Autocuration,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,
,8.0,,B,,,,CHEMBL616959,,BAO_0000357,,106.0,,,H,1333.0,2391.0,1.0,,Autocuration,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616960,,BAO_0000357,,106.0,,,H,1334.0,2391.0,1.0,,Autocuration,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,
,8.0,,F,,,,CHEMBL616961,,BAO_0000019,,106.0,,,H,1335.0,2391.0,1.0,,Autocuration,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,
,8.0,,B,,,,CHEMBL616962,,BAO_0000219,HeLa,106.0,,,H,1336.0,17211.0,1.0,308.0,Expert,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616963,,BAO_0000219,HeLa,106.0,,,H,1337.0,17211.0,1.0,308.0,Autocuration,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,
9606.0,9.0,,B,,,,CHEMBL616524,,BAO_0000357,,106.0,,,D,1338.0,6491.0,1.0,,Expert,Homo sapiens,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,
,8.0,,B,,,,CHEMBL616525,,BAO_0000219,CHO,106.0,,,H,1339.0,16190.0,1.0,449.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL872908,,BAO_0000019,,106.0,,,H,1340.0,14165.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,
,8.0,,B,,,,CHEMBL616526,,BAO_0000019,,106.0,,,H,1341.0,14165.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,
9606.0,9.0,,B,,,,CHEMBL616527,,BAO_0000357,,106.0,,,D,1342.0,4234.0,1.0,,Expert,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616528,,BAO_0000219,,106.0,,,H,1343.0,6328.0,1.0,,Expert,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,
,8.0,,B,,,,CHEMBL616529,,BAO_0000357,,106.0,,,H,1344.0,14770.0,1.0,,Autocuration,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,
,8.0,,B,,,,CHEMBL616530,,BAO_0000357,,106.0,,,H,1345.0,2598.0,1.0,,Autocuration,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,
,8.0,,B,,,,CHEMBL616531,,BAO_0000357,,106.0,,,H,1346.0,6897.0,1.0,,Expert,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616532,,BAO_0000357,,106.0,,,H,1347.0,6897.0,1.0,,Autocuration,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616533,,BAO_0000357,,106.0,,,H,1348.0,6013.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616534,,BAO_0000357,,106.0,,,H,1349.0,5843.0,1.0,,Expert,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616535,,BAO_0000357,,106.0,,,H,1350.0,14454.0,1.0,,Expert,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,
,8.0,,B,,,,CHEMBL616536,,BAO_0000357,,106.0,,,H,1351.0,16209.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,
,8.0,,B,,,,CHEMBL616537,,BAO_0000357,,106.0,,,H,1352.0,3935.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,
,8.0,,F,,,,CHEMBL616538,,BAO_0000219,CHO-K1,106.0,,,H,1353.0,13729.0,1.0,485.0,Expert,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,
,8.0,,F,,,,CHEMBL616539,,BAO_0000019,,106.0,,,H,1354.0,14251.0,1.0,,Expert,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616540,,BAO_0000019,,106.0,,,H,1355.0,17085.0,1.0,,Expert,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616429,,BAO_0000357,,106.0,,,H,1356.0,3025.0,1.0,,Autocuration,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,
,8.0,,B,,,,CHEMBL616430,,BAO_0000357,,106.0,,,H,1357.0,15315.0,1.0,,Expert,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,
9606.0,9.0,,B,,,,CHEMBL616431,,BAO_0000219,,106.0,,,D,1358.0,14214.0,1.0,,Expert,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,
9606.0,9.0,,B,,,,CHEMBL616432,,BAO_0000357,,106.0,,,D,1359.0,3804.0,1.0,,Expert,Homo sapiens,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,
9606.0,9.0,,B,,,,CHEMBL616433,,BAO_0000357,,106.0,,,D,1360.0,2391.0,1.0,,Expert,Homo sapiens,Affinity for 5-hydroxytryptamine 1B receptor subtype,
9606.0,9.0,,B,,,,CHEMBL616434,,BAO_0000357,,106.0,,,D,1361.0,4175.0,1.0,,Expert,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616435,,BAO_0000219,CHO,106.0,,,H,1362.0,17296.0,1.0,449.0,Autocuration,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,
,8.0,,B,,,,CHEMBL616436,,BAO_0000019,,106.0,,,H,1363.0,17085.0,1.0,,Expert,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,
,8.0,,B,,,,CHEMBL616437,,BAO_0000219,HeLa,106.0,,,H,1364.0,17211.0,1.0,308.0,Autocuration,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,
,8.0,,B,,,,CHEMBL616438,,BAO_0000219,HeLa,106.0,,,H,1365.0,17211.0,1.0,308.0,Autocuration,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,
,8.0,,B,,,,CHEMBL616439,,BAO_0000219,HeLa,106.0,,,H,1366.0,17211.0,1.0,308.0,Autocuration,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,
9606.0,9.0,,B,,,,CHEMBL616440,,BAO_0000357,,106.0,,,D,1367.0,15926.0,1.0,,Expert,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,
,8.0,,B,,,,CHEMBL616441,,BAO_0000219,CHO-K1,106.0,,,H,1368.0,16312.0,1.0,485.0,Autocuration,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,
,8.0,,B,,,,CHEMBL616442,,BAO_0000357,,106.0,,,H,1369.0,5843.0,1.0,,Expert,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,
,8.0,,B,,,,CHEMBL616443,,BAO_0000357,,106.0,,,H,1370.0,5843.0,1.0,,Autocuration,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616444,,BAO_0000219,CHO-K1,106.0,,,H,1371.0,16312.0,1.0,485.0,Expert,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,
9606.0,9.0,,B,,,,CHEMBL616445,,BAO_0000357,,106.0,,,D,1372.0,15926.0,1.0,,Expert,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor,
9606.0,9.0,,B,,,,CHEMBL616446,,BAO_0000357,,106.0,,,D,1373.0,15926.0,1.0,,Expert,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor,
9606.0,9.0,,B,,,,CHEMBL616447,,BAO_0000219,CHO,106.0,,,D,1374.0,4540.0,1.0,449.0,Expert,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL616448,,BAO_0000357,,106.0,,,H,1375.0,6166.0,1.0,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,
,8.0,,B,,,,CHEMBL616449,,BAO_0000219,CHO,106.0,,,H,1376.0,17296.0,1.0,449.0,Autocuration,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,
,8.0,,B,,,,CHEMBL616450,,BAO_0000219,CHO,106.0,,,H,1377.0,17296.0,1.0,449.0,Autocuration,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,
,8.0,,B,,,,CHEMBL857974,,BAO_0000219,CHO,106.0,,,H,1378.0,17296.0,1.0,449.0,Autocuration,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,
,8.0,,B,,,,CHEMBL616451,,BAO_0000219,CHO,106.0,,,H,1379.0,15779.0,1.0,449.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL616452,,BAO_0000219,CHO,106.0,,,H,1380.0,15779.0,1.0,449.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL616453,,BAO_0000219,CHO,106.0,,,H,1381.0,15779.0,1.0,449.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,
,8.0,,B,,,,CHEMBL616454,,BAO_0000219,CHO,106.0,,,H,1382.0,4199.0,1.0,449.0,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,
9606.0,9.0,,B,,,,CHEMBL616455,,BAO_0000357,,106.0,,,D,1383.0,14875.0,1.0,,Expert,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616456,,BAO_0000219,CHO,106.0,,,H,1384.0,15146.0,1.0,449.0,Autocuration,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,
,8.0,,B,,,,CHEMBL616457,,BAO_0000357,,106.0,,,H,1385.0,5213.0,1.0,,Autocuration,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,
,8.0,,B,,,,CHEMBL616458,,BAO_0000219,CHO,106.0,,,H,1386.0,14818.0,1.0,449.0,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,
,8.0,,B,,,,CHEMBL616459,,BAO_0000219,CHO,106.0,,,H,1387.0,4829.0,1.0,449.0,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",
,8.0,,F,,,,CHEMBL616460,,BAO_0000019,,106.0,,,H,1388.0,14454.0,1.0,,Expert,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,
,8.0,,F,,,,CHEMBL616461,,BAO_0000019,,106.0,,,H,1389.0,14454.0,1.0,,Expert,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,
,8.0,,F,,,,CHEMBL616462,,BAO_0000219,CHO,106.0,,,H,1390.0,14875.0,1.0,449.0,Autocuration,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",
,8.0,,F,,,,CHEMBL616463,,BAO_0000219,CHO,106.0,,,H,1391.0,14875.0,1.0,449.0,Autocuration,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",
,8.0,,F,,,,CHEMBL616464,,BAO_0000019,,105.0,,,H,1392.0,15250.0,1.0,,Autocuration,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",
,8.0,,B,,,,CHEMBL616465,,BAO_0000219,CHO,105.0,,,H,1393.0,15250.0,1.0,449.0,Autocuration,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,
,8.0,,B,,,,CHEMBL832874,,BAO_0000357,,17105.0,,,H,1394.0,15086.0,1.0,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,
9986.0,8.0,,F,,,,CHEMBL616184,,BAO_0000019,,106.0,,,H,1395.0,3025.0,1.0,,Autocuration,Oryctolagus cuniculus,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,
9986.0,8.0,,B,,,,CHEMBL616185,,BAO_0000019,,106.0,,,H,1396.0,14998.0,1.0,,Autocuration,Oryctolagus cuniculus,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,
9986.0,8.0,,B,,,,CHEMBL616186,,BAO_0000019,,106.0,,,H,1397.0,14998.0,1.0,,Intermediate,Oryctolagus cuniculus,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",
9986.0,8.0,,B,,,,CHEMBL616187,,BAO_0000019,,106.0,,,H,1398.0,14998.0,1.0,,Autocuration,Oryctolagus cuniculus,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,
,8.0,,B,,,,CHEMBL616188,,BAO_0000357,,10577.0,,,H,1399.0,13969.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,
,9.0,,B,,,,CHEMBL873475,,BAO_0000357,,10577.0,,,D,1400.0,13392.0,1.0,,Intermediate,,Binding affinity for 5-hydroxytryptamine 1B receptor,
10116.0,9.0,,B,,,2435.0,CHEMBL616189,,BAO_0000019,,10577.0,,,D,1401.0,3651.0,1.0,,Expert,Rattus norvegicus,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,Striatum
,8.0,,B,,,,CHEMBL616190,,BAO_0000357,,10577.0,,,H,1402.0,10025.0,1.0,,Expert,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,
,8.0,,B,,,,CHEMBL616191,,BAO_0000357,,10576.0,,,H,1403.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,
,8.0,,B,,,,CHEMBL616192,,BAO_0000357,,10576.0,,,H,1404.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,
,8.0,,B,,,,CHEMBL616193,,BAO_0000357,,10576.0,,,H,1405.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,
,8.0,,B,,,,CHEMBL616194,,BAO_0000357,,10576.0,,,H,1406.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,
,8.0,,B,,,,CHEMBL616195,,BAO_0000357,,10576.0,,,H,1407.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,
,8.0,,B,,,,CHEMBL616196,,BAO_0000357,,10576.0,,,H,1408.0,13863.0,1.0,,Autocuration,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,
,8.0,,B,,,10000000.0,CHEMBL616197,,BAO_0000249,,10576.0,,,H,1409.0,4622.0,1.0,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,Hippocampus
,8.0,,B,,,,CHEMBL616198,,BAO_0000019,,10576.0,,,H,1410.0,14911.0,1.0,,Intermediate,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,10000000.0,CHEMBL616199,,BAO_0000221,,10576.0,,,H,1411.0,12678.0,1.0,,Autocuration,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616200,,BAO_0000221,,10576.0,,,H,1412.0,12678.0,1.0,,Expert,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616201,,BAO_0000221,,10576.0,,,H,1413.0,14235.0,1.0,,Expert,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616202,,BAO_0000221,,10576.0,,,H,1414.0,14949.0,1.0,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616203,,BAO_0000221,,10576.0,,,H,1415.0,14949.0,1.0,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616204,,BAO_0000221,,10576.0,,,H,1416.0,14949.0,1.0,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616205,,BAO_0000221,,10576.0,,,H,1417.0,14949.0,1.0,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616206,,BAO_0000221,,10576.0,,,H,1418.0,14949.0,1.0,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,Hippocampus
,8.0,,B,,,,CHEMBL616207,,BAO_0000249,,10576.0,,,H,1419.0,16118.0,1.0,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,
,8.0,,B,,,,CHEMBL616208,,BAO_0000249,,10576.0,,,H,1420.0,3268.0,1.0,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,
,8.0,,B,,,,CHEMBL616209,,BAO_0000249,,10576.0,,,H,1421.0,3268.0,1.0,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,
,8.0,,B,,,,CHEMBL616210,,BAO_0000357,,10576.0,,,H,1422.0,16117.0,1.0,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,
,8.0,,B,,,10000000.0,CHEMBL616211,,BAO_0000221,,10576.0,,,H,1423.0,9783.0,1.0,,Expert,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616504,,BAO_0000221,,10576.0,,,H,1424.0,9783.0,1.0,,Autocuration,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,Hippocampus
10116.0,9.0,,B,,,10000000.0,CHEMBL616505,,BAO_0000221,,10576.0,,,D,1425.0,14356.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus
,8.0,,F,,,,CHEMBL616506,,BAO_0000019,,10576.0,,,H,1426.0,15740.0,1.0,,Autocuration,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,10000000.0,CHEMBL872107,,BAO_0000221,,10576.0,,,H,1427.0,12306.0,1.0,,Autocuration,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus
10116.0,9.0,,B,,,10000000.0,CHEMBL616507,,BAO_0000221,,10576.0,,,D,1428.0,13348.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,Hippocampus
,8.0,,B,,,,CHEMBL616303,,BAO_0000249,,10576.0,,,H,1429.0,10394.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,
,8.0,,B,,,10000000.0,CHEMBL616304,,BAO_0000221,,10576.0,,,H,1430.0,15260.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616305,,BAO_0000221,,10576.0,,,H,1431.0,10046.0,1.0,,Expert,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Hippocampus
,8.0,,F,,,10000000.0,CHEMBL616306,,BAO_0000221,,10576.0,,,H,1432.0,15260.0,1.0,,Intermediate,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,Hippocampus
,8.0,,B,,,,CHEMBL616307,,BAO_0000357,,10576.0,,,H,1433.0,12851.0,1.0,,Autocuration,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,
10116.0,9.0,,B,,,10000000.0,CHEMBL881829,,BAO_0000221,,10576.0,,,D,1434.0,2148.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,Hippocampus
,8.0,,B,,,,CHEMBL616308,,BAO_0000357,,10576.0,,,H,1435.0,13134.0,1.0,,Expert,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,
,8.0,,B,,,,CHEMBL616309,,BAO_0000019,,10576.0,,,H,1436.0,12462.0,1.0,,Autocuration,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,
,8.0,,B,,,,CHEMBL616310,,BAO_0000019,,10576.0,,,H,1437.0,12462.0,1.0,,Expert,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,
,8.0,,B,,,,CHEMBL616311,,BAO_0000219,CHO,10576.0,,,H,1438.0,12462.0,1.0,449.0,Autocuration,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,
,8.0,,B,,,,CHEMBL616312,,BAO_0000357,,10576.0,,,H,1439.0,11933.0,1.0,,Expert,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL616313,,BAO_0000357,,10576.0,,,H,1440.0,11933.0,1.0,,Autocuration,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,
10116.0,9.0,,B,,,10000000.0,CHEMBL616314,,BAO_0000221,,10576.0,,,D,1441.0,403.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616315,,BAO_0000221,,10576.0,,,H,1442.0,15538.0,1.0,,Autocuration,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616567,,BAO_0000221,,10576.0,,,H,1443.0,15538.0,1.0,,Autocuration,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616568,,BAO_0000221,,10576.0,,,H,1444.0,15538.0,1.0,,Autocuration,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,Hippocampus
,8.0,,B,,,,CHEMBL616569,,BAO_0000019,,10576.0,,,H,1445.0,12464.0,1.0,,Intermediate,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,
,8.0,,B,,,,CHEMBL616570,,BAO_0000357,,10576.0,,,H,1446.0,1455.0,1.0,,Expert,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,
,8.0,,B,,,,CHEMBL616571,,BAO_0000357,,10576.0,,,H,1447.0,12652.0,1.0,,Autocuration,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,
,8.0,,B,,,10000000.0,CHEMBL616572,,BAO_0000221,,10576.0,,,H,1448.0,12639.0,1.0,,Autocuration,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,Hippocampus
,8.0,,B,,,,CHEMBL616573,,BAO_0000249,,10576.0,,,H,1449.0,13949.0,1.0,,Expert,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,
10116.0,9.0,,B,,,,CHEMBL616574,,BAO_0000357,,10576.0,,,D,1450.0,12463.0,1.0,,Expert,Rattus norvegicus,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,
,8.0,,B,,,10000000.0,CHEMBL616575,,BAO_0000221,,10576.0,,,H,1451.0,14829.0,1.0,,Expert,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL872108,,BAO_0000221,,10576.0,,,H,1452.0,14829.0,1.0,,Autocuration,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,Hippocampus
,8.0,,B,,,,CHEMBL616576,,BAO_0000357,,10576.0,,,H,1453.0,12092.0,1.0,,Autocuration,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,
,8.0,,B,,,,CHEMBL616577,,BAO_0000249,,10576.0,,,H,1454.0,403.0,1.0,,Autocuration,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,
,8.0,,B,,,,CHEMBL616578,,BAO_0000249,,10576.0,,,H,1455.0,403.0,1.0,,Autocuration,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,
,8.0,,B,,,,CHEMBL616579,,BAO_0000357,,10576.0,,,H,1456.0,3967.0,1.0,,Expert,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,
10116.0,9.0,,B,,,,CHEMBL616580,,BAO_0000019,,10576.0,,,D,1457.0,12771.0,1.0,,Expert,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,
,8.0,,B,,,,CHEMBL616581,,BAO_0000019,,10576.0,,,H,1458.0,15086.0,1.0,,Autocuration,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,
,8.0,,B,,,10000000.0,CHEMBL616582,,BAO_0000221,,10576.0,,,H,1459.0,14909.0,1.0,,Autocuration,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616583,,BAO_0000221,,10576.0,,,H,1460.0,14949.0,1.0,,Expert,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus
10116.0,9.0,,B,,,10000000.0,CHEMBL616584,,BAO_0000221,,10576.0,,,D,1461.0,2309.0,1.0,,Expert,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,Hippocampus
,8.0,,B,,,,CHEMBL616585,,BAO_0000357,,10576.0,,,H,1462.0,4170.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor,
10116.0,9.0,,B,,,10000000.0,CHEMBL616586,,BAO_0000221,,10576.0,,,D,1463.0,11642.0,1.0,,Expert,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616587,,BAO_0000221,,10576.0,,,H,1464.0,11642.0,1.0,,Autocuration,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616588,,BAO_0000221,,10576.0,,,H,1465.0,12953.0,1.0,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616589,,BAO_0000221,,10576.0,,,H,1466.0,12953.0,1.0,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616590,,BAO_0000221,,10576.0,,,H,1467.0,12953.0,1.0,,Expert,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus
,8.0,,B,,,,CHEMBL616591,,BAO_0000219,CHO,10576.0,,,H,1468.0,12903.0,1.0,449.0,Expert,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",
,8.0,,B,,,,CHEMBL616592,,BAO_0000357,,10576.0,,,H,1469.0,12536.0,1.0,,Expert,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616593,,BAO_0000357,,10576.0,,,H,1470.0,10058.0,1.0,,Autocuration,,The inhibition activity of 5-HT1A at 1 uM,
,8.0,,B,,,,CHEMBL616594,,BAO_0000219,CHO-K1,10576.0,,,H,1471.0,12902.0,1.0,485.0,Expert,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",
,8.0,,B,,,,CHEMBL616595,,BAO_0000249,,10576.0,,,H,1472.0,14057.0,1.0,,Expert,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,
,8.0,,B,,,,CHEMBL616596,,BAO_0000357,,10576.0,,,H,1473.0,11296.0,1.0,,Autocuration,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,
,8.0,,B,,,10000000.0,CHEMBL616597,,BAO_0000221,,10576.0,,,H,1474.0,11296.0,1.0,,Autocuration,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616598,,BAO_0000221,,10576.0,,,H,1475.0,11296.0,1.0,,Expert,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Hippocampus
10116.0,9.0,,F,,,,CHEMBL616599,,BAO_0000249,,10576.0,,Membranes,D,1476.0,16616.0,1.0,,Expert,Rattus norvegicus,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,
10116.0,9.0,,F,,,10000000.0,CHEMBL616600,,BAO_0000249,,10576.0,,Membranes,D,1477.0,16616.0,1.0,,Expert,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Hippocampus
,8.0,,B,,,,CHEMBL616601,,BAO_0000019,,10576.0,,,H,1478.0,16567.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,
,8.0,,B,,,,CHEMBL616602,,BAO_0000019,,10576.0,,,H,1479.0,16567.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,
,8.0,,B,,,,CHEMBL616603,,BAO_0000019,,10576.0,,,H,1480.0,16567.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,
,8.0,,B,,,,CHEMBL616604,,BAO_0000019,,10576.0,,,H,1481.0,16567.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,
,8.0,,B,,,,CHEMBL616316,,BAO_0000249,,10576.0,,,H,1482.0,17136.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,
,8.0,,B,,,,CHEMBL616317,,BAO_0000249,,10576.0,,,H,1483.0,17136.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,
10116.0,9.0,,B,,,,CHEMBL616318,,BAO_0000019,,10576.0,,,D,1484.0,16616.0,1.0,,Expert,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,
,8.0,,B,,,10000000.0,CHEMBL616319,,BAO_0000221,,10576.0,,,H,1485.0,17331.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616320,,BAO_0000221,,10576.0,,,H,1486.0,17331.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,Hippocampus
10116.0,9.0,,B,,,10000000.0,CHEMBL616321,,BAO_0000221,,10576.0,,,D,1487.0,17167.0,1.0,,Expert,Rattus norvegicus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,Hippocampus
,8.0,,F,,,,CHEMBL616322,,BAO_0000019,,10576.0,,,H,1488.0,15740.0,1.0,,Autocuration,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,
,8.0,,F,,,,CHEMBL616323,,BAO_0000019,,10576.0,,,H,1489.0,15740.0,1.0,,Autocuration,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,
,8.0,,B,,,,CHEMBL616324,,BAO_0000357,,10576.0,,,H,1490.0,4671.0,1.0,,Autocuration,,Ratio of binding affinity to 5-HT 1A and D2 receptor,
,8.0,,B,,,10000000.0,CHEMBL616325,,BAO_0000221,,10576.0,,,H,1491.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616326,,BAO_0000221,,10576.0,,,H,1492.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616327,,BAO_0000221,,10576.0,,,H,1493.0,10058.0,1.0,,Autocuration,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,Hippocampus
,8.0,,B,,,,CHEMBL616328,,BAO_0000357,,10576.0,,,H,1494.0,12073.0,1.0,,Autocuration,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL858110,,BAO_0000249,,10576.0,,,H,1495.0,2759.0,1.0,,Autocuration,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),
,8.0,,F,,,,CHEMBL616329,,BAO_0000249,,10576.0,,,H,1496.0,2759.0,1.0,,Autocuration,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),
,8.0,,B,,,,CHEMBL616330,,BAO_0000249,,10576.0,,,H,1497.0,2759.0,1.0,,Autocuration,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),
,8.0,,F,,,,CHEMBL616331,,BAO_0000249,,10576.0,,,H,1498.0,2759.0,1.0,,Autocuration,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),
,8.0,,F,,,,CHEMBL616332,,BAO_0000249,,10576.0,,,H,1499.0,2759.0,1.0,,Autocuration,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,
,8.0,,B,,,955.0,CHEMBL857063,,BAO_0000249,,10576.0,,,H,1500.0,9737.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain
,8.0,,B,,,,CHEMBL616333,,BAO_0000019,,10576.0,,,H,1501.0,9737.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,
,8.0,,F,,,,CHEMBL616334,,BAO_0000019,,10576.0,,,H,1502.0,5717.0,1.0,,Expert,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,
,8.0,,B,,,10000000.0,CHEMBL616335,,BAO_0000221,,10576.0,,,H,1503.0,12253.0,1.0,,Autocuration,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Hippocampus
,8.0,,B,,,,CHEMBL616336,,BAO_0000019,,10576.0,,,H,1504.0,14025.0,1.0,,Autocuration,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,
,8.0,,B,,,,CHEMBL616337,,BAO_0000249,,10576.0,,,H,1505.0,10425.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,
,8.0,,B,,,,CHEMBL616338,,BAO_0000019,,10576.0,,,H,1506.0,14998.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,
,8.0,,B,,,10000000.0,CHEMBL616339,,BAO_0000221,,10576.0,,,H,1507.0,13694.0,1.0,,Autocuration,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616340,,BAO_0000221,,10576.0,,,H,1508.0,13694.0,1.0,,Autocuration,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,Hippocampus
,8.0,,B,,,,CHEMBL616341,,BAO_0000357,,10576.0,,,H,1509.0,4342.0,1.0,,Autocuration,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,
10116.0,9.0,,B,,,,CHEMBL616342,,BAO_0000357,,10576.0,,,D,1510.0,12936.0,1.0,,Expert,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 1A receptor,
10116.0,9.0,,B,,,,CHEMBL616343,,BAO_0000019,,10576.0,,,D,1511.0,13144.0,1.0,,Expert,Rattus norvegicus,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,
,8.0,,B,,,,CHEMBL616344,,BAO_0000019,,10576.0,,,H,1512.0,13343.0,1.0,,Expert,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,
,8.0,,B,,,,CHEMBL616345,,BAO_0000357,,10576.0,,,H,1513.0,12132.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,
,8.0,,B,,,,CHEMBL616346,,BAO_0000019,,10576.0,,,H,1514.0,15419.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,
,8.0,,B,,,10000000.0,CHEMBL616347,,BAO_0000221,,10576.0,,,H,1515.0,1479.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Hippocampus
,8.0,,B,,,,CHEMBL616348,,BAO_0000019,,10576.0,,,H,1516.0,14287.0,1.0,,Expert,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,
,8.0,,B,,,,CHEMBL616349,,BAO_0000357,,10576.0,,,H,1517.0,13116.0,1.0,,Expert,,Binding affinity at 5-hydroxytryptamine 1A receptor,
10116.0,9.0,,B,,,,CHEMBL616152,,BAO_0000249,,10576.0,,Membranes,D,1518.0,2759.0,1.0,,Expert,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,
,8.0,,B,,,,CHEMBL616153,,BAO_0000249,,10576.0,,,H,1519.0,2759.0,1.0,,Autocuration,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,
,8.0,,B,,,,CHEMBL616154,,BAO_0000019,,10576.0,,,H,1520.0,14748.0,1.0,,Expert,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",
,8.0,,B,,,,CHEMBL616155,,BAO_0000019,,10576.0,,,H,1521.0,12304.0,1.0,,Autocuration,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,
10116.0,9.0,,B,,,10000000.0,CHEMBL616156,,BAO_0000221,,10576.0,,,D,1522.0,12409.0,1.0,,Expert,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,Hippocampus
10116.0,9.0,,B,,,10000000.0,CHEMBL616157,,BAO_0000221,,10576.0,,,D,1523.0,12409.0,1.0,,Expert,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL616158,,BAO_0000221,,10576.0,,,H,1524.0,13267.0,1.0,,Autocuration,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,Hippocampus
,8.0,,B,,,,CHEMBL616159,,BAO_0000357,,10576.0,,,H,1525.0,15194.0,1.0,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,
,8.0,,B,,,,CHEMBL616160,,BAO_0000357,,10576.0,,,H,1526.0,14256.0,1.0,,Expert,,pKi value against rat 5-hydroxytryptamine 1A receptor.,
,8.0,,B,,,,CHEMBL616161,,BAO_0000019,,10576.0,,,H,1527.0,16567.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,
,8.0,,F,,,,CHEMBL616162,,BAO_0000019,,10576.0,,,H,1528.0,15740.0,1.0,,Autocuration,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,
10116.0,9.0,,B,,,,CHEMBL616163,,BAO_0000357,,12687.0,,,D,1529.0,13278.0,1.0,,Expert,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,
,8.0,,B,,,,CHEMBL616164,,BAO_0000249,,10626.0,,Membranes,H,1530.0,1970.0,1.0,,Expert,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,
,8.0,,B,,,955.0,CHEMBL616165,,BAO_0000221,,10576.0,,,H,1531.0,10034.0,1.0,,Autocuration,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,Brain
10116.0,8.0,,B,,,,CHEMBL616355,,BAO_0000019,,51.0,,,H,1532.0,13348.0,1.0,,Autocuration,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,
,8.0,,F,,,,CHEMBL616356,,BAO_0000019,,10576.0,,,H,1533.0,13630.0,1.0,,Autocuration,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,
,8.0,,B,,,955.0,CHEMBL616357,,BAO_0000221,,10576.0,,,H,1534.0,10862.0,1.0,,Autocuration,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Brain
,8.0,,B,,,,CHEMBL616358,,BAO_0000019,,10576.0,,,H,1535.0,12058.0,1.0,,Autocuration,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",
,8.0,,B,,,,CHEMBL616359,,BAO_0000357,,51.0,,,H,1536.0,4639.0,1.0,,Autocuration,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616360,,BAO_0000357,,51.0,,,H,1537.0,15453.0,1.0,,Expert,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,
,8.0,,B,,,,CHEMBL616361,,BAO_0000357,,51.0,,,H,1538.0,4820.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616362,,BAO_0000357,,51.0,,,H,1539.0,1089.0,1.0,,Autocuration,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616363,,BAO_0000249,,51.0,,Brain membranes,H,1540.0,386.0,1.0,,Autocuration,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,
,8.0,,B,,,,CHEMBL616364,,BAO_0000357,,51.0,,,H,1541.0,6011.0,1.0,,Autocuration,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,
,8.0,,B,,,,CHEMBL616365,,BAO_0000357,,51.0,,,H,1542.0,5014.0,1.0,,Autocuration,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616366,,BAO_0000357,,51.0,,,H,1543.0,4402.0,1.0,,Expert,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL872906,,BAO_0000357,,51.0,,,H,1544.0,17066.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616367,,BAO_0000357,,51.0,,,H,1545.0,17515.0,1.0,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,
,8.0,,B,,,,CHEMBL616368,,BAO_0000357,,51.0,,,H,1546.0,2474.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616369,,BAO_0000357,,51.0,,,H,1547.0,4775.0,1.0,,Autocuration,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,
9606.0,9.0,,B,,,,CHEMBL616370,,BAO_0000357,,51.0,,,D,1548.0,14294.0,1.0,,Expert,Homo sapiens,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,
9606.0,9.0,,B,,,,CHEMBL616371,,BAO_0000357,,51.0,,,D,1549.0,14294.0,1.0,,Expert,Homo sapiens,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,
,8.0,,B,,,,CHEMBL616372,,BAO_0000219,CHO,51.0,,,H,1550.0,12249.0,1.0,449.0,Autocuration,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,
,8.0,,B,,,,CHEMBL616373,,BAO_0000219,,51.0,,,H,1551.0,11376.0,1.0,,Expert,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,
,8.0,,B,,,,CHEMBL616374,,BAO_0000218,,51.0,In vivo,,H,1552.0,2474.0,1.0,,Autocuration,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,10000000.0,CHEMBL616375,,BAO_0000221,,51.0,,,H,1553.0,13311.0,1.0,,Autocuration,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus
,8.0,,B,,,,CHEMBL616376,,BAO_0000357,,51.0,,,H,1554.0,4373.0,1.0,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,
,8.0,,B,,,,CHEMBL857064,,BAO_0000357,,51.0,,,H,1555.0,1633.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,
,8.0,,B,,,,CHEMBL616377,,BAO_0000357,,51.0,,,H,1556.0,11866.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,
,8.0,,B,,,,CHEMBL616378,,BAO_0000357,,51.0,,,H,1557.0,4373.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,
,8.0,,B,,,,CHEMBL616379,,BAO_0000357,,51.0,,,H,1558.0,4687.0,1.0,,Autocuration,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616380,,BAO_0000357,,11863.0,,,H,1559.0,16946.0,1.0,,Autocuration,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616381,,BAO_0000357,,11863.0,,,H,1560.0,13291.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,
,8.0,,B,,,,CHEMBL616382,,BAO_0000357,,11863.0,,,H,1561.0,14159.0,1.0,,Autocuration,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616383,,BAO_0000357,,11863.0,,,H,1562.0,10812.0,1.0,,Autocuration,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,
10090.0,9.0,,B,,,,CHEMBL616350,,BAO_0000219,CHO,11863.0,,,D,1563.0,3032.0,1.0,449.0,Expert,Mus musculus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,
,8.0,,B,,,,CHEMBL616351,,BAO_0000357,,11863.0,,,H,1564.0,16655.0,1.0,,Autocuration,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616352,,BAO_0000357,,11863.0,,,H,1565.0,14532.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,
,8.0,,B,,,,CHEMBL616353,,BAO_0000357,,11863.0,,,H,1566.0,13944.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616354,,BAO_0000357,,11863.0,,,H,1567.0,13033.0,1.0,,Autocuration,,Binding affinity against serotonergic 5-HT1a receptor,
,8.0,,B,,,,CHEMBL616508,,BAO_0000357,,11863.0,,,H,1568.0,10321.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,
10090.0,9.0,,B,,,,CHEMBL616559,,BAO_0000357,,11863.0,,,D,1569.0,2968.0,1.0,,Expert,Mus musculus,Binding affinity for 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616560,,BAO_0000357,,11863.0,,,H,1570.0,13964.0,1.0,,Autocuration,,Binding affinity at 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616561,,BAO_0000357,,11863.0,,,H,1571.0,15527.0,1.0,,Autocuration,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",
,8.0,,B,,,,CHEMBL616562,,BAO_0000219,CHO,11863.0,,,H,1572.0,12248.0,1.0,449.0,Autocuration,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,
,8.0,,B,,,,CHEMBL616563,,BAO_0000219,CHO,11863.0,,,H,1573.0,12249.0,1.0,449.0,Autocuration,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,
,8.0,,B,,,,CHEMBL616564,,BAO_0000357,,11863.0,,,H,1574.0,15120.0,1.0,,Autocuration,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616565,,BAO_0000357,,11863.0,,,H,1575.0,13313.0,1.0,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL616566,,BAO_0000218,,11863.0,,,H,1576.0,2613.0,1.0,,Autocuration,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616989,,BAO_0000357,,11863.0,,,H,1577.0,16700.0,1.0,,Autocuration,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,
,8.0,,B,,,,CHEMBL857975,,BAO_0000357,,11863.0,,,H,1578.0,2201.0,1.0,,Autocuration,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,
10090.0,9.0,,B,,,,CHEMBL616990,,BAO_0000357,,11863.0,,,D,1579.0,1274.0,1.0,,Expert,Mus musculus,Binding affinity against 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616991,,BAO_0000357,,11863.0,,,H,1580.0,1317.0,1.0,,Autocuration,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,
,8.0,,B,,,,CHEMBL616992,,BAO_0000357,,11863.0,,,H,1581.0,12146.0,1.0,,Autocuration,,Tested against 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL616993,,BAO_0000357,,11863.0,,,H,1582.0,14059.0,1.0,,Autocuration,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,
9986.0,8.0,,B,,,,CHEMBL616994,,BAO_0000019,,106.0,,,H,1583.0,14025.0,1.0,,Expert,Oryctolagus cuniculus,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,
9986.0,8.0,,B,,,,CHEMBL616995,,BAO_0000019,,106.0,,,H,1584.0,14025.0,1.0,,Autocuration,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,
9593.0,9.0,,B,,,,CHEMBL616996,,BAO_0000219,HEK293,105571.0,,,D,1585.0,14447.0,1.0,722.0,Intermediate,Gorilla gorilla,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,
10141.0,8.0,,F,,,,CHEMBL616997,,BAO_0000218,,106.0,In vivo,,H,1586.0,3025.0,1.0,,Autocuration,Cavia porcellus,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,
10141.0,8.0,,F,,,,CHEMBL616998,,BAO_0000218,,106.0,In vivo,,H,1587.0,3025.0,1.0,,Autocuration,Cavia porcellus,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,
10141.0,8.0,,F,,,,CHEMBL616999,,BAO_0000019,,106.0,,,H,1588.0,15329.0,1.0,,Autocuration,Cavia porcellus,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,
10141.0,8.0,,F,,,,CHEMBL617000,,BAO_0000019,,106.0,,,H,1589.0,15329.0,1.0,,Autocuration,Cavia porcellus,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,
10141.0,8.0,,F,,,,CHEMBL617001,,BAO_0000019,,106.0,,,H,1590.0,15847.0,1.0,,Autocuration,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,
10141.0,8.0,,F,,,,CHEMBL858111,,BAO_0000019,,106.0,,,H,1591.0,15847.0,1.0,,Autocuration,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,
,8.0,,F,,,,CHEMBL617002,,BAO_0000019,,106.0,,,H,1592.0,14165.0,1.0,,Autocuration,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,
,8.0,,F,,,,CHEMBL617003,,BAO_0000019,,106.0,,,H,1593.0,14214.0,1.0,,Autocuration,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),
,8.0,,F,,,,CHEMBL617004,,BAO_0000019,,106.0,,,H,1594.0,14214.0,1.0,,Autocuration,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),
9606.0,9.0,,F,,,,CHEMBL617005,,BAO_0000019,,106.0,,,D,1595.0,14214.0,1.0,,Expert,Homo sapiens,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,
9606.0,9.0,,F,,,,CHEMBL616623,,BAO_0000219,CHO-K1,106.0,,,D,1596.0,13729.0,1.0,485.0,Expert,Homo sapiens,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,
,8.0,,F,,,,CHEMBL616624,,BAO_0000219,CHO,106.0,,,H,1597.0,3025.0,1.0,449.0,Autocuration,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,
,8.0,,B,,,,CHEMBL883243,,BAO_0000357,,106.0,,,H,1598.0,2391.0,1.0,,Autocuration,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,
,8.0,,F,,,,CHEMBL616625,,BAO_0000019,,106.0,,,H,1599.0,2391.0,1.0,,Autocuration,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,
,8.0,,F,,,,CHEMBL616626,,BAO_0000219,CHO,106.0,,,H,1600.0,14956.0,1.0,449.0,Expert,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",
,8.0,,F,,,,CHEMBL616627,,BAO_0000219,CHO,106.0,,,H,1601.0,2598.0,1.0,449.0,Autocuration,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,
,8.0,,F,,,,CHEMBL616628,,BAO_0000219,CHO,106.0,,,H,1602.0,2598.0,1.0,449.0,Autocuration,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,
,8.0,,F,,,,CHEMBL616629,,BAO_0000219,CHO,106.0,,,H,1603.0,2598.0,1.0,449.0,Autocuration,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,
,8.0,,F,,,,CHEMBL616630,,BAO_0000219,CHO,106.0,,,H,1604.0,2598.0,1.0,449.0,Autocuration,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,
,8.0,,F,,,,CHEMBL616631,,BAO_0000019,,106.0,,,H,1605.0,14956.0,1.0,,Expert,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",
,8.0,,F,,,,CHEMBL616632,,BAO_0000019,,106.0,,,H,1606.0,14956.0,1.0,,Autocuration,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",
9606.0,9.0,,B,,,,CHEMBL616633,,BAO_0000357,,106.0,,,D,1607.0,14214.0,1.0,,Expert,Homo sapiens,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616634,,BAO_0000219,CHO,106.0,,,H,1608.0,3463.0,1.0,449.0,Expert,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,
,8.0,,B,,,,CHEMBL616635,,BAO_0000357,,106.0,,,H,1609.0,15331.0,1.0,,Autocuration,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,
9606.0,9.0,,B,,,,CHEMBL885358,,BAO_0000357,,106.0,,,D,1610.0,16146.0,1.0,,Expert,Homo sapiens,Binding affinity against 5-hydroxytryptamine 1B receptor,
9606.0,9.0,,B,,,,CHEMBL616636,,BAO_0000219,CHO,106.0,,,D,1611.0,14159.0,1.0,449.0,Expert,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,
,8.0,,B,,,,CHEMBL616637,,BAO_0000219,CHO,106.0,,,H,1612.0,14158.0,1.0,449.0,Expert,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,
,8.0,,B,,,,CHEMBL616638,,BAO_0000357,,106.0,,,H,1613.0,14159.0,1.0,,Autocuration,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616639,,BAO_0000219,CHO,106.0,,,H,1614.0,15250.0,1.0,449.0,Expert,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,
,8.0,,B,,,,CHEMBL616640,,BAO_0000219,CHO,106.0,,,H,1615.0,15250.0,1.0,449.0,Expert,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,
,8.0,,B,,,,CHEMBL616641,,BAO_0000219,CHO,106.0,,,H,1616.0,15331.0,1.0,449.0,Expert,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,
,8.0,,B,,,,CHEMBL616642,,BAO_0000219,CHO,106.0,,,H,1617.0,15332.0,1.0,449.0,Expert,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,
,8.0,,B,,,,CHEMBL616643,,BAO_0000219,CHO,106.0,,,H,1618.0,14956.0,1.0,449.0,Expert,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,
,8.0,,B,,,,CHEMBL616644,,BAO_0000357,,106.0,,,H,1619.0,3805.0,1.0,,Autocuration,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),
,8.0,,B,,,,CHEMBL616645,,BAO_0000357,,106.0,,,H,1620.0,14875.0,1.0,,Autocuration,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,
9986.0,8.0,,F,,,,CHEMBL616646,,BAO_0000019,,105.0,,,H,1621.0,14454.0,1.0,,Autocuration,Oryctolagus cuniculus,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),
9986.0,8.0,,F,,,,CHEMBL616647,,BAO_0000019,,105.0,,,H,1622.0,14454.0,1.0,,Expert,Oryctolagus cuniculus,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),
,8.0,,B,,,,CHEMBL616509,,BAO_0000357,,105.0,,,H,1623.0,16288.0,1.0,,Autocuration,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),
,8.0,,B,,,,CHEMBL616510,,BAO_0000357,,105.0,,,H,1624.0,16288.0,1.0,,Autocuration,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),
,8.0,,B,,,,CHEMBL616511,,BAO_0000357,,105.0,,,H,1625.0,16312.0,1.0,,Autocuration,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,
9913.0,8.0,,B,,,,CHEMBL616512,,BAO_0000357,,105.0,,,H,1626.0,1348.0,1.0,,Expert,Bos taurus,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,
9913.0,8.0,,B,,,,CHEMBL616513,,BAO_0000357,,105.0,,,H,1627.0,5834.0,1.0,,Autocuration,Bos taurus,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,
9913.0,8.0,,B,,,2435.0,CHEMBL616514,,BAO_0000019,,105.0,,,H,1628.0,13366.0,1.0,,Autocuration,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Striatum
9913.0,8.0,,B,,,,CHEMBL616515,,BAO_0000357,,105.0,,,H,1629.0,1414.0,1.0,,Expert,Bos taurus,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,
9913.0,8.0,,B,,,,CHEMBL616516,,BAO_0000019,,105.0,,,H,1630.0,14998.0,1.0,,Autocuration,Bos taurus,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,
9913.0,8.0,,B,,,,CHEMBL616517,,BAO_0000357,,105.0,,,H,1631.0,11473.0,1.0,,Autocuration,Bos taurus,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,
9913.0,8.0,,B,,,,CHEMBL616518,,BAO_0000357,,105.0,,,H,1632.0,11473.0,1.0,,Autocuration,Bos taurus,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,
9913.0,8.0,,B,,,,CHEMBL616519,,BAO_0000357,,105.0,,,H,1633.0,10639.0,1.0,,Autocuration,Bos taurus,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,
9913.0,8.0,,B,,,,CHEMBL616520,,BAO_0000357,,105.0,,,H,1634.0,10639.0,1.0,,Autocuration,Bos taurus,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,
9913.0,8.0,,B,,,,CHEMBL616521,,BAO_0000357,,105.0,,,H,1635.0,1375.0,1.0,,Autocuration,Bos taurus,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,
9913.0,8.0,,B,,,,CHEMBL616522,,BAO_0000357,,105.0,,,H,1636.0,1375.0,1.0,,Autocuration,Bos taurus,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,
9913.0,8.0,,B,,,,CHEMBL884531,,BAO_0000357,,105.0,,,H,1637.0,16532.0,1.0,,Autocuration,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,
9913.0,8.0,,B,,,,CHEMBL616523,,BAO_0000357,,105.0,,,H,1638.0,11147.0,1.0,,Autocuration,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,
9913.0,8.0,,B,,,2435.0,CHEMBL616731,,BAO_0000019,,105.0,,,H,1639.0,13366.0,1.0,,Autocuration,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Striatum
9913.0,8.0,,B,,,,CHEMBL616732,,BAO_0000019,,105.0,,,H,1640.0,10444.0,1.0,,Autocuration,Bos taurus,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,
9913.0,8.0,,B,,,,CHEMBL616733,,BAO_0000357,,105.0,,,H,1641.0,16532.0,1.0,,Autocuration,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,
9913.0,8.0,,B,,,,CHEMBL616734,,BAO_0000357,,105.0,,,H,1642.0,16532.0,1.0,,Autocuration,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,
9913.0,8.0,,B,,,,CHEMBL616735,,BAO_0000249,,105.0,,,H,1643.0,12827.0,1.0,,Autocuration,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,
9913.0,8.0,,B,,,,CHEMBL616736,,BAO_0000249,,105.0,,,H,1644.0,12827.0,1.0,,Autocuration,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,
9913.0,8.0,,F,,,,CHEMBL616737,,BAO_0000019,,105.0,,,H,1645.0,12919.0,1.0,,Expert,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,
9913.0,8.0,,B,,,,CHEMBL616738,,BAO_0000019,,105.0,,,H,1646.0,14025.0,1.0,,Autocuration,Bos taurus,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,
9913.0,8.0,,F,,,,CHEMBL616739,,BAO_0000019,,105.0,,,H,1647.0,12919.0,1.0,,Expert,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,
9913.0,8.0,,F,,,,CHEMBL616740,,BAO_0000019,,105.0,,,H,1648.0,12919.0,1.0,,Expert,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,
9913.0,8.0,,F,,,,CHEMBL616741,,BAO_0000019,,105.0,,,H,1649.0,12919.0,1.0,,Expert,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,
9593.0,8.0,,B,,,,CHEMBL616742,,BAO_0000219,HEK293,105.0,,,H,1650.0,14447.0,1.0,722.0,Autocuration,Gorilla gorilla,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,
10141.0,9.0,,B,,,,CHEMBL616743,,BAO_0000019,,105570.0,,,D,1651.0,1375.0,1.0,,Intermediate,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,
10141.0,9.0,,B,,,,CHEMBL616744,,BAO_0000019,,105570.0,,,D,1652.0,1375.0,1.0,,Intermediate,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,
10141.0,9.0,,F,,,,CHEMBL616745,,BAO_0000019,,105570.0,,,D,1653.0,12409.0,1.0,,Intermediate,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,
10141.0,9.0,,F,,,,CHEMBL616746,,BAO_0000019,,105570.0,,,D,1654.0,12409.0,1.0,,Intermediate,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,
10141.0,9.0,,F,,,,CHEMBL616747,,BAO_0000019,,105570.0,,,D,1655.0,12409.0,1.0,,Intermediate,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,
10141.0,9.0,,F,,,,CHEMBL616748,,BAO_0000019,,105570.0,,,D,1656.0,12409.0,1.0,,Intermediate,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,
10141.0,9.0,,F,,,,CHEMBL616648,,BAO_0000019,,105570.0,,,D,1657.0,12409.0,1.0,,Intermediate,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,
10141.0,9.0,,B,,,,CHEMBL616649,,BAO_0000357,,105570.0,,,D,1658.0,11574.0,1.0,,Intermediate,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 1D receptor,
10141.0,9.0,,B,,,,CHEMBL616650,,BAO_0000357,,105570.0,,,D,1659.0,1558.0,1.0,,Intermediate,Cavia porcellus,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,
10141.0,9.0,,F,,,,CHEMBL616651,,BAO_0000218,,105570.0,,,D,1660.0,12409.0,1.0,,Intermediate,Cavia porcellus,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,
10141.0,9.0,,F,,,,CHEMBL616652,,BAO_0000218,,105570.0,,,D,1661.0,12409.0,1.0,,Intermediate,Cavia porcellus,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,
10141.0,9.0,,F,,,,CHEMBL616653,,BAO_0000218,,105570.0,,,D,1662.0,12409.0,1.0,,Intermediate,Cavia porcellus,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,
10141.0,9.0,,F,,,,CHEMBL616654,,BAO_0000218,,105570.0,,,D,1663.0,12409.0,1.0,,Intermediate,Cavia porcellus,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,
10141.0,9.0,,B,,,,CHEMBL616655,,BAO_0000019,,105570.0,,,D,1664.0,12253.0,1.0,,Intermediate,Cavia porcellus,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,
10141.0,9.0,,B,,,,CHEMBL616656,,BAO_0000357,,105570.0,,,D,1665.0,12936.0,1.0,,Intermediate,Cavia porcellus,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,
10141.0,8.0,,B,,,,CHEMBL616657,,BAO_0000019,,105.0,,,H,1666.0,13181.0,1.0,,Autocuration,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,
10141.0,9.0,,B,,,2435.0,CHEMBL616658,,BAO_0000357,,105570.0,,,D,1667.0,12409.0,1.0,,Intermediate,Cavia porcellus,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,Striatum
10141.0,9.0,,B,,,,CHEMBL616659,,BAO_0000357,,105570.0,,,D,1668.0,10639.0,1.0,,Intermediate,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,
,8.0,,B,,,,CHEMBL616660,,BAO_0000357,,51.0,,,H,1669.0,5254.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616661,,BAO_0000357,,106.0,,,H,1670.0,13051.0,1.0,,Autocuration,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,
,8.0,,F,,,,CHEMBL616662,,BAO_0000019,,105.0,,,H,1671.0,3463.0,1.0,,Expert,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,
,8.0,,F,,,,CHEMBL616663,,BAO_0000019,,105.0,,,H,1672.0,15315.0,1.0,,Autocuration,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,
,8.0,,F,,,,CHEMBL616664,,BAO_0000019,,105.0,,,H,1673.0,6011.0,1.0,,Autocuration,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,
9606.0,9.0,,F,,,,CHEMBL881820,,BAO_0000219,CHO,105.0,,,D,1674.0,14159.0,1.0,449.0,Expert,Homo sapiens,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",
,8.0,,F,,,,CHEMBL616665,,BAO_0000219,CHO,105.0,,,H,1675.0,14159.0,1.0,449.0,Autocuration,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",
,8.0,,B,,,,CHEMBL616666,,BAO_0000219,CHO,105.0,,,H,1676.0,15250.0,1.0,449.0,Expert,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616667,,BAO_0000219,CHO,105.0,,,H,1677.0,15250.0,1.0,449.0,Autocuration,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,
,8.0,,F,,,,CHEMBL616668,,BAO_0000219,CHO,105.0,,,H,1678.0,15331.0,1.0,449.0,Expert,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",
9606.0,9.0,,F,,,,CHEMBL616669,,BAO_0000219,CHO,105.0,,,D,1679.0,15332.0,1.0,449.0,Expert,Homo sapiens,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",
,8.0,,F,,,,CHEMBL617040,,BAO_0000219,CHO,105.0,,,H,1680.0,15332.0,1.0,449.0,Expert,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",
,8.0,,F,,,,CHEMBL617041,,BAO_0000219,CHO,105.0,,,H,1681.0,3294.0,1.0,449.0,Autocuration,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",
,8.0,,F,,,,CHEMBL617042,,BAO_0000219,CHO,105.0,,,H,1682.0,14158.0,1.0,449.0,Expert,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",
,8.0,,F,,,,CHEMBL617043,,BAO_0000219,CHO,105.0,,,H,1683.0,14956.0,1.0,449.0,Expert,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",
,8.0,,F,,,,CHEMBL617044,,BAO_0000019,,105.0,,,H,1684.0,12469.0,1.0,,Autocuration,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,
,8.0,,F,,,,CHEMBL617045,,BAO_0000219,CHO,105.0,,,H,1685.0,3463.0,1.0,449.0,Expert,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,
9606.0,9.0,,F,,,,CHEMBL617046,,BAO_0000219,CHO,105.0,,,D,1686.0,15250.0,1.0,449.0,Expert,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",
9606.0,9.0,,F,,,,CHEMBL617047,,BAO_0000219,CHO,105.0,,,D,1687.0,15250.0,1.0,449.0,Expert,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",
,8.0,,F,,,,CHEMBL617048,,BAO_0000019,,105.0,,,H,1688.0,14956.0,1.0,,Expert,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",
,8.0,,F,,,,CHEMBL616897,,BAO_0000019,,105.0,,,H,1689.0,14159.0,1.0,,Autocuration,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",
9606.0,9.0,,F,,,,CHEMBL616898,,BAO_0000019,,105.0,,,D,1690.0,14159.0,1.0,,Expert,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",
9606.0,9.0,,F,,,,CHEMBL858201,,BAO_0000219,CHO,105.0,,,D,1691.0,14499.0,1.0,449.0,Expert,Homo sapiens,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,
,8.0,,F,,,,CHEMBL616899,,BAO_0000019,,105.0,,,H,1692.0,15315.0,1.0,,Autocuration,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616900,,BAO_0000219,,105.0,In vitro,,H,1693.0,3294.0,1.0,,Autocuration,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),
,8.0,,B,,,,CHEMBL616901,,BAO_0000219,CHO,105.0,,,H,1694.0,3463.0,1.0,449.0,Expert,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,
,8.0,,B,,,,CHEMBL616902,,BAO_0000357,,105.0,,,H,1695.0,15331.0,1.0,,Autocuration,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,
9606.0,9.0,,B,,,,CHEMBL616903,,BAO_0000219,CHO,105.0,,,D,1696.0,14159.0,1.0,449.0,Expert,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,
,8.0,,B,,,,CHEMBL616904,,BAO_0000219,CHO,105.0,,,H,1697.0,14158.0,1.0,449.0,Expert,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,
,8.0,,B,,,,CHEMBL616905,,BAO_0000357,,105.0,,,H,1698.0,14159.0,1.0,,Autocuration,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616906,,BAO_0000219,CHO,105.0,,,H,1699.0,15250.0,1.0,449.0,Expert,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,
,8.0,,B,,,,CHEMBL616907,,BAO_0000219,CHO,105.0,,,H,1700.0,15250.0,1.0,449.0,Expert,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,
,8.0,,B,,,,CHEMBL616908,,BAO_0000219,CHO,105.0,,,H,1701.0,15331.0,1.0,449.0,Expert,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,
9606.0,9.0,,B,,,,CHEMBL616909,,BAO_0000219,CHO,105.0,,,D,1702.0,15332.0,1.0,449.0,Expert,Homo sapiens,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,
9606.0,9.0,,B,,,,CHEMBL616910,,BAO_0000219,CHO,105.0,,,D,1703.0,14499.0,1.0,449.0,Expert,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,
,8.0,,B,,,,CHEMBL616911,,BAO_0000219,CHO,105.0,,,H,1704.0,15332.0,1.0,449.0,Expert,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,
,8.0,,B,,,,CHEMBL616912,,BAO_0000219,CHO,105.0,,,H,1705.0,14956.0,1.0,449.0,Expert,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,
,8.0,,B,,,,CHEMBL616913,,BAO_0000357,,105.0,,,H,1706.0,3805.0,1.0,,Autocuration,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),
9606.0,9.0,,B,,,,CHEMBL616914,,BAO_0000219,CHO,105.0,,,D,1707.0,6011.0,1.0,449.0,Expert,Homo sapiens,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,
,8.0,,B,,,,CHEMBL616915,,BAO_0000219,CHO,105.0,,,H,1708.0,16190.0,1.0,449.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL616916,,BAO_0000019,,105.0,,,H,1709.0,14165.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,
9606.0,9.0,,B,,,,CHEMBL616917,,BAO_0000357,,105.0,,,D,1710.0,4234.0,1.0,,Expert,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616918,,BAO_0000357,,105.0,,,H,1711.0,15527.0,1.0,,Autocuration,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",
,8.0,,B,,,,CHEMBL616919,,BAO_0000219,,105.0,,,H,1712.0,6328.0,1.0,,Expert,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,
,8.0,,B,,,,CHEMBL616920,,BAO_0000357,,105.0,,,H,1713.0,16209.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL872914,,BAO_0000357,,105.0,,,H,1714.0,14770.0,1.0,,Autocuration,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,
,8.0,,B,,,,CHEMBL616921,,BAO_0000357,,105.0,,,H,1715.0,2598.0,1.0,,Autocuration,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,
,8.0,,B,,,,CHEMBL616922,,BAO_0000357,,105.0,,,H,1716.0,6897.0,1.0,,Expert,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616923,,BAO_0000357,,105.0,,,H,1717.0,6013.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616924,,BAO_0000357,,105.0,,,H,1718.0,5843.0,1.0,,Expert,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL875909,,BAO_0000357,,105.0,,,H,1719.0,14454.0,1.0,,Expert,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,
,8.0,,B,,,,CHEMBL616925,,BAO_0000357,,105.0,,,H,1720.0,14454.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,
,8.0,,B,,,,CHEMBL616926,,BAO_0000357,,105.0,,,H,1721.0,14454.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,
,8.0,,B,,,,CHEMBL616927,,BAO_0000357,,105.0,,,H,1722.0,15818.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,
,8.0,,F,,,,CHEMBL616928,,BAO_0000219,CHO-K1,105.0,,,H,1723.0,13729.0,1.0,485.0,Expert,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,
9606.0,9.0,,B,,,,CHEMBL616929,,BAO_0000219,,105.0,In vitro,,D,1724.0,6011.0,1.0,,Expert,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),
9606.0,9.0,,B,,,,CHEMBL616930,,BAO_0000357,,105.0,,,D,1725.0,4234.0,1.0,,Expert,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616931,,BAO_0000019,,105.0,,,H,1726.0,17085.0,1.0,,Expert,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616932,,BAO_0000357,,105.0,,,H,1727.0,3025.0,1.0,,Autocuration,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,
,8.0,,B,,,,CHEMBL616933,,BAO_0000357,,105.0,,,H,1728.0,15315.0,1.0,,Expert,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,
9606.0,9.0,,B,,,,CHEMBL616934,,BAO_0000219,,105.0,,,D,1729.0,14214.0,1.0,,Expert,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,
9606.0,9.0,,B,,,,CHEMBL616935,,BAO_0000357,,105.0,,,D,1730.0,3804.0,1.0,,Expert,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616936,,BAO_0000357,,105.0,,,H,1731.0,16700.0,1.0,,Autocuration,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,
9606.0,9.0,,B,,,,CHEMBL616937,,BAO_0000357,,105.0,,,D,1732.0,2391.0,1.0,,Expert,Homo sapiens,Affinity for 5-hydroxytryptamine 1D receptor subtype,
9606.0,9.0,,B,,,,CHEMBL616938,,BAO_0000357,,105.0,,,D,1733.0,4175.0,1.0,,Expert,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616939,,BAO_0000019,,105.0,,,H,1734.0,17085.0,1.0,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616940,,BAO_0000019,,105.0,,,H,1735.0,17085.0,1.0,,Expert,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,
9606.0,9.0,,B,,,,CHEMBL616941,,BAO_0000357,,105.0,,,D,1736.0,15926.0,1.0,,Expert,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,
,8.0,,B,,,,CHEMBL616942,,BAO_0000219,CHO-K1,105.0,,,H,1737.0,16312.0,1.0,485.0,Autocuration,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,
,8.0,,B,,,,CHEMBL616943,,BAO_0000219,CHO-K1,105.0,,,H,1738.0,16312.0,1.0,485.0,Autocuration,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,
,4.0,,B,,,,CHEMBL616944,,BAO_0000219,CHO,104802.0,,,H,1739.0,14956.0,1.0,449.0,Autocuration,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,
,8.0,,F,,,,CHEMBL616945,,BAO_0000019,,105.0,,,H,1740.0,3294.0,1.0,,Autocuration,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",
,8.0,,B,,,,CHEMBL616946,,BAO_0000357,,105.0,,,H,1741.0,12861.0,1.0,,Autocuration,,Binding activity radioligand.,
,8.0,,B,,,,CHEMBL616947,,BAO_0000019,,105.0,,,H,1742.0,12861.0,1.0,,Autocuration,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,
,8.0,,B,,,,CHEMBL616948,,BAO_0000219,CHO-K1,105.0,,,H,1743.0,16312.0,1.0,485.0,Expert,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616851,,BAO_0000357,,105.0,,,H,1744.0,5104.0,1.0,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616852,,BAO_0000357,,105.0,,,H,1745.0,5105.0,1.0,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616853,,BAO_0000357,,105.0,,,H,1746.0,14499.0,1.0,,Autocuration,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,
9606.0,9.0,,B,,,,CHEMBL616854,,BAO_0000357,,105.0,,,D,1747.0,15926.0,1.0,,Expert,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1D receptor,
9606.0,9.0,,B,,,,CHEMBL616855,,BAO_0000219,CHO,105.0,,,D,1748.0,4540.0,1.0,449.0,Expert,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL616856,,BAO_0000219,CHO,105.0,,,H,1749.0,15779.0,1.0,449.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,
,8.0,,B,,,,CHEMBL616857,,BAO_0000219,CHO,105.0,,,H,1750.0,15779.0,1.0,449.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,
,8.0,,B,,,,CHEMBL616858,,BAO_0000357,,105.0,,,H,1751.0,6166.0,1.0,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616859,,BAO_0000219,CHO,105.0,,,H,1752.0,15779.0,1.0,449.0,Autocuration,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,
,8.0,,B,,,,CHEMBL616860,,BAO_0000219,CHO,105.0,,,H,1753.0,15779.0,1.0,449.0,Autocuration,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,
,8.0,,B,,,,CHEMBL616861,,BAO_0000219,HEK293,105.0,,,H,1754.0,17451.0,1.0,722.0,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,
,8.0,,B,,,,CHEMBL616541,,BAO_0000219,HEK293,105.0,,,H,1755.0,17451.0,1.0,722.0,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,
,8.0,,B,,,,CHEMBL616542,,BAO_0000219,HEK293,105.0,,,H,1756.0,17451.0,1.0,722.0,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,
,8.0,,B,,,,CHEMBL616543,,BAO_0000219,CHO,105.0,,,H,1757.0,4199.0,1.0,449.0,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,
9606.0,9.0,,B,,,,CHEMBL616544,,BAO_0000357,,105.0,,,D,1758.0,14875.0,1.0,,Expert,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616545,,BAO_0000219,CHO,105.0,,,H,1759.0,15146.0,1.0,449.0,Autocuration,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,
,8.0,,B,,,,CHEMBL616546,,BAO_0000357,,105.0,,,H,1760.0,5213.0,1.0,,Autocuration,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,
,8.0,,B,,,,CHEMBL616547,,BAO_0000219,CHO,105.0,,,H,1761.0,14818.0,1.0,449.0,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,
,8.0,,B,,,,CHEMBL616548,,BAO_0000219,CHO,105.0,,,H,1762.0,4829.0,1.0,449.0,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",
,8.0,,F,,,,CHEMBL616549,,BAO_0000019,,105.0,,,H,1763.0,14454.0,1.0,,Expert,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,
,8.0,,F,,,,CHEMBL616550,,BAO_0000019,,105.0,,,H,1764.0,14454.0,1.0,,Expert,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,
,8.0,,B,,,,CHEMBL857066,,BAO_0000357,,108.0,,,H,1765.0,5254.0,1.0,,Autocuration,,Binding affinity against 5-HT2C receptor,
,8.0,,B,,,,CHEMBL616551,,BAO_0000357,,108.0,,,H,1766.0,5254.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616552,,BAO_0000357,,10577.0,,,H,1767.0,10639.0,1.0,,Autocuration,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,
,8.0,,F,,,,CHEMBL832876,,BAO_0000019,,10577.0,,,H,1768.0,10639.0,1.0,,Autocuration,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,
,8.0,,B,,,,CHEMBL616553,,BAO_0000019,,10577.0,,,H,1769.0,12352.0,1.0,,Expert,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",
,8.0,,B,,,,CHEMBL616554,,BAO_0000357,,10577.0,,,H,1770.0,9098.0,1.0,,Autocuration,,Binding affinity towards 5-HT1B was determined,
,8.0,,B,,,,CHEMBL616555,,BAO_0000019,,10577.0,,,H,1771.0,14430.0,1.0,,Expert,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,
,8.0,,B,,,,CHEMBL616556,,BAO_0000019,,10577.0,,,H,1772.0,13657.0,1.0,,Expert,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",
,8.0,,B,,,,CHEMBL616557,,BAO_0000019,,10577.0,,,H,1773.0,13657.0,1.0,,Autocuration,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",
,8.0,,B,,,,CHEMBL616558,,BAO_0000019,,10577.0,,,H,1774.0,15854.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,
10116.0,9.0,,B,,,,CHEMBL616749,,BAO_0000019,,10577.0,,,D,1775.0,10639.0,1.0,,Expert,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,
,8.0,,B,,,,CHEMBL616750,,BAO_0000357,,10577.0,,,H,1776.0,10025.0,1.0,,Autocuration,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,
,8.0,,B,,,,CHEMBL616751,,BAO_0000357,,10577.0,,,H,1777.0,10025.0,1.0,,Autocuration,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",
,8.0,,B,,,,CHEMBL616752,,BAO_0000249,,10577.0,,,H,1778.0,14286.0,1.0,,Autocuration,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,
,8.0,,B,,,2435.0,CHEMBL616753,,BAO_0000019,,10577.0,,,H,1779.0,3651.0,1.0,,Autocuration,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,Striatum
10116.0,9.0,,B,,,,CHEMBL616754,,BAO_0000357,,10577.0,,,D,1780.0,14178.0,1.0,,Expert,Rattus norvegicus,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616755,,BAO_0000019,,10577.0,,,H,1781.0,10639.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,
,8.0,,B,,,2435.0,CHEMBL616756,,BAO_0000019,,10577.0,,,H,1782.0,13605.0,1.0,,Autocuration,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,Striatum
,8.0,,B,,,2435.0,CHEMBL616757,,BAO_0000019,,10577.0,,,H,1783.0,5834.0,1.0,,Autocuration,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,Striatum
,8.0,,B,,,2435.0,CHEMBL616758,,BAO_0000357,,10577.0,,,H,1784.0,10922.0,1.0,,Autocuration,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,Striatum
,8.0,,B,,,,CHEMBL616759,,BAO_0000249,,10577.0,,,H,1785.0,14286.0,1.0,,Autocuration,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,
,8.0,,B,,,,CHEMBL616760,,BAO_0000357,,10577.0,,,H,1786.0,11825.0,1.0,,Autocuration,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,
,8.0,,B,,,2435.0,CHEMBL616761,,BAO_0000019,,10577.0,,,H,1787.0,14826.0,1.0,,Autocuration,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,Striatum
,8.0,,B,,,2435.0,CHEMBL616762,,BAO_0000019,,10577.0,,,H,1788.0,9699.0,1.0,,Autocuration,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,Striatum
,8.0,,B,,,,CHEMBL616763,,BAO_0000019,,10577.0,,,H,1789.0,14423.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,
,8.0,,B,,,,CHEMBL872909,,BAO_0000357,,10577.0,,,H,1790.0,10062.0,1.0,,Expert,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,
,8.0,,B,,,,CHEMBL616764,,BAO_0000357,,10577.0,,,H,1791.0,10062.0,1.0,,Autocuration,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,
10116.0,9.0,,B,,,,CHEMBL616765,,BAO_0000357,,10577.0,,,D,1792.0,12280.0,1.0,,Expert,Rattus norvegicus,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,2435.0,CHEMBL616766,,BAO_0000357,,10577.0,,,H,1793.0,15412.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,Striatum
,8.0,,B,,,2435.0,CHEMBL616767,,BAO_0000357,,10577.0,,,H,1794.0,15412.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,Striatum
,8.0,,B,,,,CHEMBL616768,,BAO_0000357,,10577.0,,,H,1795.0,10062.0,1.0,,Autocuration,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616769,,BAO_0000357,,10577.0,,,H,1796.0,11147.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL616770,,BAO_0000019,,10577.0,,,H,1797.0,9547.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,
,8.0,,B,,,,CHEMBL616771,,BAO_0000019,,10577.0,,,H,1798.0,10444.0,1.0,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,
,8.0,,B,,,2435.0,CHEMBL616772,,BAO_0000019,,10577.0,,,H,1799.0,12469.0,1.0,,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,Striatum
,8.0,,B,,,,CHEMBL616773,,BAO_0000019,,10577.0,,,H,1800.0,9098.0,1.0,,Expert,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,
,8.0,,B,,,,CHEMBL616774,,BAO_0000019,,10577.0,,,H,1801.0,9098.0,1.0,,Autocuration,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,
,8.0,,B,,,,CHEMBL616775,,BAO_0000357,,10577.0,,,H,1802.0,9699.0,1.0,,Autocuration,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616776,,BAO_0000249,,10577.0,,,H,1803.0,10394.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,
,8.0,,B,,,,CHEMBL616777,,BAO_0000357,,10577.0,,,H,1804.0,12092.0,1.0,,Autocuration,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,
,8.0,,B,,,,CHEMBL616778,,BAO_0000357,,10577.0,,,H,1805.0,16700.0,1.0,,Autocuration,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,
10116.0,9.0,,B,,,,CHEMBL616779,,BAO_0000249,,10577.0,,,D,1806.0,403.0,1.0,,Expert,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,
10116.0,9.0,,B,,,,CHEMBL616780,,BAO_0000357,,10577.0,,,D,1807.0,12771.0,1.0,,Expert,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616781,,BAO_0000019,,10577.0,,,H,1808.0,11642.0,1.0,,Autocuration,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,
,8.0,,B,,,,CHEMBL616782,,BAO_0000357,,10577.0,,,H,1809.0,12953.0,1.0,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL616783,,BAO_0000357,,10577.0,,,H,1810.0,12953.0,1.0,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,
,8.0,,B,,,2435.0,CHEMBL616784,,BAO_0000019,,10577.0,,,H,1811.0,12953.0,1.0,,Expert,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,Striatum
,8.0,,B,,,,CHEMBL616785,,BAO_0000357,,10577.0,,,H,1812.0,12953.0,1.0,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,
,8.0,,B,,,955.0,CHEMBL857067,,BAO_0000249,,10577.0,,,H,1813.0,9737.0,1.0,,Autocuration,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain
,8.0,,B,,,,CHEMBL616786,,BAO_0000019,,10577.0,,,H,1814.0,9737.0,1.0,,Autocuration,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,
,8.0,,B,,,955.0,CHEMBL616787,,BAO_0000249,,10577.0,,,H,1815.0,9737.0,1.0,,Autocuration,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain
,8.0,,B,,,,CHEMBL616788,,BAO_0000357,,10577.0,,,H,1816.0,12827.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,
,8.0,,B,,,,CHEMBL616789,,BAO_0000357,,10577.0,,,H,1817.0,5033.0,1.0,,Autocuration,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,
10116.0,9.0,,B,,,,CHEMBL616790,,BAO_0000019,,10577.0,,,D,1818.0,9786.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,
,8.0,,B,,,,CHEMBL616791,,BAO_0000357,,10577.0,,,H,1819.0,13116.0,1.0,,Expert,,Binding affinity at 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616792,,BAO_0000019,,10577.0,,,H,1820.0,16429.0,1.0,,Autocuration,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,
10116.0,9.0,,B,,,,CHEMBL616793,,BAO_0000249,,10577.0,,,D,1821.0,12409.0,1.0,,Expert,Rattus norvegicus,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,
,8.0,,B,,,,CHEMBL616794,,BAO_0000357,,10577.0,,,H,1822.0,15194.0,1.0,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL616795,,BAO_0000357,,10577.0,,,H,1823.0,15194.0,1.0,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,
,4.0,,B,,,,CHEMBL616796,,BAO_0000019,,104686.0,,,H,1824.0,5486.0,1.0,,Autocuration,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,
,8.0,,B,,,,CHEMBL616797,,BAO_0000357,,106.0,,,H,1825.0,4639.0,1.0,,Autocuration,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616798,,BAO_0000249,,106.0,,Brain membranes,H,1826.0,386.0,1.0,,Autocuration,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,
,8.0,,B,,,,CHEMBL616799,,BAO_0000357,,106.0,,,H,1827.0,2474.0,1.0,,Autocuration,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,
,8.0,,B,,,,CHEMBL616800,,BAO_0000357,,106.0,,,H,1828.0,6011.0,1.0,,Autocuration,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,
,8.0,,B,,,,CHEMBL616801,,BAO_0000357,,106.0,,,H,1829.0,5014.0,1.0,,Autocuration,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616802,,BAO_0000357,,106.0,,,H,1830.0,17515.0,1.0,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,
,8.0,,B,,,,CHEMBL616803,,BAO_0000357,,106.0,,,H,1831.0,4373.0,1.0,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,
,8.0,,B,,,,CHEMBL857068,,BAO_0000357,,106.0,,,H,1832.0,1633.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,
,8.0,,B,,,,CHEMBL616804,,BAO_0000357,,106.0,,,H,1833.0,1633.0,1.0,,Autocuration,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,
,8.0,,B,,,,CHEMBL616805,,BAO_0000357,,106.0,,,H,1834.0,4373.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,
,8.0,,B,,,,CHEMBL616806,,BAO_0000357,,106.0,,,H,1835.0,4687.0,1.0,,Autocuration,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616807,,BAO_0000357,,106.0,,,H,1836.0,11574.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1B receptor,
,8.0,,B,,,,CHEMBL616808,,BAO_0000357,,106.0,,,H,1837.0,10321.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL616809,,BAO_0000357,,106.0,,,H,1838.0,15527.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,
,8.0,,B,,,,CHEMBL616810,,BAO_0000357,,106.0,,,H,1839.0,17200.0,1.0,,Autocuration,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,
,4.0,,B,,,,CHEMBL616811,,BAO_0000224,,104802.0,,,H,1840.0,14423.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,
9913.0,8.0,,B,,,,CHEMBL616812,,BAO_0000357,,108.0,,,H,1841.0,5834.0,1.0,,Autocuration,Bos taurus,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,
9823.0,8.0,,B,,,,CHEMBL616813,,BAO_0000357,,108.0,,,H,1842.0,11473.0,1.0,,Autocuration,Sus scrofa,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,
9823.0,8.0,,B,,,,CHEMBL616814,,BAO_0000357,,108.0,,,H,1843.0,11473.0,1.0,,Autocuration,Sus scrofa,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,
9823.0,8.0,,B,,,,CHEMBL616815,,BAO_0000357,,108.0,,,H,1844.0,10639.0,1.0,,Autocuration,Sus scrofa,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,
9823.0,8.0,,B,,,,CHEMBL616816,,BAO_0000357,,108.0,,,H,1845.0,10639.0,1.0,,Autocuration,Sus scrofa,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,
9823.0,8.0,,B,,,,CHEMBL616817,,BAO_0000357,,108.0,,,H,1846.0,14331.0,1.0,,Autocuration,Sus scrofa,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,
9823.0,8.0,,B,,,,CHEMBL616818,,BAO_0000357,,108.0,,,H,1847.0,10796.0,1.0,,Autocuration,Sus scrofa,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,
9823.0,8.0,,B,,,,CHEMBL616819,,BAO_0000357,,108.0,,,H,1848.0,9098.0,1.0,,Expert,Sus scrofa,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,
9823.0,8.0,,B,,,,CHEMBL616820,,BAO_0000357,,108.0,,,H,1849.0,14331.0,1.0,,Expert,Sus scrofa,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,
9823.0,8.0,,B,,,,CHEMBL616821,,BAO_0000019,,108.0,,,H,1850.0,11828.0,1.0,,Expert,Sus scrofa,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,
9823.0,8.0,,B,,,,CHEMBL616822,,BAO_0000357,,108.0,,,H,1851.0,11866.0,1.0,,Autocuration,Sus scrofa,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,
9986.0,8.0,,B,,,,CHEMBL616823,,BAO_0000019,,108.0,,,H,1852.0,13047.0,1.0,,Autocuration,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,
10116.0,9.0,,B,,,,CHEMBL616824,,BAO_0000357,,12689.0,,,D,1853.0,188.0,1.0,,Autocuration,Rattus norvegicus,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,
10116.0,9.0,,B,,,,CHEMBL616825,,BAO_0000357,,12689.0,,,D,1854.0,11825.0,1.0,,Autocuration,Rattus norvegicus,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,
10116.0,9.0,,B,,,,CHEMBL616826,,BAO_0000357,,12689.0,,,D,1855.0,11825.0,1.0,,Autocuration,Rattus norvegicus,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,
10116.0,9.0,,B,,,,CHEMBL616827,,BAO_0000019,,12689.0,,,D,1856.0,11624.0,1.0,,Expert,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,
10116.0,9.0,,B,,,,CHEMBL616828,,BAO_0000357,,12689.0,,,D,1857.0,11139.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,
10116.0,9.0,,B,,,,CHEMBL616829,,BAO_0000357,,12689.0,,,D,1858.0,11147.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,
10116.0,9.0,,B,,,,CHEMBL616830,,BAO_0000019,,12689.0,,,D,1859.0,10444.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,
10116.0,9.0,,B,,,,CHEMBL616831,,BAO_0000357,,12689.0,,,D,1860.0,11624.0,1.0,,Expert,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1C receptor,
10116.0,9.0,,B,,,,CHEMBL616832,,BAO_0000019,,12689.0,,,D,1861.0,11662.0,1.0,,Autocuration,Rattus norvegicus,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",
10116.0,9.0,,B,,,,CHEMBL616833,,BAO_0000019,,12689.0,,,D,1862.0,11662.0,1.0,,Autocuration,Rattus norvegicus,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",
10116.0,9.0,,B,,,,CHEMBL616834,,BAO_0000019,,12689.0,,,D,1863.0,11662.0,1.0,,Expert,Rattus norvegicus,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",
10116.0,9.0,,B,,,,CHEMBL829595,,BAO_0000019,,12689.0,,,D,1864.0,11662.0,1.0,,Autocuration,Rattus norvegicus,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",
10116.0,9.0,,B,,,,CHEMBL616835,,BAO_0000357,,12689.0,,,D,1865.0,9098.0,1.0,,Autocuration,Rattus norvegicus,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,
10116.0,9.0,,B,,,,CHEMBL872910,,BAO_0000249,,12689.0,,,D,1866.0,10394.0,1.0,,Autocuration,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,
,8.0,,B,,,,CHEMBL616836,,BAO_0000357,,12689.0,,,H,1867.0,11933.0,1.0,,Expert,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,
10116.0,9.0,,B,,,,CHEMBL616837,,BAO_0000357,,12689.0,,,D,1868.0,12092.0,1.0,,Autocuration,Rattus norvegicus,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,
10116.0,9.0,,B,,,,CHEMBL616466,,BAO_0000019,,12689.0,,,D,1869.0,12253.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,
10116.0,9.0,,B,,,,CHEMBL616467,,BAO_0000219,HEK293,12689.0,,,D,1870.0,12253.0,1.0,722.0,Autocuration,Rattus norvegicus,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,
,8.0,,B,,,,CHEMBL616468,,BAO_0000357,,108.0,,,H,1871.0,1558.0,1.0,,Autocuration,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,
,8.0,,B,,,,CHEMBL616469,,BAO_0000357,,108.0,,,H,1872.0,2474.0,1.0,,Autocuration,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,
,8.0,,B,,,,CHEMBL616470,,BAO_0000357,,108.0,,,H,1873.0,2474.0,1.0,,Autocuration,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,
,8.0,,B,,,,CHEMBL616471,,BAO_0000357,,12689.0,,,H,1874.0,11574.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1C receptor,
,8.0,,B,,,,CHEMBL616472,,BAO_0000357,,12689.0,,,H,1875.0,1558.0,1.0,,Autocuration,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,
,8.0,,B,,,,CHEMBL616473,,BAO_0000357,,12689.0,,,H,1876.0,13944.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1C receptor,
,8.0,,B,,,,CHEMBL616474,,BAO_0000357,,12689.0,,,H,1877.0,13033.0,1.0,,Autocuration,,Binding affinity against serotonergic 5-HT1c receptor,
,8.0,,B,,,,CHEMBL616475,,BAO_0000357,,12689.0,,,H,1878.0,10321.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,
,8.0,,B,,,,CHEMBL616476,,BAO_0000357,,12689.0,,,H,1879.0,11866.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,
9986.0,8.0,,B,,,,CHEMBL616477,,BAO_0000019,,105.0,,,H,1880.0,14454.0,1.0,,Autocuration,Oryctolagus cuniculus,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),
,4.0,,B,,,,CHEMBL616478,,BAO_0000224,,104686.0,,,H,1881.0,11574.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,
,4.0,,B,,,,CHEMBL616479,,BAO_0000224,,104686.0,,,H,1882.0,11574.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,
,4.0,,B,,,,CHEMBL616480,,BAO_0000019,,104686.0,,,H,1883.0,13631.0,1.0,,Autocuration,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,
10116.0,5.0,,B,,,,CHEMBL616481,,BAO_0000019,,104686.0,,,D,1884.0,9630.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,
10116.0,5.0,,B,,,,CHEMBL616482,,BAO_0000249,,104686.0,,,D,1885.0,8822.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,
10116.0,5.0,,B,,,955.0,CHEMBL884713,,BAO_0000221,,104686.0,,,D,1886.0,9064.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,Brain
,4.0,,B,,,,CHEMBL616483,,BAO_0000224,,104686.0,,,H,1887.0,8868.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,
,4.0,,B,,,,CHEMBL616484,,BAO_0000224,,104686.0,,,H,1888.0,9064.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,
,4.0,,B,,,,CHEMBL616485,,BAO_0000019,,104686.0,,,H,1889.0,9806.0,1.0,,Autocuration,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,
,4.0,,B,,,,CHEMBL616486,,BAO_0000224,,104686.0,,,H,1890.0,9098.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,
,4.0,,B,,,,CHEMBL616487,,BAO_0000224,,104686.0,,,H,1891.0,8868.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,
,4.0,,B,,,,CHEMBL616488,,BAO_0000224,,104686.0,,,H,1892.0,12765.0,1.0,,Autocuration,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,
,4.0,,B,,,,CHEMBL616489,,BAO_0000019,,104686.0,,,H,1893.0,11049.0,1.0,,Autocuration,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,
,4.0,,B,,,,CHEMBL616490,,BAO_0000019,,104686.0,,,H,1894.0,11049.0,1.0,,Autocuration,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,
,4.0,,B,,,,CHEMBL616491,,BAO_0000019,,104686.0,,,H,1895.0,11049.0,1.0,,Autocuration,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,
,4.0,,B,,,,CHEMBL616492,,BAO_0000019,,104686.0,,,H,1896.0,11049.0,1.0,,Autocuration,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,
,4.0,,B,,,,CHEMBL616493,,BAO_0000019,,104686.0,,,H,1897.0,11049.0,1.0,,Autocuration,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,
,4.0,,B,,,,CHEMBL616494,,BAO_0000019,,104686.0,,,H,1898.0,11473.0,1.0,,Autocuration,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,
,4.0,,B,,,,CHEMBL616495,,BAO_0000019,,104686.0,,,H,1899.0,11473.0,1.0,,Autocuration,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,
,4.0,,B,,,,CHEMBL616496,,BAO_0000019,,104686.0,,,H,1900.0,3086.0,1.0,,Autocuration,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,
,4.0,,B,,,,CHEMBL616497,,BAO_0000019,,104686.0,,,H,1901.0,11049.0,1.0,,Autocuration,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,
,4.0,,B,,,,CHEMBL616498,,BAO_0000019,,104686.0,,,H,1902.0,11049.0,1.0,,Autocuration,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,
,4.0,,B,,,,CHEMBL616499,,BAO_0000019,,104686.0,,,H,1903.0,10639.0,1.0,,Autocuration,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,
,4.0,,B,,,,CHEMBL616500,,BAO_0000019,,104686.0,,,H,1904.0,10922.0,1.0,,Autocuration,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,
10116.0,5.0,,B,,,955.0,CHEMBL616501,,BAO_0000221,,104686.0,,,D,1905.0,9064.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Brain
,4.0,,B,,,955.0,CHEMBL616502,,BAO_0000221,,104686.0,,,H,1906.0,10748.0,1.0,,Autocuration,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,Brain
,4.0,,B,,,,CHEMBL884529,,BAO_0000249,,104686.0,,Membranes,H,1907.0,11614.0,1.0,,Autocuration,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,
,4.0,,B,,,,CHEMBL616503,,BAO_0000249,,104686.0,,Membranes,H,1908.0,11615.0,1.0,,Autocuration,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,
,4.0,,B,,,,CHEMBL616964,,BAO_0000224,,104686.0,,,H,1909.0,11615.0,1.0,,Autocuration,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL616965,,BAO_0000249,,104686.0,,Membranes,H,1910.0,11614.0,1.0,,Autocuration,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,
,4.0,,B,,,,CHEMBL616966,,BAO_0000224,,104686.0,,,H,1911.0,11702.0,1.0,,Autocuration,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,
,4.0,,B,,,,CHEMBL616967,,BAO_0000224,,104686.0,,,H,1912.0,11702.0,1.0,,Autocuration,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,
10116.0,5.0,,B,,,,CHEMBL616968,,BAO_0000224,,104686.0,,,D,1913.0,11702.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL616969,,BAO_0000224,,104686.0,,,H,1914.0,11702.0,1.0,,Autocuration,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,
,4.0,,B,,,,CHEMBL884530,,BAO_0000019,,104686.0,,,H,1915.0,13346.0,1.0,,Autocuration,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,
,4.0,,B,,,,CHEMBL616970,,BAO_0000224,,104686.0,,,H,1916.0,10025.0,1.0,,Autocuration,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL616971,,BAO_0000224,,104686.0,,,H,1917.0,10025.0,1.0,,Autocuration,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,
,4.0,,B,,,,CHEMBL616972,,BAO_0000224,,104686.0,,,H,1918.0,10025.0,1.0,,Autocuration,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",
,4.0,,B,,,,CHEMBL616973,,BAO_0000224,,104686.0,,,H,1919.0,9036.0,1.0,,Autocuration,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,
,4.0,,B,,,,CHEMBL616974,,BAO_0000224,,104686.0,,,H,1920.0,9036.0,1.0,,Autocuration,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,
,4.0,,B,,,,CHEMBL616975,,BAO_0000019,,104686.0,,,H,1921.0,9161.0,1.0,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,
,4.0,,B,,,,CHEMBL616976,,BAO_0000019,,104686.0,,,H,1922.0,12304.0,1.0,,Autocuration,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,
,4.0,,B,,,,CHEMBL616977,,BAO_0000224,,104686.0,,,H,1923.0,13276.0,1.0,,Autocuration,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,
,4.0,,B,,,,CHEMBL616978,,BAO_0000224,,104686.0,,,H,1924.0,11825.0,1.0,,Autocuration,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,
,4.0,,B,,,,CHEMBL616979,,BAO_0000224,,104686.0,,,H,1925.0,12443.0,1.0,,Autocuration,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,
,4.0,,B,,,,CHEMBL616980,,BAO_0000224,,104686.0,,,H,1926.0,13830.0,1.0,,Autocuration,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL616981,,BAO_0000249,,104686.0,,Membranes,H,1927.0,9592.0,1.0,,Autocuration,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,
,4.0,,B,,,,CHEMBL616982,,BAO_0000249,,104686.0,,Membranes,H,1928.0,9592.0,1.0,,Autocuration,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,
,4.0,,B,,,,CHEMBL616983,,BAO_0000224,,104686.0,,,H,1929.0,10881.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,
,4.0,,B,,,,CHEMBL616984,,BAO_0000019,,104686.0,,,H,1930.0,13605.0,1.0,,Autocuration,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,
10116.0,5.0,,B,,,,CHEMBL616985,,BAO_0000224,,104686.0,,,D,1931.0,11624.0,1.0,,Autocuration,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL616986,,BAO_0000224,,104686.0,,,H,1932.0,4101.0,1.0,,Autocuration,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,
,4.0,,B,,,,CHEMBL616987,,BAO_0000224,,104686.0,,,H,1933.0,4101.0,1.0,,Autocuration,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,
,4.0,,B,,,,CHEMBL616988,,BAO_0000019,,104686.0,,,H,1934.0,15360.0,1.0,,Autocuration,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,
,4.0,,B,,,,CHEMBL617243,,BAO_0000019,,104686.0,,,H,1935.0,11576.0,1.0,,Autocuration,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,
,4.0,,B,,,,CHEMBL617244,,BAO_0000019,,104686.0,,,H,1936.0,5834.0,1.0,,Autocuration,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,
10116.0,5.0,,B,,,,CHEMBL617245,,BAO_0000219,CHO-K1,104686.0,,,D,1937.0,2395.0,1.0,485.0,Autocuration,Rattus norvegicus,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,
,4.0,,B,,,,CHEMBL617246,,BAO_0000249,,104686.0,,Membranes,H,1938.0,11965.0,1.0,,Autocuration,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,
,4.0,,B,,,,CHEMBL617546,,BAO_0000224,,104686.0,,,H,1939.0,3967.0,1.0,,Autocuration,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),
,4.0,,B,,,,CHEMBL617547,,BAO_0000249,,104686.0,,Brain membranes,H,1940.0,11130.0,1.0,,Autocuration,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),
,4.0,,B,,,,CHEMBL617548,,BAO_0000219,,104686.0,In vitro,,H,1941.0,13427.0,1.0,,Autocuration,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,
,4.0,,B,,,,CHEMBL617549,,BAO_0000224,,104686.0,,,H,1942.0,9443.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617550,,BAO_0000224,,104686.0,,,H,1943.0,9443.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,
,4.0,,B,,,,CHEMBL617551,,BAO_0000224,,104686.0,,,H,1944.0,11825.0,1.0,,Autocuration,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,
,4.0,,B,,,,CHEMBL617552,,BAO_0000249,,104686.0,,Membranes,H,1945.0,12120.0,1.0,,Autocuration,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,
,4.0,,B,,,,CHEMBL617553,,BAO_0000249,,104686.0,,Membranes,H,1946.0,12120.0,1.0,,Autocuration,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,
,4.0,,F,,,1515.0,CHEMBL617554,,BAO_0000019,,104686.0,,,H,1947.0,11963.0,1.0,,Autocuration,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,Thoracic aorta
,4.0,,B,,,,CHEMBL617555,,BAO_0000019,,104686.0,,,H,1948.0,9069.0,1.0,,Autocuration,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617556,,BAO_0000224,,104686.0,,,H,1949.0,8868.0,1.0,,Autocuration,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,
,8.0,,B,,,,CHEMBL617557,,BAO_0000357,,10624.0,,,H,1950.0,17200.0,1.0,,Autocuration,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,
,8.0,,B,,,,CHEMBL617558,,BAO_0000357,,10624.0,,,H,1951.0,17200.0,1.0,,Autocuration,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,
,8.0,,B,,,,CHEMBL617559,,BAO_0000357,,17106.0,,,H,1952.0,13969.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,
,9.0,,B,,,,CHEMBL617560,,BAO_0000357,,17106.0,,,D,1953.0,13392.0,1.0,,Expert,,Binding affinity for 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL617561,,BAO_0000249,,17106.0,,,H,1954.0,1742.0,1.0,,Autocuration,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,
,8.0,,B,,,,CHEMBL617562,,BAO_0000249,,17106.0,,,H,1955.0,1742.0,1.0,,Autocuration,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,
,8.0,,B,,,2435.0,CHEMBL617563,,BAO_0000357,,17106.0,,,H,1956.0,14331.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,Striatum
,8.0,,F,,,,CHEMBL617564,,BAO_0000019,,17106.0,,,H,1957.0,12861.0,1.0,,Autocuration,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL617565,,BAO_0000019,,17106.0,,,H,1958.0,12861.0,1.0,,Expert,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL856076,,BAO_0000357,,17106.0,,,H,1959.0,12861.0,1.0,,Autocuration,,Binding activity radioligand.,
,8.0,,B,,,,CHEMBL617566,,BAO_0000019,,17106.0,,,H,1960.0,12861.0,1.0,,Autocuration,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,
,8.0,,B,,,,CHEMBL875911,,BAO_0000019,,17106.0,,,H,1961.0,12861.0,1.0,,Expert,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,
,8.0,,B,,,,CHEMBL617567,,BAO_0000019,,17106.0,,,H,1962.0,12861.0,1.0,,Autocuration,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,
,8.0,,B,,,,CHEMBL617568,,BAO_0000249,,17106.0,,,H,1963.0,675.0,1.0,,Autocuration,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,
,8.0,,B,,,,CHEMBL617569,,BAO_0000019,,17106.0,,,H,1964.0,12490.0,1.0,,Expert,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,
,8.0,,B,,,,CHEMBL617570,,BAO_0000249,,17106.0,,,H,1965.0,11828.0,1.0,,Expert,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,
,8.0,,B,,,,CHEMBL617571,,BAO_0000357,,17106.0,,,H,1966.0,11866.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,
9823.0,8.0,,B,,,,CHEMBL617572,,BAO_0000357,,105.0,,,H,1967.0,773.0,1.0,,Autocuration,Sus scrofa,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,
9986.0,8.0,,B,,,,CHEMBL617573,,BAO_0000357,,105.0,,,H,1968.0,13047.0,1.0,,Expert,Oryctolagus cuniculus,The compound was tested for intrinsic activity against 5-HT1D receptor,
9986.0,8.0,,B,,,,CHEMBL617574,,BAO_0000019,,105.0,,,H,1969.0,13047.0,1.0,,Autocuration,Oryctolagus cuniculus,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,
9986.0,8.0,,B,,,,CHEMBL617575,,BAO_0000357,,105.0,,,H,1970.0,13047.0,1.0,,Expert,Oryctolagus cuniculus,The compound was tested for binding affinity against 5-HT1D receptor,
,8.0,,B,,,,CHEMBL617576,,BAO_0000357,,10578.0,,,H,1971.0,188.0,1.0,,Autocuration,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,
,8.0,,F,,,,CHEMBL617577,,BAO_0000019,,10578.0,,,H,1972.0,10639.0,1.0,,Autocuration,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,
,8.0,,F,,,,CHEMBL617578,,BAO_0000019,,10578.0,,,H,1973.0,12438.0,1.0,,Autocuration,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL617579,,BAO_0000357,,10578.0,,,H,1974.0,12438.0,1.0,,Autocuration,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL617580,,BAO_0000019,,10578.0,,,H,1975.0,15854.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,
,8.0,,B,,,,CHEMBL617581,,BAO_0000249,,10578.0,,,H,1976.0,10394.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,
,8.0,,B,,,,CHEMBL617582,,BAO_0000357,,10578.0,,,H,1977.0,12092.0,1.0,,Autocuration,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,
,8.0,,B,,,,CHEMBL617583,,BAO_0000019,,10578.0,,,H,1978.0,3389.0,1.0,,Expert,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,
,8.0,,B,,,,CHEMBL617584,,BAO_0000357,,105.0,,,H,1979.0,6011.0,1.0,,Autocuration,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,
,8.0,,B,,,,CHEMBL617585,,BAO_0000357,,105.0,,,H,1980.0,4639.0,1.0,,Autocuration,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL875912,,BAO_0000357,,105.0,,,H,1981.0,2474.0,1.0,,Autocuration,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL617586,,BAO_0000357,,105.0,,,H,1982.0,5014.0,1.0,,Autocuration,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL617587,,BAO_0000357,,105.0,,,H,1983.0,17515.0,1.0,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,
,8.0,,B,,,,CHEMBL617588,,BAO_0000357,,105.0,,,H,1984.0,11866.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,
,8.0,,B,,,,CHEMBL857980,,BAO_0000357,,105.0,,,H,1985.0,4687.0,1.0,,Autocuration,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL617589,,BAO_0000357,,105.0,,,H,1986.0,12146.0,1.0,,Autocuration,,Tested against 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL617590,,BAO_0000357,,105.0,,,H,1987.0,10321.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL617591,,BAO_0000219,HEK293,105.0,,,H,1988.0,13267.0,1.0,722.0,Autocuration,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,
9606.0,9.0,,B,,,,CHEMBL617592,,BAO_0000357,,105.0,,,D,1989.0,1274.0,1.0,,Expert,Homo sapiens,Binding affinity against 5-Hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL617593,,BAO_0000357,,105.0,,,H,1990.0,15250.0,1.0,,Autocuration,,,
,8.0,,B,,,,CHEMBL617594,,BAO_0000219,CHO-K1,106.0,,,H,1991.0,13706.0,1.0,485.0,Autocuration,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,
,8.0,,B,,,,CHEMBL617595,,BAO_0000219,CHO-K1,105.0,,,H,1992.0,13706.0,1.0,485.0,Autocuration,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,
,8.0,,B,,,,CHEMBL617596,,BAO_0000219,HEK293,105.0,,,H,1993.0,13706.0,1.0,722.0,Autocuration,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,
,8.0,,B,,,,CHEMBL617597,,BAO_0000219,HEK293,105.0,,,H,1994.0,13706.0,1.0,722.0,Autocuration,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,
,8.0,,B,,,,CHEMBL617598,,BAO_0000019,,105.0,,,H,1995.0,13047.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,
,8.0,,B,,,,CHEMBL872916,,BAO_0000357,,105.0,,,H,1996.0,13366.0,1.0,,Autocuration,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,
,8.0,,B,,,,CHEMBL617599,,BAO_0000357,,105.0,,,H,1997.0,13366.0,1.0,,Expert,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,
,8.0,,B,,,,CHEMBL617091,,BAO_0000357,,105.0,,,H,1998.0,1558.0,1.0,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,
,8.0,,B,,,,CHEMBL617092,,BAO_0000219,CHO-K1,105.0,,,H,1999.0,12902.0,1.0,485.0,Expert,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",
,8.0,,B,,,,CHEMBL617093,,BAO_0000219,CHO-K1,105.0,,,H,2000.0,13706.0,1.0,485.0,Autocuration,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,
,8.0,,F,,,,CHEMBL617094,,BAO_0000019,,105.0,,,H,2001.0,13706.0,1.0,,Autocuration,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,
,8.0,,F,,,,CHEMBL617095,,BAO_0000019,,105.0,,,H,2002.0,13706.0,1.0,,Autocuration,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,
,8.0,,F,,,,CHEMBL617096,,BAO_0000019,,105.0,,,H,2003.0,14251.0,1.0,,Autocuration,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,
,8.0,,F,,,,CHEMBL617097,,BAO_0000019,,105.0,,,H,2004.0,14251.0,1.0,,Autocuration,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,
,8.0,,F,,,,CHEMBL617098,,BAO_0000019,,105.0,,,H,2005.0,14251.0,1.0,,Autocuration,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,
,8.0,,B,,,,CHEMBL617301,,BAO_0000357,,105.0,,,H,2006.0,13313.0,1.0,,Autocuration,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL617302,,BAO_0000357,,105.0,,,H,2007.0,13313.0,1.0,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL617303,,BAO_0000357,,105.0,,,H,2008.0,13366.0,1.0,,Autocuration,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,
,8.0,,B,,,,CHEMBL617304,,BAO_0000357,,105.0,,,H,2009.0,13051.0,1.0,,Expert,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,
,8.0,,B,,,,CHEMBL617305,,BAO_0000219,CHO,105.0,,,H,2010.0,12903.0,1.0,449.0,Expert,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",
9606.0,9.0,,B,,,,CHEMBL617306,,BAO_0000219,,105.0,,,D,2011.0,12469.0,1.0,,Autocuration,Homo sapiens,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,
,8.0,,B,,,,CHEMBL617307,,BAO_0000357,,17106.0,,,H,2012.0,5619.0,1.0,,Autocuration,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,
9986.0,8.0,,B,,,,CHEMBL617308,,BAO_0000019,,105.0,,,H,2013.0,13047.0,1.0,,Autocuration,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,
,8.0,,B,,,,CHEMBL617309,,BAO_0000357,,105.0,,,H,2014.0,16633.0,1.0,,Autocuration,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,
,8.0,,B,,,,CHEMBL617310,,BAO_0000357,,105.0,,,H,2015.0,16633.0,1.0,,Autocuration,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,
,8.0,,B,,,,CHEMBL617311,,BAO_0000357,,105.0,,,H,2016.0,16633.0,1.0,,Autocuration,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,
,8.0,,B,,,,CHEMBL617312,,BAO_0000357,,105.0,,,H,2017.0,16633.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL617313,,BAO_0000357,,105.0,,,H,2018.0,3269.0,1.0,,Autocuration,,Affinity against 5-hydroxytryptamine 1D receptor alpha,
,8.0,,B,,,,CHEMBL617314,,BAO_0000357,,105.0,,,H,2019.0,12409.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,
,8.0,,F,,,,CHEMBL617315,,BAO_0000019,,106.0,,,H,2020.0,13706.0,1.0,,Autocuration,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,
,8.0,,B,,,,CHEMBL617316,,BAO_0000219,HEK293,106.0,,,H,2021.0,13706.0,1.0,722.0,Autocuration,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,
,8.0,,B,,,,CHEMBL617317,,BAO_0000219,HEK293,106.0,,,H,2022.0,13706.0,1.0,722.0,Autocuration,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,
,8.0,,B,,,,CHEMBL617318,,BAO_0000219,CHO,106.0,,,H,2023.0,12903.0,1.0,449.0,Autocuration,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",
,8.0,,B,,,,CHEMBL617319,,BAO_0000019,,106.0,,,H,2024.0,13047.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,
,9.0,,B,,,,CHEMBL617320,,BAO_0000357,,106.0,,,D,2025.0,13366.0,1.0,,Expert,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,
,9.0,,B,,,,CHEMBL617321,,BAO_0000357,,106.0,,,D,2026.0,13366.0,1.0,,Expert,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,
,9.0,,B,,,,CHEMBL617322,,BAO_0000357,,106.0,,,D,2027.0,13366.0,1.0,,Expert,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,
,8.0,,B,,,,CHEMBL616862,,BAO_0000357,,106.0,,,H,2028.0,13366.0,1.0,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL616863,,BAO_0000357,,106.0,,,H,2029.0,13366.0,1.0,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,
,8.0,,B,,,,CHEMBL616864,,BAO_0000219,CHO,106.0,,,H,2030.0,12469.0,1.0,449.0,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,
,8.0,,B,,,,CHEMBL616865,,BAO_0000219,CHO-K1,106.0,,,H,2031.0,13706.0,1.0,485.0,Autocuration,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,
,8.0,,B,,,,CHEMBL616866,,BAO_0000219,CHO-K1,106.0,,,H,2032.0,13706.0,1.0,485.0,Autocuration,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,
,8.0,,F,,,,CHEMBL616867,,BAO_0000019,,106.0,,,H,2033.0,13706.0,1.0,,Autocuration,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,
,8.0,,B,,,,CHEMBL616868,,BAO_0000219,CHO-K1,106.0,,,H,2034.0,12902.0,1.0,485.0,Expert,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",
,8.0,,B,,,,CHEMBL616869,,BAO_0000357,,105.0,,,H,2035.0,13051.0,1.0,,Expert,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,
,8.0,,B,,,,CHEMBL616870,,BAO_0000219,CHO,106.0,,,H,2036.0,12903.0,1.0,449.0,Expert,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",
,8.0,,F,,,,CHEMBL616871,,BAO_0000219,CHO-K1,105.0,,,H,2037.0,1558.0,1.0,485.0,Autocuration,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,
,8.0,,F,,,,CHEMBL616872,,BAO_0000219,CHO-K1,105.0,,,H,2038.0,1558.0,1.0,485.0,Autocuration,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,
,8.0,,F,,,,CHEMBL616873,,BAO_0000219,CHO-K1,105.0,,,H,2039.0,1558.0,1.0,485.0,Autocuration,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,
,8.0,,F,,,,CHEMBL616838,,BAO_0000219,CHO-K1,105.0,,,H,2040.0,1558.0,1.0,485.0,Autocuration,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,
,8.0,,B,,,,CHEMBL616839,,BAO_0000357,,105.0,,,H,2041.0,1558.0,1.0,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,
9986.0,8.0,,B,,,,CHEMBL616840,,BAO_0000019,,106.0,,,H,2042.0,13047.0,1.0,,Autocuration,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,
,8.0,,B,,,,CHEMBL616841,,BAO_0000357,,105.0,,,H,2043.0,13313.0,1.0,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,
,8.0,,B,,,,CHEMBL616842,,BAO_0000357,,105.0,,,H,2044.0,13313.0,1.0,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL857976,,BAO_0000357,,105.0,,,H,2045.0,12409.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,
,8.0,,B,,,,CHEMBL616843,,BAO_0000219,CHO,10618.0,,,H,2046.0,15250.0,1.0,449.0,Autocuration,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,
9606.0,9.0,,B,,,,CHEMBL616844,,BAO_0000357,,10618.0,,,D,2047.0,1348.0,1.0,,Expert,Homo sapiens,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,
,8.0,,B,,,,CHEMBL616845,,BAO_0000357,,10618.0,,,H,2048.0,1348.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,
9606.0,9.0,,B,,,,CHEMBL616846,,BAO_0000357,,10618.0,,,D,2049.0,4234.0,1.0,,Expert,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,
,8.0,,B,,,,CHEMBL616847,,BAO_0000357,,10618.0,,,H,2050.0,16209.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL616848,,BAO_0000019,,10618.0,,,H,2051.0,10444.0,1.0,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,
,8.0,,B,,,,CHEMBL616849,,BAO_0000357,,10618.0,,,H,2052.0,3935.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,
,8.0,,B,,,,CHEMBL872911,,BAO_0000357,,10618.0,,,H,2053.0,15818.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,
,8.0,,B,,,,CHEMBL616850,,BAO_0000019,,10618.0,,,H,2054.0,17085.0,1.0,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,
9606.0,9.0,,B,,,,CHEMBL616699,,BAO_0000219,CHO,10618.0,,,D,2055.0,12936.0,1.0,449.0,Expert,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,
,8.0,,B,,,,CHEMBL616700,,BAO_0000357,,10618.0,,,H,2056.0,6166.0,1.0,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,
,8.0,,B,,,,CHEMBL616701,,BAO_0000219,CHO,10618.0,,,H,2057.0,15779.0,1.0,449.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,
,8.0,,B,,,,CHEMBL616702,,BAO_0000219,CHO,10618.0,,,H,2058.0,15779.0,1.0,449.0,Autocuration,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,
,8.0,,B,,,,CHEMBL616703,,BAO_0000219,CHO,10618.0,,,H,2059.0,15779.0,1.0,449.0,Autocuration,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,
,8.0,,B,,,,CHEMBL616704,,BAO_0000357,,10618.0,,,H,2060.0,13181.0,1.0,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,
,8.0,,B,,,,CHEMBL616705,,BAO_0000219,CHO,10618.0,,,H,2061.0,4199.0,1.0,449.0,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,
,8.0,,B,,,,CHEMBL616706,,BAO_0000357,,10618.0,,,H,2062.0,14875.0,1.0,,Autocuration,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,
,8.0,,B,,,,CHEMBL616707,,BAO_0000219,CHO,10618.0,,,H,2063.0,15146.0,1.0,449.0,Autocuration,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,
,8.0,,B,,,,CHEMBL616708,,BAO_0000357,,10618.0,,,H,2064.0,5213.0,1.0,,Autocuration,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,
,8.0,,B,,,,CHEMBL616709,,BAO_0000357,,10618.0,,,H,2065.0,12146.0,1.0,,Autocuration,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL616710,,BAO_0000219,CHO,10618.0,,,H,2066.0,13267.0,1.0,449.0,Autocuration,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,
,8.0,,B,,,,CHEMBL616711,,BAO_0000219,CHO,10618.0,,,H,2067.0,14818.0,1.0,449.0,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,
,8.0,,B,,,,CHEMBL616712,,BAO_0000219,CHO,10618.0,,,H,2068.0,4829.0,1.0,449.0,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",
,8.0,,B,,,,CHEMBL616713,,BAO_0000357,,10618.0,,,H,2069.0,4373.0,1.0,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,
,8.0,,B,,,,CHEMBL616714,,BAO_0000357,,10618.0,,,H,2070.0,4373.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,
,8.0,,B,,,,CHEMBL616715,,BAO_0000357,,10618.0,,,H,2071.0,14159.0,1.0,,Autocuration,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,
,8.0,,B,,,,CHEMBL616716,,BAO_0000357,,10618.0,,,H,2072.0,16633.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1E receptor,
,8.0,,F,,,,CHEMBL616717,,BAO_0000019,,279.0,,,H,2073.0,17085.0,1.0,,Autocuration,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",
,8.0,,F,,,,CHEMBL616718,,BAO_0000019,,279.0,,,H,2074.0,17085.0,1.0,,Expert,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",
,8.0,,F,,,,CHEMBL875905,,BAO_0000019,,279.0,,,H,2075.0,16209.0,1.0,,Autocuration,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,
,8.0,,F,,,,CHEMBL616719,,BAO_0000019,,279.0,,,H,2076.0,16209.0,1.0,,Autocuration,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,
,8.0,,F,,,,CHEMBL616720,,BAO_0000019,,279.0,,,H,2077.0,17085.0,1.0,,Expert,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",
,8.0,,B,,,,CHEMBL616721,,BAO_0000357,,279.0,,,H,2078.0,14159.0,1.0,,Autocuration,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,
,8.0,,B,,,,CHEMBL616722,,BAO_0000219,CHO,279.0,,,H,2079.0,15250.0,1.0,449.0,Autocuration,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,
,8.0,,B,,,,CHEMBL616723,,BAO_0000357,,279.0,,,H,2080.0,3805.0,1.0,,Autocuration,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),
,8.0,,B,,,,CHEMBL616724,,BAO_0000219,CHO,279.0,,,H,2081.0,16190.0,1.0,449.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,
,8.0,,B,,,,CHEMBL616725,,BAO_0000357,,279.0,,,H,2082.0,16190.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,
,8.0,,B,,,,CHEMBL616726,,BAO_0000357,,279.0,,,H,2083.0,16209.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,
,8.0,,B,,,,CHEMBL616727,,BAO_0000357,,279.0,,,H,2084.0,16209.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,
,8.0,,B,,,,CHEMBL616728,,BAO_0000357,,279.0,,,H,2085.0,16209.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,
,8.0,,B,,,,CHEMBL616729,,BAO_0000357,,279.0,,,H,2086.0,6866.0,1.0,,Autocuration,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,
,8.0,,B,,,,CHEMBL616730,,BAO_0000019,,279.0,,,H,2087.0,17085.0,1.0,,Expert,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,
,8.0,,B,,,,CHEMBL617125,,BAO_0000357,,279.0,,,H,2088.0,16312.0,1.0,,Autocuration,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,
,8.0,,B,,,,CHEMBL857977,,BAO_0000357,,279.0,,,H,2089.0,6166.0,1.0,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,
,8.0,,B,,,,CHEMBL617126,,BAO_0000219,CHO,279.0,,,H,2090.0,15779.0,1.0,449.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,
,8.0,,B,,,,CHEMBL617127,,BAO_0000219,CHO,279.0,,,H,2091.0,4199.0,1.0,449.0,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,
,8.0,,B,,,,CHEMBL617128,,BAO_0000357,,279.0,,,H,2092.0,14875.0,1.0,,Autocuration,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,
,8.0,,B,,,,CHEMBL617129,,BAO_0000219,CHO,279.0,,,H,2093.0,15146.0,1.0,449.0,Autocuration,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,
,8.0,,B,,,,CHEMBL617130,,BAO_0000357,,279.0,,,H,2094.0,5213.0,1.0,,Autocuration,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,
,8.0,,B,,,,CHEMBL617131,,BAO_0000219,CHO,279.0,,,H,2095.0,14818.0,1.0,449.0,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,
,8.0,,B,,,,CHEMBL617132,,BAO_0000219,CHO,279.0,,,H,2096.0,4829.0,1.0,449.0,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",
,8.0,,B,,,,CHEMBL617133,,BAO_0000219,CHO,279.0,,,H,2097.0,4829.0,1.0,449.0,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",
,8.0,,B,,,,CHEMBL617134,,BAO_0000357,,279.0,,,H,2098.0,4373.0,1.0,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,
,8.0,,B,,,,CHEMBL617135,,BAO_0000357,,279.0,,,H,2099.0,4373.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,
,8.0,,B,,,,CHEMBL617136,,BAO_0000357,,279.0,,,H,2100.0,5014.0,1.0,,Autocuration,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,
,4.0,,B,,,,CHEMBL617137,,BAO_0000019,,104686.0,,,H,2101.0,11662.0,1.0,,Autocuration,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",
,4.0,,B,,,,CHEMBL617138,,BAO_0000019,,104686.0,,,H,2102.0,11662.0,1.0,,Autocuration,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",
,4.0,,B,,,,CHEMBL617139,,BAO_0000019,,104686.0,,,H,2103.0,11662.0,1.0,,Autocuration,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",
,8.0,,B,,,,CHEMBL617140,,BAO_0000019,,12687.0,,,H,2104.0,14093.0,1.0,,Autocuration,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,
,4.0,,F,,,,CHEMBL617141,,BAO_0000218,,104686.0,In vivo,,H,2105.0,11200.0,1.0,,Autocuration,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",
,4.0,,F,,,,CHEMBL858112,,BAO_0000019,,104686.0,,,H,2106.0,11200.0,1.0,,Autocuration,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,
,8.0,,B,,,,CHEMBL617142,,BAO_0000019,,17005.0,,,H,2107.0,12352.0,1.0,,Intermediate,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,
9913.0,0.0,,B,,,,CHEMBL617143,,BAO_0000019,,22226.0,,,U,2108.0,13657.0,1.0,,Autocuration,Bos taurus,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",
9913.0,0.0,,B,,,,CHEMBL617144,,BAO_0000019,,22226.0,,,U,2109.0,14331.0,1.0,,Autocuration,Bos taurus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,
9913.0,0.0,,B,,,,CHEMBL617145,,BAO_0000019,,22226.0,,,U,2110.0,14331.0,1.0,,Autocuration,Bos taurus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,
,0.0,,B,,,,CHEMBL617146,,BAO_0000019,,22226.0,,,U,2111.0,14331.0,1.0,,Autocuration,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,
10141.0,4.0,,B,,,,CHEMBL617147,,BAO_0000019,,104784.0,,,H,2112.0,12685.0,1.0,,Autocuration,Cavia porcellus,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,
10141.0,4.0,,B,,,,CHEMBL617148,,BAO_0000019,,104784.0,,,H,2113.0,14389.0,1.0,,Autocuration,Cavia porcellus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,
10141.0,4.0,,B,,,,CHEMBL617149,,BAO_0000019,,104784.0,,,H,2114.0,14386.0,1.0,,Autocuration,Cavia porcellus,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,
,4.0,,B,,,,CHEMBL617150,,BAO_0000224,,104784.0,,,H,2115.0,5732.0,1.0,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,
,4.0,,B,,,,CHEMBL617151,,BAO_0000224,,104784.0,,,H,2116.0,16293.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,
,4.0,,B,,,,CHEMBL617201,,BAO_0000224,,104784.0,,,H,2117.0,2078.0,1.0,,Autocuration,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,
,8.0,,B,,,,CHEMBL617202,,BAO_0000357,,10209.0,,,H,2118.0,5486.0,1.0,,Autocuration,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,
,4.0,,B,,,,CHEMBL617203,,BAO_0000218,,104826.0,In vivo,,H,2119.0,11820.0,1.0,,Autocuration,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,
,4.0,,B,,,,CHEMBL617204,,BAO_0000019,,104826.0,,,H,2120.0,10297.0,1.0,,Autocuration,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,
,4.0,,B,,,,CHEMBL617205,,BAO_0000224,,104826.0,,,H,2121.0,13704.0,1.0,,Autocuration,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,
10090.0,5.0,,B,,,,CHEMBL617206,,BAO_0000019,,104826.0,,,D,2122.0,10297.0,1.0,,Autocuration,Mus musculus,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,
,4.0,,B,,,,CHEMBL617207,,BAO_0000218,,104826.0,In vivo,,H,2123.0,11820.0,1.0,,Autocuration,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,
10090.0,5.0,,B,,,,CHEMBL617208,,BAO_0000019,,104826.0,,,D,2124.0,10297.0,1.0,,Autocuration,Mus musculus,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,
,4.0,,B,,,,CHEMBL617209,,BAO_0000224,,104826.0,,,H,2125.0,11555.0,1.0,,Autocuration,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617210,,BAO_0000224,,104826.0,,,H,2126.0,11555.0,1.0,,Autocuration,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,
,4.0,,B,,,,CHEMBL617211,,BAO_0000224,,104826.0,,,H,2127.0,11555.0,1.0,,Autocuration,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,
10090.0,5.0,,B,,,,CHEMBL617212,,BAO_0000019,,104826.0,,,D,2128.0,10297.0,1.0,,Autocuration,Mus musculus,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,
9823.0,4.0,,B,,,,CHEMBL617213,,BAO_0000224,,104784.0,,,H,2129.0,16688.0,1.0,,Autocuration,Sus scrofa,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,
9823.0,4.0,,B,,,,CHEMBL617214,,BAO_0000224,,104784.0,,,H,2130.0,16688.0,1.0,,Autocuration,Sus scrofa,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,
,0.0,,B,,,,CHEMBL617215,,BAO_0000221,,22226.0,,,U,2131.0,5333.0,1.0,,Autocuration,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,
,0.0,,B,,,,CHEMBL617216,,BAO_0000221,,22226.0,,,U,2132.0,4437.0,1.0,,Autocuration,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,
9823.0,8.0,,B,,,,CHEMBL617217,,BAO_0000357,,17005.0,,,H,2133.0,5033.0,1.0,,Autocuration,Sus scrofa,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617218,,BAO_0000019,,104686.0,,,H,2134.0,15267.0,1.0,,Autocuration,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL872913,,BAO_0000019,,104686.0,,,H,2135.0,15267.0,1.0,,Autocuration,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617219,,BAO_0000019,,104826.0,,,H,2136.0,11820.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,
,4.0,,B,,,,CHEMBL873482,,BAO_0000224,,104686.0,,,H,2137.0,9069.0,1.0,,Autocuration,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,
10116.0,5.0,,B,,,,CHEMBL617220,,BAO_0000019,,104686.0,,,D,2138.0,9162.0,1.0,,Autocuration,Rattus norvegicus,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,
,4.0,,B,,,,CHEMBL617221,,BAO_0000019,,104686.0,,,H,2139.0,9162.0,1.0,,Autocuration,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,
,4.0,,B,,,,CHEMBL617222,,BAO_0000019,,104686.0,,,H,2140.0,9162.0,1.0,,Autocuration,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,
,4.0,,F,,,,CHEMBL875906,,BAO_0000019,,104686.0,,,H,2141.0,10428.0,1.0,,Autocuration,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,
,4.0,,B,,,,CHEMBL617223,,BAO_0000019,,104686.0,,,H,2142.0,9628.0,1.0,,Autocuration,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,
,4.0,,B,,,,CHEMBL617224,,BAO_0000224,,104686.0,,,H,2143.0,12704.0,1.0,,Autocuration,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,
10116.0,5.0,,B,,,,CHEMBL617225,,BAO_0000224,,104686.0,,,D,2144.0,15453.0,1.0,,Autocuration,Rattus norvegicus,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,
,4.0,,B,,,,CHEMBL617226,,BAO_0000224,,104686.0,,,H,2145.0,188.0,1.0,,Autocuration,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,
,4.0,,B,,,,CHEMBL617227,,BAO_0000224,,104686.0,,,H,2146.0,10349.0,1.0,,Autocuration,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,
,4.0,,B,,,,CHEMBL617228,,BAO_0000224,,104686.0,,,H,2147.0,10349.0,1.0,,Autocuration,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,
,4.0,,B,,,,CHEMBL617229,,BAO_0000224,,104686.0,,,H,2148.0,8868.0,1.0,,Autocuration,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,
,4.0,,B,,,,CHEMBL617230,,BAO_0000224,,104686.0,,,H,2149.0,10025.0,1.0,,Autocuration,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,
,4.0,,B,,,,CHEMBL617231,,BAO_0000224,,104686.0,,,H,2150.0,10025.0,1.0,,Autocuration,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",
,4.0,,B,,,,CHEMBL617232,,BAO_0000224,,104686.0,,,H,2151.0,11702.0,1.0,,Autocuration,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,
,4.0,,B,,,,CHEMBL617233,,BAO_0000224,,104686.0,,,H,2152.0,11702.0,1.0,,Autocuration,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617234,,BAO_0000224,,104686.0,,,H,2153.0,11702.0,1.0,,Autocuration,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,
,4.0,,F,,,,CHEMBL617235,,BAO_0000019,,104686.0,,,H,2154.0,11702.0,1.0,,Autocuration,,Compound was tested for the inhibition of quipazine induced head twitches in rats,
,4.0,,F,,,,CHEMBL617236,,BAO_0000019,,104686.0,,,H,2155.0,11702.0,1.0,,Autocuration,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,
,4.0,,B,,,10000000.0,CHEMBL617237,,BAO_0000221,,104686.0,,,H,2156.0,10085.0,1.0,,Autocuration,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,Hippocampus
,4.0,,B,,,10000000.0,CHEMBL617238,,BAO_0000221,,104686.0,,,H,2157.0,10085.0,1.0,,Autocuration,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,Hippocampus
10116.0,5.0,,B,,,955.0,CHEMBL617239,,BAO_0000221,,104686.0,,,D,2158.0,9630.0,1.0,,Autocuration,Rattus norvegicus,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,Brain
,4.0,,B,,,,CHEMBL617240,,BAO_0000019,,104686.0,,,H,2159.0,11070.0,1.0,,Autocuration,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,
,4.0,,B,,,,CHEMBL617241,,BAO_0000249,,104686.0,,Membranes,H,2160.0,9841.0,1.0,,Autocuration,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,
,4.0,,B,,,,CHEMBL875907,,BAO_0000249,,104686.0,,Membranes,H,2161.0,9841.0,1.0,,Autocuration,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,
,4.0,,B,,,,CHEMBL617242,,BAO_0000019,,104686.0,,,H,2162.0,13291.0,1.0,,Autocuration,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,
,4.0,,F,,,,CHEMBL617152,,BAO_0000019,,104686.0,,,H,2163.0,10590.0,1.0,,Autocuration,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,
10116.0,5.0,,B,,,955.0,CHEMBL617153,,BAO_0000221,,104686.0,,,D,2164.0,9064.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Brain
10116.0,5.0,,B,,,,CHEMBL617154,,BAO_0000249,,104686.0,,Membranes,D,2165.0,12268.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,
,4.0,,B,,,955.0,CHEMBL617155,,BAO_0000221,,104686.0,,,H,2166.0,13508.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,Brain
,4.0,,F,,,,CHEMBL617156,,BAO_0000019,,104686.0,,,H,2167.0,11279.0,1.0,,Autocuration,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,
,4.0,,F,,,,CHEMBL617157,,BAO_0000019,,104686.0,,,H,2168.0,11200.0,1.0,,Autocuration,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,
,4.0,,F,,,,CHEMBL617158,,BAO_0000019,,104686.0,,,H,2169.0,11200.0,1.0,,Autocuration,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,
,4.0,,F,,,,CHEMBL617159,,BAO_0000019,,104686.0,,,H,2170.0,11200.0,1.0,,Autocuration,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,
,4.0,,F,,,,CHEMBL617160,,BAO_0000019,,104686.0,,,H,2171.0,11200.0,1.0,,Autocuration,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,
,4.0,,F,,,,CHEMBL858113,,BAO_0000019,,104686.0,,,H,2172.0,11200.0,1.0,,Autocuration,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,
,4.0,,B,,,955.0,CHEMBL617247,,BAO_0000220,,104686.0,,,H,2173.0,9231.0,1.0,,Autocuration,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,Brain
,4.0,,B,,,,CHEMBL617248,,BAO_0000019,,104686.0,,,H,2174.0,9737.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,
,4.0,,B,,,955.0,CHEMBL617249,,BAO_0000249,,104686.0,,,H,2175.0,9737.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain
,4.0,,B,,,,CHEMBL617250,,BAO_0000019,,104686.0,,,H,2176.0,9737.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,
,4.0,,B,,,,CHEMBL617251,,BAO_0000019,,104686.0,,,H,2177.0,9737.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,
10116.0,5.0,,B,,,,CHEMBL617252,,BAO_0000019,,104686.0,,,D,2178.0,11828.0,1.0,,Autocuration,Rattus norvegicus,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617006,,BAO_0000019,,104686.0,,,H,2179.0,12253.0,1.0,,Autocuration,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,
,4.0,,B,,,,CHEMBL617007,,BAO_0000019,,104686.0,,,H,2180.0,12253.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,
,4.0,,F,,,,CHEMBL617008,,BAO_0000019,,104686.0,,,H,2181.0,11279.0,1.0,,Autocuration,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",
,4.0,,B,,,,CHEMBL617009,,BAO_0000019,,104686.0,,,H,2182.0,11866.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,
10116.0,5.0,,B,,,,CHEMBL617010,,BAO_0000224,,104686.0,,,D,2183.0,14424.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,
10116.0,5.0,,B,,,,CHEMBL857978,,BAO_0000019,,104686.0,,,D,2184.0,15180.0,1.0,,Autocuration,Rattus norvegicus,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,
10116.0,5.0,,B,,,,CHEMBL617011,,BAO_0000019,,104686.0,,,D,2185.0,15180.0,1.0,,Autocuration,Rattus norvegicus,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,
10116.0,5.0,,B,,,,CHEMBL617012,,BAO_0000019,,104686.0,,,D,2186.0,9786.0,1.0,,Autocuration,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,
,4.0,,B,,,,CHEMBL617013,,BAO_0000224,,104686.0,,,H,2187.0,12132.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,
,4.0,,B,,,,CHEMBL617014,,BAO_0000249,,104686.0,,,H,2188.0,5486.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,
,4.0,,B,,,,CHEMBL617015,,BAO_0000019,,104686.0,,,H,2189.0,15316.0,1.0,,Autocuration,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617016,,BAO_0000019,,104686.0,,,H,2190.0,16429.0,1.0,,Autocuration,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,
,4.0,,B,,,,CHEMBL617017,,BAO_0000224,,104686.0,,,H,2191.0,14617.0,1.0,,Autocuration,,pKi value for 5-hydroxytryptamine 2 receptor binding site,
,4.0,,B,,,955.0,CHEMBL617018,,BAO_0000221,,104686.0,,,H,2192.0,11351.0,1.0,,Autocuration,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,Brain
,4.0,,F,,,,CHEMBL617019,,BAO_0000019,,104686.0,,,H,2193.0,11279.0,1.0,,Autocuration,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,
,4.0,,B,,,,CHEMBL617020,,BAO_0000019,,105075.0,,,H,2194.0,9523.0,1.0,,Autocuration,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,
,4.0,,B,,,,CHEMBL617021,,BAO_0000019,,105075.0,,,H,2195.0,9523.0,1.0,,Autocuration,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,
,4.0,,B,,,,CHEMBL617022,,BAO_0000019,,105075.0,,,H,2196.0,9523.0,1.0,,Autocuration,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,
,4.0,,B,,,,CHEMBL617023,,BAO_0000019,,105075.0,,,H,2197.0,9523.0,1.0,,Autocuration,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,
,4.0,,B,,,,CHEMBL617024,,BAO_0000019,,105075.0,,,H,2198.0,9523.0,1.0,,Autocuration,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,
,4.0,,B,,,,CHEMBL617025,,BAO_0000019,,105075.0,,,H,2199.0,9523.0,1.0,,Autocuration,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,
,4.0,,B,,,,CHEMBL617026,,BAO_0000224,,105075.0,,,H,2200.0,9523.0,1.0,,Autocuration,,Hill coefficient of compound was determined,
,0.0,,B,,,,CHEMBL617027,,BAO_0000019,,22226.0,,,U,2201.0,4771.0,1.0,,Autocuration,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,
10116.0,5.0,,B,,,,CHEMBL617028,,BAO_0000019,,104686.0,,,D,2202.0,5033.0,1.0,,Autocuration,Rattus norvegicus,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,
,8.0,,B,,,,CHEMBL617029,,BAO_0000019,,12687.0,,,H,2203.0,10845.0,1.0,,Expert,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,
,8.0,,B,,,,CHEMBL875908,,BAO_0000019,,12687.0,,,H,2204.0,10845.0,1.0,,Expert,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,
,8.0,,B,,,,CHEMBL617030,,BAO_0000357,,12687.0,,,H,2205.0,16288.0,1.0,,Autocuration,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),
,8.0,,B,,,,CHEMBL617031,,BAO_0000019,,12687.0,,,H,2206.0,16288.0,1.0,,Autocuration,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),
,8.0,,B,,,,CHEMBL617032,,BAO_0000019,,12687.0,,,H,2207.0,16190.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,
10116.0,5.0,,B,,,,CHEMBL617033,,BAO_0000224,,104686.0,,,D,2208.0,12463.0,1.0,,Autocuration,Rattus norvegicus,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,
,4.0,,B,,,,CHEMBL617034,,BAO_0000224,,104686.0,,,H,2209.0,9699.0,1.0,,Autocuration,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",
,4.0,,B,,,,CHEMBL617035,,BAO_0000224,,104686.0,,,H,2210.0,9699.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,
,4.0,,B,,,,CHEMBL617036,,BAO_0000019,,104686.0,,,H,2211.0,11662.0,1.0,,Autocuration,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",
,4.0,,B,,,,CHEMBL617037,,BAO_0000224,,104784.0,,,H,2212.0,1205.0,1.0,,Autocuration,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,
,0.0,,B,,,,CHEMBL617038,,BAO_0000219,,22226.0,,,U,2213.0,11376.0,1.0,,Autocuration,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,
,4.0,,B,,,,CHEMBL617039,,BAO_0000219,,104784.0,,,H,2214.0,11376.0,1.0,,Autocuration,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",
,4.0,,B,,,,CHEMBL617161,,BAO_0000224,,104784.0,,,H,2215.0,4639.0,1.0,,Autocuration,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617162,,BAO_0000224,,104784.0,,,H,2216.0,2222.0,1.0,,Autocuration,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617163,,BAO_0000224,,104784.0,,,H,2217.0,1558.0,1.0,,Autocuration,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617164,,BAO_0000224,,104784.0,,,H,2218.0,1089.0,1.0,,Autocuration,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617165,,BAO_0000249,,104784.0,,Brain membranes,H,2219.0,386.0,1.0,,Autocuration,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,
,4.0,,B,,,,CHEMBL617166,,BAO_0000224,,104784.0,,,H,2220.0,2474.0,1.0,,Autocuration,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,
,4.0,,B,,,,CHEMBL617167,,BAO_0000224,,104784.0,,,H,2221.0,17066.0,1.0,,Autocuration,,Binding affinity towards 5-HT2 receptor,
,4.0,,B,,,,CHEMBL872912,,BAO_0000224,,104784.0,,,H,2222.0,959.0,1.0,,Autocuration,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617168,,BAO_0000224,,104784.0,,,H,2223.0,6398.0,1.0,,Autocuration,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,
,4.0,,B,,,,CHEMBL617169,,BAO_0000224,,104686.0,,,H,2224.0,11889.0,1.0,,Autocuration,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,
,4.0,,B,,,,CHEMBL617170,,BAO_0000224,,104784.0,,,H,2225.0,4221.0,1.0,,Autocuration,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617171,,BAO_0000224,,104784.0,,,H,2226.0,11026.0,1.0,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,
,4.0,,B,,,,CHEMBL617172,,BAO_0000224,,104784.0,,,H,2227.0,11866.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,
,4.0,,B,,,,CHEMBL617173,,BAO_0000224,,104784.0,,,H,2228.0,4221.0,1.0,,Autocuration,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,
,0.0,,B,,,,CHEMBL617174,,BAO_0000019,,22226.0,,,U,2229.0,13950.0,1.0,,Autocuration,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617175,,BAO_0000224,,104784.0,,,H,2230.0,1263.0,1.0,,Autocuration,,5-hydroxytryptamine 2 receptor binding affinity,
,8.0,,B,,,,CHEMBL617176,,BAO_0000357,,17005.0,,,H,2231.0,13291.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,
,8.0,,B,,,,CHEMBL617177,,BAO_0000357,,17005.0,,,H,2232.0,10812.0,1.0,,Autocuration,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,
,4.0,,B,,,,CHEMBL617178,,BAO_0000224,,104784.0,,,H,2233.0,13020.0,1.0,,Autocuration,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,
,4.0,,B,,,,CHEMBL617179,,BAO_0000224,,104784.0,,,H,2234.0,13021.0,1.0,,Autocuration,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,
,4.0,,B,,,,CHEMBL617180,,BAO_0000224,,104784.0,,,H,2235.0,13020.0,1.0,,Autocuration,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,
,8.0,,B,,,,CHEMBL617181,,BAO_0000357,,17005.0,,,H,2236.0,14532.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,
,8.0,,B,,,,CHEMBL617182,,BAO_0000357,,17005.0,,,H,2237.0,13944.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor,
,8.0,,B,,,,CHEMBL617183,,BAO_0000357,,17005.0,,,H,2238.0,14331.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor,
,8.0,,B,,,,CHEMBL617184,,BAO_0000357,,17005.0,,,H,2239.0,14118.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL617185,,BAO_0000357,,17005.0,,,H,2240.0,13033.0,1.0,,Autocuration,,Binding affinity against serotonergic 5-HT2 receptor,
,8.0,,B,,,,CHEMBL617186,,BAO_0000357,,17005.0,,,H,2241.0,10321.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL617187,,BAO_0000357,,17005.0,,,H,2242.0,12918.0,1.0,,Autocuration,,Compound was evaluated for the binding affinity at 5- HT2 receptor,
,8.0,,B,,,,CHEMBL617188,,BAO_0000357,,17005.0,,,H,2243.0,15120.0,1.0,,Autocuration,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,
,8.0,,B,,,,CHEMBL617189,,BAO_0000218,,17005.0,,,H,2244.0,2613.0,1.0,,Autocuration,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,
9606.0,5.0,,B,,,,CHEMBL617190,,BAO_0000224,,104784.0,,,D,2245.0,13378.0,1.0,,Autocuration,Homo sapiens,Inhibitory activity against cloned human 5-HT2 receptor,
9606.0,5.0,,B,,,,CHEMBL617191,,BAO_0000219,CHO,104784.0,,,D,2246.0,2331.0,1.0,449.0,Autocuration,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",
9606.0,5.0,,B,,,,CHEMBL617192,,BAO_0000219,CHO,104784.0,,,D,2247.0,2331.0,1.0,449.0,Autocuration,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",
9606.0,5.0,,B,,,,CHEMBL617193,,BAO_0000219,CHO,104784.0,,,D,2248.0,2331.0,1.0,449.0,Autocuration,Homo sapiens,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",
9606.0,5.0,,B,,,,CHEMBL617194,,BAO_0000219,CHO,104784.0,,,D,2249.0,2331.0,1.0,449.0,Autocuration,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",
,4.0,,B,,,,CHEMBL617195,,BAO_0000224,,104784.0,,,H,2250.0,4170.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL881830,,BAO_0000224,,104784.0,,,H,2251.0,15453.0,1.0,,Autocuration,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,
,8.0,,B,,,,CHEMBL617196,,BAO_0000357,,17005.0,,,H,2252.0,1479.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617197,,BAO_0000224,,104686.0,,,H,2253.0,11139.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,
,8.0,,B,,,,CHEMBL617198,,BAO_0000357,,17005.0,,,H,2254.0,13969.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL873476,,BAO_0000357,,17005.0,,,H,2255.0,13392.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617199,,BAO_0000019,,17005.0,,,H,2256.0,14430.0,1.0,,Expert,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,
10141.0,8.0,,B,,,,CHEMBL617200,,BAO_0000357,,107.0,,,H,2257.0,13181.0,1.0,,Autocuration,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617484,,BAO_0000357,,51.0,,,H,2258.0,17200.0,1.0,,Autocuration,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,
,8.0,,B,,,,CHEMBL617485,,BAO_0000357,,107.0,,,H,2259.0,17200.0,1.0,,Autocuration,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,
,8.0,,B,,,,CHEMBL617486,,BAO_0000357,,51.0,,,H,2260.0,17200.0,1.0,,Autocuration,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,
,8.0,,B,,,,CHEMBL858022,,BAO_0000357,,107.0,,,H,2261.0,13463.0,1.0,,Autocuration,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL617049,,BAO_0000219,CHO,107.0,,,H,2262.0,6347.0,1.0,449.0,Autocuration,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,
9606.0,9.0,,F,,,,CHEMBL617050,,BAO_0000219,CHO,107.0,,,D,2263.0,6857.0,1.0,449.0,Expert,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,
,8.0,,F,,,,CHEMBL617051,,BAO_0000219,,107.0,,,H,2264.0,4176.0,1.0,,Autocuration,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,
,8.0,,F,,,,CHEMBL617052,,BAO_0000219,,107.0,,,H,2265.0,4176.0,1.0,,Autocuration,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,
,8.0,,F,,,,CHEMBL617053,,BAO_0000219,,107.0,,,H,2266.0,4176.0,1.0,,Autocuration,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,
,8.0,,B,,,,CHEMBL617054,,BAO_0000219,CHO,107.0,,,H,2267.0,6347.0,1.0,449.0,Autocuration,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",
,8.0,,B,,,,CHEMBL617055,,BAO_0000219,CHO,107.0,,,H,2268.0,6347.0,1.0,449.0,Autocuration,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",
,8.0,,B,,,,CHEMBL882924,,BAO_0000357,,107.0,,,H,2269.0,15331.0,1.0,,Autocuration,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,
9606.0,9.0,,B,,,,CHEMBL617056,,BAO_0000357,,107.0,,,D,2270.0,16146.0,1.0,,Expert,Homo sapiens,Inhibition of human 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617057,,BAO_0000219,CHO,107.0,,,H,2271.0,15250.0,1.0,449.0,Autocuration,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,
,8.0,,B,,,,CHEMBL617058,,BAO_0000219,,107.0,,,H,2272.0,13631.0,1.0,,Expert,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,
,8.0,,B,,,,CHEMBL617059,,BAO_0000357,,107.0,,,H,2273.0,3805.0,1.0,,Autocuration,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),
,8.0,,B,,,,CHEMBL617060,,BAO_0000219,CHO,107.0,,,H,2274.0,4011.0,1.0,449.0,Autocuration,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,
,8.0,,B,,,,CHEMBL617061,,BAO_0000219,CHO,107.0,,,H,2275.0,4012.0,1.0,449.0,Expert,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,
,8.0,,B,,,,CHEMBL617062,,BAO_0000219,L929,107.0,,,H,2276.0,6366.0,1.0,307.0,Expert,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,
,8.0,,B,,,,CHEMBL617063,,BAO_0000219,CHO,107.0,,,H,2277.0,15949.0,1.0,449.0,Expert,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,
,8.0,,F,,,,CHEMBL617064,,BAO_0000019,,107.0,,,H,2278.0,14093.0,1.0,,Autocuration,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,
,8.0,,F,,,,CHEMBL617065,,BAO_0000019,,107.0,,,H,2279.0,13481.0,1.0,,Autocuration,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,
,8.0,,B,,,,CHEMBL617066,,BAO_0000219,CHO,107.0,,,H,2280.0,6347.0,1.0,449.0,Autocuration,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,
,8.0,,B,,,,CHEMBL617067,,BAO_0000219,CHO,107.0,,,H,2281.0,6347.0,1.0,449.0,Autocuration,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,
,8.0,,F,,,,CHEMBL617068,,BAO_0000019,,107.0,,,H,2282.0,14093.0,1.0,,Autocuration,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,
,8.0,,F,,,,CHEMBL617069,,BAO_0000019,,107.0,,,H,2283.0,14093.0,1.0,,Autocuration,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,
,8.0,,F,,,,CHEMBL617070,,BAO_0000019,,107.0,,,H,2284.0,13481.0,1.0,,Autocuration,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL617071,,BAO_0000357,,107.0,,,H,2285.0,14442.0,1.0,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,
,8.0,,B,,,,CHEMBL872915,,BAO_0000357,,107.0,,,H,2286.0,14442.0,1.0,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL617072,,BAO_0000357,,107.0,,,H,2287.0,14755.0,1.0,,Autocuration,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,
,8.0,,B,,,,CHEMBL617073,,BAO_0000357,,107.0,,,H,2288.0,16441.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,
,8.0,,B,,,,CHEMBL617074,,BAO_0000357,,107.0,,,H,2289.0,14744.0,1.0,,Autocuration,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,
,8.0,,B,,,,CHEMBL617075,,BAO_0000219,CHO,107.0,,,H,2290.0,16659.0,1.0,449.0,Expert,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,
,8.0,,B,,,,CHEMBL617076,,BAO_0000357,,107.0,,,H,2291.0,3307.0,1.0,,Autocuration,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,
9606.0,9.0,,B,,,,CHEMBL617077,,BAO_0000019,,107.0,,,D,2292.0,6857.0,1.0,,Expert,Homo sapiens,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,
,8.0,,B,,,,CHEMBL617078,,BAO_0000357,,107.0,,,H,2293.0,5635.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,
9606.0,9.0,,B,,,,CHEMBL617079,,BAO_0000357,,107.0,,,D,2294.0,4234.0,1.0,,Expert,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617080,,BAO_0000357,,107.0,,,H,2295.0,15527.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,
,8.0,,B,,,,CHEMBL617081,,BAO_0000219,CHO,107.0,,,H,2296.0,6588.0,1.0,449.0,Expert,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,
,8.0,,B,,,,CHEMBL617082,,BAO_0000219,,107.0,,,H,2297.0,13631.0,1.0,,Expert,,Binding affinity towards human 5-HT2A receptor in BEK cells,
,8.0,,B,,,,CHEMBL617083,,BAO_0000357,,107.0,,,H,2298.0,17723.0,1.0,,Autocuration,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617084,,BAO_0000357,,107.0,,,H,2299.0,14770.0,1.0,,Autocuration,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,
9606.0,9.0,,B,,,,CHEMBL617085,,BAO_0000357,,107.0,,,D,2300.0,16293.0,1.0,,Expert,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617086,,BAO_0000357,,107.0,,,H,2301.0,16209.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,
,8.0,,B,,,,CHEMBL617087,,BAO_0000219,,107.0,,,H,2302.0,12469.0,1.0,,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,
,8.0,,B,,,,CHEMBL617088,,BAO_0000357,,107.0,,,H,2303.0,15363.0,1.0,,Autocuration,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617089,,BAO_0000357,,107.0,,,H,2304.0,15363.0,1.0,,Autocuration,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617090,,BAO_0000019,,107.0,,,H,2305.0,16441.0,1.0,,Expert,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",
,8.0,,B,,,,CHEMBL617513,,BAO_0000357,,107.0,,,H,2306.0,8.0,1.0,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL617514,,BAO_0000219,HEK293,107.0,,,H,2307.0,4176.0,1.0,722.0,Autocuration,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL617515,,BAO_0000019,,107.0,,,H,2308.0,17085.0,1.0,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617516,,BAO_0000357,,107.0,,,H,2309.0,17200.0,1.0,,Autocuration,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,
9606.0,9.0,,B,,,,CHEMBL617517,,BAO_0000357,,107.0,,,D,2310.0,17200.0,1.0,,Expert,Homo sapiens,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,
9606.0,9.0,,B,,,,CHEMBL617518,,BAO_0000219,CHO,107.0,,,D,2311.0,4013.0,1.0,449.0,Expert,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,
,8.0,,B,,,,CHEMBL617519,,BAO_0000357,,107.0,,,H,2312.0,5088.0,1.0,,Autocuration,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,
9606.0,9.0,,B,,,,CHEMBL617520,,BAO_0000357,,107.0,,,D,2313.0,5088.0,1.0,,Expert,Homo sapiens,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617521,,BAO_0000357,,107.0,,,H,2314.0,5088.0,1.0,,Autocuration,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,
9606.0,9.0,,B,,,,CHEMBL617522,,BAO_0000357,,107.0,,,D,2315.0,5088.0,1.0,,Expert,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617523,,BAO_0000357,,107.0,,,H,2316.0,5088.0,1.0,,Autocuration,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL617524,,BAO_0000357,,107.0,,,H,2317.0,5088.0,1.0,,Autocuration,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,
,4.0,,B,,,,CHEMBL617525,,BAO_0000019,,104686.0,,,H,2318.0,9786.0,1.0,,Autocuration,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,
10116.0,5.0,,B,,,,CHEMBL617526,,BAO_0000019,,104686.0,,,D,2319.0,9205.0,1.0,,Autocuration,Rattus norvegicus,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,
,4.0,,B,,,,CHEMBL617527,,BAO_0000224,,104686.0,,,H,2320.0,11257.0,1.0,,Autocuration,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,
,4.0,,B,,,,CHEMBL617528,,BAO_0000019,,104686.0,,,H,2321.0,9362.0,1.0,,Autocuration,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,
,4.0,,B,,,,CHEMBL617529,,BAO_0000019,,104686.0,,,H,2322.0,9362.0,1.0,,Autocuration,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,
,4.0,,B,,,,CHEMBL617530,,BAO_0000224,,104686.0,,,H,2323.0,10590.0,1.0,,Autocuration,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,
,4.0,,B,,,,CHEMBL617531,,BAO_0000019,,104686.0,,,H,2324.0,10468.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,
,4.0,,B,,,,CHEMBL617532,,BAO_0000019,,104686.0,,,H,2325.0,13050.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,
,4.0,,B,,,,CHEMBL617533,,BAO_0000019,,104686.0,,,H,2326.0,11624.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,
,4.0,,B,,,,CHEMBL617534,,BAO_0000019,,104686.0,,,H,2327.0,10468.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,
,4.0,,B,,,,CHEMBL617535,,BAO_0000224,,104686.0,,,H,2328.0,10330.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,
,4.0,,B,,,,CHEMBL617536,,BAO_0000224,,104686.0,,,H,2329.0,10062.0,1.0,,Autocuration,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,
,4.0,,B,,,,CHEMBL617537,,BAO_0000224,,104686.0,,,H,2330.0,11642.0,1.0,,Autocuration,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617538,,BAO_0000224,,104686.0,,,H,2331.0,10062.0,1.0,,Autocuration,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617539,,BAO_0000219,,104686.0,In vitro,,H,2332.0,13427.0,1.0,,Autocuration,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,
10116.0,5.0,,B,,,,CHEMBL617540,,BAO_0000224,,104686.0,,,D,2333.0,12280.0,1.0,,Autocuration,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,
10116.0,5.0,,B,,,,CHEMBL617541,,BAO_0000224,,104686.0,,,D,2334.0,4101.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,
,4.0,,B,,,,CHEMBL617542,,BAO_0000224,,104686.0,,,H,2335.0,10062.0,1.0,,Autocuration,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617543,,BAO_0000224,,104686.0,,,H,2336.0,11147.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,
10116.0,5.0,,B,,,,CHEMBL617544,,BAO_0000219,CHO-K1,104686.0,,,D,2337.0,2395.0,1.0,485.0,Autocuration,Rattus norvegicus,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,
10116.0,5.0,,B,,,,CHEMBL617545,,BAO_0000219,CHO-K1,104686.0,,,D,2338.0,2395.0,1.0,485.0,Autocuration,Rattus norvegicus,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,
10116.0,5.0,,B,,,,CHEMBL617413,,BAO_0000019,,104686.0,,,D,2339.0,9098.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,
,4.0,,B,,,,CHEMBL617414,,BAO_0000019,,104686.0,,,H,2340.0,9098.0,1.0,,Autocuration,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,
10116.0,5.0,,B,,,,CHEMBL617415,,BAO_0000019,,104686.0,,,D,2341.0,9098.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,
,4.0,,B,,,,CHEMBL617416,,BAO_0000224,,104686.0,,,H,2342.0,9443.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617417,,BAO_0000224,,104686.0,,,H,2343.0,9443.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,
,4.0,,B,,,,CHEMBL617418,,BAO_0000019,,104686.0,,,H,2344.0,9699.0,1.0,,Autocuration,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",
,4.0,,B,,,,CHEMBL617419,,BAO_0000019,,104686.0,,,H,2345.0,9699.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,
,4.0,,B,,,,CHEMBL617420,,BAO_0000224,,104686.0,,,H,2346.0,9098.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,
10116.0,5.0,,B,,,,CHEMBL617421,,BAO_0000224,,104686.0,,,D,2347.0,3070.0,1.0,,Autocuration,Rattus norvegicus,Affinity for 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617422,,BAO_0000224,,104686.0,,,H,2348.0,9547.0,1.0,,Autocuration,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,
,4.0,,B,,,,CHEMBL617423,,BAO_0000019,,104686.0,,,H,2349.0,10444.0,1.0,,Autocuration,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,
,4.0,,B,,,,CHEMBL617424,,BAO_0000019,,104686.0,,,H,2350.0,14617.0,1.0,,Autocuration,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,
,4.0,,B,,,,CHEMBL617425,,BAO_0000019,,104686.0,,,H,2351.0,14617.0,1.0,,Autocuration,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,
,4.0,,B,,,,CHEMBL617426,,BAO_0000224,,104686.0,,,H,2352.0,11130.0,1.0,,Autocuration,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),
,4.0,,B,,,,CHEMBL617427,,BAO_0000218,,104686.0,In vivo,,H,2353.0,11130.0,1.0,,Autocuration,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),
,4.0,,B,,,955.0,CHEMBL617428,,BAO_0000221,,104686.0,,,H,2354.0,14542.0,1.0,,Autocuration,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,Brain
,4.0,,B,,,,CHEMBL617429,,BAO_0000224,,104686.0,,,H,2355.0,2797.0,1.0,,Autocuration,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,
,4.0,,B,,,,CHEMBL617430,,BAO_0000019,,104686.0,,,H,2356.0,11332.0,1.0,,Autocuration,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,
,4.0,,B,,,,CHEMBL617431,,BAO_0000019,,104686.0,,,H,2357.0,11332.0,1.0,,Autocuration,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,
,4.0,,B,,,1870.0,CHEMBL617432,,BAO_0000019,,104686.0,,,H,2358.0,10752.0,1.0,,Autocuration,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,Frontal cortex
,4.0,,B,,,,CHEMBL617433,,BAO_0000224,,104686.0,,,H,2359.0,1185.0,1.0,,Autocuration,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617434,,BAO_0000224,,104686.0,,,H,2360.0,1185.0,1.0,,Autocuration,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,
10116.0,5.0,,B,,,,CHEMBL617435,,BAO_0000224,,104686.0,,,D,2361.0,11624.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,
,4.0,,B,,,,CHEMBL617436,,BAO_0000019,,104686.0,,,H,2362.0,1344.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,
10116.0,5.0,,B,,,2435.0,CHEMBL617437,,BAO_0000019,,104686.0,,,D,2363.0,15453.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,Striatum
,4.0,,B,,,,CHEMBL617438,,BAO_0000019,,104686.0,,,H,2364.0,11662.0,1.0,,Autocuration,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",
,4.0,,B,,,,CHEMBL617439,,BAO_0000019,,104686.0,,,H,2365.0,11662.0,1.0,,Autocuration,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",
,4.0,,B,,,,CHEMBL617440,,BAO_0000224,,104686.0,,,H,2366.0,10796.0,1.0,,Autocuration,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617441,,BAO_0000224,,104686.0,,,H,2367.0,9069.0,1.0,,Autocuration,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,
10116.0,5.0,,B,,,,CHEMBL872918,,BAO_0000019,,104686.0,,,D,2368.0,8814.0,1.0,,Autocuration,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,
10116.0,5.0,,B,,,,CHEMBL617442,,BAO_0000019,,104686.0,,,D,2369.0,8908.0,1.0,,Autocuration,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,
,4.0,,B,,,,CHEMBL617443,,BAO_0000019,,104686.0,,,H,2370.0,9098.0,1.0,,Autocuration,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,
,4.0,,B,,,,CHEMBL617444,,BAO_0000019,,104686.0,,,H,2371.0,9098.0,1.0,,Autocuration,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,
,4.0,,B,,,,CHEMBL617445,,BAO_0000019,,104686.0,,,H,2372.0,9098.0,1.0,,Autocuration,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,
,4.0,,B,,,,CHEMBL617446,,BAO_0000019,,104686.0,,,H,2373.0,9098.0,1.0,,Autocuration,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,
,4.0,,B,,,,CHEMBL617447,,BAO_0000249,,104686.0,,,H,2374.0,9098.0,1.0,,Autocuration,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,
,4.0,,B,,,,CHEMBL617448,,BAO_0000019,,104686.0,,,H,2375.0,9098.0,1.0,,Autocuration,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,
,4.0,,B,,,,CHEMBL617449,,BAO_0000019,,104686.0,,,H,2376.0,9098.0,1.0,,Autocuration,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,
,4.0,,B,,,,CHEMBL617450,,BAO_0000019,,104686.0,,,H,2377.0,9161.0,1.0,,Autocuration,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,
,4.0,,B,,,,CHEMBL617451,,BAO_0000019,,104686.0,,,H,2378.0,9161.0,1.0,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,
,4.0,,B,,,,CHEMBL617452,,BAO_0000019,,104686.0,,,H,2379.0,9161.0,1.0,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,
,4.0,,B,,,,CHEMBL617453,,BAO_0000019,,104686.0,,,H,2380.0,9161.0,1.0,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,
,4.0,,B,,,,CHEMBL617660,,BAO_0000019,,104686.0,,,H,2381.0,9161.0,1.0,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,
,4.0,,B,,,,CHEMBL617661,,BAO_0000019,,104686.0,,,H,2382.0,9161.0,1.0,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,
,4.0,,B,,,,CHEMBL617662,,BAO_0000019,,104686.0,,,H,2383.0,9161.0,1.0,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,
,4.0,,B,,,,CHEMBL872919,,BAO_0000019,,104686.0,,,H,2384.0,9161.0,1.0,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,
,4.0,,B,,,,CHEMBL617663,,BAO_0000019,,104686.0,,,H,2385.0,9161.0,1.0,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,
,4.0,,B,,,,CHEMBL617664,,BAO_0000019,,104686.0,,,H,2386.0,9161.0,1.0,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,
,4.0,,B,,,,CHEMBL617665,,BAO_0000019,,104686.0,,,H,2387.0,9161.0,1.0,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,
,4.0,,B,,,,CHEMBL617666,,BAO_0000019,,104686.0,,,H,2388.0,9161.0,1.0,,Autocuration,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,
,4.0,,B,,,,CHEMBL617667,,BAO_0000019,,104686.0,,,H,2389.0,12094.0,1.0,,Autocuration,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,
,4.0,,B,,,,CHEMBL617668,,BAO_0000249,,104686.0,,,H,2390.0,12018.0,1.0,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,
,4.0,,B,,,,CHEMBL617669,,BAO_0000249,,104686.0,,,H,2391.0,10394.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,
,4.0,,B,,,,CHEMBL617670,,BAO_0000224,,104686.0,,,H,2392.0,15260.0,1.0,,Autocuration,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,
10116.0,5.0,,B,,,,CHEMBL617671,,BAO_0000224,,104686.0,,,D,2393.0,11624.0,1.0,,Autocuration,Rattus norvegicus,Inhibitory constant against 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617672,,BAO_0000224,,104686.0,,,H,2394.0,13654.0,1.0,,Autocuration,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617673,,BAO_0000019,,104686.0,,,H,2395.0,9541.0,1.0,,Autocuration,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,
,4.0,,B,,,,CHEMBL617674,,BAO_0000224,,104686.0,,,H,2396.0,11933.0,1.0,,Autocuration,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,
,4.0,,B,,,,CHEMBL617675,,BAO_0000019,,104686.0,,,H,2397.0,15538.0,1.0,,Autocuration,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,
,4.0,,B,,,,CHEMBL617676,,BAO_0000019,,104686.0,,,H,2398.0,15538.0,1.0,,Autocuration,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,
,4.0,,B,,,,CHEMBL617677,,BAO_0000019,,104686.0,,,H,2399.0,15538.0,1.0,,Autocuration,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,
,5.0,,B,,,,CHEMBL617678,,BAO_0000019,,104686.0,,,D,2400.0,8841.0,1.0,,Autocuration,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617679,,BAO_0000224,,104686.0,,,H,2401.0,1455.0,1.0,,Autocuration,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,
,4.0,,B,,,,CHEMBL617680,,BAO_0000224,,104686.0,,,H,2402.0,1455.0,1.0,,Autocuration,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,
,4.0,,B,,,,CHEMBL617681,,BAO_0000019,,104686.0,,,H,2403.0,11752.0,1.0,,Autocuration,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,
,4.0,,B,,,955.0,CHEMBL617682,,BAO_0000221,,104686.0,,,H,2404.0,11642.0,1.0,,Autocuration,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,Brain
,4.0,,B,,,,CHEMBL617683,,BAO_0000224,,104686.0,,,H,2405.0,12092.0,1.0,,Autocuration,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,
,4.0,,B,,,,CHEMBL617684,,BAO_0000224,,104686.0,,,H,2406.0,3967.0,1.0,,Autocuration,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,
10116.0,5.0,,B,,,,CHEMBL617685,,BAO_0000224,,104686.0,,,D,2407.0,12771.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor,
,4.0,,B,,,,CHEMBL617686,,BAO_0000019,,104686.0,,,H,2408.0,11642.0,1.0,,Autocuration,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,
,4.0,,B,,,,CHEMBL617687,,BAO_0000224,,104686.0,,,H,2409.0,11628.0,1.0,,Autocuration,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,
,4.0,,B,,,,CHEMBL617688,,BAO_0000224,,104686.0,,,H,2410.0,13654.0,1.0,,Autocuration,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,
,4.0,,F,,,,CHEMBL617689,,BAO_0000019,,104686.0,,,H,2411.0,11200.0,1.0,,Autocuration,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,
,4.0,,F,,,,CHEMBL617690,,BAO_0000019,,104686.0,,,H,2412.0,11200.0,1.0,,Autocuration,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,
,4.0,,F,,,,CHEMBL617691,,BAO_0000218,,104686.0,In vivo,,H,2413.0,11200.0,1.0,,Autocuration,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",
,4.0,,F,,,,CHEMBL617692,,BAO_0000218,,104686.0,In vivo,,H,2414.0,11200.0,1.0,,Autocuration,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",
,4.0,,F,,,,CHEMBL617693,,BAO_0000218,,104686.0,In vivo,,H,2415.0,11200.0,1.0,,Autocuration,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",
,4.0,,F,,,,CHEMBL617694,,BAO_0000218,,104686.0,In vivo,,H,2416.0,11200.0,1.0,,Autocuration,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",
,8.0,,B,,,955.0,CHEMBL857985,,BAO_0000221,,12687.0,,,H,2417.0,15436.0,1.0,,Expert,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,Brain
10116.0,9.0,,B,,,,CHEMBL617695,,BAO_0000019,,12687.0,,,D,2418.0,15436.0,1.0,,Expert,Rattus norvegicus,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,
,8.0,,B,,,,CHEMBL617696,,BAO_0000019,,12687.0,,,H,2419.0,14025.0,1.0,,Autocuration,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,
,8.0,,B,,,,CHEMBL617697,,BAO_0000357,,12687.0,,,H,2420.0,4342.0,1.0,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,
10116.0,9.0,,B,,,,CHEMBL617257,,BAO_0000019,,12687.0,,,D,2421.0,13735.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,
10116.0,9.0,,B,,,,CHEMBL617258,,BAO_0000357,,12687.0,,,D,2422.0,5816.0,1.0,,Expert,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,
,8.0,,B,,,,CHEMBL617259,,BAO_0000019,,12687.0,,,H,2423.0,14287.0,1.0,,Expert,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,
,8.0,,B,,,,CHEMBL617260,,BAO_0000357,,12687.0,,,H,2424.0,15738.0,1.0,,Autocuration,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,
10116.0,9.0,,B,,,,CHEMBL617261,,BAO_0000357,,12687.0,,,D,2425.0,15738.0,1.0,,Expert,Rattus norvegicus,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617262,,BAO_0000019,,12687.0,,,H,2426.0,15026.0,1.0,,Autocuration,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,
,8.0,,B,,,,CHEMBL617263,,BAO_0000019,,12687.0,,,H,2427.0,16647.0,1.0,,Expert,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,
,8.0,,B,,,,CHEMBL617264,,BAO_0000019,,12687.0,,,H,2428.0,16647.0,1.0,,Autocuration,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,
10116.0,9.0,,B,,,,CHEMBL617265,,BAO_0000019,,12687.0,,,D,2429.0,13345.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617266,,BAO_0000249,,12687.0,,Membranes,H,2430.0,1543.0,1.0,,Autocuration,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617267,,BAO_0000019,,12687.0,,,H,2431.0,12444.0,1.0,,Autocuration,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,
,8.0,,B,,,,CHEMBL617268,,BAO_0000019,,12687.0,,,H,2432.0,16404.0,1.0,,Expert,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,
,8.0,,B,,,,CHEMBL617269,,BAO_0000219,CHO,12687.0,,,H,2433.0,16404.0,1.0,449.0,Autocuration,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,
,8.0,,B,,,,CHEMBL617323,,BAO_0000357,,12687.0,,,H,2434.0,15577.0,1.0,,Expert,,Kinetic inhibition constant evaluated by measuring serotonergic activity,
,8.0,,B,,,,CHEMBL617324,,BAO_0000357,,12687.0,,,H,2435.0,15577.0,1.0,,Autocuration,,Serotonergic activity of the compound.,
,8.0,,B,,,,CHEMBL617325,,BAO_0000249,,12687.0,,,H,2436.0,2495.0,1.0,,Autocuration,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,
10116.0,9.0,,B,,,,CHEMBL617326,,BAO_0000019,,12687.0,,,D,2437.0,15042.0,1.0,,Expert,Rattus norvegicus,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,
,8.0,,B,,,,CHEMBL617327,,BAO_0000249,,12687.0,,,H,2438.0,15026.0,1.0,,Expert,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,
10116.0,9.0,,F,,,,CHEMBL617328,,BAO_0000019,,12687.0,,,D,2439.0,12919.0,1.0,,Expert,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,
10116.0,9.0,,F,,,,CHEMBL617329,,BAO_0000019,,12687.0,,,D,2440.0,12919.0,1.0,,Expert,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,
10116.0,9.0,,F,,,,CHEMBL617330,,BAO_0000019,,12687.0,,,D,2441.0,12919.0,1.0,,Expert,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,
,8.0,,B,,,,CHEMBL617331,,BAO_0000357,,12687.0,,,H,2442.0,15194.0,1.0,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL617332,,BAO_0000357,,12687.0,,,H,2443.0,15194.0,1.0,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,
,8.0,,B,,,,CHEMBL617333,,BAO_0000357,,107.0,,,H,2444.0,4820.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617334,,BAO_0000357,,107.0,,,H,2445.0,6736.0,1.0,,Autocuration,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,
,8.0,,B,,,,CHEMBL617335,,BAO_0000357,,107.0,,,H,2446.0,5163.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,
,8.0,,B,,,,CHEMBL617336,,BAO_0000357,,107.0,,,H,2447.0,5163.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,
,8.0,,B,,,,CHEMBL617337,,BAO_0000357,,107.0,,,H,2448.0,6011.0,1.0,,Autocuration,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,
9606.0,9.0,,B,,,,CHEMBL617338,,BAO_0000357,,107.0,,,D,2449.0,14294.0,1.0,,Expert,Homo sapiens,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,
,8.0,,B,,,,CHEMBL617339,,BAO_0000357,,107.0,,,H,2450.0,5014.0,1.0,,Autocuration,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617340,,BAO_0000357,,107.0,,,H,2451.0,17066.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617341,,BAO_0000357,,107.0,,,H,2452.0,17515.0,1.0,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,
,8.0,,B,,,,CHEMBL617342,,BAO_0000357,,107.0,,,H,2453.0,6736.0,1.0,,Expert,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617343,,BAO_0000357,,107.0,,,H,2454.0,5163.0,1.0,,Expert,,Affinity for 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617344,,BAO_0000219,NIH3T3,107.0,,,H,2455.0,16911.0,1.0,723.0,Expert,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,
,8.0,,B,,,,CHEMBL617345,,BAO_0000357,,107.0,,,H,2456.0,6841.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,
,8.0,,B,,,,CHEMBL617346,,BAO_0000357,,107.0,,,H,2457.0,6119.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,
,8.0,,B,,,,CHEMBL617347,,BAO_0000357,,107.0,,,H,2458.0,3962.0,1.0,,Autocuration,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617348,,BAO_0000357,,107.0,,,H,2459.0,4373.0,1.0,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,
,8.0,,B,,,,CHEMBL617349,,BAO_0000357,,107.0,,,H,2460.0,4373.0,1.0,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,
,8.0,,F,,,,CHEMBL617350,,BAO_0000019,,107.0,,,H,2461.0,3962.0,1.0,,Autocuration,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL872339,,BAO_0000357,,107.0,,,H,2462.0,1633.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,
,8.0,,B,,,,CHEMBL617351,,BAO_0000357,,107.0,,,H,2463.0,4373.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,
,8.0,,B,,,,CHEMBL617352,,BAO_0000357,,107.0,,,H,2464.0,6576.0,1.0,,Expert,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617353,,BAO_0000357,,107.0,,,H,2465.0,4687.0,1.0,,Autocuration,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617354,,BAO_0000357,,107.0,,,H,2466.0,16946.0,1.0,,Autocuration,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617355,,BAO_0000357,,107.0,,,H,2467.0,14159.0,1.0,,Autocuration,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,
10090.0,8.0,,B,,,,CHEMBL617356,,BAO_0000219,CHO,107.0,,,H,2468.0,3032.0,1.0,449.0,Expert,Mus musculus,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,
,8.0,,B,,,,CHEMBL617357,,BAO_0000357,,107.0,,,H,2469.0,16655.0,1.0,,Autocuration,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617358,,BAO_0000357,,107.0,,,H,2470.0,13964.0,1.0,,Autocuration,,Binding affinity at 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617359,,BAO_0000357,,107.0,,,H,2471.0,16989.0,1.0,,Expert,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617360,,BAO_0000357,,107.0,,,H,2472.0,16117.0,1.0,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,
,8.0,,B,,,,CHEMBL875913,,BAO_0000357,,107.0,,,H,2473.0,16700.0,1.0,,Autocuration,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,
,8.0,,B,,,,CHEMBL617361,,BAO_0000357,,107.0,,,H,2474.0,3269.0,1.0,,Autocuration,,Affinity against 5-hydroxytryptamine 2A receptor,
9606.0,9.0,,B,,,,CHEMBL617362,,BAO_0000357,,107.0,,,D,2475.0,1274.0,1.0,,Expert,Homo sapiens,Binding affinity against 5-Hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617363,,BAO_0000357,,107.0,,,H,2476.0,1317.0,1.0,,Autocuration,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,
,8.0,,B,,,,CHEMBL617364,,BAO_0000357,,107.0,,,H,2477.0,12146.0,1.0,,Autocuration,,Tested against 5-hydroxytryptamine 2A receptor,
,4.0,,B,,,,CHEMBL617365,,BAO_0000224,,105075.0,,,H,2478.0,12652.0,1.0,,Autocuration,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,
,4.0,,B,,,,CHEMBL617366,,BAO_0000224,,105075.0,,,H,2479.0,12652.0,1.0,,Autocuration,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,
,4.0,,B,,,,CHEMBL617367,,BAO_0000224,,105075.0,,,H,2480.0,12652.0,1.0,,Autocuration,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,
,4.0,,B,,,,CHEMBL617368,,BAO_0000224,,105075.0,,,H,2481.0,12652.0,1.0,,Autocuration,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,
,8.0,,B,,,,CHEMBL617369,,BAO_0000357,,107.0,,,H,2482.0,16647.0,1.0,,Autocuration,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),
9606.0,9.0,,B,,,,CHEMBL617370,,BAO_0000219,HEK293,227.0,,,D,2483.0,15851.0,1.0,722.0,Expert,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,
9606.0,9.0,,F,,,,CHEMBL617371,,BAO_0000219,CHO,227.0,,,D,2484.0,6857.0,1.0,449.0,Expert,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,
,8.0,,B,,,,CHEMBL617372,,BAO_0000357,,227.0,,,H,2485.0,3805.0,1.0,,Autocuration,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),
9606.0,9.0,,B,,,,CHEMBL617373,,BAO_0000357,,227.0,,,D,2486.0,6491.0,1.0,,Expert,Homo sapiens,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,
,8.0,,F,,,,CHEMBL617374,,BAO_0000019,,227.0,,,H,2487.0,14093.0,1.0,,Autocuration,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,
,8.0,,F,,,,CHEMBL617375,,BAO_0000019,,227.0,,,H,2488.0,13481.0,1.0,,Autocuration,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,
,8.0,,F,,,,CHEMBL617376,,BAO_0000019,,227.0,,,H,2489.0,14093.0,1.0,,Autocuration,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,
,8.0,,F,,,,CHEMBL617377,,BAO_0000019,,227.0,,,H,2490.0,14093.0,1.0,,Autocuration,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,
,8.0,,F,,,,CHEMBL617378,,BAO_0000019,,227.0,,,H,2491.0,14093.0,1.0,,Autocuration,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,
,8.0,,F,,,,CHEMBL617379,,BAO_0000019,,227.0,,,H,2492.0,13481.0,1.0,,Autocuration,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,
,8.0,,B,,,,CHEMBL617380,,BAO_0000357,,227.0,,,H,2493.0,14442.0,1.0,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,
,8.0,,B,,,,CHEMBL617381,,BAO_0000357,,227.0,,,H,2494.0,14442.0,1.0,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,
,8.0,,B,,,,CHEMBL617382,,BAO_0000357,,227.0,,,H,2495.0,14442.0,1.0,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,
,8.0,,B,,,,CHEMBL617383,,BAO_0000357,,107.0,,,H,2496.0,12369.0,1.0,,Autocuration,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617384,,BAO_0000357,,107.0,,,H,2497.0,12369.0,1.0,,Expert,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,
,8.0,,B,,,,CHEMBL617385,,BAO_0000357,,107.0,,,H,2498.0,12369.0,1.0,,Expert,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,
,8.0,,B,,,,CHEMBL617386,,BAO_0000019,,107.0,,,H,2499.0,14447.0,1.0,,Autocuration,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,
,8.0,,B,,,,CHEMBL617387,,BAO_0000019,,107.0,,,H,2500.0,14447.0,1.0,,Autocuration,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,
,8.0,,B,,,,CHEMBL617388,,BAO_0000219,NIH3T3,107.0,,,H,2501.0,17451.0,1.0,723.0,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,
,8.0,,F,,,,CHEMBL617389,,BAO_0000219,CHO,107.0,,,H,2502.0,6857.0,1.0,449.0,Autocuration,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,
9606.0,9.0,,F,,,,CHEMBL617390,,BAO_0000219,CHO,107.0,,,D,2503.0,6857.0,1.0,449.0,Expert,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,
,4.0,,B,,,,CHEMBL617391,,BAO_0000224,,104817.0,,,H,2504.0,5635.0,1.0,,Autocuration,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,
,8.0,,B,,,,CHEMBL617392,,BAO_0000357,,107.0,,,H,2505.0,12861.0,1.0,,Autocuration,,Binding activity radioligand.,
,8.0,,B,,,,CHEMBL617393,,BAO_0000019,,107.0,,,H,2506.0,12861.0,1.0,,Autocuration,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,
,8.0,,B,,,,CHEMBL617394,,BAO_0000219,L929,107.0,,,H,2507.0,5105.0,1.0,307.0,Autocuration,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,
,8.0,,B,,,,CHEMBL617395,,BAO_0000219,L929,107.0,,,H,2508.0,5104.0,1.0,307.0,Expert,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,
,8.0,,B,,,,CHEMBL617396,,BAO_0000219,L929,107.0,,,H,2509.0,5105.0,1.0,307.0,Expert,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,
,8.0,,B,,,,CHEMBL617397,,BAO_0000219,L929,107.0,,,H,2510.0,5105.0,1.0,307.0,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,
,8.0,,B,,,,CHEMBL617398,,BAO_0000357,,107.0,,,H,2511.0,5254.0,1.0,,Autocuration,,Binding affinity against 5-HT2A receptor,
,8.0,,B,,,,CHEMBL617399,,BAO_0000357,,107.0,,,H,2512.0,5254.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617400,,BAO_0000219,HEK293,107.0,,,H,2513.0,13267.0,1.0,722.0,Autocuration,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL617401,,BAO_0000219,HEK293,107.0,,,H,2514.0,13267.0,1.0,722.0,Autocuration,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,
9606.0,9.0,,B,,,,CHEMBL617402,,BAO_0000219,HEK293,107.0,,,D,2515.0,14157.0,1.0,722.0,Expert,Homo sapiens,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,
9606.0,9.0,,B,,,,CHEMBL617403,,BAO_0000219,HEK293,107.0,,,D,2516.0,12936.0,1.0,722.0,Expert,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,
,8.0,,B,,,,CHEMBL617404,,BAO_0000357,,107.0,,,H,2517.0,14068.0,1.0,,Expert,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,
9606.0,9.0,,B,,,,CHEMBL857981,,BAO_0000219,HEK293,107.0,,,D,2518.0,12936.0,1.0,722.0,Expert,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,
9606.0,9.0,,B,,,,CHEMBL617405,,BAO_0000219,HEK293,107.0,,,D,2519.0,12936.0,1.0,722.0,Expert,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,
9606.0,9.0,,B,,,,CHEMBL617253,,BAO_0000219,HEK293,107.0,,,D,2520.0,4540.0,1.0,722.0,Expert,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,
,8.0,,B,,,,CHEMBL617254,,BAO_0000357,,107.0,,,H,2521.0,6166.0,1.0,,Expert,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,
,8.0,,B,,,,CHEMBL617255,,BAO_0000219,HEK293,107.0,,,H,2522.0,17296.0,1.0,722.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL617256,,BAO_0000219,HEK293,107.0,,,H,2523.0,17296.0,1.0,722.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL616874,,BAO_0000219,HEK293,107.0,,,H,2524.0,17296.0,1.0,722.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,
9606.0,9.0,,B,,,,CHEMBL616875,,BAO_0000219,HEK293,107.0,,,D,2525.0,15779.0,1.0,722.0,Expert,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,
,8.0,,B,,,,CHEMBL616876,,BAO_0000219,HEK293,107.0,,,H,2526.0,14391.0,1.0,722.0,Expert,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL616877,,BAO_0000219,HEK293,107.0,,,H,2527.0,15851.0,1.0,722.0,Expert,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",
9606.0,9.0,,B,,,,CHEMBL616878,,BAO_0000219,HEK293,107.0,,,D,2528.0,15851.0,1.0,722.0,Expert,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,
,8.0,,B,,,,CHEMBL616879,,BAO_0000219,HEK293,107.0,,,H,2529.0,3832.0,1.0,722.0,Expert,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,
,8.0,,B,,,,CHEMBL616880,,BAO_0000219,HEK293,107.0,,,H,2530.0,3833.0,1.0,722.0,Expert,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,
9606.0,9.0,,B,,,,CHEMBL616881,,BAO_0000219,HEK293,107.0,,,D,2531.0,12936.0,1.0,722.0,Expert,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,
,8.0,,B,,,,CHEMBL616882,,BAO_0000219,NIH3T3,107.0,,,H,2532.0,17451.0,1.0,723.0,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL616883,,BAO_0000219,NIH3T3,107.0,,,H,2533.0,17451.0,1.0,723.0,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,
,8.0,,B,,,,CHEMBL616884,,BAO_0000219,NIH3T3,107.0,,,H,2534.0,17451.0,1.0,723.0,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,
,8.0,,B,,,,CHEMBL616885,,BAO_0000219,HEK293,107.0,,,H,2535.0,4199.0,1.0,722.0,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,
,8.0,,B,,,,CHEMBL616886,,BAO_0000219,CHO-K1,107.0,,,H,2536.0,1883.0,1.0,485.0,Autocuration,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,
,8.0,,B,,,,CHEMBL616887,,BAO_0000219,CHO-K1,107.0,,,H,2537.0,1883.0,1.0,485.0,Expert,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,
9606.0,9.0,,B,,,,CHEMBL616888,,BAO_0000357,,107.0,,,D,2538.0,14875.0,1.0,,Expert,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL616889,,BAO_0000219,HEK293,107.0,,,H,2539.0,15146.0,1.0,722.0,Autocuration,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,
,8.0,,B,,,,CHEMBL616890,,BAO_0000219,HEK293,107.0,,,H,2540.0,5213.0,1.0,722.0,Autocuration,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,
9606.0,9.0,,B,,,,CHEMBL616891,,BAO_0000219,CHO,107.0,,,D,2541.0,16404.0,1.0,449.0,Expert,Homo sapiens,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,
,8.0,,B,,,,CHEMBL616892,,BAO_0000219,HEK293,107.0,,,H,2542.0,14818.0,1.0,722.0,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,
,8.0,,B,,,,CHEMBL616893,,BAO_0000219,HEK293,107.0,,,H,2543.0,4829.0,1.0,722.0,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",
,8.0,,F,,,,CHEMBL616894,,BAO_0000219,NIH3T3,10620.0,,,H,2544.0,12652.0,1.0,723.0,Autocuration,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,
,8.0,,B,,,,CHEMBL616895,,BAO_0000219,NIH3T3,107.0,,,H,2545.0,4682.0,1.0,723.0,Expert,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,
,8.0,,F,,,,CHEMBL616896,,BAO_0000019,,10620.0,,,H,2546.0,12652.0,1.0,,Autocuration,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617099,,BAO_0000357,,10621.0,,,H,2547.0,4921.0,1.0,,Autocuration,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617100,,BAO_0000357,,10621.0,,,H,2548.0,4921.0,1.0,,Autocuration,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,
9986.0,8.0,,B,,,,CHEMBL884532,,BAO_0000357,,107.0,,,H,2549.0,16312.0,1.0,,Autocuration,Oryctolagus cuniculus,Binding affinity against rabbit aorta 5-HT2A receptor,
9986.0,8.0,,B,,,,CHEMBL617101,,BAO_0000357,,107.0,,,H,2550.0,14998.0,1.0,,Expert,Oryctolagus cuniculus,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,
9986.0,8.0,,B,,,,CHEMBL617102,,BAO_0000357,,107.0,,,H,2551.0,14025.0,1.0,,Expert,Oryctolagus cuniculus,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,
9986.0,8.0,,B,,,,CHEMBL617103,,BAO_0000019,,107.0,,,H,2552.0,13047.0,1.0,,Autocuration,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,
9986.0,8.0,,B,,,,CHEMBL617104,,BAO_0000357,,107.0,,,H,2553.0,13047.0,1.0,,Expert,Oryctolagus cuniculus,The compound was tested for binding affinity against 5-HT2A receptor,
,8.0,,B,,,,CHEMBL857979,,BAO_0000219,CHO-K1,10576.0,,,H,2554.0,1883.0,1.0,485.0,Autocuration,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,
,8.0,,B,,,,CHEMBL857502,,BAO_0000019,,12687.0,,,H,2555.0,13463.0,1.0,,Autocuration,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,
,8.0,,B,,,,CHEMBL617105,,BAO_0000019,,12687.0,,,H,2556.0,13463.0,1.0,,Autocuration,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,
,8.0,,B,,,945.0,CHEMBL858021,,BAO_0000019,,12687.0,,,H,2557.0,13463.0,1.0,,Autocuration,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,Stomach
10116.0,9.0,,B,,,945.0,CHEMBL875910,,BAO_0000019,,12687.0,,,D,2558.0,13463.0,1.0,,Expert,Rattus norvegicus,Binding affinity for 5-HT 2A in rat stomach fundus,Stomach
,8.0,,B,,,,CHEMBL617106,,BAO_0000019,,12687.0,,,H,2559.0,13463.0,1.0,,Autocuration,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,
,8.0,,B,,,,CHEMBL617107,,BAO_0000219,NIH3T3,12687.0,,,H,2560.0,16326.0,1.0,723.0,Expert,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,
,8.0,,F,,,,CHEMBL617108,,BAO_0000019,,12687.0,,,H,2561.0,14093.0,1.0,,Autocuration,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,
,8.0,,F,,,,CHEMBL617109,,BAO_0000019,,12687.0,,,H,2562.0,14093.0,1.0,,Autocuration,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617110,,BAO_0000357,,12687.0,,,H,2563.0,15740.0,1.0,,Autocuration,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617111,,BAO_0000357,,12687.0,,,H,2564.0,16633.0,1.0,,Autocuration,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,
10116.0,9.0,,F,,,,CHEMBL617112,,BAO_0000019,,12687.0,,,D,2565.0,17200.0,1.0,,Expert,Rattus norvegicus,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,
,8.0,,B,,,,CHEMBL617113,,BAO_0000357,,12687.0,,,H,2566.0,17133.0,1.0,,Autocuration,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617114,,BAO_0000357,,12687.0,,,H,2567.0,17133.0,1.0,,Autocuration,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617115,,BAO_0000357,,12687.0,,,H,2568.0,17133.0,1.0,,Autocuration,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,
,8.0,,F,,,,CHEMBL617116,,BAO_0000219,,12687.0,,,H,2569.0,17200.0,1.0,,Autocuration,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,
,8.0,,F,,,,CHEMBL617117,,BAO_0000019,,12687.0,,,H,2570.0,15363.0,1.0,,Autocuration,,Efficacy at 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617118,,BAO_0000357,,12687.0,,,H,2571.0,17200.0,1.0,,Autocuration,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),
10116.0,9.0,,B,,,,CHEMBL617119,,BAO_0000357,,12687.0,,,D,2572.0,17200.0,1.0,,Expert,Rattus norvegicus,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),
10116.0,9.0,,B,,,,CHEMBL617120,,BAO_0000357,,12687.0,,,D,2573.0,17200.0,1.0,,Expert,Rattus norvegicus,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),
10116.0,9.0,,F,,,,CHEMBL617121,,BAO_0000219,,12687.0,,,D,2574.0,17200.0,1.0,,Expert,Rattus norvegicus,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,
,8.0,,F,,,,CHEMBL617122,,BAO_0000219,,12687.0,,,H,2575.0,17200.0,1.0,,Autocuration,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,
,8.0,,B,,,,CHEMBL617123,,BAO_0000019,,12687.0,,,H,2576.0,17211.0,1.0,,Autocuration,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617124,,BAO_0000019,,12687.0,,,H,2577.0,17331.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,
,8.0,,B,,,,CHEMBL617600,,BAO_0000249,,12687.0,,,H,2578.0,13565.0,1.0,,Expert,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,
,8.0,,B,,,,CHEMBL617601,,BAO_0000357,,12687.0,,,H,2579.0,13730.0,1.0,,Expert,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,
,8.0,,B,,,,CHEMBL882923,,BAO_0000019,,12687.0,,,H,2580.0,12416.0,1.0,,Expert,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,
,8.0,,B,,,,CHEMBL617602,,BAO_0000357,,12687.0,,,H,2581.0,15295.0,1.0,,Autocuration,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617603,,BAO_0000019,,12687.0,,,H,2582.0,1742.0,1.0,,Autocuration,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,
,8.0,,B,,,,CHEMBL617604,,BAO_0000357,,12687.0,,,H,2583.0,15295.0,1.0,,Autocuration,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617605,,BAO_0000019,,12687.0,,,H,2584.0,14970.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL617606,,BAO_0000019,,12687.0,,,H,2585.0,16693.0,1.0,,Expert,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,
10116.0,9.0,,B,,,,CHEMBL617607,,BAO_0000019,,12687.0,,,D,2586.0,14776.0,1.0,,Expert,Rattus norvegicus,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617455,,BAO_0000249,,12687.0,,,H,2587.0,14286.0,1.0,,Autocuration,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,
10116.0,9.0,,B,,,,CHEMBL617456,,BAO_0000019,,12687.0,,,D,2588.0,17200.0,1.0,,Expert,Rattus norvegicus,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,
,8.0,,B,,,,CHEMBL617457,,BAO_0000357,,12687.0,,,H,2589.0,15306.0,1.0,,Expert,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),
10116.0,9.0,,B,,,,CHEMBL617458,,BAO_0000357,,12687.0,,,D,2590.0,14178.0,1.0,,Expert,Rattus norvegicus,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,
10116.0,9.0,,B,,,,CHEMBL617459,,BAO_0000019,,12687.0,,,D,2591.0,14229.0,1.0,,Expert,Rattus norvegicus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,
,8.0,,B,,,,CHEMBL617460,,BAO_0000357,,12687.0,,,H,2592.0,12884.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,
,8.0,,B,,,,CHEMBL617461,,BAO_0000357,,12687.0,,,H,2593.0,13149.0,1.0,,Expert,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",
10116.0,9.0,,B,,,,CHEMBL617462,,BAO_0000019,,12687.0,,,D,2594.0,15295.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,
,8.0,,B,,,,CHEMBL617463,,BAO_0000357,,12687.0,,,H,2595.0,15740.0,1.0,,Autocuration,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,
,8.0,,B,,,,CHEMBL617464,,BAO_0000019,,12687.0,,,H,2596.0,15185.0,1.0,,Autocuration,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",
,8.0,,B,,,,CHEMBL617465,,BAO_0000019,,12687.0,,,H,2597.0,15185.0,1.0,,Autocuration,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",
,8.0,,B,,,,CHEMBL617466,,BAO_0000019,,12687.0,,,H,2598.0,17529.0,1.0,,Expert,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,
,8.0,,B,,,,CHEMBL617467,,BAO_0000019,,12687.0,,,H,2599.0,14826.0,1.0,,Autocuration,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,
,8.0,,B,,,,CHEMBL617468,,BAO_0000019,,12687.0,,,H,2600.0,17211.0,1.0,,Expert,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,
,8.0,,B,,,,CHEMBL617469,,BAO_0000019,,12687.0,,,H,2601.0,14826.0,1.0,,Autocuration,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,
,8.0,,B,,,,CHEMBL617470,,BAO_0000019,,12687.0,,,H,2602.0,14093.0,1.0,,Autocuration,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617471,,BAO_0000019,,12687.0,,,H,2603.0,14093.0,1.0,,Autocuration,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,
,8.0,,B,,,,CHEMBL617472,,BAO_0000219,NIH3T3,12687.0,,,H,2604.0,13246.0,1.0,723.0,Expert,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,
,8.0,,B,,,,CHEMBL617473,,BAO_0000357,,12687.0,,,H,2605.0,13246.0,1.0,,Expert,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,
10116.0,9.0,,B,,,,CHEMBL617474,,BAO_0000019,,12687.0,,,D,2606.0,15436.0,1.0,,Expert,Rattus norvegicus,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,
10116.0,9.0,,B,,,,CHEMBL617475,,BAO_0000019,,12687.0,,,D,2607.0,15436.0,1.0,,Expert,Rattus norvegicus,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,
,8.0,,B,,,955.0,CHEMBL617476,,BAO_0000221,,12687.0,,,H,2608.0,14442.0,1.0,,Autocuration,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,Brain
,8.0,,B,,,,CHEMBL617477,,BAO_0000357,,12687.0,,,H,2609.0,12457.0,1.0,,Expert,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617478,,BAO_0000219,NIH3T3,12687.0,,,H,2610.0,12457.0,1.0,723.0,Expert,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,
,8.0,,F,,,,CHEMBL617479,,BAO_0000221,,12687.0,,,H,2611.0,14755.0,1.0,,Autocuration,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",
,8.0,,B,,,,CHEMBL617480,,BAO_0000357,,12687.0,,,H,2612.0,4707.0,1.0,,Autocuration,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,
,8.0,,B,,,,CHEMBL617481,,BAO_0000357,,12687.0,,,H,2613.0,13297.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617482,,BAO_0000019,,12687.0,,,H,2614.0,17331.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,
,8.0,,B,,,,CHEMBL617483,,BAO_0000019,,12687.0,,,H,2615.0,4664.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL621528,,BAO_0000357,,12687.0,,,H,2616.0,16633.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,
10116.0,9.0,,B,,,,CHEMBL621529,,BAO_0000219,NIH3T3,12687.0,,,D,2617.0,4664.0,1.0,723.0,Expert,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,
,8.0,,B,,,,CHEMBL621530,,BAO_0000357,,12687.0,,,H,2618.0,16133.0,1.0,,Expert,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,
,8.0,,B,,,,CHEMBL621531,,BAO_0000357,,12687.0,,,H,2619.0,16133.0,1.0,,Expert,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,
10116.0,9.0,,B,,,,CHEMBL621532,,BAO_0000019,,12687.0,,,D,2620.0,14060.0,1.0,,Expert,Rattus norvegicus,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL621533,,BAO_0000357,,12687.0,,,H,2621.0,16326.0,1.0,,Expert,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,
,8.0,,B,,,,CHEMBL621534,,BAO_0000219,CHO,12687.0,,,H,2622.0,16659.0,1.0,449.0,Expert,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,
,8.0,,B,,,,CHEMBL621535,,BAO_0000019,,12687.0,,,H,2623.0,14776.0,1.0,,Autocuration,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,
,8.0,,B,,,,CHEMBL621536,,BAO_0000357,,12687.0,,,H,2624.0,13481.0,1.0,,Autocuration,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,
,8.0,,B,,,,CHEMBL621537,,BAO_0000357,,12687.0,,,H,2625.0,17386.0,1.0,,Autocuration,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,
10116.0,9.0,,B,,,,CHEMBL621538,,BAO_0000357,,12687.0,,,D,2626.0,6611.0,1.0,,Expert,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL621539,,BAO_0000019,,12687.0,,,H,2627.0,14423.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,
,8.0,,B,,,,CHEMBL621540,,BAO_0000019,,12687.0,,,H,2628.0,15412.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,
,8.0,,B,,,,CHEMBL621541,,BAO_0000019,,12687.0,,,H,2629.0,15412.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,
,8.0,,B,,,,CHEMBL621542,,BAO_0000019,,12687.0,,,H,2630.0,6238.0,1.0,,Autocuration,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL621543,,BAO_0000357,,12687.0,,,H,2631.0,6648.0,1.0,,Expert,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,
,8.0,,B,,,,CHEMBL621544,,BAO_0000357,,12687.0,,,H,2632.0,5667.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,
10116.0,9.0,,B,,,,CHEMBL621545,,BAO_0000357,,12687.0,,,D,2633.0,6611.0,1.0,,Expert,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,
,8.0,,B,,,,CHEMBL621546,,BAO_0000357,,12687.0,,,H,2634.0,13481.0,1.0,,Autocuration,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL621547,,BAO_0000357,,12687.0,,,H,2635.0,13481.0,1.0,,Autocuration,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,
,8.0,,B,,,,CHEMBL618692,,BAO_0000219,NIH3T3,12687.0,,,H,2636.0,15558.0,1.0,723.0,Expert,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL618693,,BAO_0000357,,12687.0,,,H,2637.0,6013.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL872922,,BAO_0000357,,12687.0,,,H,2638.0,16633.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,
,8.0,,B,,,,CHEMBL618694,,BAO_0000357,,12687.0,,,H,2639.0,6013.0,1.0,,Autocuration,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,
10116.0,9.0,,B,,,,CHEMBL618695,,BAO_0000357,,12687.0,,,D,2640.0,6013.0,1.0,,Expert,Rattus norvegicus,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,
,8.0,,B,,,,CHEMBL618696,,BAO_0000357,,12687.0,,,H,2641.0,6013.0,1.0,,Autocuration,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,
,8.0,,B,,,,CHEMBL618697,,BAO_0000357,,12687.0,,,H,2642.0,6013.0,1.0,,Expert,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,
,8.0,,B,,,,CHEMBL618892,,BAO_0000357,,12687.0,,,H,2643.0,6013.0,1.0,,Autocuration,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,
,8.0,,B,,,,CHEMBL618893,,BAO_0000357,,12687.0,,,H,2644.0,6013.0,1.0,,Autocuration,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL618894,,BAO_0000357,,12687.0,,,H,2645.0,16293.0,1.0,,Autocuration,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL618895,,BAO_0000219,NIH3T3,12687.0,,,H,2646.0,17175.0,1.0,723.0,Expert,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,
10116.0,9.0,,B,,,,CHEMBL618896,,BAO_0000357,,12687.0,,,D,2647.0,13278.0,1.0,,Expert,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,
,8.0,,B,,,5383.0,CHEMBL618897,,BAO_0000019,,12687.0,,,H,2648.0,3682.0,1.0,,Autocuration,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,Caudate-putamen
,8.0,,B,,,,CHEMBL618898,,BAO_0000357,,12687.0,,,H,2649.0,2014.0,1.0,,Autocuration,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,
,8.0,,B,,,,CHEMBL618899,,BAO_0000357,,12687.0,,,H,2650.0,2014.0,1.0,,Autocuration,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,
,8.0,,B,,,,CHEMBL618900,,BAO_0000357,,12687.0,,,H,2651.0,4932.0,1.0,,Autocuration,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,
,8.0,,B,,,,CHEMBL618901,,BAO_0000019,,12687.0,,,H,2652.0,4932.0,1.0,,Autocuration,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,
,8.0,,B,,,,CHEMBL618902,,BAO_0000357,,12687.0,,,H,2653.0,3935.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,
10116.0,9.0,,B,,,10000000.0,CHEMBL618903,,BAO_0000221,,12687.0,,,D,2654.0,5432.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,Hippocampus
,8.0,,B,,,,CHEMBL618904,,BAO_0000357,,12687.0,,,H,2655.0,15818.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL618905,,BAO_0000357,,12687.0,,,H,2656.0,13672.0,1.0,,Autocuration,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,
,8.0,,B,,,,CHEMBL618906,,BAO_0000357,,12687.0,,,H,2657.0,13672.0,1.0,,Autocuration,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,
,8.0,,B,,,,CHEMBL618907,,BAO_0000219,NIH3T3,12687.0,,,H,2658.0,14749.0,1.0,723.0,Expert,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,
,8.0,,B,,,,CHEMBL618908,,BAO_0000019,,12687.0,,,H,2659.0,13462.0,1.0,,Autocuration,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,
,8.0,,B,,,,CHEMBL617909,,BAO_0000357,,12687.0,,,H,2660.0,15740.0,1.0,,Autocuration,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617910,,BAO_0000019,,12687.0,,,H,2661.0,16647.0,1.0,,Expert,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,
,8.0,,B,,,955.0,CHEMBL617911,,BAO_0000221,,12687.0,,,H,2662.0,13345.0,1.0,,Autocuration,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,Brain
,8.0,,B,,,,CHEMBL872923,,BAO_0000249,,12687.0,,,H,2663.0,16740.0,1.0,,Autocuration,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,
,8.0,,B,,,,CHEMBL617912,,BAO_0000249,,12687.0,,,H,2664.0,16740.0,1.0,,Autocuration,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,
10116.0,9.0,,B,,,,CHEMBL617913,,BAO_0000019,,12687.0,,,D,2665.0,15535.0,1.0,,Expert,Rattus norvegicus,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,
,8.0,,B,,,,CHEMBL617914,,BAO_0000249,,12687.0,,,H,2666.0,16740.0,1.0,,Expert,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,
,8.0,,B,,,,CHEMBL617915,,BAO_0000249,,12687.0,,,H,2667.0,16740.0,1.0,,Autocuration,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,
,8.0,,B,,,,CHEMBL617916,,BAO_0000249,,12687.0,,,H,2668.0,16740.0,1.0,,Autocuration,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,
10116.0,9.0,,B,,,,CHEMBL617917,,BAO_0000019,,12687.0,,,D,2669.0,4795.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617918,,BAO_0000019,,12687.0,,,H,2670.0,8.0,1.0,,Expert,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL617919,,BAO_0000019,,12687.0,,,H,2671.0,8.0,1.0,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,
10116.0,9.0,,B,,,,CHEMBL617920,,BAO_0000019,,12687.0,,,D,2672.0,17200.0,1.0,,Expert,Rattus norvegicus,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,
10116.0,9.0,,B,,,,CHEMBL617921,,BAO_0000019,,12687.0,,,D,2673.0,2148.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,
10116.0,5.0,,B,,,,CHEMBL617922,,BAO_0000224,,105102.0,,,D,2674.0,13345.0,1.0,,Expert,Rattus norvegicus,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",
,8.0,,B,,,,CHEMBL617923,,BAO_0000357,,12687.0,,,H,2675.0,5088.0,1.0,,Autocuration,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,
,8.0,,B,,,,CHEMBL617924,,BAO_0000357,,12687.0,,,H,2676.0,5088.0,1.0,,Autocuration,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,
,8.0,,B,,,,CHEMBL617925,,BAO_0000357,,12687.0,,,H,2677.0,17133.0,1.0,,Autocuration,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,
10116.0,9.0,,B,,,,CHEMBL617926,,BAO_0000357,,12687.0,,,D,2678.0,17133.0,1.0,,Expert,Rattus norvegicus,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,
,8.0,,B,,,,CHEMBL617927,,BAO_0000357,,12687.0,,,H,2679.0,16532.0,1.0,,Autocuration,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,
,8.0,,B,,,,CHEMBL617928,,BAO_0000357,,12687.0,,,H,2680.0,15086.0,1.0,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,
10116.0,9.0,,B,,,,CHEMBL617929,,BAO_0000019,,12687.0,,,D,2681.0,2309.0,1.0,,Expert,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,
,8.0,,B,,,,CHEMBL617930,,BAO_0000019,,12687.0,,,H,2682.0,12953.0,1.0,,Expert,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,
,8.0,,B,,,,CHEMBL617931,,BAO_0000019,,12687.0,,,H,2683.0,12953.0,1.0,,Autocuration,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,
,8.0,,B,,,,CHEMBL617932,,BAO_0000019,,12687.0,,,H,2684.0,12953.0,1.0,,Autocuration,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,
,8.0,,B,,,,CHEMBL617933,,BAO_0000219,CHO,12687.0,,,H,2685.0,16659.0,1.0,449.0,Autocuration,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,
,8.0,,B,,,,CHEMBL617934,,BAO_0000019,,12687.0,,,H,2686.0,16740.0,1.0,,Autocuration,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,
,8.0,,B,,,,CHEMBL617935,,BAO_0000019,,12687.0,,,H,2687.0,16740.0,1.0,,Autocuration,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,
,8.0,,B,,,,CHEMBL617936,,BAO_0000357,,12687.0,,,H,2688.0,17133.0,1.0,,Autocuration,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,
,8.0,,B,,,,CHEMBL617937,,BAO_0000019,,12687.0,,,H,2689.0,17211.0,1.0,,Autocuration,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,
,8.0,,B,,,,CHEMBL617938,,BAO_0000019,,12687.0,,,H,2690.0,17331.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,
,8.0,,B,,,,CHEMBL617939,,BAO_0000218,,12687.0,,,H,2691.0,16633.0,1.0,,Autocuration,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,
,8.0,,B,,,,CHEMBL617940,,BAO_0000218,,12687.0,,,H,2692.0,16633.0,1.0,,Autocuration,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,
,8.0,,B,,,,CHEMBL617941,,BAO_0000218,,12687.0,,,H,2693.0,16633.0,1.0,,Autocuration,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,
,8.0,,B,,,,CHEMBL617942,,BAO_0000357,,12687.0,,,H,2694.0,15026.0,1.0,,Expert,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,
,8.0,,B,,,,CHEMBL617943,,BAO_0000357,,12687.0,,,H,2695.0,15026.0,1.0,,Expert,,Ratio of pKi of 5-HT2A to that of D2 receptor,
,4.0,,B,,,,CHEMBL617944,,BAO_0000224,,105093.0,,,H,2696.0,16404.0,1.0,,Expert,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,
,4.0,,B,,,,CHEMBL617945,,BAO_0000224,,105093.0,,,H,2697.0,16404.0,1.0,,Expert,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,
,4.0,,B,,,,CHEMBL617946,,BAO_0000224,,105075.0,,,H,2698.0,16404.0,1.0,,Expert,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617947,,BAO_0000357,,12687.0,,,H,2699.0,16404.0,1.0,,Autocuration,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,
,8.0,,B,,,,CHEMBL617948,,BAO_0000357,,12687.0,,,H,2700.0,16326.0,1.0,,Expert,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,
,8.0,,F,,,,CHEMBL858116,,BAO_0000019,,12687.0,,,H,2701.0,15847.0,1.0,,Autocuration,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,
,8.0,,F,,,,CHEMBL617949,,BAO_0000019,,12687.0,,,H,2702.0,15847.0,1.0,,Autocuration,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,
,8.0,,F,,,,CHEMBL617950,,BAO_0000019,,12687.0,,,H,2703.0,15329.0,1.0,,Autocuration,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,
,8.0,,F,,,1515.0,CHEMBL617951,,BAO_0000019,,12687.0,,,H,2704.0,16404.0,1.0,,Expert,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,Thoracic aorta
,8.0,,F,,,1515.0,CHEMBL617952,,BAO_0000019,,12687.0,,,H,2705.0,16404.0,1.0,,Expert,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,Thoracic aorta
,8.0,,F,,,1515.0,CHEMBL617953,,BAO_0000019,,12687.0,,,H,2706.0,16404.0,1.0,,Autocuration,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,Thoracic aorta
,8.0,,B,,,,CHEMBL617954,,BAO_0000357,,12687.0,,,H,2707.0,12861.0,1.0,,Autocuration,,Binding activity radioligand.,
,8.0,,B,,,,CHEMBL617955,,BAO_0000019,,12687.0,,,H,2708.0,12861.0,1.0,,Expert,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,
,8.0,,B,,,,CHEMBL857071,,BAO_0000019,,12687.0,,,H,2709.0,12861.0,1.0,,Autocuration,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,
,8.0,,B,,,,CHEMBL617270,,BAO_0000019,,12687.0,,,H,2710.0,12490.0,1.0,,Expert,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,
,8.0,,B,,,,CHEMBL617271,,BAO_0000219,N1E-115,12687.0,,,H,2711.0,12827.0,1.0,339.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,
,8.0,,B,,,,CHEMBL617272,,BAO_0000219,N1E-115,12687.0,,,H,2712.0,12827.0,1.0,339.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,
,8.0,,B,,,,CHEMBL617273,,BAO_0000019,,12687.0,,,H,2713.0,12918.0,1.0,,Autocuration,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,
10116.0,9.0,,F,,,,CHEMBL617274,,BAO_0000019,,12687.0,,,D,2714.0,12919.0,1.0,,Expert,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,
,8.0,,B,,,,CHEMBL617275,,BAO_0000357,,108.0,,,H,2715.0,17723.0,1.0,,Autocuration,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617276,,BAO_0000357,,108.0,,,H,2716.0,6013.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617277,,BAO_0000357,,108.0,,,H,2717.0,16293.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617278,,BAO_0000019,,108.0,,,H,2718.0,3857.0,1.0,,Expert,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617279,,BAO_0000019,,108.0,,,H,2719.0,3857.0,1.0,,Expert,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,
,8.0,,B,,,,CHEMBL617280,,BAO_0000019,,108.0,,,H,2720.0,3857.0,1.0,,Expert,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617281,,BAO_0000357,,108.0,,,H,2721.0,15363.0,1.0,,Autocuration,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617282,,BAO_0000357,,108.0,,,H,2722.0,15363.0,1.0,,Autocuration,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617283,,BAO_0000019,,108.0,,,H,2723.0,16441.0,1.0,,Expert,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,
,8.0,,B,,,,CHEMBL617284,,BAO_0000019,,108.0,,,H,2724.0,16441.0,1.0,,Expert,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,
,8.0,,B,,,,CHEMBL617285,,BAO_0000219,HEK293,108.0,,,H,2725.0,4176.0,1.0,722.0,Autocuration,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,
,8.0,,B,,,,CHEMBL617286,,BAO_0000019,,108.0,,,H,2726.0,17085.0,1.0,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,
9606.0,9.0,,B,,,,CHEMBL617287,,BAO_0000357,,108.0,,,D,2727.0,17200.0,1.0,,Expert,Homo sapiens,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,
,8.0,,B,,,,CHEMBL617288,,BAO_0000357,,108.0,,,H,2728.0,5088.0,1.0,,Expert,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,
,8.0,,B,,,,CHEMBL617289,,BAO_0000357,,108.0,,,H,2729.0,5088.0,1.0,,Autocuration,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,
,8.0,,B,,,,CHEMBL872917,,BAO_0000357,,108.0,,,H,2730.0,5088.0,1.0,,Autocuration,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,
,8.0,,B,,,,CHEMBL617290,,BAO_0000357,,108.0,,,H,2731.0,5088.0,1.0,,Autocuration,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL617291,,BAO_0000219,CHO,108.0,,,H,2732.0,16659.0,1.0,449.0,Autocuration,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,
,8.0,,B,,,,CHEMBL617292,,BAO_0000219,CHO,108.0,,,H,2733.0,16659.0,1.0,449.0,Autocuration,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,
,8.0,,B,,,,CHEMBL617293,,BAO_0000219,NIH3T3,108.0,,,H,2734.0,17451.0,1.0,723.0,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,
9606.0,9.0,,F,,,,CHEMBL617294,,BAO_0000219,CHO,108.0,,,D,2735.0,6857.0,1.0,449.0,Expert,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,
,8.0,,B,,,,CHEMBL617295,,BAO_0000019,,108.0,,,H,2736.0,3857.0,1.0,,Expert,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,
,8.0,,B,,,,CHEMBL617296,,BAO_0000357,,108.0,,,H,2737.0,12861.0,1.0,,Autocuration,,Binding activity radioligand.,
,8.0,,B,,,,CHEMBL617297,,BAO_0000019,,108.0,,,H,2738.0,12861.0,1.0,,Autocuration,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,
,8.0,,B,,,,CHEMBL617298,,BAO_0000219,CHO,108.0,,,H,2739.0,5104.0,1.0,449.0,Expert,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,
,8.0,,B,,,,CHEMBL617299,,BAO_0000219,CHO,108.0,,,H,2740.0,5105.0,1.0,449.0,Expert,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,
,8.0,,B,,,,CHEMBL617300,,BAO_0000219,CHO,108.0,,,H,2741.0,5105.0,1.0,449.0,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,
,8.0,,B,,,,CHEMBL617454,,BAO_0000357,,108.0,,,H,2742.0,5254.0,1.0,,Autocuration,,Binding affinity against 5-HT2C receptor,
,8.0,,B,,,,CHEMBL617505,,BAO_0000219,HEK293,108.0,,,H,2743.0,13267.0,1.0,722.0,Autocuration,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,
9606.0,9.0,,B,,,,CHEMBL617506,,BAO_0000219,HEK293,108.0,,,D,2744.0,14157.0,1.0,722.0,Expert,Homo sapiens,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,
9606.0,9.0,,B,,,,CHEMBL617507,,BAO_0000219,HEK293,108.0,,,D,2745.0,12936.0,1.0,722.0,Expert,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,
,8.0,,B,,,,CHEMBL617508,,BAO_0000357,,108.0,,,H,2746.0,14068.0,1.0,,Expert,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,
9606.0,9.0,,B,,,,CHEMBL857982,,BAO_0000219,HEK293,108.0,,,D,2747.0,12936.0,1.0,722.0,Expert,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,
9606.0,9.0,,B,,,,CHEMBL617509,,BAO_0000219,HEK293,108.0,,,D,2748.0,4540.0,1.0,722.0,Expert,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,
9606.0,9.0,,B,,,,CHEMBL617510,,BAO_0000219,HEK293,108.0,,,D,2749.0,4540.0,1.0,722.0,Expert,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,
,8.0,,B,,,,CHEMBL617511,,BAO_0000357,,108.0,,,H,2750.0,6166.0,1.0,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,
,8.0,,B,,,,CHEMBL617512,,BAO_0000219,HEK293,108.0,,,H,2751.0,17296.0,1.0,722.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,
,8.0,,B,,,,CHEMBL617749,,BAO_0000219,HEK293,108.0,,,H,2752.0,17296.0,1.0,722.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,
,8.0,,B,,,,CHEMBL617750,,BAO_0000219,HEK293,108.0,,,H,2753.0,15779.0,1.0,722.0,Autocuration,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,
,8.0,,B,,,,CHEMBL617751,,BAO_0000219,HEK293,108.0,,,H,2754.0,15779.0,1.0,722.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,
,8.0,,B,,,,CHEMBL617752,,BAO_0000219,HEK293,108.0,,,H,2755.0,14391.0,1.0,722.0,Expert,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,
,8.0,,B,,,,CHEMBL617753,,BAO_0000219,HEK293,108.0,,,H,2756.0,15779.0,1.0,722.0,Autocuration,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",
,8.0,,B,,,,CHEMBL617754,,BAO_0000219,HEK293,108.0,,,H,2757.0,15851.0,1.0,722.0,Expert,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",
9606.0,9.0,,B,,,,CHEMBL617755,,BAO_0000219,HEK293,108.0,,,D,2758.0,15851.0,1.0,722.0,Expert,Homo sapiens,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,
,8.0,,B,,,,CHEMBL617756,,BAO_0000219,HEK293,108.0,,,H,2759.0,15779.0,1.0,722.0,Autocuration,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",
,8.0,,B,,,,CHEMBL617757,,BAO_0000219,HEK293,108.0,,,H,2760.0,3832.0,1.0,722.0,Expert,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,
,8.0,,B,,,,CHEMBL617758,,BAO_0000219,HEK293,108.0,,,H,2761.0,3833.0,1.0,722.0,Expert,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,
,8.0,,B,,,,CHEMBL617759,,BAO_0000219,NIH3T3,108.0,,,H,2762.0,17451.0,1.0,723.0,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL617760,,BAO_0000219,HEK293,108.0,,,H,2763.0,4199.0,1.0,722.0,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,
,8.0,,B,,,,CHEMBL617761,,BAO_0000219,CHO-K1,108.0,,,H,2764.0,1883.0,1.0,485.0,Expert,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,
9606.0,9.0,,B,,,,CHEMBL617762,,BAO_0000357,,108.0,,,D,2765.0,4321.0,1.0,,Expert,Homo sapiens,Binding affinity against 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617763,,BAO_0000357,,108.0,,,H,2766.0,14875.0,1.0,,Autocuration,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL857983,,BAO_0000219,HEK293,108.0,,,H,2767.0,15146.0,1.0,722.0,Autocuration,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,
,8.0,,B,,,,CHEMBL617764,,BAO_0000219,HEK293,108.0,,,H,2768.0,5213.0,1.0,722.0,Autocuration,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,
,8.0,,B,,,,CHEMBL617765,,BAO_0000219,HeLa,108.0,,,H,2769.0,16404.0,1.0,308.0,Autocuration,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,
,8.0,,F,,,,CHEMBL617766,,BAO_0000019,,108.0,,,H,2770.0,13267.0,1.0,,Autocuration,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,
,8.0,,F,,,10000000.0,CHEMBL617767,,BAO_0000221,,108.0,,,H,2771.0,13267.0,1.0,,Autocuration,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,Hippocampus
,8.0,,B,,,,CHEMBL617768,,BAO_0000219,HEK293,108.0,,,H,2772.0,14818.0,1.0,722.0,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,
,8.0,,B,,,,CHEMBL617769,,BAO_0000219,HEK293,108.0,,,H,2773.0,4829.0,1.0,722.0,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",
,8.0,,B,,,,CHEMBL858023,,BAO_0000357,,11864.0,,,H,2774.0,13463.0,1.0,,Autocuration,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,
,8.0,,B,,,945.0,CHEMBL617770,,BAO_0000019,,11864.0,,,H,2775.0,13463.0,1.0,,Autocuration,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,Stomach
,8.0,,B,,,945.0,CHEMBL617771,,BAO_0000019,,11864.0,,,H,2776.0,13463.0,1.0,,Autocuration,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,Stomach
,8.0,,F,,,,CHEMBL617772,,BAO_0000219,A9,11864.0,,,H,2777.0,12652.0,1.0,625.0,Autocuration,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,
,8.0,,B,,,,CHEMBL617773,,BAO_0000219,NIH3T3,11864.0,,,H,2778.0,4682.0,1.0,723.0,Autocuration,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,
,8.0,,B,,,,CHEMBL617850,,BAO_0000219,NIH3T3,11864.0,,,H,2779.0,4682.0,1.0,723.0,Autocuration,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,
,8.0,,B,,,,CHEMBL617851,,BAO_0000219,NIH3T3,11864.0,,,H,2780.0,4682.0,1.0,723.0,Autocuration,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,
,8.0,,F,,,,CHEMBL617852,,BAO_0000019,,11864.0,,,H,2781.0,12652.0,1.0,,Autocuration,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,
10090.0,8.0,,B,,,945.0,CHEMBL858024,,BAO_0000019,,12689.0,,,H,2782.0,13463.0,1.0,,Autocuration,Mus musculus,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,Stomach
10116.0,9.0,,B,,,945.0,CHEMBL617853,,BAO_0000019,,12689.0,,,D,2783.0,13463.0,1.0,,Expert,Rattus norvegicus,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,Stomach
,8.0,,B,,,,CHEMBL617854,,BAO_0000357,,108.0,,,H,2784.0,13969.0,1.0,,Expert,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,
9823.0,8.0,,B,,,,CHEMBL873477,,BAO_0000357,,108.0,,,H,2785.0,13392.0,1.0,,Expert,Sus scrofa,Binding affinity for 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617855,,BAO_0000357,,108.0,,,H,2786.0,13392.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617856,,BAO_0000019,,108.0,,,H,2787.0,14430.0,1.0,,Expert,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,
,8.0,,B,,,,CHEMBL617857,,BAO_0000019,,108.0,,,H,2788.0,1742.0,1.0,,Autocuration,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,
,8.0,,B,,,,CHEMBL617858,,BAO_0000249,,108.0,,,H,2789.0,14286.0,1.0,,Autocuration,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,
,8.0,,B,,,,CHEMBL617859,,BAO_0000357,,108.0,,,H,2790.0,5619.0,1.0,,Autocuration,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617860,,BAO_0000357,,108.0,,,H,2791.0,15086.0,1.0,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617861,,BAO_0000357,,108.0,,,H,2792.0,12861.0,1.0,,Autocuration,,Binding activity radioligand.,
,8.0,,B,,,,CHEMBL617862,,BAO_0000019,,108.0,,,H,2793.0,12861.0,1.0,,Expert,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,
,8.0,,B,,,,CHEMBL617863,,BAO_0000019,,108.0,,,H,2794.0,12861.0,1.0,,Autocuration,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,
,8.0,,B,,,,CHEMBL617864,,BAO_0000249,,108.0,,,H,2795.0,12827.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,
,8.0,,B,,,,CHEMBL617649,,BAO_0000249,,108.0,,,H,2796.0,12827.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,
9823.0,8.0,,F,,,,CHEMBL617650,,BAO_0000019,,108.0,,,H,2797.0,12919.0,1.0,,Expert,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,
9823.0,8.0,,F,,,,CHEMBL617651,,BAO_0000019,,108.0,,,H,2798.0,12919.0,1.0,,Expert,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,
9823.0,8.0,,B,,,,CHEMBL617652,,BAO_0000357,,108.0,,,H,2799.0,16429.0,1.0,,Autocuration,Sus scrofa,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,
9823.0,8.0,,B,,,,CHEMBL857072,,BAO_0000019,,108.0,,,H,2800.0,773.0,1.0,,Autocuration,Sus scrofa,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,
9823.0,8.0,,B,,,,CHEMBL617653,,BAO_0000357,,108.0,,,H,2801.0,5033.0,1.0,,Autocuration,Sus scrofa,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617654,,BAO_0000019,,12687.0,,,H,2802.0,12861.0,1.0,,Autocuration,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,
,8.0,,F,,,,CHEMBL617655,,BAO_0000019,,12689.0,,,H,2803.0,14093.0,1.0,,Autocuration,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617656,,BAO_0000357,,12689.0,,,H,2804.0,14970.0,1.0,,Expert,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,
,8.0,,B,,,,CHEMBL617657,,BAO_0000357,,12689.0,,,H,2805.0,14970.0,1.0,,Autocuration,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,
,8.0,,B,,,,CHEMBL617658,,BAO_0000357,,12689.0,,,H,2806.0,14970.0,1.0,,Autocuration,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,
10116.0,9.0,,B,,,,CHEMBL617659,,BAO_0000357,,12689.0,,,D,2807.0,14178.0,1.0,,Expert,Rattus norvegicus,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,
10116.0,9.0,,B,,,,CHEMBL617838,,BAO_0000357,,12689.0,,,D,2808.0,14178.0,1.0,,Expert,Rattus norvegicus,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,
10116.0,9.0,,B,,,,CHEMBL617839,,BAO_0000249,,12689.0,,Brain membranes,D,2809.0,14229.0,1.0,,Expert,Rattus norvegicus,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,
,8.0,,B,,,,CHEMBL617840,,BAO_0000357,,12689.0,,,H,2810.0,16532.0,1.0,,Autocuration,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,
,8.0,,B,,,,CHEMBL617841,,BAO_0000019,,12689.0,,,H,2811.0,14826.0,1.0,,Autocuration,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,
,8.0,,B,,,,CHEMBL875915,,BAO_0000019,,12689.0,,,H,2812.0,17211.0,1.0,,Autocuration,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,
,8.0,,B,,,,CHEMBL617842,,BAO_0000219,,12689.0,In vitro,,H,2813.0,17211.0,1.0,,Expert,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,
,8.0,,B,,,,CHEMBL617843,,BAO_0000219,NIH3T3,12689.0,,,H,2814.0,13246.0,1.0,723.0,Expert,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,
,8.0,,B,,,,CHEMBL617844,,BAO_0000357,,12689.0,,,H,2815.0,13246.0,1.0,,Expert,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,
,8.0,,B,,,,CHEMBL617845,,BAO_0000357,,12689.0,,,H,2816.0,12457.0,1.0,,Expert,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617846,,BAO_0000219,NIH3T3,12689.0,,,H,2817.0,12457.0,1.0,723.0,Expert,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617847,,BAO_0000357,,12689.0,,,H,2818.0,4707.0,1.0,,Autocuration,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,
,8.0,,B,,,,CHEMBL617848,,BAO_0000357,,12689.0,,,H,2819.0,13297.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617849,,BAO_0000357,,12689.0,,,H,2820.0,16633.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,
,8.0,,B,,,,CHEMBL621507,,BAO_0000357,,12689.0,,,H,2821.0,16133.0,1.0,,Expert,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,
,8.0,,B,,,,CHEMBL621508,,BAO_0000357,,12689.0,,,H,2822.0,16326.0,1.0,,Expert,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,
,8.0,,B,,,,CHEMBL621509,,BAO_0000019,,12689.0,,,H,2823.0,14423.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,
,8.0,,B,,,,CHEMBL621510,,BAO_0000019,,12689.0,,,H,2824.0,15412.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,
,8.0,,B,,,,CHEMBL621511,,BAO_0000019,,12689.0,,,H,2825.0,15412.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,
,8.0,,B,,,,CHEMBL621512,,BAO_0000219,A9,12689.0,,,H,2826.0,15558.0,1.0,625.0,Expert,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL621513,,BAO_0000357,,12689.0,,,H,2827.0,16633.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,
,8.0,,B,,,,CHEMBL621514,,BAO_0000357,,12689.0,,,H,2828.0,6013.0,1.0,,Expert,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,
,8.0,,B,,,,CHEMBL621515,,BAO_0000219,,12689.0,In vitro,,H,2829.0,17175.0,1.0,,Expert,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,
,8.0,,B,,,,CHEMBL621516,,BAO_0000219,,12689.0,,,H,2830.0,12469.0,1.0,,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,
,8.0,,B,,,5383.0,CHEMBL621517,,BAO_0000019,,12689.0,,,H,2831.0,3682.0,1.0,,Autocuration,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,Caudate-putamen
,8.0,,B,,,,CHEMBL621518,,BAO_0000357,,12689.0,,,H,2832.0,4932.0,1.0,,Autocuration,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,
,8.0,,B,,,,CHEMBL621519,,BAO_0000019,,12689.0,,,H,2833.0,4932.0,1.0,,Autocuration,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,
,8.0,,B,,,,CHEMBL621520,,BAO_0000357,,12689.0,,,H,2834.0,3935.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL621521,,BAO_0000357,,12689.0,,,H,2835.0,15818.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL621522,,BAO_0000357,,12689.0,,,H,2836.0,15818.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL621523,,BAO_0000219,,12689.0,,,H,2837.0,14749.0,1.0,,Expert,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,
,8.0,,B,,,,CHEMBL621524,,BAO_0000357,,12689.0,,,H,2838.0,15740.0,1.0,,Autocuration,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,
10116.0,9.0,,B,,,,CHEMBL621525,,BAO_0000357,,12689.0,,,D,2839.0,17133.0,1.0,,Expert,Rattus norvegicus,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,
,8.0,,B,,,,CHEMBL872921,,BAO_0000357,,12689.0,,,H,2840.0,16532.0,1.0,,Autocuration,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,
,8.0,,B,,,,CHEMBL621526,,BAO_0000357,,12689.0,,,H,2841.0,12369.0,1.0,,Autocuration,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL621527,,BAO_0000219,,12689.0,,,H,2842.0,12369.0,1.0,,Expert,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,
10116.0,9.0,,B,,,,CHEMBL617865,,BAO_0000019,,12689.0,,,D,2843.0,2309.0,1.0,,Expert,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,
,8.0,,B,,,,CHEMBL617866,,BAO_0000357,,12689.0,,,H,2844.0,12953.0,1.0,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617867,,BAO_0000019,,12689.0,,,H,2845.0,12953.0,1.0,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,
,8.0,,B,,,,CHEMBL617487,,BAO_0000357,,12689.0,,,H,2846.0,12953.0,1.0,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,
,8.0,,B,,,,CHEMBL617488,,BAO_0000357,,12689.0,,,H,2847.0,12953.0,1.0,,Expert,,Binding affinity for 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617489,,BAO_0000357,,12689.0,,,H,2848.0,17133.0,1.0,,Autocuration,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,
,8.0,,B,,,,CHEMBL617490,,BAO_0000019,,12689.0,,,H,2849.0,17211.0,1.0,,Autocuration,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,
,8.0,,B,,,,CHEMBL617491,,BAO_0000019,,12689.0,,,H,2850.0,17211.0,1.0,,Autocuration,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,
,8.0,,B,,,,CHEMBL617492,,BAO_0000019,,12689.0,,,H,2851.0,14025.0,1.0,,Autocuration,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,
,8.0,,B,,,,CHEMBL617493,,BAO_0000019,,12689.0,,,H,2852.0,14998.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,
,8.0,,B,,,,CHEMBL617494,,BAO_0000357,,12689.0,,,H,2853.0,4342.0,1.0,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,
10116.0,9.0,,B,,,,CHEMBL617495,,BAO_0000019,,12689.0,,,D,2854.0,13735.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,
,8.0,,B,,,,CHEMBL617496,,BAO_0000357,,12689.0,,,H,2855.0,13181.0,1.0,,Autocuration,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL617497,,BAO_0000219,CHO-K1,12689.0,,,H,2856.0,1883.0,1.0,485.0,Autocuration,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,
,8.0,,B,,,,CHEMBL617498,,BAO_0000357,,12689.0,,,H,2857.0,15194.0,1.0,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,
,8.0,,B,,,,CHEMBL617499,,BAO_0000357,,12689.0,,,H,2858.0,15194.0,1.0,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,
,8.0,,F,,,,CHEMBL617500,,BAO_0000019,,12689.0,,,H,2859.0,14579.0,1.0,,Autocuration,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617501,,BAO_0000357,,108.0,,,H,2860.0,4639.0,1.0,,Autocuration,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617502,,BAO_0000357,,108.0,,,H,2861.0,4820.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617503,,BAO_0000357,,227.0,,,H,2862.0,14442.0,1.0,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,
,8.0,,B,,,,CHEMBL617504,,BAO_0000357,,227.0,,,H,2863.0,14755.0,1.0,,Autocuration,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,
,8.0,,B,,,,CHEMBL617406,,BAO_0000357,,227.0,,,H,2864.0,14744.0,1.0,,Autocuration,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,
9606.0,9.0,,B,,,,CHEMBL617407,,BAO_0000019,,227.0,,,D,2865.0,6857.0,1.0,,Expert,Homo sapiens,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,
,8.0,,B,,,,CHEMBL617408,,BAO_0000357,,227.0,,,H,2866.0,16209.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL617409,,BAO_0000357,,227.0,,,H,2867.0,15363.0,1.0,,Autocuration,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,
,8.0,,B,,,,CHEMBL617410,,BAO_0000357,,227.0,,,H,2868.0,15363.0,1.0,,Autocuration,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,
,8.0,,B,,,,CHEMBL617411,,BAO_0000357,,227.0,,,H,2869.0,15363.0,1.0,,Autocuration,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,
,8.0,,B,,,,CHEMBL617412,,BAO_0000019,,227.0,,,H,2870.0,17085.0,1.0,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,
9606.0,9.0,,B,,,,CHEMBL617774,,BAO_0000357,,227.0,,,D,2871.0,17200.0,1.0,,Expert,Homo sapiens,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,
9606.0,9.0,,B,,,,CHEMBL617775,,BAO_0000219,HEK293,227.0,,,D,2872.0,15851.0,1.0,722.0,Expert,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,
9606.0,9.0,,B,,,,CHEMBL617776,,BAO_0000219,HEK293,227.0,,,D,2873.0,15851.0,1.0,722.0,Expert,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,
9606.0,9.0,,F,,,,CHEMBL617777,,BAO_0000219,CHO,227.0,,,D,2874.0,6857.0,1.0,449.0,Expert,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,
9606.0,9.0,,F,,,,CHEMBL617778,,BAO_0000219,CHO,227.0,,,D,2875.0,6857.0,1.0,449.0,Expert,Homo sapiens,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,
,8.0,,B,,,,CHEMBL617779,,BAO_0000219,HEK293,227.0,,,H,2876.0,15779.0,1.0,722.0,Autocuration,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",
,8.0,,B,,,,CHEMBL617780,,BAO_0000219,HEK293,227.0,,,H,2877.0,15851.0,1.0,722.0,Expert,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,
,8.0,,B,,,,CHEMBL617781,,BAO_0000219,HEK293,227.0,,,H,2878.0,15779.0,1.0,722.0,Autocuration,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",
9606.0,9.0,,B,,,,CHEMBL617782,,BAO_0000219,HEK293,227.0,,,D,2879.0,14157.0,1.0,722.0,Expert,Homo sapiens,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,
9606.0,9.0,,B,,,,CHEMBL617783,,BAO_0000219,HEK293,227.0,,,D,2880.0,4540.0,1.0,722.0,Expert,Homo sapiens,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,
,8.0,,B,,,,CHEMBL617784,,BAO_0000357,,227.0,,,H,2881.0,6166.0,1.0,,Autocuration,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,
,8.0,,B,,,,CHEMBL617785,,BAO_0000219,HEK293,227.0,,,H,2882.0,15779.0,1.0,722.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,
,8.0,,B,,,,CHEMBL857984,,BAO_0000219,HEK293,227.0,,,H,2883.0,14391.0,1.0,722.0,Expert,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL617786,,BAO_0000219,HEK293,227.0,,,H,2884.0,3832.0,1.0,722.0,Expert,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,
,8.0,,B,,,,CHEMBL617787,,BAO_0000219,HEK293,227.0,,,H,2885.0,3833.0,1.0,722.0,Expert,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,
9606.0,9.0,,B,,,,CHEMBL617788,,BAO_0000219,HEK293,227.0,,,D,2886.0,15851.0,1.0,722.0,Expert,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,
9606.0,9.0,,B,,,,CHEMBL617789,,BAO_0000219,HEK293,227.0,,,D,2887.0,15851.0,1.0,722.0,Expert,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,
,8.0,,B,,,,CHEMBL617790,,BAO_0000219,HEK293,227.0,,,H,2888.0,4199.0,1.0,722.0,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,
,8.0,,B,,,,CHEMBL617791,,BAO_0000219,CHO-K1,227.0,,,H,2889.0,1883.0,1.0,485.0,Expert,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,
,8.0,,B,,,,CHEMBL617608,,BAO_0000357,,227.0,,,H,2890.0,4321.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 2B receptor,
,8.0,,B,,,,CHEMBL617609,,BAO_0000219,HEK293,227.0,,,H,2891.0,15146.0,1.0,722.0,Autocuration,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,
,8.0,,B,,,,CHEMBL617610,,BAO_0000219,HEK293,227.0,,,H,2892.0,5213.0,1.0,722.0,Autocuration,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,
,8.0,,B,,,,CHEMBL617611,,BAO_0000219,HEK293,227.0,,,H,2893.0,14818.0,1.0,722.0,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,
,8.0,,B,,,,CHEMBL617612,,BAO_0000219,HEK293,227.0,,,H,2894.0,4829.0,1.0,722.0,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",
,8.0,,B,,,,CHEMBL617613,,BAO_0000219,HEK293,227.0,,,H,2895.0,4829.0,1.0,722.0,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",
9986.0,8.0,,B,,,,CHEMBL617614,,BAO_0000019,,227.0,,,H,2896.0,14025.0,1.0,,Autocuration,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,
,8.0,,B,,,945.0,CHEMBL617615,,BAO_0000019,,12688.0,,,H,2897.0,13463.0,1.0,,Expert,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,Stomach
,8.0,,B,,,945.0,CHEMBL858114,,BAO_0000357,,12688.0,,,H,2898.0,7259.0,1.0,,Expert,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,Stomach
,8.0,,B,,,945.0,CHEMBL617616,,BAO_0000357,,12688.0,,,H,2899.0,7259.0,1.0,,Autocuration,,Affinity against serotonergic receptor in the isolated rat stomach fundus,Stomach
10116.0,9.0,,F,,,945.0,CHEMBL617617,,BAO_0000019,,12688.0,,,D,2900.0,7185.0,1.0,,Expert,Rattus norvegicus,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,Stomach
10116.0,9.0,,F,,,,CHEMBL875914,,BAO_0000019,,12688.0,,,D,2901.0,7185.0,1.0,,Expert,Rattus norvegicus,Antagonistic against 5-hydroxytryptamine 2B receptor,
,8.0,,F,,,945.0,CHEMBL617618,,BAO_0000019,,12688.0,,,H,2902.0,13267.0,1.0,,Autocuration,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,Stomach
10116.0,9.0,,B,,,945.0,CHEMBL617619,,BAO_0000357,,12688.0,,,D,2903.0,13735.0,1.0,,Expert,Rattus norvegicus,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,Stomach
,8.0,,F,,,,CHEMBL617620,,BAO_0000019,,12688.0,,,H,2904.0,15738.0,1.0,,Autocuration,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,
,8.0,,F,,,,CHEMBL617621,,BAO_0000019,,12688.0,,,H,2905.0,15738.0,1.0,,Autocuration,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,
,8.0,,F,,,,CHEMBL617622,,BAO_0000019,,12688.0,,,H,2906.0,15738.0,1.0,,Autocuration,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,
10116.0,9.0,,B,,,945.0,CHEMBL617623,,BAO_0000357,,12688.0,,,D,2907.0,12936.0,1.0,,Expert,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach
10116.0,9.0,,B,,,945.0,CHEMBL617624,,BAO_0000357,,12688.0,,,D,2908.0,12936.0,1.0,,Expert,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach
10116.0,9.0,,B,,,945.0,CHEMBL617625,,BAO_0000357,,12688.0,,,D,2909.0,12936.0,1.0,,Expert,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach
10116.0,9.0,,B,,,945.0,CHEMBL617626,,BAO_0000357,,12688.0,,,D,2910.0,12936.0,1.0,,Expert,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach
,8.0,,F,,,945.0,CHEMBL617627,,BAO_0000019,,12688.0,,,H,2911.0,16404.0,1.0,,Autocuration,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Stomach
,8.0,,F,,,945.0,CHEMBL617628,,BAO_0000019,,12688.0,,,H,2912.0,16404.0,1.0,,Expert,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Stomach
,8.0,,F,,,945.0,CHEMBL617629,,BAO_0000019,,12688.0,,,H,2913.0,16404.0,1.0,,Autocuration,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,Stomach
,8.0,,F,,,945.0,CHEMBL858115,,BAO_0000019,,12688.0,,,H,2914.0,16404.0,1.0,,Autocuration,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,Stomach
10116.0,9.0,,F,,,945.0,CHEMBL617630,,BAO_0000019,,12688.0,,,D,2915.0,16404.0,1.0,,Expert,Rattus norvegicus,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,Stomach
,8.0,,F,,,1515.0,CHEMBL617631,,BAO_0000019,,12688.0,,,H,2916.0,16404.0,1.0,,Autocuration,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,Thoracic aorta
,8.0,,B,,,,CHEMBL617632,,BAO_0000357,,12688.0,,,H,2917.0,7483.0,1.0,,Autocuration,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,
,8.0,,B,,,,CHEMBL617633,,BAO_0000357,,12688.0,,,H,2918.0,7483.0,1.0,,Expert,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,
,8.0,,B,,,,CHEMBL617634,,BAO_0000357,,12688.0,,,H,2919.0,7483.0,1.0,,Autocuration,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,
,8.0,,B,,,,CHEMBL617635,,BAO_0000357,,12688.0,,,H,2920.0,7483.0,1.0,,Autocuration,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,
10116.0,9.0,,F,,,945.0,CHEMBL617637,,BAO_0000019,,12688.0,,,D,2922.0,16404.0,1.0,,Autocuration,Rattus norvegicus,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Stomach
,8.0,,B,,,,CHEMBL617638,,BAO_0000357,,227.0,,,H,2923.0,6347.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 1A receptor,
,8.0,,B,,,,CHEMBL617639,,BAO_0000357,,227.0,,,H,2924.0,4373.0,1.0,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,
,8.0,,B,,,,CHEMBL617640,,BAO_0000357,,227.0,,,H,2925.0,4373.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,
,8.0,,B,,,,CHEMBL617641,,BAO_0000357,,227.0,,,H,2926.0,4687.0,1.0,,Autocuration,,Evaluated for the binding affinity to 5-HT 2B receptor,
,8.0,,B,,,,CHEMBL617642,,BAO_0000357,,227.0,,,H,2927.0,16946.0,1.0,,Autocuration,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,
,8.0,,B,,,,CHEMBL617643,,BAO_0000357,,227.0,,,H,2928.0,16633.0,1.0,,Autocuration,,Binding affinities against 5-hydroxytryptamine 2B receptor,
,8.0,,B,,,,CHEMBL617644,,BAO_0000357,,227.0,,,H,2929.0,16633.0,1.0,,Autocuration,,Binding affinities towards 5-hydroxytryptamine 2B receptor,
,8.0,,B,,,,CHEMBL617645,,BAO_0000357,,227.0,,,H,2930.0,16633.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,
,8.0,,B,,,,CHEMBL617646,,BAO_0000357,,108.0,,,H,2931.0,15026.0,1.0,,Expert,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,
9913.0,8.0,,B,,,,CHEMBL617647,,BAO_0000357,,108.0,,,H,2932.0,15738.0,1.0,,Autocuration,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,
9913.0,8.0,,B,,,,CHEMBL617648,,BAO_0000357,,108.0,,,H,2933.0,15738.0,1.0,,Autocuration,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,
9913.0,8.0,,B,,,,CHEMBL617875,,BAO_0000357,,108.0,,,H,2934.0,15738.0,1.0,,Autocuration,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,
9913.0,8.0,,B,,,,CHEMBL617876,,BAO_0000357,,108.0,,,H,2935.0,15738.0,1.0,,Autocuration,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,
9913.0,8.0,,B,,,,CHEMBL617877,,BAO_0000357,,108.0,,,H,2936.0,16404.0,1.0,,Expert,Bos taurus,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,
9913.0,8.0,,B,,,,CHEMBL617878,,BAO_0000357,,108.0,,,H,2937.0,15026.0,1.0,,Expert,Bos taurus,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,
9913.0,8.0,,B,,,,CHEMBL617879,,BAO_0000357,,108.0,,,H,2938.0,15738.0,1.0,,Autocuration,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,
10141.0,8.0,,B,,,,CHEMBL617880,,BAO_0000019,,108.0,,,H,2939.0,16312.0,1.0,,Autocuration,Cavia porcellus,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,
10141.0,9.0,,B,,,2435.0,CHEMBL617881,,BAO_0000357,,20033.0,,,D,2940.0,5486.0,1.0,,Intermediate,Cavia porcellus,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,Striatum
,8.0,,B,,,,CHEMBL857073,,BAO_0000357,,51.0,,,H,2941.0,5254.0,1.0,,Autocuration,,Binding affinity against 5-HT1A receptor,
,8.0,,F,,,,CHEMBL617882,,BAO_0000219,CHO,108.0,,,H,2942.0,3857.0,1.0,449.0,Expert,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,
9606.0,9.0,,F,,,,CHEMBL617883,,BAO_0000219,CHO,108.0,,,D,2943.0,6857.0,1.0,449.0,Expert,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,
,8.0,,F,,,,CHEMBL617884,,BAO_0000219,,108.0,,,H,2944.0,4176.0,1.0,,Autocuration,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,
,8.0,,B,,,,CHEMBL617885,,BAO_0000219,CHO,108.0,,,H,2945.0,6347.0,1.0,449.0,Autocuration,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,
,8.0,,B,,,,CHEMBL617886,,BAO_0000219,CHO,108.0,,,H,2946.0,6347.0,1.0,449.0,Autocuration,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",
9606.0,9.0,,B,,,,CHEMBL617887,,BAO_0000357,,108.0,,,D,2947.0,16146.0,1.0,,Expert,Homo sapiens,Inhibition of human 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617888,,BAO_0000357,,108.0,,,H,2948.0,3805.0,1.0,,Autocuration,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),
,8.0,,B,,,,CHEMBL617889,,BAO_0000019,,108.0,,,H,2949.0,3857.0,1.0,,Autocuration,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,
,8.0,,B,,,,CHEMBL617890,,BAO_0000357,,108.0,,,H,2950.0,5635.0,1.0,,Autocuration,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL617891,,BAO_0000357,,108.0,,,H,2951.0,5635.0,1.0,,Autocuration,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,
,8.0,,B,,,,CHEMBL617892,,BAO_0000357,,108.0,,,H,2952.0,5635.0,1.0,,Autocuration,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,
,8.0,,B,,,,CHEMBL617893,,BAO_0000219,CHO,108.0,,,H,2953.0,4012.0,1.0,449.0,Expert,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,
,8.0,,B,,,,CHEMBL617894,,BAO_0000219,CHO,108.0,,,H,2954.0,6366.0,1.0,449.0,Expert,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,
,8.0,,B,,,,CHEMBL617895,,BAO_0000219,CHO,108.0,,,H,2955.0,15949.0,1.0,449.0,Expert,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,
,8.0,,B,,,,CHEMBL617896,,BAO_0000219,CHO,108.0,,,H,2956.0,17211.0,1.0,449.0,Autocuration,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,
9606.0,9.0,,B,,,,CHEMBL617897,,BAO_0000357,,108.0,,,D,2957.0,6491.0,1.0,,Expert,Homo sapiens,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,
,8.0,,F,,,,CHEMBL617898,,BAO_0000019,,108.0,,,H,2958.0,14093.0,1.0,,Autocuration,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,
,8.0,,F,,,,CHEMBL617899,,BAO_0000019,,108.0,,,H,2959.0,13481.0,1.0,,Autocuration,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,
10116.0,8.0,,B,,,,CHEMBL617900,,BAO_0000219,CHO,108.0,,,H,2960.0,6347.0,1.0,449.0,Expert,Rattus norvegicus,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,
,8.0,,F,,,,CHEMBL617901,,BAO_0000019,,108.0,,,H,2961.0,14093.0,1.0,,Autocuration,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,
,8.0,,F,,,,CHEMBL617902,,BAO_0000019,,108.0,,,H,2962.0,14093.0,1.0,,Autocuration,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,
,8.0,,F,,,,CHEMBL617903,,BAO_0000019,,108.0,,,H,2963.0,13481.0,1.0,,Autocuration,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,
,8.0,,B,,,,CHEMBL617904,,BAO_0000357,,108.0,,,H,2964.0,14442.0,1.0,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,
,8.0,,B,,,,CHEMBL617905,,BAO_0000357,,108.0,,,H,2965.0,14442.0,1.0,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,
,8.0,,B,,,,CHEMBL617906,,BAO_0000357,,108.0,,,H,2966.0,14442.0,1.0,,Autocuration,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,
,8.0,,B,,,,CHEMBL617907,,BAO_0000357,,108.0,,,H,2967.0,14755.0,1.0,,Autocuration,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,
,8.0,,B,,,,CHEMBL617908,,BAO_0000357,,108.0,,,H,2968.0,14744.0,1.0,,Autocuration,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,
,8.0,,B,,,,CHEMBL620617,,BAO_0000219,CHO,108.0,,,H,2969.0,16659.0,1.0,449.0,Expert,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,
9606.0,9.0,,B,,,,CHEMBL620618,,BAO_0000019,,108.0,,,D,2970.0,6857.0,1.0,,Expert,Homo sapiens,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,
,8.0,,B,,,,CHEMBL620619,,BAO_0000357,,108.0,,,H,2971.0,5635.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,
9606.0,9.0,,B,,,,CHEMBL620620,,BAO_0000357,,108.0,,,D,2972.0,4234.0,1.0,,Expert,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL620621,,BAO_0000357,,108.0,,,H,2973.0,16209.0,1.0,,Autocuration,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,
10116.0,7.0,,B,,,,CHEMBL872920,,BAO_0000249,,104698.0,,Membranes,D,2974.0,5778.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,
,6.0,,B,,,,CHEMBL620622,,BAO_0000223,,104698.0,,,H,2975.0,5094.0,1.0,,Autocuration,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,
10116.0,7.0,,B,,,,CHEMBL620623,,BAO_0000019,,104698.0,,,D,2976.0,809.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,
,6.0,,B,,,,CHEMBL620624,,BAO_0000019,,104698.0,,,H,2977.0,1578.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,
,6.0,,B,,,,CHEMBL620625,,BAO_0000019,,104698.0,,,H,2978.0,809.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,
,6.0,,B,,,,CHEMBL620626,,BAO_0000219,,104698.0,,,H,2979.0,12469.0,1.0,,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,
,6.0,,B,,,,CHEMBL621307,,BAO_0000019,,104698.0,,,H,2980.0,14290.0,1.0,,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,
,6.0,,B,,,,CHEMBL621308,,BAO_0000019,,104698.0,,,H,2981.0,14290.0,1.0,,Autocuration,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,
,6.0,,B,,,,CHEMBL621309,,BAO_0000223,,104698.0,,,H,2982.0,10609.0,1.0,,Autocuration,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,
,6.0,,B,,,,CHEMBL621310,,BAO_0000223,,104698.0,,,H,2983.0,10609.0,1.0,,Autocuration,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,
,6.0,,B,,,,CHEMBL621311,,BAO_0000223,,104698.0,,,H,2984.0,10609.0,1.0,,Autocuration,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,
,6.0,,B,,,,CHEMBL621502,,BAO_0000249,,104698.0,,,H,2985.0,15253.0,1.0,,Autocuration,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",
,6.0,,B,,,,CHEMBL621503,,BAO_0000249,,104698.0,,,H,2986.0,15253.0,1.0,,Autocuration,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",
,6.0,,B,,,,CHEMBL621504,,BAO_0000249,,104698.0,,Membranes,H,2987.0,11683.0,1.0,,Autocuration,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,
,6.0,,B,,,,CHEMBL621505,,BAO_0000223,,104698.0,,,H,2988.0,12092.0,1.0,,Autocuration,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,
,6.0,,B,,,,CHEMBL621506,,BAO_0000019,,104698.0,,,H,2989.0,1946.0,1.0,,Autocuration,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,
,6.0,,B,,,,CHEMBL619781,,BAO_0000223,,104698.0,,,H,2990.0,11623.0,1.0,,Autocuration,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,
,6.0,,B,,,,CHEMBL619782,,BAO_0000223,,104698.0,,,H,2991.0,11623.0,1.0,,Autocuration,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,
,6.0,,B,,,,CHEMBL619783,,BAO_0000019,,104698.0,,,H,2992.0,14788.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,
10116.0,7.0,,B,,,,CHEMBL619784,,BAO_0000019,,104698.0,,,D,2993.0,5432.0,1.0,,Autocuration,Rattus norvegicus,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,
,6.0,,B,,,,CHEMBL619785,,BAO_0000249,,104698.0,,,H,2994.0,14826.0,1.0,,Autocuration,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,
,6.0,,B,,,,CHEMBL619786,,BAO_0000223,,104698.0,,,H,2995.0,2222.0,1.0,,Autocuration,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,
,6.0,,B,,,,CHEMBL619787,,BAO_0000019,,104698.0,,,H,2996.0,11963.0,1.0,,Autocuration,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,
,6.0,,B,,,,CHEMBL872925,,BAO_0000019,,104698.0,,,H,2997.0,14145.0,1.0,,Autocuration,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,
,6.0,,B,,,,CHEMBL619788,,BAO_0000019,,104698.0,,,H,2998.0,17819.0,1.0,,Autocuration,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,
,6.0,,B,,,,CHEMBL619789,,BAO_0000249,,104698.0,,,H,2999.0,10394.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,
,6.0,,B,,,,CHEMBL619790,,BAO_0000249,,104698.0,,,H,3000.0,10394.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,
,6.0,,B,,,,CHEMBL619791,,BAO_0000019,,104698.0,,,H,3001.0,15034.0,1.0,,Autocuration,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,
,6.0,,B,,,,CHEMBL619792,,BAO_0000019,,104698.0,,,H,3002.0,691.0,1.0,,Autocuration,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,
,6.0,,B,,,,CHEMBL619793,,BAO_0000249,,104698.0,,Membranes,H,3003.0,12092.0,1.0,,Autocuration,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,
10116.0,7.0,,B,,,,CHEMBL619794,,BAO_0000223,,104698.0,,,D,3004.0,11752.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,
,6.0,,B,,,955.0,CHEMBL619795,,BAO_0000221,,104698.0,,,H,3005.0,11752.0,1.0,,Autocuration,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,Brain
,6.0,,B,,,,CHEMBL619796,,BAO_0000019,,104698.0,,,H,3006.0,301.0,1.0,,Autocuration,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,
,6.0,,B,,,,CHEMBL620448,,BAO_0000223,,104698.0,,,H,3007.0,16532.0,1.0,,Autocuration,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,
,6.0,,B,,,,CHEMBL620449,,BAO_0000223,,104698.0,,,H,3008.0,16532.0,1.0,,Autocuration,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,
,6.0,,B,,,,CHEMBL620450,,BAO_0000223,,104698.0,,,H,3009.0,12092.0,1.0,,Autocuration,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,
,6.0,,B,,,,CHEMBL620451,,BAO_0000223,,104698.0,,,H,3010.0,11684.0,1.0,,Autocuration,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,
,6.0,,B,,,,CHEMBL620631,,BAO_0000223,,104698.0,,,H,3011.0,11684.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,
,6.0,,B,,,,CHEMBL620632,,BAO_0000019,,104698.0,,,H,3012.0,12953.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,
,6.0,,B,,,,CHEMBL620633,,BAO_0000019,,104698.0,,,H,3013.0,12953.0,1.0,,Autocuration,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,
,6.0,,B,,,,CHEMBL620634,,BAO_0000223,,104698.0,,,H,3014.0,12953.0,1.0,,Autocuration,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,
,6.0,,B,,,,CHEMBL620635,,BAO_0000019,,104698.0,,,H,3015.0,12861.0,1.0,,Autocuration,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,
,6.0,,F,,,,CHEMBL620636,,BAO_0000218,,104698.0,In vivo,,H,3016.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620637,,BAO_0000218,,104698.0,In vivo,,H,3017.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620638,,BAO_0000218,,104698.0,In vivo,,H,3018.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620639,,BAO_0000218,,104698.0,In vivo,,H,3019.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620640,,BAO_0000218,,104698.0,In vivo,,H,3020.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620641,,BAO_0000218,,104698.0,In vivo,,H,3021.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620642,,BAO_0000218,,104698.0,In vivo,,H,3022.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620643,,BAO_0000218,,104698.0,In vivo,,H,3023.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620644,,BAO_0000218,,104698.0,In vivo,,H,3024.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620645,,BAO_0000218,,104698.0,In vivo,,H,3025.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620646,,BAO_0000218,,104698.0,In vivo,,H,3026.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620647,,BAO_0000218,,104698.0,In vivo,,H,3027.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620648,,BAO_0000218,,104698.0,In vivo,,H,3028.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620649,,BAO_0000218,,104698.0,In vivo,,H,3029.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620650,,BAO_0000218,,104698.0,In vivo,,H,3030.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620651,,BAO_0000218,,104698.0,In vivo,,H,3031.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL872875,,BAO_0000218,,104698.0,In vivo,,H,3032.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620652,,BAO_0000218,,104698.0,In vivo,,H,3033.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL620653,,BAO_0000019,,104698.0,,,H,3034.0,10609.0,1.0,,Autocuration,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,
,6.0,,B,,,,CHEMBL857076,,BAO_0000019,,104698.0,,,H,3035.0,12861.0,1.0,,Autocuration,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,
10116.0,7.0,,B,,,,CHEMBL620654,,BAO_0000019,,104698.0,,,D,3036.0,12861.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,
,6.0,,B,,,,CHEMBL620655,,BAO_0000223,,104698.0,,,H,3037.0,12861.0,1.0,,Autocuration,,Binding activity radioligand.,
,6.0,,B,,,,CHEMBL620656,,BAO_0000249,,104698.0,,Brain membranes,H,3038.0,10728.0,1.0,,Autocuration,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,
,6.0,,B,,,,CHEMBL620657,,BAO_0000249,,104698.0,,Brain membranes,H,3039.0,10728.0,1.0,,Autocuration,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,
,8.0,,B,,,,CHEMBL620658,,BAO_0000357,,108.0,,,H,3040.0,5163.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,
,8.0,,B,,,,CHEMBL620659,,BAO_0000357,,108.0,,,H,3041.0,5163.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,
,8.0,,B,,,,CHEMBL620660,,BAO_0000357,,108.0,,,H,3042.0,6011.0,1.0,,Autocuration,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,
,8.0,,B,,,,CHEMBL620661,,BAO_0000357,,108.0,,,H,3043.0,5014.0,1.0,,Autocuration,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL620662,,BAO_0000357,,108.0,,,H,3044.0,5635.0,1.0,,Autocuration,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL620663,,BAO_0000357,,108.0,,,H,3045.0,5163.0,1.0,,Expert,,Affinity for 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL620664,,BAO_0000357,,108.0,,,H,3046.0,6841.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,
,8.0,,B,,,,CHEMBL620665,,BAO_0000357,,108.0,,,H,3047.0,6119.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,
,8.0,,B,,,,CHEMBL620666,,BAO_0000357,,108.0,,,H,3048.0,4373.0,1.0,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,
,8.0,,B,,,,CHEMBL620667,,BAO_0000357,,108.0,,,H,3049.0,1633.0,1.0,,Autocuration,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,
,8.0,,B,,,,CHEMBL620668,,BAO_0000357,,108.0,,,H,3050.0,1633.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,
,8.0,,B,,,,CHEMBL620669,,BAO_0000357,,108.0,,,H,3051.0,4373.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,
,8.0,,B,,,,CHEMBL620670,,BAO_0000357,,108.0,,,H,3052.0,6576.0,1.0,,Expert,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL620671,,BAO_0000357,,108.0,,,H,3053.0,4687.0,1.0,,Autocuration,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL620672,,BAO_0000357,,108.0,,,H,3054.0,12146.0,1.0,,Autocuration,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,
,8.0,,B,,,,CHEMBL620673,,BAO_0000357,,108.0,,,H,3055.0,12146.0,1.0,,Autocuration,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,
,8.0,,B,,,,CHEMBL620674,,BAO_0000357,,108.0,,,H,3056.0,16946.0,1.0,,Autocuration,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL620675,,BAO_0000357,,108.0,,,H,3057.0,14159.0,1.0,,Autocuration,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL620676,,BAO_0000357,,108.0,,,H,3058.0,16700.0,1.0,,Autocuration,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,
,8.0,,B,,,,CHEMBL621382,,BAO_0000357,,108.0,,,H,3059.0,3269.0,1.0,,Autocuration,,Affinity against 5-hydroxytryptamine 2C receptor,
9606.0,9.0,,B,,,,CHEMBL621383,,BAO_0000357,,108.0,,,D,3060.0,1274.0,1.0,,Expert,Homo sapiens,Binding affinity against 5-hydroxytryptamine 2C receptor,
,8.0,,B,,,,CHEMBL621384,,BAO_0000357,,108.0,,,H,3061.0,1317.0,1.0,,Autocuration,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,
9913.0,8.0,,B,,,,CHEMBL621385,,BAO_0000357,,144.0,,,H,3062.0,5834.0,1.0,,Autocuration,Bos taurus,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,
9913.0,8.0,,B,,,,CHEMBL617989,,BAO_0000357,,144.0,,,H,3063.0,11147.0,1.0,,Autocuration,Bos taurus,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,
10141.0,4.0,,F,,,,CHEMBL617990,,BAO_0000019,,104714.0,,,H,3064.0,14145.0,1.0,,Expert,Cavia porcellus,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,
10141.0,4.0,,B,,,2116.0,CHEMBL875085,,BAO_0000221,,104714.0,,,H,3065.0,10561.0,1.0,,Autocuration,Cavia porcellus,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Ileum
10141.0,4.0,,F,,,,CHEMBL617991,,BAO_0000019,,104714.0,,,H,3066.0,15847.0,1.0,,Autocuration,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,
10141.0,4.0,,F,,,,CHEMBL617992,,BAO_0000019,,104714.0,,,H,3067.0,15847.0,1.0,,Autocuration,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,
10141.0,4.0,,B,,,2116.0,CHEMBL617993,,BAO_0000221,,104714.0,,,H,3068.0,10561.0,1.0,,Autocuration,Cavia porcellus,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Ileum
10141.0,4.0,,B,,,2116.0,CHEMBL617994,,BAO_0000221,,104714.0,,,H,3069.0,11454.0,1.0,,Autocuration,Cavia porcellus,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,Ileum
10141.0,4.0,,F,,,,CHEMBL617995,,BAO_0000019,,104714.0,,,H,3070.0,4639.0,1.0,,Autocuration,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,
10141.0,4.0,,F,,,,CHEMBL617996,,BAO_0000019,,104714.0,,,H,3071.0,4639.0,1.0,,Autocuration,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,
10141.0,4.0,,F,,,,CHEMBL617997,,BAO_0000019,,104714.0,,,H,3072.0,4639.0,1.0,,Autocuration,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,
10141.0,4.0,,F,,,,CHEMBL617998,,BAO_0000019,,104714.0,,,H,3073.0,4639.0,1.0,,Autocuration,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,
10141.0,4.0,,F,,,,CHEMBL617999,,BAO_0000019,,104714.0,,,H,3074.0,4639.0,1.0,,Autocuration,Cavia porcellus,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,
10141.0,4.0,,F,,,,CHEMBL618000,,BAO_0000019,,104714.0,,,H,3075.0,4639.0,1.0,,Autocuration,Cavia porcellus,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,
10141.0,4.0,,F,,,2116.0,CHEMBL617815,,BAO_0000221,,104714.0,,,H,3076.0,15253.0,1.0,,Autocuration,Cavia porcellus,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",Ileum
10141.0,4.0,,F,,,2116.0,CHEMBL617816,,BAO_0000221,,104714.0,,,H,3077.0,15253.0,1.0,,Autocuration,Cavia porcellus,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",Ileum
10141.0,4.0,,F,,,2116.0,CHEMBL617817,,BAO_0000221,,104714.0,,,H,3078.0,11963.0,1.0,,Autocuration,Cavia porcellus,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,Ileum
10141.0,4.0,,B,,,2116.0,CHEMBL617818,,BAO_0000221,,104714.0,,,H,3079.0,1946.0,1.0,,Autocuration,Cavia porcellus,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,Ileum
10141.0,4.0,,B,,,2116.0,CHEMBL617819,,BAO_0000221,,104714.0,,,H,3080.0,1946.0,1.0,,Autocuration,Cavia porcellus,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,Ileum
10141.0,4.0,,B,,,,CHEMBL617820,,BAO_0000223,,104714.0,,,H,3081.0,12045.0,1.0,,Autocuration,Cavia porcellus,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,
10141.0,4.0,,B,,,2116.0,CHEMBL617821,,BAO_0000221,,104714.0,,,H,3082.0,1559.0,1.0,,Autocuration,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Ileum
10141.0,4.0,,F,,,2116.0,CHEMBL617822,,BAO_0000221,,104714.0,,,H,3083.0,273.0,1.0,,Autocuration,Cavia porcellus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Ileum
10141.0,4.0,,F,,,2116.0,CHEMBL617823,,BAO_0000221,,104714.0,,,H,3084.0,273.0,1.0,,Autocuration,Cavia porcellus,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),Ileum
10141.0,4.0,,F,,,2116.0,CHEMBL617824,,BAO_0000221,,104714.0,,,H,3085.0,188.0,1.0,,Autocuration,Cavia porcellus,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,Ileum
10141.0,4.0,,F,,,2116.0,CHEMBL617825,,BAO_0000221,,104714.0,,,H,3086.0,12919.0,1.0,,Autocuration,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,Ileum
10141.0,4.0,,F,,,2116.0,CHEMBL617826,,BAO_0000221,,104714.0,,,H,3087.0,12918.0,1.0,,Autocuration,Cavia porcellus,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,Ileum
10141.0,4.0,,B,,,2116.0,CHEMBL617827,,BAO_0000221,,104714.0,,,H,3088.0,1559.0,1.0,,Autocuration,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Ileum
10141.0,4.0,,F,,,2116.0,CHEMBL617828,,BAO_0000221,,104714.0,,,H,3089.0,273.0,1.0,,Autocuration,Cavia porcellus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Ileum
10141.0,4.0,,B,,,2116.0,CHEMBL617829,,BAO_0000221,,104714.0,,,H,3090.0,1559.0,1.0,,Autocuration,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Ileum
10141.0,4.0,,B,,,2116.0,CHEMBL617830,,BAO_0000221,,104714.0,,,H,3091.0,1559.0,1.0,,Autocuration,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,Ileum
10141.0,4.0,,B,,,2116.0,CHEMBL617831,,BAO_0000221,,104714.0,,,H,3092.0,1559.0,1.0,,Autocuration,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,Ileum
10141.0,4.0,,B,,,2116.0,CHEMBL617832,,BAO_0000221,,104714.0,,,H,3093.0,14424.0,1.0,,Autocuration,Cavia porcellus,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,Ileum
10141.0,0.0,,B,,,,CHEMBL617833,,BAO_0000019,,22226.0,,,U,3094.0,13181.0,1.0,,Autocuration,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,
,8.0,,B,,,,CHEMBL617834,,BAO_0000357,,51.0,,,H,3095.0,5486.0,1.0,,Autocuration,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,
9606.0,5.0,,B,,,,CHEMBL617835,,BAO_0000223,,104714.0,,,D,3096.0,6491.0,1.0,,Expert,Homo sapiens,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,
,4.0,,B,,,,CHEMBL617836,,BAO_0000223,,104714.0,,,H,3097.0,6013.0,1.0,,Autocuration,,Binding affinity towards 5-HT3 receptor,
,4.0,,B,,,,CHEMBL617837,,BAO_0000223,,104714.0,,,H,3098.0,12861.0,1.0,,Autocuration,,Binding activity radioligand.,
,4.0,,B,,,,CHEMBL620392,,BAO_0000019,,104714.0,,,H,3099.0,12861.0,1.0,,Autocuration,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,
,4.0,,B,,,,CHEMBL620393,,BAO_0000223,,104714.0,,,H,3100.0,5104.0,1.0,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,
,4.0,,B,,,,CHEMBL620394,,BAO_0000223,,104714.0,,,H,3101.0,5105.0,1.0,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,
,4.0,,B,,,,CHEMBL620395,,BAO_0000223,,104714.0,,,H,3102.0,5104.0,1.0,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,
,0.0,,B,,,,CHEMBL620396,,BAO_0000019,,22226.0,,,U,3103.0,3935.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,
,4.0,,B,,,,CHEMBL620582,,BAO_0000219,NG108-15,105030.0,,,H,3104.0,13657.0,1.0,433.0,Expert,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,
,4.0,,B,,,,CHEMBL620583,,BAO_0000218,,105030.0,In vivo,,H,3105.0,10369.0,1.0,,Autocuration,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",
,4.0,,B,,,,CHEMBL620584,,BAO_0000019,,105030.0,,,H,3106.0,10369.0,1.0,,Autocuration,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),
,4.0,,B,,,,CHEMBL620585,,BAO_0000224,,105030.0,,,H,3107.0,12918.0,1.0,,Autocuration,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,
,4.0,,B,,,,CHEMBL620586,,BAO_0000224,,105030.0,,,H,3108.0,12918.0,1.0,,Autocuration,,Compound was evaluated for the binding affinity at 5- HT3 receptor,
,4.0,,B,,,,CHEMBL620587,,BAO_0000019,,105030.0,,,H,3109.0,10369.0,1.0,,Autocuration,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),
,4.0,,B,,,,CHEMBL620588,,BAO_0000019,,105030.0,,,H,3110.0,773.0,1.0,,Autocuration,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,
,4.0,,F,,,,CHEMBL620589,,BAO_0000218,,105030.0,,,H,3111.0,12918.0,1.0,,Autocuration,,5-hydroxytryptamine 3 receptor agonism in mouse,
,4.0,,B,,,,CHEMBL620590,,BAO_0000219,,105030.0,,,H,3112.0,10561.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,
,4.0,,B,,,,CHEMBL617956,,BAO_0000019,,105030.0,,,H,3113.0,12827.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,
,4.0,,B,,,,CHEMBL617957,,BAO_0000019,,105030.0,,,H,3114.0,12827.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,
,4.0,,B,,,,CHEMBL617958,,BAO_0000224,,105030.0,,,H,3115.0,12918.0,1.0,,Autocuration,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,
,4.0,,B,,,,CHEMBL617959,,BAO_0000219,,105030.0,,,H,3116.0,273.0,1.0,,Autocuration,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,
,4.0,,B,,,,CHEMBL617960,,BAO_0000219,,105030.0,,,H,3117.0,273.0,1.0,,Autocuration,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,
,4.0,,B,,,,CHEMBL617961,,BAO_0000224,,105030.0,,,H,3118.0,10561.0,1.0,,Autocuration,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,
,4.0,,B,,,,CHEMBL617962,,BAO_0000219,,105030.0,In vitro,,H,3119.0,5033.0,1.0,,Autocuration,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,
,4.0,,B,,,,CHEMBL617963,,BAO_0000219,N1E-115,105030.0,,,H,3120.0,16429.0,1.0,339.0,Autocuration,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,
,8.0,,B,,,,CHEMBL617964,,BAO_0000019,,11765.0,,,H,3121.0,10322.0,1.0,,Autocuration,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,
,8.0,,B,,,,CHEMBL617965,,BAO_0000219,,11765.0,,,H,3122.0,14331.0,1.0,,Autocuration,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,
10090.0,9.0,,B,,,,CHEMBL617966,,BAO_0000357,,10630.0,,,D,3123.0,13462.0,1.0,,Autocuration,Mus musculus,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,
,8.0,,B,,,,CHEMBL857074,,BAO_0000019,,17106.0,,,H,3124.0,12861.0,1.0,,Autocuration,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,
9823.0,8.0,,B,,,,CHEMBL617967,,BAO_0000357,,144.0,,,H,3125.0,15086.0,1.0,,Autocuration,Sus scrofa,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,
9823.0,8.0,,B,,,,CHEMBL617968,,BAO_0000357,,144.0,,,H,3126.0,12861.0,1.0,,Autocuration,Sus scrofa,Binding activity radioligand.,
9986.0,4.0,,B,,,,CHEMBL617969,,BAO_0000223,,104714.0,,,H,3127.0,10561.0,1.0,,Autocuration,Oryctolagus cuniculus,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,
9986.0,4.0,,B,,,,CHEMBL617970,,BAO_0000223,,104714.0,,,H,3128.0,10561.0,1.0,,Autocuration,Oryctolagus cuniculus,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,
9986.0,4.0,,B,,,,CHEMBL617971,,BAO_0000223,,104714.0,,,H,3129.0,10561.0,1.0,,Autocuration,Oryctolagus cuniculus,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,
9986.0,4.0,,B,,,,CHEMBL617972,,BAO_0000019,,104714.0,,,H,3130.0,10561.0,1.0,,Autocuration,Oryctolagus cuniculus,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,
9986.0,4.0,,F,,,,CHEMBL617973,,BAO_0000019,,104714.0,,,H,3131.0,273.0,1.0,,Autocuration,Oryctolagus cuniculus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),
9986.0,4.0,,F,,,,CHEMBL617974,,BAO_0000019,,104714.0,,,H,3132.0,273.0,1.0,,Autocuration,Oryctolagus cuniculus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),
9986.0,4.0,,F,,,2116.0,CHEMBL617975,,BAO_0000221,,104714.0,,,H,3133.0,273.0,1.0,,Autocuration,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Ileum
9986.0,4.0,,F,,,,CHEMBL617976,,BAO_0000019,,104714.0,,,H,3134.0,273.0,1.0,,Autocuration,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),
9986.0,4.0,,F,,,,CHEMBL617977,,BAO_0000019,,104714.0,,,H,3135.0,273.0,1.0,,Autocuration,Oryctolagus cuniculus,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),
9986.0,4.0,,F,,,,CHEMBL617978,,BAO_0000019,,104714.0,,,H,3136.0,273.0,1.0,,Autocuration,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),
9986.0,4.0,,F,,,,CHEMBL617979,,BAO_0000019,,104714.0,,,H,3137.0,273.0,1.0,,Autocuration,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),
9986.0,4.0,,B,,,,CHEMBL617980,,BAO_0000219,CHO,104714.0,,,H,3138.0,13047.0,1.0,449.0,Autocuration,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,
10116.0,7.0,,B,,,,CHEMBL617981,,BAO_0000019,,104698.0,,,D,3139.0,1650.0,1.0,,Autocuration,Rattus norvegicus,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,
,8.0,,B,,,,CHEMBL617982,,BAO_0000019,,12020.0,,,H,3140.0,16288.0,1.0,,Autocuration,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),
,8.0,,B,,,,CHEMBL617983,,BAO_0000357,,12020.0,,,H,3141.0,16288.0,1.0,,Autocuration,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),
10116.0,7.0,,B,,,,CHEMBL617984,,BAO_0000019,,104698.0,,,D,3142.0,10254.0,1.0,,Autocuration,Rattus norvegicus,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,
,6.0,,B,,,,CHEMBL617985,,BAO_0000019,,104698.0,,,H,3143.0,14532.0,1.0,,Autocuration,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",
,6.0,,F,,,948.0,CHEMBL617986,,BAO_0000218,,104698.0,In vivo,,H,3144.0,13392.0,1.0,,Autocuration,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Heart
,6.0,,F,,,948.0,CHEMBL617987,,BAO_0000019,,104698.0,,,H,3145.0,13392.0,1.0,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Heart
,6.0,,F,,,948.0,CHEMBL617988,,BAO_0000019,,104698.0,,,H,3146.0,13392.0,1.0,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Heart
,6.0,,F,,,948.0,CHEMBL617792,,BAO_0000019,,104698.0,,,H,3147.0,13392.0,1.0,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",Heart
,6.0,,F,,,948.0,CHEMBL617793,,BAO_0000019,,104698.0,,,H,3148.0,13392.0,1.0,,Autocuration,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Heart
,6.0,,F,,,,CHEMBL617794,,BAO_0000019,,104698.0,,,H,3149.0,13392.0,1.0,,Autocuration,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",
,6.0,,F,,,,CHEMBL617795,,BAO_0000019,,104698.0,,,H,3150.0,13392.0,1.0,,Autocuration,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",
,6.0,,F,,,,CHEMBL617796,,BAO_0000019,,104698.0,,,H,3151.0,13392.0,1.0,,Autocuration,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",
,6.0,,F,,,,CHEMBL617797,,BAO_0000019,,104698.0,,,H,3152.0,13392.0,1.0,,Autocuration,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",
10116.0,7.0,,F,,,,CHEMBL617798,,BAO_0000218,,104698.0,In vivo,,D,3153.0,1089.0,1.0,,Autocuration,Rattus norvegicus,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),
,6.0,,F,,,,CHEMBL617799,,BAO_0000218,,104698.0,In vivo,,H,3154.0,1089.0,1.0,,Autocuration,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),
10116.0,7.0,,F,,,,CHEMBL617800,,BAO_0000218,,104698.0,In vivo,,D,3155.0,11454.0,1.0,,Autocuration,Rattus norvegicus,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,
10116.0,7.0,,F,,,,CHEMBL617801,,BAO_0000019,,104698.0,,,D,3156.0,11454.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,
10116.0,7.0,,F,,,,CHEMBL617802,,BAO_0000218,,104698.0,In vivo,,D,3157.0,12205.0,1.0,,Autocuration,Rattus norvegicus,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,
10116.0,7.0,,F,,,,CHEMBL617803,,BAO_0000019,,104698.0,,,D,3158.0,1089.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),
,6.0,,B,,,,CHEMBL617804,,BAO_0000019,,104698.0,,,H,3159.0,5094.0,1.0,,Autocuration,,Binding affinity towards 5-HT3 receptor in rat was evaluated,
10116.0,7.0,,B,,,,CHEMBL617805,,BAO_0000019,,104698.0,,,D,3160.0,2622.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,
,6.0,,B,,,,CHEMBL617806,,BAO_0000223,,104698.0,,,H,3161.0,245.0,1.0,,Autocuration,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,
,6.0,,B,,,,CHEMBL617807,,BAO_0000019,,104698.0,,,H,3162.0,14788.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,
,6.0,,B,,,,CHEMBL617808,,BAO_0000019,,104698.0,,,H,3163.0,14788.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,
,6.0,,B,,,,CHEMBL617809,,BAO_0000249,,104698.0,,,H,3164.0,3020.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,
,6.0,,B,,,,CHEMBL617810,,BAO_0000019,,104698.0,,,H,3165.0,1742.0,1.0,,Autocuration,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,
,6.0,,B,,,955.0,CHEMBL617811,,BAO_0000249,,104698.0,,,H,3166.0,17394.0,1.0,,Autocuration,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,Brain
,6.0,,B,,,955.0,CHEMBL617812,,BAO_0000221,,104698.0,,,H,3167.0,17394.0,1.0,,Autocuration,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,Brain
,6.0,,B,,,,CHEMBL617813,,BAO_0000249,,104698.0,,,H,3168.0,17394.0,1.0,,Autocuration,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,
,6.0,,B,,,,CHEMBL617814,,BAO_0000249,,104698.0,,,H,3169.0,14286.0,1.0,,Autocuration,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,
,6.0,,B,,,,CHEMBL617698,,BAO_0000019,,104698.0,,,H,3170.0,14178.0,1.0,,Autocuration,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,
10116.0,7.0,,B,,,,CHEMBL617699,,BAO_0000019,,104698.0,,,D,3171.0,14178.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,
10116.0,7.0,,B,,,,CHEMBL617700,,BAO_0000019,,104698.0,,,D,3172.0,14178.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,
10116.0,7.0,,B,,,,CHEMBL617701,,BAO_0000223,,104698.0,,,D,3173.0,14178.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,
,6.0,,B,,,,CHEMBL617702,,BAO_0000019,,104698.0,,,H,3174.0,15034.0,1.0,,Autocuration,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,
,6.0,,B,,,,CHEMBL617703,,BAO_0000249,,104698.0,,Membranes,H,3175.0,1089.0,1.0,,Autocuration,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",
10116.0,7.0,,B,,,,CHEMBL617704,,BAO_0000019,,104698.0,,,D,3176.0,1089.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,
,6.0,,B,,,,CHEMBL617705,,BAO_0000223,,104698.0,,,H,3177.0,16532.0,1.0,,Autocuration,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,
10116.0,7.0,,B,,,,CHEMBL617706,,BAO_0000223,,104698.0,,,D,3178.0,12801.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,
,6.0,,B,,,,CHEMBL617707,,BAO_0000219,NG108-15,104698.0,,,H,3179.0,15194.0,1.0,433.0,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),
,6.0,,B,,,,CHEMBL617708,,BAO_0000219,NG108-15,104698.0,,,H,3180.0,15194.0,1.0,433.0,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,
,6.0,,B,,,,CHEMBL617709,,BAO_0000019,,104698.0,,,H,3181.0,15194.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,
,6.0,,B,,,,CHEMBL617710,,BAO_0000019,,104698.0,,,H,3182.0,15194.0,1.0,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,
,6.0,,B,,,,CHEMBL882925,,BAO_0000019,,104698.0,,,H,3183.0,15194.0,1.0,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,
,6.0,,B,,,,CHEMBL617711,,BAO_0000019,,104698.0,,,H,3184.0,15194.0,1.0,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,
,6.0,,F,,,,CHEMBL617712,,BAO_0000019,,104698.0,,,H,3185.0,10610.0,1.0,,Autocuration,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,
10116.0,7.0,,F,,,,CHEMBL617713,,BAO_0000019,,104698.0,,,D,3186.0,10355.0,1.0,,Autocuration,Rattus norvegicus,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,
,6.0,,F,,,,CHEMBL617714,,BAO_0000019,,104698.0,,,H,3187.0,691.0,1.0,,Autocuration,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",
,6.0,,F,,,,CHEMBL617715,,BAO_0000218,,104698.0,,,H,3188.0,10611.0,1.0,,Autocuration,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,
,6.0,,F,,,,CHEMBL617716,,BAO_0000218,,104698.0,In vivo,,H,3189.0,12801.0,1.0,,Autocuration,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,
,6.0,,F,,,,CHEMBL617717,,BAO_0000218,,104698.0,,,H,3190.0,10609.0,1.0,,Autocuration,,Inhibition of 5-HT evoked reflex bradycardia in rat.,
,6.0,,F,,,,CHEMBL617718,,BAO_0000218,,104698.0,In vivo,,H,3191.0,11454.0,1.0,,Autocuration,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617719,,BAO_0000218,,104698.0,In vivo,,H,3192.0,11454.0,1.0,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617720,,BAO_0000218,,104698.0,In vivo,,H,3193.0,11454.0,1.0,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),
10116.0,7.0,,F,,,,CHEMBL617721,,BAO_0000218,,104698.0,In vivo,,D,3194.0,11454.0,1.0,,Autocuration,Rattus norvegicus,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617722,,BAO_0000218,,104698.0,In vivo,,H,3195.0,11454.0,1.0,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617723,,BAO_0000218,,104698.0,In vivo,,H,3196.0,11454.0,1.0,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,
,6.0,,F,,,,CHEMBL617724,,BAO_0000218,,104698.0,In vivo,,H,3197.0,11454.0,1.0,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617725,,BAO_0000218,,104698.0,In vivo,,H,3198.0,11454.0,1.0,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617726,,BAO_0000218,,104698.0,In vivo,,H,3199.0,11454.0,1.0,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617727,,BAO_0000218,,104698.0,In vivo,,H,3200.0,11454.0,1.0,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617728,,BAO_0000218,,104698.0,In vivo,,H,3201.0,11454.0,1.0,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617729,,BAO_0000218,,104698.0,In vivo,,H,3202.0,11454.0,1.0,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617730,,BAO_0000218,,104698.0,In vivo,,H,3203.0,11454.0,1.0,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617731,,BAO_0000218,,104698.0,In vivo,,H,3204.0,11454.0,1.0,,Autocuration,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617732,,BAO_0000218,,104698.0,In vivo,,H,3205.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617733,,BAO_0000218,,104698.0,In vivo,,H,3206.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617734,,BAO_0000218,,104698.0,In vivo,,H,3207.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL872874,,BAO_0000218,,104698.0,In vivo,,H,3208.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,
,6.0,,F,,,,CHEMBL617735,,BAO_0000218,,104698.0,In vivo,,H,3209.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,
,6.0,,F,,,,CHEMBL617736,,BAO_0000218,,104698.0,In vivo,,H,3210.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,
,6.0,,F,,,,CHEMBL617737,,BAO_0000218,,104698.0,In vivo,,H,3211.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,
,6.0,,F,,,,CHEMBL617738,,BAO_0000218,,104698.0,In vivo,,H,3212.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,
,6.0,,F,,,,CHEMBL617739,,BAO_0000218,,104698.0,In vivo,,H,3213.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617740,,BAO_0000218,,104698.0,In vivo,,H,3214.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617741,,BAO_0000218,,104698.0,In vivo,,H,3215.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617742,,BAO_0000218,,104698.0,In vivo,,H,3216.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617743,,BAO_0000218,,104698.0,In vivo,,H,3217.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617744,,BAO_0000218,,104698.0,In vivo,,H,3218.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617745,,BAO_0000218,,104698.0,In vivo,,H,3219.0,11454.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,
,6.0,,F,,,,CHEMBL617746,,BAO_0000218,,104698.0,,,H,3220.0,670.0,1.0,,Autocuration,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",
,6.0,,F,,,,CHEMBL617747,,BAO_0000218,,104698.0,,,H,3221.0,670.0,1.0,,Autocuration,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",
,6.0,,F,,,,CHEMBL617748,,BAO_0000218,,104698.0,In vivo,,H,3222.0,10321.0,1.0,,Autocuration,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,
,6.0,,F,,,,CHEMBL618909,,BAO_0000218,,104698.0,In vivo,,H,3223.0,10321.0,1.0,,Autocuration,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,
,6.0,,F,,,,CHEMBL618910,,BAO_0000218,,104698.0,In vivo,,H,3224.0,10321.0,1.0,,Autocuration,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,
,6.0,,F,,,,CHEMBL618911,,BAO_0000218,,104698.0,In vivo,,H,3225.0,10321.0,1.0,,Autocuration,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,
,6.0,,F,,,,CHEMBL618912,,BAO_0000218,,104698.0,In vivo,,H,3226.0,10321.0,1.0,,Autocuration,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,
,6.0,,F,,,,CHEMBL618913,,BAO_0000218,,104698.0,In vivo,,H,3227.0,10322.0,1.0,,Autocuration,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),
,6.0,,F,,,,CHEMBL618914,,BAO_0000019,,104698.0,,,H,3228.0,15412.0,1.0,,Autocuration,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,
,6.0,,F,,,,CHEMBL618915,,BAO_0000019,,104698.0,,,H,3229.0,15412.0,1.0,,Autocuration,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,
10116.0,7.0,,B,,,,CHEMBL618916,,BAO_0000223,,104698.0,,,D,3230.0,15412.0,1.0,,Autocuration,Rattus norvegicus,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,
,6.0,,F,,,,CHEMBL618917,,BAO_0000019,,104698.0,,,H,3231.0,15412.0,1.0,,Autocuration,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,
,7.0,,B,,,10000000.0,CHEMBL618918,,BAO_0000221,,104698.0,,,D,3232.0,15412.0,1.0,,Intermediate,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,Hippocampus
10116.0,7.0,,B,,,,CHEMBL618919,,BAO_0000019,,104698.0,,,D,3233.0,15412.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,
10116.0,7.0,,B,,,,CHEMBL618920,,BAO_0000019,,104698.0,,,D,3234.0,17394.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,
,6.0,,B,,,,CHEMBL618921,,BAO_0000223,,104698.0,,,H,3235.0,12457.0,1.0,,Autocuration,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,
,6.0,,B,,,,CHEMBL618922,,BAO_0000019,,104698.0,,,H,3236.0,12457.0,1.0,,Autocuration,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,
,6.0,,B,,,,CHEMBL618923,,BAO_0000019,,104698.0,,,H,3237.0,12205.0,1.0,,Autocuration,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,
,6.0,,B,,,,CHEMBL618924,,BAO_0000019,,104698.0,,,H,3238.0,14532.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,
,6.0,,B,,,,CHEMBL618925,,BAO_0000019,,104698.0,,,H,3239.0,1122.0,1.0,,Autocuration,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,
,6.0,,B,,,,CHEMBL618926,,BAO_0000019,,104698.0,,,H,3240.0,5094.0,1.0,,Autocuration,,Binding affinity towards 5-HT3 receptor in rat was evaluated,
10141.0,9.0,,F,,,2116.0,CHEMBL618927,,BAO_0000221,,20033.0,,,D,3241.0,809.0,1.0,,Intermediate,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL618928,,BAO_0000221,,20033.0,,,D,3242.0,809.0,1.0,,Intermediate,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL618929,,BAO_0000221,,20033.0,,,D,3243.0,14290.0,1.0,,Intermediate,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL618930,,BAO_0000221,,20033.0,,,D,3244.0,14290.0,1.0,,Intermediate,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL618931,,BAO_0000221,,20033.0,,,D,3245.0,14290.0,1.0,,Intermediate,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619594,,BAO_0000221,,20033.0,,,D,3246.0,14290.0,1.0,,Intermediate,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619595,,BAO_0000221,,20033.0,,,D,3247.0,14290.0,1.0,,Intermediate,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619596,,BAO_0000221,,20033.0,,,D,3248.0,13961.0,1.0,,Intermediate,Cavia porcellus,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619755,,BAO_0000221,,20033.0,,,D,3249.0,13961.0,1.0,,Intermediate,Cavia porcellus,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619756,,BAO_0000221,,20033.0,,,D,3250.0,809.0,1.0,,Intermediate,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619757,,BAO_0000221,,20033.0,,,D,3251.0,809.0,1.0,,Intermediate,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619758,,BAO_0000221,,20033.0,,,D,3252.0,809.0,1.0,,Intermediate,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619759,,BAO_0000221,,20033.0,,,D,3253.0,14290.0,1.0,,Intermediate,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619760,,BAO_0000221,,20033.0,,,D,3254.0,14290.0,1.0,,Intermediate,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619761,,BAO_0000221,,20033.0,,,D,3255.0,14290.0,1.0,,Intermediate,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619762,,BAO_0000221,,20033.0,,,D,3256.0,14290.0,1.0,,Intermediate,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619763,,BAO_0000221,,20033.0,,,D,3257.0,14290.0,1.0,,Intermediate,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL617868,,BAO_0000221,,20033.0,,,D,3258.0,14290.0,1.0,,Intermediate,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Ileum
10141.0,9.0,,B,,,,CHEMBL617869,,BAO_0000357,,20033.0,,,D,3259.0,15034.0,1.0,,Intermediate,Cavia porcellus,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,
10141.0,9.0,,B,,,2435.0,CHEMBL882926,,BAO_0000249,,20033.0,,,D,3260.0,5094.0,1.0,,Intermediate,Cavia porcellus,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum
10141.0,9.0,,B,,,2435.0,CHEMBL617870,,BAO_0000249,,20033.0,,,D,3261.0,5094.0,1.0,,Intermediate,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum
10141.0,9.0,,B,,,2435.0,CHEMBL617871,,BAO_0000357,,20033.0,,,D,3262.0,5399.0,1.0,,Intermediate,Cavia porcellus,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,Striatum
10141.0,9.0,,B,,,2435.0,CHEMBL617872,,BAO_0000357,,20033.0,,,D,3263.0,17394.0,1.0,,Intermediate,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,Striatum
10141.0,9.0,,B,,,2435.0,CHEMBL617873,,BAO_0000357,,20033.0,,,D,3264.0,17394.0,1.0,,Intermediate,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Striatum
10141.0,9.0,,B,,,2435.0,CHEMBL617874,,BAO_0000357,,20033.0,,,D,3265.0,17394.0,1.0,,Intermediate,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Striatum
10141.0,9.0,,F,,,2116.0,CHEMBL619067,,BAO_0000221,,20033.0,,,D,3266.0,13961.0,1.0,,Intermediate,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619068,,BAO_0000221,,20033.0,,,D,3267.0,13961.0,1.0,,Intermediate,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619069,,BAO_0000221,,20033.0,,,D,3268.0,13961.0,1.0,,Intermediate,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Ileum
10141.0,9.0,,B,,,,CHEMBL619070,,BAO_0000357,,20033.0,,,D,3269.0,16946.0,1.0,,Intermediate,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,
10141.0,9.0,,B,,,,CHEMBL619071,,BAO_0000357,,20033.0,,,D,3270.0,16946.0,1.0,,Intermediate,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,
10141.0,9.0,,F,,,,CHEMBL619072,,BAO_0000019,,20033.0,,,D,3271.0,15034.0,1.0,,Intermediate,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 4 receptor,
10141.0,9.0,,F,,,,CHEMBL619073,,BAO_0000019,,20033.0,,,D,3272.0,15034.0,1.0,,Intermediate,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,
10141.0,9.0,,F,,,,CHEMBL619074,,BAO_0000019,,20033.0,,,D,3273.0,12918.0,1.0,,Intermediate,Cavia porcellus,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,
10141.0,9.0,,B,,,,CHEMBL619075,,BAO_0000357,,20033.0,,,D,3274.0,16946.0,1.0,,Intermediate,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,
10141.0,9.0,,B,,,2435.0,CHEMBL619076,,BAO_0000357,,20033.0,,,D,3275.0,17394.0,1.0,,Intermediate,Cavia porcellus,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,Striatum
10141.0,9.0,,B,,,2435.0,CHEMBL619077,,BAO_0000357,,20033.0,,,D,3276.0,15034.0,1.0,,Intermediate,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,Striatum
10141.0,9.0,,B,,,2435.0,CHEMBL619078,,BAO_0000249,,20033.0,,,D,3277.0,5094.0,1.0,,Intermediate,Cavia porcellus,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum
10141.0,9.0,,B,,,2435.0,CHEMBL619079,,BAO_0000249,,20033.0,,,D,3278.0,5094.0,1.0,,Intermediate,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum
10141.0,9.0,,B,,,2116.0,CHEMBL619080,,BAO_0000221,,20033.0,,,D,3279.0,17358.0,1.0,,Intermediate,Cavia porcellus,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,Ileum
10141.0,9.0,,B,,,,CHEMBL619081,,BAO_0000357,,20033.0,,,D,3280.0,12953.0,1.0,,Expert,Cavia porcellus,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,
10141.0,9.0,,B,,,,CHEMBL619082,,BAO_0000357,,20033.0,,,D,3281.0,12953.0,1.0,,Intermediate,Cavia porcellus,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,
10141.0,9.0,,B,,,,CHEMBL619083,,BAO_0000357,,20033.0,,,D,3282.0,12953.0,1.0,,Intermediate,Cavia porcellus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,
10141.0,9.0,,B,,,,CHEMBL619084,,BAO_0000357,,20033.0,,,D,3283.0,12953.0,1.0,,Intermediate,Cavia porcellus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,
10141.0,9.0,,F,,,2116.0,CHEMBL859397,,BAO_0000221,,20033.0,,,D,3284.0,273.0,1.0,,Intermediate,Cavia porcellus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619085,,BAO_0000221,,20033.0,,,D,3285.0,12918.0,1.0,,Intermediate,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619086,,BAO_0000221,,20033.0,,,D,3286.0,12919.0,1.0,,Intermediate,Cavia porcellus,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619087,,BAO_0000221,,20033.0,,,D,3287.0,273.0,1.0,,Intermediate,Cavia porcellus,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619088,,BAO_0000221,,20033.0,,,D,3288.0,273.0,1.0,,Intermediate,Cavia porcellus,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum
10141.0,9.0,,B,,,,CHEMBL619089,,BAO_0000357,,20033.0,,,D,3289.0,13181.0,1.0,,Intermediate,Cavia porcellus,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,
10141.0,8.0,,B,,,,CHEMBL619090,,BAO_0000357,,168.0,,,H,3290.0,13181.0,1.0,,Autocuration,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,
10141.0,9.0,,F,,,,CHEMBL619091,,BAO_0000019,,20033.0,,,D,3291.0,15034.0,1.0,,Intermediate,Cavia porcellus,Antagonistic activity against 5-hydroxytryptamine 4 receptor,
10141.0,9.0,,B,,,,CHEMBL619092,,BAO_0000357,,20033.0,,,D,3292.0,5033.0,1.0,,Intermediate,Cavia porcellus,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,
10141.0,9.0,,B,,,,CHEMBL619093,,BAO_0000019,,20033.0,,,D,3293.0,1980.0,1.0,,Intermediate,Cavia porcellus,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,
10141.0,8.0,,B,,,,CHEMBL619094,,BAO_0000219,HEK293,168.0,,,H,3294.0,13181.0,1.0,722.0,Autocuration,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,
10141.0,9.0,,B,,,,CHEMBL619095,,BAO_0000019,,20033.0,,,D,3295.0,14287.0,1.0,,Intermediate,Cavia porcellus,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,
10141.0,9.0,,B,,,,CHEMBL857988,,BAO_0000357,,20033.0,,,D,3296.0,1317.0,1.0,,Intermediate,Cavia porcellus,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,
10141.0,9.0,,B,,,,CHEMBL619096,,BAO_0000357,,20033.0,,,D,3297.0,15316.0,1.0,,Intermediate,Cavia porcellus,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,
10141.0,9.0,,B,,,2435.0,CHEMBL619097,,BAO_0000357,,20033.0,,,D,3298.0,16429.0,1.0,,Intermediate,Cavia porcellus,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,Striatum
10141.0,9.0,,B,,,10000000.0,CHEMBL619098,,BAO_0000221,,20033.0,,,D,3299.0,14818.0,1.0,,Intermediate,Cavia porcellus,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,Hippocampus
10141.0,9.0,,B,,,,CHEMBL619751,,BAO_0000357,,20033.0,,,D,3300.0,15194.0,1.0,,Intermediate,Cavia porcellus,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,
10141.0,9.0,,B,,,,CHEMBL619752,,BAO_0000357,,20033.0,,,D,3301.0,15194.0,1.0,,Intermediate,Cavia porcellus,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,
10141.0,9.0,,F,,,2116.0,CHEMBL875096,,BAO_0000221,,20033.0,,,D,3302.0,13961.0,1.0,,Intermediate,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Ileum
,8.0,,B,,,,CHEMBL619004,,BAO_0000357,,108.0,,,H,3303.0,5486.0,1.0,,Autocuration,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,
,8.0,,B,,,,CHEMBL619005,,BAO_0000357,,168.0,,,H,3304.0,16209.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL619006,,BAO_0000019,,168.0,,,H,3305.0,17085.0,1.0,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,
,8.0,,B,,,,CHEMBL619007,,BAO_0000219,HeLa,168.0,,,H,3306.0,4199.0,1.0,308.0,Autocuration,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,
,8.0,,B,,,,CHEMBL619008,,BAO_0000357,,168.0,,,H,3307.0,15146.0,1.0,,Autocuration,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,
,8.0,,B,,,,CHEMBL619009,,BAO_0000357,,168.0,,,H,3308.0,5213.0,1.0,,Autocuration,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,
,8.0,,B,,,,CHEMBL619010,,BAO_0000219,HeLa,168.0,,,H,3309.0,4829.0,1.0,308.0,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",
,8.0,,B,,,,CHEMBL619011,,BAO_0000357,,10622.0,,,H,3310.0,17358.0,1.0,,Autocuration,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,
,8.0,,B,,,,CHEMBL619012,,BAO_0000357,,10622.0,,,H,3311.0,17358.0,1.0,,Autocuration,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,
,8.0,,B,,,,CHEMBL619013,,BAO_0000219,,10622.0,,,H,3312.0,16946.0,1.0,,Autocuration,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,
,8.0,,B,,,,CHEMBL619014,,BAO_0000357,,10622.0,,,H,3313.0,17358.0,1.0,,Autocuration,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,
,8.0,,F,,,2081.0,CHEMBL857503,,BAO_0000019,,11249.0,,,H,3314.0,268.0,1.0,,Autocuration,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,Cardiac atrium
,8.0,,F,,,2081.0,CHEMBL619015,,BAO_0000019,,11249.0,,,H,3315.0,268.0,1.0,,Autocuration,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,Cardiac atrium
,8.0,,B,,,,CHEMBL619016,,BAO_0000357,,11249.0,,,H,3316.0,15086.0,1.0,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,
,8.0,,B,,,10000000.0,CHEMBL619017,,BAO_0000221,,11249.0,,,H,3317.0,14875.0,1.0,,Autocuration,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,Hippocampus
9823.0,8.0,,B,,,10000000.0,CHEMBL619018,,BAO_0000221,,168.0,,,H,3318.0,13267.0,1.0,,Autocuration,Sus scrofa,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,Hippocampus
9986.0,8.0,,B,,,,CHEMBL619019,,BAO_0000019,,168.0,,,H,3319.0,13047.0,1.0,,Autocuration,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,
10116.0,9.0,,B,,,,CHEMBL619020,,BAO_0000357,,10623.0,,,D,3320.0,1650.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,
,8.0,,F,,,,CHEMBL619021,,BAO_0000019,,10623.0,,,H,3321.0,567.0,1.0,,Autocuration,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,
,8.0,,B,,,,CHEMBL619022,,BAO_0000357,,10623.0,,,H,3322.0,17358.0,1.0,,Autocuration,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,
,8.0,,B,,,,CHEMBL619023,,BAO_0000357,,10623.0,,,H,3323.0,188.0,1.0,,Autocuration,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,
,8.0,,F,,,,CHEMBL619024,,BAO_0000019,,10623.0,,,H,3324.0,670.0,1.0,,Autocuration,,lntrinsic activity relative to 5-HT receptor,
,8.0,,F,,,,CHEMBL619025,,BAO_0000019,,10623.0,,,H,3325.0,204.0,1.0,,Autocuration,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,
,8.0,,F,,,,CHEMBL619026,,BAO_0000019,,10623.0,,,H,3326.0,1946.0,1.0,,Expert,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,
,8.0,,F,,,,CHEMBL619027,,BAO_0000019,,10623.0,,,H,3327.0,6398.0,1.0,,Autocuration,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,
,8.0,,F,,,,CHEMBL619028,,BAO_0000019,,10623.0,,,H,3328.0,6398.0,1.0,,Autocuration,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,
,8.0,,F,,,,CHEMBL619029,,BAO_0000019,,10623.0,,,H,3329.0,17358.0,1.0,,Autocuration,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,
,8.0,,F,,,,CHEMBL619030,,BAO_0000019,,10623.0,,,H,3330.0,6398.0,1.0,,Autocuration,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,
,8.0,,B,,,,CHEMBL619031,,BAO_0000357,,10623.0,,,H,3331.0,11752.0,1.0,,Expert,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,
,8.0,,F,,,,CHEMBL619032,,BAO_0000019,,10623.0,,,H,3332.0,809.0,1.0,,Autocuration,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,
10116.0,9.0,,B,,,,CHEMBL619033,,BAO_0000357,,10623.0,,,D,3333.0,14178.0,1.0,,Expert,Rattus norvegicus,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,
,8.0,,B,,,,CHEMBL619034,,BAO_0000357,,10623.0,,,H,3334.0,567.0,1.0,,Autocuration,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,
,8.0,,B,,,,CHEMBL619035,,BAO_0000357,,10623.0,,,H,3335.0,1946.0,1.0,,Autocuration,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,
,8.0,,B,,,,CHEMBL619036,,BAO_0000357,,10623.0,,,H,3336.0,1946.0,1.0,,Autocuration,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,
10116.0,9.0,,B,,,,CHEMBL619037,,BAO_0000019,,10623.0,,,D,3337.0,13961.0,1.0,,Expert,Rattus norvegicus,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,
,8.0,,B,,,2435.0,CHEMBL619038,,BAO_0000249,,10623.0,,,H,3338.0,6238.0,1.0,,Autocuration,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,Striatum
,8.0,,B,,,,CHEMBL619039,,BAO_0000249,,10623.0,,,H,3339.0,14290.0,1.0,,Autocuration,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,
,8.0,,B,,,,CHEMBL619040,,BAO_0000249,,10623.0,,,H,3340.0,14290.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,
10116.0,9.0,,B,,,2435.0,CHEMBL619041,,BAO_0000019,,10623.0,,,D,3341.0,809.0,1.0,,Expert,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Striatum
,8.0,,B,,,2435.0,CHEMBL619042,,BAO_0000019,,10623.0,,,H,3342.0,1578.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Striatum
,8.0,,B,,,2435.0,CHEMBL619043,,BAO_0000249,,10623.0,,,H,3343.0,16709.0,1.0,,Expert,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,Striatum
,8.0,,B,,,2435.0,CHEMBL619044,,BAO_0000019,,10623.0,,,H,3344.0,1946.0,1.0,,Expert,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,Striatum
,8.0,,B,,,2435.0,CHEMBL619045,,BAO_0000249,,10623.0,,,H,3345.0,15253.0,1.0,,Expert,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,Striatum
,8.0,,B,,,2435.0,CHEMBL619046,,BAO_0000249,,10623.0,,,H,3346.0,4535.0,1.0,,Expert,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,Striatum
,8.0,,B,,,,CHEMBL619047,,BAO_0000249,,10623.0,,,H,3347.0,13961.0,1.0,,Expert,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,
,8.0,,F,,,955.0,CHEMBL619048,,BAO_0000221,,10623.0,,,H,3348.0,17358.0,1.0,,Autocuration,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,Brain
,8.0,,F,,,,CHEMBL859398,,BAO_0000019,,10623.0,,,H,3349.0,15847.0,1.0,,Autocuration,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,
,8.0,,F,,,,CHEMBL619049,,BAO_0000019,,10623.0,,,H,3350.0,15847.0,1.0,,Autocuration,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,
,8.0,,F,,,,CHEMBL857886,,BAO_0000019,,10623.0,,,H,3351.0,670.0,1.0,,Autocuration,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,
,8.0,,F,,,,CHEMBL619050,,BAO_0000019,,10623.0,,,H,3352.0,670.0,1.0,,Autocuration,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,
,8.0,,F,,,,CHEMBL620591,,BAO_0000019,,10623.0,,,H,3353.0,1317.0,1.0,,Autocuration,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,
10116.0,9.0,,B,,,,CHEMBL620592,,BAO_0000357,,10623.0,,,D,3354.0,12936.0,1.0,,Expert,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 4 receptor,
,8.0,,B,,,2435.0,CHEMBL620593,,BAO_0000249,,10623.0,,,H,3355.0,4535.0,1.0,,Expert,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,Striatum
10116.0,9.0,,F,,,,CHEMBL620594,,BAO_0000019,,10623.0,,,D,3356.0,14424.0,1.0,,Expert,Rattus norvegicus,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,
,8.0,,F,,,,CHEMBL875079,,BAO_0000019,,10623.0,,,H,3357.0,14424.0,1.0,,Expert,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,
,8.0,,F,,,,CHEMBL620595,,BAO_0000019,,10623.0,,,H,3358.0,14424.0,1.0,,Expert,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,
10116.0,9.0,,F,,,,CHEMBL620596,,BAO_0000019,,10623.0,,,D,3359.0,14424.0,1.0,,Expert,Rattus norvegicus,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,
,8.0,,F,,,,CHEMBL620597,,BAO_0000019,,10623.0,,,H,3360.0,14424.0,1.0,,Autocuration,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,
,8.0,,F,,,,CHEMBL620598,,BAO_0000019,,10623.0,,,H,3361.0,14424.0,1.0,,Expert,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,
,8.0,,F,,,,CHEMBL620599,,BAO_0000218,,10623.0,,,H,3362.0,14424.0,1.0,,Expert,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),
,8.0,,F,,,,CHEMBL620600,,BAO_0000019,,10623.0,,,H,3363.0,14424.0,1.0,,Autocuration,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,
10116.0,8.0,,F,,,,CHEMBL620601,,BAO_0000019,,168.0,,,H,3364.0,1980.0,1.0,,Autocuration,Rattus norvegicus,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,
,8.0,,F,,,,CHEMBL620602,,BAO_0000019,,168.0,,,H,3365.0,4639.0,1.0,,Autocuration,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,
,8.0,,B,,,,CHEMBL620603,,BAO_0000357,,168.0,,,H,3366.0,17358.0,1.0,,Autocuration,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,
,8.0,,B,,,,CHEMBL620604,,BAO_0000357,,168.0,,,H,3367.0,17358.0,1.0,,Autocuration,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,
,8.0,,B,,,,CHEMBL620605,,BAO_0000357,,168.0,,,H,3368.0,17358.0,1.0,,Autocuration,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,
,8.0,,B,,,,CHEMBL620606,,BAO_0000357,,168.0,,,H,3369.0,1558.0,1.0,,Autocuration,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,
,8.0,,F,,,,CHEMBL620607,,BAO_0000019,,168.0,,,H,3370.0,17358.0,1.0,,Autocuration,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,
,8.0,,B,,,,CHEMBL620608,,BAO_0000357,,168.0,,,H,3371.0,16117.0,1.0,,Autocuration,,In vitro binding affinity towards 5-HT4 receptor was determined,
,8.0,,F,,,,CHEMBL620609,,BAO_0000019,,168.0,,,H,3372.0,17358.0,1.0,,Autocuration,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,
,8.0,,F,,,,CHEMBL620610,,BAO_0000019,,168.0,,,H,3373.0,17358.0,1.0,,Autocuration,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,
,8.0,,B,,,,CHEMBL620611,,BAO_0000357,,168.0,,,H,3374.0,17358.0,1.0,,Autocuration,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,
,8.0,,B,,,,CHEMBL620612,,BAO_0000357,,168.0,,,H,3375.0,17358.0,1.0,,Autocuration,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,
,8.0,,B,,,,CHEMBL620613,,BAO_0000357,,168.0,,,H,3376.0,17358.0,1.0,,Autocuration,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,
,8.0,,B,,,,CHEMBL620614,,BAO_0000357,,168.0,,,H,3377.0,17358.0,1.0,,Autocuration,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,
,8.0,,B,,,,CHEMBL620615,,BAO_0000357,,168.0,,,H,3378.0,1274.0,1.0,,Expert,,Binding affinity against 5-Hydroxytryptamine 4 receptor,
,6.0,,B,,,,CHEMBL857075,,BAO_0000249,,104698.0,,Brain membranes,H,3379.0,10728.0,1.0,,Autocuration,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,
,6.0,,B,,,,CHEMBL620616,,BAO_0000249,,104698.0,,Brain membranes,H,3380.0,11695.0,1.0,,Autocuration,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,
,6.0,,B,,,,CHEMBL619411,,BAO_0000249,,104698.0,,Brain membranes,H,3381.0,11695.0,1.0,,Autocuration,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,
,6.0,,B,,,,CHEMBL619412,,BAO_0000019,,104698.0,,,H,3382.0,12490.0,1.0,,Autocuration,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,
10116.0,7.0,,B,,,,CHEMBL619413,,BAO_0000019,,104698.0,,,D,3383.0,11828.0,1.0,,Autocuration,Rattus norvegicus,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,
,6.0,,B,,,10000000.0,CHEMBL619414,,BAO_0000221,,104698.0,,,H,3384.0,12253.0,1.0,,Autocuration,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,Hippocampus
,6.0,,B,,,,CHEMBL619415,,BAO_0000019,,104698.0,,,H,3385.0,10561.0,1.0,,Autocuration,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,
,6.0,,B,,,,CHEMBL619416,,BAO_0000019,,104698.0,,,H,3386.0,10561.0,1.0,,Autocuration,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,
,6.0,,F,,,,CHEMBL619417,,BAO_0000019,,104698.0,,,H,3387.0,14432.0,1.0,,Autocuration,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,
10116.0,7.0,,B,,,,CHEMBL619418,,BAO_0000223,,104698.0,,,D,3388.0,12936.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 3 receptor,
10116.0,7.0,,B,,,,CHEMBL619419,,BAO_0000223,,104698.0,,,D,3389.0,1274.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity against 5-Hydroxytryptamine 3 receptor,
,6.0,,B,,,,CHEMBL619420,,BAO_0000019,,104698.0,,,H,3390.0,1980.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,
,6.0,,B,,,,CHEMBL619421,,BAO_0000249,,104698.0,,,H,3391.0,670.0,1.0,,Autocuration,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,
10116.0,7.0,,B,,,,CHEMBL619422,,BAO_0000019,,104698.0,,,D,3392.0,968.0,1.0,,Autocuration,Rattus norvegicus,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,
,6.0,,B,,,,CHEMBL619423,,BAO_0000019,,104698.0,,,H,3393.0,14287.0,1.0,,Autocuration,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,
,6.0,,B,,,,CHEMBL875080,,BAO_0000019,,104698.0,,,H,3394.0,567.0,1.0,,Autocuration,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,
,6.0,,B,,,,CHEMBL619424,,BAO_0000019,,104698.0,,,H,3395.0,13267.0,1.0,,Autocuration,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,
,6.0,,B,,,,CHEMBL619425,,BAO_0000249,,104698.0,,,H,3396.0,14826.0,1.0,,Autocuration,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,
,6.0,,B,,,,CHEMBL619426,,BAO_0000223,,104698.0,,,H,3397.0,15194.0,1.0,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,
,6.0,,B,,,,CHEMBL619427,,BAO_0000223,,104698.0,,,H,3398.0,15194.0,1.0,,Autocuration,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,
10116.0,7.0,,B,,,,CHEMBL619645,,BAO_0000223,,104698.0,,,D,3399.0,10394.0,1.0,,Autocuration,Rattus norvegicus,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,
,9.0,,B,,,,CHEMBL619646,,BAO_0000249,,10576.0,,,D,3400.0,13657.0,1.0,,Expert,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",
,8.0,,F,,,955.0,CHEMBL619647,,BAO_0000221,,12020.0,,,H,3401.0,1879.0,1.0,,Autocuration,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,Brain
,8.0,,F,,,,CHEMBL619648,,BAO_0000019,,12020.0,,,H,3402.0,1879.0,1.0,,Autocuration,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,
,8.0,,F,,,,CHEMBL619165,,BAO_0000019,,12020.0,,,H,3403.0,1879.0,1.0,,Autocuration,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,
,8.0,,F,,,,CHEMBL620719,,BAO_0000218,,12020.0,In vivo,,H,3404.0,204.0,1.0,,Autocuration,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,
,8.0,,B,,,,CHEMBL872924,,BAO_0000019,,12020.0,,,H,3405.0,1879.0,1.0,,Autocuration,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,
,8.0,,B,,,,CHEMBL620720,,BAO_0000357,,12020.0,,,H,3406.0,1879.0,1.0,,Autocuration,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,
,8.0,,B,,,,CHEMBL620721,,BAO_0000019,,12020.0,,,H,3407.0,1879.0,1.0,,Autocuration,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,
,8.0,,B,,,,CHEMBL620722,,BAO_0000019,,12020.0,,,H,3408.0,1879.0,1.0,,Autocuration,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,
,6.0,,B,,,,CHEMBL620723,,BAO_0000019,,104698.0,,,H,3409.0,10641.0,1.0,,Autocuration,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",
,8.0,,B,,,,CHEMBL620724,,BAO_0000019,,12020.0,,,H,3410.0,773.0,1.0,,Autocuration,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,
,6.0,,B,,,,CHEMBL620725,,BAO_0000249,,104698.0,,,H,3411.0,11952.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,
10116.0,9.0,,F,,,,CHEMBL620726,,BAO_0000019,,12020.0,,,D,3412.0,14145.0,1.0,,Autocuration,Rattus norvegicus,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,
,8.0,,B,,,,CHEMBL620727,,BAO_0000357,,144.0,,,H,3413.0,17066.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 3 receptor,
,4.0,,B,,,,CHEMBL620728,,BAO_0000223,,104714.0,,,H,3414.0,6398.0,1.0,,Autocuration,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,
,0.0,,B,,,,CHEMBL620729,,BAO_0000019,,22226.0,,,U,3415.0,10321.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,
,4.0,,F,,,,CHEMBL858288,,BAO_0000019,,104714.0,,,H,3416.0,511.0,1.0,,Autocuration,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,
,4.0,,B,,,,CHEMBL620730,,BAO_0000223,,104714.0,,,H,3417.0,4639.0,1.0,,Autocuration,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,
,4.0,,B,,,,CHEMBL620731,,BAO_0000223,,104714.0,,,H,3418.0,4639.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor,
10141.0,4.0,,F,,,,CHEMBL620732,,BAO_0000019,,104714.0,,,H,3419.0,4639.0,1.0,,Autocuration,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,
10141.0,4.0,,F,,,,CHEMBL618042,,BAO_0000019,,104714.0,,,H,3420.0,4639.0,1.0,,Autocuration,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,
10141.0,4.0,,F,,,,CHEMBL618043,,BAO_0000019,,104714.0,,,H,3421.0,4639.0,1.0,,Autocuration,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,
,4.0,,B,,,,CHEMBL618044,,BAO_0000223,,104714.0,,,H,3422.0,1558.0,1.0,,Autocuration,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,
,4.0,,F,,,,CHEMBL618045,,BAO_0000019,,104714.0,,,H,3423.0,268.0,1.0,,Autocuration,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,
,4.0,,B,,,,CHEMBL618046,,BAO_0000223,,104714.0,,,H,3424.0,2474.0,1.0,,Autocuration,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,
,4.0,,F,,,,CHEMBL618047,,BAO_0000019,,104714.0,,,H,3425.0,5067.0,1.0,,Autocuration,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,
,4.0,,F,,,,CHEMBL875084,,BAO_0000019,,104714.0,,,H,3426.0,5067.0,1.0,,Autocuration,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,
,4.0,,F,,,,CHEMBL618048,,BAO_0000019,,104714.0,,,H,3427.0,5067.0,1.0,,Autocuration,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,
,4.0,,B,,,,CHEMBL618049,,BAO_0000223,,104714.0,,,H,3428.0,5067.0,1.0,,Autocuration,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,
,4.0,,F,,,,CHEMBL619764,,BAO_0000019,,104714.0,,,H,3429.0,5067.0,1.0,,Autocuration,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,
,4.0,,F,,,,CHEMBL619765,,BAO_0000019,,104714.0,,,H,3430.0,5067.0,1.0,,Autocuration,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,
,4.0,,F,,,,CHEMBL619766,,BAO_0000019,,104714.0,,,H,3431.0,5067.0,1.0,,Autocuration,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,
,4.0,,B,,,,CHEMBL619767,,BAO_0000223,,104714.0,,,H,3432.0,5067.0,1.0,,Autocuration,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,
,4.0,,B,,,,CHEMBL619768,,BAO_0000223,,104714.0,,,H,3433.0,5067.0,1.0,,Autocuration,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,
,4.0,,F,,,,CHEMBL619769,,BAO_0000019,,104714.0,,,H,3434.0,5067.0,1.0,,Autocuration,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,
,4.0,,B,,,,CHEMBL619770,,BAO_0000223,,104714.0,,,H,3435.0,5067.0,1.0,,Autocuration,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,
,4.0,,B,,,,CHEMBL619771,,BAO_0000223,,104714.0,,,H,3436.0,5067.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor,
,4.0,,B,,,,CHEMBL619772,,BAO_0000219,,104714.0,,,H,3437.0,14331.0,1.0,,Autocuration,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,
,4.0,,B,,,,CHEMBL619773,,BAO_0000223,,104714.0,,,H,3438.0,5067.0,1.0,,Autocuration,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,
,4.0,,B,,,,CHEMBL619774,,BAO_0000219,NG108-15,104714.0,,,H,3439.0,6179.0,1.0,433.0,Autocuration,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,
,4.0,,B,,,,CHEMBL875083,,BAO_0000019,,104714.0,,,H,3440.0,4265.0,1.0,,Autocuration,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,
,4.0,,B,,,,CHEMBL620718,,BAO_0000219,NG108-15,104714.0,,,H,3441.0,4265.0,1.0,433.0,Autocuration,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,
,4.0,,B,,,,CHEMBL618127,,BAO_0000223,,104714.0,,,H,3442.0,17358.0,1.0,,Autocuration,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,
,4.0,,B,,,,CHEMBL618128,,BAO_0000223,,104714.0,,,H,3443.0,17358.0,1.0,,Autocuration,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,
,4.0,,B,,,,CHEMBL618129,,BAO_0000219,,104714.0,In vitro,,H,3444.0,13628.0,1.0,,Autocuration,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,
,4.0,,B,,,,CHEMBL618130,,BAO_0000223,,104714.0,,,H,3445.0,4612.0,1.0,,Autocuration,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,
,4.0,,F,,,,CHEMBL618131,,BAO_0000019,,104714.0,,,H,3446.0,17358.0,1.0,,Autocuration,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,
10141.0,4.0,,F,,,,CHEMBL618132,,BAO_0000019,,104714.0,,,H,3447.0,4639.0,1.0,,Autocuration,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,
10141.0,4.0,,F,,,,CHEMBL618133,,BAO_0000019,,104714.0,,,H,3448.0,4639.0,1.0,,Autocuration,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,
10141.0,4.0,,F,,,,CHEMBL618134,,BAO_0000019,,104714.0,,,H,3449.0,4639.0,1.0,,Autocuration,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,
10141.0,4.0,,F,,,,CHEMBL618135,,BAO_0000019,,104714.0,,,H,3450.0,4639.0,1.0,,Autocuration,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,
,4.0,,B,,,,CHEMBL618136,,BAO_0000223,,104714.0,,,H,3451.0,511.0,1.0,,Autocuration,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,
,4.0,,B,,,,CHEMBL618137,,BAO_0000223,,104714.0,,,H,3452.0,1479.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor,
,4.0,,B,,,,CHEMBL618138,,BAO_0000223,,104714.0,,,H,3453.0,1317.0,1.0,,Autocuration,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,
,4.0,,B,,,,CHEMBL618139,,BAO_0000223,,104714.0,,,H,3454.0,12146.0,1.0,,Autocuration,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,
,4.0,,B,,,,CHEMBL618140,,BAO_0000223,,104714.0,,,H,3455.0,12146.0,1.0,,Autocuration,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,
,4.0,,B,,,,CHEMBL618141,,BAO_0000223,,104714.0,,,H,3456.0,13969.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,
,8.0,,B,,,,CHEMBL873478,,BAO_0000357,,108.0,,,H,3457.0,13392.0,1.0,,Expert,,Binding affinity for 5-hydroxytryptamine 2C receptor,
,6.0,,B,,,,CHEMBL618142,,BAO_0000223,,104698.0,,,H,3458.0,13392.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor,
,8.0,,B,,,,CHEMBL618143,,BAO_0000357,,144.0,,,H,3459.0,14159.0,1.0,,Autocuration,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,
,8.0,,B,,,,CHEMBL618144,,BAO_0000357,,144.0,,,H,3460.0,1558.0,1.0,,Autocuration,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,
,8.0,,B,,,,CHEMBL618145,,BAO_0000357,,144.0,,,H,3461.0,16655.0,1.0,,Autocuration,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,
,4.0,,B,,,,CHEMBL618146,,BAO_0000223,,104714.0,,,H,3462.0,13020.0,1.0,,Autocuration,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,
,4.0,,B,,,,CHEMBL618147,,BAO_0000223,,104714.0,,,H,3463.0,13021.0,1.0,,Autocuration,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,
,4.0,,B,,,,CHEMBL618148,,BAO_0000223,,104714.0,,,H,3464.0,13020.0,1.0,,Autocuration,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,
,8.0,,B,,,,CHEMBL618149,,BAO_0000019,,144.0,,,H,3465.0,10321.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,
,8.0,,B,,,,CHEMBL872927,,BAO_0000357,,144.0,,,H,3466.0,15818.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,
,8.0,,B,,,,CHEMBL618150,,BAO_0000357,,144.0,,,H,3467.0,15818.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,
,8.0,,B,,,,CHEMBL618151,,BAO_0000357,,144.0,,,H,3468.0,17358.0,1.0,,Autocuration,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,
,8.0,,B,,,,CHEMBL875094,,BAO_0000357,,144.0,,,H,3469.0,2222.0,1.0,,Autocuration,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,
,8.0,,B,,,,CHEMBL618152,,BAO_0000019,,144.0,,,H,3470.0,10322.0,1.0,,Autocuration,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,
,8.0,,B,,,,CHEMBL618153,,BAO_0000357,,144.0,,,H,3471.0,16117.0,1.0,,Autocuration,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,
,8.0,,B,,,,CHEMBL618888,,BAO_0000357,,144.0,,,H,3472.0,17200.0,1.0,,Autocuration,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,
,8.0,,F,,,,CHEMBL618889,,BAO_0000019,,144.0,,,H,3473.0,17358.0,1.0,,Autocuration,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,
,8.0,,B,,,,CHEMBL618890,,BAO_0000357,,144.0,,,H,3474.0,16700.0,1.0,,Autocuration,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,
,8.0,,B,,,,CHEMBL618891,,BAO_0000019,,144.0,,,H,3475.0,1980.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,
,8.0,,B,,,,CHEMBL619054,,BAO_0000019,,144.0,,,H,3476.0,1980.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,
,4.0,,B,,,,CHEMBL619055,,BAO_0000223,,104714.0,,,H,3477.0,12409.0,1.0,,Autocuration,,Binding affinity against the 5-hydroxytryptamine 3 receptor,
,8.0,,B,,,,CHEMBL619056,,BAO_0000357,,144.0,,,H,3478.0,4365.0,1.0,,Autocuration,,Binding affinity against human 5-hydroxytryptamine 3A receptor,
,8.0,,F,,,,CHEMBL619057,,BAO_0000019,,144.0,,,H,3479.0,4365.0,1.0,,Autocuration,,Percent efficacy against 5-hydroxytryptamine 3A receptor,
,8.0,,B,,,,CHEMBL619058,,BAO_0000357,,144.0,,,H,3480.0,4365.0,1.0,,Autocuration,,Binding affinity against human 5-hydroxytryptamine 3A receptor,
10116.0,9.0,,F,,,,CHEMBL619059,,BAO_0000219,Oocytes,12020.0,,,D,3481.0,6769.0,1.0,,Expert,Rattus norvegicus,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,
10116.0,9.0,,F,,,,CHEMBL619060,,BAO_0000219,Oocytes,12020.0,,,D,3482.0,6769.0,1.0,,Expert,Rattus norvegicus,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,
10116.0,9.0,,F,,,,CHEMBL875095,,BAO_0000219,Oocytes,12020.0,,,D,3483.0,6769.0,1.0,,Expert,Rattus norvegicus,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,
10141.0,9.0,,F,,,2116.0,CHEMBL619061,,BAO_0000221,,20033.0,,,D,3484.0,809.0,1.0,,Intermediate,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,Ileum
10141.0,9.0,,F,,,2116.0,CHEMBL619062,,BAO_0000221,,20033.0,,,D,3485.0,809.0,1.0,,Intermediate,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,Ileum
10141.0,9.0,,F,,,,CHEMBL619063,,BAO_0000019,,20033.0,,,D,3486.0,14290.0,1.0,,Intermediate,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,
10141.0,9.0,,B,,,2116.0,CHEMBL619064,,BAO_0000221,,20033.0,,,D,3487.0,17358.0,1.0,,Intermediate,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,Ileum
10141.0,9.0,,B,,,,CHEMBL619065,,BAO_0000357,,20033.0,,,D,3488.0,17358.0,1.0,,Intermediate,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,
10141.0,9.0,,B,,,2116.0,CHEMBL619066,,BAO_0000221,,20033.0,,,D,3489.0,17358.0,1.0,,Intermediate,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,Ileum
,8.0,,B,,,2116.0,CHEMBL619775,,BAO_0000221,,10209.0,,,H,3490.0,17386.0,1.0,,Autocuration,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Ileum
,8.0,,B,,,,CHEMBL619776,,BAO_0000357,,10209.0,,,H,3491.0,3269.0,1.0,,Autocuration,,Affinity against 5-hydroxytryptamine 7 receptor,
10141.0,4.0,,B,,,,CHEMBL619777,,BAO_0000224,,104841.0,,,H,3492.0,7721.0,1.0,,Autocuration,Cavia porcellus,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,
10141.0,4.0,,B,,,,CHEMBL619778,,BAO_0000224,,104841.0,,,H,3493.0,7721.0,1.0,,Autocuration,Cavia porcellus,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,
10141.0,4.0,,B,,,2116.0,CHEMBL619779,,BAO_0000221,,104841.0,,,H,3494.0,9117.0,1.0,,Autocuration,Cavia porcellus,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,Ileum
10141.0,4.0,,B,,,,CHEMBL619780,,BAO_0000224,,104841.0,,,H,3495.0,7721.0,1.0,,Autocuration,Cavia porcellus,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",
10141.0,4.0,,B,,,,CHEMBL619166,,BAO_0000224,,104841.0,,,H,3496.0,7721.0,1.0,,Autocuration,Cavia porcellus,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",
10141.0,4.0,,F,,,,CHEMBL619167,,BAO_0000019,,104841.0,,,H,3497.0,15796.0,1.0,,Autocuration,Cavia porcellus,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,
10141.0,4.0,,F,,,,CHEMBL619168,,BAO_0000019,,104841.0,,,H,3498.0,15796.0,1.0,,Autocuration,Cavia porcellus,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,
9606.0,9.0,,B,,,2081.0,CHEMBL619169,,BAO_0000219,,168.0,,,D,3499.0,15650.0,1.0,,Expert,Homo sapiens,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,Cardiac atrium
9606.0,9.0,,B,,,2081.0,CHEMBL619170,,BAO_0000219,,168.0,,,D,3500.0,15650.0,1.0,,Expert,Homo sapiens,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,Cardiac atrium
9606.0,5.0,,F,,,,CHEMBL619171,,BAO_0000019,,104841.0,,,D,3501.0,6866.0,1.0,,Autocuration,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",
9606.0,9.0,,F,,,2081.0,CHEMBL619172,,BAO_0000219,,168.0,,,D,3502.0,15650.0,1.0,,Expert,Homo sapiens,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",Cardiac atrium
10090.0,0.0,,B,,,,CHEMBL619173,,BAO_0000019,,22226.0,,,U,3503.0,10063.0,1.0,,Autocuration,Mus musculus,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,
10090.0,0.0,,B,,,,CHEMBL619174,,BAO_0000019,,22226.0,,,U,3504.0,12665.0,1.0,,Autocuration,Mus musculus,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,
,4.0,,B,,,,CHEMBL619175,,BAO_0000019,,104705.0,,,H,3505.0,7504.0,1.0,,Autocuration,,5-hydroxytryptamine receptor binding affinity was determined in rats,
,4.0,,B,,,,CHEMBL619176,,BAO_0000224,,104705.0,,,H,3506.0,7504.0,1.0,,Autocuration,,Binding affinity at rat 5-hydroxytryptamine receptor.,
,4.0,,B,,,,CHEMBL619177,,BAO_0000019,,104705.0,,,H,3507.0,7038.0,1.0,,Autocuration,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,
,4.0,,B,,,,CHEMBL619178,,BAO_0000224,,104705.0,,,H,3508.0,7626.0,1.0,,Autocuration,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,
,4.0,,B,,,,CHEMBL619179,,BAO_0000224,,104705.0,,,H,3509.0,7626.0,1.0,,Autocuration,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,
,4.0,,F,,,945.0,CHEMBL619180,,BAO_0000019,,104705.0,,,H,3510.0,7185.0,1.0,,Autocuration,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,Stomach
,4.0,,F,,,945.0,CHEMBL619181,,BAO_0000019,,104705.0,,,H,3511.0,7185.0,1.0,,Autocuration,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,Stomach
,4.0,,F,,,,CHEMBL619182,,BAO_0000019,,104705.0,,,H,3512.0,7185.0,1.0,,Autocuration,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,
,4.0,,B,,,,CHEMBL619183,,BAO_0000224,,104705.0,,,H,3513.0,6960.0,1.0,,Autocuration,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,
,4.0,,B,,,,CHEMBL619184,,BAO_0000224,,104705.0,,,H,3514.0,6960.0,1.0,,Autocuration,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",
,8.0,,B,,,10000000.0,CHEMBL619185,,BAO_0000221,,10576.0,,,H,3515.0,12416.0,1.0,,Autocuration,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Hippocampus
,8.0,,B,,,,CHEMBL619186,,BAO_0000357,,12198.0,,,H,3516.0,15753.0,1.0,,Expert,,Binding affinity for rat 5-hydroxytryptamine transporter.,
,4.0,,B,,,,CHEMBL619187,,BAO_0000019,,104705.0,,,H,3517.0,8062.0,1.0,,Autocuration,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,
10116.0,5.0,,B,,,,CHEMBL619188,,BAO_0000019,,104705.0,,,D,3518.0,9036.0,1.0,,Autocuration,Rattus norvegicus,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,
10116.0,5.0,,B,,,,CHEMBL619189,,BAO_0000224,,104705.0,,,D,3519.0,15067.0,1.0,,Autocuration,Rattus norvegicus,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,
10116.0,9.0,,F,,,955.0,CHEMBL619190,,BAO_0000019,,12198.0,,,D,3520.0,15753.0,1.0,,Expert,Rattus norvegicus,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,Brain
10116.0,9.0,,F,,,2037.0,CHEMBL619191,,BAO_0000221,,12198.0,,,D,3521.0,15753.0,1.0,,Expert,Rattus norvegicus,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,Cerebellum
10116.0,5.0,,B,,,,CHEMBL619192,,BAO_0000019,,104705.0,,,D,3522.0,15295.0,1.0,,Autocuration,Rattus norvegicus,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,
10116.0,5.0,,B,,,,CHEMBL619193,,BAO_0000224,,104705.0,,,D,3523.0,6347.0,1.0,,Autocuration,Rattus norvegicus,Percent binding affinity against 5-hydroxytryptamine receptor,
,0.0,,B,,,,CHEMBL619194,,BAO_0000019,,22226.0,,,U,3524.0,6763.0,1.0,,Autocuration,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,
10116.0,5.0,,B,,,,CHEMBL619195,,BAO_0000224,,104705.0,,,D,3525.0,12092.0,1.0,,Autocuration,Rattus norvegicus,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,
10116.0,5.0,,B,,,,CHEMBL619196,,BAO_0000224,,104705.0,,,D,3526.0,1579.0,1.0,,Autocuration,Rattus norvegicus,Affinity against 5-hydroxytryptamine receptor was determined,
10116.0,5.0,,B,,,945.0,CHEMBL619197,,BAO_0000019,,104705.0,,,D,3527.0,1579.0,1.0,,Autocuration,Rattus norvegicus,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Stomach
9606.0,9.0,,B,,,,CHEMBL619198,,BAO_0000219,,121.0,In vitro,,D,3528.0,5963.0,1.0,,Expert,Homo sapiens,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,
9606.0,9.0,,B,,,,CHEMBL875081,,BAO_0000219,,121.0,In vitro,,D,3529.0,5963.0,1.0,,Expert,Homo sapiens,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,
,8.0,,B,,,,CHEMBL884712,,BAO_0000357,,18065.0,,,H,3530.0,5030.0,1.0,,Autocuration,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,
,8.0,,B,,,,CHEMBL884710,,BAO_0000357,,121.0,,,H,3531.0,15796.0,1.0,,Expert,,Inhibition of 5-hydroxytryptamine reuptake,
,8.0,,F,,,,CHEMBL619199,,BAO_0000019,,18065.0,,,H,3532.0,15413.0,1.0,,Autocuration,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",
,8.0,,F,,,,CHEMBL619200,,BAO_0000019,,18065.0,,,H,3533.0,15413.0,1.0,,Autocuration,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",
,8.0,,F,,,,CHEMBL619201,,BAO_0000019,,18065.0,,,H,3534.0,15413.0,1.0,,Autocuration,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",
,8.0,,F,,,,CHEMBL619202,,BAO_0000019,,18065.0,,,H,3535.0,12409.0,1.0,,Autocuration,,Tested for 5-hydroxytryptamine receptor uptake,
9606.0,9.0,,B,,,,CHEMBL619203,,BAO_0000219,CHO,51.0,,,D,3536.0,16909.0,1.0,449.0,Expert,Homo sapiens,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,
9606.0,9.0,,F,,,,CHEMBL619204,,BAO_0000019,,51.0,,,D,3537.0,16909.0,1.0,,Expert,Homo sapiens,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,
9606.0,8.0,,B,,,,CHEMBL619205,,BAO_0000249,,10576.0,,,H,3538.0,15629.0,1.0,,Autocuration,Homo sapiens,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,
,8.0,,B,,,,CHEMBL619206,,BAO_0000357,,10576.0,,,H,3539.0,15629.0,1.0,,Autocuration,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,
,8.0,,B,,,,CHEMBL619207,,BAO_0000249,,10576.0,,,H,3540.0,15629.0,1.0,,Expert,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,
,8.0,,F,,,2435.0,CHEMBL619208,,BAO_0000019,,10825.0,,,H,3541.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,Striatum
,8.0,,F,,,2435.0,CHEMBL619209,,BAO_0000019,,10825.0,,,H,3542.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,Striatum
,8.0,,F,,,2435.0,CHEMBL619210,,BAO_0000019,,10825.0,,,H,3543.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,Striatum
,8.0,,F,,,2435.0,CHEMBL619211,,BAO_0000019,,10825.0,,,H,3544.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,Striatum
,8.0,,F,,,2435.0,CHEMBL619212,,BAO_0000019,,10825.0,,,H,3545.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,Striatum
,8.0,,F,,,2435.0,CHEMBL620681,,BAO_0000019,,10825.0,,,H,3546.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,Striatum
,8.0,,F,,,2435.0,CHEMBL620682,,BAO_0000019,,10825.0,,,H,3547.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,Striatum
,8.0,,F,,,2435.0,CHEMBL620683,,BAO_0000019,,10825.0,,,H,3548.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,Striatum
,8.0,,F,,,2435.0,CHEMBL620684,,BAO_0000019,,10825.0,,,H,3549.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,Striatum
,8.0,,F,,,2435.0,CHEMBL620685,,BAO_0000019,,10825.0,,,H,3550.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,Striatum
,8.0,,F,,,2435.0,CHEMBL620686,,BAO_0000019,,10825.0,,,H,3551.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,Striatum
,8.0,,F,,,349.0,CHEMBL620687,,BAO_0000019,,10825.0,,,H,3552.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,Limbic system
,8.0,,F,,,349.0,CHEMBL620688,,BAO_0000019,,10825.0,,,H,3553.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Limbic system
,8.0,,F,,,349.0,CHEMBL620689,,BAO_0000019,,10825.0,,,H,3554.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,Limbic system
,8.0,,F,,,349.0,CHEMBL620690,,BAO_0000019,,10825.0,,,H,3555.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,Limbic system
,8.0,,F,,,349.0,CHEMBL620691,,BAO_0000019,,10825.0,,,H,3556.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,Limbic system
,8.0,,F,,,349.0,CHEMBL620692,,BAO_0000019,,10825.0,,,H,3557.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,Limbic system
,8.0,,F,,,349.0,CHEMBL620693,,BAO_0000019,,10825.0,,,H,3558.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,Limbic system
,8.0,,B,,,,CHEMBL620694,,BAO_0000357,,168.0,,,H,3559.0,1274.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 4 receptor,
,8.0,,F,,,,CHEMBL857986,,BAO_0000019,,168.0,,,H,3560.0,17358.0,1.0,,Autocuration,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,
,8.0,,B,,,,CHEMBL620695,,BAO_0000357,,168.0,,,H,3561.0,14532.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,
,8.0,,B,,,,CHEMBL620696,,BAO_0000357,,168.0,,,H,3562.0,16989.0,1.0,,Expert,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,
,8.0,,B,,,,CHEMBL620697,,BAO_0000357,,168.0,,,H,3563.0,17200.0,1.0,,Autocuration,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,
,8.0,,B,,,,CHEMBL620698,,BAO_0000357,,168.0,,,H,3564.0,15779.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 4 receptor,
,8.0,,B,,,,CHEMBL620699,,BAO_0000357,,168.0,,,H,3565.0,15779.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,
,8.0,,B,,,,CHEMBL620700,,BAO_0000357,,168.0,,,H,3566.0,15779.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,
,8.0,,B,,,,CHEMBL620701,,BAO_0000219,COS-7,168.0,,,H,3567.0,15650.0,1.0,643.0,Autocuration,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,
,8.0,,B,,,,CHEMBL875082,,BAO_0000219,COS-7,168.0,,,H,3568.0,15650.0,1.0,643.0,Autocuration,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,
,8.0,,B,,,,CHEMBL620702,,BAO_0000219,COS-7,168.0,,,H,3569.0,15650.0,1.0,643.0,Autocuration,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,
,8.0,,B,,,,CHEMBL620703,,BAO_0000219,COS-7,168.0,,,H,3570.0,15650.0,1.0,643.0,Autocuration,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,
,8.0,,B,,,,CHEMBL620704,,BAO_0000219,C6,168.0,,,H,3571.0,17046.0,1.0,673.0,Autocuration,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,
,8.0,,B,,,,CHEMBL620705,,BAO_0000219,C6,168.0,,,H,3572.0,17046.0,1.0,673.0,Expert,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,
,8.0,,B,,,,CHEMBL620706,,BAO_0000219,C6,168.0,,,H,3573.0,15650.0,1.0,673.0,Expert,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,
,8.0,,B,,,,CHEMBL620707,,BAO_0000219,C6,168.0,,,H,3574.0,17046.0,1.0,673.0,Expert,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,
,8.0,,B,,,,CHEMBL620708,,BAO_0000357,,10624.0,,,H,3575.0,17066.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 5 receptor,
,8.0,,B,,,,CHEMBL620709,,BAO_0000357,,105.0,,,H,3576.0,17200.0,1.0,,Autocuration,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,
9606.0,9.0,,B,,,,CHEMBL620710,,BAO_0000357,,10624.0,,,D,3577.0,16146.0,1.0,,Expert,Homo sapiens,Binding affinity against 5-hydroxytryptamine 5A receptor,
,8.0,,B,,,,CHEMBL620711,,BAO_0000219,CHO,10624.0,,,H,3578.0,15250.0,1.0,449.0,Autocuration,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,
9606.0,9.0,,B,,,,CHEMBL620712,,BAO_0000357,,10624.0,,,D,3579.0,6491.0,1.0,,Expert,Homo sapiens,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,
9606.0,9.0,,B,,,,CHEMBL620713,,BAO_0000357,,10624.0,,,D,3580.0,17066.0,1.0,,Expert,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 5A receptor,
9606.0,9.0,,B,,,,CHEMBL620714,,BAO_0000357,,10624.0,,,D,3581.0,17066.0,1.0,,Expert,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,
9606.0,9.0,,B,,,,CHEMBL620715,,BAO_0000357,,10624.0,,,D,3582.0,4234.0,1.0,,Expert,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,
,8.0,,B,,,,CHEMBL620716,,BAO_0000357,,10624.0,,,H,3583.0,6013.0,1.0,,Autocuration,,Binding affinity towards 5-HT5A receptor,
,8.0,,B,,,,CHEMBL620717,,BAO_0000357,,10624.0,,,H,3584.0,17175.0,1.0,,Expert,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,
,8.0,,B,,,,CHEMBL618072,,BAO_0000357,,10624.0,,,H,3585.0,15818.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,
,8.0,,B,,,,CHEMBL857987,,BAO_0000357,,10624.0,,,H,3586.0,6166.0,1.0,,Autocuration,,Binding affinity towards cloned human 5-HT5A receptor was determined,
,8.0,,B,,,,CHEMBL618073,,BAO_0000219,HEK293,10624.0,,,H,3587.0,15779.0,1.0,722.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,
,8.0,,B,,,,CHEMBL618074,,BAO_0000219,HEK293,10624.0,,,H,3588.0,15779.0,1.0,722.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,
,8.0,,B,,,,CHEMBL618075,,BAO_0000219,HEK293,10624.0,,,H,3589.0,5213.0,1.0,722.0,Autocuration,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),
10090.0,9.0,,B,,,,CHEMBL618076,,BAO_0000357,,10625.0,,,D,3590.0,17066.0,1.0,,Expert,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,
10090.0,9.0,,B,,,,CHEMBL618077,,BAO_0000357,,10625.0,,,D,3591.0,17066.0,1.0,,Expert,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,
10090.0,9.0,,B,,,,CHEMBL618078,,BAO_0000357,,10625.0,,,D,3592.0,17066.0,1.0,,Expert,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,
10090.0,9.0,,B,,,,CHEMBL881821,,BAO_0000357,,10625.0,,,D,3593.0,17066.0,1.0,,Expert,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,
10090.0,9.0,,B,,,,CHEMBL618079,,BAO_0000357,,10625.0,,,D,3594.0,17066.0,1.0,,Expert,Mus musculus,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,
,8.0,,B,,,,CHEMBL618080,,BAO_0000357,,10625.0,,,H,3595.0,17175.0,1.0,,Expert,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,
,8.0,,B,,,,CHEMBL618081,,BAO_0000219,HEK293,10576.0,,,H,3596.0,16190.0,1.0,722.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,
,8.0,,B,,,,CHEMBL618082,,BAO_0000219,HEK293,10626.0,,,H,3597.0,16190.0,1.0,722.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,
,8.0,,B,,,,CHEMBL618083,,BAO_0000357,,10624.0,,,H,3598.0,4820.0,1.0,,Expert,,Binding affinity towards 5-HT5a receptor,
9606.0,9.0,,B,,,,CHEMBL618084,,BAO_0000357,,10624.0,,,D,3599.0,17066.0,1.0,,Expert,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 5A receptor,
,8.0,,B,,,,CHEMBL618085,,BAO_0000357,,10624.0,,,H,3600.0,17066.0,1.0,,Expert,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,
,8.0,,B,,,,CHEMBL618086,,BAO_0000357,,10624.0,,,H,3601.0,17175.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,
,8.0,,B,,,,CHEMBL875092,,BAO_0000357,,10624.0,,,H,3602.0,16633.0,1.0,,Autocuration,,Binding affinities against 5-hydroxytryptamine 5A receptor,
,8.0,,B,,,,CHEMBL618087,,BAO_0000357,,10624.0,,,H,3603.0,16633.0,1.0,,Autocuration,,Binding affinities towards 5-hydroxytryptamine 5A receptor,
,8.0,,B,,,,CHEMBL872926,,BAO_0000357,,10624.0,,,H,3604.0,16700.0,1.0,,Autocuration,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,
10141.0,4.0,,F,,,,CHEMBL618088,,BAO_0000019,,104714.0,,,H,3605.0,4639.0,1.0,,Autocuration,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,
,4.0,,B,,,,CHEMBL618089,,BAO_0000223,,104714.0,,,H,3606.0,5486.0,1.0,,Autocuration,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,
9606.0,9.0,,B,,,,CHEMBL618090,,BAO_0000357,,10627.0,,,D,3607.0,16146.0,1.0,,Expert,Homo sapiens,Inhibition of human 5-hydroxytryptamine 6 receptor,
9606.0,9.0,,B,,,,CHEMBL618091,,BAO_0000357,,10627.0,,,D,3608.0,17273.0,1.0,,Expert,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,
,8.0,,B,,,,CHEMBL618092,,BAO_0000357,,10627.0,,,H,3609.0,17687.0,1.0,,Autocuration,,Inhibition against human 5-hydroxytryptamine 6 receptor,
9606.0,9.0,,B,,,,CHEMBL618093,,BAO_0000357,,10627.0,,,D,3610.0,6491.0,1.0,,Expert,Homo sapiens,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,
,8.0,,B,,,,CHEMBL618094,,BAO_0000219,HeLa,10627.0,,,H,3611.0,16190.0,1.0,308.0,Expert,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,
9606.0,9.0,,B,,,,CHEMBL618095,,BAO_0000357,,10627.0,,,D,3612.0,17066.0,1.0,,Expert,Homo sapiens,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,
9606.0,9.0,,B,,,,CHEMBL875093,,BAO_0000357,,10627.0,,,D,3613.0,17066.0,1.0,,Expert,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor,
9606.0,9.0,,B,,,,CHEMBL618096,,BAO_0000357,,10627.0,,,D,3614.0,17066.0,1.0,,Expert,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,
9606.0,9.0,,B,,,,CHEMBL618118,,BAO_0000357,,10627.0,,,D,3615.0,17066.0,1.0,,Expert,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,
9606.0,9.0,,B,,,,CHEMBL618119,,BAO_0000357,,10627.0,,,D,3616.0,3555.0,1.0,,Expert,Homo sapiens,Binding affinity against 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL618120,,BAO_0000357,,10627.0,,,H,3617.0,5808.0,1.0,,Expert,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL618121,,BAO_0000357,,10627.0,,,H,3618.0,6013.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL618122,,BAO_0000219,HEK293,10627.0,,,H,3619.0,15818.0,1.0,722.0,Expert,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",
,8.0,,B,,,,CHEMBL618123,,BAO_0000357,,10627.0,,,H,3620.0,16209.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,
,8.0,,B,,,,CHEMBL618124,,BAO_0000219,HEK293,10627.0,,,H,3621.0,3935.0,1.0,722.0,Expert,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,
,8.0,,B,,,,CHEMBL618125,,BAO_0000357,,10627.0,,,H,3622.0,15818.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,
9606.0,9.0,,B,,,,CHEMBL618126,,BAO_0000219,HEK293,10627.0,,,D,3623.0,3805.0,1.0,722.0,Expert,Homo sapiens,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,
,8.0,,B,,,,CHEMBL618236,,BAO_0000019,,10627.0,,,H,3624.0,16441.0,1.0,,Expert,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,
,8.0,,B,,,,CHEMBL618237,,BAO_0000019,,10627.0,,,H,3625.0,16441.0,1.0,,Expert,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,
,8.0,,B,,,,CHEMBL618238,,BAO_0000219,COS-7,10627.0,,,H,3626.0,6786.0,1.0,643.0,Expert,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,
9606.0,9.0,,B,,,,CHEMBL618239,,BAO_0000357,,10627.0,,,D,3627.0,4234.0,1.0,,Expert,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL618240,,BAO_0000019,,10627.0,,,H,3628.0,17085.0,1.0,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL618241,,BAO_0000357,,10627.0,,,H,3629.0,17200.0,1.0,,Autocuration,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,
,8.0,,B,,,,CHEMBL859399,,BAO_0000219,HEK293,10627.0,,,H,3630.0,17451.0,1.0,722.0,Autocuration,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,
,8.0,,F,,,,CHEMBL618242,,BAO_0000019,,10627.0,,,H,3631.0,3935.0,1.0,,Autocuration,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,
,8.0,,B,,,,CHEMBL857991,,BAO_0000357,,10627.0,,,H,3632.0,5033.0,1.0,,Autocuration,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL619951,,BAO_0000357,,10627.0,,,H,3633.0,4540.0,1.0,,Expert,,Binding affinity against human 5-hydroxytryptamine 6 receptor,
9606.0,9.0,,B,,,,CHEMBL619952,,BAO_0000219,HeLa,10627.0,,,D,3634.0,4540.0,1.0,308.0,Expert,Homo sapiens,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,
9606.0,9.0,,B,,,,CHEMBL619953,,BAO_0000219,HeLa,10627.0,,,D,3635.0,4540.0,1.0,308.0,Expert,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,
,8.0,,B,,,,CHEMBL619954,,BAO_0000219,HeLa,10627.0,,,H,3636.0,17296.0,1.0,308.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,
,8.0,,B,,,,CHEMBL619955,,BAO_0000219,HeLa,10627.0,,,H,3637.0,17296.0,1.0,308.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,
,8.0,,B,,,,CHEMBL619956,,BAO_0000219,HeLa,10627.0,,,H,3638.0,17296.0,1.0,308.0,Autocuration,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,
,8.0,,B,,,,CHEMBL619957,,BAO_0000219,CHO,10627.0,,,H,3639.0,15779.0,1.0,449.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL619958,,BAO_0000219,HEK293,10627.0,,,H,3640.0,15779.0,1.0,722.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,
,8.0,,B,,,,CHEMBL620627,,BAO_0000219,HEK293,10627.0,,,H,3641.0,15779.0,1.0,722.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,
,8.0,,B,,,,CHEMBL620628,,BAO_0000219,HEK293,10627.0,,,H,3642.0,15779.0,1.0,722.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,
,8.0,,B,,,,CHEMBL620629,,BAO_0000219,HeLa,10627.0,,,H,3643.0,15779.0,1.0,308.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,
,8.0,,B,,,,CHEMBL620630,,BAO_0000357,,10627.0,,,H,3644.0,6166.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL620782,,BAO_0000219,HeLa,10627.0,,,H,3645.0,17451.0,1.0,308.0,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,
,8.0,,B,,,,CHEMBL620783,,BAO_0000357,,10627.0,,,H,3646.0,15316.0,1.0,,Autocuration,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL620784,,BAO_0000357,,10627.0,,,H,3647.0,4199.0,1.0,,Expert,,Binding affinity against human 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL620785,,BAO_0000219,HeLa,10627.0,,,H,3648.0,15146.0,1.0,308.0,Expert,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,
,8.0,,B,,,,CHEMBL857992,,BAO_0000357,,10627.0,,,H,3649.0,5213.0,1.0,,Autocuration,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),
,8.0,,B,,,,CHEMBL620786,,BAO_0000219,,10627.0,,,H,3650.0,16429.0,1.0,,Autocuration,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,
,8.0,,B,,,,CHEMBL620787,,BAO_0000219,HeLa,10627.0,,,H,3651.0,14818.0,1.0,308.0,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,
,8.0,,B,,,,CHEMBL620788,,BAO_0000219,HeLa,10627.0,,,H,3652.0,4829.0,1.0,308.0,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",
,8.0,,B,,,,CHEMBL620789,,BAO_0000219,HeLa,10627.0,,,H,3653.0,4829.0,1.0,308.0,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",
,8.0,,B,,,,CHEMBL620790,,BAO_0000219,HeLa,10627.0,,,H,3654.0,4829.0,1.0,308.0,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",
,8.0,,B,,,,CHEMBL620791,,BAO_0000219,CHO,10628.0,,,H,3655.0,15250.0,1.0,449.0,Autocuration,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,
,8.0,,B,,,,CHEMBL620792,,BAO_0000019,,10628.0,,,H,3656.0,14423.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,
,8.0,,B,,,,CHEMBL620793,,BAO_0000357,,10628.0,,,H,3657.0,15086.0,1.0,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL620794,,BAO_0000357,,10628.0,,,H,3658.0,4342.0,1.0,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,
9606.0,9.0,,B,,,,CHEMBL620795,,BAO_0000219,HeLa,10627.0,,,D,3659.0,16190.0,1.0,308.0,Autocuration,Homo sapiens,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,
,8.0,,B,,,,CHEMBL620796,,BAO_0000357,,10627.0,,,H,3660.0,4820.0,1.0,,Expert,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL620797,,BAO_0000357,,10627.0,,,H,3661.0,4639.0,1.0,,Autocuration,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,
9606.0,9.0,,F,,,,CHEMBL620798,,BAO_0000019,,10627.0,,,D,3662.0,17066.0,1.0,,Expert,Homo sapiens,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,
,8.0,,B,,,,CHEMBL620799,,BAO_0000357,,10627.0,,,H,3663.0,6011.0,1.0,,Autocuration,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,
,8.0,,B,,,,CHEMBL620800,,BAO_0000357,,10627.0,,,H,3664.0,17066.0,1.0,,Expert,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL620801,,BAO_0000357,,10627.0,,,H,3665.0,17515.0,1.0,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,
,8.0,,B,,,,CHEMBL875100,,BAO_0000357,,10627.0,,,H,3666.0,5014.0,1.0,,Autocuration,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL620802,,BAO_0000357,,10627.0,,,H,3667.0,4373.0,1.0,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,
,8.0,,F,,,,CHEMBL620803,,BAO_0000019,,10627.0,,,H,3668.0,17066.0,1.0,,Expert,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,
,8.0,,F,,,,CHEMBL620804,,BAO_0000019,,10627.0,,,H,3669.0,17066.0,1.0,,Expert,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,
,8.0,,B,,,,CHEMBL620805,,BAO_0000357,,10627.0,,,H,3670.0,4373.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,
,8.0,,B,,,,CHEMBL620806,,BAO_0000357,,10627.0,,,H,3671.0,4687.0,1.0,,Autocuration,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL620807,,BAO_0000357,,10627.0,,,H,3672.0,16946.0,1.0,,Autocuration,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,
,8.0,,B,,,,CHEMBL620808,,BAO_0000357,,10627.0,,,H,3673.0,16946.0,1.0,,Autocuration,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,
,8.0,,B,,,,CHEMBL620809,,BAO_0000357,,10627.0,,,H,3674.0,16633.0,1.0,,Autocuration,,Binding affinities against 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL620810,,BAO_0000357,,10627.0,,,H,3675.0,16633.0,1.0,,Autocuration,,Binding affinities towards 5-hydroxytryptamine 6 receptor,
9606.0,9.0,,B,,,,CHEMBL620811,,BAO_0000357,,10627.0,,,D,3676.0,17066.0,1.0,,Expert,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL620812,,BAO_0000357,,10627.0,,,H,3677.0,16700.0,1.0,,Autocuration,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,
,8.0,,B,,,,CHEMBL620813,,BAO_0000357,,10627.0,,,H,3678.0,3269.0,1.0,,Autocuration,,Affinity against 5-hydroxytryptamine 6 receptor,
,8.0,,B,,,,CHEMBL620814,,BAO_0000357,,10627.0,,,H,3679.0,5486.0,1.0,,Autocuration,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],
9606.0,9.0,,B,,,,CHEMBL620815,,BAO_0000357,,10209.0,,,D,3680.0,16146.0,1.0,,Expert,Homo sapiens,Inhibition of human 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL620816,,BAO_0000219,HEK293,10209.0,,,H,3681.0,5014.0,1.0,722.0,Autocuration,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,
,8.0,,B,,,,CHEMBL620817,,BAO_0000357,,10209.0,,,H,3682.0,15463.0,1.0,,Autocuration,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL620818,,BAO_0000357,,10209.0,,,H,3683.0,3805.0,1.0,,Autocuration,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),
,8.0,,B,,,,CHEMBL620819,,BAO_0000219,HEK293,10209.0,,,H,3684.0,5014.0,1.0,722.0,Expert,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,
9606.0,9.0,,B,,,,CHEMBL620820,,BAO_0000357,,10209.0,,,D,3685.0,6491.0,1.0,,Expert,Homo sapiens,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,
,8.0,,B,,,,CHEMBL620821,,BAO_0000219,CHO,10209.0,,,H,3686.0,16190.0,1.0,449.0,Autocuration,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,
9606.0,9.0,,B,,,,CHEMBL620822,,BAO_0000357,,10209.0,,,D,3687.0,17066.0,1.0,,Expert,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 7 receptor,
9606.0,9.0,,B,,,,CHEMBL620823,,BAO_0000357,,10209.0,,,D,3688.0,17066.0,1.0,,Expert,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,
9606.0,9.0,,B,,,,CHEMBL620824,,BAO_0000357,,10209.0,,,D,3689.0,3555.0,1.0,,Expert,Homo sapiens,Binding affinity against 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL620825,,BAO_0000219,CHO,10209.0,,,H,3690.0,6588.0,1.0,449.0,Expert,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,
,8.0,,B,,,,CHEMBL872930,,BAO_0000357,,10209.0,,,H,3691.0,15463.0,1.0,,Autocuration,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,
,8.0,,B,,,,CHEMBL620826,,BAO_0000357,,10209.0,,,H,3692.0,6013.0,1.0,,Autocuration,,Binding affinity towards 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL620827,,BAO_0000357,,10209.0,,,H,3693.0,16209.0,1.0,,Autocuration,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL620828,,BAO_0000357,,10209.0,,,H,3694.0,3935.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL620829,,BAO_0000357,,10209.0,,,H,3695.0,15818.0,1.0,,Autocuration,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL620830,,BAO_0000219,HEK293,10209.0,,,H,3696.0,5014.0,1.0,722.0,Expert,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,
,8.0,,B,,,,CHEMBL620831,,BAO_0000019,,10209.0,,,H,3697.0,16441.0,1.0,,Expert,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,
,8.0,,B,,,,CHEMBL620832,,BAO_0000019,,10209.0,,,H,3698.0,16441.0,1.0,,Expert,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,
9606.0,9.0,,B,,,,CHEMBL621548,,BAO_0000357,,10209.0,,,D,3699.0,4234.0,1.0,,Expert,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL621549,,BAO_0000019,,10209.0,,,H,3700.0,17085.0,1.0,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL621550,,BAO_0000357,,10209.0,,,H,3701.0,17200.0,1.0,,Autocuration,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,
,8.0,,B,,,,CHEMBL621551,,BAO_0000219,CHO,10209.0,,,H,3702.0,17451.0,1.0,449.0,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,
,8.0,,B,,,,CHEMBL621552,,BAO_0000019,,10209.0,,,H,3703.0,17085.0,1.0,,Autocuration,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,
,8.0,,B,,,,CHEMBL857077,,BAO_0000357,,10209.0,,,H,3704.0,5104.0,1.0,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL618158,,BAO_0000357,,10209.0,,,H,3705.0,5104.0,1.0,,Autocuration,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,
9606.0,9.0,,B,,,,CHEMBL618159,,BAO_0000219,COS-7,10209.0,,,D,3706.0,5033.0,1.0,643.0,Expert,Homo sapiens,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,
,8.0,,B,,,,CHEMBL875101,,BAO_0000219,COS-7,10209.0,,,H,3707.0,5486.0,1.0,643.0,Autocuration,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,
9606.0,9.0,,B,,,,CHEMBL618160,,BAO_0000219,HEK293,10209.0,,,D,3708.0,4540.0,1.0,722.0,Expert,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,
,8.0,,B,,,,CHEMBL618161,,BAO_0000357,,10209.0,,,H,3709.0,6166.0,1.0,,Expert,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,
,8.0,,B,,,,CHEMBL618162,,BAO_0000219,HEK293,10209.0,,,H,3710.0,17342.0,1.0,722.0,Expert,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,
,8.0,,B,,,,CHEMBL618163,,BAO_0000357,,10209.0,,,H,3711.0,17342.0,1.0,,Expert,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,
,8.0,,B,,,,CHEMBL618164,,BAO_0000357,,10209.0,,,H,3712.0,17296.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 7 human receptors,
,8.0,,B,,,,CHEMBL618165,,BAO_0000219,,10209.0,,,H,3713.0,16429.0,1.0,,Expert,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,
,8.0,,B,,,,CHEMBL618166,,BAO_0000219,HEK293,10209.0,,,H,3714.0,15779.0,1.0,722.0,Autocuration,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,
,8.0,,B,,,,CHEMBL857989,,BAO_0000219,HEK293,10209.0,,,H,3715.0,15779.0,1.0,722.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,
,8.0,,B,,,,CHEMBL619888,,BAO_0000219,HEK293,10209.0,,,H,3716.0,15779.0,1.0,722.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,
,8.0,,B,,,,CHEMBL619889,,BAO_0000219,HEK293,10209.0,,,H,3717.0,15779.0,1.0,722.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,
,8.0,,B,,,,CHEMBL619890,,BAO_0000219,HEK293,10209.0,,,H,3718.0,15779.0,1.0,722.0,Autocuration,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,
,8.0,,B,,,,CHEMBL619891,,BAO_0000219,CHO,10209.0,,,H,3719.0,17451.0,1.0,449.0,Autocuration,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,
,8.0,,B,,,,CHEMBL619892,,BAO_0000219,HEK293,10209.0,,,H,3720.0,4199.0,1.0,722.0,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),
,9.0,,B,,,,CHEMBL619893,,BAO_0000219,HEK293,10209.0,,,D,3721.0,4199.0,1.0,722.0,Expert,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,
,8.0,,B,,,,CHEMBL619894,,BAO_0000219,HEK293,10209.0,,,H,3722.0,4199.0,1.0,722.0,Autocuration,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),
,9.0,,B,,,,CHEMBL619895,,BAO_0000219,HEK293,10209.0,,,D,3723.0,3680.0,1.0,722.0,Intermediate,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,
,9.0,,B,,,,CHEMBL619896,,BAO_0000357,,10209.0,,,D,3724.0,3680.0,1.0,,Intermediate,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,
,8.0,,B,,,,CHEMBL619897,,BAO_0000219,COS-7,10209.0,,,H,3725.0,15316.0,1.0,643.0,Autocuration,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,
,8.0,,B,,,,CHEMBL619898,,BAO_0000219,HEK293,10209.0,,,H,3726.0,15146.0,1.0,722.0,Autocuration,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,
,8.0,,B,,,,CHEMBL619899,,BAO_0000219,HEK293,10209.0,,,H,3727.0,5213.0,1.0,722.0,Expert,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,
,8.0,,B,,,,CHEMBL619900,,BAO_0000219,HEK293,10209.0,,,H,3728.0,5213.0,1.0,722.0,Autocuration,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),
9606.0,9.0,,B,,,,CHEMBL619901,,BAO_0000219,HEK293,10209.0,,,D,3729.0,14818.0,1.0,722.0,Expert,Homo sapiens,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,
,8.0,,B,,,,CHEMBL620580,,BAO_0000219,HEK293,10209.0,,,H,3730.0,14818.0,1.0,722.0,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,
,8.0,,B,,,,CHEMBL620581,,BAO_0000219,HEK293,10209.0,,,H,3731.0,14818.0,1.0,722.0,Autocuration,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,
,8.0,,B,,,,CHEMBL620733,,BAO_0000219,HEK293,10209.0,,,H,3732.0,4829.0,1.0,722.0,Autocuration,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",
9606.0,9.0,,B,,,,CHEMBL620734,,BAO_0000357,,10209.0,,,D,3733.0,17200.0,1.0,,Autocuration,Homo sapiens,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,
10090.0,9.0,,B,,,,CHEMBL620735,,BAO_0000357,,10022.0,,,D,3734.0,17066.0,1.0,,Expert,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,
9986.0,8.0,,B,,,,CHEMBL620736,,BAO_0000019,,10209.0,,,H,3735.0,14025.0,1.0,,Autocuration,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,
,8.0,,B,,,,CHEMBL620737,,BAO_0000219,CHO,11923.0,,,H,3736.0,15250.0,1.0,449.0,Autocuration,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,
,8.0,,B,,,,CHEMBL620738,,BAO_0000219,CHO,11923.0,,,H,3737.0,16372.0,1.0,449.0,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,
,8.0,,B,,,,CHEMBL620739,,BAO_0000219,CHO,11923.0,,,H,3738.0,16372.0,1.0,449.0,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,
,8.0,,B,,,,CHEMBL620740,,BAO_0000219,CHO,11923.0,,,H,3739.0,16372.0,1.0,449.0,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,
,8.0,,B,,,,CHEMBL620741,,BAO_0000219,CHO,11923.0,,,H,3740.0,16372.0,1.0,449.0,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,
,8.0,,B,,,,CHEMBL620742,,BAO_0000219,CHO,11923.0,,,H,3741.0,16372.0,1.0,449.0,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,
,8.0,,B,,,,CHEMBL620743,,BAO_0000219,CHO,11923.0,,,H,3742.0,16372.0,1.0,449.0,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,
,8.0,,B,,,,CHEMBL620744,,BAO_0000219,CHO,11923.0,,,H,3743.0,16372.0,1.0,449.0,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,
,8.0,,B,,,,CHEMBL620745,,BAO_0000219,CHO,11923.0,,,H,3744.0,16372.0,1.0,449.0,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,
,8.0,,B,,,,CHEMBL620746,,BAO_0000219,CHO,11923.0,,,H,3745.0,16372.0,1.0,449.0,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,
,8.0,,B,,,,CHEMBL620747,,BAO_0000219,CHO,11923.0,,,H,3746.0,16372.0,1.0,449.0,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,
,8.0,,B,,,,CHEMBL620748,,BAO_0000219,CHO,11923.0,,,H,3747.0,16372.0,1.0,449.0,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,
,8.0,,B,,,,CHEMBL620749,,BAO_0000219,CHO,11923.0,,,H,3748.0,16372.0,1.0,449.0,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,
,8.0,,B,,,,CHEMBL620750,,BAO_0000357,,11923.0,,,H,3749.0,17066.0,1.0,,Expert,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,
10116.0,9.0,,B,,,,CHEMBL620751,,BAO_0000357,,11923.0,,,D,3750.0,17066.0,1.0,,Expert,Rattus norvegicus,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL620752,,BAO_0000357,,11923.0,,,H,3751.0,17386.0,1.0,,Expert,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL872929,,BAO_0000019,,11923.0,,,H,3752.0,14423.0,1.0,,Autocuration,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,
10116.0,9.0,,B,,,,CHEMBL620753,,BAO_0000357,,11923.0,,,D,3753.0,15874.0,1.0,,Expert,Rattus norvegicus,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,
10116.0,9.0,,B,,,,CHEMBL620754,,BAO_0000357,,11923.0,,,D,3754.0,15874.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,
10116.0,9.0,,B,,,,CHEMBL620755,,BAO_0000219,CHO,11923.0,,,D,3755.0,16372.0,1.0,449.0,Expert,Rattus norvegicus,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,
,8.0,,B,,,,CHEMBL620756,,BAO_0000357,,11923.0,,,H,3756.0,4622.0,1.0,,Autocuration,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,
,8.0,,B,,,,CHEMBL620757,,BAO_0000357,,11923.0,,,H,3757.0,15086.0,1.0,,Autocuration,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL620758,,BAO_0000219,CHO,11923.0,,,H,3758.0,16372.0,1.0,449.0,Autocuration,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",
,8.0,,B,,,,CHEMBL620759,,BAO_0000219,CHO,11923.0,,,H,3759.0,16372.0,1.0,449.0,Autocuration,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",
,8.0,,B,,,,CHEMBL620760,,BAO_0000219,CHO,11923.0,,,H,3760.0,16372.0,1.0,449.0,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,
,8.0,,B,,,,CHEMBL620761,,BAO_0000219,CHO,11923.0,,,H,3761.0,16372.0,1.0,449.0,Autocuration,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,
,8.0,,F,,,2116.0,CHEMBL620762,,BAO_0000221,,11923.0,,,H,3762.0,17386.0,1.0,,Autocuration,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Ileum
,8.0,,F,,,2116.0,CHEMBL620763,,BAO_0000221,,11923.0,,,H,3763.0,17386.0,1.0,,Autocuration,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Ileum
,8.0,,F,,,2116.0,CHEMBL620764,,BAO_0000221,,11923.0,,,H,3764.0,17386.0,1.0,,Autocuration,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,Ileum
10116.0,9.0,,B,,,,CHEMBL857990,,BAO_0000249,,11923.0,,Membranes,D,3765.0,5831.0,1.0,,Expert,Rattus norvegicus,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,
,8.0,,B,,,,CHEMBL620765,,BAO_0000357,,11923.0,,,H,3766.0,4342.0,1.0,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,
,8.0,,B,,,,CHEMBL620766,,BAO_0000357,,11923.0,,,H,3767.0,17319.0,1.0,,Expert,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,
,8.0,,B,,,1898.0,CHEMBL620767,,BAO_0000019,,11923.0,,,H,3768.0,17342.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,Hypothalamus
,8.0,,B,,,,CHEMBL620768,,BAO_0000357,,11923.0,,,H,3769.0,17342.0,1.0,,Autocuration,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,
,8.0,,B,,,1898.0,CHEMBL619051,,BAO_0000249,,11923.0,,,H,3770.0,3680.0,1.0,,Expert,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,Hypothalamus
,8.0,,B,,,,CHEMBL619052,,BAO_0000357,,11923.0,,,H,3771.0,3680.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 7 receptor,
10116.0,9.0,,F,,,,CHEMBL619053,,BAO_0000219,HEK293,11923.0,,,D,3772.0,17319.0,1.0,722.0,Expert,Rattus norvegicus,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,
10116.0,9.0,,F,,,,CHEMBL619703,,BAO_0000219,HEK293,11923.0,,,D,3773.0,17319.0,1.0,722.0,Expert,Rattus norvegicus,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,
10116.0,9.0,,F,,,,CHEMBL619704,,BAO_0000219,HEK293,11923.0,,,D,3774.0,17319.0,1.0,722.0,Autocuration,Rattus norvegicus,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,
,8.0,,B,,,,CHEMBL619851,,BAO_0000357,,10209.0,,,H,3775.0,4820.0,1.0,,Expert,,Binding affinity towards 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL619852,,BAO_0000357,,10209.0,,,H,3776.0,4639.0,1.0,,Autocuration,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,
,8.0,,B,,,,CHEMBL619853,,BAO_0000357,,10209.0,,,H,3777.0,6011.0,1.0,,Autocuration,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,
9606.0,9.0,,B,,,,CHEMBL619854,,BAO_0000357,,10209.0,,,D,3778.0,17066.0,1.0,,Expert,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL619855,,BAO_0000357,,10209.0,,,H,3779.0,17066.0,1.0,,Expert,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL619856,,BAO_0000357,,10209.0,,,H,3780.0,17515.0,1.0,,Autocuration,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,
,8.0,,B,,,,CHEMBL619857,,BAO_0000357,,10209.0,,,H,3781.0,4373.0,1.0,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,
,8.0,,F,,,,CHEMBL619858,,BAO_0000019,,10209.0,,,H,3782.0,17066.0,1.0,,Expert,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,
,8.0,,B,,,,CHEMBL619859,,BAO_0000357,,10209.0,,,H,3783.0,4373.0,1.0,,Autocuration,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,
,8.0,,B,,,,CHEMBL619860,,BAO_0000357,,10209.0,,,H,3784.0,4373.0,1.0,,Autocuration,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,
,8.0,,B,,,,CHEMBL619861,,BAO_0000357,,10209.0,,,H,3785.0,4687.0,1.0,,Autocuration,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL619862,,BAO_0000357,,10209.0,,,H,3786.0,17342.0,1.0,,Expert,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL619863,,BAO_0000357,,10209.0,,,H,3787.0,16946.0,1.0,,Autocuration,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,
,8.0,,B,,,,CHEMBL619864,,BAO_0000357,,10209.0,,,H,3788.0,16946.0,1.0,,Autocuration,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,
,8.0,,B,,,,CHEMBL872928,,BAO_0000357,,10209.0,,,H,3789.0,16633.0,1.0,,Autocuration,,Binding affinities against 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL619865,,BAO_0000357,,10209.0,,,H,3790.0,16633.0,1.0,,Autocuration,,Binding affinities towards 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL619866,,BAO_0000357,,10209.0,,,H,3791.0,17066.0,1.0,,Expert,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,
,8.0,,B,,,,CHEMBL619867,,BAO_0000357,,10209.0,,,H,3792.0,16700.0,1.0,,Autocuration,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,
,8.0,,B,,,2116.0,CHEMBL619868,,BAO_0000221,,10209.0,,,H,3793.0,17386.0,1.0,,Autocuration,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Ileum
,8.0,,F,,,,CHEMBL619869,,BAO_0000019,,55.0,,,H,3794.0,14080.0,1.0,,Autocuration,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,
9606.0,9.0,,F,,,,CHEMBL619870,,BAO_0000019,,55.0,,,D,3795.0,14080.0,1.0,,Expert,Homo sapiens,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,
,8.0,,B,,,,CHEMBL619871,,BAO_0000357,,55.0,,,H,3796.0,409.0,1.0,,Autocuration,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,
,8.0,,B,,,,CHEMBL619872,,BAO_0000357,,55.0,,,H,3797.0,409.0,1.0,,Autocuration,,In vitro inhibition of human recombinant lipoxygenase enzyme,
,8.0,,B,,,,CHEMBL619873,,BAO_0000357,,55.0,,,H,3798.0,409.0,1.0,,Autocuration,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,
,8.0,,B,,,178.0,CHEMBL619874,,BAO_0000357,,55.0,,,H,3799.0,11090.0,1.0,,Expert,,Inhibition of 5-lipoxygenase in human whole blood.,Blood
,8.0,,B,,,178.0,CHEMBL619875,,BAO_0000357,,55.0,,,H,3800.0,11090.0,1.0,,Expert,,Inhibition of 5-lipoxygenase in human whole blood.,Blood
,8.0,,B,,,,CHEMBL619876,,BAO_0000357,,55.0,,,H,3801.0,948.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,
,8.0,,B,,,,CHEMBL619877,,BAO_0000357,,55.0,,,H,3802.0,948.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),
,8.0,,F,,,,CHEMBL619878,,BAO_0000219,,55.0,,,H,3803.0,13622.0,1.0,,Expert,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,
,8.0,,F,,,178.0,CHEMBL619879,,BAO_0000019,,55.0,,,H,3804.0,13622.0,1.0,,Autocuration,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,Blood
,8.0,,B,,,,CHEMBL619880,,BAO_0000357,,55.0,,,H,3805.0,9637.0,1.0,,Autocuration,,In vitro inhibition of 5-lipoxygenase from human polymorphs,
,8.0,,B,,,,CHEMBL619881,,BAO_0000357,,55.0,,,H,3806.0,11320.0,1.0,,Autocuration,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),
,8.0,,B,,,,CHEMBL619882,,BAO_0000357,,55.0,,,H,3807.0,11320.0,1.0,,Expert,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,
,8.0,,B,,,,CHEMBL619883,,BAO_0000357,,55.0,,,H,3808.0,6838.0,1.0,,Autocuration,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,
9606.0,9.0,,B,,,178.0,CHEMBL619884,,BAO_0000357,,55.0,,,D,3809.0,17667.0,1.0,,Expert,Homo sapiens,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),Blood
,8.0,,B,,,,CHEMBL619885,,BAO_0000357,,55.0,,,H,3810.0,12703.0,1.0,,Autocuration,,In vitro potency against human 5-Lipoxygenase,
9606.0,9.0,,F,,,,CHEMBL619886,,BAO_0000019,,55.0,,,D,3811.0,14312.0,1.0,,Expert,Homo sapiens,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,
,8.0,,F,,,178.0,CHEMBL619887,,BAO_0000019,,55.0,,,H,3812.0,14312.0,1.0,,Autocuration,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,Blood
,8.0,,F,,,,CHEMBL875097,,BAO_0000019,,55.0,,,H,3813.0,5364.0,1.0,,Autocuration,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,
,8.0,,B,,,,CHEMBL618001,,BAO_0000219,,55.0,,,H,3814.0,951.0,1.0,,Autocuration,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,
,8.0,,B,,,,CHEMBL618002,,BAO_0000219,,55.0,,,H,3815.0,951.0,1.0,,Autocuration,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,
,8.0,,B,,,,CHEMBL618003,,BAO_0000219,,55.0,,,H,3816.0,951.0,1.0,,Autocuration,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,
,8.0,,B,,,,CHEMBL618004,,BAO_0000219,,55.0,,,H,3817.0,951.0,1.0,,Autocuration,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,
,8.0,,B,,,,CHEMBL618005,,BAO_0000219,,55.0,,,H,3818.0,12365.0,1.0,,Autocuration,,Inhibition of human 5-lipoxygenase in human cells,
,8.0,,B,,,,CHEMBL618006,,BAO_0000357,,55.0,,,H,3819.0,10603.0,1.0,,Expert,,Inhibition of human neutrophil 5-lipoxygenase,
,8.0,,B,,,,CHEMBL875086,,BAO_0000019,,55.0,,,H,3820.0,10501.0,1.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,
,8.0,,B,,,178.0,CHEMBL618007,,BAO_0000357,,55.0,,,H,3821.0,12281.0,1.0,,Expert,,Inhibition of 5-lipoxygenase from human whole blood,Blood
,8.0,,B,,,,CHEMBL618008,,BAO_0000357,,55.0,,,H,3822.0,2567.0,1.0,,Autocuration,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,
,8.0,,B,,,,CHEMBL618009,,BAO_0000219,,55.0,,,H,3823.0,2567.0,1.0,,Autocuration,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,
,8.0,,B,,,,CHEMBL618010,,BAO_0000357,,55.0,,,H,3824.0,10193.0,1.0,,Expert,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,
,8.0,,B,,,,CHEMBL618011,,BAO_0000357,,55.0,,,H,3825.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,
,8.0,,B,,,,CHEMBL618012,,BAO_0000357,,55.0,,,H,3826.0,13623.0,1.0,,Expert,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,
,8.0,,B,,,,CHEMBL882927,,BAO_0000357,,55.0,,,H,3827.0,12780.0,1.0,,Autocuration,,Tested against 5-lipoxygenase,
,8.0,,B,,,,CHEMBL618013,,BAO_0000357,,55.0,,,H,3828.0,12780.0,1.0,,Autocuration,,Tested for activity against 5-Lipoxygenase (5-LO),
,8.0,,B,,,,CHEMBL618014,,BAO_0000357,,55.0,,,H,3829.0,12780.0,1.0,,Autocuration,,Tested for activity against 5-lipoxygenase,
,8.0,,B,,,,CHEMBL618015,,BAO_0000357,,55.0,,,H,3830.0,11966.0,1.0,,Autocuration,,Tested for inhibition of 5-HPETE production by human 5-LO,
,8.0,,F,,,,CHEMBL618016,,BAO_0000019,,55.0,,,H,3831.0,5364.0,1.0,,Autocuration,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,
,8.0,,B,,,,CHEMBL618017,,BAO_0000357,,55.0,,,H,3832.0,13165.0,1.0,,Expert,,Inhibition of Human 5-lipoxygenase,
,8.0,,B,,,,CHEMBL618018,,BAO_0000019,,55.0,,,H,3833.0,5364.0,1.0,,Autocuration,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,
,8.0,,B,,,,CHEMBL875087,,BAO_0000219,,55.0,,,H,3834.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],
,8.0,,B,,,,CHEMBL618019,,BAO_0000219,,55.0,,,H,3835.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],
,8.0,,B,,,,CHEMBL618020,,BAO_0000019,,55.0,,,H,3836.0,14863.0,1.0,,Autocuration,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,
,8.0,,B,,,,CHEMBL618021,,BAO_0000019,,55.0,,,H,3837.0,14863.0,1.0,,Autocuration,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,
,8.0,,B,,,178.0,CHEMBL618022,,BAO_0000357,,55.0,,,H,3838.0,11087.0,1.0,,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),Blood
,8.0,,B,,,,CHEMBL618023,,BAO_0000357,,55.0,,,H,3839.0,455.0,1.0,,Autocuration,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,
,8.0,,B,,,,CHEMBL618024,,BAO_0000357,,55.0,,,H,3840.0,13183.0,1.0,,Autocuration,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),
,8.0,,B,,,,CHEMBL873950,,BAO_0000019,,55.0,,,H,3841.0,10319.0,1.0,,Expert,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,
,8.0,,B,,,,CHEMBL618025,,BAO_0000357,,55.0,,,H,3842.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,
,8.0,,B,,,,CHEMBL618026,,BAO_0000219,,55.0,,,H,3843.0,951.0,1.0,,Autocuration,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,
,8.0,,B,,,,CHEMBL618027,,BAO_0000219,,55.0,,,H,3844.0,951.0,1.0,,Autocuration,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,
,8.0,,B,,,,CHEMBL618028,,BAO_0000219,,55.0,,,H,3845.0,951.0,1.0,,Autocuration,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,
,8.0,,B,,,,CHEMBL618029,,BAO_0000219,,55.0,,,H,3846.0,951.0,1.0,,Autocuration,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,
,8.0,,B,,,,CHEMBL618030,,BAO_0000357,,55.0,,,H,3847.0,9859.0,1.0,,Expert,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,
,8.0,,B,,,,CHEMBL618031,,BAO_0000357,,55.0,,,H,3848.0,9859.0,1.0,,Expert,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,
,8.0,,B,,,,CHEMBL618032,,BAO_0000357,,55.0,,,H,3849.0,9859.0,1.0,,Autocuration,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,
,8.0,,B,,,,CHEMBL618033,,BAO_0000357,,55.0,,,H,3850.0,2567.0,1.0,,Autocuration,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,
,8.0,,B,,,,CHEMBL618034,,BAO_0000357,,55.0,,,H,3851.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,
,8.0,,B,,,,CHEMBL875088,,BAO_0000357,,55.0,,,H,3852.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,
,8.0,,B,,,,CHEMBL618035,,BAO_0000019,,55.0,,,H,3853.0,949.0,1.0,,Autocuration,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,
,8.0,,B,,,,CHEMBL618036,,BAO_0000019,,55.0,,,H,3854.0,949.0,1.0,,Autocuration,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,
,8.0,,B,,,,CHEMBL618037,,BAO_0000357,,55.0,,,H,3855.0,10603.0,1.0,,Expert,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,
,8.0,,B,,,,CHEMBL618038,,BAO_0000357,,55.0,,,H,3856.0,10603.0,1.0,,Expert,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,
,8.0,,F,,,,CHEMBL618761,,BAO_0000019,,55.0,,,H,3857.0,10603.0,1.0,,Autocuration,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,
,8.0,,B,,,,CHEMBL618762,,BAO_0000357,,55.0,,,H,3858.0,10603.0,1.0,,Expert,,Inhibition of lipoxygenase at the concentration of 0.1 uM,
,8.0,,B,,,,CHEMBL618763,,BAO_0000357,,55.0,,,H,3859.0,10603.0,1.0,,Expert,,Inhibition of lipoxygenase at the concentration of 1 uM,
,8.0,,B,,,,CHEMBL618764,,BAO_0000357,,55.0,,,H,3860.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,
9606.0,9.0,,B,,,,CHEMBL618765,,BAO_0000357,,55.0,,,D,3861.0,14580.0,1.0,,Expert,Homo sapiens,Inhibition of 5-Lipoxygenase (5-LOX),
,8.0,,B,,,,CHEMBL618766,,BAO_0000357,,17087.0,,,H,3862.0,11090.0,1.0,,Expert,,Inhibition of 5-lipoxygenase in mouse macrophages.,
,8.0,,B,,,,CHEMBL618767,,BAO_0000357,,17087.0,,,H,3863.0,11090.0,1.0,,Expert,,Inhibition of 5-lipoxygenase in mouse macrophages.,
,8.0,,B,,,,CHEMBL619380,,BAO_0000357,,17087.0,,,H,3864.0,6339.0,1.0,,Autocuration,,Inhibitory activity against lipoxygenase-2 in mice,
,8.0,,B,,,,CHEMBL619381,,BAO_0000357,,17087.0,,,H,3865.0,6339.0,1.0,,Expert,,Inhibitory activity against murine lipoxygenase-2.,
10090.0,9.0,,B,,,,CHEMBL619382,,BAO_0000357,,17087.0,,,D,3866.0,12281.0,1.0,,Expert,Mus musculus,Inhibition of 5-lipoxygenase from mouse macrophage,
,8.0,,B,,,,CHEMBL619383,,BAO_0000357,,17087.0,,,H,3867.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,
9823.0,8.0,,B,,,,CHEMBL619384,,BAO_0000019,,55.0,,,H,3868.0,11089.0,1.0,,Autocuration,Sus scrofa,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,
9823.0,8.0,,B,,,,CHEMBL619385,,BAO_0000019,,55.0,,,H,3869.0,10091.0,1.0,,Autocuration,Sus scrofa,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,
9986.0,8.0,,B,,,,CHEMBL882928,,BAO_0000019,,55.0,,,H,3870.0,14352.0,1.0,,Autocuration,Oryctolagus cuniculus,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,
10116.0,9.0,,B,,,,CHEMBL619386,,BAO_0000019,,12166.0,,,D,3871.0,13329.0,1.0,,Expert,Rattus norvegicus,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,
,8.0,,B,,,,CHEMBL619387,,BAO_0000019,,12166.0,,,H,3872.0,13329.0,1.0,,Autocuration,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",
,8.0,,B,,,,CHEMBL619388,,BAO_0000019,,12166.0,,,H,3873.0,13329.0,1.0,,Autocuration,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",
,8.0,,B,,,,CHEMBL619389,,BAO_0000019,,12166.0,,,H,3874.0,13329.0,1.0,,Autocuration,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",
,8.0,,B,,,,CHEMBL619390,,BAO_0000019,,12166.0,,,H,3875.0,13329.0,1.0,,Expert,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),
,8.0,,B,,,,CHEMBL619391,,BAO_0000019,,12166.0,,,H,3876.0,13329.0,1.0,,Expert,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",
,8.0,,B,,,,CHEMBL619392,,BAO_0000019,,12166.0,,,H,3877.0,13329.0,1.0,,Autocuration,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,
,8.0,,B,,,,CHEMBL619393,,BAO_0000019,,12166.0,,,H,3878.0,11311.0,1.0,,Autocuration,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),
,8.0,,B,,,,CHEMBL619394,,BAO_0000019,,12166.0,,,H,3879.0,11311.0,1.0,,Autocuration,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,
,8.0,,B,,,,CHEMBL619395,,BAO_0000219,RBL-1,12166.0,,,H,3880.0,105.0,1.0,702.0,Autocuration,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",
,8.0,,B,,,,CHEMBL619396,,BAO_0000219,RBL-1,12166.0,,,H,3881.0,105.0,1.0,702.0,Autocuration,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",
,8.0,,B,,,,CHEMBL619397,,BAO_0000357,,12166.0,,,H,3882.0,9138.0,1.0,,Autocuration,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),
,8.0,,B,,,,CHEMBL619398,,BAO_0000357,,12166.0,,,H,3883.0,9138.0,1.0,,Autocuration,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",
,8.0,,B,,,,CHEMBL619399,,BAO_0000357,,12166.0,,,H,3884.0,9138.0,1.0,,Autocuration,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",
,8.0,,B,,,,CHEMBL619400,,BAO_0000357,,12166.0,,,H,3885.0,14427.0,1.0,,Autocuration,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,
,8.0,,B,,,,CHEMBL619401,,BAO_0000019,,12166.0,,,H,3886.0,13329.0,1.0,,Autocuration,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",
,8.0,,B,,,,CHEMBL619402,,BAO_0000019,,12166.0,,,H,3887.0,13329.0,1.0,,Autocuration,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",
10116.0,9.0,,B,,,,CHEMBL619403,,BAO_0000219,RBL-2H3,12166.0,,,D,3888.0,14427.0,1.0,663.0,Expert,Rattus norvegicus,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,
,8.0,,B,,,,CHEMBL619404,,BAO_0000357,,12166.0,,,H,3889.0,14427.0,1.0,,Autocuration,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,
,8.0,,B,,,,CHEMBL619405,,BAO_0000357,,12166.0,,,H,3890.0,14427.0,1.0,,Autocuration,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,
,8.0,,B,,,,CHEMBL619406,,BAO_0000219,RBL-1,12166.0,,,H,3891.0,10293.0,1.0,702.0,Expert,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,
10116.0,9.0,,B,,,,CHEMBL619407,,BAO_0000219,RBL-1,12166.0,,,D,3892.0,338.0,1.0,702.0,Expert,Rattus norvegicus,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,
,8.0,,B,,,,CHEMBL619408,,BAO_0000357,,12166.0,,,H,3893.0,303.0,1.0,,Autocuration,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),
,8.0,,B,,,,CHEMBL619409,,BAO_0000219,RBL-1,12166.0,,,H,3894.0,303.0,1.0,702.0,Autocuration,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,
,8.0,,B,,,,CHEMBL619410,,BAO_0000219,RBL-1,12166.0,,,H,3895.0,9247.0,1.0,702.0,Expert,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,
,8.0,,B,,,,CHEMBL619753,,BAO_0000219,RBL-1,12166.0,,,H,3896.0,9247.0,1.0,702.0,Autocuration,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,
,8.0,,B,,,,CHEMBL619754,,BAO_0000219,RBL-1,12166.0,,,H,3897.0,137.0,1.0,702.0,Autocuration,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,
,8.0,,B,,,,CHEMBL619903,,BAO_0000357,,12166.0,,,H,3898.0,11481.0,1.0,,Expert,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,
,8.0,,B,,,,CHEMBL619904,,BAO_0000357,,12166.0,,,H,3899.0,11481.0,1.0,,Expert,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",
,8.0,,B,,,,CHEMBL619905,,BAO_0000357,,12166.0,,,H,3900.0,9029.0,1.0,,Expert,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,
,8.0,,B,,,,CHEMBL619906,,BAO_0000019,,12166.0,,,H,3901.0,1701.0,1.0,,Autocuration,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,
,8.0,,B,,,,CHEMBL619907,,BAO_0000019,,12166.0,,,H,3902.0,1701.0,1.0,,Autocuration,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,
,8.0,,B,,,,CHEMBL619908,,BAO_0000019,,12166.0,,,H,3903.0,1701.0,1.0,,Autocuration,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,
,8.0,,B,,,,CHEMBL619909,,BAO_0000019,,12166.0,,,H,3904.0,1701.0,1.0,,Autocuration,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,
,8.0,,F,,,,CHEMBL619910,,BAO_0000219,RBL-1,12166.0,,,H,3905.0,13358.0,1.0,702.0,Expert,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,
,8.0,,B,,,,CHEMBL882929,,BAO_0000219,RBL-1,12166.0,,,H,3906.0,1175.0,1.0,702.0,Expert,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,
,8.0,,B,,,,CHEMBL619911,,BAO_0000219,RBL-1,12166.0,,,H,3907.0,8797.0,1.0,702.0,Expert,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,
,8.0,,B,,,,CHEMBL619912,,BAO_0000019,,12166.0,,,H,3908.0,8797.0,1.0,,Autocuration,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,
10116.0,9.0,,B,,,,CHEMBL619913,,BAO_0000357,,12166.0,,,D,3909.0,577.0,1.0,,Expert,Rattus norvegicus,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,
,8.0,,B,,,,CHEMBL619914,,BAO_0000219,RBL-1,12166.0,,,H,3910.0,9295.0,1.0,702.0,Expert,,In vitro inhibitory activity against RBL-1 5-LO,
,8.0,,B,,,,CHEMBL619915,,BAO_0000219,RBL-1,12166.0,,,H,3911.0,9295.0,1.0,702.0,Autocuration,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),
,8.0,,B,,,,CHEMBL619916,,BAO_0000219,RBL-1,12166.0,,,H,3912.0,9295.0,1.0,702.0,Autocuration,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),
,8.0,,B,,,,CHEMBL619917,,BAO_0000218,,12166.0,,,H,3913.0,9295.0,1.0,,Autocuration,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,
,8.0,,B,,,,CHEMBL619918,,BAO_0000357,,12166.0,,,H,3914.0,9295.0,1.0,,Autocuration,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,
,8.0,,B,,,,CHEMBL619919,,BAO_0000218,,12166.0,,,H,3915.0,216.0,1.0,,Autocuration,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,
,8.0,,B,,,,CHEMBL883710,,BAO_0000219,RBL-1,12166.0,,,H,3916.0,11090.0,1.0,702.0,Autocuration,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,
,8.0,,B,,,178.0,CHEMBL619920,,BAO_0000019,,12166.0,,,H,3917.0,11090.0,1.0,,Autocuration,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,Blood
,8.0,,B,,,,CHEMBL619921,,BAO_0000357,,12166.0,,,H,3918.0,10091.0,1.0,,Expert,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,
,8.0,,F,,,,CHEMBL619922,,BAO_0000019,,12166.0,,,H,3919.0,10274.0,1.0,,Autocuration,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,
,8.0,,F,,,,CHEMBL619923,,BAO_0000219,,12166.0,,,H,3920.0,13622.0,1.0,,Autocuration,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,
,8.0,,B,,,,CHEMBL619924,,BAO_0000219,RBL-1,12166.0,,,H,3921.0,12118.0,1.0,702.0,Expert,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,
,8.0,,B,,,,CHEMBL619925,,BAO_0000357,,12166.0,,,H,3922.0,12576.0,1.0,,Expert,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,
,8.0,,B,,,,CHEMBL619926,,BAO_0000219,RBL-1,12166.0,,,H,3923.0,9546.0,1.0,702.0,Expert,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,
,8.0,,B,,,,CHEMBL619927,,BAO_0000219,RBL-1,12166.0,,,H,3924.0,9521.0,1.0,702.0,Autocuration,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,
,8.0,,B,,,,CHEMBL619928,,BAO_0000219,RBL-1,12166.0,,,H,3925.0,10626.0,1.0,702.0,Expert,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,
,8.0,,B,,,,CHEMBL619929,,BAO_0000219,RBL-1,12166.0,,,H,3926.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase,
,8.0,,B,,,,CHEMBL875089,,BAO_0000219,RBL-1,12166.0,,,H,3927.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,
,8.0,,B,,,,CHEMBL619930,,BAO_0000219,RBL-1,12166.0,,,H,3928.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,
,8.0,,B,,,,CHEMBL619931,,BAO_0000219,RBL-1,12166.0,,,H,3929.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,
,8.0,,B,,,,CHEMBL619932,,BAO_0000219,RBL-1,12166.0,,,H,3930.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,
,8.0,,B,,,,CHEMBL619933,,BAO_0000219,RBL-1,12166.0,,,H,3931.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,
,8.0,,B,,,,CHEMBL619934,,BAO_0000219,RBL-1,12166.0,,,H,3932.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,
,8.0,,B,,,,CHEMBL619935,,BAO_0000219,RBL-1,12166.0,,,H,3933.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,
,8.0,,B,,,,CHEMBL619936,,BAO_0000219,RBL-1,12166.0,,,H,3934.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,
,8.0,,B,,,,CHEMBL619937,,BAO_0000219,RBL-1,12166.0,,,H,3935.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,
,8.0,,B,,,,CHEMBL619938,,BAO_0000219,RBL-1,12166.0,,,H,3936.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,
,8.0,,B,,,,CHEMBL619939,,BAO_0000219,RBL-1,12166.0,,,H,3937.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,
,8.0,,B,,,,CHEMBL619940,,BAO_0000219,RBL-1,12166.0,,,H,3938.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,
,8.0,,B,,,,CHEMBL875090,,BAO_0000219,RBL-1,12166.0,,,H,3939.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,
,8.0,,B,,,,CHEMBL619941,,BAO_0000219,RBL-1,12166.0,,,H,3940.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,
,8.0,,B,,,,CHEMBL619942,,BAO_0000219,RBL-1,12166.0,,,H,3941.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,
,8.0,,B,,,,CHEMBL883711,,BAO_0000219,RBL-1,12166.0,,,H,3942.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,
,8.0,,B,,,,CHEMBL619943,,BAO_0000219,RBL-1,12166.0,,,H,3943.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,
,8.0,,B,,,,CHEMBL619944,,BAO_0000219,RBL-1,12166.0,,,H,3944.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,
,8.0,,B,,,,CHEMBL619945,,BAO_0000219,RBL-1,12166.0,,,H,3945.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,
,8.0,,B,,,,CHEMBL619946,,BAO_0000219,RBL-1,12166.0,,,H,3946.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,
,8.0,,B,,,,CHEMBL619947,,BAO_0000219,RBL-1,12166.0,,,H,3947.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,
,8.0,,B,,,,CHEMBL619948,,BAO_0000219,RBL-1,12166.0,,,H,3948.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,
,8.0,,B,,,,CHEMBL619949,,BAO_0000219,RBL-1,12166.0,,,H,3949.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,
,8.0,,B,,,,CHEMBL619950,,BAO_0000019,,12166.0,,,H,3950.0,9401.0,1.0,,Expert,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,
,8.0,,B,,,,CHEMBL618050,,BAO_0000019,,12166.0,,,H,3951.0,10325.0,1.0,,Autocuration,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,
,8.0,,F,,,,CHEMBL875091,,BAO_0000219,RBL-2H3,12166.0,,,H,3952.0,1556.0,1.0,663.0,Expert,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,
,8.0,,F,,,,CHEMBL618051,,BAO_0000219,RBL-2H3,12166.0,,,H,3953.0,1556.0,1.0,663.0,Expert,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,
10116.0,9.0,,B,,,,CHEMBL618052,,BAO_0000219,RBL-1,12166.0,,,D,3954.0,961.0,1.0,702.0,Expert,Rattus norvegicus,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,
,8.0,,B,,,,CHEMBL618053,,BAO_0000019,,12166.0,,,H,3955.0,6838.0,1.0,,Autocuration,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,
,8.0,,B,,,,CHEMBL618054,,BAO_0000019,,12166.0,,,H,3956.0,10325.0,1.0,,Expert,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),
10116.0,9.0,,B,,,,CHEMBL618055,,BAO_0000219,RBL-1,12166.0,,,D,3957.0,9209.0,1.0,702.0,Expert,Rattus norvegicus,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,
,8.0,,B,,,,CHEMBL618056,,BAO_0000219,RBL-1,12166.0,,,H,3958.0,11520.0,1.0,702.0,Expert,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,
,8.0,,B,,,,CHEMBL618057,,BAO_0000357,,12166.0,,,H,3959.0,137.0,1.0,,Autocuration,,In vitro inhibitory activity against 5-lipoxygenase was determined,
,8.0,,B,,,,CHEMBL618058,,BAO_0000219,RBL-1,12166.0,,,H,3960.0,4717.0,1.0,702.0,Autocuration,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,
,8.0,,B,,,,CHEMBL618059,,BAO_0000219,RBL-1,12166.0,,,H,3961.0,10636.0,1.0,702.0,Expert,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,
10116.0,9.0,,F,,,,CHEMBL618060,,BAO_0000019,,12166.0,,,D,3962.0,14312.0,1.0,,Expert,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,
,8.0,,B,,,,CHEMBL618061,,BAO_0000219,RBL-1,12166.0,,,H,3963.0,1203.0,1.0,702.0,Autocuration,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,
,8.0,,B,,,,CHEMBL618062,,BAO_0000019,,12166.0,,,H,3964.0,1203.0,1.0,,Autocuration,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,
,8.0,,B,,,,CHEMBL618063,,BAO_0000219,RBL-1,12166.0,,,H,3965.0,13622.0,1.0,702.0,Expert,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,
,8.0,,B,,,,CHEMBL618064,,BAO_0000357,,12166.0,,,H,3966.0,9793.0,1.0,,Autocuration,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,
10116.0,9.0,,B,,,,CHEMBL618065,,BAO_0000219,RBL-1,12166.0,,,D,3967.0,1143.0,1.0,702.0,Expert,Rattus norvegicus,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,
10116.0,9.0,,B,,,,CHEMBL618066,,BAO_0000219,RBL-1,12166.0,,,D,3968.0,11854.0,1.0,702.0,Expert,Rattus norvegicus,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,
,8.0,,B,,,,CHEMBL618067,,BAO_0000219,RBL-1,12166.0,,,H,3969.0,3595.0,1.0,702.0,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),
,8.0,,B,,,,CHEMBL618068,,BAO_0000219,RBL-1,12166.0,,,H,3970.0,3595.0,1.0,702.0,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),
10116.0,9.0,,B,,,,CHEMBL618069,,BAO_0000219,RBL-1,12166.0,,,D,3971.0,10501.0,1.0,702.0,Expert,Rattus norvegicus,Inhibition of 5-lipoxygenase in rat RBL-1 cells,
,8.0,,B,,,,CHEMBL618070,,BAO_0000219,RBL-1,12166.0,,,H,3972.0,12526.0,1.0,702.0,Expert,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,
,8.0,,F,,,349.0,CHEMBL618071,,BAO_0000019,,10825.0,,,H,3973.0,10034.0,1.0,,Autocuration,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,Limbic system
,8.0,,F,,,349.0,CHEMBL619247,,BAO_0000019,,10825.0,,,H,3974.0,10034.0,1.0,,Autocuration,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Limbic system
,8.0,,F,,,,CHEMBL619248,,BAO_0000019,,10825.0,,,H,3975.0,10034.0,1.0,,Autocuration,,Approximate dose levels for a half maximal reduction of 5-HTP levels,
,8.0,,B,,,10000000.0,CHEMBL619249,,BAO_0000221,,10576.0,,,H,3976.0,10046.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Hippocampus
,8.0,,B,,,10000000.0,CHEMBL619250,,BAO_0000221,,10576.0,,,H,3977.0,10046.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Hippocampus
,8.0,,B,,,,CHEMBL619251,,BAO_0000019,,10577.0,,,H,3978.0,10046.0,1.0,,Autocuration,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,
9615.0,8.0,,F,,,178.0,CHEMBL619252,,BAO_0000019,,55.0,,,H,3979.0,12079.0,1.0,,Autocuration,Canis lupus familiaris,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,Blood
,8.0,,F,,,178.0,CHEMBL619253,,BAO_0000019,,55.0,,,H,3980.0,12079.0,1.0,,Autocuration,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,Blood
,8.0,,B,,,,CHEMBL619254,,BAO_0000219,,12166.0,,,H,3981.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],
,8.0,,B,,,,CHEMBL619255,,BAO_0000219,,17140.0,,,H,3982.0,12338.0,1.0,,Expert,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,
,8.0,,B,,,,CHEMBL619256,,BAO_0000219,,17140.0,,,H,3983.0,12143.0,1.0,,Expert,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,
,8.0,,B,,,,CHEMBL875418,,BAO_0000219,,17140.0,,,H,3984.0,12143.0,1.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),
,8.0,,B,,,,CHEMBL619257,,BAO_0000219,,17140.0,,,H,3985.0,12143.0,1.0,,Expert,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,
,8.0,,B,,,,CHEMBL619258,,BAO_0000219,,17140.0,,,H,3986.0,12143.0,1.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,
,8.0,,B,,,,CHEMBL619259,,BAO_0000357,,17140.0,,,H,3987.0,12365.0,1.0,,Expert,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,
,8.0,,B,,,,CHEMBL619260,,BAO_0000357,,17140.0,,,H,3988.0,13500.0,1.0,,Expert,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,
9615.0,8.0,,F,,,178.0,CHEMBL619261,,BAO_0000218,,55.0,In vivo,,H,3989.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL619263,,BAO_0000218,,55.0,In vivo,,H,3990.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL619264,,BAO_0000218,,55.0,In vivo,,H,3991.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL619265,,BAO_0000218,,55.0,In vivo,,H,3992.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL619266,,BAO_0000218,,55.0,In vivo,,H,3993.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL619902,,BAO_0000218,,55.0,In vivo,,H,3994.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620058,,BAO_0000218,,55.0,In vivo,,H,3995.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620059,,BAO_0000218,,55.0,In vivo,,H,3996.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620060,,BAO_0000218,,55.0,In vivo,,H,3997.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620061,,BAO_0000218,,55.0,In vivo,,H,3998.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620062,,BAO_0000218,,55.0,In vivo,,H,3999.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620063,,BAO_0000218,,55.0,In vivo,,H,4000.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620064,,BAO_0000218,,55.0,In vivo,,H,4001.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620065,,BAO_0000218,,55.0,In vivo,,H,4002.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620066,,BAO_0000218,,55.0,In vivo,,H,4003.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620067,,BAO_0000218,,55.0,In vivo,,H,4004.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620068,,BAO_0000218,,55.0,In vivo,,H,4005.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620069,,BAO_0000218,,55.0,In vivo,,H,4006.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620070,,BAO_0000218,,55.0,In vivo,,H,4007.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620071,,BAO_0000218,,55.0,In vivo,,H,4008.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620072,,BAO_0000218,,55.0,In vivo,,H,4009.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620036,,BAO_0000218,,55.0,In vivo,,H,4010.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL857702,,BAO_0000218,,55.0,In vivo,,H,4011.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620037,,BAO_0000218,,55.0,In vivo,,H,4012.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620038,,BAO_0000218,,55.0,In vivo,,H,4013.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620039,,BAO_0000218,,55.0,In vivo,,H,4014.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620040,,BAO_0000218,,55.0,In vivo,,H,4015.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620041,,BAO_0000218,,55.0,In vivo,,H,4016.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620042,,BAO_0000218,,55.0,In vivo,,H,4017.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620043,,BAO_0000218,,55.0,In vivo,,H,4018.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620044,,BAO_0000218,,55.0,In vivo,,H,4019.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620045,,BAO_0000218,,55.0,In vivo,,H,4020.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620046,,BAO_0000218,,55.0,In vivo,,H,4021.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620047,,BAO_0000218,,55.0,In vivo,,H,4022.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620048,,BAO_0000218,,55.0,In vivo,,H,4023.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL857703,,BAO_0000218,,55.0,In vivo,,H,4024.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620049,,BAO_0000218,,55.0,In vivo,,H,4025.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620050,,BAO_0000218,,55.0,In vivo,,H,4026.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL620051,,BAO_0000218,,55.0,In vivo,,H,4027.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL619213,,BAO_0000218,,55.0,In vivo,,H,4028.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL619214,,BAO_0000218,,55.0,In vivo,,H,4029.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL619804,,BAO_0000218,,55.0,In vivo,,H,4030.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL619805,,BAO_0000218,,55.0,In vivo,,H,4031.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL619806,,BAO_0000218,,55.0,In vivo,,H,4032.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL619807,,BAO_0000218,,55.0,In vivo,,H,4033.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,F,,,178.0,CHEMBL619808,,BAO_0000218,,55.0,In vivo,,H,4034.0,12832.0,1.0,,Autocuration,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood
9615.0,8.0,,B,,,,CHEMBL619809,,BAO_0000218,,55.0,,,H,4035.0,3595.0,1.0,,Autocuration,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,
9615.0,8.0,,B,,,,CHEMBL619810,,BAO_0000218,,55.0,,,H,4036.0,3595.0,1.0,,Autocuration,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,
9615.0,8.0,,B,,,,CHEMBL619811,,BAO_0000218,,55.0,,,H,4037.0,3595.0,1.0,,Autocuration,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,
9615.0,8.0,,B,,,,CHEMBL620769,,BAO_0000218,,55.0,,,H,4038.0,3595.0,1.0,,Autocuration,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,
9615.0,8.0,,B,,,,CHEMBL620770,,BAO_0000218,,55.0,,,H,4039.0,3595.0,1.0,,Autocuration,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,
9615.0,8.0,,B,,,,CHEMBL620771,,BAO_0000218,,55.0,,,H,4040.0,3595.0,1.0,,Autocuration,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,
9615.0,8.0,,B,,,,CHEMBL620772,,BAO_0000218,,55.0,,,H,4041.0,3595.0,1.0,,Autocuration,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,
9615.0,8.0,,B,,,,CHEMBL620773,,BAO_0000218,,55.0,,,H,4042.0,3595.0,1.0,,Autocuration,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,
10141.0,8.0,,B,,,,CHEMBL620774,,BAO_0000357,,55.0,,,H,4043.0,9203.0,1.0,,Autocuration,Cavia porcellus,Ability to inhibit 5-lipoxygenase in guinea pig,
10141.0,8.0,,B,,,,CHEMBL620775,,BAO_0000357,,55.0,,,H,4044.0,82.0,1.0,,Expert,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),
10141.0,8.0,,B,,,,CHEMBL620776,,BAO_0000357,,55.0,,,H,4045.0,11090.0,1.0,,Autocuration,Cavia porcellus,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,
10141.0,8.0,,B,,,178.0,CHEMBL620777,,BAO_0000218,,55.0,,,H,4046.0,12832.0,1.0,,Autocuration,Cavia porcellus,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",Blood
10141.0,8.0,,B,,,,CHEMBL620778,,BAO_0000357,,55.0,,,H,4047.0,1065.0,1.0,,Autocuration,Cavia porcellus,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,
10141.0,8.0,,B,,,,CHEMBL620779,,BAO_0000357,,55.0,,,H,4048.0,1065.0,1.0,,Autocuration,Cavia porcellus,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,
10141.0,8.0,,B,,,,CHEMBL621500,,BAO_0000019,,55.0,,,H,4049.0,12832.0,1.0,,Expert,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,
10141.0,8.0,,B,,,,CHEMBL621501,,BAO_0000019,,55.0,,,H,4050.0,12832.0,1.0,,Expert,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,
10141.0,8.0,,B,,,,CHEMBL618098,,BAO_0000019,,55.0,,,H,4051.0,12832.0,1.0,,Autocuration,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,
10141.0,8.0,,B,,,,CHEMBL618099,,BAO_0000019,,55.0,,,H,4052.0,10504.0,1.0,,Autocuration,Cavia porcellus,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,
10141.0,8.0,,B,,,,CHEMBL618100,,BAO_0000357,,55.0,,,H,4053.0,7788.0,1.0,,Autocuration,Cavia porcellus,Inhibitory activity against 5-lipoxygenase,
10141.0,8.0,,B,,,,CHEMBL618101,,BAO_0000357,,55.0,,,H,4054.0,10001.0,1.0,,Autocuration,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,
10141.0,8.0,,B,,,,CHEMBL618102,,BAO_0000357,,55.0,,,H,4055.0,10193.0,1.0,,Autocuration,Cavia porcellus,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,
10141.0,8.0,,B,,,,CHEMBL618103,,BAO_0000357,,55.0,,,H,4056.0,13243.0,1.0,,Autocuration,Cavia porcellus,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,
10141.0,8.0,,B,,,,CHEMBL618104,,BAO_0000357,,55.0,,,H,4057.0,13243.0,1.0,,Autocuration,Cavia porcellus,Inhibitory activity uM,
10141.0,8.0,,B,,,,CHEMBL883712,,BAO_0000219,,55.0,,,H,4058.0,969.0,1.0,,Autocuration,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,
10141.0,8.0,,B,,,,CHEMBL618105,,BAO_0000357,,55.0,,,H,4059.0,10001.0,1.0,,Autocuration,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at 10 uM,
10141.0,8.0,,B,,,,CHEMBL618106,,BAO_0000357,,55.0,,,H,4060.0,7788.0,1.0,,Autocuration,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,
10141.0,8.0,,B,,,,CHEMBL618107,,BAO_0000357,,55.0,,,H,4061.0,10001.0,1.0,,Autocuration,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,
10141.0,8.0,,B,,,,CHEMBL618108,,BAO_0000357,,55.0,,,H,4062.0,10193.0,1.0,,Autocuration,Cavia porcellus,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,
10141.0,8.0,,B,,,,CHEMBL618109,,BAO_0000357,,55.0,,,H,4063.0,13243.0,1.0,,Autocuration,Cavia porcellus,Inhibitory activity uM,
10141.0,8.0,,B,,,,CHEMBL618110,,BAO_0000357,,55.0,,,H,4064.0,13243.0,1.0,,Autocuration,Cavia porcellus,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,
10141.0,8.0,,B,,,,CHEMBL618111,,BAO_0000357,,55.0,,,H,4065.0,13243.0,1.0,,Expert,Cavia porcellus,Inhibitory activity uM,
10141.0,8.0,,F,,,,CHEMBL618112,,BAO_0000019,,55.0,,,H,4066.0,13243.0,1.0,,Autocuration,Cavia porcellus,Inhibitory activity uM,
10141.0,8.0,,B,,,,CHEMBL618113,,BAO_0000019,,55.0,,,H,4067.0,10504.0,1.0,,Autocuration,Cavia porcellus,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,
10141.0,8.0,,B,,,,CHEMBL618114,,BAO_0000357,,55.0,,,H,4068.0,7788.0,1.0,,Autocuration,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,
10141.0,8.0,,F,,,2116.0,CHEMBL620871,,BAO_0000221,,55.0,,,H,4069.0,10546.0,1.0,,Expert,Cavia porcellus,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,Ileum
,8.0,,B,,,,CHEMBL620872,,BAO_0000357,,55.0,,,H,4070.0,13183.0,1.0,,Autocuration,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),
,8.0,,B,,,,CHEMBL620873,,BAO_0000357,,55.0,,,H,4071.0,13183.0,1.0,,Autocuration,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),
,8.0,,B,,,,CHEMBL620874,,BAO_0000357,,55.0,,,H,4072.0,2578.0,1.0,,Autocuration,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),
,8.0,,B,,,,CHEMBL620875,,BAO_0000357,,55.0,,,H,4073.0,12780.0,1.0,,Expert,,In vitro inhibition of human 5-Lipoxygenase.,
10116.0,0.0,,B,,,2107.0,CHEMBL620876,,BAO_0000251,,22226.0,,Microsomes,U,4074.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620877,,BAO_0000251,,22226.0,,Microsomes,U,4075.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL857854,,BAO_0000251,,22226.0,,Microsomes,U,4076.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620878,,BAO_0000251,,22226.0,,Microsomes,U,4077.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620879,,BAO_0000251,,22226.0,,Microsomes,U,4078.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620880,,BAO_0000251,,22226.0,,Microsomes,U,4079.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620881,,BAO_0000251,,22226.0,,Microsomes,U,4080.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620882,,BAO_0000251,,22226.0,,Microsomes,U,4081.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620883,,BAO_0000251,,22226.0,,Microsomes,U,4082.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620884,,BAO_0000251,,22226.0,,Microsomes,U,4083.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620885,,BAO_0000251,,22226.0,,Microsomes,U,4084.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620886,,BAO_0000251,,22226.0,,Microsomes,U,4085.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620887,,BAO_0000251,,22226.0,,Microsomes,U,4086.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618039,,BAO_0000251,,22226.0,,Microsomes,U,4087.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618040,,BAO_0000251,,22226.0,,Microsomes,U,4088.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618041,,BAO_0000251,,22226.0,,Microsomes,U,4089.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618216,,BAO_0000251,,22226.0,,Microsomes,U,4090.0,7411.0,1.0,,Autocuration,Rattus norvegicus,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618217,,BAO_0000251,,22226.0,,Microsomes,U,4091.0,7411.0,1.0,,Autocuration,Rattus norvegicus,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618218,,BAO_0000251,,22226.0,,Microsomes,U,4092.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618219,,BAO_0000251,,22226.0,,Microsomes,U,4093.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618220,,BAO_0000251,,22226.0,,Microsomes,U,4094.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618221,,BAO_0000251,,22226.0,,Microsomes,U,4095.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618222,,BAO_0000251,,22226.0,,Microsomes,U,4096.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618223,,BAO_0000251,,22226.0,,Microsomes,U,4097.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618224,,BAO_0000251,,22226.0,,Microsomes,U,4098.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618225,,BAO_0000251,,22226.0,,Microsomes,U,4099.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618226,,BAO_0000251,,22226.0,,Microsomes,U,4100.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618227,,BAO_0000251,,22226.0,,Microsomes,U,4101.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618228,,BAO_0000251,,22226.0,,Microsomes,U,4102.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618229,,BAO_0000251,,22226.0,,Microsomes,U,4103.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618230,,BAO_0000251,,22226.0,,Microsomes,U,4104.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618231,,BAO_0000251,,22226.0,,Microsomes,U,4105.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618232,,BAO_0000251,,22226.0,,Microsomes,U,4106.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618233,,BAO_0000251,,22226.0,,Microsomes,U,4107.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618234,,BAO_0000251,,22226.0,,Microsomes,U,4108.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618235,,BAO_0000251,,22226.0,,Microsomes,U,4109.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618115,,BAO_0000251,,22226.0,,Microsomes,U,4110.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618116,,BAO_0000251,,22226.0,,Microsomes,U,4111.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL618117,,BAO_0000251,,22226.0,,Microsomes,U,4112.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL619968,,BAO_0000251,,22226.0,,Microsomes,U,4113.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL619969,,BAO_0000251,,22226.0,,Microsomes,U,4114.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL619970,,BAO_0000251,,22226.0,,Microsomes,U,4115.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL619971,,BAO_0000251,,22226.0,,Microsomes,U,4116.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL619972,,BAO_0000251,,22226.0,,Microsomes,U,4117.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL619973,,BAO_0000251,,22226.0,,Microsomes,U,4118.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL619974,,BAO_0000251,,22226.0,,Microsomes,U,4119.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL619975,,BAO_0000251,,22226.0,,Microsomes,U,4120.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Liver
10116.0,0.0,,B,,,,CHEMBL619976,,BAO_0000251,,22226.0,,Microsomes,U,4121.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,
10116.0,0.0,,B,,,2107.0,CHEMBL619977,,BAO_0000251,,22226.0,,Microsomes,U,4122.0,7411.0,1.0,,Autocuration,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Liver
10116.0,0.0,,B,,,2107.0,CHEMBL619978,,BAO_0000251,,22226.0,,Microsomes,U,4123.0,7411.0,1.0,,Autocuration,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Liver
10116.0,0.0,,B,,,2107.0,CHEMBL619979,,BAO_0000251,,22226.0,,Microsomes,U,4124.0,7411.0,1.0,,Autocuration,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Liver
10116.0,0.0,,B,,,2107.0,CHEMBL619980,,BAO_0000251,,22226.0,,Microsomes,U,4125.0,7411.0,1.0,,Autocuration,Rattus norvegicus,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Liver
10116.0,0.0,,B,,,2107.0,CHEMBL619981,,BAO_0000251,,22226.0,,Microsomes,U,4126.0,7411.0,1.0,,Autocuration,Rattus norvegicus,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Liver
9606.0,1.0,,F,,,,CHEMBL619982,,BAO_0000219,RPMI-8226,80433.0,,,N,4127.0,10797.0,1.0,741.0,Intermediate,Homo sapiens,In vitro inhibition of 7226/S myeloma cancer cell line,
9606.0,1.0,,F,,,,CHEMBL619983,,BAO_0000219,BEL-7404 tumor cell line,80698.0,,,N,4128.0,6881.0,1.0,993.0,Intermediate,Homo sapiens,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),
9606.0,1.0,,F,,,,CHEMBL620031,,BAO_0000219,786-0,80640.0,,,N,4129.0,3838.0,1.0,391.0,Intermediate,Homo sapiens,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,
9606.0,1.0,,F,,,,CHEMBL620032,,BAO_0000219,786-0,80640.0,,,N,4130.0,3838.0,1.0,391.0,Intermediate,Homo sapiens,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,
10029.0,1.0,,F,,,,CHEMBL620033,,BAO_0000219,V79,81264.0,,,N,4131.0,12981.0,1.0,505.0,Expert,Cricetulus griseus,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,
10029.0,1.0,,F,,,,CHEMBL620034,,BAO_0000219,V79,81264.0,,,N,4132.0,12981.0,1.0,505.0,Expert,Cricetulus griseus,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,
10116.0,1.0,,F,,,,CHEMBL620035,,BAO_0000219,7800C1 cell line,80635.0,,,N,4133.0,7653.0,1.0,1119.0,Intermediate,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,
10116.0,1.0,,F,,,,CHEMBL618318,,BAO_0000219,7800C1 cell line,80635.0,,,N,4134.0,7653.0,1.0,1119.0,Intermediate,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,
10116.0,1.0,,F,,,,CHEMBL618319,,BAO_0000219,7800C1 cell line,80635.0,,,N,4135.0,7653.0,1.0,1119.0,Intermediate,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,
10116.0,1.0,,F,,,,CHEMBL618320,,BAO_0000219,7800C1 cell line,80635.0,,,N,4136.0,7653.0,1.0,1119.0,Intermediate,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,
10116.0,1.0,,F,,,,CHEMBL618321,,BAO_0000219,7800C1 cell line,80635.0,,,N,4137.0,7653.0,1.0,1119.0,Intermediate,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,
10116.0,1.0,,F,,,,CHEMBL883118,,BAO_0000219,7800C1 cell line,80635.0,,,N,4138.0,7653.0,1.0,1119.0,Intermediate,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,
9606.0,1.0,,F,,,,CHEMBL883795,,BAO_0000219,786-0,80640.0,,,N,4139.0,17229.0,1.0,391.0,Intermediate,Homo sapiens,In vitro antitumor activity against renal 786-0 tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL618322,,BAO_0000219,786-0,80640.0,,,N,4140.0,12858.0,1.0,391.0,Intermediate,Homo sapiens,Cytotoxic activity against 786-0 Renal cancer cell line,
9606.0,1.0,,F,,,,CHEMBL618323,,BAO_0000219,786-0,80640.0,,,N,4141.0,16325.0,1.0,391.0,Intermediate,Homo sapiens,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,
9606.0,1.0,,F,,,,CHEMBL618324,,BAO_0000219,786-0,80640.0,,,N,4142.0,16325.0,1.0,391.0,Intermediate,Homo sapiens,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,
9606.0,1.0,,F,,,,CHEMBL618325,,BAO_0000219,786-0,80640.0,,,N,4143.0,5858.0,1.0,391.0,Intermediate,Homo sapiens,In vitro antitumor activity against human renal 786-0 cell line,
9606.0,1.0,,F,,,,CHEMBL875416,,BAO_0000219,786-0,80640.0,,,N,4144.0,16325.0,1.0,391.0,Intermediate,Homo sapiens,Inhibition of Renal cancer in 786-0 cancer cell lines,
9606.0,1.0,,F,,,,CHEMBL618326,,BAO_0000219,786-0,80640.0,,,N,4145.0,14696.0,1.0,391.0,Intermediate,Homo sapiens,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,
9606.0,1.0,,F,,,,CHEMBL618327,,BAO_0000219,786-0,80640.0,,,N,4146.0,3786.0,1.0,391.0,Intermediate,Homo sapiens,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,
9606.0,1.0,,F,,,,CHEMBL619215,,BAO_0000219,786-0,80640.0,,,N,4147.0,14696.0,1.0,391.0,Intermediate,Homo sapiens,inhibition of the growth of renal cancer(786-0) cell line,
9606.0,1.0,,F,,,,CHEMBL619216,,BAO_0000219,786-0,80640.0,,,N,4148.0,14769.0,1.0,391.0,Intermediate,Homo sapiens,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),
9606.0,1.0,,F,,,,CHEMBL619217,,BAO_0000219,786-0,80640.0,,,N,4149.0,15354.0,1.0,391.0,Intermediate,Homo sapiens,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,
9606.0,1.0,,F,,,,CHEMBL619218,,BAO_0000219,786-0,80640.0,,,N,4150.0,14255.0,1.0,391.0,Intermediate,Homo sapiens,The IC50 value was measured on 786-0 cell line in ovarian tumor,
9606.0,1.0,,F,,,,CHEMBL619219,,BAO_0000219,786-0,80640.0,,,N,4151.0,14255.0,1.0,391.0,Intermediate,Homo sapiens,The IC50 value was measured on 786-0 cell line in ovarian tumor t,
9606.0,1.0,,F,,,,CHEMBL619220,,BAO_0000219,786-0,80640.0,,,N,4152.0,14255.0,1.0,391.0,Intermediate,Homo sapiens,The IC50 value was measured on 786-0 cell line in renal tumor type.,
9606.0,1.0,,F,,,,CHEMBL619221,,BAO_0000219,786-0,80640.0,,,N,4153.0,14696.0,1.0,391.0,Intermediate,Homo sapiens,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,
9606.0,1.0,,F,,,,CHEMBL619222,,BAO_0000219,786-0,80640.0,,,N,4154.0,12016.0,1.0,391.0,Intermediate,Homo sapiens,Tested for cytotoxic activity against renal cancer 786-0 cell line,
9606.0,1.0,,F,,,,CHEMBL857454,,BAO_0000219,786-0,80640.0,,,N,4155.0,2597.0,1.0,391.0,Intermediate,Homo sapiens,Compound was tested for growth inhibitory activity against 786-0 cell line,
,8.0,,B,,,,CHEMBL619223,,BAO_0000219,RBL-1,12166.0,,,H,4156.0,12526.0,1.0,702.0,Autocuration,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,
,8.0,,B,,,,CHEMBL619224,,BAO_0000219,RBL-1,12166.0,,,H,4157.0,12526.0,1.0,702.0,Autocuration,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,
,8.0,,B,,,,CHEMBL619225,,BAO_0000019,,12166.0,,,H,4158.0,14799.0,1.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,
,8.0,,B,,,,CHEMBL619226,,BAO_0000219,RBL-1,12166.0,,,H,4159.0,3595.0,1.0,702.0,Expert,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),
,8.0,,B,,,,CHEMBL619227,,BAO_0000219,RBL-1,12166.0,,,H,4160.0,3595.0,1.0,702.0,Expert,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),
,8.0,,B,,,,CHEMBL619228,,BAO_0000357,,12166.0,,,H,4161.0,12767.0,1.0,,Autocuration,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,
,8.0,,B,,,,CHEMBL619229,,BAO_0000219,,12166.0,,,H,4162.0,10997.0,1.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,
,8.0,,B,,,,CHEMBL619230,,BAO_0000219,RBL-1,12166.0,,,H,4163.0,11388.0,1.0,702.0,Autocuration,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,
,8.0,,B,,,,CHEMBL619231,,BAO_0000357,,12166.0,,,H,4164.0,167.0,1.0,,Autocuration,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,
,8.0,,B,,,,CHEMBL619232,,BAO_0000357,,12166.0,,,H,4165.0,167.0,1.0,,Autocuration,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",
,8.0,,B,,,,CHEMBL619233,,BAO_0000357,,12166.0,,,H,4166.0,13744.0,1.0,,Expert,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,
,8.0,,B,,,,CHEMBL619234,,BAO_0000357,,12166.0,,,H,4167.0,1630.0,1.0,,Autocuration,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,
,8.0,,B,,,,CHEMBL619235,,BAO_0000357,,12166.0,,,H,4168.0,1630.0,1.0,,Autocuration,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),
10116.0,9.0,,B,,,,CHEMBL619236,,BAO_0000019,,12166.0,,,D,4169.0,969.0,1.0,,Expert,Rattus norvegicus,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",
,8.0,,B,,,,CHEMBL619237,,BAO_0000219,RBL-1,12166.0,,,H,4170.0,13621.0,1.0,702.0,Autocuration,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,
,8.0,,B,,,,CHEMBL619238,,BAO_0000357,,12166.0,,,H,4171.0,10089.0,1.0,,Autocuration,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,
,8.0,,B,,,,CHEMBL619239,,BAO_0000357,,12166.0,,,H,4172.0,10193.0,1.0,,Expert,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,
,8.0,,B,,,,CHEMBL619240,,BAO_0000357,,12166.0,,,H,4173.0,11966.0,1.0,,Autocuration,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,
,8.0,,B,,,,CHEMBL875417,,BAO_0000019,,12166.0,,,H,4174.0,12251.0,1.0,,Autocuration,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,
,8.0,,B,,,,CHEMBL619241,,BAO_0000219,RBL-1,12166.0,,,H,4175.0,211.0,1.0,702.0,Autocuration,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),
,8.0,,F,,,,CHEMBL619242,,BAO_0000019,,12166.0,,,H,4176.0,12251.0,1.0,,Expert,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,
,8.0,,B,,,,CHEMBL883796,,BAO_0000219,RBL-1,12166.0,,,H,4177.0,12495.0,1.0,702.0,Autocuration,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,
,8.0,,B,,,,CHEMBL619243,,BAO_0000357,,12166.0,,,H,4178.0,414.0,1.0,,Autocuration,,Tested for its inhibitory activity against 5-lipoxygenase,
,8.0,,B,,,,CHEMBL619244,,BAO_0000357,,12166.0,,,H,4179.0,414.0,1.0,,Autocuration,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,
,8.0,,B,,,,CHEMBL619245,,BAO_0000019,,12166.0,,,H,4180.0,10325.0,1.0,,Expert,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",
,8.0,,B,,,,CHEMBL619246,,BAO_0000019,,12166.0,,,H,4181.0,11966.0,1.0,,Expert,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,
,8.0,,B,,,,CHEMBL619984,,BAO_0000219,RBL-1,12166.0,,,H,4182.0,165.0,1.0,702.0,Expert,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,
,8.0,,B,,,,CHEMBL619985,,BAO_0000219,RBL-1,12166.0,,,H,4183.0,165.0,1.0,702.0,Autocuration,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,
,8.0,,B,,,,CHEMBL619986,,BAO_0000219,RBL-1,12166.0,,,H,4184.0,165.0,1.0,702.0,Autocuration,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,
,8.0,,B,,,,CHEMBL619987,,BAO_0000219,RBL-1,12166.0,,,H,4185.0,165.0,1.0,702.0,Expert,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,
,8.0,,B,,,,CHEMBL619988,,BAO_0000218,,12166.0,,,H,4186.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,
,8.0,,B,,,,CHEMBL619989,,BAO_0000219,RBL-1,12166.0,,,H,4187.0,11311.0,1.0,702.0,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,
,8.0,,B,,,,CHEMBL619990,,BAO_0000219,RBL-1,12166.0,,,H,4188.0,11311.0,1.0,702.0,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,
,8.0,,B,,,,CHEMBL619991,,BAO_0000219,,12166.0,,,H,4189.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],
,8.0,,B,,,,CHEMBL619992,,BAO_0000219,,12166.0,,,H,4190.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),
,8.0,,B,,,,CHEMBL619993,,BAO_0000218,,12166.0,In vivo,,H,4191.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),
,8.0,,F,,,,CHEMBL619994,,BAO_0000219,RBL-2H3,12166.0,,,H,4192.0,11311.0,1.0,663.0,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,
,8.0,,F,,,,CHEMBL619995,,BAO_0000219,RBL-2H3,12166.0,,,H,4193.0,11311.0,1.0,663.0,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,
,8.0,,B,,,,CHEMBL619996,,BAO_0000019,,12166.0,,,H,4194.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],
,8.0,,B,,,,CHEMBL619997,,BAO_0000019,,12166.0,,,H,4195.0,11732.0,1.0,,Autocuration,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,
,8.0,,B,,,,CHEMBL619998,,BAO_0000019,,12166.0,,,H,4196.0,11732.0,1.0,,Expert,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,
,8.0,,B,,,,CHEMBL619999,,BAO_0000019,,12166.0,,,H,4197.0,11087.0,1.0,,Expert,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,
,8.0,,B,,,,CHEMBL620000,,BAO_0000019,,12166.0,,,H,4198.0,11087.0,1.0,,Autocuration,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,
,8.0,,B,,,,CHEMBL620001,,BAO_0000219,RBL-1,12166.0,,,H,4199.0,11087.0,1.0,702.0,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,
10116.0,9.0,,B,,,,CHEMBL620002,,BAO_0000357,,12166.0,,,D,4200.0,11087.0,1.0,,Expert,Rattus norvegicus,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,
,8.0,,B,,,,CHEMBL620003,,BAO_0000219,RBL-1,12166.0,,,H,4201.0,496.0,1.0,702.0,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,
,8.0,,F,,,,CHEMBL620004,,BAO_0000219,RBL-1,12166.0,,,H,4202.0,13986.0,1.0,702.0,Expert,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,
,8.0,,B,,,,CHEMBL874063,,BAO_0000357,,12166.0,,,H,4203.0,11520.0,1.0,,Autocuration,,Compound was evaluated for the inhibition of 5-lipoxygenase,
,8.0,,B,,,,CHEMBL620005,,BAO_0000219,RBL-1,12166.0,,,H,4204.0,10293.0,1.0,702.0,Autocuration,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,
,8.0,,B,,,,CHEMBL620006,,BAO_0000219,RBL-1,12166.0,,,H,4205.0,303.0,1.0,702.0,Autocuration,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,
,8.0,,B,,,,CHEMBL620007,,BAO_0000219,RBL-1,12166.0,,,H,4206.0,303.0,1.0,702.0,Autocuration,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,
,8.0,,B,,,,CHEMBL620008,,BAO_0000219,RBL-1,12166.0,,,H,4207.0,9247.0,1.0,702.0,Autocuration,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,
10116.0,9.0,,B,,,,CHEMBL620009,,BAO_0000219,RBL-1,12166.0,,,D,4208.0,9247.0,1.0,702.0,Expert,Rattus norvegicus,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,
,8.0,,B,,,,CHEMBL620010,,BAO_0000219,RBL-1,12166.0,,,H,4209.0,9247.0,1.0,702.0,Autocuration,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,
,8.0,,B,,,,CHEMBL620011,,BAO_0000219,RBL-1,12166.0,,,H,4210.0,9247.0,1.0,702.0,Autocuration,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,
,8.0,,B,,,,CHEMBL620677,,BAO_0000219,RBL-1,12166.0,,,H,4211.0,9247.0,1.0,702.0,Autocuration,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,
,8.0,,B,,,,CHEMBL620678,,BAO_0000219,RBL-1,12166.0,,,H,4212.0,9247.0,1.0,702.0,Autocuration,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,
,8.0,,B,,,,CHEMBL620679,,BAO_0000219,RBL-1,12166.0,,,H,4213.0,9247.0,1.0,702.0,Autocuration,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,
,8.0,,B,,,,CHEMBL620680,,BAO_0000219,RBL-1,12166.0,,,H,4214.0,9247.0,1.0,702.0,Autocuration,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,
10116.0,9.0,,B,,,,CHEMBL620838,,BAO_0000357,,12166.0,,,D,4215.0,11481.0,1.0,,Expert,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase at 10 uM,
,8.0,,B,,,,CHEMBL620839,,BAO_0000357,,12166.0,,,H,4216.0,105.0,1.0,,Autocuration,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,
,8.0,,B,,,,CHEMBL620840,,BAO_0000357,,12166.0,,,H,4217.0,9029.0,1.0,,Expert,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,
,8.0,,B,,,,CHEMBL620841,,BAO_0000219,RBL-1,12166.0,,,H,4218.0,1175.0,1.0,702.0,Expert,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,
,8.0,,B,,,,CHEMBL620842,,BAO_0000219,RBL-1,12166.0,,,H,4219.0,12118.0,1.0,702.0,Autocuration,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,
,8.0,,B,,,,CHEMBL620843,,BAO_0000219,RBL-1,12166.0,,,H,4220.0,12118.0,1.0,702.0,Autocuration,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,
,8.0,,B,,,,CHEMBL620844,,BAO_0000219,RBL-1,12166.0,,,H,4221.0,12118.0,1.0,702.0,Autocuration,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,
,8.0,,B,,,,CHEMBL620845,,BAO_0000219,RBL-1,12166.0,,,H,4222.0,9225.0,1.0,702.0,Autocuration,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,
,8.0,,B,,,,CHEMBL620846,,BAO_0000019,,12166.0,,,H,4223.0,9401.0,1.0,,Autocuration,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,
,8.0,,B,,,,CHEMBL873951,,BAO_0000357,,12166.0,,,H,4224.0,137.0,1.0,,Autocuration,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,
,8.0,,B,,,,CHEMBL620847,,BAO_0000357,,12166.0,,,H,4225.0,137.0,1.0,,Autocuration,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,
,8.0,,B,,,,CHEMBL620848,,BAO_0000219,RBL-1,12166.0,,,H,4226.0,4717.0,1.0,702.0,Autocuration,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,
,8.0,,B,,,,CHEMBL620849,,BAO_0000219,RBL-1,12166.0,,,H,4227.0,3595.0,1.0,702.0,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,
,8.0,,B,,,,CHEMBL620850,,BAO_0000219,RBL-1,12166.0,,,H,4228.0,10501.0,1.0,702.0,Autocuration,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,
,8.0,,B,,,,CHEMBL620851,,BAO_0000219,RBL-1,12166.0,,,H,4229.0,10501.0,1.0,702.0,Autocuration,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,
,8.0,,B,,,,CHEMBL620852,,BAO_0000219,RBL-1,12166.0,,,H,4230.0,10501.0,1.0,702.0,Autocuration,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,
,8.0,,B,,,,CHEMBL875098,,BAO_0000219,RBL-1,12166.0,,,H,4231.0,12526.0,1.0,702.0,Autocuration,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,
10116.0,9.0,,B,,,,CHEMBL620853,,BAO_0000219,RBL-1,12166.0,,,D,4232.0,14799.0,1.0,702.0,Expert,Rattus norvegicus,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,
,8.0,,B,,,,CHEMBL620854,,BAO_0000019,,12166.0,,,H,4233.0,14799.0,1.0,,Autocuration,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,
,8.0,,B,,,,CHEMBL620855,,BAO_0000219,RBL-1,12166.0,,,H,4234.0,3595.0,1.0,702.0,Autocuration,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,
,8.0,,B,,,,CHEMBL839884,,BAO_0000219,RBL-1,12166.0,,,H,4235.0,3595.0,1.0,702.0,Expert,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,
,8.0,,B,,,,CHEMBL620856,,BAO_0000219,RBL-1,12166.0,,,H,4236.0,12526.0,1.0,702.0,Autocuration,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,
,8.0,,B,,,,CHEMBL620857,,BAO_0000219,RBL-1,12166.0,,,H,4237.0,12526.0,1.0,702.0,Autocuration,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,
,8.0,,B,,,,CHEMBL620858,,BAO_0000019,,12166.0,,,H,4238.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,
,8.0,,B,,,,CHEMBL620859,,BAO_0000019,,12166.0,,,H,4239.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,
,8.0,,B,,,,CHEMBL620860,,BAO_0000019,,12166.0,,,H,4240.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,
,8.0,,B,,,,CHEMBL620861,,BAO_0000019,,12166.0,,,H,4241.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,
,8.0,,B,,,,CHEMBL620862,,BAO_0000357,,12166.0,,,H,4242.0,9138.0,1.0,,Expert,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),
,8.0,,B,,,,CHEMBL620863,,BAO_0000357,,12166.0,,,H,4243.0,9138.0,1.0,,Autocuration,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,
,8.0,,B,,,,CHEMBL620864,,BAO_0000019,,12166.0,,,H,4244.0,11966.0,1.0,,Autocuration,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,
,8.0,,B,,,,CHEMBL620865,,BAO_0000219,RBL-1,12166.0,,,H,4245.0,165.0,1.0,702.0,Autocuration,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,
,8.0,,B,,,,CHEMBL620866,,BAO_0000219,RBL-1,12166.0,,,H,4246.0,165.0,1.0,702.0,Autocuration,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,
,8.0,,B,,,,CHEMBL620867,,BAO_0000219,RBL-2H3,12166.0,,,H,4247.0,11311.0,1.0,663.0,Autocuration,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,
,8.0,,B,,,,CHEMBL620868,,BAO_0000219,RBL-2H3,12166.0,,,H,4248.0,11311.0,1.0,663.0,Autocuration,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,
,8.0,,F,,,,CHEMBL620869,,BAO_0000219,RBL-2H3,12166.0,,,H,4249.0,11311.0,1.0,663.0,Autocuration,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,
,8.0,,F,,,,CHEMBL873952,,BAO_0000019,,12166.0,,,H,4250.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,
,8.0,,B,,,,CHEMBL875099,,BAO_0000357,,12166.0,,,H,4251.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibition of isolated 5-lipoxygenase,
,8.0,,F,,,,CHEMBL620870,,BAO_0000219,RBL-2H3,12166.0,,,H,4252.0,11311.0,1.0,663.0,Autocuration,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,
,8.0,,B,,,,CHEMBL618261,,BAO_0000019,,12166.0,,,H,4253.0,11087.0,1.0,,Autocuration,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,
,8.0,,B,,,,CHEMBL618262,,BAO_0000019,,12166.0,,,H,4254.0,11087.0,1.0,,Autocuration,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,
,8.0,,B,,,,CHEMBL619428,,BAO_0000019,,12166.0,,,H,4255.0,11087.0,1.0,,Autocuration,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,
,8.0,,B,,,,CHEMBL619429,,BAO_0000019,,12166.0,,,H,4256.0,11087.0,1.0,,Autocuration,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,
,8.0,,B,,,,CHEMBL619430,,BAO_0000019,,12166.0,,,H,4257.0,11087.0,1.0,,Autocuration,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,
,8.0,,B,,,,CHEMBL620017,,BAO_0000219,RBL-1,12166.0,,,H,4258.0,496.0,1.0,702.0,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,
,8.0,,B,,,,CHEMBL620018,,BAO_0000219,RBL-1,12166.0,,,H,4259.0,496.0,1.0,702.0,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,
,8.0,,F,,,,CHEMBL620019,,BAO_0000219,RBL-1,12166.0,,,H,4260.0,13986.0,1.0,702.0,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,
,8.0,,F,,,,CHEMBL620020,,BAO_0000219,RBL-1,12166.0,,,H,4261.0,13986.0,1.0,702.0,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,
,8.0,,F,,,,CHEMBL620021,,BAO_0000219,RBL-1,12166.0,,,H,4262.0,13986.0,1.0,702.0,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,
,8.0,,F,,,,CHEMBL620022,,BAO_0000219,RBL-1,12166.0,,,H,4263.0,13986.0,1.0,702.0,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,
,8.0,,F,,,,CHEMBL620023,,BAO_0000219,RBL-1,12166.0,,,H,4264.0,13986.0,1.0,702.0,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,
,8.0,,F,,,,CHEMBL620024,,BAO_0000219,RBL-1,12166.0,,,H,4265.0,13986.0,1.0,702.0,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,
,8.0,,F,,,,CHEMBL620025,,BAO_0000219,RBL-1,12166.0,,,H,4266.0,13986.0,1.0,702.0,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,
,8.0,,F,,,,CHEMBL620026,,BAO_0000219,RBL-1,12166.0,,,H,4267.0,13986.0,1.0,702.0,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,
,8.0,,F,,,,CHEMBL620027,,BAO_0000219,RBL-1,12166.0,,,H,4268.0,13986.0,1.0,702.0,Autocuration,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,
10116.0,9.0,,F,,,,CHEMBL620028,,BAO_0000019,,12166.0,,,D,4269.0,13986.0,1.0,,Expert,Rattus norvegicus,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,
,8.0,,B,,,,CHEMBL620029,,BAO_0000357,,12166.0,,,H,4270.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,
,8.0,,B,,,,CHEMBL620030,,BAO_0000357,,12166.0,,,H,4271.0,9295.0,1.0,,Autocuration,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,
,8.0,,B,,,,CHEMBL875415,,BAO_0000219,RBL-1,12166.0,,,H,4272.0,4717.0,1.0,702.0,Autocuration,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,
,8.0,,B,,,,CHEMBL618256,,BAO_0000219,RBL-1,12166.0,,,H,4273.0,4717.0,1.0,702.0,Autocuration,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,
,8.0,,B,,,,CHEMBL618257,,BAO_0000219,RBL-1,12166.0,,,H,4274.0,11854.0,1.0,702.0,Autocuration,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,
,8.0,,B,,,,CHEMBL618258,,BAO_0000219,RBL-1,12166.0,,,H,4275.0,11854.0,1.0,702.0,Autocuration,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,
,8.0,,B,,,,CHEMBL618259,,BAO_0000219,RBL-1,12166.0,,,H,4276.0,11854.0,1.0,702.0,Autocuration,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,
,8.0,,B,,,,CHEMBL618260,,BAO_0000019,,12166.0,,,H,4277.0,10193.0,1.0,,Autocuration,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,
,8.0,,B,,,,CHEMBL618215,,BAO_0000219,RBL-1,12166.0,,,H,4278.0,9295.0,1.0,702.0,Autocuration,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,
,8.0,,B,,,,CHEMBL618390,,BAO_0000219,RBL-1,12166.0,,,H,4279.0,9295.0,1.0,702.0,Autocuration,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,
,8.0,,B,,,,CHEMBL618391,,BAO_0000219,RBL-1,12166.0,,,H,4280.0,9295.0,1.0,702.0,Autocuration,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,
,8.0,,B,,,,CHEMBL618392,,BAO_0000219,RBL-1,12166.0,,,H,4281.0,9295.0,1.0,702.0,Autocuration,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,
,8.0,,B,,,,CHEMBL618393,,BAO_0000219,RBL-1,12166.0,,,H,4282.0,165.0,1.0,702.0,Autocuration,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,
,8.0,,B,,,,CHEMBL618394,,BAO_0000219,,12166.0,,,H,4283.0,11311.0,1.0,,Autocuration,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,
9606.0,8.0,,B,,,,CHEMBL618395,,BAO_0000219,RBL-1,12166.0,,,H,4284.0,10489.0,1.0,702.0,Expert,Homo sapiens,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),
10116.0,9.0,,B,,,,CHEMBL618396,,BAO_0000219,RBL-1,12166.0,,,D,4285.0,10489.0,1.0,702.0,Expert,Rattus norvegicus,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),
10116.0,9.0,,B,,,,CHEMBL858253,,BAO_0000219,RBL-1,12166.0,,,D,4286.0,10489.0,1.0,702.0,Expert,Rattus norvegicus,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),
10116.0,9.0,,B,,,,CHEMBL618397,,BAO_0000019,,12166.0,,,D,4287.0,14799.0,1.0,,Autocuration,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,
3847.0,8.0,,B,,,,CHEMBL618398,,BAO_0000357,,12054.0,,,H,4288.0,9295.0,1.0,,Autocuration,Glycine max,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),
,0.0,,B,,,,CHEMBL618399,,BAO_0000019,,22226.0,,,U,4289.0,16811.0,1.0,,Autocuration,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",
,8.0,,B,,,,CHEMBL618400,,BAO_0000357,,55.0,,,H,4290.0,168.0,1.0,,Expert,,In vitro inhibition of 5-Lipoxygenase; Inactive.,
,8.0,,B,,,,CHEMBL618401,,BAO_0000357,,55.0,,,H,4291.0,6309.0,1.0,,Autocuration,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,
,8.0,,B,,,,CHEMBL618402,,BAO_0000357,,55.0,,,H,4292.0,6309.0,1.0,,Autocuration,,Inhibitory concentration against 5-lipoxygenase; No inhibition,
,8.0,,B,,,,CHEMBL876400,,BAO_0000219,RBL-1,55.0,,,H,4293.0,3092.0,1.0,702.0,Autocuration,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,
,8.0,,B,,,,CHEMBL618403,,BAO_0000357,,55.0,,,H,4294.0,168.0,1.0,,Expert,,Inhibitory activity against 5-lipoxygenase.,
,8.0,,B,,,,CHEMBL618404,,BAO_0000357,,55.0,,,H,4295.0,168.0,1.0,,Autocuration,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,
,8.0,,B,,,,CHEMBL618405,,BAO_0000357,,55.0,,,H,4296.0,168.0,1.0,,Autocuration,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,
,8.0,,B,,,,CHEMBL618406,,BAO_0000357,,55.0,,,H,4297.0,168.0,1.0,,Autocuration,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,
,8.0,,F,,,,CHEMBL618407,,BAO_0000019,,55.0,,,H,4298.0,12338.0,1.0,,Expert,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,
,8.0,,B,,,,CHEMBL618408,,BAO_0000357,,55.0,,,H,4299.0,4501.0,1.0,,Autocuration,,Tested for the inhibitory activity against 5-lipoxygenase,
,8.0,,B,,,,CHEMBL618409,,BAO_0000357,,55.0,,,H,4300.0,1132.0,1.0,,Autocuration,,Compound was tested for its inhibitory activity against 5-lipoxygenase,
,8.0,,B,,,,CHEMBL618410,,BAO_0000357,,55.0,,,H,4301.0,2117.0,1.0,,Autocuration,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,
,8.0,,B,,,,CHEMBL618411,,BAO_0000357,,55.0,,,H,4302.0,168.0,1.0,,Autocuration,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,
,8.0,,B,,,,CHEMBL618412,,BAO_0000357,,55.0,,,H,4303.0,168.0,1.0,,Autocuration,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,
,8.0,,B,,,,CHEMBL618413,,BAO_0000219,RBL-1,12166.0,,,H,4304.0,13575.0,1.0,702.0,Autocuration,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,
,8.0,,B,,,,CHEMBL618414,,BAO_0000357,,12166.0,,,H,4305.0,11089.0,1.0,,Autocuration,,,
,8.0,,B,,,,CHEMBL618415,,BAO_0000357,,10102.0,,,H,4306.0,216.0,1.0,,Autocuration,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),
,8.0,,B,,,,CHEMBL618416,,BAO_0000019,,10102.0,,,H,4307.0,13165.0,1.0,,Autocuration,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,
,8.0,,B,,,,CHEMBL876401,,BAO_0000357,,10102.0,,,H,4308.0,3278.0,1.0,,Autocuration,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,
,8.0,,B,,,,CHEMBL618417,,BAO_0000357,,10102.0,,,H,4309.0,3278.0,1.0,,Expert,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,
,8.0,,B,,,,CHEMBL618418,,BAO_0000357,,10102.0,,,H,4310.0,11966.0,1.0,,Autocuration,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,
,8.0,,B,,,,CHEMBL618419,,BAO_0000357,,10102.0,,,H,4311.0,175.0,1.0,,Autocuration,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",
,8.0,,B,,,,CHEMBL618420,,BAO_0000357,,10102.0,,,H,4312.0,175.0,1.0,,Autocuration,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",
,8.0,,B,,,,CHEMBL618421,,BAO_0000357,,10102.0,,,H,4313.0,13449.0,1.0,,Autocuration,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,
,8.0,,B,,,,CHEMBL618422,,BAO_0000019,,11238.0,,,H,4314.0,12014.0,1.0,,Autocuration,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,
,8.0,,B,,,,CHEMBL618423,,BAO_0000019,,11238.0,,,H,4315.0,12014.0,1.0,,Autocuration,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),
,8.0,,B,,,,CHEMBL618424,,BAO_0000019,,11238.0,,,H,4316.0,12014.0,1.0,,Autocuration,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),
,2.0,,B,,,,CHEMBL618425,,BAO_0000220,,100284.0,,,S,4317.0,99.0,1.0,,Intermediate,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,
9606.0,0.0,,F,,,,CHEMBL618426,,BAO_0000019,,22226.0,,,U,4318.0,4349.0,1.0,,Autocuration,Homo sapiens,The dark toxicity against 543 human galactophore carcinoma cells,
9606.0,1.0,,F,,,,CHEMBL618427,,BAO_0000219,Panel (56 tumour cell lines),80623.0,,,N,4319.0,4071.0,1.0,390.0,Expert,Homo sapiens,Tested in vitro for cytotoxicity against 56 human tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL618428,,BAO_0000219,5637,80008.0,,,N,4320.0,17589.0,1.0,345.0,Expert,Homo sapiens,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,
9606.0,1.0,,F,,,,CHEMBL618429,,BAO_0000219,5637,80008.0,,,N,4321.0,15002.0,1.0,345.0,Intermediate,Homo sapiens,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,
9606.0,1.0,,F,,,,CHEMBL618430,,BAO_0000219,5637,80008.0,,,N,4322.0,13958.0,1.0,345.0,Intermediate,Homo sapiens,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",
9606.0,1.0,,F,,,,CHEMBL618431,,BAO_0000219,5637,80008.0,,,N,4323.0,17589.0,1.0,345.0,Expert,Homo sapiens,Growth inhibition against human 5637 cell lines,
9606.0,1.0,,F,,,,CHEMBL883799,,BAO_0000219,5637,80008.0,,,N,4324.0,16748.0,1.0,345.0,Expert,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells.,
9606.0,1.0,,F,,,,CHEMBL618432,,BAO_0000219,5637,80008.0,,,N,4325.0,16747.0,1.0,345.0,Intermediate,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells,
9606.0,1.0,,F,,,,CHEMBL618433,,BAO_0000219,5637,80008.0,,,N,4326.0,16747.0,1.0,345.0,Intermediate,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells,
9913.0,9.0,,B,,,,CHEMBL618434,,BAO_0000357,,10443.0,,,D,4327.0,15285.0,1.0,,Expert,Bos taurus,In vitro inhibition of bovine trypsin(Trp).,
9527.0,8.0,,B,,,,CHEMBL618435,,BAO_0000219,CV-1,240.0,,,H,4328.0,3726.0,1.0,407.0,Expert,Cercopithecidae,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,
,8.0,,B,,,,CHEMBL876402,,BAO_0000357,,10577.0,,,H,4329.0,5033.0,1.0,,Autocuration,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,
,6.0,,F,,,,CHEMBL618436,,BAO_0000019,,104698.0,,,H,4330.0,11756.0,1.0,,Autocuration,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,
,0.0,,F,,,,CHEMBL618437,,BAO_0000218,,22226.0,In vivo,,U,4331.0,11953.0,1.0,,Autocuration,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,
10141.0,9.0,,B,,,,CHEMBL618438,,BAO_0000357,,20033.0,,,D,4332.0,5033.0,1.0,,Intermediate,Cavia porcellus,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,
10116.0,8.0,,A,,,,CHEMBL883800,,BAO_0000251,,17045.0,,Microsomes,H,4333.0,11347.0,1.0,,Expert,Rattus norvegicus,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,
10116.0,8.0,,A,,,,CHEMBL618439,,BAO_0000251,,17045.0,,Microsomes,H,4334.0,11347.0,1.0,,Expert,Rattus norvegicus,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,
,0.0,,F,,,,CHEMBL618440,,BAO_0000019,,22226.0,,,U,4335.0,1229.0,1.0,,Intermediate,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,
,0.0,,F,,,,CHEMBL618441,,BAO_0000019,,22226.0,,,U,4336.0,1229.0,1.0,,Intermediate,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,
5691.0,8.0,,B,,,,CHEMBL618442,,BAO_0000019,,11938.0,,,H,4337.0,17588.0,1.0,,Expert,Trypanosoma brucei,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,
5691.0,8.0,,B,,,,CHEMBL618443,,BAO_0000019,,11938.0,,,H,4338.0,17588.0,1.0,,Autocuration,Trypanosoma brucei,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,
9940.0,8.0,,B,,,,CHEMBL619158,,BAO_0000019,,11938.0,,,H,4339.0,17588.0,1.0,,Expert,Ovis aries,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,
9940.0,8.0,,B,,,,CHEMBL620974,,BAO_0000019,,11938.0,,,H,4340.0,17588.0,1.0,,Autocuration,Ovis aries,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,
,8.0,,B,,,,CHEMBL620975,,BAO_0000357,,11938.0,,,H,4341.0,16485.0,1.0,,Autocuration,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,
9606.0,0.0,,F,,,,CHEMBL620976,,BAO_0000019,,22226.0,,,U,4342.0,4337.0,1.0,,Intermediate,Homo sapiens,Average inhibitory concentration against 60 human cell lines was reported,
9606.0,0.0,,F,,,,CHEMBL620977,,BAO_0000019,,22226.0,,,U,4343.0,4112.0,1.0,,Expert,Homo sapiens,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL620978,,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),80315.0,,,N,4344.0,16160.0,1.0,542.0,Intermediate,Homo sapiens,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,
9606.0,1.0,,F,,,,CHEMBL620979,,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),80315.0,,,N,4345.0,16160.0,1.0,542.0,Intermediate,Homo sapiens,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,
,1.0,,F,,,,CHEMBL620980,,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),80315.0,,,N,4346.0,17376.0,1.0,542.0,Expert,,In vitro mean growth inhibitory activity against 60-cell panel,
,1.0,,F,,,,CHEMBL620981,,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),80315.0,,,N,4347.0,17376.0,1.0,542.0,Expert,,In vitro mean growth lethal concentration against 60-cell panel,
,1.0,,F,,,,CHEMBL620982,,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),80315.0,,,N,4348.0,17376.0,1.0,542.0,Expert,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,
,1.0,,F,,,,CHEMBL620983,,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),80315.0,,,N,4349.0,17376.0,1.0,542.0,Expert,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,
,4.0,,F,,,,CHEMBL620984,,BAO_0000019,,104775.0,,,H,4350.0,3241.0,1.0,,Autocuration,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,
,4.0,,F,,,,CHEMBL620985,,BAO_0000019,,104775.0,,,H,4351.0,3241.0,1.0,,Autocuration,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,
,8.0,,B,,,,CHEMBL620986,,BAO_0000357,,275.0,,,H,4352.0,3725.0,1.0,,Expert,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,
5833.0,1.0,,F,,,,CHEMBL620987,,BAO_0000218,,50425.0,,,N,4353.0,10805.0,1.0,,Expert,Plasmodium falciparum,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,
5833.0,1.0,,F,,,,CHEMBL620988,,BAO_0000218,,50425.0,,,N,4354.0,10805.0,1.0,,Expert,Plasmodium falciparum,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,
5833.0,1.0,,F,,,,CHEMBL620989,,BAO_0000218,,50425.0,,,N,4355.0,10805.0,1.0,,Expert,Plasmodium falciparum,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,
5833.0,1.0,,F,,,,CHEMBL620990,,BAO_0000218,,50425.0,,,N,4356.0,10805.0,1.0,,Expert,Plasmodium falciparum,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,
5833.0,1.0,,F,,,,CHEMBL620991,,BAO_0000218,,50425.0,,,N,4357.0,10805.0,1.0,,Intermediate,Plasmodium falciparum,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,
10090.0,1.0,,F,,,,CHEMBL620992,,BAO_0000218,6C3HED,80628.0,,,N,4358.0,10144.0,1.0,850.0,Intermediate,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,
10090.0,1.0,,F,,,,CHEMBL620993,,BAO_0000218,6C3HED,80628.0,,,N,4359.0,10144.0,1.0,850.0,Intermediate,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,
10090.0,1.0,,F,,,,CHEMBL620994,,BAO_0000218,6C3HED,80628.0,,,N,4360.0,10144.0,1.0,850.0,Intermediate,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,
10090.0,1.0,,F,,,,CHEMBL620995,,BAO_0000218,6C3HED,80628.0,,,N,4361.0,10144.0,1.0,850.0,Intermediate,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,
10090.0,1.0,,F,,,,CHEMBL620996,,BAO_0000218,6C3HED,80628.0,,,N,4362.0,10144.0,1.0,850.0,Intermediate,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,
10090.0,1.0,,F,,,,CHEMBL875581,,BAO_0000218,6C3HED,80628.0,,,N,4363.0,10144.0,1.0,850.0,Intermediate,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,
10090.0,0.0,,F,,,,CHEMBL620997,,BAO_0000218,,22224.0,In vivo,,U,4364.0,10685.0,1.0,,Autocuration,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,
10090.0,0.0,,F,,,,CHEMBL620998,,BAO_0000218,,22224.0,In vivo,,U,4365.0,10685.0,1.0,,Autocuration,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,
10090.0,0.0,,F,,,,CHEMBL620999,,BAO_0000218,,22224.0,In vivo,,U,4366.0,10685.0,1.0,,Autocuration,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),
10090.0,0.0,,F,,,,CHEMBL621000,,BAO_0000218,,22224.0,In vivo,,U,4367.0,10685.0,1.0,,Autocuration,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,
10090.0,0.0,,F,,,,CHEMBL621001,,BAO_0000218,,22224.0,In vivo,,U,4368.0,10685.0,1.0,,Autocuration,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,
10090.0,0.0,,F,,,,CHEMBL621002,,BAO_0000218,,22224.0,In vivo,,U,4369.0,10685.0,1.0,,Autocuration,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,
10090.0,0.0,,F,,,,CHEMBL621003,,BAO_0000218,,22224.0,In vivo,,U,4370.0,10685.0,1.0,,Autocuration,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,
10090.0,0.0,,F,,,,CHEMBL621004,,BAO_0000218,,22224.0,In vivo,,U,4371.0,10685.0,1.0,,Autocuration,Mus musculus,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",
10090.0,0.0,,F,,,,CHEMBL621005,,BAO_0000218,,22224.0,In vivo,,U,4372.0,10685.0,1.0,,Autocuration,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),
10090.0,0.0,,F,,,,CHEMBL621006,,BAO_0000218,,22224.0,In vivo,,U,4373.0,10685.0,1.0,,Autocuration,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),
10090.0,0.0,,F,,,,CHEMBL621007,,BAO_0000218,,22224.0,In vivo,,U,4374.0,10685.0,1.0,,Autocuration,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,
10090.0,0.0,,F,,,,CHEMBL621008,,BAO_0000218,,22224.0,,,U,4375.0,10144.0,1.0,,Autocuration,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,
10090.0,0.0,,F,,,,CHEMBL621009,,BAO_0000218,,22224.0,,,U,4376.0,10144.0,1.0,,Autocuration,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,
10090.0,0.0,,F,,,,CHEMBL857705,,BAO_0000218,,22224.0,,,U,4377.0,10144.0,1.0,,Autocuration,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,
10090.0,0.0,,F,,,,CHEMBL619828,,BAO_0000218,,22224.0,,,U,4378.0,10144.0,1.0,,Autocuration,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,
10090.0,0.0,,F,,,,CHEMBL619829,,BAO_0000218,,22224.0,,,U,4379.0,10685.0,1.0,,Autocuration,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,
10090.0,0.0,,F,,,,CHEMBL619830,,BAO_0000218,,22224.0,,,U,4380.0,10685.0,1.0,,Autocuration,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,
10090.0,0.0,,F,,,,CHEMBL619831,,BAO_0000218,,22224.0,,,U,4381.0,10685.0,1.0,,Autocuration,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,
10090.0,0.0,,F,,,,CHEMBL619832,,BAO_0000218,,22224.0,,,U,4382.0,10685.0,1.0,,Autocuration,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,
10090.0,0.0,,A,,,,CHEMBL619833,,BAO_0000218,,22224.0,,,U,4383.0,10685.0,1.0,,Autocuration,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,
10090.0,0.0,,A,,,,CHEMBL619834,,BAO_0000218,,22224.0,,,U,4384.0,10685.0,1.0,,Autocuration,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,
10090.0,0.0,,A,,,,CHEMBL619835,,BAO_0000218,,22224.0,,,U,4385.0,10685.0,1.0,,Autocuration,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,
10090.0,0.0,,A,,,,CHEMBL619836,,BAO_0000218,,22224.0,,,U,4386.0,10685.0,1.0,,Autocuration,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,
10090.0,1.0,,F,,,,CHEMBL619837,,BAO_0000218,6C3HED,80628.0,,,N,4387.0,8831.0,1.0,850.0,Intermediate,Mus musculus,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",
,0.0,,F,,,,CHEMBL619838,,BAO_0000218,,22224.0,In vivo,,U,4388.0,11704.0,1.0,,Autocuration,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,
10090.0,1.0,,A,,,,CHEMBL619839,,BAO_0000218,,50594.0,,,N,4389.0,11704.0,1.0,,Intermediate,Mus musculus,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,
10090.0,1.0,,F,,,,CHEMBL619840,,BAO_0000218,6C3HED,80628.0,In vivo,,N,4390.0,10685.0,1.0,850.0,Intermediate,Mus musculus,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,
10090.0,1.0,,F,,,,CHEMBL619841,,BAO_0000218,6C3HED,80628.0,In vivo,,N,4391.0,10685.0,1.0,850.0,Intermediate,Mus musculus,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,
10090.0,1.0,,F,,,,CHEMBL857704,,BAO_0000218,6C3HED,80628.0,,,N,4392.0,11368.0,1.0,850.0,Expert,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),
10090.0,1.0,,F,,,,CHEMBL619842,,BAO_0000218,6C3HED,80628.0,,,N,4393.0,11368.0,1.0,850.0,Intermediate,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),
10090.0,1.0,,F,,,,CHEMBL619843,,BAO_0000218,6C3HED,80628.0,,,N,4394.0,11368.0,1.0,850.0,Expert,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),
1280.0,0.0,,B,,,,CHEMBL619844,,BAO_0000019,,22226.0,,,U,4395.0,17763.0,1.0,,Autocuration,Staphylococcus aureus,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",
10116.0,0.0,,B,,,2107.0,CHEMBL857855,,BAO_0000251,,22226.0,,Microsomes,U,4396.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL619845,,BAO_0000251,,22226.0,,Microsomes,U,4397.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL619846,,BAO_0000251,,22226.0,,Microsomes,U,4398.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL619847,,BAO_0000251,,22226.0,,Microsomes,U,4399.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL619848,,BAO_0000251,,22226.0,,Microsomes,U,4400.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620893,,BAO_0000251,,22226.0,,Microsomes,U,4401.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620894,,BAO_0000251,,22226.0,,Microsomes,U,4402.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620895,,BAO_0000251,,22226.0,,Microsomes,U,4403.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620896,,BAO_0000251,,22226.0,,Microsomes,U,4404.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620897,,BAO_0000251,,22226.0,,Microsomes,U,4405.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620898,,BAO_0000251,,22226.0,,Microsomes,U,4406.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Liver
10116.0,0.0,,B,,,2107.0,CHEMBL620899,,BAO_0000251,,22226.0,,Microsomes,U,4407.0,7411.0,1.0,,Autocuration,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Liver
9527.0,0.0,,A,,,1969.0,CHEMBL620900,,BAO_0000218,,22224.0,In vivo,,U,4408.0,347.0,1.0,,Autocuration,Cercopithecidae,The apparent total plasma clearance in monkey,Plasma
9527.0,0.0,,A,,,,CHEMBL620901,,BAO_0000218,,22224.0,In vivo,,U,4409.0,3341.0,1.0,,Autocuration,Cercopithecidae,Compound was evaluated for Hepatic clearance in monkey,
9527.0,0.0,,A,,,,CHEMBL620902,,BAO_0000218,,22224.0,In vivo,,U,4410.0,17853.0,1.0,,Autocuration,Cercopithecidae,Lower clearance in monkey (i.v.) at 0.5 mpk,
9527.0,0.0,,A,,,,CHEMBL620903,,BAO_0000218,,22224.0,In vivo,,U,4411.0,4514.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance in rhesus monkey,
9527.0,0.0,,A,,,,CHEMBL620904,,BAO_0000218,,22224.0,In vivo,,U,4412.0,6062.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,
9527.0,0.0,,A,,,,CHEMBL620905,,BAO_0000218,,22224.0,In vivo,,U,4413.0,6821.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance of compound was determined in monkey,
9527.0,0.0,,A,,,,CHEMBL620906,,BAO_0000218,,22224.0,In vivo,,U,4414.0,6057.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance was calculated in rhesus monkey,
9527.0,0.0,,A,,,,CHEMBL875420,,BAO_0000218,,22224.0,In vivo,,U,4415.0,5145.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance in rhesus monkey,
9527.0,0.0,,A,,,,CHEMBL620907,,BAO_0000218,,22224.0,In vivo,,U,4416.0,6641.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),
9527.0,0.0,,A,,,,CHEMBL620908,,BAO_0000218,,22224.0,In vivo,,U,4417.0,5472.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance was evaluated in rhesus,
9527.0,0.0,,A,,,,CHEMBL620909,,BAO_0000218,,22224.0,In vivo,,U,4418.0,4257.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,
9527.0,0.0,,A,,,,CHEMBL620910,,BAO_0000218,,22224.0,In vivo,,U,4419.0,5546.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,
9527.0,0.0,,A,,,,CHEMBL620911,,BAO_0000218,,22224.0,In vivo,,U,4420.0,5334.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),
9527.0,0.0,,A,,,,CHEMBL620912,,BAO_0000218,,22224.0,In vivo,,U,4421.0,5334.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),
9527.0,0.0,,A,,,,CHEMBL620913,,BAO_0000218,,22224.0,In vivo,,U,4422.0,17509.0,1.0,,Autocuration,Cercopithecidae,Cmax 24 hr after 2 mg/kg oral administration in monkeys,
9527.0,0.0,,A,,,,CHEMBL620914,,BAO_0000218,,22224.0,In vivo,,U,4423.0,6535.0,1.0,,Autocuration,Cercopithecidae,Cmax in monkey after administration of 1 mg/kg iv,
9527.0,0.0,,A,,,,CHEMBL620915,,BAO_0000218,,22224.0,In vivo,,U,4424.0,5668.0,1.0,,Autocuration,Cercopithecidae,Cmax was determine after peroral administration at 10 mpk in Rhesus,
9527.0,0.0,,A,,,,CHEMBL620916,,BAO_0000218,,22224.0,In vivo,,U,4425.0,5922.0,1.0,,Autocuration,Cercopithecidae,Cmax in cynomolgus monkey by iv administration,
9527.0,0.0,,A,,,,CHEMBL620917,,BAO_0000218,,22224.0,In vivo,,U,4426.0,5922.0,1.0,,Autocuration,Cercopithecidae,Cmax in cynomolgus monkey by po administration,
9527.0,0.0,,A,,,,CHEMBL620918,,BAO_0000218,,22224.0,In vivo,,U,4427.0,6078.0,1.0,,Autocuration,Cercopithecidae,Cmax value evaluated in monkey,
9527.0,0.0,,A,,,,CHEMBL620919,,BAO_0000218,,22224.0,In vivo,,U,4428.0,2661.0,1.0,,Autocuration,Cercopithecidae,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,
9527.0,0.0,,A,,,1969.0,CHEMBL620920,,BAO_0000218,,22224.0,In vivo,,U,4429.0,3249.0,1.0,,Autocuration,Cercopithecidae,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,Plasma
9527.0,0.0,,A,,,1969.0,CHEMBL620921,,BAO_0000218,,22224.0,In vivo,,U,4430.0,3249.0,1.0,,Autocuration,Cercopithecidae,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,Plasma
9527.0,0.0,,A,,,1969.0,CHEMBL620922,,BAO_0000218,,22224.0,In vivo,,U,4431.0,5553.0,1.0,,Autocuration,Cercopithecidae,Maximal plasma concentration in squirrel monkeys,Plasma
9527.0,0.0,,A,,,,CHEMBL620923,,BAO_0000218,,22224.0,In vivo,,U,4432.0,1916.0,1.0,,Autocuration,Cercopithecidae,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,
9527.0,0.0,,A,,,1969.0,CHEMBL620924,,BAO_0000218,,22224.0,In vivo,,U,4433.0,6227.0,1.0,,Autocuration,Cercopithecidae,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,Plasma
9527.0,0.0,,A,,,,CHEMBL620925,,BAO_0000218,,22224.0,In vivo,,U,4434.0,4809.0,1.0,,Autocuration,Cercopithecidae,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),
9527.0,0.0,,A,,,,CHEMBL620926,,BAO_0000218,,22224.0,In vivo,,U,4435.0,5355.0,1.0,,Autocuration,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,
9527.0,0.0,,A,,,,CHEMBL620927,,BAO_0000218,,22224.0,In vivo,,U,4436.0,5355.0,1.0,,Autocuration,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,
9527.0,0.0,,A,,,,CHEMBL620928,,BAO_0000218,,22224.0,In vivo,,U,4437.0,5355.0,1.0,,Autocuration,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,
9527.0,0.0,,A,,,,CHEMBL620929,,BAO_0000218,,22224.0,In vivo,,U,4438.0,5355.0,1.0,,Autocuration,Cercopithecidae,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,
9527.0,0.0,,A,,,1969.0,CHEMBL620930,,BAO_0000218,,22224.0,In vivo,,U,4439.0,6221.0,1.0,,Autocuration,Cercopithecidae,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,Plasma
9527.0,0.0,,A,,,,CHEMBL620931,,BAO_0000218,,22224.0,,,U,4440.0,167.0,1.0,,Autocuration,Cercopithecidae,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,
9527.0,0.0,,A,,,,CHEMBL620932,,BAO_0000218,,22224.0,,,U,4441.0,167.0,1.0,,Autocuration,Cercopithecidae,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,
9443.0,0.0,,A,,,,CHEMBL620933,,BAO_0000218,,22224.0,In vivo,,U,4442.0,4257.0,1.0,,Autocuration,monkey,Absolute bioavailability was evaluated in monkey,
9443.0,0.0,,A,,,,CHEMBL620934,,BAO_0000218,,22224.0,In vivo,,U,4443.0,6221.0,1.0,,Autocuration,monkey,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,
9443.0,0.0,,A,,,,CHEMBL620935,,BAO_0000218,,22224.0,In vivo,,U,4444.0,17667.0,1.0,,Autocuration,monkey,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,
9544.0,0.0,,A,,,,CHEMBL620936,,BAO_0000218,,22224.0,In vivo,,U,4445.0,17267.0,1.0,,Autocuration,Macaca mulatta,Bioavailability of compound was determined in rhesus monkey,
38020.0,0.0,,A,,,,CHEMBL620937,,BAO_0000218,,22224.0,In vivo,,U,4446.0,4256.0,1.0,,Autocuration,marmosets,Bioavailability determined after oral administration in marmoset,
9541.0,0.0,,A,,,,CHEMBL620938,,BAO_0000218,,22224.0,In vivo,,U,4447.0,4256.0,1.0,,Autocuration,Macaca fascicularis,Oral bioavailability in cynomolgus monkey,
9443.0,0.0,,A,,,,CHEMBL620939,,BAO_0000218,,22224.0,In vivo,,U,4448.0,17853.0,1.0,,Autocuration,monkey,Bioavailability in monkey (p.o.) at 2.0 mpk,
9443.0,0.0,,A,,,,CHEMBL620940,,BAO_0000218,,22224.0,In vivo,,U,4449.0,16365.0,1.0,,Autocuration,monkey,Bioavailability was evaluated after oral administration in monkey,
9541.0,0.0,,A,,,,CHEMBL620941,,BAO_0000218,,22224.0,In vivo,,U,4450.0,1916.0,1.0,,Autocuration,Macaca fascicularis,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,
9544.0,0.0,,A,,,,CHEMBL620942,,BAO_0000218,,22224.0,In vivo,,U,4451.0,5334.0,1.0,,Autocuration,Macaca mulatta,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),
9544.0,0.0,,A,,,,CHEMBL620943,,BAO_0000218,,22224.0,In vivo,,U,4452.0,5334.0,1.0,,Autocuration,Macaca mulatta,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),
9443.0,0.0,,A,,,,CHEMBL620944,,BAO_0000218,,22224.0,In vivo,,U,4453.0,17592.0,1.0,,Autocuration,monkey,Bioavailability of the compound was determined in monkey,
9521.0,0.0,,A,,,,CHEMBL620945,,BAO_0000218,,22224.0,In vivo,,U,4454.0,1399.0,1.0,,Autocuration,Saimiri sciureus,Bioavailability in squirrel monkey (dose 5 mg/kg),
9443.0,0.0,,A,,,,CHEMBL620946,,BAO_0000218,,22224.0,In vivo,,U,4455.0,4809.0,1.0,,Autocuration,monkey,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),
9443.0,0.0,,A,,,,CHEMBL620947,,BAO_0000218,,22224.0,In vivo,,U,4456.0,3341.0,1.0,,Autocuration,monkey,Oral bioavailability in monkey,
9521.0,0.0,,A,,,,CHEMBL620948,,BAO_0000218,,22224.0,In vivo,,U,4457.0,64.0,1.0,,Autocuration,Saimiri sciureus,Compound was tested for bioavailability in squirrel monkey,
9544.0,0.0,,A,,,,CHEMBL620949,,BAO_0000218,,22224.0,In vivo,,U,4458.0,5005.0,1.0,,Autocuration,Macaca mulatta,Oral bioavailability in Rhesus monkey,
9544.0,0.0,,A,,,,CHEMBL620950,,BAO_0000218,,22224.0,In vivo,,U,4459.0,5005.0,1.0,,Autocuration,Macaca mulatta,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),
9541.0,0.0,,A,,,,CHEMBL620951,,BAO_0000218,,22224.0,In vivo,,U,4460.0,5237.0,1.0,,Autocuration,Macaca fascicularis,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,
9541.0,0.0,,A,,,,CHEMBL620952,,BAO_0000218,,22224.0,In vivo,,U,4461.0,5237.0,1.0,,Autocuration,Macaca fascicularis,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,
9443.0,0.0,,A,,,,CHEMBL875421,,BAO_0000218,,22224.0,In vivo,,U,4462.0,5302.0,1.0,,Autocuration,monkey,Oral bioavailability in monkey (dose 5 mg/kg),
9443.0,0.0,,A,,,,CHEMBL620953,,BAO_0000218,,22224.0,In vivo,,U,4463.0,17667.0,1.0,,Autocuration,monkey,Oral bioavailability of compound at 5 mg/kg in monkey,
9615.0,1.0,,A,,,,CHEMBL873491,,BAO_0000218,,50588.0,In vivo,,N,4464.0,6161.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,
9615.0,1.0,,A,,,,CHEMBL620954,,BAO_0000218,,50588.0,In vivo,,N,4465.0,6161.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,
9615.0,1.0,,A,,,1969.0,CHEMBL620955,,BAO_0000218,,50588.0,,,N,4466.0,3854.0,1.0,,Intermediate,Canis lupus familiaris,Plasma half life determined,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL618097,,BAO_0000218,,50588.0,,,N,4467.0,993.0,1.0,,Intermediate,Canis lupus familiaris,Plasma half life in dog,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL618268,,BAO_0000218,,50588.0,,,N,4468.0,4514.0,1.0,,Intermediate,Canis lupus familiaris,Plasma half-life in Beagle dogs,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL618269,,BAO_0000218,,50588.0,In vivo,,N,4469.0,5334.0,1.0,,Intermediate,Canis lupus familiaris,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL618270,,BAO_0000218,,50588.0,In vivo,,N,4470.0,5334.0,1.0,,Intermediate,Canis lupus familiaris,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),Plasma
9615.0,1.0,,A,,,,CHEMBL618271,,BAO_0000218,,50588.0,In vivo,,N,4471.0,1466.0,1.0,,Intermediate,Canis lupus familiaris,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,
9615.0,1.0,,A,,,,CHEMBL873493,,BAO_0000218,,50588.0,In vivo,,N,4472.0,1466.0,1.0,,Intermediate,Canis lupus familiaris,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,
9615.0,1.0,,A,,,,CHEMBL621031,,BAO_0000218,,50588.0,,,N,4473.0,5313.0,1.0,,Intermediate,Canis lupus familiaris,Tested for the half life period in dog,
9615.0,1.0,,A,,,,CHEMBL621032,,BAO_0000218,,50588.0,In vivo,,N,4474.0,5313.0,1.0,,Intermediate,Canis lupus familiaris,Tested for the half life period in dog at dosage of 10 mpk,
9615.0,1.0,,A,,,,CHEMBL621033,,BAO_0000218,,50588.0,,,N,4475.0,3880.0,1.0,,Intermediate,Canis lupus familiaris,The compound was tested for half life in dog,
9615.0,1.0,,A,,,1969.0,CHEMBL621034,,BAO_0000218,,50588.0,,,N,4476.0,3639.0,1.0,,Intermediate,Canis lupus familiaris,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",Plasma
9615.0,1.0,,A,,,,CHEMBL621035,,BAO_0000218,,50588.0,,,N,4477.0,3880.0,1.0,,Intermediate,Canis lupus familiaris,The half life was determined,
9615.0,1.0,,A,,,1969.0,CHEMBL621036,,BAO_0000218,,50588.0,,,N,4478.0,3918.0,1.0,,Intermediate,Canis lupus familiaris,The plasma half-life in dogs,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL621037,,BAO_0000218,,50588.0,,,N,4479.0,16452.0,1.0,,Intermediate,Canis lupus familiaris,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,Plasma
9615.0,1.0,,A,,,,CHEMBL619812,,BAO_0000218,,50588.0,,,N,4480.0,17796.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog,
9615.0,1.0,,A,,,,CHEMBL619813,,BAO_0000218,,50588.0,In vivo,,N,4481.0,5983.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,
9615.0,1.0,,A,,,,CHEMBL873335,,BAO_0000218,,50588.0,In vivo,,N,4482.0,1466.0,1.0,,Intermediate,Canis lupus familiaris,tmax upon peroral administration of 10.0 mg/Kg dose in dog,
9615.0,1.0,,A,,,,CHEMBL619814,,BAO_0000218,,50588.0,In vivo,,N,4483.0,16456.0,1.0,,Intermediate,Canis lupus familiaris,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,
9669.0,1.0,,A,,,,CHEMBL619815,,BAO_0000218,,50506.0,In vivo,,N,4484.0,6113.0,1.0,,Expert,Mustela putorius furo,Cmax in ferrets after 30 mg/kg oral dose,
9669.0,1.0,,F,,,,CHEMBL619816,,BAO_0000218,,50506.0,In vivo,,N,4485.0,6113.0,1.0,,Expert,Mustela putorius furo,Emesis in ferrets at 30 mg/kg oral dose,
9541.0,0.0,,A,,,,CHEMBL619817,,BAO_0000218,,22224.0,In vivo,,U,4486.0,17796.0,1.0,,Autocuration,Macaca fascicularis,Bioavailability in cynomolgus monkey,
9541.0,1.0,,A,,,,CHEMBL619818,,BAO_0000218,,100710.0,In vivo,,N,4487.0,17796.0,1.0,,Intermediate,Macaca fascicularis,Volume of distribution in cynomolgus,
10141.0,0.0,,A,,,1969.0,CHEMBL619819,,BAO_0000218,,22224.0,,,U,4488.0,5308.0,1.0,,Autocuration,Cavia porcellus,AUC tested in guinea pig when 3 mg/kg dose was given perorally,Plasma
10141.0,0.0,,A,,,,CHEMBL619820,,BAO_0000218,,22224.0,,,U,4489.0,4877.0,1.0,,Autocuration,Cavia porcellus,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,
10141.0,0.0,,A,,,,CHEMBL875419,,BAO_0000218,,22224.0,,,U,4490.0,4876.0,1.0,,Autocuration,Cavia porcellus,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",
10141.0,0.0,,A,,,1969.0,CHEMBL619821,,BAO_0000218,,22224.0,In vivo,,U,4491.0,4878.0,1.0,,Autocuration,Cavia porcellus,AUC in guinea pig after 3mg/kg oral dose,Plasma
10141.0,0.0,,A,,,,CHEMBL619822,,BAO_0000218,,22224.0,In vivo,,U,4492.0,5308.0,1.0,,Autocuration,Cavia porcellus,Bioavailability in guinea pig was tested,
10141.0,0.0,,A,,,,CHEMBL619823,,BAO_0000218,,22224.0,In vivo,,U,4493.0,4877.0,1.0,,Autocuration,Cavia porcellus,Tested for oral bioavailability in guinea pig at 5 mg/kg,
10141.0,0.0,,A,,,,CHEMBL619824,,BAO_0000218,,22224.0,In vivo,,U,4494.0,4876.0,1.0,,Autocuration,Cavia porcellus,Tested for the oral bioavailability of the compound,
10141.0,0.0,,A,,,,CHEMBL619825,,BAO_0000218,,22224.0,In vivo,,U,4495.0,4876.0,1.0,,Autocuration,Cavia porcellus,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,
10141.0,0.0,,A,,,,CHEMBL619826,,BAO_0000218,,22224.0,In vivo,,U,4496.0,5308.0,1.0,,Autocuration,Cavia porcellus,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,
10141.0,0.0,,A,,,2048.0,CHEMBL619827,,BAO_0000218,,22224.0,In vivo,,U,4497.0,4877.0,1.0,,Autocuration,Cavia porcellus,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Lung
10141.0,0.0,,A,,,,CHEMBL618167,,BAO_0000218,,22224.0,In vivo,,U,4498.0,4878.0,1.0,,Autocuration,Cavia porcellus,Cmax in guinea pig after 3mg/kg oral dose,
10141.0,0.0,,A,,,178.0,CHEMBL618168,,BAO_0000019,,22224.0,,,U,4499.0,5689.0,1.0,,Autocuration,Cavia porcellus,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,Blood
10141.0,0.0,,A,,,955.0,CHEMBL618169,,BAO_0000019,,22224.0,,,U,4500.0,5689.0,1.0,,Autocuration,Cavia porcellus,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,Brain
10141.0,0.0,,A,,,,CHEMBL618170,,BAO_0000019,,22224.0,,,U,4501.0,5689.0,1.0,,Autocuration,Cavia porcellus,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,
10141.0,0.0,,A,,,160.0,CHEMBL618171,,BAO_0000019,,22224.0,,,U,4502.0,5689.0,1.0,,Autocuration,Cavia porcellus,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,Intestine
10141.0,0.0,,A,,,2113.0,CHEMBL618172,,BAO_0000019,,22224.0,,,U,4503.0,5689.0,1.0,,Autocuration,Cavia porcellus,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,Kidney
10141.0,0.0,,A,,,2107.0,CHEMBL618173,,BAO_0000019,,22224.0,,,U,4504.0,5689.0,1.0,,Autocuration,Cavia porcellus,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,Liver
10141.0,0.0,,A,,,,CHEMBL618174,,BAO_0000019,,22224.0,,,U,4505.0,5689.0,1.0,,Autocuration,Cavia porcellus,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,
10141.0,0.0,,A,,,2106.0,CHEMBL875408,,BAO_0000019,,22224.0,,,U,4506.0,5689.0,1.0,,Autocuration,Cavia porcellus,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,Spleen
10141.0,0.0,,A,,,,CHEMBL839827,,BAO_0000218,,22224.0,In vivo,,U,4507.0,14465.0,1.0,,Autocuration,Cavia porcellus,Elimination T1/2 in Guinea pig (PO dose),
10141.0,0.0,,A,,,,CHEMBL618175,,BAO_0000019,,22224.0,,,U,4508.0,5689.0,1.0,,Autocuration,Cavia porcellus,Partition coefficient was measured as -log (counts per min ),
10141.0,0.0,,A,,,,CHEMBL618176,,BAO_0000218,,22224.0,In vivo,,U,4509.0,611.0,1.0,,Autocuration,Cavia porcellus,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,
10141.0,0.0,,A,,,,CHEMBL618177,,BAO_0000218,,22224.0,In vivo,,U,4510.0,611.0,1.0,,Autocuration,Cavia porcellus,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,
10141.0,0.0,,A,,,,CHEMBL618178,,BAO_0000218,,22224.0,In vivo,,U,4511.0,14465.0,1.0,,Autocuration,Cavia porcellus,Elimination T1/2 in Guinea pig (PO dose),
10141.0,0.0,,A,,,,CHEMBL618179,,BAO_0000218,,22224.0,In vivo,,U,4512.0,4876.0,1.0,,Autocuration,Cavia porcellus,"Tested for the half life period of the compound, intravenously",
10141.0,0.0,,A,,,,CHEMBL873489,,BAO_0000019,,22224.0,,,U,4513.0,5689.0,1.0,,Autocuration,Cavia porcellus,Half-life was measured,
10141.0,0.0,,A,,,,CHEMBL618180,,BAO_0000019,,22224.0,,,U,4514.0,7515.0,1.0,,Autocuration,Cavia porcellus,The time required for onset of inotropy after addition of a single dose of delta F75,
10141.0,0.0,,A,,,,CHEMBL618181,,BAO_0000218,,22224.0,In vivo,,U,4515.0,17667.0,1.0,,Autocuration,Cavia porcellus,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,
10141.0,0.0,,A,,,,CHEMBL618182,,BAO_0000218,,22224.0,In vivo,,U,4516.0,17667.0,1.0,,Autocuration,Cavia porcellus,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,
10029.0,0.0,,A,,,,CHEMBL618183,,BAO_0000218,,22224.0,In vivo,,U,4517.0,4727.0,1.0,,Autocuration,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,
10090.0,1.0,,A,,,,CHEMBL618184,,BAO_0000218,,50594.0,In vivo,,N,4518.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,
10090.0,1.0,,A,,,,CHEMBL618185,,BAO_0000218,,50594.0,In vivo,,N,4519.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,
10090.0,1.0,,A,,,,CHEMBL618186,,BAO_0000218,,50594.0,In vivo,,N,4520.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,
10090.0,1.0,,A,,,,CHEMBL618187,,BAO_0000218,,50594.0,In vivo,,N,4521.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,
10090.0,1.0,,A,,,,CHEMBL618188,,BAO_0000218,,50594.0,In vivo,,N,4522.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,
10090.0,1.0,,A,,,,CHEMBL875409,,BAO_0000218,,50594.0,In vivo,,N,4523.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,
10090.0,1.0,,A,,,,CHEMBL618189,,BAO_0000218,,50594.0,In vivo,,N,4524.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,
10090.0,1.0,,A,,,178.0,CHEMBL618190,,BAO_0000218,,50594.0,In vivo,,N,4525.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,Blood
10090.0,1.0,,A,,,178.0,CHEMBL618191,,BAO_0000218,,50594.0,In vivo,,N,4526.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,Blood
10090.0,1.0,,A,,,178.0,CHEMBL618192,,BAO_0000218,,50594.0,In vivo,,N,4527.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,Blood
10090.0,1.0,,A,,,10000001.0,CHEMBL618193,,BAO_0000218,,50594.0,In vivo,,N,4528.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,Bone
10090.0,1.0,,A,,,10000001.0,CHEMBL618194,,BAO_0000218,,50594.0,In vivo,,N,4529.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,Bone
10090.0,1.0,,A,,,10000001.0,CHEMBL618195,,BAO_0000218,,50594.0,In vivo,,N,4530.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,Bone
10090.0,1.0,,A,,,955.0,CHEMBL618196,,BAO_0000218,,50594.0,In vivo,,N,4531.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,Brain
10090.0,1.0,,A,,,955.0,CHEMBL618197,,BAO_0000218,,50594.0,In vivo,,N,4532.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,Brain
10090.0,1.0,,A,,,955.0,CHEMBL618198,,BAO_0000218,,50594.0,In vivo,,N,4533.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,Brain
10090.0,1.0,,A,,,948.0,CHEMBL618199,,BAO_0000218,,50594.0,In vivo,,N,4534.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,Heart
10090.0,1.0,,A,,,948.0,CHEMBL618200,,BAO_0000218,,50594.0,In vivo,,N,4535.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,Heart
10090.0,1.0,,A,,,948.0,CHEMBL618201,,BAO_0000218,,50594.0,In vivo,,N,4536.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,Heart
10090.0,1.0,,A,,,160.0,CHEMBL618202,,BAO_0000218,,50594.0,In vivo,,N,4537.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,Intestine
10090.0,1.0,,A,,,160.0,CHEMBL618203,,BAO_0000218,,50594.0,In vivo,,N,4538.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,Intestine
10090.0,1.0,,A,,,160.0,CHEMBL618204,,BAO_0000218,,50594.0,In vivo,,N,4539.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,Intestine
10090.0,1.0,,A,,,2113.0,CHEMBL618205,,BAO_0000218,,50594.0,In vivo,,N,4540.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL618206,,BAO_0000218,,50594.0,In vivo,,N,4541.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL618207,,BAO_0000218,,50594.0,In vivo,,N,4542.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,Kidney
10090.0,1.0,,A,,,2107.0,CHEMBL618208,,BAO_0000218,,50594.0,In vivo,,N,4543.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL618932,,BAO_0000218,,50594.0,In vivo,,N,4544.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL618933,,BAO_0000218,,50594.0,In vivo,,N,4545.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,Liver
10090.0,1.0,,A,,,2048.0,CHEMBL618934,,BAO_0000218,,50594.0,In vivo,,N,4546.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL618935,,BAO_0000218,,50594.0,In vivo,,N,4547.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL618936,,BAO_0000218,,50594.0,In vivo,,N,4548.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,Lung
10090.0,1.0,,A,,,2385.0,CHEMBL618937,,BAO_0000218,,50594.0,In vivo,,N,4549.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,Muscle tissue
10090.0,1.0,,A,,,2385.0,CHEMBL618938,,BAO_0000218,,50594.0,In vivo,,N,4550.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,Muscle tissue
10090.0,1.0,,A,,,2385.0,CHEMBL619104,,BAO_0000218,,50594.0,In vivo,,N,4551.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,Muscle tissue
10090.0,1.0,,A,,,2106.0,CHEMBL619105,,BAO_0000218,,50594.0,In vivo,,N,4552.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,Spleen
10090.0,1.0,,A,,,2106.0,CHEMBL619106,,BAO_0000218,,50594.0,In vivo,,N,4553.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,Spleen
10090.0,1.0,,A,,,2106.0,CHEMBL619107,,BAO_0000218,,50594.0,In vivo,,N,4554.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,Spleen
10090.0,1.0,,A,,,945.0,CHEMBL875410,,BAO_0000218,,50594.0,In vivo,,N,4555.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,Stomach
10090.0,1.0,,A,,,945.0,CHEMBL619108,,BAO_0000218,,50594.0,In vivo,,N,4556.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,Stomach
10090.0,1.0,,A,,,945.0,CHEMBL619109,,BAO_0000218,,50594.0,In vivo,,N,4557.0,3655.0,1.0,,Intermediate,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,Stomach
10090.0,1.0,,A,,,,CHEMBL619110,,BAO_0000218,,50594.0,In vivo,,N,4558.0,16597.0,1.0,,Intermediate,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,
10090.0,1.0,,F,,,,CHEMBL619111,,BAO_0000218,,50594.0,In vivo,,N,4559.0,16597.0,1.0,,Intermediate,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,
10090.0,1.0,,A,,,,CHEMBL619112,,BAO_0000218,,50594.0,In vivo,,N,4560.0,16597.0,1.0,,Intermediate,Mus musculus,MRT value at a dose of 10 mg/kg intravenous administration in mice.,
10090.0,1.0,,A,,,,CHEMBL619113,,BAO_0000218,,50594.0,In vivo,,N,4561.0,16597.0,1.0,,Intermediate,Mus musculus,MRT value at a dose of 10 mg/kg peroral administration in mice.,
10090.0,1.0,,A,,,,CHEMBL619114,,BAO_0000218,,50594.0,In vivo,,N,4562.0,17764.0,1.0,,Intermediate,Mus musculus,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,
10090.0,1.0,,F,,,,CHEMBL619115,,BAO_0000218,,50594.0,In vivo,,N,4563.0,17764.0,1.0,,Intermediate,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,
9606.0,1.0,,F,,,,CHEMBL619116,,BAO_0000219,A2780,81034.0,,,N,4564.0,3830.0,1.0,478.0,Intermediate,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,
9606.0,1.0,,F,,,,CHEMBL619117,,BAO_0000219,A2780,81034.0,,,N,4565.0,3829.0,1.0,478.0,Intermediate,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,
9606.0,1.0,,F,,,,CHEMBL619118,,BAO_0000219,A2780,81034.0,,,N,4566.0,2040.0,1.0,478.0,Intermediate,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell lines.,
9606.0,1.0,,F,,,,CHEMBL619119,,BAO_0000219,A2780,81034.0,,,N,4567.0,15684.0,1.0,478.0,Intermediate,Homo sapiens,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,
9606.0,1.0,,F,,,,CHEMBL619120,,BAO_0000219,A2780,81034.0,,,N,4568.0,15684.0,1.0,478.0,Intermediate,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,
9606.0,1.0,,F,,,,CHEMBL619121,,BAO_0000219,A2780,81034.0,,,N,4569.0,15684.0,1.0,478.0,Intermediate,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,
9606.0,1.0,,F,,,,CHEMBL619122,,BAO_0000219,A2780,81034.0,,,N,4570.0,15684.0,1.0,478.0,Intermediate,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,
9606.0,1.0,,F,,,,CHEMBL619123,,BAO_0000219,A2780,81034.0,,,N,4571.0,15684.0,1.0,478.0,Intermediate,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,
9606.0,1.0,,F,,,,CHEMBL619124,,BAO_0000219,A2780,81034.0,,,N,4572.0,15684.0,1.0,478.0,Intermediate,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,
9606.0,1.0,,F,,,,CHEMBL619125,,BAO_0000219,A2780,81034.0,,,N,4573.0,2859.0,1.0,478.0,Intermediate,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell line,
9606.0,1.0,,F,,,,CHEMBL875411,,BAO_0000219,A2780,81034.0,,,N,4574.0,5618.0,1.0,478.0,Intermediate,Homo sapiens,In vitro inhibitory activity against human tumor cell line A2780,
9606.0,1.0,,F,,,,CHEMBL619126,,BAO_0000219,A2780,81034.0,,,N,4575.0,15684.0,1.0,478.0,Intermediate,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,
9606.0,1.0,,F,,,,CHEMBL619127,,BAO_0000219,A2780,81034.0,,,N,4576.0,15684.0,1.0,478.0,Intermediate,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,
9606.0,1.0,,F,,,,CHEMBL619128,,BAO_0000219,A2780,81034.0,,,N,4577.0,15684.0,1.0,478.0,Intermediate,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,
9606.0,1.0,,F,,,,CHEMBL619129,,BAO_0000219,A2780,81034.0,,,N,4578.0,15684.0,1.0,478.0,Intermediate,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,
9606.0,1.0,,F,,,,CHEMBL619130,,BAO_0000219,A2780,81034.0,,,N,4579.0,2113.0,1.0,478.0,Intermediate,Homo sapiens,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL619131,,BAO_0000219,A2780,81034.0,,,N,4580.0,2113.0,1.0,478.0,Intermediate,Homo sapiens,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,
9606.0,1.0,,F,,,,CHEMBL619132,,BAO_0000219,A2780,81034.0,,,N,4581.0,16745.0,1.0,478.0,Intermediate,Homo sapiens,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,
9606.0,1.0,,F,,,,CHEMBL619133,,BAO_0000218,A2780,81034.0,,,N,4582.0,16597.0,1.0,478.0,Expert,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,
9606.0,1.0,,F,,,,CHEMBL619134,,BAO_0000219,A2780,81034.0,,,N,4583.0,15684.0,1.0,478.0,Intermediate,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,
9606.0,1.0,,F,,,,CHEMBL619135,,BAO_0000219,A2780,81034.0,,,N,4584.0,15684.0,1.0,478.0,Intermediate,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,
9606.0,1.0,,F,,,,CHEMBL619136,,BAO_0000219,A2780,81034.0,,,N,4585.0,2040.0,1.0,478.0,Intermediate,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,
9606.0,1.0,,F,,,,CHEMBL619137,,BAO_0000219,A2780,81034.0,,,N,4586.0,2040.0,1.0,478.0,Intermediate,Homo sapiens,Relative resistance factor in A2780 cisplatin-resistant line,
9606.0,1.0,,F,,,,CHEMBL883713,,BAO_0000219,A2780,81034.0,,,N,4587.0,16165.0,1.0,478.0,Intermediate,Homo sapiens,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,
9606.0,1.0,,F,,,,CHEMBL875412,,BAO_0000219,A2780,81034.0,,,N,4588.0,16165.0,1.0,478.0,Intermediate,Homo sapiens,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,
9606.0,1.0,,F,,,,CHEMBL619138,,BAO_0000218,A2780,81034.0,,,N,4589.0,16597.0,1.0,478.0,Expert,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,
9606.0,1.0,,F,,,,CHEMBL619262,,BAO_0000218,A2780,81034.0,,,N,4590.0,16597.0,1.0,478.0,Expert,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,
9606.0,1.0,,F,,,,CHEMBL619139,,BAO_0000219,A2780,81034.0,,,N,4591.0,3992.0,1.0,478.0,Intermediate,Homo sapiens,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,
9606.0,1.0,,F,,,,CHEMBL619140,,BAO_0000219,A2780,81034.0,,,N,4592.0,10553.0,1.0,478.0,Intermediate,Homo sapiens,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,
9606.0,1.0,,F,,,,CHEMBL619141,,BAO_0000219,A2780,81034.0,,,N,4593.0,15608.0,1.0,478.0,Intermediate,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,
9606.0,1.0,,F,,,,CHEMBL619142,,BAO_0000219,A2780,81034.0,,,N,4594.0,15608.0,1.0,478.0,Intermediate,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,
9606.0,1.0,,F,,,,CHEMBL619143,,BAO_0000219,A2780,81034.0,,,N,4595.0,15608.0,1.0,478.0,Intermediate,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,
9606.0,1.0,,F,,,,CHEMBL619144,,BAO_0000219,A2780,81034.0,,,N,4596.0,15608.0,1.0,478.0,Intermediate,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,
9606.0,1.0,,F,,,,CHEMBL619145,,BAO_0000219,A2780,81034.0,,,N,4597.0,15608.0,1.0,478.0,Intermediate,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,
9606.0,1.0,,F,,,,CHEMBL619146,,BAO_0000219,A2780,81034.0,,,N,4598.0,15608.0,1.0,478.0,Intermediate,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,
9606.0,1.0,,F,,,,CHEMBL619147,,BAO_0000219,A2780,81034.0,,,N,4599.0,15569.0,1.0,478.0,Intermediate,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,
9606.0,1.0,,F,,,,CHEMBL619148,,BAO_0000219,A2780,81034.0,,,N,4600.0,17420.0,1.0,478.0,Intermediate,Homo sapiens,Antiproliferative effect of compound on A2780/DX cell line,
9606.0,1.0,,F,,,,CHEMBL619149,,BAO_0000219,A2780,81034.0,,,N,4601.0,17420.0,1.0,478.0,Intermediate,Homo sapiens,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,
9606.0,1.0,,F,,,,CHEMBL619150,,BAO_0000219,A2780,81034.0,,,N,4602.0,15099.0,1.0,478.0,Intermediate,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),
9606.0,1.0,,F,,,,CHEMBL619151,,BAO_0000219,A2780,81034.0,,,N,4603.0,15099.0,1.0,478.0,Intermediate,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),
9606.0,1.0,,F,,,,CHEMBL883794,,BAO_0000219,A2780,81034.0,,,N,4604.0,17672.0,1.0,478.0,Intermediate,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL619152,,BAO_0000219,A2780,81034.0,,,N,4605.0,17672.0,1.0,478.0,Intermediate,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL619153,,BAO_0000219,A2780,81034.0,,,N,4606.0,17270.0,1.0,478.0,Intermediate,Homo sapiens,In vitro cytotoxicity against A2780ADR cell line,
9606.0,1.0,,F,,,,CHEMBL619154,,BAO_0000219,A2780,81034.0,,,N,4607.0,17270.0,1.0,478.0,Intermediate,Homo sapiens,In vitro cytotoxicity against A2780CIS cell line,
9606.0,1.0,,F,,,,CHEMBL619155,,BAO_0000219,A2780,81034.0,,,N,4608.0,5574.0,1.0,478.0,Intermediate,Homo sapiens,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,
9606.0,1.0,,F,,,,CHEMBL619156,,BAO_0000219,A2780,81034.0,,,N,4609.0,2113.0,1.0,478.0,Intermediate,Homo sapiens,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,
9606.0,1.0,,F,,,,CHEMBL619157,,BAO_0000219,A2780,81034.0,,,N,4610.0,16913.0,1.0,478.0,Intermediate,Homo sapiens,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",
9606.0,1.0,,F,,,,CHEMBL619797,,BAO_0000219,A2780,81034.0,,,N,4611.0,16913.0,1.0,478.0,Intermediate,Homo sapiens,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",
9544.0,0.0,,A,,,,CHEMBL619798,,BAO_0000218,,22224.0,In vivo,,U,4612.0,17839.0,1.0,,Autocuration,Macaca mulatta,Oral bioavailability of compound in rhesus macaques,
9443.0,0.0,,A,,,,CHEMBL619799,,BAO_0000218,,22224.0,In vivo,,U,4613.0,6821.0,1.0,,Autocuration,monkey,Oral bioavailability in monkey,
9443.0,0.0,,A,,,,CHEMBL619800,,BAO_0000218,,22224.0,In vivo,,U,4614.0,6078.0,1.0,,Autocuration,monkey,Oral bioavailability evaluated in monkey,
9443.0,0.0,,A,,,,CHEMBL619801,,BAO_0000218,,22224.0,In vivo,,U,4615.0,6535.0,1.0,,Autocuration,monkey,Oral bioavailability in monkey (dose 1 mg/kg p.o.),
9544.0,0.0,,A,,,,CHEMBL619802,,BAO_0000218,,22224.0,In vivo,,U,4616.0,4449.0,1.0,,Autocuration,Macaca mulatta,Oral bioavailability in Rhesus monkey,
9544.0,0.0,,A,,,,CHEMBL619803,,BAO_0000218,,22224.0,In vivo,,U,4617.0,6057.0,1.0,,Autocuration,Macaca mulatta,Oral bioavailability was calculated in rhesus monkey,
9541.0,0.0,,A,,,,CHEMBL619965,,BAO_0000218,,22224.0,In vivo,,U,4618.0,5922.0,1.0,,Autocuration,Macaca fascicularis,Oral bioavailability in cynomolgus monkey,
9443.0,0.0,,A,,,,CHEMBL619966,,BAO_0000218,,22224.0,In vivo,,U,4619.0,5940.0,1.0,,Autocuration,monkey,Oral bioavailability in monkey,
9443.0,0.0,,A,,,,CHEMBL619967,,BAO_0000218,,22224.0,In vivo,,U,4620.0,6265.0,1.0,,Autocuration,monkey,Oral bioavailability in monkey,
9443.0,0.0,,A,,,,CHEMBL620073,,BAO_0000218,,22224.0,In vivo,,U,4621.0,6265.0,1.0,,Autocuration,monkey,Oral bioavailability in monkey (dose 1 mg/kg),
9443.0,0.0,,A,,,,CHEMBL620074,,BAO_0000218,,22224.0,In vivo,,U,4622.0,6265.0,1.0,,Autocuration,monkey,Oral bioavailability in monkey (dose 5 mg/kg),
9443.0,0.0,,A,,,,CHEMBL620075,,BAO_0000218,,22224.0,In vivo,,U,4623.0,5940.0,1.0,,Autocuration,monkey,Oral bioavailability in monkey,
9443.0,0.0,,A,,,,CHEMBL620076,,BAO_0000218,,22224.0,In vivo,,U,4624.0,5940.0,1.0,,Autocuration,monkey,Oral bioavailability in monkey,
9544.0,0.0,,A,,,,CHEMBL620077,,BAO_0000218,,22224.0,In vivo,,U,4625.0,4514.0,1.0,,Autocuration,Macaca mulatta,Oral bioavailability in rhesus monkey,
9544.0,0.0,,A,,,,CHEMBL620078,,BAO_0000218,,22224.0,In vivo,,U,4626.0,5546.0,1.0,,Autocuration,Macaca mulatta,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,
9521.0,0.0,,A,,,,CHEMBL620079,,BAO_0000218,,22224.0,In vivo,,U,4627.0,5553.0,1.0,,Autocuration,Saimiri sciureus,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,
9443.0,0.0,,A,,,,CHEMBL620080,,BAO_0000218,,22224.0,In vivo,,U,4628.0,6641.0,1.0,,Autocuration,monkey,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),
9544.0,0.0,,A,,,,CHEMBL620081,,BAO_0000218,,22224.0,In vivo,,U,4629.0,5472.0,1.0,,Autocuration,Macaca mulatta,Oral bioavailability in Rhesus monkey,
9544.0,0.0,,A,,,,CHEMBL620082,,BAO_0000218,,22224.0,In vivo,,U,4630.0,5668.0,1.0,,Autocuration,Macaca mulatta,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),
9443.0,0.0,,A,,,,CHEMBL620083,,BAO_0000218,,22224.0,In vivo,,U,4631.0,5711.0,1.0,,Autocuration,monkey,Oral bioavailability in monkey at 10 mg/kg of the compound,
9544.0,0.0,,A,,,,CHEMBL620084,,BAO_0000218,,22224.0,In vivo,,U,4632.0,5145.0,1.0,,Autocuration,Macaca mulatta,Bioavailability in Rhesus monkey,
9527.0,0.0,,A,,,,CHEMBL620085,,BAO_0000218,,22224.0,,,U,4633.0,3443.0,1.0,,Autocuration,Cercopithecidae,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,
9527.0,0.0,,A,,,,CHEMBL874595,,BAO_0000218,,22224.0,,,U,4634.0,3443.0,1.0,,Autocuration,Cercopithecidae,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,
9527.0,0.0,,A,,,,CHEMBL873352,,BAO_0000218,,22224.0,In vivo,,U,4635.0,3249.0,1.0,,Autocuration,Cercopithecidae,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,
9527.0,0.0,,A,,,,CHEMBL620086,,BAO_0000218,,22224.0,In vivo,,U,4636.0,3249.0,1.0,,Autocuration,Cercopithecidae,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,
9527.0,0.0,,A,,,,CHEMBL620087,,BAO_0000218,,22224.0,In vivo,,U,4637.0,5355.0,1.0,,Autocuration,Cercopithecidae,Mean residence time was determined after intravenous administration in cynomolgus monkeys,
9527.0,0.0,,A,,,,CHEMBL620088,,BAO_0000218,,22224.0,In vivo,,U,4638.0,5355.0,1.0,,Autocuration,Cercopithecidae,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,
9527.0,0.0,,A,,,,CHEMBL620089,,BAO_0000218,,22224.0,In vivo,,U,4639.0,5355.0,1.0,,Autocuration,Cercopithecidae,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,
9527.0,0.0,,A,,,,CHEMBL620090,,BAO_0000218,,22224.0,In vivo,,U,4640.0,4809.0,1.0,,Autocuration,Cercopithecidae,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),
9527.0,0.0,,A,,,,CHEMBL620091,,BAO_0000218,,22224.0,In vivo,,U,4641.0,4809.0,1.0,,Autocuration,Cercopithecidae,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),
9527.0,0.0,,A,,,,CHEMBL620092,,BAO_0000251,,22224.0,,Microsomes,U,4642.0,14294.0,1.0,,Autocuration,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),
9527.0,0.0,,A,,,,CHEMBL620093,,BAO_0000251,,22224.0,,Microsomes,U,4643.0,14294.0,1.0,,Autocuration,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),
9527.0,0.0,,A,,,,CHEMBL620094,,BAO_0000251,,22224.0,,Microsomes,U,4644.0,14294.0,1.0,,Autocuration,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),
9527.0,0.0,,A,,,,CHEMBL620095,,BAO_0000251,,22224.0,,Microsomes,U,4645.0,14294.0,1.0,,Autocuration,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),
9527.0,0.0,,A,,,,CHEMBL620096,,BAO_0000218,,22224.0,In vivo,,U,4646.0,3443.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,
9527.0,0.0,,A,,,,CHEMBL620097,,BAO_0000218,,22224.0,In vivo,,U,4647.0,3443.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,
9527.0,0.0,,A,,,,CHEMBL620098,,BAO_0000019,,22224.0,,,U,4648.0,11271.0,1.0,,Autocuration,Cercopithecidae,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,
9527.0,0.0,,A,,,,CHEMBL620099,,BAO_0000218,,22224.0,,,U,4649.0,3443.0,1.0,,Autocuration,Cercopithecidae,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,
9527.0,0.0,,A,,,,CHEMBL620100,,BAO_0000218,,22224.0,,,U,4650.0,3443.0,1.0,,Autocuration,Cercopithecidae,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,
9527.0,0.0,,A,,,,CHEMBL620101,,BAO_0000019,,22224.0,,,U,4651.0,6821.0,1.0,,Autocuration,Cercopithecidae,Elimination Half-life of compound was determined in monkey,
9527.0,0.0,,A,,,,CHEMBL620102,,BAO_0000019,,22224.0,,,U,4652.0,17267.0,1.0,,Autocuration,Cercopithecidae,Half life of compound was determined in rhesus monkey,
9527.0,0.0,,A,,,1969.0,CHEMBL620103,,BAO_0000366,,22224.0,,,U,4653.0,5819.0,1.0,,Autocuration,Cercopithecidae,Half life in monkey plasma,Plasma
9527.0,0.0,,A,,,1969.0,CHEMBL620104,,BAO_0000366,,22224.0,,,U,4654.0,5819.0,1.0,,Autocuration,Cercopithecidae,Half life in monkey plasma; Not detected,Plasma
9527.0,0.0,,A,,,,CHEMBL874596,,BAO_0000218,,22224.0,In vivo,,U,4655.0,1916.0,1.0,,Autocuration,Cercopithecidae,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,
9527.0,0.0,,A,,,,CHEMBL873490,,BAO_0000218,,22224.0,In vivo,,U,4656.0,17509.0,1.0,,Autocuration,Cercopithecidae,Half-life 24 hr after 2 mg/kg iv administration in monkeys,
9527.0,0.0,,A,,,,CHEMBL620105,,BAO_0000019,,22224.0,,,U,4657.0,1399.0,1.0,,Autocuration,Cercopithecidae,Terminal half life of the compound.,
9527.0,0.0,,A,,,,CHEMBL620780,,BAO_0000218,,22224.0,In vivo,,U,4658.0,1916.0,1.0,,Autocuration,Cercopithecidae,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,
9527.0,0.0,,A,,,,CHEMBL620781,,BAO_0000218,,22224.0,In vivo,,U,4659.0,4809.0,1.0,,Autocuration,Cercopithecidae,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),
9527.0,0.0,,A,,,,CHEMBL620956,,BAO_0000218,,22224.0,,,U,4660.0,5546.0,1.0,,Autocuration,Cercopithecidae,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,
9527.0,0.0,,A,,,1088.0,CHEMBL620957,,BAO_0000218,,22224.0,,,U,4661.0,3443.0,1.0,,Autocuration,Cercopithecidae,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Urine
9527.0,0.0,,A,,,1088.0,CHEMBL620958,,BAO_0000218,,22224.0,,,U,4662.0,3443.0,1.0,,Autocuration,Cercopithecidae,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Urine
9527.0,0.0,,A,,,,CHEMBL620959,,BAO_0000218,,22224.0,In vivo,,U,4663.0,4257.0,1.0,,Autocuration,Cercopithecidae,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,
9527.0,0.0,,A,,,,CHEMBL620960,,BAO_0000218,,22224.0,In vivo,,U,4664.0,6221.0,1.0,,Autocuration,Cercopithecidae,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,
9527.0,0.0,,A,,,,CHEMBL620961,,BAO_0000218,,22224.0,In vivo,,U,4665.0,5472.0,1.0,,Autocuration,Cercopithecidae,Volume of distribution was evaluated in rhesus,
10029.0,0.0,,A,,,,CHEMBL620962,,BAO_0000218,,22224.0,In vivo,,U,4666.0,4727.0,1.0,,Autocuration,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,
10029.0,0.0,,A,,,,CHEMBL620963,,BAO_0000218,,22224.0,In vivo,,U,4667.0,4727.0,1.0,,Autocuration,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,
10029.0,0.0,,A,,,,CHEMBL620964,,BAO_0000218,,22224.0,In vivo,,U,4668.0,4727.0,1.0,,Autocuration,Cricetulus griseus,Bioavailability in hamster was determined,
10029.0,0.0,,A,,,,CHEMBL620965,,BAO_0000218,,22224.0,In vivo,,U,4669.0,4727.0,1.0,,Autocuration,Cricetulus griseus,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,
10029.0,0.0,,A,,,,CHEMBL620966,,BAO_0000218,,22224.0,In vivo,,U,4670.0,4727.0,1.0,,Autocuration,Cricetulus griseus,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,
10029.0,0.0,,A,,,178.0,CHEMBL620967,,BAO_0000221,,22224.0,,,U,4671.0,4727.0,1.0,,Autocuration,Cricetulus griseus,Half life of compound was determined in hamster blood,Blood
9823.0,0.0,,A,,,,CHEMBL620968,,BAO_0000019,,22224.0,,,U,4672.0,1452.0,1.0,,Autocuration,Sus scrofa,Michaelis-Menten constant of the compound.,
9823.0,0.0,,A,,,,CHEMBL874597,,BAO_0000019,,22224.0,,,U,4673.0,1452.0,1.0,,Autocuration,Sus scrofa,Vmax value was measured at 0 uM concentration of silyl ether.,
9823.0,0.0,,A,,,,CHEMBL620969,,BAO_0000019,,22224.0,,,U,4674.0,1452.0,1.0,,Autocuration,Sus scrofa,Vmax value was measured at 10 uM concentration of silyl ether.,
9823.0,0.0,,A,,,,CHEMBL620970,,BAO_0000019,,22224.0,,,U,4675.0,1452.0,1.0,,Autocuration,Sus scrofa,Vmax value was measured at 5 uM concentration of silyl ether.,
9606.0,9.0,,B,,,,CHEMBL620971,,BAO_0000357,,235.0,,,D,4676.0,11706.0,1.0,,Expert,Homo sapiens,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,
9606.0,0.0,,A,,,,CHEMBL620972,,BAO_0000218,,22224.0,,,U,4677.0,1916.0,1.0,,Autocuration,Homo sapiens,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,
9606.0,0.0,,A,,,,CHEMBL620973,,BAO_0000019,,22224.0,,,U,4678.0,17791.0,1.0,,Autocuration,Homo sapiens,Compound was evaluated for area under the curve expressed as (h*ug/ml),
9606.0,0.0,,A,,,,CHEMBL618243,,BAO_0000019,,22224.0,,,U,4679.0,7766.0,1.0,,Autocuration,Homo sapiens,Active metabolite of ifosfamide determined in humans; A-Active,
9606.0,0.0,,A,,,,CHEMBL618244,,BAO_0000019,,22224.0,,,U,4680.0,6567.0,1.0,,Autocuration,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,
9606.0,0.0,,A,,,,CHEMBL618245,,BAO_0000019,,22224.0,,,U,4681.0,6567.0,1.0,,Autocuration,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,
9606.0,0.0,,A,,,,CHEMBL618246,,BAO_0000019,,22224.0,,,U,4682.0,6567.0,1.0,,Autocuration,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,
9606.0,0.0,,A,,,,CHEMBL618247,,BAO_0000019,,22224.0,,,U,4683.0,6567.0,1.0,,Autocuration,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,
9606.0,0.0,,A,,,,CHEMBL618248,,BAO_0000218,,22224.0,,,U,4684.0,17791.0,1.0,,Autocuration,Homo sapiens,Compound was evaluated for oral bioavailability in human,
9606.0,0.0,,A,,,1088.0,CHEMBL618249,,BAO_0000019,,22224.0,,,U,4685.0,7766.0,1.0,,Autocuration,Homo sapiens,Metabolite of ifosfamide determined in urine; NF-Not found,Urine
9606.0,0.0,,A,,,,CHEMBL618250,,BAO_0000019,,22224.0,,,U,4686.0,6852.0,1.0,,Autocuration,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),
9606.0,0.0,,A,,,,CHEMBL874598,,BAO_0000019,,22224.0,,,U,4687.0,6852.0,1.0,,Autocuration,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,
9606.0,0.0,,A,,,,CHEMBL618251,,BAO_0000019,,22224.0,,,U,4688.0,6852.0,1.0,,Autocuration,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,
9606.0,0.0,,A,,,,CHEMBL618252,,BAO_0000019,,22224.0,,,U,4689.0,6852.0,1.0,,Autocuration,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,
9606.0,0.0,,A,,,,CHEMBL618253,,BAO_0000019,,22224.0,,,U,4690.0,6852.0,1.0,,Autocuration,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,
9606.0,0.0,,A,,,,CHEMBL618254,,BAO_0000019,,22224.0,,,U,4691.0,6852.0,1.0,,Autocuration,Homo sapiens,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),
9606.0,0.0,,A,,,,CHEMBL618255,,BAO_0000019,,22224.0,,,U,4692.0,6852.0,1.0,,Autocuration,Homo sapiens,Percent of compound in healthy individuals (Group D),
9606.0,0.0,,A,,,2107.0,CHEMBL618983,,BAO_0000251,,22224.0,,Microsomes,U,4693.0,4397.0,1.0,,Autocuration,Homo sapiens,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Liver
9606.0,0.0,,A,,,,CHEMBL618984,,BAO_0000019,,22224.0,,,U,4694.0,17409.0,1.0,,Autocuration,Homo sapiens,Binding towards human plasma protein at 10 uM,
9606.0,0.0,,A,,,,CHEMBL618985,,BAO_0000019,,22224.0,,,U,4695.0,17409.0,1.0,,Autocuration,Homo sapiens,Binding towards human plasma protein at 100 uM,
9606.0,0.0,,A,,,,CHEMBL618986,,BAO_0000019,,22224.0,,,U,4696.0,17176.0,1.0,,Autocuration,Homo sapiens,Human plasma protein binding activity was determined,
9606.0,0.0,,A,,,,CHEMBL618987,,BAO_0000019,,22224.0,,,U,4697.0,15444.0,1.0,,Autocuration,Homo sapiens,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),
9606.0,0.0,,A,,,,CHEMBL618988,,BAO_0000019,,22224.0,,,U,4698.0,17267.0,1.0,,Autocuration,Homo sapiens,Percent binding of compound towards human plasma protein was determined,
9606.0,0.0,,A,,,2107.0,CHEMBL618989,,BAO_0000251,,22224.0,In vitro,Microsomes,U,4699.0,5944.0,1.0,,Autocuration,Homo sapiens,Plasma clearance in human liver microsomes,Liver
9606.0,0.0,,A,,,2107.0,CHEMBL618990,,BAO_0000251,,22224.0,In vitro,Microsomes,U,4700.0,5668.0,1.0,,Autocuration,Homo sapiens,In vitro intrinsic clearance in human liver microsome,Liver
9606.0,0.0,,A,,,2107.0,CHEMBL618991,,BAO_0000251,,22224.0,In vitro,Microsomes,U,4701.0,5669.0,1.0,,Autocuration,Homo sapiens,In vitro intrinsic clearance in human liver microsome,Liver
9606.0,0.0,,A,,,,CHEMBL876725,,BAO_0000251,,22224.0,In vitro,Microsomes,U,4702.0,5041.0,1.0,,Autocuration,Homo sapiens,In vitro microsome metabolism clearance in human was determined,
9606.0,0.0,,A,,,,CHEMBL618992,,BAO_0000251,,22224.0,In vitro,Microsomes,U,4703.0,5041.0,1.0,,Autocuration,Homo sapiens,In vitro microsome metabolism clearance in human was determined; High,
9606.0,0.0,,A,,,,CHEMBL618993,,BAO_0000251,,22224.0,In vitro,Microsomes,U,4704.0,5041.0,1.0,,Autocuration,Homo sapiens,In vitro microsome metabolism clearance in human was determined; ND denotes no data,
9606.0,0.0,,A,,,2107.0,CHEMBL618994,,BAO_0000251,,22224.0,In vitro,Microsomes,U,4705.0,5676.0,1.0,,Autocuration,Homo sapiens,Pharmacokinetic property (clearance) in human liver microsome,Liver
9606.0,0.0,,A,,,2107.0,CHEMBL618995,,BAO_0000251,,22224.0,In vitro,Microsomes,U,4706.0,5944.0,1.0,,Autocuration,Homo sapiens,Plasma clearance in human liver microsomes,Liver
9606.0,0.0,,A,,,2107.0,CHEMBL618996,,BAO_0000251,,22224.0,In vitro,Microsomes,U,4707.0,17538.0,1.0,,Autocuration,Homo sapiens,In vitro clearance in human liver microsomes,Liver
9606.0,0.0,,A,,,2107.0,CHEMBL618997,,BAO_0000251,,22224.0,In vitro,Microsomes,U,4708.0,6331.0,1.0,,Autocuration,Homo sapiens,Intrinsic clearance in human liver microsomes was determined,Liver
9606.0,0.0,,A,,,2107.0,CHEMBL618998,,BAO_0000251,,22224.0,In vitro,Microsomes,U,4709.0,5948.0,1.0,,Autocuration,Homo sapiens,Intrinsic clearance in human liver microsomes was determined,Liver
9606.0,0.0,,A,,,,CHEMBL618999,,BAO_0000218,,22224.0,In vivo,,U,4710.0,5965.0,1.0,,Autocuration,Homo sapiens,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,
9606.0,0.0,,A,,,,CHEMBL620223,,BAO_0000218,,22224.0,In vivo,,U,4711.0,1916.0,1.0,,Autocuration,Homo sapiens,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,
9606.0,0.0,,A,,,,CHEMBL620224,,BAO_0000218,,22224.0,,,U,4712.0,5965.0,1.0,,Autocuration,Homo sapiens,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,
9606.0,0.0,,A,,,,CHEMBL620225,,BAO_0000019,,22224.0,,,U,4713.0,1299.0,1.0,,Autocuration,Homo sapiens,Stability in human plasma 2 hr after incubation expressed as percent concentration,
9606.0,0.0,,A,,,,CHEMBL620226,,BAO_0000019,,22224.0,,,U,4714.0,1299.0,1.0,,Autocuration,Homo sapiens,Stability in human plasma 4 hr after incubation expressed as percent concentration,
9606.0,0.0,,A,,,1088.0,CHEMBL620227,,BAO_0000019,,22224.0,,,U,4715.0,7766.0,1.0,,Autocuration,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine
9606.0,0.0,,A,,,1088.0,CHEMBL876726,,BAO_0000019,,22224.0,,,U,4716.0,7766.0,1.0,,Autocuration,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine
9606.0,0.0,,A,,,1088.0,CHEMBL620228,,BAO_0000019,,22224.0,,,U,4717.0,7766.0,1.0,,Autocuration,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine
9606.0,0.0,,A,,,1088.0,CHEMBL620229,,BAO_0000019,,22224.0,,,U,4718.0,7766.0,1.0,,Autocuration,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine
10090.0,1.0,,F,,,,CHEMBL620230,,BAO_0000218,,50594.0,In vivo,,N,4719.0,17764.0,1.0,,Intermediate,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,
10090.0,1.0,,F,,,,CHEMBL620231,,BAO_0000218,,50594.0,In vivo,,N,4720.0,17764.0,1.0,,Intermediate,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,
10090.0,1.0,,F,,,,CHEMBL620232,,BAO_0000218,,50594.0,In vivo,,N,4721.0,17764.0,1.0,,Intermediate,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,
10090.0,1.0,,F,,,,CHEMBL620233,,BAO_0000218,,50594.0,In vivo,,N,4722.0,17764.0,1.0,,Intermediate,Mus musculus,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,
10090.0,1.0,,A,,,,CHEMBL620234,,BAO_0000218,,50594.0,,,N,4723.0,14294.0,1.0,,Intermediate,Mus musculus,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),
10090.0,1.0,,A,,,,CHEMBL620235,,BAO_0000218,,50594.0,,,N,4724.0,14294.0,1.0,,Intermediate,Mus musculus,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),
10090.0,1.0,,A,,,,CHEMBL620236,,BAO_0000218,,50594.0,,,N,4725.0,14294.0,1.0,,Intermediate,Mus musculus,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),
10090.0,1.0,,A,,,2107.0,CHEMBL620237,,BAO_0000218,,50594.0,,,N,4726.0,6251.0,1.0,,Intermediate,Mus musculus,In vitro metabolic potential in mouse liver microsomes,Liver
10090.0,1.0,,A,,,,CHEMBL620238,,BAO_0000218,,50594.0,,,N,4727.0,17582.0,1.0,,Intermediate,Mus musculus,Ability of compound to bind to plasma protein was evaluated in HSA cells,
10090.0,1.0,,A,,,2369.0,CHEMBL620239,,BAO_0000218,,50594.0,,,N,4728.0,17811.0,1.0,,Intermediate,Mus musculus,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),Adrenal gland
10090.0,1.0,,A,,,955.0,CHEMBL620240,,BAO_0000218,,50594.0,,,N,4729.0,17811.0,1.0,,Intermediate,Mus musculus,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,Brain
10090.0,1.0,,A,,,955.0,CHEMBL620241,,BAO_0000218,,50594.0,,,N,4730.0,17811.0,1.0,,Intermediate,Mus musculus,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,Brain
10090.0,1.0,,A,,,,CHEMBL876727,,BAO_0000218,,50594.0,,,N,4731.0,17811.0,1.0,,Intermediate,Mus musculus,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),
10090.0,1.0,,A,,,2113.0,CHEMBL620242,,BAO_0000218,,50594.0,,,N,4732.0,17811.0,1.0,,Intermediate,Mus musculus,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),Kidney
10090.0,1.0,,A,,,,CHEMBL620243,,BAO_0000218,,50594.0,,,N,4733.0,17811.0,1.0,,Intermediate,Mus musculus,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),
10090.0,1.0,,A,,,,CHEMBL620244,,BAO_0000218,,50594.0,,,N,4734.0,5288.0,1.0,,Intermediate,Mus musculus,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,
10090.0,1.0,,A,,,1977.0,CHEMBL620245,,BAO_0000218,,50594.0,,,N,4735.0,2717.0,1.0,,Intermediate,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,Serum
10090.0,1.0,,A,,,1977.0,CHEMBL620246,,BAO_0000218,,50594.0,,,N,4736.0,2717.0,1.0,,Intermediate,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,Serum
10090.0,1.0,,A,,,1977.0,CHEMBL620247,,BAO_0000218,,50594.0,,,N,4737.0,2717.0,1.0,,Intermediate,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,Serum
10090.0,1.0,,A,,,1969.0,CHEMBL620248,,BAO_0000218,,50594.0,In vivo,,N,4738.0,17753.0,1.0,,Intermediate,Mus musculus,Half life of compound was determined in plasma of mice at 24 mg/Kg,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL873497,,BAO_0000218,,50594.0,In vivo,,N,4739.0,17753.0,1.0,,Intermediate,Mus musculus,Half life of compound was determined in plasma of mice at 40 mg/Kg,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL620249,,BAO_0000218,,50594.0,In vivo,,N,4740.0,17753.0,1.0,,Intermediate,Mus musculus,Half life of compound was determined in plasma of mice at 5 mg/Kg,Plasma
10090.0,1.0,,F,,,,CHEMBL620250,,BAO_0000218,,50594.0,In vivo,,N,4741.0,17764.0,1.0,,Intermediate,Mus musculus,Half life after intraperitoneal administration in mice at 18 uM/kg,
10090.0,1.0,,F,,,,CHEMBL620251,,BAO_0000218,,50594.0,In vivo,,N,4742.0,17764.0,1.0,,Intermediate,Mus musculus,Half life after intraperitoneal administration in mice at 23 uM/kg,
10090.0,1.0,,F,,,,CHEMBL620252,,BAO_0000218,,50594.0,In vivo,,N,4743.0,17764.0,1.0,,Intermediate,Mus musculus,Half life after intraperitoneal administration in mice at 25 uM/kg,
10090.0,1.0,,F,,,,CHEMBL620253,,BAO_0000218,,50594.0,In vivo,,N,4744.0,17764.0,1.0,,Intermediate,Mus musculus,Half life after intraperitoneal administration in mice at 26 uM/kg,
10090.0,1.0,,F,,,,CHEMBL620254,,BAO_0000218,,50594.0,In vivo,,N,4745.0,17764.0,1.0,,Intermediate,Mus musculus,Half life after intravenous administration in mice at 23 uM/kg,
10090.0,1.0,,A,,,,CHEMBL620255,,BAO_0000218,,50594.0,In vivo,,N,4746.0,17764.0,1.0,,Intermediate,Mus musculus,Half life after intravenous administration in mice at 24 uM/kg,
10090.0,1.0,,A,,,,CHEMBL620256,,BAO_0000218,,50594.0,In vivo,,N,4747.0,16597.0,1.0,,Intermediate,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,
10090.0,1.0,,A,,,,CHEMBL876728,,BAO_0000218,,50594.0,In vivo,,N,4748.0,2675.0,1.0,,Intermediate,Mus musculus,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,
10090.0,1.0,,A,,,,CHEMBL620257,,BAO_0000218,,50594.0,In vivo,,N,4749.0,2675.0,1.0,,Intermediate,Mus musculus,Maximum time required to reach Cp max was evaluated in mice after oral administration,
10090.0,1.0,,A,,,,CHEMBL620258,,BAO_0000218,,50594.0,In vivo,,N,4750.0,16597.0,1.0,,Intermediate,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),
10090.0,1.0,,A,,,,CHEMBL620259,,BAO_0000218,,50594.0,In vivo,,N,4751.0,4890.0,1.0,,Intermediate,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",
10090.0,1.0,,A,,,,CHEMBL620260,,BAO_0000218,,50594.0,In vivo,,N,4752.0,429.0,1.0,,Intermediate,Mus musculus,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,
10090.0,1.0,,A,,,178.0,CHEMBL620261,,BAO_0000218,,50594.0,In vivo,,N,4753.0,17837.0,1.0,,Intermediate,Mus musculus,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,Blood
10090.0,1.0,,A,,,,CHEMBL620262,,BAO_0000218,,50594.0,In vivo,,N,4754.0,16597.0,1.0,,Intermediate,Mus musculus,Half life at a dose of 10 mg/kg intravenous administration in mice.,
10090.0,1.0,,A,,,,CHEMBL620263,,BAO_0000218,,50594.0,In vivo,,N,4755.0,16597.0,1.0,,Intermediate,Mus musculus,Half life at a dose of 10 mg/kg peroral administration in mice.,
10090.0,1.0,,A,,,,CHEMBL620264,,BAO_0000218,,50594.0,,,N,4756.0,6619.0,1.0,,Intermediate,Mus musculus,Half life in ob/ob mice,
10090.0,1.0,,A,,,,CHEMBL620265,,BAO_0000218,,50594.0,In vivo,,N,4757.0,4066.0,1.0,,Intermediate,Mus musculus,Half-life at a single subcutaneous administration of 40 mg/kg in mice,
10090.0,1.0,,A,,,,CHEMBL620266,,BAO_0000218,,50594.0,,,N,4758.0,4239.0,1.0,,Intermediate,Mus musculus,Half-life was measured in mouse,
10090.0,1.0,,A,,,,CHEMBL620267,,BAO_0000218,,50594.0,In vivo,,N,4759.0,5969.0,1.0,,Intermediate,Mus musculus,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,
10090.0,1.0,,A,,,,CHEMBL619364,,BAO_0000218,,50594.0,,,N,4760.0,8999.0,1.0,,Intermediate,Mus musculus,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,
10090.0,1.0,,A,,,,CHEMBL619365,,BAO_0000218,,50594.0,,,N,4761.0,8999.0,1.0,,Intermediate,Mus musculus,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,
10090.0,1.0,,A,,,955.0,CHEMBL619366,,BAO_0000218,,50594.0,,,N,4762.0,17641.0,1.0,,Intermediate,Mus musculus,T2 in brain of mice at the oral dose of 50 mg/kg,Brain
10090.0,1.0,,A,,,2113.0,CHEMBL619367,,BAO_0000218,,50594.0,,,N,4763.0,17641.0,1.0,,Intermediate,Mus musculus,T2 in kidney of mice at the oral dose of 50 mg/kg,Kidney
10090.0,1.0,,A,,,2107.0,CHEMBL619368,,BAO_0000218,,50594.0,,,N,4764.0,17641.0,1.0,,Intermediate,Mus musculus,T2 in liver of mice at the oral dose of 50 mg/kg,Liver
10090.0,1.0,,A,,,2048.0,CHEMBL619369,,BAO_0000218,,50594.0,,,N,4765.0,17641.0,1.0,,Intermediate,Mus musculus,T2 in lungs of mice at the oral dose of 50 mg/kg,Lung
10090.0,1.0,,A,,,2106.0,CHEMBL876729,,BAO_0000218,,50594.0,,,N,4766.0,17641.0,1.0,,Intermediate,Mus musculus,T2 in spleen of mice at the oral dose of 50 mg/kg,Spleen
10090.0,1.0,,A,,,,CHEMBL619370,,BAO_0000218,,50594.0,In vivo,,N,4767.0,16597.0,1.0,,Intermediate,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,
10090.0,1.0,,A,,,,CHEMBL619371,,BAO_0000218,,50594.0,In vivo,,N,4768.0,4890.0,1.0,,Intermediate,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",
10090.0,1.0,,A,,,,CHEMBL619372,,BAO_0000218,,50594.0,In vivo,,N,4769.0,429.0,1.0,,Intermediate,Mus musculus,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,
10090.0,1.0,,A,,,,CHEMBL620012,,BAO_0000218,,50594.0,In vivo,,N,4770.0,429.0,1.0,,Intermediate,Mus musculus,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,
10090.0,1.0,,A,,,,CHEMBL620013,,BAO_0000218,,50594.0,In vivo,,N,4771.0,5969.0,1.0,,Intermediate,Mus musculus,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,
9606.0,1.0,,F,,,,CHEMBL620014,,BAO_0000219,A2780,81034.0,,,N,4772.0,16913.0,1.0,478.0,Intermediate,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",
9606.0,1.0,,F,,,,CHEMBL620015,,BAO_0000219,A2780,81034.0,,,N,4773.0,16913.0,1.0,478.0,Intermediate,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",
9606.0,1.0,,F,,,,CHEMBL621010,,BAO_0000219,A2780,81034.0,,,N,4774.0,16913.0,1.0,478.0,Intermediate,Homo sapiens,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",
9606.0,1.0,,F,,,,CHEMBL621011,,BAO_0000219,A2780,81034.0,,,N,4775.0,16913.0,1.0,478.0,Intermediate,Homo sapiens,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",
9606.0,1.0,,F,,,,CHEMBL621012,,BAO_0000219,A2780,81034.0,,,N,4776.0,16913.0,1.0,478.0,Intermediate,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",
9606.0,1.0,,F,,,,CHEMBL621013,,BAO_0000219,A2780,81034.0,,,N,4777.0,16913.0,1.0,478.0,Intermediate,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",
9606.0,1.0,,F,,,,CHEMBL621014,,BAO_0000219,A2780,81034.0,,,N,4778.0,17270.0,1.0,478.0,Intermediate,Homo sapiens,In vitro cytotoxicity against A2780TAX cell line,
9606.0,1.0,,F,,,,CHEMBL618154,,BAO_0000219,A2780cisR,80017.0,,,N,4779.0,5618.0,1.0,481.0,Intermediate,Homo sapiens,In vitro inhibitory activity against human tumor cell line A2780cis,
9606.0,1.0,,F,,,,CHEMBL618155,,BAO_0000219,A2780,81034.0,,,N,4780.0,17777.0,1.0,478.0,Expert,Homo sapiens,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,
9606.0,1.0,,F,,,,CHEMBL618156,,BAO_0000219,A2780cisR,80017.0,,,N,4781.0,16112.0,1.0,481.0,Intermediate,Homo sapiens,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,
9606.0,1.0,,F,,,,CHEMBL618157,,BAO_0000219,A2780cisR,80017.0,,,N,4782.0,15748.0,1.0,481.0,Intermediate,Homo sapiens,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),
9606.0,1.0,,F,,,,CHEMBL618328,,BAO_0000219,A2780,81034.0,,,N,4783.0,6633.0,1.0,478.0,Intermediate,Homo sapiens,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,
9606.0,1.0,,F,,,,CHEMBL618329,,BAO_0000219,A2780,81034.0,,,N,4784.0,16930.0,1.0,478.0,Intermediate,Homo sapiens,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,
9606.0,1.0,,F,,,,CHEMBL618330,,BAO_0000219,A2780,81034.0,,,N,4785.0,17496.0,1.0,478.0,Intermediate,Homo sapiens,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,
9606.0,1.0,,F,,,,CHEMBL618331,,BAO_0000219,A2780,81034.0,,,N,4786.0,12989.0,1.0,478.0,Expert,Homo sapiens,In vitro antitumor activity against A2780cisR cell line.,
9606.0,1.0,,F,,,,CHEMBL618332,,BAO_0000219,A2780,81034.0,,,N,4787.0,4840.0,1.0,478.0,Intermediate,Homo sapiens,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),
9606.0,1.0,,F,,,,CHEMBL618333,,BAO_0000219,A2780,81034.0,,,N,4788.0,12989.0,1.0,478.0,Expert,Homo sapiens,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,
9606.0,1.0,,F,,,,CHEMBL618334,,BAO_0000219,A2780cisR,80017.0,,,N,4789.0,16745.0,1.0,481.0,Intermediate,Homo sapiens,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,
9606.0,1.0,,F,,,,CHEMBL618335,,BAO_0000219,A2780,81034.0,,,N,4790.0,16597.0,1.0,478.0,Expert,Homo sapiens,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,
10116.0,9.0,,B,,,,CHEMBL618336,,BAO_0000019,,11736.0,,,D,4791.0,16547.0,1.0,,Expert,Rattus norvegicus,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,
,8.0,,F,,,,CHEMBL618337,,BAO_0000019,,11736.0,,,H,4792.0,16547.0,1.0,,Expert,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),
10116.0,9.0,,F,,,,CHEMBL618338,,BAO_0000019,,11736.0,,,D,4793.0,16547.0,1.0,,Expert,Rattus norvegicus,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),
9606.0,9.0,,F,,,,CHEMBL618339,,BAO_0000219,HEK293,278.0,,,D,4794.0,15856.0,1.0,722.0,Expert,Homo sapiens,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,
9606.0,9.0,,F,,,,CHEMBL618340,,BAO_0000219,HEK293,278.0,,,D,4795.0,15856.0,1.0,722.0,Expert,Homo sapiens,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,
10090.0,9.0,,B,,,,CHEMBL618341,,BAO_0000019,,11831.0,,,D,4796.0,16547.0,1.0,,Expert,Mus musculus,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,
,8.0,,F,,,,CHEMBL618342,,BAO_0000019,,11831.0,,,H,4797.0,16547.0,1.0,,Expert,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),
10090.0,9.0,,F,,,,CHEMBL618343,,BAO_0000019,,11831.0,,,D,4798.0,16547.0,1.0,,Expert,Mus musculus,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),
,8.0,,B,,,,CHEMBL621038,,BAO_0000357,,280.0,,,H,4799.0,17402.0,1.0,,Expert,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,
9606.0,0.0,,F,,,,CHEMBL621039,,BAO_0000219,T-cells,22226.0,,,U,4800.0,11746.0,1.0,574.0,Autocuration,Homo sapiens,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),
9606.0,0.0,,F,,,,CHEMBL621040,,BAO_0000219,T-cells,22226.0,,,U,4801.0,11746.0,1.0,574.0,Autocuration,Homo sapiens,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,
9606.0,1.0,,F,,,,CHEMBL621041,,BAO_0000219,A-375,80018.0,,,N,4802.0,5455.0,1.0,455.0,Intermediate,Homo sapiens,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,
9606.0,1.0,,F,,,,CHEMBL621042,,BAO_0000219,A-375,80018.0,,,N,4803.0,2068.0,1.0,455.0,Intermediate,Homo sapiens,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,
9606.0,1.0,,F,,,,CHEMBL621043,,BAO_0000219,A-375,80018.0,,,N,4804.0,2683.0,1.0,455.0,Intermediate,Homo sapiens,In vitro antitumor activity against A375cell line extracted form melanoma,
9606.0,1.0,,F,,,,CHEMBL621044,,BAO_0000219,A-375,80018.0,,,N,4805.0,15313.0,1.0,455.0,Expert,Homo sapiens,Inhibition of cell growth in (A375) melan cell line,
9606.0,1.0,,F,,,,CHEMBL621045,,BAO_0000219,A-375,80018.0,,,N,4806.0,13739.0,1.0,455.0,Intermediate,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,
9606.0,1.0,,F,,,,CHEMBL621046,,BAO_0000219,A-375,80018.0,,,N,4807.0,13739.0,1.0,455.0,Intermediate,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,
9606.0,1.0,,F,,,,CHEMBL621047,,BAO_0000219,A-375,80018.0,,,N,4808.0,14750.0,1.0,455.0,Intermediate,Homo sapiens,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,
9606.0,1.0,,F,,,,CHEMBL621048,,BAO_0000219,A-427,80019.0,,,N,4809.0,14777.0,1.0,797.0,Intermediate,Homo sapiens,Antiproliferative activity measured against A427 human lung carcinoma,
9606.0,1.0,,F,,,,CHEMBL883798,,BAO_0000219,A-427,80019.0,,,N,4810.0,14777.0,1.0,797.0,Intermediate,Homo sapiens,Antiproliferative activity measured against A427 human lung carcinoma,
9606.0,1.0,,F,,,,CHEMBL621049,,BAO_0000219,A-427,80019.0,,,N,4811.0,17672.0,1.0,797.0,Intermediate,Homo sapiens,Cytotoxicity against lung carcinoma A427 tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL621050,,BAO_0000219,A-427,80019.0,,,N,4812.0,14368.0,1.0,797.0,Intermediate,Homo sapiens,Inhibition of large cell lung carcinoma (A427),
9606.0,1.0,,F,,,,CHEMBL621051,,BAO_0000219,A-427,80019.0,,,N,4813.0,14368.0,1.0,797.0,Intermediate,Homo sapiens,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,
9606.0,1.0,,F,,,,CHEMBL621052,,BAO_0000219,A-427,80019.0,,,N,4814.0,13866.0,1.0,797.0,Intermediate,Homo sapiens,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,
9606.0,1.0,,F,,,,CHEMBL621053,,BAO_0000219,A-427,80019.0,,,N,4815.0,2545.0,1.0,797.0,Intermediate,Homo sapiens,Inhibitory concentration in human lung carcinoma A427 cell line,
9606.0,1.0,,F,,,,CHEMBL621054,,BAO_0000219,A-427,80019.0,,,N,4816.0,2545.0,1.0,797.0,Intermediate,Homo sapiens,Inhibitory concentration in human lung carcinoma A427/VCR cell line,
9527.0,0.0,,A,,,,CHEMBL621055,,BAO_0000218,,22224.0,In vivo,,U,4817.0,6062.0,1.0,,Autocuration,Cercopithecidae,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,
9527.0,0.0,,A,,,,CHEMBL876398,,BAO_0000218,,22224.0,In vivo,,U,4818.0,4578.0,1.0,,Autocuration,Cercopithecidae,Tested for volume of distribution upon iv administration to african green monkey,
9527.0,0.0,,A,,,,CHEMBL621056,,BAO_0000218,,22224.0,In vivo,,U,4819.0,17592.0,1.0,,Autocuration,Cercopithecidae,Volume of distribution in monkey,
9544.0,0.0,,A,,,,CHEMBL621057,,BAO_0000218,,22224.0,In vivo,,U,4820.0,5005.0,1.0,,Autocuration,Macaca mulatta,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,
9544.0,0.0,,A,,,,CHEMBL621058,,BAO_0000218,,22224.0,In vivo,,U,4821.0,5005.0,1.0,,Autocuration,Macaca mulatta,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,
9527.0,0.0,,A,,,,CHEMBL621059,,BAO_0000218,,22224.0,In vivo,,U,4822.0,5922.0,1.0,,Autocuration,Cercopithecidae,Pharmacokinetic property(Vdss) in cynomolgus monkey,
9527.0,0.0,,A,,,,CHEMBL621060,,BAO_0000218,,22224.0,In vivo,,U,4823.0,5355.0,1.0,,Autocuration,Cercopithecidae,The distribution volume after intravenous administration in cynomolgus monkeys,
9527.0,0.0,,A,,,,CHEMBL621061,,BAO_0000218,,22224.0,In vivo,,U,4824.0,5355.0,1.0,,Autocuration,Cercopithecidae,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,
9527.0,0.0,,A,,,,CHEMBL621062,,BAO_0000218,,22224.0,In vivo,,U,4825.0,5355.0,1.0,,Autocuration,Cercopithecidae,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,
9527.0,0.0,,A,,,,CHEMBL621063,,BAO_0000218,,22224.0,In vivo,,U,4826.0,6057.0,1.0,,Autocuration,Cercopithecidae,Volume displacement was calculated in rhesus monkey,
9527.0,0.0,,A,,,,CHEMBL621064,,BAO_0000218,,22224.0,In vivo,,U,4827.0,5145.0,1.0,,Autocuration,Cercopithecidae,Volume of distribution in steady state was determined in rhesus monkey,
9527.0,0.0,,A,,,,CHEMBL621065,,BAO_0000218,,22224.0,In vivo,,U,4828.0,6821.0,1.0,,Autocuration,Cercopithecidae,Volume of distribution of compound was determined in monkey,
9527.0,0.0,,A,,,,CHEMBL621066,,BAO_0000218,,22224.0,In vivo,,U,4829.0,5334.0,1.0,,Autocuration,Cercopithecidae,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),
9527.0,0.0,,A,,,,CHEMBL621067,,BAO_0000218,,22224.0,In vivo,,U,4830.0,5334.0,1.0,,Autocuration,Cercopithecidae,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),
9527.0,0.0,,A,,,,CHEMBL621068,,BAO_0000218,,22224.0,In vivo,,U,4831.0,6641.0,1.0,,Autocuration,Cercopithecidae,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),
9527.0,0.0,,A,,,,CHEMBL876399,,BAO_0000218,,22224.0,In vivo,,U,4832.0,2661.0,1.0,,Autocuration,Cercopithecidae,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,
9527.0,0.0,,A,,,,CHEMBL621069,,BAO_0000218,,22224.0,In vivo,,U,4833.0,6535.0,1.0,,Autocuration,Cercopithecidae,Volume distribution in monkey after administration of 1 mg/kg iv,
9527.0,0.0,,A,,,,CHEMBL621070,,BAO_0000218,,22224.0,In vivo,,U,4834.0,4809.0,1.0,,Autocuration,Cercopithecidae,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),
9527.0,0.0,,A,,,,CHEMBL621071,,BAO_0000218,,22224.0,In vivo,,U,4835.0,6062.0,1.0,,Autocuration,Cercopithecidae,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,
9527.0,0.0,,A,,,,CHEMBL621072,,BAO_0000218,,22224.0,In vivo,,U,4836.0,3443.0,1.0,,Autocuration,Cercopithecidae,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,
9527.0,0.0,,A,,,,CHEMBL618209,,BAO_0000218,,22224.0,In vivo,,U,4837.0,4578.0,1.0,,Autocuration,Cercopithecidae,Oral systemic bioavailability upon iv administration to african green monkey,
9527.0,0.0,,A,,,,CHEMBL618210,,BAO_0000218,,22224.0,In vivo,,U,4838.0,4809.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),
9527.0,0.0,,A,,,,CHEMBL618211,,BAO_0000019,,22224.0,,,U,4839.0,11271.0,1.0,,Autocuration,Cercopithecidae,Baboon plasma free fraction. ,
9527.0,0.0,,A,,,,CHEMBL618212,,BAO_0000218,,22224.0,,,U,4840.0,6057.0,1.0,,Autocuration,Cercopithecidae,Area under the curve was calculated in rhesus monkey after iv administration,
9527.0,0.0,,A,,,,CHEMBL618213,,BAO_0000019,,22224.0,,,U,4841.0,6057.0,1.0,,Autocuration,Cercopithecidae,Area under the curve was calculated in rhesus monkey after peroral administration,
9527.0,0.0,,A,,,,CHEMBL618214,,BAO_0000019,,22224.0,,,U,4842.0,17853.0,1.0,,Autocuration,Cercopithecidae,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,
9527.0,0.0,,A,,,,CHEMBL873492,,BAO_0000218,,22224.0,In vivo,,U,4843.0,5302.0,1.0,,Autocuration,Cercopithecidae,Half life period in monkey after 5 mg/kg dose,
9527.0,0.0,,A,,,,CHEMBL618272,,BAO_0000218,,22224.0,In vivo,,U,4844.0,4257.0,1.0,,Autocuration,Cercopithecidae,Half-life was determined in monkey after 3 mg/kg of i.v. dose,
9527.0,0.0,,A,,,,CHEMBL618273,,BAO_0000218,,22224.0,In vivo,,U,4845.0,4257.0,1.0,,Autocuration,Cercopithecidae,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,
9527.0,0.0,,A,,,1969.0,CHEMBL618274,,BAO_0000218,,22224.0,In vivo,,U,4846.0,13501.0,1.0,,Autocuration,Cercopithecidae,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Plasma
9527.0,0.0,,A,,,,CHEMBL618275,,BAO_0000218,,22224.0,In vivo,,U,4847.0,5394.0,1.0,,Autocuration,Cercopithecidae,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,
9527.0,0.0,,A,,,,CHEMBL618276,,BAO_0000218,,22224.0,In vivo,,U,4848.0,2661.0,1.0,,Autocuration,Cercopithecidae,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,
9527.0,0.0,,A,,,,CHEMBL618277,,BAO_0000019,,22224.0,,,U,4849.0,3341.0,1.0,,Autocuration,Cercopithecidae,Compound was evaluated for terminal half life in monkey,
9527.0,0.0,,A,,,,CHEMBL618278,,BAO_0000218,,22224.0,In vivo,,U,4850.0,3045.0,1.0,,Autocuration,Cercopithecidae,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,
9544.0,0.0,,A,,,1969.0,CHEMBL618279,,BAO_0000218,,22224.0,In vivo,,U,4851.0,5005.0,1.0,,Autocuration,Macaca mulatta,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Plasma
9527.0,0.0,,A,,,,CHEMBL618280,,BAO_0000019,,22224.0,,,U,4852.0,4847.0,1.0,,Autocuration,Cercopithecidae,Half life of compound was determined in squirrel monkey,
9541.0,0.0,,A,,,,CHEMBL618281,,BAO_0000218,,22224.0,In vivo,,U,4853.0,4256.0,1.0,,Autocuration,Macaca fascicularis,Half life after iv administration in cynomolgus monkey,
9527.0,0.0,,A,,,1969.0,CHEMBL618282,,BAO_0000218,,22224.0,In vivo,,U,4854.0,6535.0,1.0,,Autocuration,Cercopithecidae,Half life in monkey plasma after administration of 1 mg/kg iv,Plasma
9527.0,0.0,,A,,,,CHEMBL618283,,BAO_0000019,,22224.0,,,U,4855.0,6057.0,1.0,,Autocuration,Cercopithecidae,Half life was calculated in rhesus monkey,
9527.0,0.0,,A,,,,CHEMBL618284,,BAO_0000019,,22224.0,,,U,4856.0,17592.0,1.0,,Autocuration,Cercopithecidae,Half life in monkey,
9527.0,0.0,,A,,,,CHEMBL618285,,BAO_0000218,,22224.0,In vivo,,U,4857.0,6641.0,1.0,,Autocuration,Cercopithecidae,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),
9527.0,0.0,,A,,,,CHEMBL618286,,BAO_0000019,,22224.0,,,U,4858.0,5472.0,1.0,,Autocuration,Cercopithecidae,Half life was evaluated in rhesus,
9527.0,0.0,,A,,,,CHEMBL618287,,BAO_0000218,,22224.0,In vivo,,U,4859.0,6221.0,1.0,,Autocuration,Cercopithecidae,Half life period after oral administration (2.5 mg/kg) in monkey was determined,
9527.0,0.0,,A,,,,CHEMBL618288,,BAO_0000218,,22224.0,In vivo,,U,4860.0,5668.0,1.0,,Autocuration,Cercopithecidae,Half life period was determine after peroral administration at 10 mpk in Rhesus,
9527.0,0.0,,A,,,,CHEMBL876393,,BAO_0000218,,22224.0,In vivo,,U,4861.0,4809.0,1.0,,Autocuration,Cercopithecidae,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),
9527.0,0.0,,A,,,,CHEMBL618289,,BAO_0000218,,22224.0,In vivo,,U,4862.0,5546.0,1.0,,Autocuration,Cercopithecidae,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,
9527.0,0.0,,A,,,,CHEMBL618290,,BAO_0000218,,22224.0,In vivo,,U,4863.0,5553.0,1.0,,Autocuration,Cercopithecidae,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,
9527.0,0.0,,A,,,,CHEMBL618291,,BAO_0000019,,22224.0,,,U,4864.0,6078.0,1.0,,Autocuration,Cercopithecidae,Half-life was calculated in monkey,
9527.0,0.0,,A,,,,CHEMBL618292,,BAO_0000019,,22224.0,,,U,4865.0,5147.0,1.0,,Autocuration,Cercopithecidae,Half-life in Squirrel monkey,
9527.0,0.0,,A,,,,CHEMBL618293,,BAO_0000019,,22224.0,,,U,4866.0,5145.0,1.0,,Autocuration,Cercopithecidae,Half-life in rhesus monkey,
9527.0,0.0,,A,,,,CHEMBL618294,,BAO_0000218,,22224.0,In vivo,,U,4867.0,6062.0,1.0,,Autocuration,Cercopithecidae,Half-life was measured in monkey after an iv dose of 1 mg/kg,
9527.0,0.0,,A,,,,CHEMBL618295,,BAO_0000218,,22224.0,In vivo,,U,4868.0,5355.0,1.0,,Autocuration,Cercopithecidae,Half-life period after intravenous administration in cynomolgus monkeys,
9527.0,0.0,,A,,,,CHEMBL618296,,BAO_0000218,,22224.0,In vivo,,U,4869.0,5355.0,1.0,,Autocuration,Cercopithecidae,Half-life period after oral administration in cynomolgus monkeys,
9527.0,0.0,,A,,,,CHEMBL618297,,BAO_0000218,,22224.0,In vivo,,U,4870.0,5355.0,1.0,,Autocuration,Cercopithecidae,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,
9606.0,0.0,,A,,,1088.0,CHEMBL618298,,BAO_0000019,,22224.0,,,U,4871.0,7766.0,1.0,,Autocuration,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine
9606.0,0.0,,A,,,1088.0,CHEMBL618299,,BAO_0000019,,22224.0,,,U,4872.0,7766.0,1.0,,Autocuration,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine
9606.0,0.0,,A,,,1088.0,CHEMBL618300,,BAO_0000019,,22224.0,,,U,4873.0,7766.0,1.0,,Autocuration,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine
9606.0,0.0,,A,,,1088.0,CHEMBL618301,,BAO_0000019,,22224.0,,,U,4874.0,7766.0,1.0,,Autocuration,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine
9606.0,0.0,,A,,,1088.0,CHEMBL618302,,BAO_0000019,,22224.0,,,U,4875.0,7766.0,1.0,,Autocuration,Homo sapiens,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Urine
9606.0,0.0,,A,,,1088.0,CHEMBL876394,,BAO_0000019,,22224.0,,,U,4876.0,7766.0,1.0,,Autocuration,Homo sapiens,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Urine
9606.0,0.0,,A,,,1088.0,CHEMBL618303,,BAO_0000019,,22224.0,,,U,4877.0,7766.0,1.0,,Autocuration,Homo sapiens,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Urine
9606.0,0.0,,A,,,1088.0,CHEMBL618304,,BAO_0000019,,22224.0,,,U,4878.0,7766.0,1.0,,Autocuration,Homo sapiens,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Urine
9606.0,0.0,,A,,,,CHEMBL618305,,BAO_0000218,,22224.0,In vivo,,U,4879.0,1916.0,1.0,,Autocuration,Homo sapiens,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,
9606.0,0.0,,A,,,,CHEMBL618306,,BAO_0000218,,22224.0,In vivo,,U,4880.0,16643.0,1.0,,Autocuration,Homo sapiens,Oral bioavailability in human,
9606.0,0.0,,A,,,,CHEMBL618307,,BAO_0000019,,22224.0,,,U,4881.0,17248.0,1.0,,Autocuration,Homo sapiens,Compound was tested for human plasma protein binding,
9606.0,0.0,,A,,,,CHEMBL618308,,BAO_0000019,,22224.0,,,U,4882.0,17248.0,1.0,,Autocuration,Homo sapiens,Compound was tested for human plasma protein binding; Not determined,
9606.0,0.0,,A,,,,CHEMBL618309,,BAO_0000019,,22224.0,,,U,4883.0,6241.0,1.0,,Autocuration,Homo sapiens,Protein binding activity of compound in human plasma; % Free,
9606.0,0.0,,A,,,,CHEMBL618310,,BAO_0000019,,22224.0,,,U,4884.0,17716.0,1.0,,Autocuration,Homo sapiens,Unbound fraction (plasma),
9606.0,0.0,,A,,,1969.0,CHEMBL873353,,BAO_0000366,,22224.0,,,U,4885.0,17605.0,1.0,,Autocuration,Homo sapiens,Half life for the hydrolysis of compound in human blood serum,Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL618311,,BAO_0000366,,22224.0,,,U,4886.0,17625.0,1.0,,Autocuration,Homo sapiens,Half life period in human plasma using phosphate buffer (0.08 M),Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL618312,,BAO_0000366,,22224.0,,,U,4887.0,17625.0,1.0,,Autocuration,Homo sapiens,Half life period in human plasma using phosphate buffer (0.1 M),Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL618313,,BAO_0000366,,22224.0,,,U,4888.0,17747.0,1.0,,Autocuration,Homo sapiens,Half-life in human plasma was determined,Plasma
9606.0,0.0,,A,,,,CHEMBL618314,,BAO_0000019,,22224.0,,,U,4889.0,15613.0,1.0,,Autocuration,Homo sapiens,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,
9606.0,0.0,,A,,,,CHEMBL618315,,BAO_0000019,,22224.0,,,U,4890.0,354.0,1.0,,Autocuration,Homo sapiens,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),
9606.0,0.0,,A,,,,CHEMBL618316,,BAO_0000019,,22224.0,,,U,4891.0,3741.0,1.0,,Autocuration,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",
9606.0,0.0,,A,,,,CHEMBL618317,,BAO_0000019,,22224.0,,,U,4892.0,3741.0,1.0,,Autocuration,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",
9606.0,0.0,,A,,,,CHEMBL620138,,BAO_0000019,,22224.0,,,U,4893.0,3741.0,1.0,,Autocuration,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",
9606.0,0.0,,A,,,,CHEMBL858280,,BAO_0000019,,22224.0,,,U,4894.0,17599.0,1.0,,Autocuration,Homo sapiens,Partition coefficient (logP),
9606.0,0.0,,A,,,,CHEMBL620139,,BAO_0000019,,22224.0,,,U,4895.0,5486.0,1.0,,Autocuration,Homo sapiens,In vitro metabolic stability in human was measured as pmol/min/mg/protein,
9606.0,0.0,,A,,,,CHEMBL620140,,BAO_0000251,,22224.0,,Microsomes,U,4896.0,5600.0,1.0,,Autocuration,Homo sapiens,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,
9606.0,0.0,,A,,,,CHEMBL620141,,BAO_0000019,,22224.0,,,U,4897.0,14294.0,1.0,,Autocuration,Homo sapiens,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),
9606.0,0.0,,A,,,,CHEMBL620142,,BAO_0000019,,22224.0,,,U,4898.0,14294.0,1.0,,Autocuration,Homo sapiens,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),
9606.0,0.0,,A,,,,CHEMBL620143,,BAO_0000019,,22224.0,,,U,4899.0,14294.0,1.0,,Autocuration,Homo sapiens,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),
9606.0,0.0,,A,,,,CHEMBL620144,,BAO_0000251,,22224.0,,Microsomes,U,4900.0,14294.0,1.0,,Autocuration,Homo sapiens,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),
9606.0,0.0,,A,,,,CHEMBL620145,,BAO_0000251,,22224.0,,Microsomes,U,4901.0,14294.0,1.0,,Autocuration,Homo sapiens,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),
9606.0,0.0,,A,,,,CHEMBL620146,,BAO_0000251,,22224.0,,Microsomes,U,4902.0,14294.0,1.0,,Autocuration,Homo sapiens,Metabolism of compound in human microsomes; Trace,
9606.0,0.0,,A,,,2107.0,CHEMBL620147,,BAO_0000251,,22224.0,,Microsomes,U,4903.0,6260.0,1.0,,Autocuration,Homo sapiens,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Liver
9606.0,0.0,,A,,,,CHEMBL620148,,BAO_0000251,,22224.0,,Microsomes,U,4904.0,6187.0,1.0,,Autocuration,Homo sapiens,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,
9606.0,0.0,,A,,,2107.0,CHEMBL620149,,BAO_0000251,,22224.0,,Microsomes,U,4905.0,6251.0,1.0,,Autocuration,Homo sapiens,In vitro metabolic potential in human liver microsomes,Liver
9606.0,0.0,,A,,,,CHEMBL876412,,BAO_0000019,,22224.0,,,U,4906.0,3246.0,1.0,,Autocuration,Homo sapiens,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,
9606.0,0.0,,A,,,,CHEMBL619352,,BAO_0000019,,22224.0,,,U,4907.0,17313.0,1.0,,Autocuration,Homo sapiens,Tested for human plasma protein binding of the compound; Not tested,
9606.0,0.0,,A,,,,CHEMBL619353,,BAO_0000019,,22224.0,,,U,4908.0,6227.0,1.0,,Autocuration,Homo sapiens,Compound was tested for percent protein binding (PB) in human,
9606.0,0.0,,A,,,1969.0,CHEMBL619354,,BAO_0000019,,22224.0,,,U,4909.0,5530.0,1.0,,Autocuration,Homo sapiens,Protein binding in human plasma,Plasma
9606.0,0.0,,A,,,,CHEMBL619355,,BAO_0000019,,22224.0,,,U,4910.0,6108.0,1.0,,Autocuration,Homo sapiens,Permeability coefficient (B to A) in Caco-2 cell,
9606.0,0.0,,A,,,,CHEMBL619356,,BAO_0000019,,22224.0,,,U,4911.0,6108.0,1.0,,Autocuration,Homo sapiens,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,
9606.0,0.0,,A,,,,CHEMBL619357,,BAO_0000019,,22224.0,,,U,4912.0,2774.0,1.0,,Autocuration,Homo sapiens,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),
9606.0,0.0,,A,,,,CHEMBL619358,,BAO_0000019,,22224.0,,,U,4913.0,16643.0,1.0,,Autocuration,Homo sapiens,In vitro rate of absorption observed as Caco-2 permeability in humans,
9606.0,0.0,,A,,,,CHEMBL619359,,BAO_0000219,Caco-2,22224.0,,,U,4914.0,17582.0,1.0,495.0,Autocuration,Homo sapiens,Cellular permeability of compound was determined in Caco-2 cells; High,
9606.0,0.0,,A,,,,CHEMBL619360,,BAO_0000219,Caco-2,22224.0,,,U,4915.0,6838.0,1.0,495.0,Autocuration,Homo sapiens,Permeability in Caco-2 cells of compound,
9606.0,0.0,,A,,,,CHEMBL619361,,BAO_0000019,,22224.0,,,U,4916.0,6108.0,1.0,,Autocuration,Homo sapiens,Permeability coefficient (A to B) in Caco-2 cell,
9606.0,0.0,,A,,,,CHEMBL619362,,BAO_0000019,,22224.0,,,U,4917.0,6108.0,1.0,,Autocuration,Homo sapiens,Permeability coefficient (B to A) in Caco-2 cell,
9606.0,0.0,,A,,,,CHEMBL619363,,BAO_0000019,,22224.0,,,U,4918.0,6108.0,1.0,,Autocuration,Homo sapiens,Permeability coefficient (Papp) (Caco-2 cell monolayer),
9606.0,0.0,,A,,,,CHEMBL618942,,BAO_0000019,,22224.0,,,U,4919.0,2146.0,1.0,,Autocuration,Homo sapiens,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,
9606.0,0.0,,A,,,,CHEMBL618943,,BAO_0000019,,22224.0,,,U,4920.0,4514.0,1.0,,Autocuration,Homo sapiens,Compound was tested for protein binding in human plasma,
9606.0,0.0,,A,,,,CHEMBL618944,,BAO_0000019,,22224.0,,,U,4921.0,6108.0,1.0,,Autocuration,Homo sapiens,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,
9606.0,0.0,,A,,,1088.0,CHEMBL618945,,BAO_0000019,,22224.0,,,U,4922.0,7766.0,1.0,,Autocuration,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,Urine
10090.0,1.0,,A,,,,CHEMBL618946,,BAO_0000218,,50594.0,In vivo,,N,4923.0,5969.0,1.0,,Intermediate,Mus musculus,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,
10090.0,1.0,,A,,,,CHEMBL876413,,BAO_0000218,,50594.0,In vivo,,N,4924.0,3277.0,1.0,,Intermediate,Mus musculus,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),
10090.0,1.0,,A,,,,CHEMBL618947,,BAO_0000218,,50594.0,In vivo,,N,4925.0,3802.0,1.0,,Intermediate,Mus musculus,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,
10090.0,1.0,,A,,,1969.0,CHEMBL618948,,BAO_0000218,,50594.0,In vivo,,N,4926.0,2862.0,1.0,,Intermediate,Mus musculus,Time taken to reach maximum concentration in plasma upon oral administration in mouse,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL618949,,BAO_0000218,,50594.0,In vivo,,N,4927.0,6348.0,1.0,,Intermediate,Mus musculus,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Plasma
10090.0,1.0,,F,,,,CHEMBL618950,,BAO_0000218,,50594.0,In vivo,,N,4928.0,17764.0,1.0,,Intermediate,Mus musculus,Tmax after intraperitoneal administration in mice at 23 uM/kg,
10090.0,1.0,,A,,,,CHEMBL618951,,BAO_0000218,,50594.0,In vivo,,N,4929.0,5781.0,1.0,,Intermediate,Mus musculus,Tmax after oral administration at 30 mg/kg in ICR mouse,
10090.0,1.0,,A,,,,CHEMBL618952,,BAO_0000218,,50594.0,In vivo,,N,4930.0,17764.0,1.0,,Intermediate,Mus musculus,Tmax after peroral administration in mice at 2.4 uM/kg,
10090.0,1.0,,A,,,,CHEMBL618953,,BAO_0000218,,50594.0,In vivo,,N,4931.0,4066.0,1.0,,Intermediate,Mus musculus,Tmax at a single subcutaneous administration of 40 mg/kg in mice,
10090.0,1.0,,A,,,955.0,CHEMBL618954,,BAO_0000218,,50594.0,In vivo,,N,4932.0,17641.0,1.0,,Intermediate,Mus musculus,Tmax in brain of mice at the oral dose of 50 mg/kg,Brain
10090.0,1.0,,A,,,2113.0,CHEMBL618955,,BAO_0000218,,50594.0,In vivo,,N,4933.0,17641.0,1.0,,Intermediate,Mus musculus,Tmax in kidney of mice at the oral dose of 50 mg/kg,Kidney
10090.0,1.0,,A,,,2107.0,CHEMBL618956,,BAO_0000218,,50594.0,In vivo,,N,4934.0,17641.0,1.0,,Intermediate,Mus musculus,Tmax in liver of mice at the oral dose of 50 mg/kg,Liver
10090.0,1.0,,A,,,2048.0,CHEMBL618957,,BAO_0000218,,50594.0,In vivo,,N,4935.0,17641.0,1.0,,Intermediate,Mus musculus,Tmax in lungs of mice at the oral dose of 50 mg/kg,Lung
10090.0,1.0,,F,,,,CHEMBL618958,,BAO_0000218,,50594.0,In vivo,,N,4936.0,17764.0,1.0,,Intermediate,Mus musculus,Tmax in mice at 18 uM/kg i.p. administration,
10090.0,1.0,,F,,,,CHEMBL618959,,BAO_0000218,,50594.0,In vivo,,N,4937.0,17764.0,1.0,,Intermediate,Mus musculus,Tmax in mice at 23 uM/kg i.v. administration,
10090.0,1.0,,F,,,,CHEMBL618960,,BAO_0000218,,50594.0,In vivo,,N,4938.0,17764.0,1.0,,Intermediate,Mus musculus,Tmax in mice at 25 uM/kg i.p. administration,
10090.0,1.0,,F,,,,CHEMBL876723,,BAO_0000218,,50594.0,In vivo,,N,4939.0,17764.0,1.0,,Intermediate,Mus musculus,Tmax in mice at 26 uM/kg i.p. administration,
10090.0,1.0,,A,,,2106.0,CHEMBL618961,,BAO_0000218,,50594.0,In vivo,,N,4940.0,17641.0,1.0,,Intermediate,Mus musculus,Tmax in spleen of mice at the oral dose of 50 mg/kg,Spleen
10090.0,1.0,,A,,,,CHEMBL618962,,BAO_0000218,,50594.0,In vivo,,N,4941.0,16597.0,1.0,,Intermediate,Mus musculus,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,
10090.0,1.0,,A,,,,CHEMBL618963,,BAO_0000218,,50594.0,In vivo,,N,4942.0,16597.0,1.0,,Intermediate,Mus musculus,Tmax value at a dose of 10 mg/kg peroral administration in mice.,
10090.0,1.0,,A,,,,CHEMBL618964,,BAO_0000218,,50594.0,,,N,4943.0,5951.0,1.0,,Intermediate,Mus musculus,Tmax value in IRC mice,
10090.0,1.0,,A,,,,CHEMBL618965,,BAO_0000218,,50594.0,In vivo,,N,4944.0,5506.0,1.0,,Intermediate,Mus musculus,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,
10090.0,1.0,,A,,,,CHEMBL618966,,BAO_0000218,,50594.0,In vivo,,N,4945.0,5506.0,1.0,,Intermediate,Mus musculus,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,
10090.0,1.0,,A,,,1088.0,CHEMBL618967,,BAO_0000218,,50594.0,,,N,4946.0,429.0,1.0,,Intermediate,Mus musculus,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),Urine
10090.0,1.0,,A,,,1088.0,CHEMBL618968,,BAO_0000218,,50594.0,,,N,4947.0,429.0,1.0,,Intermediate,Mus musculus,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),Urine
10090.0,1.0,,A,,,1088.0,CHEMBL618969,,BAO_0000218,,50594.0,,,N,4948.0,4066.0,1.0,,Intermediate,Mus musculus,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),Urine
10090.0,1.0,,A,,,,CHEMBL618970,,BAO_0000218,,50594.0,,,N,4949.0,17734.0,1.0,,Intermediate,Mus musculus,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,
10090.0,1.0,,A,,,,CHEMBL618971,,BAO_0000218,,50594.0,,,N,4950.0,17734.0,1.0,,Intermediate,Mus musculus,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,
10090.0,1.0,,A,,,,CHEMBL618972,,BAO_0000218,,50594.0,In vivo,,N,4951.0,6062.0,1.0,,Intermediate,Mus musculus,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,
10090.0,1.0,,A,,,,CHEMBL618973,,BAO_0000218,,50594.0,In vivo,,N,4952.0,5969.0,1.0,,Intermediate,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,
10090.0,1.0,,A,,,,CHEMBL618974,,BAO_0000218,,50594.0,In vivo,,N,4953.0,5969.0,1.0,,Intermediate,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,
10090.0,1.0,,A,,,,CHEMBL618975,,BAO_0000218,,50594.0,In vivo,,N,4954.0,5969.0,1.0,,Intermediate,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,
10090.0,1.0,,A,,,,CHEMBL618976,,BAO_0000218,,50594.0,In vivo,,N,4955.0,5980.0,1.0,,Intermediate,Mus musculus,Vd in mice,
10090.0,1.0,,A,,,,CHEMBL618977,,BAO_0000218,,50594.0,In vivo,,N,4956.0,17592.0,1.0,,Intermediate,Mus musculus,Volume of distribution in mouse,
10090.0,1.0,,A,,,,CHEMBL876724,,BAO_0000218,,50594.0,In vivo,,N,4957.0,6348.0,1.0,,Intermediate,Mus musculus,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,
10090.0,1.0,,A,,,,CHEMBL618978,,BAO_0000218,,50594.0,In vivo,,N,4958.0,17753.0,1.0,,Intermediate,Mus musculus,Volume of distribution of compound in plasma was determined at 24 mg/Kg,
10090.0,1.0,,A,,,,CHEMBL618979,,BAO_0000218,,50594.0,In vivo,,N,4959.0,17753.0,1.0,,Intermediate,Mus musculus,Volume of distribution of compound in plasma was determined at 40 mg/Kg,
10090.0,1.0,,A,,,,CHEMBL618980,,BAO_0000218,,50594.0,In vivo,,N,4960.0,17753.0,1.0,,Intermediate,Mus musculus,Volume of distribution of compound in plasma was determined at 5 mg/Kg,
10090.0,1.0,,A,,,,CHEMBL618981,,BAO_0000218,,50594.0,In vivo,,N,4961.0,4239.0,1.0,,Intermediate,Mus musculus,Pharmacokinetic property (vdss) was measured in mouse,
10090.0,1.0,,A,,,,CHEMBL618982,,BAO_0000218,,50594.0,In vivo,,N,4962.0,2862.0,1.0,,Intermediate,Mus musculus,Value distribution upon iv administration in mouse,
10090.0,1.0,,A,,,,CHEMBL620150,,BAO_0000218,,50594.0,In vivo,,N,4963.0,17734.0,1.0,,Intermediate,Mus musculus,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,
10090.0,1.0,,A,,,,CHEMBL620151,,BAO_0000218,,50594.0,In vivo,,N,4964.0,2675.0,1.0,,Intermediate,Mus musculus,Volume of distribution was evaluated in mice after intravenous administration,
10090.0,1.0,,A,,,,CHEMBL620152,,BAO_0000218,,50594.0,In vivo,,N,4965.0,2675.0,1.0,,Intermediate,Mus musculus,Volume of distribution was evaluated in mice after oral administration,
10090.0,1.0,,A,,,,CHEMBL620153,,BAO_0000218,,50594.0,In vivo,,N,4966.0,17837.0,1.0,,Intermediate,Mus musculus,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,
10090.0,1.0,,A,,,,CHEMBL876395,,BAO_0000218,,50594.0,In vivo,,N,4967.0,5727.0,1.0,,Intermediate,Mus musculus,Steady state volume of distribution was determined in mice,
10090.0,1.0,,A,,,,CHEMBL620154,,BAO_0000218,,50594.0,In vivo,,N,4968.0,17852.0,1.0,,Intermediate,Mus musculus,Volume distribution (steady state) of compound was determined in mouse,
10090.0,1.0,,A,,,,CHEMBL620155,,BAO_0000218,,50594.0,In vivo,,N,4969.0,17764.0,1.0,,Intermediate,Mus musculus,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,
10090.0,1.0,,A,,,,CHEMBL620156,,BAO_0000218,,50594.0,In vivo,,N,4970.0,16597.0,1.0,,Intermediate,Mus musculus,Vss value at a dose of 10 mg/kg intravenous administration in mice.,
10090.0,1.0,,A,,,,CHEMBL620157,,BAO_0000218,,50594.0,In vivo,,N,4971.0,6062.0,1.0,,Intermediate,Mus musculus,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,
10090.0,1.0,,A,,,2113.0,CHEMBL620158,,BAO_0000218,,50594.0,In vivo,,N,4972.0,16438.0,1.0,,Intermediate,Mus musculus,Biodistribution of compound (oxidized form) in in kidney tissue,Kidney
10090.0,1.0,,A,,,178.0,CHEMBL620159,,BAO_0000218,,50594.0,In vivo,,N,4973.0,16438.0,1.0,,Intermediate,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,Blood
10090.0,1.0,,A,,,178.0,CHEMBL620160,,BAO_0000218,,50594.0,In vivo,,N,4974.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Blood
10090.0,1.0,,A,,,178.0,CHEMBL620161,,BAO_0000218,,50594.0,In vivo,,N,4975.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Blood
9606.0,1.0,,F,,,,CHEMBL620162,,BAO_0000219,A-427,80019.0,,,N,4976.0,10708.0,1.0,797.0,Intermediate,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,
9606.0,1.0,,F,,,,CHEMBL620163,,BAO_0000219,A-431,80852.0,,,N,4977.0,16597.0,1.0,500.0,Expert,Homo sapiens,Inhibition of A431 human squamous cell carcinoma cell proliferation,
9606.0,1.0,,F,,,,CHEMBL620833,,BAO_0000219,A-431,80852.0,,,N,4978.0,16062.0,1.0,500.0,Expert,Homo sapiens,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,
9606.0,1.0,,F,,,,CHEMBL876396,,BAO_0000219,A-431,80852.0,,,N,4979.0,16062.0,1.0,500.0,Expert,Homo sapiens,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,
9606.0,1.0,,F,,,,CHEMBL620834,,BAO_0000219,A-431,80852.0,,,N,4980.0,16958.0,1.0,500.0,Expert,Homo sapiens,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,
9606.0,1.0,,F,,,,CHEMBL620835,,BAO_0000219,A-431,80852.0,,,N,4981.0,6700.0,1.0,500.0,Expert,Homo sapiens,Inhibition of A431 human carcinoma cell proliferation,
9606.0,1.0,,F,,,,CHEMBL620836,,BAO_0000219,A-431,80852.0,,,N,4982.0,17226.0,1.0,500.0,Expert,Homo sapiens,In vitro inhibition of A431 (human carcinoma) cell basal growth.,
9606.0,1.0,,F,,,,CHEMBL620837,,BAO_0000219,A-431,80852.0,,,N,4983.0,6828.0,1.0,500.0,Intermediate,Homo sapiens,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,
9606.0,1.0,,F,,,,CHEMBL621017,,BAO_0000219,A-431,80852.0,,,N,4984.0,12314.0,1.0,500.0,Intermediate,Homo sapiens,In vitro cytotoxicity against epidermoid carcinoma cell line,
9606.0,9.0,,F,,,,CHEMBL621018,,BAO_0000218,A-431,9.0,,,D,4985.0,13412.0,1.0,500.0,Expert,Homo sapiens,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",
9606.0,1.0,,F,,,,CHEMBL621019,,BAO_0000219,A-431,80852.0,,,N,4986.0,13299.0,1.0,500.0,Intermediate,Homo sapiens,Antiproliferative activity of compound was measured on human tumor cell line A431.,
9606.0,1.0,,F,,,,CHEMBL621020,,BAO_0000219,A-431,80852.0,,,N,4987.0,17420.0,1.0,500.0,Intermediate,Homo sapiens,Antiproliferative effect of compound on A431 cell line expressing mutant p53,
9606.0,1.0,,F,,,,CHEMBL621021,,BAO_0000219,A-431,80852.0,,,N,4988.0,13678.0,1.0,500.0,Intermediate,Homo sapiens,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,
,8.0,,F,,,,CHEMBL621022,,BAO_0000219,A-431,9.0,,,H,4989.0,14171.0,1.0,500.0,Expert,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,
9606.0,1.0,,F,,,,CHEMBL621023,,BAO_0000219,A-431,80852.0,,,N,4990.0,6333.0,1.0,500.0,Expert,Homo sapiens,Tested for antiproliferative activity against human A431 cells,
9606.0,9.0,,F,,,,CHEMBL621024,,BAO_0000219,A-431,9.0,,,D,4991.0,2356.0,1.0,500.0,Expert,Homo sapiens,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,
9606.0,1.0,,F,,,,CHEMBL621025,,BAO_0000219,A-431,80852.0,,,N,4992.0,15578.0,1.0,500.0,Expert,Homo sapiens,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,
9606.0,1.0,,F,,,,CHEMBL621026,,BAO_0000219,A-431,80852.0,,,N,4993.0,5126.0,1.0,500.0,Expert,Homo sapiens,Inhibition of A431 cell proliferation,
9606.0,1.0,,F,,,,CHEMBL621027,,BAO_0000219,A-431,80852.0,,,N,4994.0,6844.0,1.0,500.0,Expert,Homo sapiens,Cytotoxic effect on A431 human epidermoid carcinoma cells,
9606.0,1.0,,F,,,,CHEMBL876397,,BAO_0000219,A-431,80852.0,,,N,4995.0,6844.0,1.0,500.0,Expert,Homo sapiens,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),
9606.0,1.0,,F,,,,CHEMBL883797,,BAO_0000219,A-431,80852.0,,,N,4996.0,4925.0,1.0,500.0,Intermediate,Homo sapiens,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,
9606.0,1.0,,F,,,,CHEMBL621028,,BAO_0000219,A-431,80852.0,,,N,4997.0,4925.0,1.0,500.0,Intermediate,Homo sapiens,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,
9606.0,1.0,,F,,,,CHEMBL621029,,BAO_0000219,A-431,80852.0,,,N,4998.0,13978.0,1.0,500.0,Intermediate,Homo sapiens,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,
9606.0,1.0,,F,,,,CHEMBL621030,,BAO_0000219,A-431,80852.0,,,N,4999.0,16786.0,1.0,500.0,Intermediate,Homo sapiens,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,
,8.0,,F,,,,CHEMBL621147,,BAO_0000219,A-431,9.0,,,H,5000.0,13412.0,1.0,500.0,Expert,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,
9606.0,1.0,,F,,,,CHEMBL621148,,BAO_0000218,A-431,80852.0,,,N,5001.0,17824.0,1.0,500.0,Intermediate,Homo sapiens,In vivo antiproliferative activity against A431 cell line,
9606.0,9.0,,F,,,,CHEMBL621149,,BAO_0000219,A-431,9.0,,,D,5002.0,12751.0,1.0,500.0,Expert,Homo sapiens,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,
9606.0,1.0,,F,,,,CHEMBL621150,,BAO_0000219,A-431,80852.0,,,N,5003.0,12380.0,1.0,500.0,Expert,Homo sapiens,Inhibition of A431 human epidermoid carcinoma cell proliferation,
9606.0,9.0,,F,,,,CHEMBL621151,,BAO_0000219,A-431,9.0,,,D,5004.0,4959.0,1.0,500.0,Expert,Homo sapiens,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,
9606.0,1.0,,F,,,,CHEMBL621152,,BAO_0000219,A-431,80852.0,,,N,5005.0,6333.0,1.0,500.0,Intermediate,Homo sapiens,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),
9606.0,1.0,,F,,,,CHEMBL621153,,BAO_0000219,A-431,80852.0,,,N,5006.0,6333.0,1.0,500.0,Intermediate,Homo sapiens,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),
9606.0,1.0,,F,,,,CHEMBL884000,,BAO_0000219,A-431,80852.0,,,N,5007.0,6333.0,1.0,500.0,Intermediate,Homo sapiens,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),
9606.0,9.0,,F,,,,CHEMBL621154,,BAO_0000019,,9.0,,,D,5008.0,5296.0,1.0,,Expert,Homo sapiens,Inhibition of EGFR overexpressing A431 cell proliferation,
9606.0,1.0,,F,,,,CHEMBL621155,,BAO_0000219,A-431,80852.0,,,N,5009.0,12624.0,1.0,500.0,Expert,Homo sapiens,Inhibition of A431 cell proliferation,
9606.0,9.0,,F,,,,CHEMBL621156,,BAO_0000219,A-431,9.0,,,D,5010.0,14926.0,1.0,500.0,Expert,Homo sapiens,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,
9606.0,9.0,,F,,,,CHEMBL621157,,BAO_0000219,A-431,9.0,,,D,5011.0,14926.0,1.0,500.0,Expert,Homo sapiens,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",
,8.0,,F,,,,CHEMBL621158,,BAO_0000219,A-431,9.0,,,H,5012.0,14926.0,1.0,500.0,Expert,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),
9606.0,1.0,,F,,,,CHEMBL621159,,BAO_0000219,A-431,80852.0,,,N,5013.0,15144.0,1.0,500.0,Intermediate,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL621160,,BAO_0000219,A-431,80852.0,,,N,5014.0,15144.0,1.0,500.0,Intermediate,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL621161,,BAO_0000219,A-431,80852.0,,,N,5015.0,5245.0,1.0,500.0,Intermediate,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,
9606.0,1.0,,F,,,,CHEMBL621162,,BAO_0000219,A-431,80852.0,,,N,5016.0,5245.0,1.0,500.0,Intermediate,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,
9606.0,1.0,,F,,,,CHEMBL621163,,BAO_0000219,A-431,80852.0,,,N,5017.0,5245.0,1.0,500.0,Intermediate,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,
9606.0,1.0,,F,,,,CHEMBL621164,,BAO_0000219,A-431,80852.0,,,N,5018.0,5245.0,1.0,500.0,Intermediate,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,
9606.0,1.0,,F,,,,CHEMBL621165,,BAO_0000219,A-431,80852.0,,,N,5019.0,5245.0,1.0,500.0,Intermediate,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,
9527.0,0.0,,A,,,,CHEMBL619159,,BAO_0000019,,22224.0,,,U,5020.0,5922.0,1.0,,Autocuration,Cercopithecidae,Half-life period in cynomolgus monkey,
9527.0,0.0,,A,,,1969.0,CHEMBL619160,,BAO_0000366,,22224.0,In vitro,,U,5021.0,1116.0,1.0,,Autocuration,Cercopithecidae,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",Plasma
9527.0,0.0,,A,,,,CHEMBL619161,,BAO_0000218,,22224.0,In vivo,,U,5022.0,17853.0,1.0,,Autocuration,Cercopithecidae,Longer half-life in monkey (i.v.) at 0.5 mpk,
9527.0,0.0,,A,,,1969.0,CHEMBL619162,,BAO_0000366,,22224.0,,,U,5023.0,993.0,1.0,,Autocuration,Cercopithecidae,Plasma half life in monkey,Plasma
9527.0,0.0,,A,,,1969.0,CHEMBL619163,,BAO_0000366,,22224.0,,,U,5024.0,4514.0,1.0,,Autocuration,Cercopithecidae,Plasma half-life in rhesus monkey,Plasma
9527.0,0.0,,A,,,1969.0,CHEMBL619164,,BAO_0000218,,22224.0,In vivo,,U,5025.0,5334.0,1.0,,Autocuration,Cercopithecidae,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Plasma
9527.0,0.0,,A,,,1969.0,CHEMBL619320,,BAO_0000218,,22224.0,In vivo,,U,5026.0,5334.0,1.0,,Autocuration,Cercopithecidae,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Plasma
9527.0,0.0,,A,,,,CHEMBL619321,,BAO_0000218,,22224.0,In vivo,,U,5027.0,4578.0,1.0,,Autocuration,Cercopithecidae,Tested for half life upon iv administration to african green monkey,
9527.0,0.0,,A,,,,CHEMBL873336,,BAO_0000218,,22224.0,In vivo,,U,5028.0,2661.0,1.0,,Autocuration,Cercopithecidae,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,
9527.0,0.0,,A,,,,CHEMBL619322,,BAO_0000218,,22224.0,In vivo,,U,5029.0,5355.0,1.0,,Autocuration,Cercopithecidae,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,
9527.0,0.0,,A,,,,CHEMBL619323,,BAO_0000218,,22224.0,In vivo,,U,5030.0,5355.0,1.0,,Autocuration,Cercopithecidae,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,
9527.0,0.0,,A,,,,CHEMBL619324,,BAO_0000218,,22224.0,In vivo,,U,5031.0,5355.0,1.0,,Autocuration,Cercopithecidae,The time for peak concentration value after oral administration in cynomolgus monkeys,
9527.0,0.0,,A,,,,CHEMBL619325,,BAO_0000019,,22224.0,,,U,5032.0,11271.0,1.0,,Autocuration,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,
9527.0,0.0,,A,,,,CHEMBL876411,,BAO_0000019,,22224.0,,,U,5033.0,11271.0,1.0,,Autocuration,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,
9527.0,0.0,,A,,,,CHEMBL619326,,BAO_0000019,,22224.0,,,U,5034.0,11271.0,1.0,,Autocuration,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,
9527.0,0.0,,A,,,,CHEMBL619327,,BAO_0000019,,22224.0,,,U,5035.0,11271.0,1.0,,Autocuration,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,
9527.0,0.0,,A,,,,CHEMBL619328,,BAO_0000019,,22224.0,,,U,5036.0,11271.0,1.0,,Autocuration,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,
9527.0,0.0,,A,,,,CHEMBL619329,,BAO_0000019,,22224.0,,,U,5037.0,11271.0,1.0,,Autocuration,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,
9527.0,0.0,,A,,,,CHEMBL619330,,BAO_0000019,,22224.0,,,U,5038.0,11271.0,1.0,,Autocuration,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,
9527.0,0.0,,A,,,,CHEMBL619331,,BAO_0000019,,22224.0,,,U,5039.0,11271.0,1.0,,Autocuration,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,
9527.0,0.0,,A,,,,CHEMBL619332,,BAO_0000019,,22224.0,,,U,5040.0,11271.0,1.0,,Autocuration,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,
9527.0,0.0,,A,,,,CHEMBL619333,,BAO_0000019,,22224.0,,,U,5041.0,11271.0,1.0,,Autocuration,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,
9527.0,0.0,,A,,,,CHEMBL619334,,BAO_0000019,,22224.0,,,U,5042.0,11271.0,1.0,,Autocuration,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,
9527.0,0.0,,A,,,,CHEMBL619335,,BAO_0000019,,22224.0,,,U,5043.0,11271.0,1.0,,Autocuration,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,
9527.0,0.0,,A,,,,CHEMBL619336,,BAO_0000019,,22224.0,,,U,5044.0,11271.0,1.0,,Autocuration,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,
9527.0,0.0,,A,,,,CHEMBL619337,,BAO_0000019,,22224.0,,,U,5045.0,11271.0,1.0,,Autocuration,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,
9527.0,0.0,,A,,,,CHEMBL619338,,BAO_0000019,,22224.0,,,U,5046.0,11271.0,1.0,,Autocuration,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,
9527.0,0.0,,A,,,,CHEMBL619339,,BAO_0000019,,22224.0,,,U,5047.0,11271.0,1.0,,Autocuration,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,
10116.0,1.0,,A,,,,CHEMBL619340,,BAO_0000218,,50597.0,In vivo,,N,5048.0,5809.0,1.0,,Intermediate,Rattus norvegicus,Bioavailability in rat (cannulated) (dose 2 mg/kg),
10116.0,1.0,,A,,,1969.0,CHEMBL873496,,BAO_0000218,,50597.0,In vivo,,N,5049.0,17720.0,1.0,,Intermediate,Rattus norvegicus,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Plasma
10116.0,1.0,,A,,,1969.0,CHEMBL619341,,BAO_0000218,,50597.0,,,N,5050.0,3546.0,1.0,,Intermediate,Rattus norvegicus,AUC value in rat after IV administration at a dose of 10 mg/kg,Plasma
10116.0,1.0,,A,,,1969.0,CHEMBL619342,,BAO_0000218,,50597.0,,,N,5051.0,3546.0,1.0,,Intermediate,Rattus norvegicus,AUC value in rat after oral administration at a dose of 10 mg/kg,Plasma
10116.0,1.0,,A,,,,CHEMBL619343,,BAO_0000218,,50597.0,In vivo,,N,5052.0,3546.0,1.0,,Intermediate,Rattus norvegicus,Cmax value in rat after oral administration at a dose of 10 mg/kg,
10116.0,1.0,,A,,,,CHEMBL619344,,BAO_0000218,,50597.0,In vivo,,N,5053.0,3546.0,1.0,,Intermediate,Rattus norvegicus,Bioavailability in rat after oral administration at a dose of 10 mg/kg,
10116.0,1.0,,A,,,,CHEMBL619345,,BAO_0000218,,50597.0,In vivo,,N,5054.0,3546.0,1.0,,Intermediate,Rattus norvegicus,Tmax value in rat after oral administration at a dose of 10 mg/kg,
10116.0,1.0,,A,,,,CHEMBL619346,,BAO_0000218,,50597.0,,,N,5055.0,3546.0,1.0,,Intermediate,Rattus norvegicus,Vc value in rat after IV administration at a dose of 10 mg/kg,
10116.0,1.0,,A,,,,CHEMBL619347,,BAO_0000218,,50597.0,In vivo,,N,5056.0,3546.0,1.0,,Intermediate,Rattus norvegicus,Half life period in rat after IV administration at a dose of 10 mg/kg,
9557.0,0.0,,A,,,,CHEMBL619348,,BAO_0000019,,22224.0,,,U,5057.0,10625.0,1.0,,Autocuration,Papio hamadryas,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,
9557.0,0.0,,A,,,,CHEMBL619349,,BAO_0000019,,22224.0,,,U,5058.0,10625.0,1.0,,Autocuration,Papio hamadryas,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),
9557.0,0.0,,A,,,,CHEMBL619350,,BAO_0000019,,22224.0,,,U,5059.0,10625.0,1.0,,Autocuration,Papio hamadryas,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),
9557.0,0.0,,A,,,,CHEMBL619351,,BAO_0000019,,22224.0,,,U,5060.0,10625.0,1.0,,Autocuration,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,
9557.0,0.0,,A,,,,CHEMBL875953,,BAO_0000019,,22224.0,,,U,5061.0,10625.0,1.0,,Autocuration,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,
9557.0,0.0,,A,,,,CHEMBL621716,,BAO_0000019,,22224.0,,,U,5062.0,10625.0,1.0,,Autocuration,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,
9557.0,0.0,,A,,,,CHEMBL621717,,BAO_0000019,,22224.0,,,U,5063.0,10625.0,1.0,,Autocuration,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,
9557.0,0.0,,A,,,,CHEMBL621718,,BAO_0000019,,22224.0,,,U,5064.0,10625.0,1.0,,Autocuration,Papio hamadryas,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,
9615.0,0.0,,A,,,,CHEMBL621719,,BAO_0000019,,22224.0,,,U,5065.0,3510.0,1.0,,Autocuration,beagle,Area under curve after 1 mpk peroral administration to beagles,
9615.0,0.0,,A,,,,CHEMBL621720,,BAO_0000019,,22224.0,,,U,5066.0,3510.0,1.0,,Autocuration,beagle,Area under curve after 2 mpk peroral administration to beagles,
9615.0,0.0,,A,,,,CHEMBL621721,,BAO_0000218,,22224.0,In vivo,,U,5067.0,3510.0,1.0,,Autocuration,beagle,Cmax value after 1 mpk peroral administration to beagles,
9606.0,0.0,,A,,,1088.0,CHEMBL621722,,BAO_0000019,,22224.0,,,U,5068.0,7766.0,1.0,,Autocuration,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,Urine
9606.0,0.0,,A,,,1088.0,CHEMBL621723,,BAO_0000019,,22224.0,,,U,5069.0,7766.0,1.0,,Autocuration,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,Urine
9606.0,0.0,,A,,,1088.0,CHEMBL621724,,BAO_0000019,,22224.0,,,U,5070.0,7766.0,1.0,,Autocuration,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,Urine
9606.0,0.0,,A,,,1088.0,CHEMBL623443,,BAO_0000019,,22224.0,,,U,5071.0,7766.0,1.0,,Autocuration,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,Urine
9606.0,0.0,,A,,,1088.0,CHEMBL623444,,BAO_0000019,,22224.0,,,U,5072.0,7766.0,1.0,,Autocuration,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,Urine
9606.0,0.0,,A,,,1088.0,CHEMBL623445,,BAO_0000019,,22224.0,,,U,5073.0,7766.0,1.0,,Autocuration,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,Urine
9606.0,0.0,,A,,,1088.0,CHEMBL623446,,BAO_0000019,,22224.0,,,U,5074.0,7766.0,1.0,,Autocuration,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,Urine
9606.0,0.0,,A,,,2107.0,CHEMBL623447,,BAO_0000251,,22224.0,,Microsomes,U,5075.0,16643.0,1.0,,Autocuration,Homo sapiens,Metabolic stability observed at 30 min after administration in human liver microsomes,Liver
9606.0,0.0,,A,,,,CHEMBL623448,,BAO_0000019,,22224.0,,,U,5076.0,6852.0,1.0,,Autocuration,Homo sapiens,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,
9606.0,0.0,,A,,,,CHEMBL623449,,BAO_0000019,,22224.0,,,U,5077.0,6852.0,1.0,,Autocuration,Homo sapiens,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,
9606.0,0.0,,A,,,,CHEMBL623450,,BAO_0000019,,22224.0,,,U,5078.0,6852.0,1.0,,Autocuration,Homo sapiens,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,
9606.0,0.0,,A,,,2107.0,CHEMBL623451,,BAO_0000251,,22224.0,,Microsomes,U,5079.0,6567.0,1.0,,Autocuration,Homo sapiens,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Liver
9606.0,0.0,,A,,,,CHEMBL623452,,BAO_0000019,,22224.0,,,U,5080.0,6570.0,1.0,,Autocuration,Homo sapiens,Metabolic stability (% remaining at 30 mins) in human S9.,
9606.0,0.0,,A,,,,CHEMBL623453,,BAO_0000019,,22224.0,,,U,5081.0,6570.0,1.0,,Autocuration,Homo sapiens,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,
9606.0,0.0,,A,,,2107.0,CHEMBL623454,,BAO_0000251,,22224.0,,Microsomes,U,5082.0,5237.0,1.0,,Autocuration,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes,Liver
9606.0,0.0,,A,,,2107.0,CHEMBL623455,,BAO_0000251,,22224.0,,Microsomes,U,5083.0,5237.0,1.0,,Autocuration,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Liver
9606.0,0.0,,A,,,2107.0,CHEMBL624371,,BAO_0000251,,22224.0,,Microsomes,U,5084.0,5237.0,1.0,,Autocuration,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Liver
9606.0,0.0,,A,,,,CHEMBL624372,,BAO_0000218,,22224.0,,,U,5085.0,5202.0,1.0,,Autocuration,Homo sapiens,First pass metabolism and metabolic bioavailability using human hepatic microsomes,
9606.0,0.0,,A,,,,CHEMBL624373,,BAO_0000019,,22224.0,,,U,5086.0,5481.0,1.0,,Autocuration,Homo sapiens,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,
9606.0,0.0,,A,,,,CHEMBL624374,,BAO_0000019,,22224.0,,,U,5087.0,5481.0,1.0,,Autocuration,Homo sapiens,Percent remaining in human plasma after incubation for 60 min at 37 C.,
9606.0,0.0,,A,,,,CHEMBL624556,,BAO_0000019,,22224.0,,,U,5088.0,3956.0,1.0,,Autocuration,Homo sapiens,The percent remaining in human plasma after 30 min was determined,
9606.0,0.0,,A,,,1969.0,CHEMBL624557,,BAO_0000366,,22224.0,,,U,5089.0,5074.0,1.0,,Autocuration,Homo sapiens,Conversion rate of the prodrug in human plasma,Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL624558,,BAO_0000366,,22224.0,,,U,5090.0,5074.0,1.0,,Autocuration,Homo sapiens,Conversion rate of the prodrug in human plasma; ND means no data,Plasma
9606.0,0.0,,A,,,178.0,CHEMBL624559,,BAO_0000221,,22224.0,,,U,5091.0,4727.0,1.0,,Autocuration,Homo sapiens,Half life of compound was determined in human blood,Blood
9606.0,0.0,,A,,,,CHEMBL624560,,BAO_0000019,,22224.0,,,U,5092.0,5965.0,1.0,,Autocuration,Homo sapiens,Half life of compound was determined in man with once daily dosing,
9606.0,0.0,,A,,,,CHEMBL624561,,BAO_0000251,,22224.0,In vitro,Microsomes,U,5093.0,5732.0,1.0,,Autocuration,Homo sapiens,Half life in human microsomes,
9606.0,0.0,,A,,,1969.0,CHEMBL624562,,BAO_0000366,,22224.0,,,U,5094.0,5819.0,1.0,,Autocuration,Homo sapiens,Half life in human plasma,Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL624563,,BAO_0000366,,22224.0,,,U,5095.0,5819.0,1.0,,Autocuration,Homo sapiens,Half life in human plasma; Not detected,Plasma
9606.0,0.0,,A,,,,CHEMBL624564,,BAO_0000218,,22224.0,In vivo,,U,5096.0,1916.0,1.0,,Autocuration,Homo sapiens,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,
9606.0,0.0,,A,,,2107.0,CHEMBL624565,,BAO_0000251,,22224.0,In vitro,Microsomes,U,5097.0,6597.0,1.0,,Autocuration,Homo sapiens,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Liver
9606.0,0.0,,A,,,1969.0,CHEMBL875152,,BAO_0000366,,22224.0,,,U,5098.0,5229.0,1.0,,Autocuration,Homo sapiens,Half-life in human plasma,Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL624566,,BAO_0000366,,22224.0,,,U,5099.0,5229.0,1.0,,Autocuration,Homo sapiens,Half-life of the parent prodrug in plasma,Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL873805,,BAO_0000366,,22224.0,In vitro,,U,5100.0,2192.0,1.0,,Autocuration,Homo sapiens,In vitro half life in human plasma was determined,Plasma
9606.0,0.0,,A,,,2107.0,CHEMBL624567,,BAO_0000251,,22224.0,In vitro,Microsomes,U,5101.0,3032.0,1.0,,Autocuration,Homo sapiens,The compound was tested In Vitro for half life in human liver microsomes.,Liver
9606.0,0.0,,A,,,,CHEMBL624568,,BAO_0000218,,22224.0,In vivo,,U,5102.0,1916.0,1.0,,Autocuration,Homo sapiens,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,
9606.0,0.0,,A,,,,CHEMBL624569,,BAO_0000218,,22224.0,In vivo,,U,5103.0,17716.0,1.0,,Autocuration,Homo sapiens,Observed volume of distribution,
9606.0,0.0,,A,,,,CHEMBL624570,,BAO_0000218,,22224.0,In vivo,,U,5104.0,15778.0,1.0,,Autocuration,Homo sapiens,Oral bioavailability in human,
9606.0,0.0,,A,,,,CHEMBL624571,,BAO_0000019,,22224.0,,,U,5105.0,17313.0,1.0,,Autocuration,Homo sapiens,Tested for human plasma protein binding of the compound,
9606.0,0.0,,A,,,,CHEMBL624572,,BAO_0000019,,22224.0,,,U,5106.0,4231.0,1.0,,Autocuration,Homo sapiens,"First order rate constant, k was determined in human plasma",
9606.0,0.0,,A,,,,CHEMBL624573,,BAO_0000019,,22224.0,,,U,5107.0,4755.0,1.0,,Autocuration,Homo sapiens,Observed rate constant in 80% human plasma at 37 degree Centigrade,
9606.0,0.0,,A,,,,CHEMBL875153,,BAO_0000019,,22224.0,,,U,5108.0,4755.0,1.0,,Autocuration,Homo sapiens,Observed rate constant in 80% human plasma at 37 degree Centigrade,
9606.0,0.0,,A,,,2107.0,CHEMBL624574,,BAO_0000251,,22224.0,,Microsomes,U,5109.0,16907.0,1.0,,Autocuration,Homo sapiens,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Liver
9606.0,0.0,,A,,,,CHEMBL624575,,BAO_0000019,,22224.0,,,U,5110.0,10839.0,1.0,,Autocuration,Homo sapiens,The compound was tested for the plasma binding in human,
9606.0,0.0,,A,,,,CHEMBL624576,,BAO_0000019,,22224.0,,,U,5111.0,10839.0,1.0,,Autocuration,Homo sapiens,Plasma protein binding (human),
9606.0,0.0,,A,,,2107.0,CHEMBL624577,,BAO_0000251,,22224.0,In vitro,Microsomes,U,5112.0,3199.0,1.0,,Autocuration,Homo sapiens,Compound was evaluated for half-life in human liver microsomes,Liver
9606.0,0.0,,A,,,178.0,CHEMBL624578,,BAO_0000221,,22224.0,In vitro,,U,5113.0,1345.0,1.0,,Autocuration,Homo sapiens,Half life measured in vitro for its stability in human blood,Blood
9606.0,0.0,,A,,,1977.0,CHEMBL622796,,BAO_0000019,,22224.0,,,U,5114.0,4297.0,1.0,,Autocuration,Homo sapiens,Half life in human serum,Serum
9606.0,0.0,,A,,,1977.0,CHEMBL622797,,BAO_0000019,,22224.0,,,U,5115.0,4297.0,1.0,,Autocuration,Homo sapiens,Half life in human serum; ND=not determined,Serum
9606.0,0.0,,A,,,,CHEMBL622798,,BAO_0000019,,22224.0,,,U,5116.0,4297.0,1.0,,Autocuration,Homo sapiens,Half life were determined in CEM-SS cell extract in decomposition step 1,
9606.0,0.0,,A,,,,CHEMBL622799,,BAO_0000019,,22224.0,,,U,5117.0,4297.0,1.0,,Autocuration,Homo sapiens,Half life were determined in CEM-SS cell extract in decomposition step 2,
9606.0,0.0,,A,,,1969.0,CHEMBL622800,,BAO_0000366,,22224.0,,,U,5118.0,4231.0,1.0,,Autocuration,Homo sapiens,Half life of the in human plasma,Plasma
9606.0,0.0,,A,,,,CHEMBL622801,,BAO_0000220,,22224.0,In vitro,S9,U,5119.0,5633.0,1.0,,Autocuration,Homo sapiens,Half life period in human hepatic S9 fraction was determined,
9606.0,0.0,,A,,,2107.0,CHEMBL622802,,BAO_0000251,,22224.0,In vitro,Microsomes,U,5120.0,5633.0,1.0,,Autocuration,Homo sapiens,Half life period in human liver microsome was determined,Liver
9606.0,0.0,,A,,,,CHEMBL622803,,BAO_0000019,,22224.0,,,U,5121.0,17791.0,1.0,,Autocuration,Homo sapiens,Half life period was determined; 6-7,
9606.0,0.0,,A,,,,CHEMBL875154,,BAO_0000019,,22224.0,,,U,5122.0,17791.0,1.0,,Autocuration,Homo sapiens,Half life period was evaluated in human,
9606.0,0.0,,A,,,1969.0,CHEMBL622804,,BAO_0000366,,22224.0,,,U,5123.0,3160.0,1.0,,Autocuration,Homo sapiens,Half life time in human plasma,Plasma
10090.0,1.0,,A,,,955.0,CHEMBL622805,,BAO_0000218,,50594.0,In vivo,,N,5124.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Brain
10090.0,1.0,,A,,,948.0,CHEMBL622611,,BAO_0000218,,50594.0,In vivo,,N,5125.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Heart
10090.0,1.0,,A,,,948.0,CHEMBL622612,,BAO_0000218,,50594.0,In vivo,,N,5126.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Heart
10090.0,1.0,,A,,,2113.0,CHEMBL875160,,BAO_0000218,,50594.0,In vivo,,N,5127.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL622613,,BAO_0000218,,50594.0,In vivo,,N,5128.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL622614,,BAO_0000218,,50594.0,In vivo,,N,5129.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Kidney
10090.0,1.0,,A,,,2107.0,CHEMBL622615,,BAO_0000218,,50594.0,In vivo,,N,5130.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Liver
10090.0,1.0,,A,,,2107.0,CHEMBL622616,,BAO_0000218,,50594.0,In vivo,,N,5131.0,16438.0,1.0,,Intermediate,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL622617,,BAO_0000218,,50594.0,In vivo,,N,5132.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Liver
10090.0,1.0,,A,,,2106.0,CHEMBL622618,,BAO_0000218,,50594.0,In vivo,,N,5133.0,16438.0,1.0,,Intermediate,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,Spleen
10090.0,1.0,,A,,,2106.0,CHEMBL622619,,BAO_0000218,,50594.0,In vivo,,N,5134.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Spleen
10090.0,1.0,,A,,,2106.0,CHEMBL622620,,BAO_0000218,,50594.0,In vivo,,N,5135.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Spleen
10090.0,1.0,,A,,,955.0,CHEMBL622621,,BAO_0000218,,50594.0,In vivo,,N,5136.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Brain
10090.0,1.0,,A,,,178.0,CHEMBL622622,,BAO_0000218,,50594.0,In vivo,,N,5137.0,16438.0,1.0,,Intermediate,Mus musculus,Biodistribution of compound (oxidized form) in blood tissue,Blood
10090.0,1.0,,A,,,178.0,CHEMBL622623,,BAO_0000218,,50594.0,In vivo,,N,5138.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Blood
10090.0,1.0,,A,,,178.0,CHEMBL622624,,BAO_0000218,,50594.0,In vivo,,N,5139.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Blood
10090.0,1.0,,A,,,178.0,CHEMBL622625,,BAO_0000218,,50594.0,In vivo,,N,5140.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Blood
10090.0,1.0,,A,,,178.0,CHEMBL622626,,BAO_0000218,,50594.0,In vivo,,N,5141.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Blood
10090.0,1.0,,A,,,178.0,CHEMBL622627,,BAO_0000218,,50594.0,In vivo,,N,5142.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Blood
10090.0,1.0,,A,,,955.0,CHEMBL622628,,BAO_0000218,,50594.0,In vivo,,N,5143.0,16438.0,1.0,,Intermediate,Mus musculus,Biodistribution of compound (oxidized form) in brain tissue of mice,Brain
10090.0,1.0,,A,,,955.0,CHEMBL622629,,BAO_0000218,,50594.0,In vivo,,N,5144.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Brain
10090.0,1.0,,A,,,955.0,CHEMBL622630,,BAO_0000218,,50594.0,In vivo,,N,5145.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Brain
10090.0,1.0,,A,,,955.0,CHEMBL622631,,BAO_0000218,,50594.0,In vivo,,N,5146.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Brain
10090.0,1.0,,A,,,955.0,CHEMBL622632,,BAO_0000218,,50594.0,In vivo,,N,5147.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Brain
10090.0,1.0,,A,,,955.0,CHEMBL622633,,BAO_0000218,,50594.0,In vivo,,N,5148.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",Brain
10090.0,1.0,,A,,,948.0,CHEMBL622634,,BAO_0000218,,50594.0,In vivo,,N,5149.0,16438.0,1.0,,Intermediate,Mus musculus,Biodistribution of compound (oxidized form) in heart tissue of mice,Heart
10090.0,1.0,,A,,,948.0,CHEMBL622635,,BAO_0000218,,50594.0,In vivo,,N,5150.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Heart
10090.0,1.0,,A,,,948.0,CHEMBL875161,,BAO_0000218,,50594.0,In vivo,,N,5151.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Heart
10090.0,1.0,,A,,,948.0,CHEMBL622636,,BAO_0000218,,50594.0,In vivo,,N,5152.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Heart
10090.0,1.0,,A,,,948.0,CHEMBL623335,,BAO_0000218,,50594.0,In vivo,,N,5153.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Heart
10090.0,1.0,,A,,,948.0,CHEMBL623336,,BAO_0000218,,50594.0,In vivo,,N,5154.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Heart
10090.0,1.0,,A,,,2113.0,CHEMBL623337,,BAO_0000218,,50594.0,In vivo,,N,5155.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL623338,,BAO_0000218,,50594.0,In vivo,,N,5156.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL623339,,BAO_0000218,,50594.0,In vivo,,N,5157.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL623524,,BAO_0000218,,50594.0,In vivo,,N,5158.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL623525,,BAO_0000218,,50594.0,In vivo,,N,5159.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Kidney
10090.0,1.0,,A,,,2107.0,CHEMBL623526,,BAO_0000218,,50594.0,In vivo,,N,5160.0,16438.0,1.0,,Intermediate,Mus musculus,Biodistribution of compound (oxidized form) in liver tissue,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL623527,,BAO_0000218,,50594.0,In vivo,,N,5161.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Liver
10090.0,1.0,,A,,,2107.0,CHEMBL623528,,BAO_0000218,,50594.0,In vivo,,N,5162.0,16438.0,1.0,,Intermediate,Mus musculus,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Liver
9606.0,1.0,,F,,,,CHEMBL624615,,BAO_0000219,A-431,80852.0,,,N,5163.0,5245.0,1.0,500.0,Intermediate,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,
9606.0,1.0,,F,,,,CHEMBL621672,,BAO_0000219,A-431,80852.0,,,N,5164.0,5245.0,1.0,500.0,Intermediate,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,
,1.0,,F,,,,CHEMBL621673,,BAO_0000218,A-431,80852.0,,,N,5165.0,16289.0,1.0,500.0,Expert,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",
,1.0,,F,,,,CHEMBL621674,,BAO_0000218,A-431,80852.0,,,N,5166.0,16289.0,1.0,500.0,Expert,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",
9606.0,9.0,,F,,,,CHEMBL884002,,BAO_0000219,A-431,9.0,,,D,5167.0,16093.0,1.0,500.0,Expert,Homo sapiens,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,
9606.0,1.0,,F,,,,CHEMBL621850,,BAO_0000219,A-431,80852.0,,,N,5168.0,16825.0,1.0,500.0,Intermediate,Homo sapiens,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",
9606.0,1.0,,F,,,,CHEMBL621851,,BAO_0000219,A-431,80852.0,,,N,5169.0,4848.0,1.0,500.0,Intermediate,Homo sapiens,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,
9606.0,9.0,,F,,,,CHEMBL621852,,BAO_0000219,A-431,9.0,,,D,5170.0,14827.0,1.0,500.0,Expert,Homo sapiens,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,
9606.0,9.0,,F,,,,CHEMBL621853,,BAO_0000219,A-431,9.0,,,D,5171.0,14827.0,1.0,500.0,Expert,Homo sapiens,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,
,1.0,,F,,,,CHEMBL621854,,BAO_0000218,A-431,80852.0,,,N,5172.0,16289.0,1.0,500.0,Expert,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",
,1.0,,F,,,,CHEMBL621855,,BAO_0000218,A-431,80852.0,,,N,5173.0,16289.0,1.0,500.0,Expert,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",
,1.0,,F,,,,CHEMBL623724,,BAO_0000218,A-431,80852.0,,,N,5174.0,16289.0,1.0,500.0,Expert,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",
,1.0,,F,,,,CHEMBL623725,,BAO_0000218,A-431,80852.0,,,N,5175.0,16289.0,1.0,500.0,Expert,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",
,1.0,,F,,,,CHEMBL623726,,BAO_0000218,A-431,80852.0,,,N,5176.0,16289.0,1.0,500.0,Expert,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",
9606.0,9.0,,F,,,,CHEMBL623727,,BAO_0000219,A-431,9.0,,,D,5177.0,16289.0,1.0,500.0,Expert,Homo sapiens,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",
,8.0,,F,,,,CHEMBL623728,,BAO_0000219,A-431,9.0,,,H,5178.0,16289.0,1.0,500.0,Expert,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,
,1.0,,F,,,,CHEMBL623729,,BAO_0000218,A-431,80852.0,,,N,5179.0,16289.0,1.0,500.0,Expert,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",
,1.0,,F,,,,CHEMBL623730,,BAO_0000218,A-431,80852.0,,,N,5180.0,16289.0,1.0,500.0,Expert,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",
,1.0,,F,,,,CHEMBL623731,,BAO_0000218,A-431,80852.0,,,N,5181.0,16289.0,1.0,500.0,Expert,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",
10090.0,1.0,,F,,,,CHEMBL623732,,BAO_0000218,A-431,80852.0,,,N,5182.0,14555.0,1.0,500.0,Expert,Mus musculus,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",
10090.0,1.0,,F,,,,CHEMBL623733,,BAO_0000218,A-431,80852.0,,,N,5183.0,14555.0,1.0,500.0,Expert,Mus musculus,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",
10090.0,1.0,,F,,,,CHEMBL623734,,BAO_0000218,A-431,80852.0,,,N,5184.0,14555.0,1.0,500.0,Expert,Mus musculus,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",
10090.0,1.0,,F,,,,CHEMBL623735,,BAO_0000218,A-431,80852.0,,,N,5185.0,14555.0,1.0,500.0,Expert,Mus musculus,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",
9606.0,1.0,,F,,,,CHEMBL623736,,BAO_0000219,A-431,80852.0,,,N,5186.0,1937.0,1.0,500.0,Expert,Homo sapiens,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,
9606.0,1.0,,F,,,,CHEMBL623737,,BAO_0000219,A-431,80852.0,,,N,5187.0,13739.0,1.0,500.0,Intermediate,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,
9606.0,1.0,,F,,,,CHEMBL623738,,BAO_0000219,A-431,80852.0,,,N,5188.0,3558.0,1.0,500.0,Intermediate,Homo sapiens,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,
9606.0,1.0,,F,,,,CHEMBL875168,,BAO_0000219,A-431,80852.0,,,N,5189.0,3558.0,1.0,500.0,Intermediate,Homo sapiens,Dose giving a 50% decrease in the living cell number (A437 cells),
9606.0,1.0,,F,,,,CHEMBL623739,,BAO_0000219,A549,80682.0,,,N,5190.0,17686.0,1.0,646.0,Expert,Homo sapiens,In vitro inhibitory concentration against proliferation of A459 cell line.,
9606.0,1.0,,F,,,,CHEMBL623740,,BAO_0000219,A549,80682.0,,,N,5191.0,5305.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,
9606.0,1.0,,F,,,,CHEMBL624424,,BAO_0000219,A549,80682.0,,,N,5192.0,3614.0,1.0,646.0,Intermediate,Homo sapiens,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,
9606.0,1.0,,F,,,,CHEMBL624425,,BAO_0000219,A498,80021.0,,,N,5193.0,17229.0,1.0,624.0,Intermediate,Homo sapiens,In vitro antitumor activity against renal A498 tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL624426,,BAO_0000219,A498,80021.0,,,N,5194.0,15935.0,1.0,624.0,Intermediate,Homo sapiens,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",
9606.0,1.0,,F,,,,CHEMBL624427,,BAO_0000219,A498,80021.0,,,N,5195.0,15935.0,1.0,624.0,Intermediate,Homo sapiens,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",
9606.0,1.0,,F,,,,CHEMBL624428,,BAO_0000219,A498,80021.0,,,N,5196.0,15560.0,1.0,624.0,Intermediate,Homo sapiens,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,
9606.0,1.0,,F,,,,CHEMBL624429,,BAO_0000219,A498,80021.0,,,N,5197.0,13891.0,1.0,624.0,Intermediate,Homo sapiens,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,
9606.0,1.0,,F,,,,CHEMBL624620,,BAO_0000219,A498,80021.0,,,N,5198.0,13891.0,1.0,624.0,Intermediate,Homo sapiens,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,
9606.0,1.0,,F,,,,CHEMBL624621,,BAO_0000219,A498,80021.0,,,N,5199.0,13788.0,1.0,624.0,Intermediate,Homo sapiens,Cytotoxicity on kidney carcinoma (A-498) cell line,
9606.0,1.0,,F,,,,CHEMBL624622,,BAO_0000219,A498,80021.0,,,N,5200.0,15403.0,1.0,624.0,Intermediate,Homo sapiens,Compound was evaluated against Human cell line renal A498,
9606.0,1.0,,F,,,,CHEMBL624623,,BAO_0000219,A498,80021.0,,,N,5201.0,1009.0,1.0,624.0,Intermediate,Homo sapiens,Compound was tested for inhibition of A498 human renal cancer cell line,
9606.0,1.0,,F,,,,CHEMBL874365,,BAO_0000219,A498,80021.0,,,N,5202.0,1043.0,1.0,624.0,Intermediate,Homo sapiens,Growth inhibitory activity against A498 human cancer cell line,
9606.0,1.0,,F,,,,CHEMBL624624,,BAO_0000219,A498,80021.0,,,N,5203.0,5858.0,1.0,624.0,Intermediate,Homo sapiens,In vitro antitumor activity against human renal A498 cell line,
9606.0,1.0,,F,,,,CHEMBL624625,,BAO_0000219,A498,80021.0,,,N,5204.0,5958.0,1.0,624.0,Intermediate,Homo sapiens,In vitro cytotoxic activity against renal (A498) cell line,
9606.0,1.0,,F,,,,CHEMBL624626,,BAO_0000219,A498,80021.0,,,N,5205.0,5506.0,1.0,624.0,Intermediate,Homo sapiens,In vitro cytotoxic activity against human renal cancer (A498) cell line,
9606.0,1.0,,F,,,,CHEMBL624627,,BAO_0000219,A498,80021.0,,,N,5206.0,12781.0,1.0,624.0,Intermediate,Homo sapiens,Tested for cytostatic activity against renal A498 cell line,
9606.0,1.0,,F,,,,CHEMBL883157,,BAO_0000219,A498,80021.0,,,N,5207.0,14399.0,1.0,624.0,Intermediate,Homo sapiens,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,
9606.0,1.0,,F,,,,CHEMBL624628,,BAO_0000219,A498,80021.0,,,N,5208.0,5958.0,1.0,624.0,Expert,Homo sapiens,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,
9615.0,0.0,,A,,,,CHEMBL624629,,BAO_0000218,,22224.0,In vivo,,U,5209.0,3510.0,1.0,,Autocuration,beagle,Cmax value after 2 mpk peroral administration to beagles,
9615.0,0.0,,A,,,,CHEMBL623551,beagle,BAO_0000218,,22224.0,In vivo,,U,5210.0,3510.0,1.0,,Autocuration,Canis lupus familiaris,Bioavailability,
9615.0,0.0,,A,,,,CHEMBL623552,beagle,BAO_0000218,,22224.0,In vivo,,U,5211.0,3510.0,1.0,,Autocuration,Canis lupus familiaris,Bioavailability after 1 mpk peroral administration to beagles,
9615.0,0.0,,A,,,,CHEMBL623553,beagle,BAO_0000218,,22224.0,In vivo,,U,5212.0,3510.0,1.0,,Autocuration,Canis lupus familiaris,Bioavailability after 2 mpk peroral administration to beagles,
9913.0,0.0,,A,,,,CHEMBL623554,,BAO_0000019,,22224.0,,,U,5213.0,3085.0,1.0,,Autocuration,Bos taurus,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,
9913.0,0.0,,A,,,,CHEMBL623555,,BAO_0000019,,22224.0,,,U,5214.0,3085.0,1.0,,Autocuration,Bos taurus,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,
9913.0,0.0,,A,,,,CHEMBL623556,,BAO_0000019,,22224.0,,,U,5215.0,3085.0,1.0,,Autocuration,Bos taurus,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,
9913.0,0.0,,A,,,,CHEMBL623557,,BAO_0000019,,22224.0,,,U,5216.0,9372.0,1.0,,Autocuration,Bos taurus,Solubility against bovine alpha-chymotrypsin,
9913.0,0.0,,A,,,,CHEMBL623558,,BAO_0000019,,22224.0,,,U,5217.0,3085.0,1.0,,Autocuration,Bos taurus,Rate constant of the bovine serum albumin catalyzed reaction of the compound,
9913.0,0.0,,A,,,,CHEMBL623559,,BAO_0000019,,22224.0,,,U,5218.0,3085.0,1.0,,Autocuration,Bos taurus,Rate constant of the bovine serum albumin catalyzed reaction of the compound,
9913.0,0.0,,A,,,2106.0,CHEMBL623560,,BAO_0000221,,22224.0,,,U,5219.0,1469.0,1.0,,Autocuration,Bos taurus,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,Spleen
9913.0,0.0,,A,,,,CHEMBL623561,,BAO_0000019,,22224.0,,,U,5220.0,4297.0,1.0,,Autocuration,Bos taurus,Half life in culture medium containing 10% of heat inactivated foetal calf serum,
9913.0,0.0,,A,,,,CHEMBL623562,,BAO_0000019,,22224.0,,,U,5221.0,4297.0,1.0,,Autocuration,Bos taurus,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,
9913.0,0.0,,A,,,,CHEMBL623563,,BAO_0000019,,22224.0,,,U,5222.0,17585.0,1.0,,Autocuration,Bos taurus,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,
9913.0,0.0,,A,,,2106.0,CHEMBL623564,,BAO_0000221,,22224.0,,,U,5223.0,1336.0,1.0,,Autocuration,Bos taurus,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,Spleen
9913.0,0.0,,A,,,,CHEMBL873806,,BAO_0000019,,22224.0,,,U,5224.0,3085.0,1.0,,Autocuration,Bos taurus,Half life in presence of 2 mg/mL BSA at pH 8.8,
9913.0,0.0,,A,,,,CHEMBL623565,,BAO_0000019,,22224.0,,,U,5225.0,2857.0,1.0,,Autocuration,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,
9913.0,0.0,,A,,,,CHEMBL623566,,BAO_0000019,,22224.0,,,U,5226.0,2857.0,1.0,,Autocuration,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,
9913.0,0.0,,A,,,,CHEMBL623567,,BAO_0000019,,22224.0,,,U,5227.0,2857.0,1.0,,Autocuration,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,
9913.0,0.0,,A,,,,CHEMBL623568,,BAO_0000019,,22224.0,,,U,5228.0,1540.0,1.0,,Autocuration,Bos taurus,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),
9615.0,1.0,,A,,,1969.0,CHEMBL623569,,BAO_0000218,,50588.0,,,N,5229.0,6316.0,1.0,,Intermediate,Canis lupus familiaris,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL623570,,BAO_0000218,,50588.0,,,N,5230.0,17594.0,1.0,,Intermediate,Canis lupus familiaris,AUC after administration at 100 mg/kg/day in dogs,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL624254,,BAO_0000218,,50588.0,,,N,5231.0,4953.0,1.0,,Intermediate,Canis lupus familiaris,AUC in dog at 0-24 hr by peroral administration at 3 mpk,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL624255,,BAO_0000218,,50588.0,,,N,5232.0,16907.0,1.0,,Intermediate,Canis lupus familiaris,AUC value after 15 mg/kg iv dose in Dogs,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL624256,,BAO_0000218,,50588.0,,,N,5233.0,16907.0,1.0,,Intermediate,Canis lupus familiaris,AUC value after 30 mg/kg po dose in Dogs,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL624257,,BAO_0000218,,50588.0,,,N,5234.0,2959.0,1.0,,Intermediate,Canis lupus familiaris,AUC value after administration of 4 mg/Kg oral dose in dog,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL624258,,BAO_0000218,,50588.0,,,N,5235.0,17594.0,1.0,,Intermediate,Canis lupus familiaris,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,Plasma
9615.0,1.0,,A,,,,CHEMBL875277,,BAO_0000218,,50588.0,,,N,5236.0,5356.0,1.0,,Intermediate,Canis lupus familiaris,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,
9615.0,1.0,,A,,,,CHEMBL622667,,BAO_0000218,,50588.0,,,N,5237.0,16807.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,
9615.0,1.0,,A,,,,CHEMBL622668,,BAO_0000218,,50588.0,,,N,5238.0,4527.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,
9615.0,1.0,,A,,,,CHEMBL622669,,BAO_0000218,,50588.0,,,N,5239.0,4527.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,
9615.0,1.0,,A,,,,CHEMBL622670,,BAO_0000218,,50588.0,,,N,5240.0,15660.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve determined in dogs after intravenous administration of 3 mg/kg,
9615.0,1.0,,A,,,,CHEMBL622671,,BAO_0000218,,50588.0,,,N,5241.0,15660.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve determined in dogs after oral administration of 10 mg/kg,
9615.0,1.0,,A,,,,CHEMBL622672,,BAO_0000218,,50588.0,,,N,5242.0,5802.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,
9615.0,1.0,,A,,,,CHEMBL622673,,BAO_0000218,,50588.0,,,N,5243.0,3598.0,1.0,,Expert,Canis lupus familiaris,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,
9615.0,1.0,,A,,,,CHEMBL622674,,BAO_0000218,,50588.0,,,N,5244.0,3598.0,1.0,,Expert,Canis lupus familiaris,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,
9615.0,1.0,,A,,,,CHEMBL622675,,BAO_0000218,,50588.0,,,N,5245.0,5944.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),
9615.0,1.0,,A,,,,CHEMBL622676,,BAO_0000218,,50588.0,,,N,5246.0,5944.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,
9615.0,1.0,,A,,,,CHEMBL622677,,BAO_0000218,,50588.0,,,N,5247.0,5944.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),
9615.0,1.0,,A,,,,CHEMBL622678,,BAO_0000218,,50588.0,,,N,5248.0,5944.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,
9615.0,1.0,,A,,,,CHEMBL622679,,BAO_0000218,,50588.0,,,N,5249.0,4186.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve in dog after administration of 20 mg/kg dose through peroral route,
9615.0,1.0,,A,,,,CHEMBL622680,,BAO_0000218,,50588.0,,,N,5250.0,5007.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),
9615.0,1.0,,A,,,,CHEMBL622681,,BAO_0000218,,50588.0,,,N,5251.0,5668.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve was determine after peroral administration at 10 mpk in dog,
9615.0,1.0,,A,,,,CHEMBL875278,,BAO_0000218,,50588.0,,,N,5252.0,5668.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve was determine after peroral administration at 5 mpk in dog,
9615.0,1.0,,A,,,,CHEMBL622682,,BAO_0000218,,50588.0,,,N,5253.0,5006.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve was determined,
9615.0,1.0,,A,,,,CHEMBL622683,,BAO_0000218,,50588.0,,,N,5254.0,5006.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve in dogs,
9615.0,1.0,,A,,,,CHEMBL622684,,BAO_0000218,,50588.0,,,N,5255.0,3771.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve in dogs at 10 mg/kg dose fo oral administration,
9615.0,1.0,,A,,,,CHEMBL622685,,BAO_0000218,,50588.0,,,N,5256.0,3771.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),
9615.0,1.0,,A,,,,CHEMBL622686,,BAO_0000218,,50588.0,,,N,5257.0,3771.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,
9615.0,1.0,,A,,,,CHEMBL618344,,BAO_0000218,,50588.0,,,N,5258.0,1916.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,
9615.0,1.0,,A,,,,CHEMBL875582,,BAO_0000218,,50588.0,,,N,5259.0,5302.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve value in dog at a dose of 5 mg/kg,
9615.0,1.0,,A,,,,CHEMBL618345,,BAO_0000218,,50588.0,,,N,5260.0,5600.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve was determined after 0.1 mg/kg iv administration in dog,
9615.0,1.0,,A,,,,CHEMBL618346,,BAO_0000218,,50588.0,,,N,5261.0,5600.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve was determined after 0.3 mg/kg po administration in dog,
9615.0,1.0,,A,,,,CHEMBL618347,,BAO_0000218,,50588.0,,,N,5262.0,17764.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,
9615.0,1.0,,A,,,,CHEMBL618348,,BAO_0000218,,50588.0,,,N,5263.0,4368.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,
9606.0,0.0,,A,,,,CHEMBL618349,,BAO_0000019,,22224.0,,,U,5264.0,5318.0,1.0,,Autocuration,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,
9606.0,0.0,,A,,,,CHEMBL618350,,BAO_0000019,,22224.0,,,U,5265.0,5318.0,1.0,,Autocuration,Homo sapiens,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,
9606.0,0.0,,A,,,,CHEMBL618351,,BAO_0000019,,22224.0,,,U,5266.0,5318.0,1.0,,Autocuration,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,
9606.0,0.0,,A,,,,CHEMBL618352,,BAO_0000019,,22224.0,,,U,5267.0,5318.0,1.0,,Autocuration,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,
9606.0,0.0,,A,,,178.0,CHEMBL873494,,BAO_0000221,,22224.0,,,U,5268.0,14518.0,1.0,,Autocuration,Homo sapiens,Time taken to reduce 50% of the concentration of compound in blood plasma,Blood
9606.0,0.0,,A,,,1969.0,CHEMBL618353,,BAO_0000366,,22224.0,,,U,5269.0,2209.0,1.0,,Autocuration,Homo sapiens,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL618354,,BAO_0000366,,22224.0,,,U,5270.0,6787.0,1.0,,Autocuration,Homo sapiens,Half life in human plasma,Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL875583,,BAO_0000366,,22224.0,,,U,5271.0,4898.0,1.0,,Autocuration,Homo sapiens,Half life in human plasma was reported,Plasma
9606.0,0.0,,A,,,1977.0,CHEMBL618355,,BAO_0000019,,22224.0,,,U,5272.0,6072.0,1.0,,Autocuration,Homo sapiens,Half life in human serum,Serum
9606.0,0.0,,A,,,1969.0,CHEMBL618356,,BAO_0000366,,22224.0,,,U,5273.0,16907.0,1.0,,Autocuration,Homo sapiens,Half life upon exposure to human plasma,Plasma
9606.0,0.0,,A,,,,CHEMBL618357,,BAO_0000251,,22224.0,In vitro,Microsomes,U,5274.0,5656.0,1.0,,Autocuration,Homo sapiens,t1/2 in human microsomes,
9606.0,0.0,,A,,,1969.0,CHEMBL618358,,BAO_0000366,,22224.0,,,U,5275.0,4755.0,1.0,,Autocuration,Homo sapiens,Half life period in 80% human plasma at 37 degree Centigrade,Plasma
9606.0,0.0,,A,,,14.0,CHEMBL618359,,BAO_0000221,,22224.0,,,U,5276.0,17503.0,1.0,,Autocuration,Homo sapiens,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),Zone of skin
9606.0,0.0,,A,,,1969.0,CHEMBL618360,,BAO_0000366,,22224.0,In vitro,,U,5277.0,12357.0,1.0,,Autocuration,Homo sapiens,Half-life measured in in vitro Cathepsin B assay in human plasma,Plasma
9606.0,0.0,,A,,,,CHEMBL618361,,BAO_0000019,,22224.0,,,U,5278.0,3076.0,1.0,,Autocuration,Homo sapiens,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,
9606.0,0.0,,A,,,2107.0,CHEMBL618362,,BAO_0000251,,22224.0,In vitro,Microsomes,U,5279.0,6410.0,1.0,,Autocuration,Homo sapiens,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Liver
9606.0,0.0,,A,,,1969.0,CHEMBL618363,,BAO_0000366,,22224.0,,,U,5280.0,3741.0,1.0,,Autocuration,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL618364,,BAO_0000366,,22224.0,,,U,5281.0,3741.0,1.0,,Autocuration,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL875584,,BAO_0000366,,22224.0,,,U,5282.0,3741.0,1.0,,Autocuration,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Plasma
9606.0,0.0,,A,,,,CHEMBL618365,,BAO_0000019,,22224.0,,,U,5283.0,1540.0,1.0,,Autocuration,Homo sapiens,Half-life in the CEM cell extracts,
9606.0,0.0,,A,,,1969.0,CHEMBL873495,,BAO_0000366,,22224.0,,,U,5284.0,2905.0,1.0,,Autocuration,Homo sapiens,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL618366,,BAO_0000366,,22224.0,,,U,5285.0,2905.0,1.0,,Autocuration,Homo sapiens,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,Plasma
9606.0,0.0,,A,,,,CHEMBL618367,,BAO_0000019,,22224.0,,,U,5286.0,5523.0,1.0,,Autocuration,Homo sapiens,Half-life was determined,
9606.0,0.0,,A,,,178.0,CHEMBL618368,,BAO_0000221,,22224.0,,,U,5287.0,1499.0,1.0,,Autocuration,Homo sapiens,Half-life (human blood stability),Blood
9606.0,0.0,,A,,,178.0,CHEMBL618369,,BAO_0000221,,22224.0,,,U,5288.0,1499.0,1.0,,Autocuration,Homo sapiens,Half-life (human blood stability); no data,Blood
9606.0,0.0,,A,,,1969.0,CHEMBL618370,,BAO_0000366,,22224.0,,,U,5289.0,17065.0,1.0,,Autocuration,Homo sapiens,Half-life in human plasma,Plasma
9606.0,0.0,,A,,,,CHEMBL618371,,BAO_0000019,,22224.0,,,U,5290.0,6861.0,1.0,,Autocuration,Homo sapiens,CYP3A4 metabolism half-life (t1/2),
9606.0,0.0,,A,,,178.0,CHEMBL618372,,BAO_0000221,,22224.0,,,U,5291.0,1499.0,1.0,,Autocuration,Homo sapiens,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),Blood
9606.0,0.0,,A,,,1969.0,CHEMBL618373,,BAO_0000366,,22224.0,In vitro,,U,5292.0,530.0,1.0,,Autocuration,Homo sapiens,In vitro half life in human plasma,Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL618374,,BAO_0000366,,22224.0,In vitro,,U,5293.0,1116.0,1.0,,Autocuration,Homo sapiens,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL618375,,BAO_0000366,,22224.0,In vitro,,U,5294.0,6695.0,1.0,,Autocuration,Homo sapiens,In vitro hydrolysis in human plasma,Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL618376,,BAO_0000366,,22224.0,In vitro,,U,5295.0,6695.0,1.0,,Autocuration,Homo sapiens,In vitro hydrolysis in human plasma; no data,Plasma
9606.0,0.0,,A,,,2107.0,CHEMBL618377,,BAO_0000251,,22224.0,In vitro,Microsomes,U,5296.0,10.0,1.0,,Autocuration,Homo sapiens,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Liver
9606.0,0.0,,A,,,1969.0,CHEMBL618378,,BAO_0000366,,22224.0,,,U,5297.0,993.0,1.0,,Autocuration,Homo sapiens,Plasma half life in human,Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL618379,,BAO_0000366,,22224.0,,,U,5298.0,15429.0,1.0,,Autocuration,Homo sapiens,Stability after incubation with human plasma (at 37 degree C),Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL618380,,BAO_0000366,,22224.0,,,U,5299.0,1675.0,1.0,,Autocuration,Homo sapiens,T1/2 was evaluated in human plasma,Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL618381,,BAO_0000366,,22224.0,,,U,5300.0,2209.0,1.0,,Autocuration,Homo sapiens,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL618382,,BAO_0000366,,22224.0,,,U,5301.0,2209.0,1.0,,Autocuration,Homo sapiens,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",Plasma
9606.0,0.0,,A,,,,CHEMBL618383,,BAO_0000019,,22224.0,,,U,5302.0,5318.0,1.0,,Autocuration,Homo sapiens,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,
9606.0,0.0,,A,,,,CHEMBL618384,,BAO_0000019,,22224.0,In vitro,,U,5303.0,2412.0,1.0,,Autocuration,Homo sapiens,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,
9606.0,0.0,,A,,,,CHEMBL618385,,BAO_0000019,,22224.0,In vitro,,U,5304.0,2412.0,1.0,,Autocuration,Homo sapiens,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,
9606.0,0.0,,A,,,1969.0,CHEMBL619099,,BAO_0000366,,22224.0,,,U,5305.0,2906.0,1.0,,Autocuration,Homo sapiens,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,Plasma
9606.0,0.0,,A,,,1969.0,CHEMBL619100,,BAO_0000366,,22224.0,,,U,5306.0,2906.0,1.0,,Autocuration,Homo sapiens,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,Plasma
9606.0,0.0,,A,,,,CHEMBL619101,,BAO_0000019,,22224.0,,,U,5307.0,5495.0,1.0,,Autocuration,Homo sapiens,Time taken for 50% to be consumed by serum PON1 was determined,
9606.0,0.0,,A,,,,CHEMBL619102,,BAO_0000019,,22224.0,,,U,5308.0,5495.0,1.0,,Autocuration,Homo sapiens,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,
9606.0,0.0,,A,,,2107.0,CHEMBL619103,,BAO_0000251,,22224.0,,Microsomes,U,5309.0,4397.0,1.0,,Autocuration,Homo sapiens,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Liver
10095.0,0.0,,A,,,,CHEMBL619268,,BAO_0000218,,22224.0,,,U,5310.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,
10095.0,0.0,,A,,,,CHEMBL619269,,BAO_0000218,,22224.0,,,U,5311.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,
10095.0,0.0,,A,,,,CHEMBL619270,,BAO_0000218,,22224.0,,,U,5312.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,
10095.0,0.0,,A,,,,CHEMBL619271,,BAO_0000218,,22224.0,,,U,5313.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,
10095.0,0.0,,A,,,,CHEMBL875585,,BAO_0000218,,22224.0,,,U,5314.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,
10095.0,0.0,,A,,,,CHEMBL619272,,BAO_0000218,,22224.0,,,U,5315.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,
9606.0,1.0,,F,,,,CHEMBL619273,,BAO_0000219,786-0,80640.0,,,N,5316.0,6058.0,1.0,391.0,Intermediate,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line 786-0,
9606.0,1.0,,F,,,,CHEMBL619274,,BAO_0000219,786-0,80640.0,,,N,5317.0,17708.0,1.0,391.0,Intermediate,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,
9606.0,1.0,,F,,,,CHEMBL619275,,BAO_0000219,786-0,80640.0,,,N,5318.0,14017.0,1.0,391.0,Expert,Homo sapiens,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,
9606.0,1.0,,F,,,,CHEMBL619276,,BAO_0000219,786-0,80640.0,,,N,5319.0,16818.0,1.0,391.0,Intermediate,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",
9606.0,1.0,,F,,,,CHEMBL619277,,BAO_0000219,786-0,80640.0,,,N,5320.0,16818.0,1.0,391.0,Intermediate,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",
9606.0,1.0,,F,,,,CHEMBL619278,,BAO_0000219,786-0,80640.0,,,N,5321.0,16818.0,1.0,391.0,Intermediate,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",
9606.0,1.0,,F,,,,CHEMBL619279,,BAO_0000219,786-0,80640.0,,,N,5322.0,11970.0,1.0,391.0,Intermediate,Homo sapiens,Tested for cytotoxicity against 786-0 cell lines in renal cancer,
9606.0,1.0,,F,,,,CHEMBL858458,,BAO_0000219,786-0,80640.0,,,N,5323.0,12400.0,1.0,391.0,Intermediate,Homo sapiens,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,
9606.0,1.0,,F,,,,CHEMBL619280,,BAO_0000219,786-0,80640.0,,,N,5324.0,12888.0,1.0,391.0,Expert,Homo sapiens,Cytotoxic effect on renal cancer line 786-0,
9606.0,1.0,,F,,,,CHEMBL619281,,BAO_0000219,786-0,80640.0,,,N,5325.0,15300.0,1.0,391.0,Intermediate,Homo sapiens,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,
9606.0,1.0,,F,,,,CHEMBL619282,,BAO_0000219,786-0,80640.0,,,N,5326.0,14769.0,1.0,391.0,Intermediate,Homo sapiens,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),
9606.0,1.0,,F,,,,CHEMBL619283,,BAO_0000219,786-0,80640.0,,,N,5327.0,15895.0,1.0,391.0,Intermediate,Homo sapiens,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",
9606.0,1.0,,F,,,,CHEMBL619284,,BAO_0000219,786-0,80640.0,,,N,5328.0,17376.0,1.0,391.0,Intermediate,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,
9606.0,1.0,,F,,,,CHEMBL619285,,BAO_0000219,786-0,80640.0,,,N,5329.0,14882.0,1.0,391.0,Intermediate,Homo sapiens,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,
9606.0,1.0,,F,,,,CHEMBL619286,,BAO_0000219,786-0,80640.0,,,N,5330.0,14882.0,1.0,391.0,Intermediate,Homo sapiens,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),
9606.0,1.0,,F,,,,CHEMBL619287,,BAO_0000219,786-0,80640.0,,,N,5331.0,15176.0,1.0,391.0,Intermediate,Homo sapiens,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,
9606.0,1.0,,F,,,,CHEMBL857455,,BAO_0000219,786-0,80640.0,,,N,5332.0,12696.0,1.0,391.0,Intermediate,Homo sapiens,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,
9606.0,1.0,,F,,,,CHEMBL883801,,BAO_0000219,786-0,80640.0,,,N,5333.0,2496.0,1.0,391.0,Intermediate,Homo sapiens,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),
9606.0,1.0,,F,,,,CHEMBL619288,,BAO_0000219,791T cell line,80641.0,,,N,5334.0,11831.0,1.0,972.0,Intermediate,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,
9606.0,1.0,,F,,,,CHEMBL619289,,BAO_0000219,791T cell line,80641.0,,,N,5335.0,11831.0,1.0,972.0,Intermediate,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),
9606.0,1.0,,F,,,,CHEMBL619290,,BAO_0000219,791T cell line,80641.0,,,N,5336.0,11831.0,1.0,972.0,Intermediate,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,
9606.0,1.0,,F,,,,CHEMBL619291,,BAO_0000219,791T cell line,80641.0,,,N,5337.0,11831.0,1.0,972.0,Intermediate,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),
9606.0,1.0,,F,,,,CHEMBL619292,,BAO_0000219,791T cell line,80641.0,,,N,5338.0,11831.0,1.0,972.0,Intermediate,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),
9606.0,1.0,,F,,,,CHEMBL619293,,BAO_0000219,791T cell line,80641.0,,,N,5339.0,11831.0,1.0,972.0,Intermediate,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,
9606.0,1.0,,F,,,,CHEMBL619294,,BAO_0000219,791T cell line,80641.0,,,N,5340.0,11831.0,1.0,972.0,Intermediate,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),
9606.0,1.0,,F,,,,CHEMBL619295,,BAO_0000219,791T cell line,80641.0,,,N,5341.0,11831.0,1.0,972.0,Intermediate,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),
9606.0,1.0,,F,,,,CHEMBL619296,,BAO_0000219,791T cell line,80641.0,,,N,5342.0,11831.0,1.0,972.0,Intermediate,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),
9606.0,1.0,,F,,,,CHEMBL619297,,BAO_0000219,791T cell line,80641.0,,,N,5343.0,11831.0,1.0,972.0,Intermediate,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,
9606.0,1.0,,F,,,,CHEMBL619298,,BAO_0000219,786-0,80640.0,,,N,5344.0,12782.0,1.0,391.0,Intermediate,Homo sapiens,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,
,0.0,,F,,,,CHEMBL619299,,BAO_0000019,,22226.0,,,U,5345.0,1229.0,1.0,,Intermediate,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,
9606.0,1.0,,F,,,,CHEMBL619300,,BAO_0000219,RPMI-8226,80433.0,,,N,5346.0,15313.0,1.0,741.0,Expert,Homo sapiens,Inhibition of cell growth in drug resistant 8226 myeloma cell line,
9606.0,1.0,,F,,,,CHEMBL619301,,BAO_0000219,RPMI-8226,80433.0,,,N,5347.0,15313.0,1.0,741.0,Expert,Homo sapiens,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,
9606.0,1.0,,F,,,,CHEMBL619302,,BAO_0000219,RPMI-8226,80433.0,,,N,5348.0,11544.0,1.0,741.0,Intermediate,Homo sapiens,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,
9606.0,1.0,,F,,,,CHEMBL619303,,BAO_0000219,RPMI-8226,80433.0,,,N,5349.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,
9606.0,1.0,,F,,,,CHEMBL619304,,BAO_0000219,RPMI-8226,80433.0,,,N,5350.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,
9606.0,1.0,,F,,,,CHEMBL857706,,BAO_0000219,RPMI-8226,80433.0,,,N,5351.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),
9606.0,1.0,,F,,,,CHEMBL619305,,BAO_0000219,RPMI-8226,80433.0,,,N,5352.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),
9606.0,1.0,,F,,,,CHEMBL619306,,BAO_0000219,RPMI-8226,80433.0,,,N,5353.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),
9606.0,1.0,,F,,,,CHEMBL619307,,BAO_0000219,RPMI-8226,80433.0,,,N,5354.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),
9606.0,1.0,,F,,,,CHEMBL619308,,BAO_0000219,RPMI-8226,80433.0,,,N,5355.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),
9606.0,1.0,,F,,,,CHEMBL619309,,BAO_0000219,RPMI-8226,80433.0,,,N,5356.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),
9606.0,1.0,,F,,,,CHEMBL619310,,BAO_0000219,RPMI-8226,80433.0,,,N,5357.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),
9606.0,1.0,,F,,,,CHEMBL619311,,BAO_0000219,A498,80021.0,,,N,5358.0,14769.0,1.0,624.0,Intermediate,Homo sapiens,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),
9606.0,1.0,,F,,,,CHEMBL619312,,BAO_0000219,A498,80021.0,,,N,5359.0,15354.0,1.0,624.0,Intermediate,Homo sapiens,Compound was tested for the growth inhibition of A498 renal tumor cell line,
9606.0,1.0,,F,,,,CHEMBL619313,,BAO_0000219,A498,80021.0,,,N,5360.0,17445.0,1.0,624.0,Intermediate,Homo sapiens,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),
9606.0,1.0,,F,,,,CHEMBL619314,,BAO_0000219,A498,80021.0,,,N,5361.0,4337.0,1.0,624.0,Intermediate,Homo sapiens,In vitro inhibitory concentration against renal cancer cell line A498,
9606.0,1.0,,F,,,,CHEMBL619959,,BAO_0000219,A498,80021.0,,,N,5362.0,15277.0,1.0,624.0,Intermediate,Homo sapiens,Cytotoxicity against A 498 tumor cell line,
9606.0,1.0,,F,,,,CHEMBL619960,,BAO_0000219,A498,80021.0,,,N,5363.0,4812.0,1.0,624.0,Intermediate,Homo sapiens,In vitro antitumor activity against A498 human cancer cell line,
9606.0,1.0,,F,,,,CHEMBL619961,,BAO_0000219,A498,80021.0,,,N,5364.0,4812.0,1.0,624.0,Intermediate,Homo sapiens,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),
9606.0,1.0,,F,,,,CHEMBL619962,,BAO_0000219,A498,80021.0,,,N,5365.0,4995.0,1.0,624.0,Intermediate,Homo sapiens,Inhibitory dose required against A498 human tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL875586,,BAO_0000219,A498,80021.0,,,N,5366.0,5847.0,1.0,624.0,Intermediate,Homo sapiens,Anticancer activity against one renal cancer (A498 cell line),
9606.0,1.0,,F,,,,CHEMBL619963,,BAO_0000219,A498,80021.0,,,N,5367.0,6557.0,1.0,624.0,Intermediate,Homo sapiens,In vitro cytotoxicity against melanoma A498 cell line,
9606.0,1.0,,F,,,,CHEMBL619964,,BAO_0000219,A498,80021.0,,,N,5368.0,2597.0,1.0,624.0,Intermediate,Homo sapiens,Compound was tested for growth inhibitory activity against A498 cell line,
9606.0,1.0,,F,,,,CHEMBL620108,,BAO_0000219,A498,80021.0,,,N,5369.0,6058.0,1.0,624.0,Intermediate,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line A498,
9606.0,1.0,,F,,,,CHEMBL620109,,BAO_0000219,A498,80021.0,,,N,5370.0,17708.0,1.0,624.0,Intermediate,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,
9606.0,1.0,,F,,,,CHEMBL620110,,BAO_0000219,A498,80021.0,,,N,5371.0,15176.0,1.0,624.0,Intermediate,Homo sapiens,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,
9606.0,1.0,,F,,,,CHEMBL620111,,BAO_0000219,A498,80021.0,,,N,5372.0,15300.0,1.0,624.0,Intermediate,Homo sapiens,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,
9606.0,1.0,,F,,,,CHEMBL620112,,BAO_0000219,A498,80021.0,,,N,5373.0,11970.0,1.0,624.0,Intermediate,Homo sapiens,Tested for cytotoxicity against A498 cell lines in renal cancer,
9606.0,1.0,,F,,,,CHEMBL620113,,BAO_0000219,A498,80021.0,,,N,5374.0,12400.0,1.0,624.0,Intermediate,Homo sapiens,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,
9606.0,1.0,,F,,,,CHEMBL620114,,BAO_0000219,A498,80021.0,,,N,5375.0,12888.0,1.0,624.0,Expert,Homo sapiens,Cytotoxic effect on renal cancer lines A498,
9606.0,1.0,,F,,,,CHEMBL620115,,BAO_0000219,A498,80021.0,,,N,5376.0,3030.0,1.0,624.0,Intermediate,Homo sapiens,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,
9606.0,1.0,,F,,,,CHEMBL620116,,BAO_0000219,A498,80021.0,,,N,5377.0,14769.0,1.0,624.0,Intermediate,Homo sapiens,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),
9606.0,1.0,,F,,,,CHEMBL620117,,BAO_0000219,A498,80021.0,,,N,5378.0,17376.0,1.0,624.0,Intermediate,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,
9606.0,1.0,,F,,,,CHEMBL620118,,BAO_0000219,A498,80021.0,,,N,5379.0,16558.0,1.0,624.0,Intermediate,Homo sapiens,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,
9606.0,1.0,,F,,,,CHEMBL620119,,BAO_0000219,A498,80021.0,,,N,5380.0,5194.0,1.0,624.0,Intermediate,Homo sapiens,Cytotoxicity against human kidney carcinoma cell lines A4982LM,
9606.0,1.0,,F,,,,CHEMBL620120,,BAO_0000219,A498,80021.0,,,N,5381.0,10708.0,1.0,624.0,Intermediate,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,
9606.0,1.0,,F,,,,CHEMBL620121,,BAO_0000219,A549,80682.0,,,N,5382.0,16880.0,1.0,646.0,Expert,Homo sapiens,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,
9606.0,1.0,,F,,,,CHEMBL620122,,BAO_0000219,A549,80682.0,,,N,5383.0,10196.0,1.0,646.0,Intermediate,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line,
9606.0,1.0,,F,,,,CHEMBL620123,,BAO_0000219,A549,80682.0,,,N,5384.0,10196.0,1.0,646.0,Intermediate,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,
9606.0,1.0,,F,,,,CHEMBL620124,,BAO_0000219,A549,80682.0,,,N,5385.0,10196.0,1.0,646.0,Intermediate,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,
9606.0,1.0,,F,,,,CHEMBL620125,,BAO_0000219,A549,80682.0,,,N,5386.0,12083.0,1.0,646.0,Intermediate,Homo sapiens,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",
9606.0,1.0,,F,,,,CHEMBL620126,,BAO_0000219,A549,80682.0,,,N,5387.0,16464.0,1.0,646.0,Expert,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,
9606.0,1.0,,F,,,,CHEMBL883027,,BAO_0000219,A549,80682.0,,,N,5388.0,16464.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,
9606.0,1.0,,F,,,,CHEMBL620127,,BAO_0000219,A549,80682.0,,,N,5389.0,16470.0,1.0,646.0,Expert,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line,
9606.0,1.0,,F,,,,CHEMBL620128,,BAO_0000219,A549,80682.0,,,N,5390.0,16470.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),
9606.0,1.0,,F,,,,CHEMBL620129,,BAO_0000219,A549,80682.0,,,N,5391.0,16470.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line),
9606.0,1.0,,F,,,,CHEMBL620130,,BAO_0000219,A549,80682.0,,,N,5392.0,16470.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,
9606.0,1.0,,F,,,,CHEMBL620131,,BAO_0000219,A549,80682.0,,,N,5393.0,16582.0,1.0,646.0,Expert,Homo sapiens,In vitro cytotoxicity against human non small-cell-lung cell line A549.,
9606.0,1.0,,F,,,,CHEMBL620132,,BAO_0000219,A549,80682.0,,,N,5394.0,15935.0,1.0,646.0,Intermediate,Homo sapiens,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",
9606.0,1.0,,F,,,,CHEMBL620133,,BAO_0000219,A549,80682.0,,,N,5395.0,15935.0,1.0,646.0,Intermediate,Homo sapiens,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",
9606.0,1.0,,F,,,,CHEMBL620134,,BAO_0000219,A549,80682.0,,,N,5396.0,16597.0,1.0,646.0,Expert,Homo sapiens,Inhibition of A549 human lung carcinoma cell proliferation,
9606.0,1.0,,F,,,,CHEMBL620135,,BAO_0000219,A549,80682.0,,,N,5397.0,17376.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line,
9606.0,1.0,,F,,,,CHEMBL620136,,BAO_0000219,A549,80682.0,,,N,5398.0,16496.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,
9606.0,1.0,,F,,,,CHEMBL620137,,BAO_0000219,A549,80682.0,,,N,5399.0,16152.0,1.0,646.0,Intermediate,Homo sapiens,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,
9606.0,1.0,,F,,,,CHEMBL620268,,BAO_0000219,A549,80682.0,,,N,5400.0,16152.0,1.0,646.0,Intermediate,Homo sapiens,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,
9606.0,1.0,,F,,,,CHEMBL620269,,BAO_0000219,A549,80682.0,,,N,5401.0,16464.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,
9606.0,1.0,,F,,,,CHEMBL620270,,BAO_0000219,A549,80682.0,,,N,5402.0,2288.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,
9606.0,1.0,,F,,,,CHEMBL620271,,BAO_0000219,A549,80682.0,,,N,5403.0,17350.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,
9606.0,1.0,,F,,,,CHEMBL620272,,BAO_0000219,A549,80682.0,,,N,5404.0,4090.0,1.0,646.0,Expert,Homo sapiens,Inhibition of A549 cancer cell proliferation,
9606.0,1.0,,F,,,,CHEMBL620273,,BAO_0000219,A549,80682.0,,,N,5405.0,4090.0,1.0,646.0,Expert,Homo sapiens,Inhibition of A549 cancer cell proliferation (Not tested),
9606.0,1.0,,F,,,,CHEMBL620274,,BAO_0000219,A549,80682.0,,,N,5406.0,17350.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,
9606.0,1.0,,F,,,,CHEMBL620275,,BAO_0000219,A549,80682.0,,,N,5407.0,4197.0,1.0,646.0,Intermediate,Homo sapiens,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,
9606.0,1.0,,F,,,,CHEMBL620276,,BAO_0000219,A549,80682.0,,,N,5408.0,17072.0,1.0,646.0,Intermediate,Homo sapiens,Antiproliferative potency determined as inhibitory concentration against A549 cells,
9606.0,1.0,,F,,,,CHEMBL620277,,BAO_0000219,A549,80682.0,,,N,5409.0,17072.0,1.0,646.0,Intermediate,Homo sapiens,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,
9606.0,1.0,,F,,,,CHEMBL620278,,BAO_0000219,A549,80682.0,,,N,5410.0,5194.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity against Renal cell lines A549 was determined,
9615.0,1.0,,A,,,,CHEMBL620279,,BAO_0000218,,50588.0,,,N,5411.0,4257.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve was determined in dog after a 3 mg/kg of oral dose,
9615.0,1.0,,A,,,,CHEMBL620280,,BAO_0000218,,50588.0,,,N,5412.0,6123.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve was determined in dog after oral administration at 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL620281,,BAO_0000218,,50588.0,,,N,5413.0,1337.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,
9615.0,1.0,,A,,,,CHEMBL620282,,BAO_0000218,,50588.0,,,N,5414.0,1337.0,1.0,,Intermediate,Canis lupus familiaris,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,
9615.0,1.0,,A,,,,CHEMBL621134,,BAO_0000218,,50588.0,,,N,5415.0,8833.0,1.0,,Intermediate,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),
9615.0,1.0,,A,,,,CHEMBL621135,,BAO_0000218,,50588.0,,,N,5416.0,8833.0,1.0,,Intermediate,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),
9615.0,1.0,,A,,,,CHEMBL621136,,BAO_0000218,,50588.0,,,N,5417.0,8833.0,1.0,,Intermediate,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),
9615.0,1.0,,A,,,,CHEMBL621137,,BAO_0000218,,50588.0,,,N,5418.0,8833.0,1.0,,Intermediate,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),
9615.0,1.0,,A,,,1969.0,CHEMBL621138,,BAO_0000218,,50588.0,,,N,5419.0,17657.0,1.0,,Intermediate,Canis lupus familiaris,Area under plasma concentration time curve in dog upon oral administration,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL875587,,BAO_0000218,,50588.0,,,N,5420.0,17650.0,1.0,,Intermediate,Canis lupus familiaris,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,Plasma
9615.0,1.0,,A,,,,CHEMBL621139,,BAO_0000218,,50588.0,,,N,5421.0,1977.0,1.0,,Intermediate,Canis lupus familiaris,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,
9615.0,1.0,,A,,,,CHEMBL621140,,BAO_0000218,,50588.0,,,N,5422.0,1977.0,1.0,,Intermediate,Canis lupus familiaris,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,
9615.0,1.0,,A,,,,CHEMBL621141,,BAO_0000218,,50588.0,,,N,5423.0,3132.0,1.0,,Intermediate,Canis lupus familiaris,Area under the curve for the compound was obtained when tested in dog,
9615.0,1.0,,A,,,,CHEMBL621142,,BAO_0000218,,50588.0,,,N,5424.0,5473.0,1.0,,Intermediate,Canis lupus familiaris,Area under the curve at a dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL621143,,BAO_0000218,,50588.0,,,N,5425.0,5474.0,1.0,,Intermediate,Canis lupus familiaris,Area under the curve at a dose of 1 mg/kg (oral),
9615.0,1.0,,A,,,,CHEMBL621144,,BAO_0000218,,50588.0,,,N,5426.0,5474.0,1.0,,Intermediate,Canis lupus familiaris,Area under the curve at i.v. dose of 0.2 mg/kg,
9615.0,1.0,,A,,,,CHEMBL621145,,BAO_0000218,,50588.0,,,N,5427.0,6062.0,1.0,,Intermediate,Canis lupus familiaris,Area under the curve was measured in dog after an iv dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL621146,,BAO_0000218,,50588.0,,,N,5428.0,4709.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL622567,,BAO_0000218,,50588.0,,,N,5429.0,2652.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,
9615.0,1.0,,A,,,,CHEMBL622568,,BAO_0000218,,50588.0,,,N,5430.0,2652.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,
9615.0,1.0,,A,,,,CHEMBL622569,,BAO_0000218,,50588.0,,,N,5431.0,2877.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for area under the curve in dog blood.,
9615.0,1.0,,A,,,,CHEMBL622570,,BAO_0000218,,50588.0,,,N,5432.0,5444.0,1.0,,Intermediate,Canis lupus familiaris,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,
9615.0,1.0,,A,,,1969.0,CHEMBL622571,,BAO_0000218,,50588.0,,,N,5433.0,5130.0,1.0,,Intermediate,Canis lupus familiaris,AUC in dog after oral dose (1 mg/kg),Plasma
9615.0,1.0,,A,,,,CHEMBL622572,,BAO_0000218,,50588.0,,,N,5434.0,6265.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL622573,,BAO_0000218,,50588.0,,,N,5435.0,4657.0,1.0,,Intermediate,Canis lupus familiaris,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",
9615.0,1.0,,A,,,,CHEMBL622574,,BAO_0000218,,50588.0,,,N,5436.0,16367.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic parameter AUC after intravenous administration to dogs,
9615.0,1.0,,A,,,,CHEMBL622575,,BAO_0000218,,50588.0,,,N,5437.0,16367.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic parameter AUC after oral administration to dogs,
9615.0,1.0,,A,,,,CHEMBL622576,,BAO_0000218,,50588.0,,,N,5438.0,9579.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,
9615.0,1.0,,A,,,,CHEMBL622577,,BAO_0000218,,50588.0,,,N,5439.0,9579.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,
9615.0,1.0,,A,,,,CHEMBL622578,,BAO_0000218,,50588.0,,,N,5440.0,5983.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,
9615.0,1.0,,A,,,,CHEMBL622579,,BAO_0000218,,50588.0,,,N,5441.0,6241.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL622580,,BAO_0000218,,50588.0,,,N,5442.0,5313.0,1.0,,Intermediate,Canis lupus familiaris,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",
9615.0,1.0,,A,,,,CHEMBL622581,,BAO_0000218,,50588.0,,,N,5443.0,5313.0,1.0,,Intermediate,Canis lupus familiaris,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",
9615.0,1.0,,A,,,,CHEMBL622582,,BAO_0000218,,50588.0,,,N,5444.0,6642.0,1.0,,Intermediate,Canis lupus familiaris,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),
9615.0,1.0,,A,,,,CHEMBL622583,,BAO_0000218,,50588.0,,,N,5445.0,6642.0,1.0,,Intermediate,Canis lupus familiaris,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),
9615.0,1.0,,A,,,,CHEMBL622584,,BAO_0000218,,50588.0,,,N,5446.0,6641.0,1.0,,Intermediate,Canis lupus familiaris,Oral AUCN in dog (dosed at 0.5 mpk iv ),
9615.0,1.0,,A,,,,CHEMBL622585,,BAO_0000218,,50588.0,,,N,5447.0,6642.0,1.0,,Intermediate,Canis lupus familiaris,Oral AUCN in dog (dosed at 0.5 mpk iv ),
9615.0,1.0,,A,,,,CHEMBL622586,,BAO_0000218,,50588.0,,,N,5448.0,17791.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for oral bioavailability in dog; 90-100,
9615.0,1.0,,A,,,,CHEMBL623281,,BAO_0000218,,50588.0,,,N,5449.0,17655.0,1.0,,Intermediate,Canis lupus familiaris,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,
9615.0,1.0,,A,,,,CHEMBL623282,,BAO_0000218,,50588.0,,,N,5450.0,17655.0,1.0,,Intermediate,Canis lupus familiaris,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,
9615.0,1.0,,A,,,,CHEMBL623283,,BAO_0000218,,50588.0,,,N,5451.0,6596.0,1.0,,Intermediate,Canis lupus familiaris,PAPP (membrane permeability) in dog kidney cell monolayer assay,
9615.0,1.0,,A,,,,CHEMBL623284,,BAO_0000218,,50588.0,,,N,5452.0,3880.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL623285,,BAO_0000218,,50588.0,,,N,5453.0,16367.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability administered orally at a dose of 10 mg/kg to dogs,
9615.0,1.0,,A,,,1969.0,CHEMBL623463,,BAO_0000218,,50588.0,,,N,5454.0,17409.0,1.0,,Intermediate,Canis lupus familiaris,Plasma protein binding towards dog plasma at 10 uM,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL875952,,BAO_0000218,,50588.0,,,N,5455.0,17409.0,1.0,,Intermediate,Canis lupus familiaris,Plasma protein binding towards dog plasma at 100 uM,Plasma
9615.0,1.0,,A,,,,CHEMBL621705,,BAO_0000218,,50588.0,In vivo,,N,5456.0,2959.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog (dose 4 mg/kg p.o.),
9615.0,1.0,,A,,,,CHEMBL621706,,BAO_0000218,,50588.0,In vivo,,N,5457.0,13501.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,
9615.0,1.0,,A,,,,CHEMBL621707,,BAO_0000218,,50588.0,In vivo,,N,5458.0,4527.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,
9615.0,1.0,,A,,,,CHEMBL621708,,BAO_0000218,,50588.0,In vivo,,N,5459.0,15145.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dogs,
9615.0,1.0,,A,,,,CHEMBL621709,,BAO_0000218,,50588.0,In vivo,,N,5460.0,4219.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability,
9615.0,1.0,,A,,,,CHEMBL621710,,BAO_0000218,,50588.0,In vivo,,N,5461.0,17538.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),
9615.0,1.0,,A,,,,CHEMBL621711,,BAO_0000218,,50588.0,In vivo,,N,5462.0,17538.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,
9615.0,1.0,,A,,,,CHEMBL621712,,BAO_0000218,,50588.0,In vivo,,N,5463.0,1466.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog (dose 10.0 mg/kg p.o.),
9615.0,1.0,,A,,,,CHEMBL621713,,BAO_0000218,,50588.0,In vivo,,N,5464.0,17650.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,
9615.0,1.0,,A,,,,CHEMBL621714,,BAO_0000218,,50588.0,In vivo,,N,5465.0,3132.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,
10095.0,0.0,,A,,,,CHEMBL621715,,BAO_0000218,,22224.0,,,U,5466.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,
10095.0,0.0,,A,,,2107.0,CHEMBL623717,,BAO_0000218,,22224.0,,,U,5467.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,Liver
10095.0,0.0,,A,,,2107.0,CHEMBL623718,,BAO_0000218,,22224.0,,,U,5468.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,Liver
10095.0,0.0,,A,,,2107.0,CHEMBL623719,,BAO_0000218,,22224.0,,,U,5469.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,Liver
10095.0,0.0,,A,,,,CHEMBL623720,,BAO_0000218,,22224.0,,,U,5470.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,
10095.0,0.0,,A,,,,CHEMBL623721,,BAO_0000218,,22224.0,,,U,5471.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,
10095.0,0.0,,A,,,2385.0,CHEMBL623722,,BAO_0000218,,22224.0,,,U,5472.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,Muscle tissue
10095.0,0.0,,A,,,2385.0,CHEMBL623723,,BAO_0000218,,22224.0,,,U,5473.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,Muscle tissue
10095.0,0.0,,A,,,2385.0,CHEMBL618543,,BAO_0000218,,22224.0,,,U,5474.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,Muscle tissue
10095.0,0.0,,A,,,2106.0,CHEMBL618544,,BAO_0000218,,22224.0,,,U,5475.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,Spleen
10095.0,0.0,,A,,,2106.0,CHEMBL875155,,BAO_0000218,,22224.0,,,U,5476.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,Spleen
10095.0,0.0,,A,,,,CHEMBL618545,,BAO_0000218,,22224.0,,,U,5477.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,
10095.0,0.0,,A,,,,CHEMBL618546,,BAO_0000218,,22224.0,,,U,5478.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,
10095.0,0.0,,A,,,,CHEMBL623529,,BAO_0000218,,22224.0,,,U,5479.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,
10095.0,0.0,,A,,,,CHEMBL623530,,BAO_0000218,,22224.0,,,U,5480.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,
10095.0,0.0,,A,,,,CHEMBL621764,,BAO_0000218,,22224.0,,,U,5481.0,2413.0,1.0,,Autocuration,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,
9527.0,0.0,,A,,,,CHEMBL621765,,BAO_0000019,,22224.0,,,U,5482.0,17827.0,1.0,,Autocuration,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),
9527.0,0.0,,A,,,2037.0,CHEMBL621766,,BAO_0000019,,22224.0,,,U,5483.0,17827.0,1.0,,Autocuration,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Cerebellum
9527.0,0.0,,A,,,1870.0,CHEMBL621767,,BAO_0000019,,22224.0,,,U,5484.0,17827.0,1.0,,Autocuration,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Frontal cortex
9527.0,0.0,,A,,,,CHEMBL621768,,BAO_0000019,,22224.0,,,U,5485.0,17827.0,1.0,,Autocuration,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),
9527.0,0.0,,A,,,2435.0,CHEMBL621769,,BAO_0000019,,22224.0,,,U,5486.0,17827.0,1.0,,Autocuration,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),Striatum
9527.0,0.0,,A,,,,CHEMBL621770,,BAO_0000019,,22224.0,,,U,5487.0,17827.0,1.0,,Autocuration,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),
9527.0,0.0,,A,,,2037.0,CHEMBL621771,,BAO_0000019,,22224.0,,,U,5488.0,17827.0,1.0,,Autocuration,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Cerebellum
9527.0,0.0,,A,,,1870.0,CHEMBL621772,,BAO_0000019,,22224.0,,,U,5489.0,17827.0,1.0,,Autocuration,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Frontal cortex
9527.0,0.0,,A,,,,CHEMBL621773,,BAO_0000019,,22224.0,,,U,5490.0,17827.0,1.0,,Autocuration,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),
9527.0,0.0,,A,,,2435.0,CHEMBL621774,,BAO_0000019,,22224.0,,,U,5491.0,17827.0,1.0,,Autocuration,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),Striatum
9527.0,0.0,,A,,,,CHEMBL621775,,BAO_0000218,,22224.0,,,U,5492.0,17791.0,1.0,,Autocuration,Cercopithecidae,Compound was evaluated for oral bioavailability in rats,
9527.0,0.0,,A,,,1969.0,CHEMBL621776,,BAO_0000218,,22224.0,In vivo,,U,5493.0,17667.0,1.0,,Autocuration,Cercopithecidae,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,Plasma
9527.0,0.0,,A,,,,CHEMBL621777,,BAO_0000019,,22224.0,,,U,5494.0,17791.0,1.0,,Autocuration,Cercopithecidae,Half life period was evaluated in monkey,
9527.0,0.0,,A,,,,CHEMBL875162,,BAO_0000218,,22224.0,In vivo,,U,5495.0,110.0,1.0,,Autocuration,Cercopithecidae,Half-life in rhesus monkeys by intravenous administration of dose,
10090.0,1.0,,A,,,1969.0,CHEMBL621778,,BAO_0000218,,50594.0,,,N,5496.0,5781.0,1.0,,Intermediate,Mus musculus,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL621779,,BAO_0000218,,50594.0,,,N,5497.0,17734.0,1.0,,Intermediate,Mus musculus,AUC after intraperitoneal administration of 100 mg/kg in mice,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL622479,,BAO_0000218,,50594.0,,,N,5498.0,17718.0,1.0,,Intermediate,Mus musculus,AUC value was determined after oral administration,Plasma
10090.0,1.0,,A,,,,CHEMBL622480,,BAO_0000218,,50594.0,,,N,5499.0,4573.0,1.0,,Intermediate,Mus musculus,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,
10090.0,1.0,,A,,,,CHEMBL622481,,BAO_0000218,,50594.0,,,N,5500.0,3277.0,1.0,,Intermediate,Mus musculus,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),
10090.0,1.0,,A,,,,CHEMBL622482,,BAO_0000218,,50594.0,,,N,5501.0,2862.0,1.0,,Intermediate,Mus musculus,Area under curve by ioral administration in mouse,
10090.0,1.0,,A,,,,CHEMBL622483,,BAO_0000218,,50594.0,,,N,5502.0,2862.0,1.0,,Intermediate,Mus musculus,Area under curve by iv administration in mouse,
10090.0,1.0,,A,,,,CHEMBL622484,,BAO_0000218,,50594.0,,,N,5503.0,5951.0,1.0,,Intermediate,Mus musculus,Area under curve at 0-8 hr in IRC mice after peroral administration,
10090.0,1.0,,A,,,,CHEMBL622641,,BAO_0000218,,50594.0,,,N,5504.0,17729.0,1.0,,Intermediate,Mus musculus,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,
10090.0,1.0,,A,,,,CHEMBL622642,,BAO_0000218,,50594.0,,,N,5505.0,17728.0,1.0,,Intermediate,Mus musculus,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,
10090.0,1.0,,A,,,,CHEMBL622643,,BAO_0000218,,50594.0,,,N,5506.0,17728.0,1.0,,Intermediate,Mus musculus,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,
10090.0,1.0,,A,,,,CHEMBL622644,,BAO_0000218,,50594.0,,,N,5507.0,17729.0,1.0,,Intermediate,Mus musculus,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,
9606.0,1.0,,F,,,,CHEMBL622645,,BAO_0000219,RPMI-8226,80433.0,,,N,5508.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,
9606.0,1.0,,F,,,,CHEMBL622646,,BAO_0000219,RPMI-8226,80433.0,,,N,5509.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,
9606.0,1.0,,F,,,,CHEMBL621238,,BAO_0000219,RPMI-8226,80433.0,,,N,5510.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),
9606.0,1.0,,F,,,,CHEMBL621239,,BAO_0000219,RPMI-8226,80433.0,,,N,5511.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),
9606.0,1.0,,F,,,,CHEMBL621240,,BAO_0000219,RPMI-8226,80433.0,,,N,5512.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),
9606.0,1.0,,F,,,,CHEMBL621241,,BAO_0000219,RPMI-8226,80433.0,,,N,5513.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),
9606.0,1.0,,F,,,,CHEMBL621242,,BAO_0000219,RPMI-8226,80433.0,,,N,5514.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),
9606.0,1.0,,F,,,,CHEMBL620350,,BAO_0000219,RPMI-8226,80433.0,,,N,5515.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),
9606.0,1.0,,F,,,,CHEMBL620351,,BAO_0000219,RPMI-8226,80433.0,,,N,5516.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,
9606.0,1.0,,F,,,,CHEMBL620352,,BAO_0000219,RPMI-8226,80433.0,,,N,5517.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,
9606.0,1.0,,F,,,,CHEMBL620353,,BAO_0000219,RPMI-8226,80433.0,,,N,5518.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),
9606.0,1.0,,F,,,,CHEMBL620354,,BAO_0000219,RPMI-8226,80433.0,,,N,5519.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),
9606.0,1.0,,F,,,,CHEMBL620355,,BAO_0000219,RPMI-8226,80433.0,,,N,5520.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),
9606.0,1.0,,F,,,,CHEMBL620356,,BAO_0000219,RPMI-8226,80433.0,,,N,5521.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),
9606.0,1.0,,F,,,,CHEMBL620357,,BAO_0000219,RPMI-8226,80433.0,,,N,5522.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),
9606.0,1.0,,F,,,,CHEMBL620358,,BAO_0000219,RPMI-8226,80433.0,,,N,5523.0,9424.0,1.0,741.0,Intermediate,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),
9606.0,1.0,,F,,,,CHEMBL620359,,BAO_0000219,RPMI-8226,80433.0,,,N,5524.0,9424.0,1.0,741.0,Expert,Homo sapiens,In vitro inhibition of human 8226 myeloma tumor cell line growth.,
9606.0,1.0,,F,,,,CHEMBL620360,,BAO_0000219,RPMI-8226,80433.0,,,N,5525.0,11544.0,1.0,741.0,Intermediate,Homo sapiens,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,
9606.0,1.0,,F,,,,CHEMBL620361,,BAO_0000219,RPMI-8226,80433.0,,,N,5526.0,17378.0,1.0,741.0,Intermediate,Homo sapiens,Cytotoxicity of compound against 8226/DOX1V cells,
9606.0,1.0,,F,,,,CHEMBL620362,,BAO_0000219,RPMI-8226,80433.0,,,N,5527.0,17378.0,1.0,741.0,Intermediate,Homo sapiens,Cytotoxicity of compound against 8226/S cells,
9606.0,1.0,,F,,,,CHEMBL620363,,BAO_0000219,RPMI-8226,80433.0,,,N,5528.0,17079.0,1.0,741.0,Intermediate,Homo sapiens,Inhibitory concentration against 8226 myeloma cancer cell line,
9606.0,1.0,,F,,,,CHEMBL620364,,BAO_0000219,RPMI-8226,80433.0,,,N,5529.0,17079.0,1.0,741.0,Intermediate,Homo sapiens,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,
9606.0,1.0,,F,,,,CHEMBL620365,,BAO_0000219,833K,80647.0,,,N,5530.0,13466.0,1.0,854.0,Intermediate,Homo sapiens,Inhibition of cell growth was studied in human teratocarcinoma (833K).,
9606.0,1.0,,F,,,,CHEMBL620366,,BAO_0000219,833K,80647.0,,,N,5531.0,13466.0,1.0,854.0,Intermediate,Homo sapiens,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',
9606.0,1.0,,F,,,,CHEMBL620367,,BAO_0000219,833K,80647.0,,,N,5532.0,2392.0,1.0,854.0,Expert,Homo sapiens,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,
9606.0,1.0,,F,,,,CHEMBL620368,,BAO_0000219,833K,80647.0,,,N,5533.0,2392.0,1.0,854.0,Intermediate,Homo sapiens,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,
,0.0,,B,,,,CHEMBL620369,,BAO_0000019,,22226.0,,,U,5534.0,6608.0,1.0,,Autocuration,,Inhibitory activity against caspase-1,
1351.0,8.0,,B,,,,CHEMBL620370,,BAO_0000357,,45.0,,,H,5535.0,10199.0,1.0,,Autocuration,Enterococcus faecalis,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,
9606.0,1.0,,F,,,,CHEMBL620371,,BAO_0000219,8701-BC,80648.0,,,N,5536.0,17749.0,1.0,705.0,Intermediate,Homo sapiens,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,
9606.0,1.0,,F,,,,CHEMBL620372,,BAO_0000219,8701-BC,80648.0,,,N,5537.0,17749.0,1.0,705.0,Intermediate,Homo sapiens,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,
,0.0,,F,,,,CHEMBL876492,,BAO_0000019,,22226.0,,,U,5538.0,1229.0,1.0,,Intermediate,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,
,0.0,,F,,,,CHEMBL620373,,BAO_0000019,,22226.0,,,U,5539.0,1229.0,1.0,,Intermediate,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,
,0.0,,F,,,,CHEMBL620374,,BAO_0000019,,22226.0,,,U,5540.0,1229.0,1.0,,Intermediate,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,
,0.0,,B,,,,CHEMBL620375,,BAO_0000019,,22226.0,,,U,5541.0,6390.0,1.0,,Autocuration,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,
1314.0,0.0,,F,,,,CHEMBL857902,,BAO_0000019,,22226.0,,,U,5542.0,16219.0,1.0,,Autocuration,Streptococcus pyogenes,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,
1314.0,0.0,,F,,,,CHEMBL620376,,BAO_0000019,,22226.0,,,U,5543.0,16219.0,1.0,,Autocuration,Streptococcus pyogenes,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,
,8.0,,B,,,,CHEMBL620377,,BAO_0000357,,11922.0,,,H,5544.0,17043.0,1.0,,Autocuration,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,
9606.0,1.0,,F,,,,CHEMBL620378,,BAO_0000219,KB ,81115.0,,,N,5545.0,6929.0,1.0,324.0,Intermediate,Homo sapiens,Tested for in vitro cytotoxic potency of compound in 9KB assay,
9606.0,1.0,,A,,,,CHEMBL620379,,BAO_0000219,KB ,81115.0,,,N,5546.0,6929.0,1.0,324.0,Intermediate,Homo sapiens,Tested for in vitro cytotoxic potency of compound in 9KB assay,
9606.0,0.0,,F,,,,CHEMBL620380,,BAO_0000219,,22226.0,,,U,5547.0,7083.0,1.0,,Autocuration,Homo sapiens,In vitro cytotoxicity of compound was tested against 9KB cells.,
10116.0,1.0,,F,,,,CHEMBL884006,,BAO_0000219,9L,80653.0,,,N,5548.0,12446.0,1.0,392.0,Intermediate,Rattus norvegicus,Cytotoxic concentration against 9L cells was determined on day 3,
10116.0,1.0,,F,,,,CHEMBL620381,,BAO_0000219,9L,80653.0,,,N,5549.0,15345.0,1.0,392.0,Expert,Rattus norvegicus,Tested in vitro for anticancer activity against 9L cells,
10116.0,1.0,,F,,,,CHEMBL620382,,BAO_0000219,9L,80653.0,,,N,5550.0,15345.0,1.0,392.0,Expert,Rattus norvegicus,Tested in vitro for anticancer activity against 9L cells; Not determined,
9606.0,1.0,,F,,,,CHEMBL620383,,BAO_0000219,A549,80682.0,,,N,5551.0,6301.0,1.0,646.0,Intermediate,Homo sapiens,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,
9606.0,1.0,,F,,,,CHEMBL876493,,BAO_0000219,A549,80682.0,,,N,5552.0,4833.0,1.0,646.0,Intermediate,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,
9606.0,1.0,,F,,,,CHEMBL620384,,BAO_0000219,A549,80682.0,,,N,5553.0,4833.0,1.0,646.0,Intermediate,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,
9606.0,1.0,,F,,,,CHEMBL620385,,BAO_0000219,A549,80682.0,,,N,5554.0,4833.0,1.0,646.0,Intermediate,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,
9606.0,1.0,,F,,,,CHEMBL620386,,BAO_0000219,A549,80682.0,,,N,5555.0,13330.0,1.0,646.0,Expert,Homo sapiens,Cytotoxicity against human lung carcinoma A549 cell line,
9606.0,9.0,,F,,,,CHEMBL620387,,BAO_0000219,A549,25.0,,,D,5556.0,17517.0,1.0,646.0,Expert,Homo sapiens,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,
9606.0,9.0,,F,,,,CHEMBL621404,,BAO_0000219,A549,25.0,,,D,5557.0,17517.0,1.0,646.0,Expert,Homo sapiens,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",
9606.0,1.0,,F,,,,CHEMBL621405,,BAO_0000219,A549,80682.0,,,N,5558.0,14425.0,1.0,646.0,Intermediate,Homo sapiens,"In vitro growth inhibition of A549, lung carcinoma",
9606.0,1.0,,F,,,,CHEMBL621406,,BAO_0000219,A549,80682.0,,,N,5559.0,14425.0,1.0,646.0,Intermediate,Homo sapiens,"In vitro growth inhibition of A549, lung carcinoma.",
9606.0,1.0,,F,,,,CHEMBL621407,,BAO_0000219,A549,80682.0,,,N,5560.0,5228.0,1.0,646.0,Expert,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,
9606.0,1.0,,F,,,,CHEMBL621408,,BAO_0000219,A549,80682.0,,,N,5561.0,5351.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic activity against human lung cancer A549 cell line was determined,
9606.0,1.0,,F,,,,CHEMBL885345,,BAO_0000219,A549,80682.0,,,N,5562.0,12198.0,1.0,646.0,Expert,Homo sapiens,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,
9606.0,1.0,,F,,,,CHEMBL621409,,BAO_0000219,A549,80682.0,,,N,5563.0,13891.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity concentration against human lung carcinoma A-549 cell line,
9606.0,1.0,,F,,,,CHEMBL876034,,BAO_0000219,A549,80682.0,,,N,5564.0,5677.0,1.0,646.0,Expert,Homo sapiens,Cytotoxicity in A549 (human carcinoma) cell line.,
9606.0,1.0,,F,,,,CHEMBL621410,,BAO_0000219,A549,80682.0,,,N,5565.0,13788.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity on lung carcinoma (A-549) cell line,
9606.0,1.0,,F,,,,CHEMBL621411,,BAO_0000219,A549,80682.0,,,N,5566.0,13384.0,1.0,646.0,Expert,Homo sapiens,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,
9606.0,1.0,,F,,,,CHEMBL621412,,BAO_0000219,A549,80682.0,,,N,5567.0,6726.0,1.0,646.0,Intermediate,Homo sapiens,Effective dose of compound against replication of A549 cell line was evaluated,
9606.0,1.0,,F,,,,CHEMBL621413,,BAO_0000219,A549,80682.0,,,N,5568.0,3455.0,1.0,646.0,Expert,Homo sapiens,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,
9606.0,1.0,,F,,,,CHEMBL621414,,BAO_0000219,A549,80682.0,,,N,5569.0,5726.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),
9606.0,1.0,,F,,,,CHEMBL621415,,BAO_0000219,A549,80682.0,,,N,5570.0,5726.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,
9606.0,1.0,,F,,,,CHEMBL621416,,BAO_0000219,A549,80682.0,,,N,5571.0,3936.0,1.0,646.0,Intermediate,Homo sapiens,The compound was evaluated for antiproliferative activity against A549 cell line,
9606.0,1.0,,F,,,,CHEMBL621417,,BAO_0000219,A549,80682.0,,,N,5572.0,14991.0,1.0,646.0,Intermediate,Homo sapiens,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,
9606.0,1.0,,F,,,,CHEMBL621418,,BAO_0000219,A549,80682.0,,,N,5573.0,5243.0,1.0,646.0,Intermediate,Homo sapiens,Concentration required for growth inhibition of human lung carcinoma cell line A549,
9606.0,1.0,,F,,,,CHEMBL621419,,BAO_0000219,A549,80682.0,,,N,5574.0,12858.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,
9606.0,1.0,,F,,,,CHEMBL621420,,BAO_0000219,A549,80682.0,,,N,5575.0,6776.0,1.0,646.0,Intermediate,Homo sapiens,Growth inhibition against A549 cell line was evaluated,
9606.0,1.0,,F,,,,CHEMBL875823,,BAO_0000219,A549,80682.0,,,N,5576.0,16558.0,1.0,646.0,Intermediate,Homo sapiens,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,
9606.0,1.0,,F,,,,CHEMBL621421,,BAO_0000219,A549,80682.0,,,N,5577.0,4583.0,1.0,646.0,Expert,Homo sapiens,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,
9606.0,1.0,,F,,,,CHEMBL621422,,BAO_0000219,A549,80682.0,,,N,5578.0,13514.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,
9606.0,1.0,,F,,,,CHEMBL884014,,BAO_0000219,A549,80682.0,,,N,5579.0,15166.0,1.0,646.0,Expert,Homo sapiens,Chemosensitivity against DT-diaphorase rich A549 cell lines,
9606.0,1.0,,F,,,,CHEMBL621423,,BAO_0000219,A549,80682.0,,,N,5580.0,13873.0,1.0,646.0,Intermediate,Homo sapiens,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,
9606.0,1.0,,F,,,,CHEMBL621424,,BAO_0000219,A549,80682.0,,,N,5581.0,6447.0,1.0,646.0,Expert,Homo sapiens,In vitro cytotoxicity against human A549 (lung cancer) cell line.,
9606.0,1.0,,F,,,,CHEMBL621425,,BAO_0000219,A549,80682.0,,,N,5582.0,2068.0,1.0,646.0,Intermediate,Homo sapiens,In vitro antitumor activity against A549 (lung) human tumor cell lines.,
9606.0,1.0,,F,,,,CHEMBL621426,,BAO_0000219,A549,80682.0,,,N,5583.0,1863.0,1.0,646.0,Expert,Homo sapiens,In vitro cytotoxic activity against human lung carcinoma A549 cell line,
9606.0,1.0,,F,,,,CHEMBL621427,,BAO_0000219,A549,80682.0,,,N,5584.0,13873.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,
9606.0,1.0,,F,,,,CHEMBL621428,,BAO_0000219,A549,80682.0,,,N,5585.0,13873.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,
9606.0,1.0,,F,,,,CHEMBL621429,,BAO_0000219,A549,80682.0,,,N,5586.0,13873.0,1.0,646.0,Expert,Homo sapiens,Tested against A549 lung carcinoma in the sulforhodamine B assay.,
9606.0,1.0,,F,,,,CHEMBL621430,,BAO_0000219,A549,80682.0,,,N,5587.0,579.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),
9606.0,1.0,,F,,,,CHEMBL621431,,BAO_0000219,A549,80682.0,,,N,5588.0,579.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,
9606.0,1.0,,F,,,,CHEMBL621432,,BAO_0000219,A549,80682.0,,,N,5589.0,4584.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,
9606.0,1.0,,F,,,,CHEMBL621433,,BAO_0000219,A549,80682.0,,,N,5590.0,5421.0,1.0,646.0,Expert,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,
9606.0,1.0,,F,,,,CHEMBL875824,,BAO_0000219,A549,80682.0,,,N,5591.0,5421.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,
9606.0,1.0,,F,,,,CHEMBL621434,,BAO_0000219,A549,80682.0,,,N,5592.0,5421.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,
9606.0,1.0,,F,,,,CHEMBL621435,,BAO_0000219,A549,80682.0,,,N,5593.0,5421.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,
9606.0,1.0,,F,,,,CHEMBL621436,,BAO_0000219,A549,80682.0,,,N,5594.0,14188.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,
9606.0,1.0,,F,,,,CHEMBL621437,,BAO_0000219,A549,80682.0,,,N,5595.0,14188.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,
9606.0,1.0,,F,,,,CHEMBL621438,,BAO_0000219,A549,80682.0,,,N,5596.0,15354.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for the growth inhibition of A549 lung tumor cell line,
9606.0,1.0,,F,,,,CHEMBL621439,,BAO_0000219,A549,80682.0,,,N,5597.0,14253.0,1.0,646.0,Expert,Homo sapiens,Growth inhibition of human non-small-lung carcinoma (A549) cell line,
9606.0,1.0,,F,,,,CHEMBL621440,,BAO_0000219,A549,80682.0,,,N,5598.0,13873.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,
9615.0,1.0,,A,,,,CHEMBL621441,,BAO_0000218,,50588.0,In vivo,,N,5599.0,3043.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (conscious),
9615.0,1.0,,A,,,,CHEMBL621442,,BAO_0000218,,50588.0,In vivo,,N,5600.0,3045.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for the oral bioavailability after oral administration in dog.,
9615.0,1.0,,A,,,,CHEMBL621443,,BAO_0000218,,50588.0,In vivo,,N,5601.0,3022.0,1.0,,Intermediate,Canis lupus familiaris,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,
9615.0,1.0,,A,,,,CHEMBL621444,,BAO_0000218,,50588.0,In vivo,,N,5602.0,4453.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL625133,,BAO_0000218,,50588.0,In vivo,,N,5603.0,1696.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL625134,,BAO_0000218,,50588.0,In vivo,,N,5604.0,5045.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL625135,,BAO_0000218,,50588.0,In vivo,,N,5605.0,5356.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (fasted),
9615.0,1.0,,A,,,,CHEMBL625136,,BAO_0000218,,50588.0,In vivo,,N,5606.0,17764.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,
9615.0,1.0,,A,,,,CHEMBL625137,,BAO_0000218,,50588.0,In vivo,,N,5607.0,6448.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL625138,,BAO_0000218,,50588.0,In vivo,,N,5608.0,1475.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL625139,,BAO_0000218,,50588.0,In vivo,,N,5609.0,3788.0,1.0,,Intermediate,Canis lupus familiaris,Percent bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL872264,,BAO_0000218,,50588.0,In vivo,,N,5610.0,3639.0,1.0,,Intermediate,Canis lupus familiaris,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,
9615.0,1.0,,A,,,,CHEMBL625140,,BAO_0000218,,50588.0,In vivo,,N,5611.0,13397.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL624436,,BAO_0000218,,50588.0,In vivo,,N,5612.0,2137.0,1.0,,Intermediate,Canis lupus familiaris,The compound was evaluated for bioavailability in dogs; 34-44,
9615.0,1.0,,A,,,,CHEMBL624437,,BAO_0000218,,50588.0,In vivo,,N,5613.0,2959.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog (dose 4 mg/kg p.o.),
9615.0,1.0,,A,,,,CHEMBL872261,,BAO_0000218,,50588.0,In vivo,,N,5614.0,6448.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL624438,,BAO_0000218,,50588.0,,,N,5615.0,6084.0,1.0,,Intermediate,Canis lupus familiaris,8 hour trough Blood level in dog was measured after administration of compound,
9615.0,1.0,,A,,,1969.0,CHEMBL624439,,BAO_0000218,,50588.0,In vivo,,N,5616.0,3639.0,1.0,,Intermediate,Canis lupus familiaris,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,Plasma
9615.0,1.0,,A,,,,CHEMBL624440,,BAO_0000218,,50588.0,,,N,5617.0,6316.0,1.0,,Intermediate,Canis lupus familiaris,C24 after oral administration at 5 mg/kg,
9615.0,1.0,,A,,,,CHEMBL624441,,BAO_0000218,,50588.0,,,N,5618.0,5238.0,1.0,,Intermediate,Canis lupus familiaris,Clearance after oral and iv dosing in dogs,
9615.0,1.0,,A,,,1969.0,CHEMBL624442,,BAO_0000218,,50588.0,,,N,5619.0,17796.0,1.0,,Intermediate,Canis lupus familiaris,Clearance of the drug was measured in the plasma of dog,Plasma
9615.0,1.0,,A,,,,CHEMBL624443,,BAO_0000218,,50588.0,,,N,5620.0,2652.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,
9615.0,1.0,,A,,,,CHEMBL624444,,BAO_0000218,,50588.0,In vivo,,N,5621.0,5654.0,1.0,,Intermediate,Canis lupus familiaris,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL624445,,BAO_0000218,,50588.0,In vivo,,N,5622.0,6621.0,1.0,,Intermediate,Canis lupus familiaris,Clearance of compound was determined in dogs,
9615.0,1.0,,A,,,,CHEMBL624446,,BAO_0000218,,50588.0,In vivo,,N,5623.0,6505.0,1.0,,Intermediate,Canis lupus familiaris,Clearance on i.v. administration of 2 mg/kg was measured in dog,
9615.0,1.0,,A,,,,CHEMBL624447,,BAO_0000218,,50588.0,In vivo,,N,5624.0,5802.0,1.0,,Intermediate,Canis lupus familiaris,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,
9615.0,1.0,,A,,,,CHEMBL624448,,BAO_0000218,,50588.0,In vivo,,N,5625.0,17267.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in dog was determined,
9615.0,1.0,,A,,,,CHEMBL624449,,BAO_0000218,,50588.0,In vivo,,N,5626.0,4521.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,
9615.0,1.0,,A,,,,CHEMBL624450,,BAO_0000218,,50588.0,In vivo,,N,5627.0,6535.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in dog after administration of 0.25 mg/kg iv,
9615.0,1.0,,A,,,,CHEMBL875942,,BAO_0000218,,50588.0,In vivo,,N,5628.0,6535.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in dog after administration of 1 mg/kg iv,
9615.0,1.0,,A,,,,CHEMBL624451,,BAO_0000218,,50588.0,In vivo,,N,5629.0,6535.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in dogs,
9615.0,1.0,,A,,,,CHEMBL624452,,BAO_0000218,,50588.0,In vivo,,N,5630.0,5542.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,
9615.0,1.0,,A,,,,CHEMBL624453,,BAO_0000218,,50588.0,In vivo,,N,5631.0,5199.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,
9615.0,1.0,,A,,,,CHEMBL624454,,BAO_0000218,,50588.0,In vivo,,N,5632.0,16907.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance after 15 mg/kg iv dose in Dogs,
9615.0,1.0,,A,,,,CHEMBL624455,,BAO_0000218,,50588.0,In vivo,,N,5633.0,16907.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance after 30 mg/kg po dose in Dogs,
9615.0,1.0,,A,,,,CHEMBL624456,,BAO_0000218,,50588.0,In vivo,,N,5634.0,16367.0,1.0,,Intermediate,Canis lupus familiaris,Plasma administration to dogs,
9615.0,1.0,,A,,,,CHEMBL624457,,BAO_0000218,,50588.0,In vivo,,N,5635.0,5505.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance was determined,
9615.0,1.0,,A,,,,CHEMBL624458,,BAO_0000218,,50588.0,In vivo,,N,5636.0,6215.0,1.0,,Intermediate,Canis lupus familiaris,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,
9615.0,1.0,,A,,,,CHEMBL624459,,BAO_0000218,,50588.0,In vivo,,N,5637.0,1466.0,1.0,,Intermediate,Canis lupus familiaris,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,
9606.0,2.0,,A,,,2107.0,CHEMBL624460,,BAO_0000251,,102164.0,In vitro,Microsomes,S,5638.0,5007.0,1.0,,Intermediate,Homo sapiens,Intrinsic clearance in human liver microsomes,Liver
9606.0,2.0,,A,,,2107.0,CHEMBL624461,,BAO_0000251,,102164.0,In vitro,Microsomes,S,5639.0,5007.0,1.0,,Intermediate,Homo sapiens,Intrinsic clearance in human liver microsomes,Liver
9615.0,1.0,,A,,,,CHEMBL875943,,BAO_0000218,,50588.0,In vivo,,N,5640.0,16452.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,
9615.0,1.0,,A,,,,CHEMBL624462,,BAO_0000218,,50588.0,In vivo,,N,5641.0,16452.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,
9615.0,1.0,,A,,,,CHEMBL624463,,BAO_0000218,,50588.0,In vivo,,N,5642.0,16452.0,1.0,,Intermediate,Canis lupus familiaris,Clearance in dog (dose 1 mg/kg i.v.),
9615.0,1.0,,A,,,,CHEMBL624464,,BAO_0000218,,50588.0,In vivo,,N,5643.0,6221.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,
9615.0,1.0,,A,,,,CHEMBL624465,,BAO_0000218,,50588.0,In vivo,,N,5644.0,5007.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),
9615.0,1.0,,A,,,,CHEMBL624466,,BAO_0000218,,50588.0,In vivo,,N,5645.0,5668.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance after peroral administration at 10 mpk in dog,
9615.0,1.0,,A,,,,CHEMBL624467,,BAO_0000218,,50588.0,In vivo,,N,5646.0,5668.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance after peroral administration at 5 mpk in dog,
9615.0,1.0,,A,,,,CHEMBL624468,,BAO_0000218,,50588.0,In vivo,,N,5647.0,5668.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance after peroral administration at 5 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL624469,,BAO_0000218,,50588.0,In vivo,,N,5648.0,15660.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance was measured in dog,
9615.0,1.0,,A,,,,CHEMBL624470,,BAO_0000218,,50588.0,In vivo,,N,5649.0,15660.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance was measured in dog,
9615.0,1.0,,A,,,,CHEMBL624471,,BAO_0000218,,50588.0,In vivo,,N,5650.0,5983.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,
9615.0,1.0,,A,,,,CHEMBL624472,,BAO_0000218,,50588.0,In vivo,,N,5651.0,5600.0,1.0,,Intermediate,Canis lupus familiaris,Total clearance was determined after 0.1 mg/kg iv administration in dog,
9615.0,1.0,,A,,,,CHEMBL622775,,BAO_0000218,,50588.0,In vivo,,N,5652.0,17764.0,1.0,,Intermediate,Canis lupus familiaris,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,
9615.0,1.0,,A,,,,CHEMBL622776,,BAO_0000218,,50588.0,In vivo,,N,5653.0,6039.0,1.0,,Intermediate,Canis lupus familiaris,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,
9615.0,1.0,,A,,,,CHEMBL622777,,BAO_0000218,,50588.0,In vivo,,N,5654.0,6039.0,1.0,,Intermediate,Canis lupus familiaris,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,
9615.0,1.0,,A,,,,CHEMBL622778,,BAO_0000218,,50588.0,In vivo,,N,5655.0,6039.0,1.0,,Intermediate,Canis lupus familiaris,Clearance after peroral administration of 0.2 mg/kg in dog was determined,
9615.0,1.0,,A,,,,CHEMBL622779,,BAO_0000218,,50588.0,In vivo,,N,5656.0,4368.0,1.0,,Intermediate,Canis lupus familiaris,Clearance by intravenous administration of 1.2 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL622780,,BAO_0000218,,50588.0,In vivo,,N,5657.0,4305.0,1.0,,Intermediate,Canis lupus familiaris,Clearance by iv administration in dogs at a dose of 1 mg/kg,
9615.0,1.0,,A,,,1969.0,CHEMBL622781,,BAO_0000218,,50588.0,In vivo,,N,5658.0,1918.0,1.0,,Intermediate,Canis lupus familiaris,Clearance value was evaluated in dog plasma,Plasma
9615.0,1.0,,A,,,,CHEMBL622782,,BAO_0000218,,50588.0,In vivo,,N,5659.0,6005.0,1.0,,Intermediate,Canis lupus familiaris,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,
9615.0,1.0,,A,,,1969.0,CHEMBL622783,,BAO_0000218,,50588.0,In vivo,,N,5660.0,4839.0,1.0,,Intermediate,Canis lupus familiaris,Compound was tested for plasma clearance in dog,Plasma
9615.0,1.0,,A,,,,CHEMBL622784,,BAO_0000218,,50588.0,In vivo,,N,5661.0,4239.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic property (Plasma clearance) was measured in dog,
10090.0,1.0,,A,,,,CHEMBL622785,,BAO_0000218,,50594.0,,,N,5662.0,17729.0,1.0,,Intermediate,Mus musculus,Area under curve when injected perorally in mice at a dose of 50 mg/kg,
10090.0,1.0,,A,,,,CHEMBL622786,,BAO_0000218,,50594.0,,,N,5663.0,17728.0,1.0,,Intermediate,Mus musculus,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,
10090.0,1.0,,A,,,,CHEMBL622787,,BAO_0000218,,50594.0,,,N,5664.0,5302.0,1.0,,Intermediate,Mus musculus,Area under curve value in mouse at a dose of 10 mg/kg,
10090.0,1.0,,A,,,,CHEMBL875949,,BAO_0000218,,50594.0,,,N,5665.0,5506.0,1.0,,Intermediate,Mus musculus,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,
10090.0,1.0,,A,,,,CHEMBL622788,,BAO_0000218,,50594.0,,,N,5666.0,5506.0,1.0,,Intermediate,Mus musculus,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,
10090.0,1.0,,F,,,,CHEMBL622789,,BAO_0000218,,50594.0,,,N,5667.0,17764.0,1.0,,Intermediate,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,
10090.0,1.0,,F,,,,CHEMBL622790,,BAO_0000218,,50594.0,,,N,5668.0,17764.0,1.0,,Intermediate,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,
10090.0,1.0,,F,,,,CHEMBL622791,,BAO_0000218,,50594.0,,,N,5669.0,17764.0,1.0,,Intermediate,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,
10090.0,1.0,,F,,,,CHEMBL622792,,BAO_0000218,,50594.0,,,N,5670.0,17764.0,1.0,,Intermediate,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,
10090.0,1.0,,A,,,,CHEMBL622793,,BAO_0000218,,50594.0,,,N,5671.0,17764.0,1.0,,Intermediate,Mus musculus,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,
10090.0,1.0,,A,,,,CHEMBL622794,,BAO_0000218,,50594.0,,,N,5672.0,17753.0,1.0,,Intermediate,Mus musculus,Area under curve was determined for the compound at 24 mg/Kg,
10090.0,1.0,,A,,,,CHEMBL622795,,BAO_0000218,,50594.0,,,N,5673.0,17753.0,1.0,,Intermediate,Mus musculus,Area under curve was determined for the compound at 40 mg/Kg,
10090.0,1.0,,A,,,,CHEMBL621803,,BAO_0000218,,50594.0,,,N,5674.0,17753.0,1.0,,Intermediate,Mus musculus,Area under curve was determined for the compound at 5 mg/Kg,
10090.0,1.0,,A,,,,CHEMBL621804,,BAO_0000218,,50594.0,,,N,5675.0,3132.0,1.0,,Intermediate,Mus musculus,Area under the curve for the compound is obtained at dose 25 mg/kg,
10090.0,1.0,,A,,,,CHEMBL621805,,BAO_0000218,,50594.0,,,N,5676.0,3132.0,1.0,,Intermediate,Mus musculus,Area under the curve for the compound was obtained when tested in mouse,
10090.0,1.0,,A,,,,CHEMBL621806,,BAO_0000218,,50594.0,,,N,5677.0,17837.0,1.0,,Intermediate,Mus musculus,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,
10090.0,1.0,,A,,,,CHEMBL621807,,BAO_0000218,,50594.0,,,N,5678.0,17837.0,1.0,,Intermediate,Mus musculus,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,
10090.0,1.0,,A,,,,CHEMBL621808,,BAO_0000218,,50594.0,,,N,5679.0,6062.0,1.0,,Intermediate,Mus musculus,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,
10090.0,1.0,,A,,,,CHEMBL621809,,BAO_0000218,,50594.0,,,N,5680.0,4066.0,1.0,,Intermediate,Mus musculus,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,
10090.0,1.0,,A,,,,CHEMBL621810,,BAO_0000218,,50594.0,,,N,5681.0,16597.0,1.0,,Intermediate,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),
10090.0,1.0,,A,,,,CHEMBL875164,,BAO_0000218,,50594.0,,,N,5682.0,14239.0,1.0,,Intermediate,Mus musculus,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,
10090.0,1.0,,A,,,,CHEMBL621811,,BAO_0000218,,50594.0,,,N,5683.0,14239.0,1.0,,Intermediate,Mus musculus,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,
10090.0,1.0,,A,,,,CHEMBL621812,,BAO_0000218,,50594.0,,,N,5684.0,4890.0,1.0,,Intermediate,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, area under curve",
10090.0,1.0,,A,,,,CHEMBL621813,,BAO_0000218,,50594.0,,,N,5685.0,429.0,1.0,,Intermediate,Mus musculus,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),
10090.0,1.0,,A,,,,CHEMBL621814,,BAO_0000218,,50594.0,,,N,5686.0,429.0,1.0,,Intermediate,Mus musculus,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),
10090.0,1.0,,A,,,,CHEMBL621815,,BAO_0000218,,50594.0,,,N,5687.0,5969.0,1.0,,Intermediate,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,
10090.0,1.0,,A,,,,CHEMBL621816,,BAO_0000218,,50594.0,,,N,5688.0,5969.0,1.0,,Intermediate,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,
10090.0,1.0,,A,,,,CHEMBL621817,,BAO_0000218,,50594.0,,,N,5689.0,5969.0,1.0,,Intermediate,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,
10090.0,1.0,,A,,,,CHEMBL621818,,BAO_0000218,,50594.0,,,N,5690.0,6091.0,1.0,,Intermediate,Mus musculus,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,
10090.0,1.0,,A,,,,CHEMBL621819,,BAO_0000218,,50594.0,,,N,5691.0,6091.0,1.0,,Intermediate,Mus musculus,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,
10090.0,1.0,,A,,,,CHEMBL621820,,BAO_0000218,,50594.0,,,N,5692.0,6091.0,1.0,,Intermediate,Mus musculus,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,
10090.0,1.0,,A,,,,CHEMBL621821,,BAO_0000218,,50594.0,,,N,5693.0,6091.0,1.0,,Intermediate,Mus musculus,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,
10090.0,1.0,,A,,,,CHEMBL621822,,BAO_0000218,,50594.0,,,N,5694.0,6178.0,1.0,,Intermediate,Mus musculus,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,
10090.0,1.0,,A,,,,CHEMBL619474,,BAO_0000218,,50594.0,,,N,5695.0,6178.0,1.0,,Intermediate,Mus musculus,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,
10090.0,1.0,,A,,,,CHEMBL619475,,BAO_0000218,,50594.0,,,N,5696.0,6619.0,1.0,,Intermediate,Mus musculus,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",
10090.0,1.0,,A,,,,CHEMBL619476,,BAO_0000218,,50594.0,,,N,5697.0,6619.0,1.0,,Intermediate,Mus musculus,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",
10090.0,1.0,,A,,,,CHEMBL619477,,BAO_0000218,,50594.0,,,N,5698.0,3760.0,1.0,,Intermediate,Mus musculus,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",
10090.0,1.0,,A,,,,CHEMBL619478,,BAO_0000218,,50594.0,,,N,5699.0,3760.0,1.0,,Intermediate,Mus musculus,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",
10090.0,1.0,,A,,,,CHEMBL619479,,BAO_0000218,,50594.0,,,N,5700.0,3760.0,1.0,,Intermediate,Mus musculus,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",
10090.0,1.0,,A,,,,CHEMBL619480,,BAO_0000218,,50594.0,,,N,5701.0,3760.0,1.0,,Intermediate,Mus musculus,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",
10090.0,1.0,,A,,,,CHEMBL619481,,BAO_0000218,,50594.0,,,N,5702.0,3192.0,1.0,,Intermediate,Mus musculus,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,
10090.0,1.0,,A,,,,CHEMBL619482,,BAO_0000218,,50594.0,,,N,5703.0,3192.0,1.0,,Intermediate,Mus musculus,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,
10090.0,1.0,,A,,,,CHEMBL619483,,BAO_0000218,,50594.0,,,N,5704.0,2675.0,1.0,,Intermediate,Mus musculus,Area under the curve was evaluated in mice after intravenous administration,
10090.0,1.0,,A,,,,CHEMBL619484,,BAO_0000218,,50594.0,,,N,5705.0,2675.0,1.0,,Intermediate,Mus musculus,Area under the curve was evaluated in mice after oral administration,
10090.0,1.0,,A,,,1969.0,CHEMBL619485,,BAO_0000218,,50594.0,,,N,5706.0,16597.0,1.0,,Intermediate,Mus musculus,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL619486,,BAO_0000218,,50594.0,,,N,5707.0,16597.0,1.0,,Intermediate,Mus musculus,AUC total value at a dose of 10 mg/kg peroral administration in mice.,Plasma
10090.0,1.0,,A,,,,CHEMBL619487,,BAO_0000218,,50594.0,,,N,5708.0,16597.0,1.0,,Intermediate,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),
10090.0,1.0,,A,,,,CHEMBL619488,,BAO_0000218,,50594.0,,,N,5709.0,17734.0,1.0,,Intermediate,Mus musculus,AUMC after intraperitoneal administration of 100 mg/kg in mice,
10090.0,1.0,,A,,,178.0,CHEMBL620106,,BAO_0000218,,50594.0,In vivo,,N,5710.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,Blood
,1.0,,F,,,,CHEMBL620107,,BAO_0000219,9L,80653.0,,,N,5711.0,15345.0,1.0,392.0,Intermediate,,The compound was tested in vitro for anticancer activity against 9L cells,
10116.0,0.0,,F,,,,CHEMBL620283,,BAO_0000019,,22226.0,,,U,5712.0,2181.0,1.0,,Autocuration,Rattus norvegicus,Anti proliferation activity determined; Weak effect,
10116.0,0.0,,F,,,,CHEMBL875176,,BAO_0000219,,22226.0,,,U,5713.0,2181.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,
10116.0,0.0,,F,,,,CHEMBL620284,,BAO_0000219,,22226.0,,,U,5714.0,2181.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,
10116.0,0.0,,F,,,,CHEMBL623515,,BAO_0000219,,22226.0,,,U,5715.0,2181.0,1.0,,Autocuration,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,
10090.0,0.0,,F,,,,CHEMBL623516,,BAO_0000019,,22226.0,,,U,5716.0,10486.0,1.0,,Autocuration,Mus musculus,The cytotoxic activity was in vitro tested by 9PS assay method,
10090.0,0.0,,F,,,,CHEMBL623517,,BAO_0000019,,22226.0,,,U,5717.0,10486.0,1.0,,Autocuration,Mus musculus,The cytotoxic activity was in vitro tested by 9PS assay method.,
,0.0,,A,,,,CHEMBL857878,,BAO_0000019,,22224.0,,,U,5718.0,15508.0,1.0,,Autocuration,,Partition coefficient (logD6.5),
9606.0,1.0,,F,,,,CHEMBL623518,,BAO_0000219,A2780,81034.0,,,N,5719.0,5242.0,1.0,478.0,Expert,Homo sapiens,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,
9606.0,1.0,,F,,,,CHEMBL624195,,BAO_0000219,A-375,80018.0,,,N,5720.0,16167.0,1.0,455.0,Intermediate,Homo sapiens,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),
9606.0,1.0,,F,,,,CHEMBL624196,,BAO_0000219,A-431,80852.0,,,N,5721.0,4782.0,1.0,500.0,Expert,Homo sapiens,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,
9606.0,9.0,,F,,,,CHEMBL624197,,BAO_0000219,A-431,9.0,,,D,5722.0,16093.0,1.0,500.0,Expert,Homo sapiens,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,
9606.0,1.0,,F,,,,CHEMBL624198,,BAO_0000219,A498,80021.0,,,N,5723.0,2596.0,1.0,624.0,Intermediate,Homo sapiens,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,
9606.0,1.0,,F,,,,CHEMBL621287,,BAO_0000219,A498,80021.0,,,N,5724.0,2596.0,1.0,624.0,Intermediate,Homo sapiens,in vitro cytotoxicity against A 498 cancer cell line,
9606.0,1.0,,F,,,,CHEMBL621288,,BAO_0000219,A498,80021.0,,,N,5725.0,3239.0,1.0,624.0,Intermediate,Homo sapiens,In vitro cytotoxic activity against renal (A 498) cancer cell line.,
9606.0,1.0,,F,,,,CHEMBL876496,,BAO_0000219,A498,80021.0,,,N,5726.0,1847.0,1.0,624.0,Intermediate,Homo sapiens,Cytotoxic activity against A 498 renal cancer cell lines.,
9606.0,1.0,,F,,,,CHEMBL621289,,BAO_0000219,A498,80021.0,,,N,5727.0,10553.0,1.0,624.0,Intermediate,Homo sapiens,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,
1280.0,0.0,,F,,,,CHEMBL621290,,BAO_0000019,,22226.0,,,U,5728.0,16219.0,1.0,,Autocuration,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,
1280.0,0.0,,F,,,,CHEMBL621291,,BAO_0000019,,22226.0,,,U,5729.0,16219.0,1.0,,Autocuration,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,
1280.0,0.0,,F,,,,CHEMBL621292,,BAO_0000019,,22226.0,,,U,5730.0,16219.0,1.0,,Autocuration,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,
1280.0,0.0,,F,,,,CHEMBL621293,,BAO_0000019,,22226.0,,,U,5731.0,16219.0,1.0,,Autocuration,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,
9606.0,1.0,,F,,,,CHEMBL621294,,BAO_0000219,A549,80682.0,,,N,5732.0,4782.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory concentration required against A 549 lung cancer cell line,
9606.0,1.0,,F,,,,CHEMBL621295,,BAO_0000219,A549,80682.0,,,N,5733.0,11805.0,1.0,646.0,Intermediate,Homo sapiens,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,
9606.0,1.0,,F,,,,CHEMBL884007,,BAO_0000219,A549,80682.0,,,N,5734.0,11805.0,1.0,646.0,Intermediate,Homo sapiens,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,
9606.0,1.0,,F,,,,CHEMBL621296,,BAO_0000219,A549,80682.0,,,N,5735.0,2007.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against lung cancer A 549 cell lines,
9606.0,1.0,,F,,,,CHEMBL621297,,BAO_0000219,A549,80682.0,,,N,5736.0,4594.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for its cytotoxicity against A 549 cell line,
9606.0,1.0,,F,,,,CHEMBL839828,,BAO_0000219,A549,80682.0,,,N,5737.0,6018.0,1.0,646.0,Expert,Homo sapiens,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",
9606.0,1.0,,F,,,,CHEMBL620397,,BAO_0000219,A549,80682.0,,,N,5738.0,6018.0,1.0,646.0,Intermediate,Homo sapiens,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",
9606.0,1.0,,F,,,,CHEMBL620398,,BAO_0000219,A549,80682.0,,,N,5739.0,3599.0,1.0,646.0,Expert,Homo sapiens,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,
9606.0,1.0,,F,,,,CHEMBL620399,,BAO_0000219,A549,80682.0,,,N,5740.0,2551.0,1.0,646.0,Intermediate,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,
9606.0,1.0,,F,,,,CHEMBL620400,,BAO_0000219,A549,80682.0,,,N,5741.0,16132.0,1.0,646.0,Expert,Homo sapiens,In vitro inhibition of A549 (human lung cancer) cell growth.,
9606.0,1.0,,F,,,,CHEMBL620401,,BAO_0000219,A549,80682.0,,,N,5742.0,16132.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,
9606.0,1.0,,F,,,,CHEMBL620402,,BAO_0000219,A549,80682.0,,,N,5743.0,2551.0,1.0,646.0,Expert,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,
9606.0,1.0,,F,,,,CHEMBL620403,,BAO_0000219,A549,80682.0,,,N,5744.0,2551.0,1.0,646.0,Expert,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),
,0.0,,F,,,,CHEMBL620404,,BAO_0000218,,22226.0,,,U,5745.0,11913.0,1.0,,Autocuration,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,
,4.0,,F,,,,CHEMBL620405,,BAO_0000218,,104694.0,In vivo,,H,5746.0,12621.0,1.0,,Autocuration,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,
,4.0,,F,,,,CHEMBL620406,,BAO_0000218,,104694.0,In vivo,,H,5747.0,12621.0,1.0,,Autocuration,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,
,4.0,,F,,,,CHEMBL620407,,BAO_0000218,,104694.0,In vivo,,H,5748.0,12621.0,1.0,,Autocuration,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,
,4.0,,F,,,,CHEMBL620408,,BAO_0000218,,104694.0,In vivo,,H,5749.0,12621.0,1.0,,Autocuration,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,
,4.0,,F,,,,CHEMBL620409,,BAO_0000218,,104694.0,In vivo,,H,5750.0,12621.0,1.0,,Autocuration,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,
9606.0,1.0,,F,,,,CHEMBL620410,,BAO_0000219,A498,80021.0,,,N,5751.0,3600.0,1.0,624.0,Expert,Homo sapiens,Inhibition of A-498 human Renal cell proliferation,
10116.0,0.0,,F,,,,CHEMBL620411,,BAO_0000019,,22226.0,,,U,5752.0,1796.0,1.0,,Autocuration,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",
10116.0,0.0,,F,,,,CHEMBL620412,,BAO_0000019,,22226.0,,,U,5753.0,1796.0,1.0,,Autocuration,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",
10116.0,0.0,,F,,,,CHEMBL876596,,BAO_0000019,,22226.0,,,U,5754.0,1796.0,1.0,,Autocuration,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",
9606.0,1.0,,F,,,,CHEMBL620413,,BAO_0000219,A 172,80012.0,,,N,5755.0,16464.0,1.0,622.0,Expert,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,
9606.0,1.0,,F,,,,CHEMBL620414,,BAO_0000219,A 172,80012.0,,,N,5756.0,16464.0,1.0,622.0,Intermediate,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,
9606.0,1.0,,F,,,,CHEMBL620415,,BAO_0000219,A 172,80012.0,,,N,5757.0,16464.0,1.0,622.0,Intermediate,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,
9606.0,1.0,,F,,,,CHEMBL620416,,BAO_0000219,A549,80682.0,,,N,5758.0,13617.0,1.0,646.0,Expert,Homo sapiens,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,
9606.0,1.0,,F,,,,CHEMBL620417,,BAO_0000219,A549,80682.0,,,N,5759.0,4584.0,1.0,646.0,Intermediate,Homo sapiens,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,
9606.0,1.0,,F,,,,CHEMBL620418,,BAO_0000219,A549,80682.0,,,N,5760.0,13799.0,1.0,646.0,Expert,Homo sapiens,Cytotoxic activity evaluated against A549 tumor cells,
9606.0,1.0,,F,,,,CHEMBL620419,,BAO_0000219,A549,80682.0,,,N,5761.0,16726.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,
9606.0,1.0,,F,,,,CHEMBL620420,,BAO_0000219,A549,80682.0,,,N,5762.0,16109.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,
9606.0,1.0,,F,,,,CHEMBL620421,,BAO_0000219,A549,80682.0,,,N,5763.0,16109.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,
9606.0,1.0,,F,,,,CHEMBL620422,,BAO_0000219,A549,80682.0,,,N,5764.0,15474.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,
9606.0,1.0,,F,,,,CHEMBL620423,,BAO_0000219,A549,80682.0,,,N,5765.0,6851.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity of compound against A549 cell line,
9606.0,1.0,,F,,,,CHEMBL620424,,BAO_0000219,A549,80682.0,,,N,5766.0,17534.0,1.0,646.0,Expert,Homo sapiens,Cytotoxicity against human lung cell carcinoma A549 cell line,
9606.0,1.0,,F,,,,CHEMBL620425,,BAO_0000219,A549,80682.0,,,N,5767.0,2621.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,
9606.0,1.0,,F,,,,CHEMBL620426,,BAO_0000219,A549,80682.0,,,N,5768.0,830.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL620427,,BAO_0000219,A549,80682.0,,,N,5769.0,14255.0,1.0,646.0,Intermediate,Homo sapiens,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,
9606.0,1.0,,F,,,,CHEMBL620428,,BAO_0000219,A549,80682.0,,,N,5770.0,14255.0,1.0,646.0,Intermediate,Homo sapiens,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,
9606.0,1.0,,F,,,,CHEMBL620429,,BAO_0000219,A549,80682.0,,,N,5771.0,1590.0,1.0,646.0,Intermediate,Homo sapiens,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,
9606.0,1.0,,F,,,,CHEMBL620430,,BAO_0000219,A549,80682.0,,,N,5772.0,6146.0,1.0,646.0,Expert,Homo sapiens,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,
9606.0,1.0,,F,,,,CHEMBL839887,,BAO_0000219,A549,80682.0,,,N,5773.0,17427.0,1.0,646.0,Expert,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,
9606.0,1.0,,F,,,,CHEMBL620431,,BAO_0000219,A549,80682.0,,,N,5774.0,5280.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,
9606.0,1.0,,F,,,,CHEMBL884010,,BAO_0000219,A549,80682.0,,,N,5775.0,16786.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,
9606.0,1.0,,F,,,,CHEMBL620538,,BAO_0000219,A549,80682.0,,,N,5776.0,5895.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against A549 (human lung cancer),
9606.0,1.0,,F,,,,CHEMBL620539,,BAO_0000219,A549,80682.0,,,N,5777.0,14297.0,1.0,646.0,Expert,Homo sapiens,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,
9606.0,1.0,,F,,,,CHEMBL623373,,BAO_0000218,A549,80682.0,,,N,5778.0,17824.0,1.0,646.0,Intermediate,Homo sapiens,In vivo antiproliferative activity against A549 cell line,
9606.0,1.0,,F,,,,CHEMBL623374,,BAO_0000219,A549,80682.0,,,N,5779.0,14368.0,1.0,646.0,Intermediate,Homo sapiens,Inhibition of non-small-cell lung adenocarcinoma (A549),
9606.0,1.0,,F,,,,CHEMBL623375,,BAO_0000219,A549,80682.0,,,N,5780.0,14368.0,1.0,646.0,Intermediate,Homo sapiens,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,
9606.0,1.0,,F,,,,CHEMBL623376,,BAO_0000219,A549,80682.0,,,N,5781.0,14254.0,1.0,646.0,Intermediate,Homo sapiens,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,
9606.0,1.0,,F,,,,CHEMBL623377,,BAO_0000219,A549,80682.0,,,N,5782.0,15897.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),
9606.0,1.0,,F,,,,CHEMBL623378,,BAO_0000219,A549,80682.0,,,N,5783.0,13866.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,
9606.0,1.0,,F,,,,CHEMBL623379,,BAO_0000219,A549,80682.0,,,N,5784.0,13370.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory activity of compound against human A549 lung carcinoma cell line.,
9606.0,1.0,,F,,,,CHEMBL623380,,BAO_0000219,A549,80682.0,,,N,5785.0,4862.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory activity against A549 lung cancer cell line,
9606.0,1.0,,F,,,,CHEMBL623381,,BAO_0000219,A549,80682.0,,,N,5786.0,4862.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,
9606.0,1.0,,F,,,,CHEMBL623382,,BAO_0000219,A549,80682.0,,,N,5787.0,4862.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,
9606.0,1.0,,F,,,,CHEMBL623383,,BAO_0000219,A549,80682.0,,,N,5788.0,15970.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory concentration against A549 (lung cancer) cell line,
9606.0,1.0,,F,,,,CHEMBL623384,,BAO_0000219,A549,80682.0,,,N,5789.0,17713.0,1.0,646.0,Expert,Homo sapiens,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,
9606.0,1.0,,F,,,,CHEMBL623385,,BAO_0000219,A549,80682.0,,,N,5790.0,4833.0,1.0,646.0,Intermediate,Homo sapiens,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,
9606.0,1.0,,F,,,,CHEMBL623386,,BAO_0000219,A549,80682.0,,,N,5791.0,13736.0,1.0,646.0,Expert,Homo sapiens,Activity against A549 cancer cell line.,
9606.0,1.0,,F,,,,CHEMBL884105,,BAO_0000219,A549,80682.0,,,N,5792.0,4312.0,1.0,646.0,Intermediate,Homo sapiens,The compound was evaluated for cytotoxicity against A549 cell line,
9606.0,1.0,,F,,,,CHEMBL623387,,BAO_0000219,A549,80682.0,,,N,5793.0,5421.0,1.0,646.0,Intermediate,Homo sapiens,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,
9606.0,1.0,,F,,,,CHEMBL621568,,BAO_0000219,A549,80682.0,,,N,5794.0,5421.0,1.0,646.0,Intermediate,Homo sapiens,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,
9606.0,1.0,,F,,,,CHEMBL621569,,BAO_0000219,A549,80682.0,,,N,5795.0,14717.0,1.0,646.0,Intermediate,Homo sapiens,Growth inhibitory activity was measured for human A549 tumor cell line.,
9606.0,1.0,,F,,,,CHEMBL621570,,BAO_0000219,A549,80682.0,,,N,5796.0,4634.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory activity against A549 lung cancer cell line,
9606.0,1.0,,F,,,,CHEMBL621571,,BAO_0000219,A549,80682.0,,,N,5797.0,1149.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory activity against A549 cell line; inactive,
9606.0,1.0,,F,,,,CHEMBL621572,,BAO_0000219,A549,80682.0,,,N,5798.0,5421.0,1.0,646.0,Expert,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,
9606.0,1.0,,F,,,,CHEMBL621573,,BAO_0000219,A549,80682.0,,,N,5799.0,5421.0,1.0,646.0,Expert,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,
9606.0,1.0,,F,,,,CHEMBL621574,,BAO_0000219,A549,80682.0,,,N,5800.0,5421.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,
9606.0,1.0,,F,,,,CHEMBL621575,,BAO_0000219,A549,80682.0,,,N,5801.0,3320.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),
9606.0,1.0,,F,,,,CHEMBL621576,,BAO_0000219,A549,80682.0,,,N,5802.0,3320.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),
9606.0,1.0,,F,,,,CHEMBL621577,,BAO_0000219,A549,80682.0,,,N,5803.0,3320.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),
9606.0,1.0,,F,,,,CHEMBL621578,,BAO_0000219,A549,80682.0,,,N,5804.0,3320.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),
9606.0,1.0,,F,,,,CHEMBL621579,,BAO_0000219,A549,80682.0,,,N,5805.0,3320.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),
9606.0,1.0,,F,,,,CHEMBL621580,,BAO_0000219,A549,80682.0,,,N,5806.0,5726.0,1.0,646.0,Intermediate,Homo sapiens,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,
9615.0,1.0,,A,,,,CHEMBL621581,,BAO_0000218,,50588.0,In vivo,,N,5807.0,17800.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance (in vivo) in mongrel dogs was determined,
9615.0,1.0,,A,,,,CHEMBL621582,,BAO_0000218,,50588.0,In vivo,,N,5808.0,5985.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance was measured in dog,
9615.0,1.0,,A,,,,CHEMBL621583,,BAO_0000218,,50588.0,In vivo,,N,5809.0,5530.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,
9615.0,1.0,,A,,,,CHEMBL621584,,BAO_0000218,,50588.0,In vivo,,N,5810.0,5530.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,
9615.0,1.0,,A,,,1969.0,CHEMBL621585,,BAO_0000218,,50588.0,In vivo,,N,5811.0,4839.0,1.0,,Intermediate,Canis lupus familiaris,Tested for plasma clearance in dog,Plasma
9615.0,1.0,,A,,,,CHEMBL621586,,BAO_0000218,,50588.0,In vivo,,N,5812.0,3639.0,1.0,,Intermediate,Canis lupus familiaris,The compound was tested for clearance in dog plasma.,
9615.0,1.0,,A,,,,CHEMBL875835,,BAO_0000218,,50588.0,In vivo,,N,5813.0,4838.0,1.0,,Intermediate,Canis lupus familiaris,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",
9615.0,1.0,,A,,,,CHEMBL621587,,BAO_0000218,,50588.0,In vivo,,N,5814.0,4137.0,1.0,,Intermediate,Canis lupus familiaris,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,
9615.0,1.0,,A,,,1969.0,CHEMBL621588,,BAO_0000218,,50588.0,In vivo,,N,5815.0,5017.0,1.0,,Intermediate,Canis lupus familiaris,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Plasma
9615.0,1.0,,A,,,2107.0,CHEMBL621589,,BAO_0000218,,50588.0,In vitro,Microsomes,N,5816.0,17538.0,1.0,,Intermediate,Canis lupus familiaris,In vitro clearance in dog liver microsomes,Liver
9615.0,1.0,,A,,,,CHEMBL621590,,BAO_0000218,,50588.0,In vivo,,N,5817.0,6161.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,
9615.0,1.0,,A,,,,CHEMBL621591,,BAO_0000218,,50588.0,In vivo,,N,5818.0,6161.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,
9615.0,1.0,,A,,,,CHEMBL621592,,BAO_0000218,,50588.0,In vivo,,N,5819.0,1696.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in dog,
9615.0,1.0,,A,,,,CHEMBL621593,,BAO_0000218,,50588.0,In vivo,,N,5820.0,6762.0,1.0,,Intermediate,Canis lupus familiaris,Clearance rate in dog,
9615.0,1.0,,A,,,1969.0,CHEMBL621594,,BAO_0000218,,50588.0,In vivo,,N,5821.0,5932.0,1.0,,Intermediate,Canis lupus familiaris,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Plasma
9615.0,1.0,,A,,,,CHEMBL621595,,BAO_0000218,,50588.0,In vivo,,N,5822.0,6305.0,1.0,,Intermediate,Canis lupus familiaris,Clearance in dogs,
9615.0,1.0,,A,,,,CHEMBL621596,,BAO_0000218,,50588.0,In vivo,,N,5823.0,4942.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in dogs,
9615.0,1.0,,A,,,,CHEMBL621597,,BAO_0000218,,50588.0,In vivo,,N,5824.0,4219.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance was determined,
9615.0,1.0,,A,,,,CHEMBL621598,,BAO_0000218,,50588.0,In vivo,,N,5825.0,17853.0,1.0,,Intermediate,Canis lupus familiaris,Lower clearance in dog (i.v.) at 0.5 mpk,
9615.0,1.0,,A,,,,CHEMBL621599,,BAO_0000218,,50588.0,In vivo,,N,5826.0,4514.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in Beagle dogs,
9615.0,1.0,,A,,,,CHEMBL875836,,BAO_0000218,,50588.0,In vivo,,N,5827.0,6448.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance (Clp) in dog,
9615.0,1.0,,A,,,,CHEMBL621600,,BAO_0000218,,50588.0,In vivo,,N,5828.0,6227.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL621601,,BAO_0000218,,50588.0,In vivo,,N,5829.0,6227.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance (pharmacokinetic parameter) in dog was determined,
9615.0,1.0,,A,,,,CHEMBL618474,,BAO_0000218,,50588.0,In vivo,,N,5830.0,6062.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL618475,,BAO_0000218,,50588.0,In vivo,,N,5831.0,6821.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance of compound was determined in dog,
9615.0,1.0,,A,,,,CHEMBL624524,,BAO_0000218,,50588.0,In vivo,,N,5832.0,4709.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance after intravenous administration of 1 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL624525,,BAO_0000218,,50588.0,In vivo,,N,5833.0,4521.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,
9615.0,1.0,,A,,,,CHEMBL624526,,BAO_0000218,,50588.0,In vivo,,N,5834.0,5374.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in dog was determined,
9615.0,1.0,,A,,,,CHEMBL624527,,BAO_0000218,,50588.0,In vivo,,N,5835.0,6057.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance was calculated in dog,
9615.0,1.0,,A,,,,CHEMBL624528,,BAO_0000218,,50588.0,In vivo,,N,5836.0,4727.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance at the dose of 2 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL624529,,BAO_0000218,,50588.0,In vivo,,N,5837.0,5145.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in dog,
9615.0,1.0,,A,,,,CHEMBL624530,,BAO_0000218,,50588.0,In vivo,,N,5838.0,17657.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in dog,
9615.0,1.0,,A,,,,CHEMBL624531,,BAO_0000218,,50588.0,In vivo,,N,5839.0,17657.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in dog; Unable to calculate,
9615.0,1.0,,A,,,,CHEMBL624532,,BAO_0000218,,50588.0,In vivo,,N,5840.0,5145.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in rhesus monkey,
9615.0,1.0,,A,,,,CHEMBL624533,,BAO_0000218,,50588.0,In vivo,,N,5841.0,6642.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),
9615.0,1.0,,A,,,,CHEMBL624534,,BAO_0000218,,50588.0,In vivo,,N,5842.0,6641.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),
9615.0,1.0,,A,,,,CHEMBL624535,,BAO_0000218,,50588.0,In vivo,,N,5843.0,6642.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),
9615.0,1.0,,A,,,,CHEMBL624536,,BAO_0000218,,50588.0,In vivo,,N,5844.0,5472.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance was evaluated in dog,
9615.0,1.0,,A,,,,CHEMBL624537,,BAO_0000218,,50588.0,In vivo,,N,5845.0,5472.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance was evaluated in dog; Not tested,
9615.0,1.0,,A,,,,CHEMBL624538,,BAO_0000218,,50588.0,In vivo,,N,5846.0,5472.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance was evaluated in rhesus,
9615.0,1.0,,A,,,,CHEMBL624539,,BAO_0000218,,50588.0,In vivo,,N,5847.0,5472.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance was evaluated in rhesus; Not tested,
9615.0,1.0,,A,,,,CHEMBL624540,,BAO_0000218,,50588.0,In vivo,,N,5848.0,4257.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,
9615.0,1.0,,A,,,,CHEMBL624541,,BAO_0000218,,50588.0,In vivo,,N,5849.0,6679.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,
9615.0,1.0,,A,,,,CHEMBL624542,,BAO_0000218,,50588.0,In vivo,,N,5850.0,5546.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,
9615.0,1.0,,A,,,,CHEMBL624543,,BAO_0000218,,50588.0,In vivo,,N,5851.0,6348.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,
9615.0,1.0,,A,,,,CHEMBL624544,,BAO_0000218,,50588.0,In vivo,,N,5852.0,5474.0,1.0,,Intermediate,Canis lupus familiaris,Clearance value at a dose of 0.2 mg/kg i.v.,
9615.0,1.0,,A,,,1969.0,CHEMBL624545,,BAO_0000218,,50588.0,In vivo,,N,5853.0,6316.0,1.0,,Intermediate,Canis lupus familiaris,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,Plasma
9615.0,1.0,,A,,,,CHEMBL624546,,BAO_0000218,,50588.0,In vivo,,N,5854.0,17594.0,1.0,,Intermediate,Canis lupus familiaris,Cmax after oral dose of compound at 3 mg/kg in dogs,
9615.0,1.0,,A,,,,CHEMBL875957,,BAO_0000218,,50588.0,In vivo,,N,5855.0,17594.0,1.0,,Intermediate,Canis lupus familiaris,Cmax after single intravenous bolus of 1 mg/kg in dogs,
9615.0,1.0,,A,,,,CHEMBL624547,,BAO_0000218,,50588.0,In vivo,,N,5856.0,5802.0,1.0,,Intermediate,Canis lupus familiaris,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,
9615.0,1.0,,A,,,,CHEMBL624548,,BAO_0000218,,50588.0,In vivo,,N,5857.0,6535.0,1.0,,Intermediate,Canis lupus familiaris,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,
9615.0,1.0,,A,,,,CHEMBL624549,,BAO_0000218,,50588.0,In vivo,,N,5858.0,6535.0,1.0,,Intermediate,Canis lupus familiaris,Cmax in dog after administration of 1 mg/kg iv,
9615.0,1.0,,A,,,1969.0,CHEMBL624550,,BAO_0000218,,50588.0,In vivo,,N,5859.0,1466.0,1.0,,Intermediate,Canis lupus familiaris,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,Plasma
9615.0,1.0,,A,,,,CHEMBL621613,,BAO_0000218,,50588.0,In vivo,,N,5860.0,6505.0,1.0,,Intermediate,Canis lupus familiaris,Cmax on p.o. administration of 10 mg/kg was measured in dog,
9615.0,1.0,,A,,,,CHEMBL621614,,BAO_0000218,,50588.0,In vivo,,N,5861.0,5668.0,1.0,,Intermediate,Canis lupus familiaris,Cmax was determine after peroral administration at 10 mpk in dog,
9615.0,1.0,,A,,,,CHEMBL623431,,BAO_0000218,,50588.0,In vivo,,N,5862.0,5668.0,1.0,,Intermediate,Canis lupus familiaris,Cmax was determine after peroral administration at 5 mpk in dog,
9615.0,1.0,,A,,,,CHEMBL623432,,BAO_0000218,,50588.0,In vivo,,N,5863.0,5668.0,1.0,,Intermediate,Canis lupus familiaris,Cmax was determine after peroral administration at 5 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL623433,,BAO_0000218,,50588.0,In vivo,,N,5864.0,5600.0,1.0,,Intermediate,Canis lupus familiaris,Cmax after 0.3 mg/kg po administration in dog,
9615.0,1.0,,A,,,,CHEMBL623434,,BAO_0000218,,50588.0,In vivo,,N,5865.0,17764.0,1.0,,Intermediate,Canis lupus familiaris,Cmax after peroral administration in dogs at 2.4 uM/kg,
9615.0,1.0,,A,,,,CHEMBL623435,,BAO_0000218,,50588.0,In vivo,,N,5866.0,6123.0,1.0,,Intermediate,Canis lupus familiaris,Cmax in dog after oral administration at 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL623436,,BAO_0000218,,50588.0,In vivo,,N,5867.0,6123.0,1.0,,Intermediate,Canis lupus familiaris,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,
9615.0,1.0,,A,,,,CHEMBL875958,,BAO_0000218,,50588.0,In vivo,,N,5868.0,6757.0,1.0,,Intermediate,Canis lupus familiaris,Cmax upon oral administration in male Beagle dog at 10 mg/kg,
9615.0,1.0,,A,,,,CHEMBL623437,,BAO_0000218,,50588.0,In vivo,,N,5869.0,16907.0,1.0,,Intermediate,Canis lupus familiaris,Cmax value after 15 mg/kg iv dose in Dogs,
10090.0,1.0,,A,,,178.0,CHEMBL623438,,BAO_0000218,,50594.0,In vivo,,N,5870.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Blood
10090.0,1.0,,A,,,178.0,CHEMBL623439,,BAO_0000218,,50594.0,In vivo,,N,5871.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Blood
10090.0,1.0,,A,,,10000001.0,CHEMBL623440,,BAO_0000218,,50594.0,In vivo,,N,5872.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Bone
10090.0,1.0,,A,,,10000001.0,CHEMBL623441,,BAO_0000218,,50594.0,In vivo,,N,5873.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Bone
10090.0,1.0,,A,,,10000001.0,CHEMBL623442,,BAO_0000218,,50594.0,In vivo,,N,5874.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Bone
10090.0,1.0,,A,,,,CHEMBL623469,,BAO_0000218,,50594.0,In vivo,,N,5875.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,
10090.0,1.0,,A,,,,CHEMBL623470,,BAO_0000218,,50594.0,In vivo,,N,5876.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,
10090.0,1.0,,A,,,,CHEMBL623471,,BAO_0000218,,50594.0,In vivo,,N,5877.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,
10090.0,1.0,,A,,,948.0,CHEMBL623472,,BAO_0000218,,50594.0,In vivo,,N,5878.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Heart
10090.0,1.0,,A,,,948.0,CHEMBL623473,,BAO_0000218,,50594.0,In vivo,,N,5879.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Heart
10090.0,1.0,,A,,,948.0,CHEMBL623474,,BAO_0000218,,50594.0,In vivo,,N,5880.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Heart
10090.0,1.0,,A,,,2113.0,CHEMBL623475,,BAO_0000218,,50594.0,In vivo,,N,5881.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL623476,,BAO_0000218,,50594.0,In vivo,,N,5882.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL623477,,BAO_0000218,,50594.0,In vivo,,N,5883.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Kidney
10090.0,1.0,,A,,,160.0,CHEMBL621896,,BAO_0000218,,50594.0,In vivo,,N,5884.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intestine
10090.0,1.0,,A,,,160.0,CHEMBL621897,,BAO_0000218,,50594.0,In vivo,,N,5885.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intestine
10090.0,1.0,,A,,,160.0,CHEMBL621898,,BAO_0000218,,50594.0,In vivo,,N,5886.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intestine
10090.0,1.0,,A,,,2107.0,CHEMBL621899,,BAO_0000218,,50594.0,In vivo,,N,5887.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL621900,,BAO_0000218,,50594.0,In vivo,,N,5888.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL621901,,BAO_0000218,,50594.0,In vivo,,N,5889.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Liver
10090.0,1.0,,A,,,2048.0,CHEMBL621902,,BAO_0000218,,50594.0,In vivo,,N,5890.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL621903,,BAO_0000218,,50594.0,In vivo,,N,5891.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL622587,,BAO_0000218,,50594.0,In vivo,,N,5892.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Lung
10090.0,1.0,,A,,,2385.0,CHEMBL620285,,BAO_0000218,,50594.0,In vivo,,N,5893.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Muscle tissue
10090.0,1.0,,A,,,2385.0,CHEMBL875285,,BAO_0000218,,50594.0,In vivo,,N,5894.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Muscle tissue
10090.0,1.0,,A,,,2385.0,CHEMBL620286,,BAO_0000218,,50594.0,In vivo,,N,5895.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Muscle tissue
10090.0,1.0,,A,,,,CHEMBL620287,,BAO_0000218,,50594.0,In vivo,,N,5896.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,
10090.0,1.0,,A,,,,CHEMBL620288,,BAO_0000218,,50594.0,In vivo,,N,5897.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,
10090.0,1.0,,A,,,,CHEMBL620289,,BAO_0000218,,50594.0,In vivo,,N,5898.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,
10090.0,1.0,,A,,,160.0,CHEMBL620290,,BAO_0000218,,50594.0,In vivo,,N,5899.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intestine
10090.0,1.0,,A,,,160.0,CHEMBL620291,,BAO_0000218,,50594.0,In vivo,,N,5900.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intestine
10090.0,1.0,,A,,,160.0,CHEMBL620292,,BAO_0000218,,50594.0,In vivo,,N,5901.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intestine
10090.0,1.0,,A,,,2106.0,CHEMBL620293,,BAO_0000218,,50594.0,In vivo,,N,5902.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Spleen
10090.0,1.0,,A,,,2106.0,CHEMBL620294,,BAO_0000218,,50594.0,In vivo,,N,5903.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Spleen
10090.0,1.0,,A,,,2106.0,CHEMBL618614,,BAO_0000218,,50594.0,In vivo,,N,5904.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Spleen
10090.0,1.0,,A,,,945.0,CHEMBL618615,,BAO_0000218,,50594.0,In vivo,,N,5905.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Stomach
10090.0,1.0,,A,,,945.0,CHEMBL618616,,BAO_0000218,,50594.0,In vivo,,N,5906.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Stomach
9606.0,1.0,,F,,,,CHEMBL618617,,BAO_0000219,A 172,80012.0,,,N,5907.0,2036.0,1.0,622.0,Expert,Homo sapiens,Cytotoxicity against A-172 human tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL618618,,BAO_0000219,A 172,80012.0,,,N,5908.0,2357.0,1.0,622.0,Intermediate,Homo sapiens,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,
9606.0,1.0,,F,,,,CHEMBL618619,,BAO_0000219,A204,80014.0,,,N,5909.0,1457.0,1.0,623.0,Intermediate,Homo sapiens,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,
9606.0,1.0,,F,,,,CHEMBL618620,,BAO_0000219,A2780,81034.0,,,N,5910.0,4379.0,1.0,478.0,Intermediate,Homo sapiens,Tested for antiproliferative activity against A-2780 tumoral cell line,
9606.0,1.0,,F,,,,CHEMBL618621,,BAO_0000219,A-375,80018.0,,,N,5911.0,1093.0,1.0,455.0,Intermediate,Homo sapiens,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,
9606.0,1.0,,F,,,,CHEMBL618622,,BAO_0000219,A-375,80018.0,,,N,5912.0,12152.0,1.0,455.0,Intermediate,Homo sapiens,Tested in vitro against A-375 cell line human melanoma,
9606.0,1.0,,F,,,,CHEMBL618623,,BAO_0000219,A-427,80019.0,,,N,5913.0,16464.0,1.0,797.0,Expert,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,
9606.0,1.0,,F,,,,CHEMBL618624,,BAO_0000219,A-427,80019.0,,,N,5914.0,16464.0,1.0,797.0,Intermediate,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,
9606.0,1.0,,F,,,,CHEMBL618625,,BAO_0000219,A-427,80019.0,,,N,5915.0,16582.0,1.0,797.0,Expert,Homo sapiens,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,
9606.0,1.0,,F,,,,CHEMBL618626,,BAO_0000219,A-427,80019.0,,,N,5916.0,16464.0,1.0,797.0,Intermediate,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,
9606.0,1.0,,F,,,,CHEMBL618627,,BAO_0000219,A-427,80019.0,,,N,5917.0,10413.0,1.0,797.0,Intermediate,Homo sapiens,Antitumor activity on A-427 lung carcinoma cell lines,
9606.0,1.0,,F,,,,CHEMBL618628,,BAO_0000219,A-427,80019.0,,,N,5918.0,6418.0,1.0,797.0,Intermediate,Homo sapiens,Cytotoxic activity against human A-427 lung tumor cell line,
9606.0,1.0,,F,,,,CHEMBL618629,,BAO_0000219,A-427,80019.0,,,N,5919.0,17134.0,1.0,797.0,Expert,Homo sapiens,In vitro antitumor effects against human A-427 cell lines.,
9606.0,1.0,,F,,,,CHEMBL618630,,BAO_0000219,A-427,80019.0,,,N,5920.0,16132.0,1.0,797.0,Expert,Homo sapiens,In vitro inhibition of A-427 (human lung cancer) cell growth.,
9606.0,1.0,,F,,,,CHEMBL618631,,BAO_0000219,A-427,80019.0,,,N,5921.0,16132.0,1.0,797.0,Intermediate,Homo sapiens,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,
9606.0,1.0,,F,,,,CHEMBL618632,,BAO_0000219,A-427,80019.0,,,N,5922.0,16780.0,1.0,797.0,Intermediate,Homo sapiens,Cytotoxic activity of compound against A-427 lung human tumor cell line,
9606.0,1.0,,F,,,,CHEMBL618633,,BAO_0000219,A-431,80852.0,,,N,5923.0,4085.0,1.0,500.0,Expert,Homo sapiens,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,
9606.0,1.0,,F,,,,CHEMBL619315,,BAO_0000219,A498,80021.0,,,N,5924.0,1276.0,1.0,624.0,Intermediate,Homo sapiens,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,
9606.0,1.0,,F,,,,CHEMBL619316,,BAO_0000219,A498,80021.0,,,N,5925.0,3498.0,1.0,624.0,Expert,Homo sapiens,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,
9606.0,1.0,,F,,,,CHEMBL619317,,BAO_0000219,A498,80021.0,,,N,5926.0,1169.0,1.0,624.0,Intermediate,Homo sapiens,Cytotoxicity against human kidney carcinoma A-498cell lines,
9606.0,1.0,,F,,,,CHEMBL619318,,BAO_0000219,A498,80021.0,,,N,5927.0,4450.0,1.0,624.0,Intermediate,Homo sapiens,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,
9606.0,1.0,,F,,,,CHEMBL619319,,BAO_0000219,A498,80021.0,,,N,5928.0,3311.0,1.0,624.0,Intermediate,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,
9606.0,1.0,,F,,,,CHEMBL619739,,BAO_0000219,A498,80021.0,,,N,5929.0,4461.0,1.0,624.0,Intermediate,Homo sapiens,Antitumor cytotoxic activity against A-498 cell line was determined,
9606.0,1.0,,F,,,,CHEMBL619740,,BAO_0000219,A498,80021.0,,,N,5930.0,3311.0,1.0,624.0,Intermediate,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,
9606.0,1.0,,F,,,,CHEMBL883158,,BAO_0000219,A498,80021.0,,,N,5931.0,3311.0,1.0,624.0,Intermediate,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,
9606.0,1.0,,F,,,,CHEMBL884012,,BAO_0000219,A498,80021.0,,,N,5932.0,1457.0,1.0,624.0,Intermediate,Homo sapiens,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,
9606.0,1.0,,F,,,,CHEMBL619741,,BAO_0000219,A498,80021.0,,,N,5933.0,3664.0,1.0,624.0,Intermediate,Homo sapiens,In vitro inhibitory activity against A-498 ovarian cancer cell lines,
9606.0,1.0,,F,,,,CHEMBL619742,,BAO_0000219,A498,80021.0,,,N,5934.0,15895.0,1.0,624.0,Intermediate,Homo sapiens,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",
9606.0,1.0,,F,,,,CHEMBL876610,,BAO_0000219,A549,80682.0,,,N,5935.0,11843.0,1.0,646.0,Intermediate,Homo sapiens,Inhibition of growth lung non-small cell carcinoma A-549 cell line,
9606.0,1.0,,F,,,,CHEMBL619743,,BAO_0000219,A549,80682.0,,,N,5936.0,11843.0,1.0,646.0,Intermediate,Homo sapiens,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,
9606.0,1.0,,F,,,,CHEMBL619744,,BAO_0000219,A549,80682.0,,,N,5937.0,17705.0,1.0,646.0,Intermediate,Homo sapiens,In vitro antiproliferative activity against human A-549 NSCL cell line,
9606.0,1.0,,F,,,,CHEMBL619745,,BAO_0000219,A549,80682.0,,,N,5938.0,17705.0,1.0,646.0,Intermediate,Homo sapiens,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,
9606.0,1.0,,F,,,,CHEMBL619746,,BAO_0000219,A549,80682.0,,,N,5939.0,4369.0,1.0,646.0,Intermediate,Homo sapiens,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,
9606.0,1.0,,F,,,,CHEMBL619747,,BAO_0000219,A549,80682.0,,,N,5940.0,4369.0,1.0,646.0,Intermediate,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,
9606.0,1.0,,F,,,,CHEMBL619748,,BAO_0000219,A549,80682.0,,,N,5941.0,4369.0,1.0,646.0,Intermediate,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,
9606.0,1.0,,F,,,,CHEMBL619749,,BAO_0000219,A549,80682.0,,,N,5942.0,4369.0,1.0,646.0,Intermediate,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,
9606.0,1.0,,F,,,,CHEMBL619750,,BAO_0000219,A549,80682.0,,,N,5943.0,4369.0,1.0,646.0,Intermediate,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,
9606.0,1.0,,F,,,,CHEMBL624014,,BAO_0000219,A549,80682.0,,,N,5944.0,4369.0,1.0,646.0,Intermediate,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,
9606.0,1.0,,F,,,,CHEMBL624015,,BAO_0000219,A549,80682.0,,,N,5945.0,4369.0,1.0,646.0,Intermediate,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,
9606.0,1.0,,F,,,,CHEMBL885344,,BAO_0000219,A549,80682.0,,,N,5946.0,4787.0,1.0,646.0,Expert,Homo sapiens,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,
9606.0,1.0,,F,,,,CHEMBL623224,,BAO_0000219,A549,80682.0,,,N,5947.0,4787.0,1.0,646.0,Intermediate,Homo sapiens,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,
9606.0,1.0,,F,,,,CHEMBL623225,,BAO_0000219,A549,80682.0,,,N,5948.0,6513.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic activity against A-549 cell line,
9606.0,1.0,,F,,,,CHEMBL622698,,BAO_0000219,A549,80682.0,,,N,5949.0,6690.0,1.0,646.0,Intermediate,Homo sapiens,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,
9606.0,1.0,,F,,,,CHEMBL622699,,BAO_0000219,A549,80682.0,,,N,5950.0,6690.0,1.0,646.0,Intermediate,Homo sapiens,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,
9606.0,1.0,,F,,,,CHEMBL622700,,BAO_0000219,A549,80682.0,,,N,5951.0,12263.0,1.0,646.0,Expert,Homo sapiens,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",
9606.0,1.0,,F,,,,CHEMBL622701,,BAO_0000219,A549,80682.0,,,N,5952.0,1054.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),
9606.0,1.0,,F,,,,CHEMBL622702,,BAO_0000219,A549,80682.0,,,N,5953.0,1359.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),
9606.0,1.0,,F,,,,CHEMBL622703,,BAO_0000219,A549,80682.0,,,N,5954.0,3547.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic activity against human lung carcinoma (A-549) cell line,
9606.0,1.0,,F,,,,CHEMBL622704,,BAO_0000219,A549,80682.0,,,N,5955.0,5771.0,1.0,646.0,Expert,Homo sapiens,Cytotoxic activity towards A-549 cells,
9606.0,1.0,,F,,,,CHEMBL622705,,BAO_0000219,A549,80682.0,,,N,5956.0,14425.0,1.0,646.0,Intermediate,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.",
9606.0,1.0,,F,,,,CHEMBL622706,,BAO_0000219,A549,80682.0,,,N,5957.0,14425.0,1.0,646.0,Intermediate,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma",
9606.0,1.0,,F,,,,CHEMBL622707,,BAO_0000219,A549,80682.0,,,N,5958.0,14425.0,1.0,646.0,Intermediate,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.",
9606.0,1.0,,F,,,,CHEMBL622708,,BAO_0000219,A549,80682.0,,,N,5959.0,14425.0,1.0,646.0,Intermediate,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",
9606.0,1.0,,F,,,,CHEMBL622709,,BAO_0000219,A549,80682.0,,,N,5960.0,5280.0,1.0,646.0,Intermediate,Homo sapiens,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,
9606.0,1.0,,F,,,,CHEMBL622710,,BAO_0000219,A549,80682.0,,,N,5961.0,15176.0,1.0,646.0,Intermediate,Homo sapiens,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,
9606.0,1.0,,F,,,,CHEMBL622711,,BAO_0000219,A549,80682.0,,,N,5962.0,15300.0,1.0,646.0,Intermediate,Homo sapiens,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,
9606.0,1.0,,F,,,,CHEMBL622712,,BAO_0000218,A549,80682.0,,,N,5963.0,17824.0,1.0,646.0,Intermediate,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",
9606.0,1.0,,F,,,,CHEMBL622713,,BAO_0000218,A549,80682.0,,,N,5964.0,17824.0,1.0,646.0,Intermediate,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",
9606.0,1.0,,F,,,,CHEMBL622714,,BAO_0000218,A549,80682.0,,,N,5965.0,17824.0,1.0,646.0,Intermediate,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",
9606.0,1.0,,F,,,,CHEMBL622715,,BAO_0000218,A549,80682.0,,,N,5966.0,17824.0,1.0,646.0,Intermediate,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",
9606.0,1.0,,F,,,,CHEMBL622716,,BAO_0000218,A549,80682.0,,,N,5967.0,17824.0,1.0,646.0,Intermediate,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",
9606.0,1.0,,F,,,,CHEMBL622717,,BAO_0000219,A549,80682.0,,,N,5968.0,17824.0,1.0,646.0,Intermediate,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",
9606.0,1.0,,F,,,,CHEMBL622718,,BAO_0000218,A549,80682.0,,,N,5969.0,17528.0,1.0,646.0,Intermediate,Homo sapiens,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),
9606.0,1.0,,F,,,,CHEMBL622719,,BAO_0000219,A549,80682.0,,,N,5970.0,6870.0,1.0,646.0,Expert,Homo sapiens,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,
9606.0,1.0,,F,,,,CHEMBL622720,,BAO_0000219,A549,80682.0,,,N,5971.0,6870.0,1.0,646.0,Intermediate,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,
9606.0,1.0,,F,,,,CHEMBL622721,,BAO_0000219,A549,80682.0,,,N,5972.0,6870.0,1.0,646.0,Intermediate,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,
9606.0,1.0,,F,,,,CHEMBL622722,,BAO_0000219,A549,80682.0,,,N,5973.0,6870.0,1.0,646.0,Intermediate,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,
9606.0,1.0,,F,,,,CHEMBL876030,,BAO_0000219,A549,80682.0,,,N,5974.0,16726.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,
9606.0,1.0,,F,,,,CHEMBL620206,,BAO_0000219,A549,80682.0,,,N,5975.0,6170.0,1.0,646.0,Intermediate,Homo sapiens,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",
9606.0,1.0,,F,,,,CHEMBL620207,,BAO_0000219,A549,80682.0,,,N,5976.0,6583.0,1.0,646.0,Expert,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,
9606.0,1.0,,F,,,,CHEMBL620208,,BAO_0000219,A549,80682.0,,,N,5977.0,6583.0,1.0,646.0,Expert,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,
9606.0,1.0,,F,,,,CHEMBL620209,,BAO_0000219,A549,80682.0,,,N,5978.0,6583.0,1.0,646.0,Expert,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,
9606.0,1.0,,F,,,,CHEMBL620210,,BAO_0000219,A549,80682.0,,,N,5979.0,6583.0,1.0,646.0,Expert,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,
9606.0,1.0,,F,,,,CHEMBL621639,,BAO_0000219,A549,80682.0,,,N,5980.0,6583.0,1.0,646.0,Expert,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,
9606.0,1.0,,F,,,,CHEMBL621640,,BAO_0000219,A549,80682.0,,,N,5981.0,17321.0,1.0,646.0,Intermediate,Homo sapiens,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,
9606.0,1.0,,F,,,,CHEMBL621641,,BAO_0000219,A549,80682.0,,,N,5982.0,17528.0,1.0,646.0,Expert,Homo sapiens,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,
9606.0,1.0,,F,,,,CHEMBL621642,,BAO_0000219,A549,80682.0,,,N,5983.0,12888.0,1.0,646.0,Expert,Homo sapiens,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,
9606.0,1.0,,F,,,,CHEMBL621643,,BAO_0000219,A549,80682.0,,,N,5984.0,4312.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,
9606.0,1.0,,F,,,,CHEMBL621644,,BAO_0000219,A549,80682.0,,,N,5985.0,4312.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,
9606.0,1.0,,F,,,,CHEMBL621645,,BAO_0000219,A549,80682.0,,,N,5986.0,4312.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,
10090.0,1.0,,F,,,,CHEMBL621646,,BAO_0000219,A549,80682.0,,,N,5987.0,17737.0,1.0,646.0,Intermediate,Mus musculus,In vitro antiproliferative activity against A549 cell line,
,1.0,,F,,,,CHEMBL621647,,BAO_0000219,A549,80682.0,,,N,5988.0,6630.0,1.0,646.0,Intermediate,,Synergism with indomethacin in A549 cells,
,1.0,,F,,,,CHEMBL621648,,BAO_0000219,A549,80682.0,,,N,5989.0,6630.0,1.0,646.0,Intermediate,,Synergism with tolmetin in A549 cells,
,1.0,,F,,,,CHEMBL621649,,BAO_0000219,A549,80682.0,,,N,5990.0,6630.0,1.0,646.0,Intermediate,,Synergism with sulindac in A549 cells,
,1.0,,F,,,,CHEMBL621650,,BAO_0000219,A549,80682.0,,,N,5991.0,6630.0,1.0,646.0,Intermediate,,Antagonism of indomethacin in A549 cells,
,1.0,,F,,,,CHEMBL621651,,BAO_0000219,A549,80682.0,,,N,5992.0,6630.0,1.0,646.0,Intermediate,,Antagonism of sulindac in A549 cells,
,1.0,,F,,,,CHEMBL621652,,BAO_0000219,A549,80682.0,,,N,5993.0,6630.0,1.0,646.0,Intermediate,,Antagonism of tolmetin in A549 cells,
,1.0,,F,,,,CHEMBL621653,,BAO_0000219,A549,80682.0,,,N,5994.0,6630.0,1.0,646.0,Intermediate,,Synergism with indomethacin in A549 cells,
,1.0,,F,,,,CHEMBL621654,,BAO_0000219,A549,80682.0,,,N,5995.0,6630.0,1.0,646.0,Intermediate,,Synergism with sulindac in A549 cells,
,1.0,,F,,,,CHEMBL621655,,BAO_0000219,A549,80682.0,,,N,5996.0,6630.0,1.0,646.0,Intermediate,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,
9615.0,1.0,,A,,,,CHEMBL621656,,BAO_0000218,,50588.0,In vivo,,N,5997.0,16907.0,1.0,,Intermediate,Canis lupus familiaris,Cmax value after 30 mg/kg po dose in Dogs,
9615.0,1.0,,A,,,,CHEMBL621657,,BAO_0000218,,50588.0,In vivo,,N,5998.0,5944.0,1.0,,Intermediate,Canis lupus familiaris,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),
9615.0,1.0,,A,,,,CHEMBL621658,,BAO_0000218,,50588.0,In vivo,,N,5999.0,5944.0,1.0,,Intermediate,Canis lupus familiaris,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,
9615.0,1.0,,A,,,,CHEMBL621659,,BAO_0000218,,50588.0,In vivo,,N,6000.0,5944.0,1.0,,Intermediate,Canis lupus familiaris,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),
9615.0,1.0,,A,,,,CHEMBL621660,,BAO_0000218,,50588.0,In vivo,,N,6001.0,5944.0,1.0,,Intermediate,Canis lupus familiaris,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,
9615.0,1.0,,A,,,,CHEMBL621661,,BAO_0000218,,50588.0,In vivo,,N,6002.0,2959.0,1.0,,Intermediate,Canis lupus familiaris,Cmax value after administration of 4 mg/Kg oral dose in dog,
9615.0,1.0,,A,,,,CHEMBL621662,,BAO_0000218,,50588.0,In vivo,,N,6003.0,6241.0,1.0,,Intermediate,Canis lupus familiaris,Cmax value in dog,
9615.0,1.0,,A,,,,CHEMBL621663,,BAO_0000218,,50588.0,In vivo,,N,6004.0,6241.0,1.0,,Intermediate,Canis lupus familiaris,Cmax value in dogs after oral administration at 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL621664,,BAO_0000218,,50588.0,In vivo,,N,6005.0,2652.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,
9615.0,1.0,,A,,,1969.0,CHEMBL621665,,BAO_0000218,,50588.0,In vivo,,N,6006.0,1806.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL621666,,BAO_0000218,,50588.0,In vivo,,N,6007.0,1806.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,Plasma
9615.0,1.0,,A,,,,CHEMBL621667,,BAO_0000218,,50588.0,In vivo,,N,6008.0,1021.0,1.0,,Intermediate,Canis lupus familiaris,Concentration maxima after oral dosing in dogs,
9615.0,1.0,,A,,,,CHEMBL876738,,BAO_0000218,,50588.0,In vivo,,N,6009.0,1021.0,1.0,,Intermediate,Canis lupus familiaris,Concentration maxima after oral dosing in dogs; not available,
9615.0,1.0,,A,,,,CHEMBL621668,,BAO_0000218,,50588.0,In vivo,,N,6010.0,1021.0,1.0,,Intermediate,Canis lupus familiaris,Concentration maxima after oral dosing in dogs; not available,
9615.0,1.0,,A,,,,CHEMBL621669,,BAO_0000218,,50588.0,In vivo,,N,6011.0,5444.0,1.0,,Intermediate,Canis lupus familiaris,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,
9615.0,1.0,,A,,,,CHEMBL621670,,BAO_0000218,,50588.0,In vivo,,N,6012.0,5444.0,1.0,,Intermediate,Canis lupus familiaris,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,
9615.0,1.0,,A,,,,CHEMBL621671,,BAO_0000218,,50588.0,In vivo,,N,6013.0,5444.0,1.0,,Intermediate,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL622360,,BAO_0000218,,50588.0,In vivo,,N,6014.0,5444.0,1.0,,Intermediate,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,
9615.0,1.0,,A,,,,CHEMBL622361,,BAO_0000218,,50588.0,In vivo,,N,6015.0,5444.0,1.0,,Intermediate,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,
9615.0,1.0,,A,,,1969.0,CHEMBL622362,,BAO_0000218,,50588.0,In vivo,,N,6016.0,5130.0,1.0,,Intermediate,Canis lupus familiaris,Cmax in dog plasma after oral dose (1 mg/kg),Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL622363,,BAO_0000218,,50588.0,In vivo,,N,6017.0,3249.0,1.0,,Intermediate,Canis lupus familiaris,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL622364,,BAO_0000218,,50588.0,In vivo,,N,6018.0,5473.0,1.0,,Intermediate,Canis lupus familiaris,Maximal plasma concentration at a dose of 1 mg/kg,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL622365,,BAO_0000218,,50588.0,In vivo,,N,6019.0,5474.0,1.0,,Intermediate,Canis lupus familiaris,Maximal plasma concentration at a dose of 1 mg/kg (oral),Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL622533,,BAO_0000218,,50588.0,In vivo,,N,6020.0,4657.0,1.0,,Intermediate,Canis lupus familiaris,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,Plasma
9615.0,1.0,,A,,,,CHEMBL622534,,BAO_0000218,,50588.0,In vivo,,N,6021.0,3031.0,1.0,,Intermediate,Canis lupus familiaris,Maximum concentration of compound in dog was evaluated.,
9615.0,1.0,,A,,,,CHEMBL622535,,BAO_0000218,,50588.0,In vivo,,N,6022.0,4527.0,1.0,,Intermediate,Canis lupus familiaris,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,
9615.0,1.0,,A,,,,CHEMBL876739,,BAO_0000218,,50588.0,In vivo,,N,6023.0,4186.0,1.0,,Intermediate,Canis lupus familiaris,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,
9615.0,1.0,,A,,,,CHEMBL622536,,BAO_0000218,,50588.0,In vivo,,N,6024.0,5007.0,1.0,,Intermediate,Canis lupus familiaris,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),
9615.0,1.0,,A,,,1969.0,CHEMBL622537,,BAO_0000218,,50588.0,In vivo,,N,6025.0,3132.0,1.0,,Intermediate,Canis lupus familiaris,Maximum concentration obtained in dog plasma was determined,Plasma
9615.0,1.0,,A,,,,CHEMBL622538,,BAO_0000218,,50588.0,In vivo,,N,6026.0,5006.0,1.0,,Intermediate,Canis lupus familiaris,Maximum concentration was determined,
9615.0,1.0,,A,,,,CHEMBL627867,,BAO_0000218,,50588.0,In vivo,,N,6027.0,4727.0,1.0,,Intermediate,Canis lupus familiaris,Maximum concentration at the dose of 2 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL627868,,BAO_0000218,,50588.0,In vivo,,N,6028.0,1916.0,1.0,,Intermediate,Canis lupus familiaris,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,
9615.0,1.0,,A,,,1969.0,CHEMBL627869,,BAO_0000218,,50588.0,In vivo,,N,6029.0,1918.0,1.0,,Intermediate,Canis lupus familiaris,Maximum concentration was evaluated in dog plasma,Plasma
9615.0,1.0,,A,,,,CHEMBL627870,,BAO_0000218,,50588.0,In vivo,,N,6030.0,3045.0,1.0,,Intermediate,Canis lupus familiaris,Maximum concentration was evaluated after 75 min after administration in dog,
9615.0,1.0,,A,,,1969.0,CHEMBL627871,,BAO_0000218,,50588.0,In vivo,,N,6031.0,9579.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration determined in dog after oral administration of 17b,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL627872,,BAO_0000218,,50588.0,In vivo,,N,6032.0,9579.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration determined in dog after oral administration of 2b,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL627873,,BAO_0000218,,50588.0,In vivo,,N,6033.0,933.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration in dog,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL627874,,BAO_0000218,,50588.0,In vivo,,N,6034.0,17839.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL627875,,BAO_0000218,,50588.0,In vivo,,N,6035.0,17839.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL627876,,BAO_0000218,,50588.0,In vivo,,N,6036.0,17839.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL627877,,BAO_0000218,,50588.0,In vivo,,N,6037.0,17839.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL627878,,BAO_0000218,,50588.0,In vivo,,N,6038.0,6348.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL627879,,BAO_0000218,,50588.0,In vivo,,N,6039.0,16367.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL875355,,BAO_0000218,,50588.0,In vivo,,N,6040.0,1337.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL627880,,BAO_0000218,,50588.0,In vivo,,N,6041.0,1337.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL627881,,BAO_0000218,,50588.0,In vivo,,N,6042.0,5199.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL627882,,BAO_0000218,,50588.0,In vivo,,N,6043.0,17650.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL627883,,BAO_0000218,,50588.0,In vivo,,N,6044.0,6679.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL628526,,BAO_0000218,,50588.0,In vivo,,N,6045.0,5356.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL628527,,BAO_0000218,,50588.0,In vivo,,N,6046.0,5356.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL628528,,BAO_0000218,,50588.0,In vivo,,N,6047.0,6227.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL628529,,BAO_0000218,,50588.0,In vivo,,N,6048.0,6227.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL628530,,BAO_0000218,,50588.0,In vivo,,N,6049.0,6227.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL625243,,BAO_0000218,,50588.0,In vivo,,N,6050.0,6227.0,1.0,,Intermediate,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL625244,,BAO_0000218,,50588.0,In vivo,,N,6051.0,3598.0,1.0,,Expert,Canis lupus familiaris,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,Plasma
9615.0,1.0,,A,,,,CHEMBL625245,,BAO_0000218,,50588.0,In vivo,,N,6052.0,4368.0,1.0,,Intermediate,Canis lupus familiaris,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL625246,,BAO_0000218,,50588.0,In vivo,,N,6053.0,6265.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,
10090.0,1.0,,A,,,945.0,CHEMBL625247,,BAO_0000218,,50594.0,In vivo,,N,6054.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Stomach
10090.0,1.0,,A,,,1088.0,CHEMBL625248,,BAO_0000218,,50594.0,In vivo,,N,6055.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Urine
10090.0,1.0,,A,,,1088.0,CHEMBL625249,,BAO_0000218,,50594.0,In vivo,,N,6056.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,Urine
10090.0,1.0,,A,,,1088.0,CHEMBL625250,,BAO_0000218,,50594.0,In vivo,,N,6057.0,7767.0,1.0,,Intermediate,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,Urine
10090.0,1.0,,A,,,,CHEMBL625251,,BAO_0000218,,50594.0,,,N,6058.0,17811.0,1.0,,Intermediate,Mus musculus,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,
10090.0,1.0,,A,,,,CHEMBL875356,,BAO_0000218,,50594.0,,,N,6059.0,17811.0,1.0,,Intermediate,Mus musculus,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,
10090.0,1.0,,A,,,,CHEMBL625252,,BAO_0000218,,50594.0,,,N,6060.0,17827.0,1.0,,Intermediate,Mus musculus,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),
10090.0,1.0,,A,,,178.0,CHEMBL625253,,BAO_0000218,,50594.0,,,N,6061.0,17827.0,1.0,,Intermediate,Mus musculus,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Blood
10090.0,1.0,,A,,,,CHEMBL625254,,BAO_0000218,,50594.0,,,N,6062.0,17827.0,1.0,,Intermediate,Mus musculus,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),
10090.0,1.0,,A,,,,CHEMBL625255,,BAO_0000218,,50594.0,,,N,6063.0,17827.0,1.0,,Intermediate,Mus musculus,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),
10090.0,1.0,,A,,,,CHEMBL625256,,BAO_0000218,,50594.0,,,N,6064.0,17827.0,1.0,,Intermediate,Mus musculus,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),
10090.0,1.0,,A,,,178.0,CHEMBL625257,,BAO_0000218,,50594.0,,,N,6065.0,17827.0,1.0,,Intermediate,Mus musculus,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Blood
10090.0,1.0,,A,,,178.0,CHEMBL625258,,BAO_0000218,,50594.0,,,N,6066.0,17827.0,1.0,,Intermediate,Mus musculus,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),Blood
10090.0,1.0,,A,,,,CHEMBL625259,,BAO_0000218,,50594.0,,,N,6067.0,17827.0,1.0,,Intermediate,Mus musculus,Compound was evaluated for washout rate in mice (Radiolabeled compound),
10090.0,1.0,,A,,,,CHEMBL625260,,BAO_0000218,,50594.0,,,N,6068.0,17827.0,1.0,,Intermediate,Mus musculus,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,
10090.0,1.0,,A,,,,CHEMBL625261,,BAO_0000218,,50594.0,,,N,6069.0,17827.0,1.0,,Intermediate,Mus musculus,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",
10090.0,1.0,,A,,,,CHEMBL625262,,BAO_0000218,,50594.0,,,N,6070.0,17827.0,1.0,,Intermediate,Mus musculus,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",
10090.0,1.0,,A,,,,CHEMBL622639,,BAO_0000218,,50594.0,,,N,6071.0,17827.0,1.0,,Intermediate,Mus musculus,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",
10090.0,1.0,,A,,,,CHEMBL622640,,BAO_0000218,,50594.0,,,N,6072.0,17257.0,1.0,,Intermediate,Mus musculus,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,
10090.0,1.0,,A,,,,CHEMBL622812,,BAO_0000218,,50594.0,,,N,6073.0,17257.0,1.0,,Intermediate,Mus musculus,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,
10090.0,1.0,,A,,,,CHEMBL622813,,BAO_0000218,,50594.0,,,N,6074.0,17257.0,1.0,,Intermediate,Mus musculus,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,
10090.0,1.0,,A,,,,CHEMBL622814,,BAO_0000218,,50594.0,,,N,6075.0,17257.0,1.0,,Intermediate,Mus musculus,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,
10090.0,1.0,,A,,,,CHEMBL622815,,BAO_0000218,,50594.0,,,N,6076.0,17827.0,1.0,,Intermediate,Mus musculus,Time at maximum activity in mice (Radiolabeled compound),
10090.0,1.0,,A,,,,CHEMBL625342,,BAO_0000218,,50594.0,,,N,6077.0,3760.0,1.0,,Intermediate,Mus musculus,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,
10090.0,1.0,,A,,,,CHEMBL625343,,BAO_0000218,,50594.0,,,N,6078.0,3760.0,1.0,,Intermediate,Mus musculus,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,
10090.0,1.0,,A,,,,CHEMBL877591,,BAO_0000218,,50594.0,,,N,6079.0,17409.0,1.0,,Intermediate,Mus musculus,Binding towards mouse plasma protein at 10 uM,
10090.0,1.0,,A,,,,CHEMBL625344,,BAO_0000218,,50594.0,,,N,6080.0,17409.0,1.0,,Intermediate,Mus musculus,Binding towards mouse plasma protein at 100 uM,
10090.0,1.0,,A,,,,CHEMBL625345,,BAO_0000218,,50594.0,In vivo,,N,6081.0,2675.0,1.0,,Intermediate,Mus musculus,Bioavailability was evaluated in mice after intravenous administration,
10090.0,1.0,,A,,,,CHEMBL625346,,BAO_0000218,,50594.0,In vivo,,N,6082.0,2675.0,1.0,,Intermediate,Mus musculus,Bioavailability was evaluated in mice after oral administration,
10090.0,1.0,,A,,,,CHEMBL625347,,BAO_0000218,,50594.0,In vivo,,N,6083.0,3132.0,1.0,,Intermediate,Mus musculus,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,
10090.0,1.0,,A,,,,CHEMBL625348,,BAO_0000218,,50594.0,In vivo,,N,6084.0,3132.0,1.0,,Intermediate,Mus musculus,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,
10090.0,1.0,,A,,,,CHEMBL625349,,BAO_0000218,,50594.0,In vivo,,N,6085.0,16597.0,1.0,,Intermediate,Mus musculus,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,
10090.0,1.0,,A,,,,CHEMBL625350,,BAO_0000218,,50594.0,In vivo,,N,6086.0,2862.0,1.0,,Intermediate,Mus musculus,Oral bioavailability in mouse,
10090.0,1.0,,A,,,,CHEMBL882952,,BAO_0000218,,50594.0,In vivo,,N,6087.0,17764.0,1.0,,Intermediate,Mus musculus,Oral bioavailability after intravenous administration in mice at 24 uM/kg,
10090.0,1.0,,A,,,955.0,CHEMBL625351,,BAO_0000218,,50594.0,In vivo,,N,6088.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Brain
10090.0,1.0,,A,,,955.0,CHEMBL625352,,BAO_0000218,,50594.0,In vivo,,N,6089.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Brain
10090.0,1.0,,A,,,955.0,CHEMBL877592,,BAO_0000218,,50594.0,In vivo,,N,6090.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Brain
10090.0,1.0,,A,,,955.0,CHEMBL625353,,BAO_0000218,,50594.0,In vivo,,N,6091.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Brain
10090.0,1.0,,A,,,955.0,CHEMBL625354,,BAO_0000218,,50594.0,In vivo,,N,6092.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Brain
10090.0,1.0,,A,,,955.0,CHEMBL626019,,BAO_0000218,,50594.0,In vivo,,N,6093.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Brain
10090.0,1.0,,A,,,948.0,CHEMBL626020,,BAO_0000218,,50594.0,In vivo,,N,6094.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Heart
10090.0,1.0,,A,,,948.0,CHEMBL626021,,BAO_0000218,,50594.0,In vivo,,N,6095.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Heart
10090.0,1.0,,A,,,948.0,CHEMBL626022,,BAO_0000218,,50594.0,In vivo,,N,6096.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Heart
10090.0,1.0,,A,,,948.0,CHEMBL626192,,BAO_0000218,,50594.0,In vivo,,N,6097.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Heart
9606.0,1.0,,F,,,,CHEMBL626193,,BAO_0000219,A549,80682.0,,,N,6098.0,1276.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),
9606.0,1.0,,F,,,,CHEMBL626194,,BAO_0000219,A549,80682.0,,,N,6099.0,3498.0,1.0,646.0,Expert,Homo sapiens,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,
9606.0,1.0,,F,,,,CHEMBL626195,,BAO_0000219,A549,80682.0,,,N,6100.0,1169.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity against human lung carcinoma A-549 cell lines,
9606.0,1.0,,F,,,,CHEMBL626196,,BAO_0000219,A549,80682.0,,,N,6101.0,4450.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,
9606.0,1.0,,F,,,,CHEMBL626197,,BAO_0000219,A549,80682.0,,,N,6102.0,358.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549,
9606.0,1.0,,F,,,,CHEMBL626198,,BAO_0000219,A549,80682.0,,,N,6103.0,358.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,
9606.0,1.0,,F,,,,CHEMBL626199,,BAO_0000219,A549,80682.0,,,N,6104.0,358.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,
9606.0,1.0,,F,,,,CHEMBL626200,,BAO_0000219,A549,80682.0,,,N,6105.0,358.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,
9606.0,1.0,,F,,,,CHEMBL626201,,BAO_0000219,A549,80682.0,,,N,6106.0,358.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,
9606.0,1.0,,F,,,,CHEMBL626202,,BAO_0000219,A549,80682.0,,,N,6107.0,358.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,
9606.0,1.0,,F,,,,CHEMBL626203,,BAO_0000219,A549,80682.0,,,N,6108.0,358.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,
9606.0,1.0,,F,,,,CHEMBL626204,,BAO_0000219,A549,80682.0,,,N,6109.0,15167.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against A-549 human lung cancer cells,
9606.0,1.0,,F,,,,CHEMBL624701,,BAO_0000219,A549,80682.0,,,N,6110.0,4139.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,
9606.0,1.0,,F,,,,CHEMBL624702,,BAO_0000219,A549,80682.0,,,N,6111.0,833.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,
9606.0,1.0,,F,,,,CHEMBL624703,,BAO_0000219,A549,80682.0,,,N,6112.0,15718.0,1.0,646.0,Expert,Homo sapiens,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,
9606.0,1.0,,F,,,,CHEMBL624704,,BAO_0000219,A549,80682.0,,,N,6113.0,12373.0,1.0,646.0,Intermediate,Homo sapiens,Tested in vitro for cytotoxicity against A-549 lung cancer cells,
9606.0,1.0,,F,,,,CHEMBL624705,,BAO_0000219,A549,80682.0,,,N,6114.0,637.0,1.0,646.0,Intermediate,Homo sapiens,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,
9606.0,1.0,,F,,,,CHEMBL624706,,BAO_0000219,A549,80682.0,,,N,6115.0,14867.0,1.0,646.0,Expert,Homo sapiens,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,
9606.0,1.0,,F,,,,CHEMBL624707,,BAO_0000219,A549,80682.0,,,N,6116.0,4461.0,1.0,646.0,Intermediate,Homo sapiens,Antitumor cytotoxic activity against A-549 cell line was determined,
9606.0,1.0,,F,,,,CHEMBL624708,,BAO_0000219,A549,80682.0,,,N,6117.0,5406.0,1.0,646.0,Intermediate,Homo sapiens,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",
9606.0,1.0,,F,,,,CHEMBL624709,,BAO_0000219,A549,80682.0,,,N,6118.0,4457.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,
9606.0,1.0,,F,,,,CHEMBL884107,,BAO_0000219,A549,80682.0,,,N,6119.0,1386.0,1.0,646.0,Expert,Homo sapiens,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,
9606.0,1.0,,F,,,,CHEMBL624710,,BAO_0000219,A549,80682.0,,,N,6120.0,3265.0,1.0,646.0,Intermediate,Homo sapiens,Antitumoral activity was assayed against A-549 cell line,
9606.0,1.0,,F,,,,CHEMBL624711,,BAO_0000219,A549,80682.0,,,N,6121.0,2359.0,1.0,646.0,Intermediate,Homo sapiens,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,
9606.0,1.0,,F,,,,CHEMBL624712,,BAO_0000219,A549,80682.0,,,N,6122.0,4457.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,
9606.0,1.0,,F,,,,CHEMBL624713,,BAO_0000219,A549,80682.0,,,N,6123.0,12454.0,1.0,646.0,Expert,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,
9606.0,1.0,,F,,,,CHEMBL624714,,BAO_0000219,A549,80682.0,,,N,6124.0,1481.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for inhibition of cell growth of A-549 cells,
9606.0,1.0,,F,,,,CHEMBL624715,,BAO_0000219,A549,80682.0,,,N,6125.0,1750.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,
9606.0,1.0,,F,,,,CHEMBL624716,,BAO_0000219,A549,80682.0,,,N,6126.0,5065.0,1.0,646.0,Intermediate,Homo sapiens,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,
9606.0,1.0,,F,,,,CHEMBL619505,,BAO_0000219,A549,80682.0,,,N,6127.0,808.0,1.0,646.0,Expert,Homo sapiens,In vitro cytotoxicity against A549-human lung carcinoma cells.,
9606.0,1.0,,F,,,,CHEMBL619506,,BAO_0000219,A549,80682.0,,,N,6128.0,16364.0,1.0,646.0,Expert,Homo sapiens,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,
9606.0,1.0,,F,,,,CHEMBL619507,,BAO_0000219,A549,80682.0,,,N,6129.0,1847.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic activity against A-549 cell lines.,
9606.0,1.0,,F,,,,CHEMBL619508,,BAO_0000219,A549,80682.0,,,N,6130.0,1747.0,1.0,646.0,Expert,Homo sapiens,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,
9606.0,1.0,,F,,,,CHEMBL619509,,BAO_0000219,A549,80682.0,,,N,6131.0,1003.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity against human A549 non small cell lung cell lines,
9606.0,1.0,,F,,,,CHEMBL619510,,BAO_0000219,A549,80682.0,,,N,6132.0,15313.0,1.0,646.0,Expert,Homo sapiens,Inhibition of cell growth in (A-549) lung cell line,
9606.0,1.0,,F,,,,CHEMBL619511,,BAO_0000219,A549,80682.0,,,N,6133.0,3122.0,1.0,646.0,Intermediate,Homo sapiens,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,
9606.0,1.0,,F,,,,CHEMBL619512,,BAO_0000219,A549,80682.0,,,N,6134.0,16049.0,1.0,646.0,Intermediate,Homo sapiens,In vitro antitumor activity against A-549 tumor cells.,
9606.0,1.0,,F,,,,CHEMBL619513,,BAO_0000219,A549,80682.0,,,N,6135.0,17134.0,1.0,646.0,Expert,Homo sapiens,In vitro antitumor effects against human A-549 cell lines.,
9606.0,1.0,,F,,,,CHEMBL619514,,BAO_0000219,A549,80682.0,,,N,6136.0,6406.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxic activity of compound against A-549 cell line,
9606.0,1.0,,F,,,,CHEMBL619515,,BAO_0000219,A549,80682.0,,,N,6137.0,627.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against human lung carcinoma A-549 cell line,
9606.0,1.0,,F,,,,CHEMBL619516,,BAO_0000219,A549,80682.0,,,N,6138.0,12307.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against human non-small cell lung carcinoma A549,
9606.0,1.0,,F,,,,CHEMBL884005,,BAO_0000219,A549,80682.0,,,N,6139.0,17861.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,
9606.0,1.0,,F,,,,CHEMBL619517,,BAO_0000219,A549,80682.0,,,N,6140.0,6682.0,1.0,646.0,Expert,Homo sapiens,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,
9606.0,1.0,,F,,,,CHEMBL619518,,BAO_0000219,A549,80682.0,,,N,6141.0,6663.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory concentration of compound against A-549 cell line,
9606.0,1.0,,F,,,,CHEMBL619519,,BAO_0000219,A549,80682.0,,,N,6142.0,2454.0,1.0,646.0,Intermediate,Homo sapiens,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,
9606.0,1.0,,F,,,,CHEMBL876489,,BAO_0000219,A549,80682.0,,,N,6143.0,14709.0,1.0,646.0,Intermediate,Homo sapiens,cytotoxic activity against leukemia (A-549) cancer cell line,
9606.0,1.0,,F,,,,CHEMBL619520,,BAO_0000219,A549,80682.0,,,N,6144.0,15718.0,1.0,646.0,Expert,Homo sapiens,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,
9606.0,1.0,,F,,,,CHEMBL619521,,BAO_0000219,A549,80682.0,,,N,6145.0,15718.0,1.0,646.0,Intermediate,Homo sapiens,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,
9606.0,1.0,,F,,,,CHEMBL619522,,BAO_0000219,A549,80682.0,,,N,6146.0,17130.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),
9606.0,1.0,,F,,,,CHEMBL619523,,BAO_0000219,A549,80682.0,,,N,6147.0,17130.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),
9606.0,1.0,,F,,,,CHEMBL619524,,BAO_0000219,A549,80682.0,,,N,6148.0,17130.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),
9606.0,1.0,,F,,,,CHEMBL619525,,BAO_0000219,A549,80682.0,,,N,6149.0,17130.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),
,1.0,,F,,,,CHEMBL619526,,BAO_0000219,A549,80682.0,,,N,6150.0,6630.0,1.0,646.0,Intermediate,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,
9606.0,1.0,,F,,,,CHEMBL619527,,BAO_0000219,A549,80682.0,,,N,6151.0,16726.0,1.0,646.0,Intermediate,Homo sapiens,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,
9606.0,1.0,,F,,,,CHEMBL619528,,BAO_0000219,A549,80682.0,,,N,6152.0,17846.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity against A549 cells; No cytotoxicity,
9606.0,1.0,,F,,,,CHEMBL619529,,BAO_0000219,A549,80682.0,,,N,6153.0,3415.0,1.0,646.0,Expert,Homo sapiens,Cytotoxicity against human lung carcinoma (A549) cell lines,
9606.0,1.0,,F,,,,CHEMBL619530,,BAO_0000219,A549,80682.0,,,N,6154.0,3415.0,1.0,646.0,Expert,Homo sapiens,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,
9606.0,1.0,,F,,,,CHEMBL876490,,BAO_0000219,A549,80682.0,,,N,6155.0,5609.0,1.0,646.0,Intermediate,Homo sapiens,In vitro anticancer activity against human lung (A549) cell line,
9606.0,1.0,,F,,,,CHEMBL619531,,BAO_0000219,A549,80682.0,,,N,6156.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,
9606.0,1.0,,F,,,,CHEMBL619532,,BAO_0000219,A549,80682.0,,,N,6157.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,
9606.0,1.0,,F,,,,CHEMBL619533,,BAO_0000219,A549,80682.0,,,N,6158.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,
9606.0,1.0,,F,,,,CHEMBL619534,,BAO_0000219,A549,80682.0,,,N,6159.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,
9606.0,1.0,,F,,,,CHEMBL620164,,BAO_0000219,A549,80682.0,,,N,6160.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,
9606.0,1.0,,F,,,,CHEMBL620165,,BAO_0000219,A549,80682.0,,,N,6161.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,
9606.0,1.0,,F,,,,CHEMBL620166,,BAO_0000219,A549,80682.0,,,N,6162.0,16295.0,1.0,646.0,Expert,Homo sapiens,Inhibition of A549 human lung tumor cell proliferation,
9606.0,1.0,,F,,,,CHEMBL620167,,BAO_0000219,A549,80682.0,,,N,6163.0,16825.0,1.0,646.0,Intermediate,Homo sapiens,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",
9606.0,1.0,,F,,,,CHEMBL620168,,BAO_0000219,A549,80682.0,,,N,6164.0,3439.0,1.0,646.0,Expert,Homo sapiens,In vitro cytotoxicity against human tumor cell line A549,
9606.0,1.0,,F,,,,CHEMBL620338,,BAO_0000219,A549,80682.0,,,N,6165.0,10870.0,1.0,646.0,Intermediate,Homo sapiens,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,
9606.0,1.0,,F,,,,CHEMBL620339,,BAO_0000219,A549,80682.0,,,N,6166.0,4845.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,
9606.0,1.0,,F,,,,CHEMBL620340,,BAO_0000219,A549,80682.0,,,N,6167.0,5822.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,
9606.0,1.0,,F,,,,CHEMBL620341,,BAO_0000219,A549,80682.0,,,N,6168.0,5822.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,
9606.0,1.0,,F,,,,CHEMBL876491,,BAO_0000219,A549,80682.0,,,N,6169.0,5822.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,
9606.0,1.0,,F,,,,CHEMBL620342,,BAO_0000219,A549,80682.0,,,N,6170.0,16381.0,1.0,646.0,Intermediate,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,
9606.0,1.0,,F,,,,CHEMBL620343,,BAO_0000219,A549,80682.0,,,N,6171.0,16381.0,1.0,646.0,Intermediate,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,
9606.0,1.0,,F,,,,CHEMBL620344,,BAO_0000219,A549,80682.0,,,N,6172.0,16381.0,1.0,646.0,Intermediate,Homo sapiens,% inhibition against A549 cells (lung cancer) at 4 ug/mL,
9606.0,1.0,,F,,,,CHEMBL620345,,BAO_0000219,A549,80682.0,,,N,6173.0,5609.0,1.0,646.0,Intermediate,Homo sapiens,In vitro anticancer activity against human lung (A549) cell line,
9606.0,1.0,,F,,,,CHEMBL620346,,BAO_0000219,A549,80682.0,,,N,6174.0,4644.0,1.0,646.0,Intermediate,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,
9606.0,1.0,,F,,,,CHEMBL620347,,BAO_0000219,A549,80682.0,,,N,6175.0,4644.0,1.0,646.0,Intermediate,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,
9606.0,1.0,,F,,,,CHEMBL620348,,BAO_0000219,A549,80682.0,,,N,6176.0,4644.0,1.0,646.0,Intermediate,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,
9606.0,1.0,,F,,,,CHEMBL620349,,BAO_0000219,A549,80682.0,,,N,6177.0,4644.0,1.0,646.0,Intermediate,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,
9606.0,1.0,,F,,,,CHEMBL618667,,BAO_0000219,A549,80682.0,,,N,6178.0,5822.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,
9606.0,1.0,,F,,,,CHEMBL618668,,BAO_0000219,A549,80682.0,,,N,6179.0,3415.0,1.0,646.0,Expert,Homo sapiens,Percentage inhibition of human lung carcinoma (A549) cell lines,
9606.0,1.0,,F,,,,CHEMBL876031,,BAO_0000219,A549,80682.0,,,N,6180.0,16726.0,1.0,646.0,Intermediate,Homo sapiens,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,
9606.0,1.0,,F,,,,CHEMBL618759,,BAO_0000219,A549,80682.0,,,N,6181.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",
9606.0,1.0,,F,,,,CHEMBL618760,,BAO_0000219,A549,80682.0,,,N,6182.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,
9606.0,1.0,,F,,,,CHEMBL619000,,BAO_0000219,A549,80682.0,,,N,6183.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,
9606.0,1.0,,F,,,,CHEMBL619001,,BAO_0000219,A549,80682.0,,,N,6184.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",
9606.0,1.0,,F,,,,CHEMBL619002,,BAO_0000219,A549,80682.0,,,N,6185.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",
9606.0,1.0,,F,,,,CHEMBL619003,,BAO_0000219,A549,80682.0,,,N,6186.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",
9606.0,1.0,,F,,,,CHEMBL619597,,BAO_0000219,A549,80682.0,,,N,6187.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",
9606.0,1.0,,F,,,,CHEMBL619598,,BAO_0000219,A549,80682.0,,,N,6188.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",
9606.0,1.0,,F,,,,CHEMBL619599,,BAO_0000219,A549,80682.0,,,N,6189.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,
9606.0,1.0,,F,,,,CHEMBL619600,,BAO_0000219,A549,80682.0,,,N,6190.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,
9606.0,1.0,,F,,,,CHEMBL619601,,BAO_0000219,A549,80682.0,,,N,6191.0,16726.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,
9606.0,1.0,,F,,,,CHEMBL619602,,BAO_0000219,A549,80682.0,,,N,6192.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,
9606.0,1.0,,F,,,,CHEMBL619603,,BAO_0000219,A549,80682.0,,,N,6193.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,
9606.0,1.0,,F,,,,CHEMBL619604,,BAO_0000219,A549,80682.0,,,N,6194.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,
9606.0,1.0,,F,,,,CHEMBL619605,,BAO_0000219,A549,80682.0,,,N,6195.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,
9615.0,1.0,,A,,,,CHEMBL619606,,BAO_0000218,,50588.0,In vivo,,N,6196.0,6084.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,
9615.0,1.0,,A,,,,CHEMBL876032,,BAO_0000218,,50588.0,In vivo,,N,6197.0,6084.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic activity (Cmax) in dog,
9615.0,1.0,,A,,,,CHEMBL619607,,BAO_0000218,,50588.0,In vivo,,N,6198.0,4809.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),
9615.0,1.0,,A,,,,CHEMBL619608,,BAO_0000218,,50588.0,In vivo,,N,6199.0,5983.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,
9615.0,1.0,,A,,,,CHEMBL619609,,BAO_0000218,,50588.0,In vivo,,N,6200.0,6251.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,
9615.0,1.0,,A,,,1969.0,CHEMBL619610,,BAO_0000218,,50588.0,In vivo,,N,6201.0,5932.0,1.0,,Intermediate,Canis lupus familiaris,Cmax in dog plasma after 30mg/kg oral dose,Plasma
9615.0,1.0,,A,,,178.0,CHEMBL619611,,BAO_0000218,,50588.0,In vivo,,N,6202.0,4273.0,1.0,,Intermediate,Canis lupus familiaris,Tested for the peak blood level in dog,Blood
9615.0,1.0,,A,,,,CHEMBL619612,,BAO_0000218,,50588.0,In vivo,,N,6203.0,5313.0,1.0,,Intermediate,Canis lupus familiaris,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",
9615.0,1.0,,A,,,,CHEMBL619613,,BAO_0000218,,50588.0,In vivo,,N,6204.0,5313.0,1.0,,Intermediate,Canis lupus familiaris,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",
9615.0,1.0,,A,,,178.0,CHEMBL619614,,BAO_0000218,,50588.0,In vivo,,N,6205.0,6221.0,1.0,,Intermediate,Canis lupus familiaris,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,Blood
9615.0,1.0,,A,,,,CHEMBL619615,,BAO_0000218,,50588.0,,,N,6206.0,4709.0,1.0,,Intermediate,Canis lupus familiaris,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL619616,,BAO_0000218,,50588.0,,,N,6207.0,167.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,
9615.0,1.0,,A,,,1969.0,CHEMBL619617,,BAO_0000218,,50588.0,,,N,6208.0,6241.0,1.0,,Intermediate,Canis lupus familiaris,Final plasma concentration in dogs after oral administration at 1 mg/kg,Plasma
9615.0,1.0,,A,,,,CHEMBL619618,,BAO_0000218,,50588.0,,,N,6209.0,344.0,1.0,,Intermediate,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,
9615.0,1.0,,A,,,,CHEMBL876033,,BAO_0000218,,50588.0,,,N,6210.0,344.0,1.0,,Intermediate,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,
9615.0,1.0,,A,,,,CHEMBL619619,,BAO_0000218,,50588.0,,,N,6211.0,344.0,1.0,,Intermediate,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,
9615.0,1.0,,A,,,,CHEMBL619620,,BAO_0000218,,50588.0,,,N,6212.0,2189.0,1.0,,Intermediate,Canis lupus familiaris,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,
9615.0,1.0,,A,,,1088.0,CHEMBL619621,,BAO_0000218,,50588.0,,,N,6213.0,2189.0,1.0,,Intermediate,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,Urine
9615.0,1.0,,A,,,1088.0,CHEMBL619622,,BAO_0000218,,50588.0,,,N,6214.0,2189.0,1.0,,Intermediate,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,Urine
9615.0,1.0,,A,,,1088.0,CHEMBL618874,,BAO_0000218,,50588.0,,,N,6215.0,2189.0,1.0,,Intermediate,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,Urine
9615.0,1.0,,A,,,,CHEMBL618875,,BAO_0000218,,50588.0,In vivo,,N,6216.0,4257.0,1.0,,Intermediate,Canis lupus familiaris,Absolute bioavailability was evaluated in dog,
9615.0,1.0,,A,,,,CHEMBL618876,,BAO_0000218,,50588.0,In vivo,,N,6217.0,6221.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,
9615.0,1.0,,A,,,,CHEMBL618877,,BAO_0000218,,50588.0,In vivo,,N,6218.0,6215.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability after peroral administration (1 mg/kg) was determined in dog,
9615.0,1.0,,A,,,,CHEMBL618878,,BAO_0000218,,50588.0,In vivo,,N,6219.0,17267.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL618879,,BAO_0000218,,50588.0,In vivo,,N,6220.0,6621.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL618880,,BAO_0000218,,50588.0,In vivo,,N,6221.0,3854.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability after intravenous administration in dogs,
9615.0,1.0,,A,,,,CHEMBL618881,,BAO_0000218,,50588.0,In vivo,,N,6222.0,3854.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability after peroral administration in dogs,
9615.0,1.0,,A,,,,CHEMBL618882,,BAO_0000218,,50588.0,In vivo,,N,6223.0,5007.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),
9615.0,1.0,,A,,,,CHEMBL624226,,BAO_0000218,,50588.0,In vivo,,N,6224.0,4333.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,
9615.0,1.0,,A,,,1969.0,CHEMBL624227,,BAO_0000218,,50588.0,In vivo,,N,6225.0,4333.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,Plasma
9615.0,1.0,,A,,,,CHEMBL624228,,BAO_0000218,,50588.0,In vivo,,N,6226.0,5006.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability,
9615.0,1.0,,A,,,,CHEMBL624229,,BAO_0000218,,50588.0,In vivo,,N,6227.0,5199.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability,
9615.0,1.0,,A,,,,CHEMBL624230,,BAO_0000218,,50588.0,In vivo,,N,6228.0,4368.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability by intravenous administration of 1.2 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL624231,,BAO_0000218,,50588.0,In vivo,,N,6229.0,3771.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL624232,,BAO_0000218,,50588.0,In vivo,,N,6230.0,4953.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL625127,,BAO_0000218,,50588.0,In vivo,,N,6231.0,5064.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL625128,,BAO_0000218,,50588.0,In vivo,,N,6232.0,17657.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621675,,BAO_0000218,,50588.0,In vivo,,N,6233.0,17796.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621676,,BAO_0000218,,50588.0,In vivo,,N,6234.0,17853.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog (p.o.) at 2.0 mpk,
9615.0,1.0,,A,,,,CHEMBL621677,,BAO_0000218,,50588.0,In vivo,,N,6235.0,4521.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),
9615.0,1.0,,A,,,,CHEMBL621678,,BAO_0000218,,50588.0,In vivo,,N,6236.0,4521.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,
9615.0,1.0,,A,,,,CHEMBL621679,,BAO_0000218,,50588.0,In vivo,,N,6237.0,5006.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621680,,BAO_0000218,,50588.0,In vivo,,N,6238.0,16365.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability was evaluated after oral administration in dog,
9615.0,1.0,,A,,,,CHEMBL621681,,BAO_0000218,,50588.0,In vivo,,N,6239.0,1916.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,
9615.0,1.0,,A,,,,CHEMBL876740,,BAO_0000218,,50588.0,In vivo,,N,6240.0,1918.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability was evaluated in dog,
9615.0,1.0,,A,,,,CHEMBL621682,,BAO_0000218,,50588.0,In vivo,,N,6241.0,4239.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621683,,BAO_0000218,,50588.0,In vivo,,N,6242.0,6505.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621684,,BAO_0000218,,50588.0,In vivo,,N,6243.0,5334.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),
9615.0,1.0,,A,,,,CHEMBL621685,,BAO_0000218,,50588.0,In vivo,,N,6244.0,5334.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),
9615.0,1.0,,A,,,,CHEMBL621686,,BAO_0000218,,50588.0,In vivo,,N,6245.0,4809.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),
9615.0,1.0,,A,,,,CHEMBL621687,,BAO_0000218,,50588.0,In vivo,,N,6246.0,6348.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,
9615.0,1.0,,A,,,,CHEMBL621688,,BAO_0000218,,50588.0,In vivo,,N,6247.0,6005.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL621689,,BAO_0000218,,50588.0,In vivo,,N,6248.0,17804.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability of compound in dog was determined after peroral administration,
9615.0,1.0,,A,,,,CHEMBL621690,,BAO_0000218,,50588.0,In vivo,,N,6249.0,3184.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621691,,BAO_0000218,,50588.0,In vivo,,N,6250.0,1806.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,
9615.0,1.0,,A,,,,CHEMBL875941,,BAO_0000218,,50588.0,In vivo,,N,6251.0,1806.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,
9615.0,1.0,,A,,,,CHEMBL621692,,BAO_0000218,,50588.0,In vivo,,N,6252.0,1806.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for oral bioavailability in dogs; 37-38 %,
9615.0,1.0,,A,,,,CHEMBL621693,,BAO_0000218,,50588.0,In vivo,,N,6253.0,4839.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621694,,BAO_0000218,,50588.0,In vivo,,N,6254.0,5017.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),
10090.0,1.0,,A,,,948.0,CHEMBL621695,,BAO_0000218,,50594.0,In vivo,,N,6255.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Heart
10090.0,1.0,,A,,,948.0,CHEMBL621696,,BAO_0000218,,50594.0,In vivo,,N,6256.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Heart
10090.0,1.0,,A,,,2113.0,CHEMBL621697,,BAO_0000218,,50594.0,In vivo,,N,6257.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL621698,,BAO_0000218,,50594.0,In vivo,,N,6258.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL623420,,BAO_0000218,,50594.0,In vivo,,N,6259.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL623421,,BAO_0000218,,50594.0,In vivo,,N,6260.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL623422,,BAO_0000218,,50594.0,In vivo,,N,6261.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL623423,,BAO_0000218,,50594.0,In vivo,,N,6262.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Kidney
10090.0,1.0,,A,,,2107.0,CHEMBL623424,,BAO_0000218,,50594.0,In vivo,,N,6263.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL623425,,BAO_0000218,,50594.0,In vivo,,N,6264.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL623426,,BAO_0000218,,50594.0,In vivo,,N,6265.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL623427,,BAO_0000218,,50594.0,In vivo,,N,6266.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL623428,,BAO_0000218,,50594.0,In vivo,,N,6267.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL875947,,BAO_0000218,,50594.0,In vivo,,N,6268.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Liver
10090.0,1.0,,A,,,2048.0,CHEMBL623429,,BAO_0000218,,50594.0,In vivo,,N,6269.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL623430,,BAO_0000218,,50594.0,In vivo,,N,6270.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL622588,,BAO_0000218,,50594.0,In vivo,,N,6271.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL622589,,BAO_0000218,,50594.0,In vivo,,N,6272.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL622751,,BAO_0000218,,50594.0,In vivo,,N,6273.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL622752,,BAO_0000218,,50594.0,In vivo,,N,6274.0,846.0,1.0,,Intermediate,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Lung
10090.0,1.0,,A,,,,CHEMBL622753,,BAO_0000218,CCRF S-180,50594.0,,,N,6275.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,
10090.0,1.0,,A,,,,CHEMBL622647,,BAO_0000218,CCRF S-180,50594.0,,,N,6276.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,
10090.0,1.0,,A,,,,CHEMBL875163,,BAO_0000218,CCRF S-180,50594.0,,,N,6277.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,
10090.0,1.0,,A,,,,CHEMBL622648,,BAO_0000218,CCRF S-180,50594.0,,,N,6278.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,
10090.0,1.0,,A,,,,CHEMBL622649,,BAO_0000218,CCRF S-180,50594.0,,,N,6279.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,
10090.0,1.0,,A,,,955.0,CHEMBL622650,,BAO_0000218,CCRF S-180,50594.0,,,N,6280.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,Brain
10090.0,1.0,,A,,,955.0,CHEMBL622651,,BAO_0000218,CCRF S-180,50594.0,,,N,6281.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,Brain
10090.0,1.0,,A,,,955.0,CHEMBL622652,,BAO_0000218,CCRF S-180,50594.0,,,N,6282.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,Brain
10090.0,1.0,,A,,,955.0,CHEMBL622653,,BAO_0000218,CCRF S-180,50594.0,,,N,6283.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,Brain
10090.0,1.0,,A,,,955.0,CHEMBL622654,,BAO_0000218,CCRF S-180,50594.0,,,N,6284.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,Brain
10090.0,1.0,,A,,,948.0,CHEMBL622655,,BAO_0000218,CCRF S-180,50594.0,,,N,6285.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,Heart
10090.0,1.0,,A,,,948.0,CHEMBL622656,,BAO_0000218,CCRF S-180,50594.0,,,N,6286.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,Heart
10090.0,1.0,,A,,,948.0,CHEMBL622657,,BAO_0000218,CCRF S-180,50594.0,,,N,6287.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,Heart
10090.0,1.0,,A,,,948.0,CHEMBL622658,,BAO_0000218,CCRF S-180,50594.0,,,N,6288.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,Heart
10090.0,1.0,,A,,,948.0,CHEMBL622659,,BAO_0000218,CCRF S-180,50594.0,,,N,6289.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,Heart
10090.0,1.0,,A,,,2113.0,CHEMBL624630,,BAO_0000218,CCRF S-180,50594.0,,,N,6290.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL624631,,BAO_0000218,CCRF S-180,50594.0,,,N,6291.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL624632,,BAO_0000218,CCRF S-180,50594.0,,,N,6292.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,Kidney
9606.0,1.0,,F,,,,CHEMBL624633,,BAO_0000219,A549,80682.0,,,N,6293.0,17130.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,
9606.0,1.0,,F,,,,CHEMBL624634,,BAO_0000219,A549,80682.0,,,N,6294.0,17130.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,
9606.0,1.0,,F,,,,CHEMBL624635,,BAO_0000219,A549,80682.0,,,N,6295.0,17130.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),
9606.0,1.0,,F,,,,CHEMBL624636,,BAO_0000219,A549,80682.0,,,N,6296.0,17130.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),
9606.0,1.0,,F,,,,CHEMBL857055,,BAO_0000219,A549,80682.0,,,N,6297.0,3263.0,1.0,646.0,Expert,Homo sapiens,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,
9606.0,1.0,,F,,,,CHEMBL624637,,BAO_0000219,A549,80682.0,,,N,6298.0,6663.0,1.0,646.0,Expert,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,
9606.0,1.0,,F,,,,CHEMBL624638,,BAO_0000219,A549,80682.0,,,N,6299.0,6663.0,1.0,646.0,Expert,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,
9606.0,1.0,,F,,,,CHEMBL874366,,BAO_0000219,A549,80682.0,,,N,6300.0,6663.0,1.0,646.0,Expert,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,
9606.0,1.0,,F,,,,CHEMBL624639,,BAO_0000219,A549,80682.0,,,N,6301.0,6663.0,1.0,646.0,Expert,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,
9606.0,1.0,,F,,,,CHEMBL624640,,BAO_0000219,A549,80682.0,,,N,6302.0,6663.0,1.0,646.0,Expert,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,
9606.0,1.0,,F,,,,CHEMBL624641,,BAO_0000219,A549,80682.0,,,N,6303.0,6663.0,1.0,646.0,Intermediate,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,
9606.0,1.0,,F,,,,CHEMBL624642,,BAO_0000219,A549,80682.0,,,N,6304.0,6663.0,1.0,646.0,Intermediate,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,
9606.0,1.0,,F,,,,CHEMBL624643,,BAO_0000219,A549,80682.0,,,N,6305.0,6663.0,1.0,646.0,Intermediate,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,
9606.0,1.0,,F,,,,CHEMBL624644,,BAO_0000219,A549,80682.0,,,N,6306.0,6663.0,1.0,646.0,Intermediate,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,
9606.0,1.0,,F,,,,CHEMBL624645,,BAO_0000219,A549,80682.0,,,N,6307.0,6663.0,1.0,646.0,Intermediate,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,
9606.0,1.0,,F,,,,CHEMBL619445,,BAO_0000219,A549,80682.0,,,N,6308.0,3983.0,1.0,646.0,Intermediate,Homo sapiens,The compound was evaluated for its cytotoxic potency against A-549 cell line,
9606.0,1.0,,F,,,,CHEMBL839886,,BAO_0000219,A549,80682.0,,,N,6309.0,11141.0,1.0,646.0,Expert,Homo sapiens,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,
9606.0,1.0,,F,,,,CHEMBL619446,,BAO_0000219,A549,80682.0,,,N,6310.0,5076.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic activity of compound against A-549 tumor cell line.,
9606.0,1.0,,F,,,,CHEMBL619447,,BAO_0000219,A549,80682.0,,,N,6311.0,3311.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,
9606.0,1.0,,F,,,,CHEMBL619448,,BAO_0000219,A549,80682.0,,,N,6312.0,3311.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,
9606.0,1.0,,F,,,,CHEMBL619449,,BAO_0000219,A549,80682.0,,,N,6313.0,3311.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,
9606.0,1.0,,F,,,,CHEMBL619450,,BAO_0000219,A549,80682.0,,,N,6314.0,5076.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,
9606.0,1.0,,F,,,,CHEMBL619451,,BAO_0000219,A549,80682.0,,,N,6315.0,4150.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),
9606.0,1.0,,F,,,,CHEMBL619452,,BAO_0000219,A549,80682.0,,,N,6316.0,2150.0,1.0,646.0,Expert,Homo sapiens,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,
9606.0,1.0,,F,,,,CHEMBL619453,,BAO_0000219,A549,80682.0,,,N,6317.0,4644.0,1.0,646.0,Intermediate,Homo sapiens,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,
9606.0,1.0,,F,,,,CHEMBL874367,,BAO_0000219,A549,80682.0,,,N,6318.0,263.0,1.0,646.0,Intermediate,Homo sapiens,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,
9606.0,1.0,,F,,,,CHEMBL619454,,BAO_0000219,A549,80682.0,,,N,6319.0,11333.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic concentration against A-549 tumor cells.,
9606.0,1.0,,F,,,,CHEMBL619455,,BAO_0000219,A549,80682.0,,,N,6320.0,11333.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,
9606.0,1.0,,F,,,,CHEMBL619456,,BAO_0000219,A549,80682.0,,,N,6321.0,15895.0,1.0,646.0,Intermediate,Homo sapiens,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",
470.0,1.0,,F,,,,CHEMBL619457,,BAO_0000218,,50191.0,,,N,6322.0,16677.0,1.0,,Expert,Acinetobacter baumannii,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,
471.0,1.0,,F,,,,CHEMBL619458,,BAO_0000218,,50192.0,,,N,6323.0,10624.0,1.0,,Intermediate,Acinetobacter calcoaceticus,Activity against Acinetobacter calcoaceticus (AC54),
5059.0,1.0,,F,,,,CHEMBL619459,,BAO_0000218,,50274.0,,,N,6324.0,16717.0,1.0,,Expert,Aspergillus flavus,In vitro antifungal activity against Aspergillus flavus CM74,
5059.0,1.0,,F,,,,CHEMBL619460,,BAO_0000218,,50274.0,,,N,6325.0,16717.0,1.0,,Expert,Aspergillus flavus,In vitro antifungal activity against Aspergillus flavus CM74,
746128.0,1.0,,F,,,,CHEMBL619461,,BAO_0000218,,50416.0,,,N,6326.0,5513.0,1.0,,Intermediate,Aspergillus fumigatus,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,
746128.0,1.0,,F,,,,CHEMBL619462,,BAO_0000218,,50416.0,,,N,6327.0,15962.0,1.0,,Intermediate,Aspergillus fumigatus,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),
746128.0,1.0,,F,,,,CHEMBL620388,,BAO_0000218,,50416.0,,,N,6328.0,15962.0,1.0,,Intermediate,Aspergillus fumigatus,Antimicrobial activity against Aspergillus fumigatus (MIC),
746128.0,1.0,,F,,,,CHEMBL620389,,BAO_0000218,,50416.0,,,N,6329.0,15962.0,1.0,,Intermediate,Aspergillus fumigatus,Antimicrobial activity against Aspergillus fumigatus (MIC),
746128.0,1.0,,F,,,,CHEMBL620390,,BAO_0000218,,50416.0,,,N,6330.0,15962.0,1.0,,Intermediate,Aspergillus fumigatus,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),
746128.0,1.0,,F,,,,CHEMBL620391,,BAO_0000218,,50416.0,,,N,6331.0,16717.0,1.0,,Expert,Aspergillus fumigatus,In vitro antifungal activity against Aspergillus fumigatus 48238E,
746128.0,1.0,,F,,,,CHEMBL621073,,BAO_0000218,,50416.0,,,N,6332.0,16717.0,1.0,,Expert,Aspergillus fumigatus,In vitro antifungal activity against Aspergillus fumigatus 48238E,
1655.0,1.0,,F,,,,CHEMBL621074,,BAO_0000218,,50296.0,,,N,6333.0,8117.0,1.0,,Intermediate,Actinomyces naeslundii,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,
1656.0,1.0,,F,,,,CHEMBL621075,,BAO_0000218,,50366.0,,,N,6334.0,8117.0,1.0,,Intermediate,Actinomyces viscosus,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,
6277.0,1.0,,F,,,,CHEMBL619554,,BAO_0000218,,50535.0,,,N,6335.0,15472.0,1.0,,Intermediate,Acanthocheilonema viteae,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),
6277.0,1.0,,F,,,,CHEMBL619555,,BAO_0000218,,50535.0,,,N,6336.0,15472.0,1.0,,Intermediate,Acanthocheilonema viteae,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),
714.0,1.0,,F,,,,CHEMBL619556,,BAO_0000218,,50169.0,,,N,6337.0,16443.0,1.0,,Intermediate,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,
714.0,1.0,,F,,,,CHEMBL619557,,BAO_0000218,,50169.0,,,N,6338.0,16443.0,1.0,,Intermediate,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,
714.0,1.0,,F,,,,CHEMBL619558,,BAO_0000218,,50169.0,,,N,6339.0,16443.0,1.0,,Intermediate,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,
9606.0,1.0,,F,,,,CHEMBL619559,,BAO_0000219,A549,80682.0,,,N,6340.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,
9606.0,1.0,,F,,,,CHEMBL619560,,BAO_0000219,A549,80682.0,,,N,6341.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,
9606.0,1.0,,F,,,,CHEMBL619561,,BAO_0000219,A549,80682.0,,,N,6342.0,16381.0,1.0,646.0,Intermediate,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,
9606.0,1.0,,F,,,,CHEMBL619562,,BAO_0000219,A549,80682.0,,,N,6343.0,16381.0,1.0,646.0,Intermediate,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,
9606.0,1.0,,F,,,,CHEMBL619563,,BAO_0000219,A549,80682.0,,,N,6344.0,16381.0,1.0,646.0,Intermediate,Homo sapiens,% inhibition against A549 cells (lung cancer) at 4 ug/mL,
9606.0,1.0,,F,,,,CHEMBL857457,,BAO_0000219,A549,80682.0,,,N,6345.0,16381.0,1.0,646.0,Intermediate,Homo sapiens,GI values against A549 cells (lung cancer),
9606.0,1.0,,F,,,,CHEMBL619564,,BAO_0000219,A549,80682.0,,,N,6346.0,17206.0,1.0,646.0,Intermediate,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,
9606.0,1.0,,F,,,,CHEMBL619565,,BAO_0000219,A549,80682.0,,,N,6347.0,16325.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory activity against A549 human adenocarcinoma,
9606.0,1.0,,F,,,,CHEMBL619566,,BAO_0000218,A549,80682.0,,,N,6348.0,10708.0,1.0,646.0,Intermediate,Homo sapiens,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,
9606.0,1.0,,F,,,,CHEMBL619567,,BAO_0000218,A549,80682.0,,,N,6349.0,10708.0,1.0,646.0,Intermediate,Homo sapiens,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,
9606.0,1.0,,F,,,,CHEMBL619568,,BAO_0000219,A549,80682.0,,,N,6350.0,17376.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line,
9606.0,1.0,,F,,,,CHEMBL619569,,BAO_0000219,A549,80682.0,,,N,6351.0,17376.0,1.0,646.0,Intermediate,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,
9606.0,1.0,,F,,,,CHEMBL619570,,BAO_0000219,A549,80682.0,,,N,6352.0,17488.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity against human A549 lung cells,
9606.0,1.0,,F,,,,CHEMBL619571,,BAO_0000218,A549,80682.0,,,N,6353.0,17404.0,1.0,646.0,Intermediate,Homo sapiens,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,
9606.0,1.0,,F,,,,CHEMBL619572,,BAO_0000219,A549,80682.0,,,N,6354.0,10958.0,1.0,646.0,Expert,Homo sapiens,Growth inhibition of A549 (human lung carcinoma) cell line.,
9606.0,1.0,,F,,,,CHEMBL619573,,BAO_0000219,A549,80682.0,,,N,6355.0,17099.0,1.0,646.0,Expert,Homo sapiens,Effective dose required for inhibitory activity against A549 human tumor cell line.,
9606.0,1.0,,F,,,,CHEMBL619574,,BAO_0000219,A549,80682.0,,,N,6356.0,17099.0,1.0,646.0,Intermediate,Homo sapiens,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,
9606.0,1.0,,F,,,,CHEMBL619575,,BAO_0000219,A549,80682.0,,,N,6357.0,4096.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,
9606.0,1.0,,F,,,,CHEMBL619576,,BAO_0000219,A549,80682.0,,,N,6358.0,4096.0,1.0,646.0,Expert,Homo sapiens,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,
9606.0,1.0,,F,,,,CHEMBL619577,,BAO_0000219,A549,80682.0,,,N,6359.0,4096.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,
9606.0,1.0,,F,,,,CHEMBL619578,,BAO_0000219,A549,80682.0,,,N,6360.0,2525.0,1.0,646.0,Intermediate,Homo sapiens,In vitro inhibitory activity against A549 tumor cell culture,
9606.0,1.0,,F,,,,CHEMBL884009,,BAO_0000219,A549,80682.0,,,N,6361.0,2525.0,1.0,646.0,Intermediate,Homo sapiens,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,
9606.0,1.0,,F,,,,CHEMBL619579,,BAO_0000219,A549,80682.0,,,N,6362.0,5302.0,1.0,646.0,Intermediate,Homo sapiens,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),
9606.0,1.0,,F,,,,CHEMBL619580,,BAO_0000219,A549,80682.0,,,N,6363.0,16325.0,1.0,646.0,Intermediate,Homo sapiens,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,
9606.0,1.0,,F,,,,CHEMBL619581,,BAO_0000219,A549,80682.0,,,N,6364.0,16939.0,1.0,646.0,Intermediate,Homo sapiens,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,
9606.0,1.0,,F,,,,CHEMBL619582,,BAO_0000219,A549,80682.0,,,N,6365.0,17229.0,1.0,646.0,Intermediate,Homo sapiens,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL619583,,BAO_0000219,A549,80682.0,,,N,6366.0,17380.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,
9606.0,1.0,,F,,,,CHEMBL876502,,BAO_0000219,A549,80682.0,,,N,6367.0,17380.0,1.0,646.0,Intermediate,Homo sapiens,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,
9606.0,1.0,,F,,,,CHEMBL619584,,BAO_0000219,A549,80682.0,,,N,6368.0,1903.0,1.0,646.0,Intermediate,Homo sapiens,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,
9606.0,1.0,,F,,,,CHEMBL619585,,BAO_0000219,A549,80682.0,,,N,6369.0,3838.0,1.0,646.0,Intermediate,Homo sapiens,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,
9606.0,1.0,,F,,,,CHEMBL619586,,BAO_0000219,A549,80682.0,,,N,6370.0,14696.0,1.0,646.0,Intermediate,Homo sapiens,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,
9606.0,1.0,,F,,,,CHEMBL619587,,BAO_0000219,A549,80682.0,,,N,6371.0,3838.0,1.0,646.0,Intermediate,Homo sapiens,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,
9606.0,1.0,,F,,,,CHEMBL619588,,BAO_0000219,A549,80682.0,,,N,6372.0,1522.0,1.0,646.0,Intermediate,Homo sapiens,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,
9606.0,1.0,,F,,,,CHEMBL619589,,BAO_0000219,A549,80682.0,,,N,6373.0,12400.0,1.0,646.0,Intermediate,Homo sapiens,Tested in vitro for cytotoxicity in A549/ATCC cell lines,
9606.0,1.0,,F,,,,CHEMBL619590,,BAO_0000219,A549,80682.0,,,N,6374.0,14696.0,1.0,646.0,Intermediate,Homo sapiens,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,
9606.0,1.0,,F,,,,CHEMBL619591,,BAO_0000219,A549,80682.0,,,N,6375.0,14769.0,1.0,646.0,Intermediate,Homo sapiens,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),
9606.0,1.0,,F,,,,CHEMBL619592,,BAO_0000219,A549,80682.0,,,N,6376.0,14696.0,1.0,646.0,Intermediate,Homo sapiens,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,
9606.0,1.0,,F,,,,CHEMBL619593,,BAO_0000219,A549,80682.0,,,N,6377.0,1888.0,1.0,646.0,Intermediate,Homo sapiens,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,
9606.0,1.0,,F,,,,CHEMBL620217,,BAO_0000219,A549,80682.0,,,N,6378.0,12016.0,1.0,646.0,Intermediate,Homo sapiens,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,
9606.0,1.0,,F,,,,CHEMBL620218,,BAO_0000219,A549,80682.0,,,N,6379.0,6058.0,1.0,646.0,Intermediate,Homo sapiens,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,
9606.0,1.0,,F,,,,CHEMBL620219,,BAO_0000219,A549,80682.0,,,N,6380.0,17708.0,1.0,646.0,Intermediate,Homo sapiens,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,
9606.0,1.0,,F,,,,CHEMBL620220,,BAO_0000219,A549,80682.0,,,N,6381.0,12301.0,1.0,646.0,Intermediate,Homo sapiens,Antitumor activity against A549/ATCC cell line,
9606.0,1.0,,F,,,,CHEMBL625141,,BAO_0000219,A549,80682.0,,,N,6382.0,11970.0,1.0,646.0,Intermediate,Homo sapiens,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,
9606.0,1.0,,F,,,,CHEMBL625142,,BAO_0000219,A549,80682.0,,,N,6383.0,11818.0,1.0,646.0,Expert,Homo sapiens,In vitro cytotoxicity against A549/ATCC cell line.,
9606.0,1.0,,F,,,,CHEMBL625143,,BAO_0000219,A549,80682.0,,,N,6384.0,12400.0,1.0,646.0,Intermediate,Homo sapiens,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,
9606.0,1.0,,F,,,,CHEMBL625144,,BAO_0000219,A549,80682.0,,,N,6385.0,3381.0,1.0,646.0,Intermediate,Homo sapiens,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,
9606.0,1.0,,F,,,,CHEMBL622474,,BAO_0000219,A549,80682.0,,,N,6386.0,17376.0,1.0,646.0,Intermediate,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,
9606.0,1.0,,F,,,,CHEMBL884104,,BAO_0000219,A549,80682.0,,,N,6387.0,10708.0,1.0,646.0,Intermediate,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,
9606.0,0.0,,F,,,,CHEMBL622475,,BAO_0000219,,22226.0,,,U,6388.0,2964.0,1.0,,Autocuration,Homo sapiens,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,
9615.0,0.0,,A,,,,CHEMBL622476,,BAO_0000218,,22224.0,In vivo,,U,6389.0,5005.0,1.0,,Intermediate,Canis lupus familiaris,Compound was tested for oral bioavailability in dogs,
9615.0,1.0,,A,,,,CHEMBL875831,,BAO_0000218,,50588.0,In vivo,,N,6390.0,6229.0,1.0,,Intermediate,Canis lupus familiaris,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,
9615.0,1.0,,A,,,,CHEMBL622477,,BAO_0000218,,50588.0,In vivo,,N,6391.0,6229.0,1.0,,Intermediate,Canis lupus familiaris,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,
9615.0,1.0,,A,,,,CHEMBL622478,,BAO_0000218,,50588.0,In vivo,,N,6392.0,5374.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL623172,,BAO_0000218,,50588.0,In vivo,,N,6393.0,5374.0,1.0,,Intermediate,Canis lupus familiaris,Compound was tested for the oral bioavailability in dog; No availability,
9615.0,1.0,,A,,,,CHEMBL623173,,BAO_0000218,,50588.0,In vivo,,N,6394.0,6265.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),
9615.0,1.0,,A,,,,CHEMBL623174,,BAO_0000218,,50588.0,In vivo,,N,6395.0,5654.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,
9615.0,1.0,,A,,,,CHEMBL623175,,BAO_0000218,,50588.0,In vivo,,N,6396.0,5654.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,
9615.0,1.0,,A,,,,CHEMBL623340,,BAO_0000218,,50588.0,In vivo,,N,6397.0,16456.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),
9615.0,1.0,,A,,,,CHEMBL623341,,BAO_0000218,,50588.0,In vivo,,N,6398.0,5302.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),
9615.0,1.0,,A,,,,CHEMBL623342,,BAO_0000218,,50588.0,In vivo,,N,6399.0,3624.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),
9615.0,1.0,,A,,,,CHEMBL623343,,BAO_0000218,,50588.0,In vivo,,N,6400.0,16452.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability of active FTIs in dogs,
9615.0,1.0,,A,,,,CHEMBL623344,,BAO_0000218,,50588.0,In vivo,,N,6401.0,5802.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),
9615.0,1.0,,A,,,,CHEMBL623345,,BAO_0000218,,50588.0,In vivo,,N,6402.0,3598.0,1.0,,Expert,Canis lupus familiaris,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,
9615.0,1.0,,A,,,,CHEMBL875832,,BAO_0000218,,50588.0,In vivo,,N,6403.0,17839.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL623346,,BAO_0000218,,50588.0,In vivo,,N,6404.0,6762.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL623347,,BAO_0000218,,50588.0,In vivo,,N,6405.0,6821.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL623348,,BAO_0000218,,50588.0,In vivo,,N,6406.0,6821.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability of compound was determined in dog; Not tested,
9615.0,1.0,,A,,,,CHEMBL623349,,BAO_0000218,,50588.0,In vivo,,N,6407.0,5210.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL623350,,BAO_0000218,,50588.0,In vivo,,N,6408.0,6227.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability (10 mg/kg) was determined in dog,
9615.0,1.0,,A,,,,CHEMBL623351,,BAO_0000218,,50588.0,In vivo,,N,6409.0,761.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability,
9615.0,1.0,,A,,,,CHEMBL623352,,BAO_0000218,,50588.0,In vivo,,N,6410.0,761.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),
9615.0,1.0,,A,,,,CHEMBL623353,,BAO_0000218,,50588.0,In vivo,,N,6411.0,761.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability administered in solution in rats,
9615.0,1.0,,A,,,,CHEMBL875833,,BAO_0000218,,50588.0,In vivo,,N,6412.0,16907.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability after 30 mg/kg po dose in Dogs,
9615.0,1.0,,A,,,,CHEMBL623354,,BAO_0000218,,50588.0,In vivo,,N,6413.0,5474.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability at a dose of 1 mg/kg in dogs,
9615.0,1.0,,A,,,,CHEMBL623355,,BAO_0000218,,50588.0,In vivo,,N,6414.0,6535.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 1 mg/kg p.o.),
9615.0,1.0,,A,,,,CHEMBL623356,,BAO_0000218,,50588.0,In vivo,,N,6415.0,6535.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in Dog; ND = not determined,
9615.0,1.0,,A,,,,CHEMBL623357,,BAO_0000218,,50588.0,In vivo,,N,6416.0,3352.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL623358,,BAO_0000218,,50588.0,In vivo,,N,6417.0,6168.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL623359,,BAO_0000218,,50588.0,In vivo,,N,6418.0,5988.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL623360,,BAO_0000218,,50588.0,In vivo,,N,6419.0,4942.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL623361,,BAO_0000218,,50588.0,In vivo,,N,6420.0,4942.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dogs; No data,
9615.0,1.0,,A,,,,CHEMBL623362,,BAO_0000218,,50588.0,In vivo,,N,6421.0,14541.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability measured in dogs,
9615.0,1.0,,A,,,,CHEMBL623363,,BAO_0000218,,50588.0,In vivo,,N,6422.0,4449.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL623364,,BAO_0000218,,50588.0,In vivo,,N,6423.0,6057.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability was calculated in dog,
9615.0,1.0,,A,,,,CHEMBL875834,,BAO_0000218,,50588.0,In vivo,,N,6424.0,5600.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability after 0.3 mg/kg po administration in dog,
9615.0,1.0,,A,,,,CHEMBL623365,,BAO_0000218,,50588.0,In vivo,,N,6425.0,5542.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (i.v. dosing),
9615.0,1.0,,A,,,,CHEMBL623366,,BAO_0000218,,50588.0,In vivo,,N,6426.0,5542.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL623367,,BAO_0000218,,50588.0,In vivo,,N,6427.0,5546.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,
9615.0,1.0,,A,,,,CHEMBL623368,,BAO_0000218,,50588.0,In vivo,,N,6428.0,4514.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in Beagle dogs,
9615.0,1.0,,A,,,,CHEMBL623369,,BAO_0000218,,50588.0,In vivo,,N,6429.0,3624.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL623370,,BAO_0000218,,50588.0,In vivo,,N,6430.0,3854.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL623371,,BAO_0000218,,50588.0,In vivo,,N,6431.0,5836.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL623372,,BAO_0000218,,50588.0,In vivo,,N,6432.0,5940.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621351,,BAO_0000218,,50588.0,In vivo,,N,6433.0,6168.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621352,,BAO_0000218,,50588.0,In vivo,,N,6434.0,6227.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621353,,BAO_0000218,,50588.0,In vivo,,N,6435.0,6251.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621354,,BAO_0000218,,50588.0,In vivo,,N,6436.0,6448.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621355,,BAO_0000218,,50588.0,In vivo,,N,6437.0,6647.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621356,,BAO_0000218,,50588.0,In vivo,,N,6438.0,5940.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621357,,BAO_0000218,,50588.0,In vivo,,N,6439.0,933.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621358,,BAO_0000218,,50588.0,In vivo,,N,6440.0,5210.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621359,,BAO_0000218,,50588.0,In vivo,,N,6441.0,6642.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),
9615.0,1.0,,A,,,,CHEMBL621360,,BAO_0000218,,50588.0,In vivo,,N,6442.0,6641.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),
9615.0,1.0,,A,,,,CHEMBL621361,,BAO_0000218,,50588.0,In vivo,,N,6443.0,6642.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),
9615.0,1.0,,A,,,,CHEMBL621362,,BAO_0000218,,50588.0,In vivo,,N,6444.0,5472.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621363,,BAO_0000218,,50588.0,In vivo,,N,6445.0,5985.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621364,,BAO_0000218,,50588.0,In vivo,,N,6446.0,15660.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621166,,BAO_0000218,,50588.0,In vivo,,N,6447.0,5530.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),
9615.0,1.0,,A,,,,CHEMBL621167,,BAO_0000218,,50588.0,In vivo,,N,6448.0,5530.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 1 mg/kg i.v.),
9615.0,1.0,,A,,,,CHEMBL621168,,BAO_0000218,,50588.0,In vivo,,N,6449.0,6305.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability (F) in dogs,
9615.0,1.0,,A,,,,CHEMBL621169,,BAO_0000218,,50588.0,In vivo,,N,6450.0,5210.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL875950,,BAO_0000218,,50588.0,In vivo,,N,6451.0,5238.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL621170,,BAO_0000218,,50588.0,In vivo,,N,6452.0,5668.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),
9615.0,1.0,,A,,,,CHEMBL621171,,BAO_0000218,,50588.0,In vivo,,N,6453.0,5668.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability after peroral administration at 5 mpk in Dog,
9615.0,1.0,,A,,,,CHEMBL621172,,BAO_0000218,,50588.0,In vivo,,N,6454.0,5668.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),
9615.0,1.0,,A,,,,CHEMBL621173,,BAO_0000218,,50588.0,In vivo,,N,6455.0,6084.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),
10090.0,1.0,,A,,,2113.0,CHEMBL621174,,BAO_0000218,CCRF S-180,50594.0,,,N,6456.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL621175,,BAO_0000218,CCRF S-180,50594.0,,,N,6457.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,Kidney
10090.0,1.0,,A,,,2107.0,CHEMBL621176,,BAO_0000218,CCRF S-180,50594.0,,,N,6458.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL621177,,BAO_0000218,CCRF S-180,50594.0,,,N,6459.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL621178,,BAO_0000218,CCRF S-180,50594.0,,,N,6460.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL621179,,BAO_0000218,CCRF S-180,50594.0,,,N,6461.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL621180,,BAO_0000218,CCRF S-180,50594.0,,,N,6462.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,Liver
10090.0,1.0,,A,,,2048.0,CHEMBL875951,,BAO_0000218,CCRF S-180,50594.0,,,N,6463.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL621181,,BAO_0000218,CCRF S-180,50594.0,,,N,6464.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL621182,,BAO_0000218,CCRF S-180,50594.0,,,N,6465.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL621183,,BAO_0000218,CCRF S-180,50594.0,,,N,6466.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL621184,,BAO_0000218,CCRF S-180,50594.0,,,N,6467.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,Lung
10090.0,1.0,,A,,,,CHEMBL621185,,BAO_0000218,CCRF S-180,50594.0,,,N,6468.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,
10090.0,1.0,,A,,,,CHEMBL621186,,BAO_0000218,CCRF S-180,50594.0,,,N,6469.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,
10090.0,1.0,,A,,,,CHEMBL621187,,BAO_0000218,CCRF S-180,50594.0,,,N,6470.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,
10090.0,1.0,,A,,,,CHEMBL621188,,BAO_0000218,CCRF S-180,50594.0,,,N,6471.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,
10090.0,1.0,,A,,,,CHEMBL621189,,BAO_0000218,CCRF S-180,50594.0,,,N,6472.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,
10090.0,1.0,,A,,,2106.0,CHEMBL621190,,BAO_0000218,CCRF S-180,50594.0,,,N,6473.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,Spleen
10090.0,1.0,,A,,,2106.0,CHEMBL618520,,BAO_0000218,CCRF S-180,50594.0,,,N,6474.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,Spleen
10090.0,1.0,,A,,,2106.0,CHEMBL621739,,BAO_0000218,CCRF S-180,50594.0,,,N,6475.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,Spleen
10090.0,1.0,,A,,,2106.0,CHEMBL621740,,BAO_0000218,CCRF S-180,50594.0,,,N,6476.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,Spleen
10090.0,1.0,,A,,,2106.0,CHEMBL621741,,BAO_0000218,CCRF S-180,50594.0,,,N,6477.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,Spleen
10090.0,1.0,,A,,,,CHEMBL621742,,BAO_0000218,CCRF S-180,50594.0,,,N,6478.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,
10090.0,1.0,,A,,,,CHEMBL621743,,BAO_0000218,CCRF S-180,50594.0,,,N,6479.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,
10090.0,1.0,,A,,,,CHEMBL621744,,BAO_0000218,CCRF S-180,50594.0,,,N,6480.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,
10090.0,1.0,,A,,,,CHEMBL621745,,BAO_0000218,CCRF S-180,50594.0,,,N,6481.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,
10090.0,1.0,,A,,,,CHEMBL621746,,BAO_0000218,CCRF S-180,50594.0,,,N,6482.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,
10090.0,1.0,,A,,,,CHEMBL621747,,BAO_0000218,CCRF S-180,50594.0,,,N,6483.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,
10090.0,1.0,,A,,,,CHEMBL621748,,BAO_0000218,CCRF S-180,50594.0,,,N,6484.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,
10090.0,1.0,,A,,,,CHEMBL621749,,BAO_0000218,CCRF S-180,50594.0,,,N,6485.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,
10090.0,1.0,,A,,,,CHEMBL621750,,BAO_0000218,CCRF S-180,50594.0,,,N,6486.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,
10090.0,1.0,,A,,,,CHEMBL621751,,BAO_0000218,CCRF S-180,50594.0,,,N,6487.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,
10090.0,1.0,,A,,,948.0,CHEMBL621752,,BAO_0000218,CCRF S-180,50594.0,,,N,6488.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,Heart
10090.0,1.0,,A,,,948.0,CHEMBL621753,,BAO_0000218,CCRF S-180,50594.0,,,N,6489.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,Heart
10090.0,1.0,,A,,,948.0,CHEMBL875955,,BAO_0000218,CCRF S-180,50594.0,,,N,6490.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,Heart
10090.0,1.0,,A,,,948.0,CHEMBL621754,,BAO_0000218,CCRF S-180,50594.0,,,N,6491.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,Heart
10090.0,1.0,,A,,,948.0,CHEMBL621755,,BAO_0000218,CCRF S-180,50594.0,,,N,6492.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,Heart
10090.0,1.0,,A,,,2107.0,CHEMBL621756,,BAO_0000218,CCRF S-180,50594.0,,,N,6493.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL624199,,BAO_0000218,CCRF S-180,50594.0,,,N,6494.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL624200,,BAO_0000218,CCRF S-180,50594.0,,,N,6495.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL624375,,BAO_0000218,CCRF S-180,50594.0,,,N,6496.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL624376,,BAO_0000218,CCRF S-180,50594.0,,,N,6497.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,Liver
10090.0,1.0,,A,,,2048.0,CHEMBL624377,,BAO_0000218,CCRF S-180,50594.0,,,N,6498.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL624378,,BAO_0000218,CCRF S-180,50594.0,,,N,6499.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,Lung
107673.0,1.0,,F,,,,CHEMBL857901,,BAO_0000218,,50067.0,,,N,6500.0,12269.0,1.0,,Intermediate,aeinetobacter anitrotap,Compound tested for the antimicrobial activity against Acinetobacter anitratus,
107673.0,1.0,,F,,,,CHEMBL875274,,BAO_0000218,,50067.0,,,N,6501.0,12269.0,1.0,,Intermediate,Acinetobacter calcoaceticus subsp. anitratus,Compound tested for the antimicrobial activity against Acinetobacter anitratus,
107673.0,1.0,,F,,,,CHEMBL624379,,BAO_0000218,,50067.0,,,N,6502.0,12269.0,1.0,,Intermediate,Acinetobacter calcoaceticus subsp. anitratus,Compound tested for the antimicrobial activity against Acinetobacter anitratus,
107673.0,1.0,,F,,,,CHEMBL624380,,BAO_0000218,,50067.0,,,N,6503.0,12269.0,1.0,,Intermediate,aeinetobacter anitrotap,Compound tested for the antimicrobial activity against Acinetobacter anitratus,
471.0,1.0,,F,,,,CHEMBL624381,,BAO_0000218,,50192.0,,,N,6504.0,10624.0,1.0,,Intermediate,Acinetobacter calcoaceticus,Activity against Acinetobacter calcoaceticus (AC54),
28377.0,1.0,,F,,,,CHEMBL624382,,BAO_0000218,,50714.0,,,N,6505.0,17216.0,1.0,,Intermediate,Anolis carolinensis,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,
28377.0,1.0,,F,,,,CHEMBL624383,,BAO_0000218,,50714.0,,,N,6506.0,17216.0,1.0,,Intermediate,Anolis carolinensis,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,
1655.0,1.0,,F,,,,CHEMBL624384,,BAO_0000218,,50296.0,,,N,6507.0,9560.0,1.0,,Intermediate,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii 631,
1655.0,1.0,,F,,,,CHEMBL624385,,BAO_0000218,,50296.0,,,N,6508.0,9560.0,1.0,,Intermediate,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii B74,
1655.0,1.0,,F,,,,CHEMBL624386,,BAO_0000218,,50296.0,,,N,6509.0,9560.0,1.0,,Intermediate,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii N/3,
1655.0,1.0,,F,,,,CHEMBL624387,,BAO_0000218,,50296.0,,,N,6510.0,9560.0,1.0,,Intermediate,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii N/9,
1655.0,1.0,,F,,,,CHEMBL624388,,BAO_0000218,,50296.0,,,N,6511.0,9560.0,1.0,,Intermediate,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii 631,
1655.0,1.0,,F,,,,CHEMBL624389,,BAO_0000218,,50296.0,,,N,6512.0,9560.0,1.0,,Intermediate,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii N/9,
1655.0,1.0,,F,,,,CHEMBL624390,,BAO_0000218,,50296.0,,,N,6513.0,9560.0,1.0,,Intermediate,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii B74,
1655.0,1.0,,F,,,,CHEMBL875275,,BAO_0000218,,50296.0,,,N,6514.0,9560.0,1.0,,Intermediate,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii N/3,
85549.0,1.0,,F,,,,CHEMBL624391,,BAO_0000218,,50056.0,,,N,6515.0,114.0,1.0,,Intermediate,Artemia salina,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,
85549.0,1.0,,F,,,,CHEMBL623636,,BAO_0000218,,50056.0,,,N,6516.0,114.0,1.0,,Intermediate,Artemia salina,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",
6253.0,1.0,,F,,,,CHEMBL623637,,BAO_0000218,,50532.0,,,N,6517.0,10841.0,1.0,,Intermediate,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,
6253.0,1.0,,F,,,,CHEMBL623638,,BAO_0000218,,50532.0,,,N,6518.0,10841.0,1.0,,Intermediate,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,
6253.0,1.0,,F,,,,CHEMBL623639,,BAO_0000218,,50532.0,,,N,6519.0,10841.0,1.0,,Intermediate,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,
6253.0,1.0,,F,,,,CHEMBL623640,,BAO_0000218,,50532.0,,,N,6520.0,10841.0,1.0,,Intermediate,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,
6253.0,1.0,,F,,,,CHEMBL623641,,BAO_0000218,,50532.0,,,N,6521.0,10841.0,1.0,,Intermediate,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,
6253.0,1.0,,F,,,,CHEMBL623642,,BAO_0000218,,50532.0,,,N,6522.0,10841.0,1.0,,Intermediate,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,
6253.0,1.0,,F,,,,CHEMBL623643,,BAO_0000218,,50532.0,,,N,6523.0,10841.0,1.0,,Intermediate,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,
6253.0,1.0,,F,,,,CHEMBL623644,,BAO_0000218,,50532.0,,,N,6524.0,10841.0,1.0,,Intermediate,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,
6253.0,1.0,,F,,,,CHEMBL623645,,BAO_0000218,,50532.0,,,N,6525.0,10841.0,1.0,,Intermediate,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,
6253.0,1.0,,F,,,,CHEMBL623646,,BAO_0000218,,50532.0,,,N,6526.0,10841.0,1.0,,Intermediate,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,
6253.0,1.0,,F,,,,CHEMBL623647,,BAO_0000218,,50532.0,,,N,6527.0,10841.0,1.0,,Intermediate,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,
6253.0,1.0,,F,,,,CHEMBL623648,,BAO_0000218,,50532.0,,,N,6528.0,10841.0,1.0,,Intermediate,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,
1656.0,1.0,,F,,,,CHEMBL623649,,BAO_0000218,,50366.0,,,N,6529.0,8117.0,1.0,,Intermediate,Actinomyces viscosus,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,
1656.0,1.0,,F,,,,CHEMBL623650,,BAO_0000218,,50366.0,,,N,6530.0,8117.0,1.0,,Intermediate,Actinomyces viscosus,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,
1656.0,1.0,,F,,,,CHEMBL623651,,BAO_0000218,,50366.0,,,N,6531.0,9560.0,1.0,,Intermediate,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus 8A06,
1656.0,1.0,,F,,,,CHEMBL623652,,BAO_0000218,,50366.0,,,N,6532.0,9560.0,1.0,,Expert,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus M-100,
1656.0,1.0,,F,,,,CHEMBL623653,,BAO_0000218,,50366.0,,,N,6533.0,9560.0,1.0,,Intermediate,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus M-626,
1656.0,1.0,,F,,,,CHEMBL623654,,BAO_0000218,,50366.0,,,N,6534.0,9560.0,1.0,,Intermediate,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus T14V,
1656.0,1.0,,F,,,,CHEMBL623655,,BAO_0000218,,50366.0,,,N,6535.0,9560.0,1.0,,Intermediate,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus 8A06,
1656.0,1.0,,F,,,,CHEMBL623656,,BAO_0000218,,50366.0,,,N,6536.0,9560.0,1.0,,Intermediate,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus M-100,
1656.0,1.0,,F,,,,CHEMBL623657,,BAO_0000218,,50366.0,,,N,6537.0,9560.0,1.0,,Expert,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,
1656.0,1.0,,F,,,,CHEMBL623658,,BAO_0000218,,50366.0,,,N,6538.0,9560.0,1.0,,Intermediate,Actinomyces viscosus,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",
1656.0,1.0,,F,,,,CHEMBL623659,,BAO_0000218,,50366.0,,,N,6539.0,9560.0,1.0,,Intermediate,Actinomyces viscosus,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",
1656.0,1.0,,F,,,,CHEMBL623660,,BAO_0000218,,50366.0,,,N,6540.0,9560.0,1.0,,Intermediate,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus 626,
1656.0,1.0,,F,,,,CHEMBL623661,,BAO_0000218,,50366.0,,,N,6541.0,9560.0,1.0,,Intermediate,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus T14V,
6277.0,1.0,,F,,,,CHEMBL875281,,BAO_0000218,,50535.0,,,N,6542.0,10986.0,1.0,,Intermediate,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,
6277.0,1.0,,F,,,,CHEMBL623662,,BAO_0000218,,50535.0,,,N,6543.0,10986.0,1.0,,Intermediate,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,
6277.0,1.0,,F,,,,CHEMBL623663,,BAO_0000218,,50535.0,,,N,6544.0,10986.0,1.0,,Intermediate,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,
6277.0,1.0,,F,,,,CHEMBL623664,,BAO_0000218,,50535.0,,,N,6545.0,10986.0,1.0,,Intermediate,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,
6277.0,1.0,,F,,,,CHEMBL623665,,BAO_0000218,,50535.0,,,N,6546.0,10986.0,1.0,,Intermediate,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,
9606.0,1.0,,F,,,,CHEMBL621856,,BAO_0000219,A673,80023.0,,,N,6547.0,10708.0,1.0,165.0,Intermediate,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,
9606.0,1.0,,F,,,,CHEMBL620432,,BAO_0000219,A704,80661.0,,,N,6548.0,10708.0,1.0,645.0,Intermediate,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,
10116.0,0.0,,F,,,,CHEMBL620433,,BAO_0000219,,22226.0,,,U,6549.0,416.0,1.0,,Autocuration,Rattus norvegicus,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,
10090.0,1.0,,F,,,,CHEMBL620434,,BAO_0000219,A9,80024.0,,,N,6550.0,14354.0,1.0,625.0,Intermediate,Mus musculus,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,
10090.0,1.0,,F,,,,CHEMBL620435,,BAO_0000219,A9,80024.0,,,N,6551.0,14354.0,1.0,625.0,Intermediate,Mus musculus,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,
9606.0,1.0,,F,,,,CHEMBL620436,,BAO_0000219,A9,80024.0,,,N,6552.0,5116.0,1.0,625.0,Intermediate,Homo sapiens,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,
9606.0,1.0,,F,,,,CHEMBL876597,,BAO_0000219,A9,80024.0,,,N,6553.0,5116.0,1.0,625.0,Intermediate,Homo sapiens,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,
9606.0,1.0,,F,,,,CHEMBL620437,,BAO_0000219,Human ovarian carcinoma cell line,81037.0,,,N,6554.0,15694.0,1.0,874.0,Expert,Homo sapiens,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,
10090.0,1.0,,F,,,,CHEMBL620438,,BAO_0000219,A9,80024.0,,,N,6555.0,13038.0,1.0,625.0,Expert,Mus musculus,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",
10090.0,1.0,,F,,,,CHEMBL620439,,BAO_0000219,A9,80024.0,,,N,6556.0,13038.0,1.0,625.0,Expert,Mus musculus,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,
10090.0,1.0,,F,,,,CHEMBL619657,,BAO_0000219,A9,80024.0,,,N,6557.0,10923.0,1.0,625.0,Expert,Mus musculus,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,
10090.0,1.0,,F,,,,CHEMBL619658,,BAO_0000219,A9,80024.0,,,N,6558.0,10923.0,1.0,625.0,Intermediate,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,
10090.0,1.0,,F,,,,CHEMBL619659,,BAO_0000219,A9,80024.0,,,N,6559.0,10923.0,1.0,625.0,Intermediate,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,
,8.0,,F,,,,CHEMBL619660,,BAO_0000019,,10649.0,,,H,6560.0,10923.0,1.0,,Expert,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",
10090.0,1.0,,F,,,,CHEMBL619661,,BAO_0000219,A9,80024.0,,,N,6561.0,10923.0,1.0,625.0,Intermediate,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,
10090.0,1.0,,F,,,,CHEMBL619662,,BAO_0000219,A9,80024.0,,,N,6562.0,10923.0,1.0,625.0,Intermediate,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,
10029.0,1.0,,F,,,,CHEMBL619663,,BAO_0000219,AA6,80663.0,,,N,6563.0,8158.0,1.0,975.0,Intermediate,Cricetulus griseus,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,
9606.0,0.0,,F,,,,CHEMBL619664,,BAO_0000219,,22226.0,,,U,6564.0,15494.0,1.0,,Autocuration,Homo sapiens,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,
9606.0,0.0,,F,,,,CHEMBL619665,,BAO_0000219,,22226.0,,,U,6565.0,15494.0,1.0,,Autocuration,Homo sapiens,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",
9606.0,1.0,,F,,,,CHEMBL883244,,BAO_0000219,AA5,80662.0,,,N,6566.0,12348.0,1.0,974.0,Intermediate,Homo sapiens,Anti -HIV activity was measured against AA5/HIV-1(IIIB),
9606.0,1.0,,F,,,,CHEMBL884011,,BAO_0000219,AA5,80662.0,,,N,6567.0,12348.0,1.0,974.0,Intermediate,Homo sapiens,Cytotoxicity was measured against AA5/HIV-1(IIIB),
9606.0,1.0,,F,,,,CHEMBL619666,,BAO_0000219,AA5,80662.0,,,N,6568.0,2726.0,1.0,974.0,Intermediate,Homo sapiens,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,
9606.0,1.0,,F,,,,CHEMBL619667,,BAO_0000219,U-937,80566.0,,,N,6569.0,2726.0,1.0,379.0,Intermediate,Homo sapiens,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,
10029.0,1.0,,F,,,,CHEMBL619668,,BAO_0000219,UV4,80578.0,,,N,6570.0,10747.0,1.0,274.0,Intermediate,Cricetulus griseus,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,
10029.0,1.0,,F,,,,CHEMBL619669,,BAO_0000219,CHO-AA8,80089.0,,,N,6571.0,11005.0,1.0,185.0,Expert,Cricetulus griseus,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",
10029.0,1.0,,F,,,,CHEMBL876608,,BAO_0000219,CHO-AA8,80089.0,,,N,6572.0,12687.0,1.0,185.0,Intermediate,Cricetulus griseus,Average intracellular compound concentration when the hypoxic SER=1.6,
10029.0,1.0,,F,,,,CHEMBL619670,,BAO_0000219,CHO-AA8,80089.0,,,N,6573.0,12687.0,1.0,185.0,Intermediate,Cricetulus griseus,Average intracellular compound concentration when the hypoxic SER=1.6.,
10029.0,1.0,,F,,,,CHEMBL619671,,BAO_0000219,CHO-AA8,80089.0,,,N,6574.0,12687.0,1.0,185.0,Intermediate,Cricetulus griseus,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,
10029.0,1.0,,F,,,,CHEMBL619672,,BAO_0000219,CHO-AA8,80089.0,,,N,6575.0,12687.0,1.0,185.0,Intermediate,Cricetulus griseus,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,
10029.0,1.0,,F,,,,CHEMBL619673,,BAO_0000219,CHO-AA8,80089.0,,,N,6576.0,12687.0,1.0,185.0,Intermediate,Cricetulus griseus,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,
10029.0,1.0,,F,,,,CHEMBL619674,,BAO_0000219,CHO-AA8,80089.0,,,N,6577.0,13436.0,1.0,185.0,Intermediate,Cricetulus griseus,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",
10029.0,1.0,,F,,,,CHEMBL619675,,BAO_0000219,CHO-AA8,80089.0,,,N,6578.0,13435.0,1.0,185.0,Intermediate,Cricetulus griseus,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",
10029.0,1.0,,F,,,,CHEMBL619676,,BAO_0000219,CHO-AA8,80089.0,,,N,6579.0,13302.0,1.0,185.0,Intermediate,Cricetulus griseus,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,
10029.0,1.0,,F,,,,CHEMBL619677,,BAO_0000219,CHO-AA8,80089.0,,,N,6580.0,12687.0,1.0,185.0,Intermediate,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,
10029.0,1.0,,A,,,,CHEMBL619678,,BAO_0000219,CHO-AA8,80089.0,,,N,6581.0,12687.0,1.0,185.0,Intermediate,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,
10029.0,1.0,,A,,,,CHEMBL619679,,BAO_0000219,CHO-AA8,80089.0,,,N,6582.0,12687.0,1.0,185.0,Intermediate,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,
10029.0,1.0,,A,,,,CHEMBL619680,,BAO_0000219,CHO-AA8,80089.0,,,N,6583.0,12878.0,1.0,185.0,Expert,Cricetulus griseus,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,
10029.0,1.0,,A,,,,CHEMBL621457,,BAO_0000219,CHO-AA8,80089.0,,,N,6584.0,12878.0,1.0,185.0,Intermediate,Cricetulus griseus,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,
10029.0,1.0,,F,,,,CHEMBL876609,,BAO_0000219,CHO-AA8,80089.0,,,N,6585.0,14367.0,1.0,185.0,Expert,Cricetulus griseus,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,
10029.0,1.0,,F,,,,CHEMBL621458,,BAO_0000219,CHO-AA8,80089.0,,,N,6586.0,14367.0,1.0,185.0,Intermediate,Cricetulus griseus,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,
36483.0,1.0,,F,,,,CHEMBL621459,,BAO_0000219,CHO-AA8,80089.0,,,N,6587.0,12398.0,1.0,185.0,Expert,hampster,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,
10029.0,1.0,,F,,,,CHEMBL621460,,BAO_0000219,CHO-AA8,80089.0,,,N,6588.0,12878.0,1.0,185.0,Expert,Cricetulus griseus,Aerobic growth inhibition in Chinese hamster cell line AA8,
10029.0,1.0,,F,,,,CHEMBL621461,,BAO_0000219,CHO-AA8,80089.0,,,N,6589.0,13820.0,1.0,185.0,Expert,Cricetulus griseus,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,
10029.0,1.0,,F,,,,CHEMBL621462,,BAO_0000219,CHO-AA8,80089.0,,,N,6590.0,13436.0,1.0,185.0,Expert,Cricetulus griseus,Inhibition of growth under aerobic conditions in AA8 cells,
9615.0,1.0,,A,,,,CHEMBL621463,,BAO_0000218,,50588.0,In vivo,,N,6591.0,6084.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),
9615.0,1.0,,A,,,,CHEMBL621464,,BAO_0000218,,50588.0,In vivo,,N,6592.0,5711.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog at 10 mg/kg of the compound,
9615.0,1.0,,A,,,,CHEMBL621465,,BAO_0000218,,50588.0,In vivo,,N,6593.0,4353.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),
9615.0,1.0,,A,,,,CHEMBL621466,,BAO_0000218,,50588.0,In vivo,,N,6594.0,4353.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),
9615.0,1.0,,A,,,,CHEMBL621467,,BAO_0000218,,50588.0,In vivo,,N,6595.0,17800.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (mongrel),
9615.0,1.0,,A,,,,CHEMBL621468,,BAO_0000218,,50588.0,In vivo,,N,6596.0,3994.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),
9615.0,1.0,,F,,,,CHEMBL876734,,BAO_0000218,,50588.0,In vivo,,N,6597.0,3994.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),
9615.0,1.0,,A,,,,CHEMBL618476,,BAO_0000218,,50588.0,In vivo,,N,6598.0,5145.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL618477,,BAO_0000218,,50588.0,In vivo,,N,6599.0,16452.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),
9615.0,1.0,,A,,,,CHEMBL618478,,BAO_0000218,,50588.0,In vivo,,N,6600.0,16452.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),
9615.0,1.0,,A,,,,CHEMBL618479,,BAO_0000218,,50588.0,In vivo,,N,6601.0,5983.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,
9615.0,1.0,,A,,,,CHEMBL618480,,BAO_0000218,,50588.0,In vivo,,N,6602.0,4273.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL618481,,BAO_0000218,,50588.0,In vivo,,N,6603.0,12500.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog (dose 3-10 mg/kg),
9615.0,1.0,,A,,,1969.0,CHEMBL618482,,BAO_0000218,,50588.0,In vivo,,N,6604.0,12500.0,1.0,,Intermediate,Canis lupus familiaris,The compound was tested for bioavailability of compound in plasma of dog; Complete,Plasma
9615.0,1.0,,A,,,,CHEMBL618483,,BAO_0000218,,50588.0,In vivo,,N,6605.0,3639.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL618484,,BAO_0000218,,50588.0,In vivo,,N,6606.0,3880.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL618485,,BAO_0000218,,50588.0,In vivo,,N,6607.0,4838.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL618486,,BAO_0000218,,50588.0,In vivo,,N,6608.0,15600.0,1.0,,Intermediate,Canis lupus familiaris,oral bioavailability was measured in dogs,
9615.0,1.0,,A,,,,CHEMBL618487,,BAO_0000218,,50588.0,,,N,6609.0,17248.0,1.0,,Intermediate,Canis lupus familiaris,Compound was tested for plasma protein binding in dog; Not determined,
9615.0,1.0,,A,,,,CHEMBL618488,,BAO_0000218,,50588.0,,,N,6610.0,17248.0,1.0,,Intermediate,Canis lupus familiaris,Compound was tested for plasma protein binding of dog,
9615.0,1.0,,A,,,,CHEMBL876735,,BAO_0000218,,50588.0,,,N,6611.0,17248.0,1.0,,Intermediate,Canis lupus familiaris,Compound was tested for plasma protein binding of dog; Not determined,
9615.0,1.0,,A,,,,CHEMBL618489,,BAO_0000218,,50588.0,,,N,6612.0,17443.0,1.0,,Intermediate,Canis lupus familiaris,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,
9615.0,1.0,,A,,,,CHEMBL618490,,BAO_0000218,,50588.0,In vivo,,N,6613.0,4186.0,1.0,,Intermediate,Canis lupus familiaris,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,
9615.0,1.0,,A,,,,CHEMBL618491,,BAO_0000218,,50588.0,,,N,6614.0,3749.0,1.0,,Intermediate,Canis lupus familiaris,Half life was determined,
9615.0,1.0,,A,,,,CHEMBL618492,,BAO_0000218,,50588.0,In vivo,,N,6615.0,3249.0,1.0,,Intermediate,Canis lupus familiaris,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,
9615.0,1.0,,A,,,,CHEMBL873354,,BAO_0000218,,50588.0,,,N,6616.0,3022.0,1.0,,Intermediate,Canis lupus familiaris,Half life was evaluated in dog,
9615.0,1.0,,A,,,,CHEMBL618493,,BAO_0000218,,50588.0,,,N,6617.0,3749.0,1.0,,Intermediate,Canis lupus familiaris,Half life was determined,
9615.0,1.0,,A,,,,CHEMBL618494,,BAO_0000218,,50588.0,In vivo,,N,6618.0,2517.0,1.0,,Intermediate,Canis lupus familiaris,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),
9615.0,1.0,,A,,,948.0,CHEMBL618495,,BAO_0000218,,50588.0,In vivo,,N,6619.0,2517.0,1.0,,Intermediate,Canis lupus familiaris,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),Heart
9615.0,1.0,,A,,,2113.0,CHEMBL618496,,BAO_0000218,,50588.0,In vivo,,N,6620.0,2517.0,1.0,,Intermediate,Canis lupus familiaris,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),Kidney
9615.0,1.0,,A,,,2107.0,CHEMBL618497,,BAO_0000218,,50588.0,In vivo,,N,6621.0,2517.0,1.0,,Intermediate,Canis lupus familiaris,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),Liver
9615.0,1.0,,A,,,2048.0,CHEMBL618498,,BAO_0000218,,50588.0,In vivo,,N,6622.0,2517.0,1.0,,Intermediate,Canis lupus familiaris,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),Lung
9615.0,1.0,,A,,,2106.0,CHEMBL618499,,BAO_0000218,,50588.0,In vivo,,N,6623.0,2517.0,1.0,,Intermediate,Canis lupus familiaris,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),Spleen
9615.0,1.0,,A,,,,CHEMBL876736,,BAO_0000218,,50588.0,,,N,6624.0,3639.0,1.0,,Intermediate,Canis lupus familiaris,LogP in dog,
9615.0,1.0,,A,,,,CHEMBL618500,,BAO_0000218,,50588.0,,,N,6625.0,6227.0,1.0,,Intermediate,Canis lupus familiaris,Partition coefficient (logP),
9615.0,1.0,,A,,,,CHEMBL857831,,BAO_0000218,,50588.0,,,N,6626.0,6227.0,1.0,,Intermediate,Canis lupus familiaris,Partition coefficient in dog,
9615.0,1.0,,A,,,,CHEMBL618501,,BAO_0000218,,50588.0,In vivo,,N,6627.0,17764.0,1.0,,Intermediate,Canis lupus familiaris,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,
9615.0,1.0,,A,,,,CHEMBL618502,,BAO_0000218,,50588.0,In vivo,,N,6628.0,4809.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),
9615.0,1.0,,A,,,,CHEMBL618503,,BAO_0000218,,50588.0,,,N,6629.0,5600.0,1.0,,Intermediate,Canis lupus familiaris,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,
9615.0,1.0,,A,,,,CHEMBL618504,,BAO_0000218,,50588.0,,,N,6630.0,14294.0,1.0,,Intermediate,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),
9615.0,1.0,,A,,,,CHEMBL618505,,BAO_0000218,,50588.0,,,N,6631.0,14294.0,1.0,,Intermediate,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),
9615.0,1.0,,A,,,,CHEMBL618506,,BAO_0000218,,50588.0,,,N,6632.0,14294.0,1.0,,Intermediate,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes; Trace,
9615.0,1.0,,A,,,2107.0,CHEMBL618507,,BAO_0000218,,50588.0,,,N,6633.0,6251.0,1.0,,Intermediate,Canis lupus familiaris,In vitro metabolic potential in dog liver microsomes,Liver
9615.0,1.0,,A,,,,CHEMBL876737,,BAO_0000218,,50588.0,In vivo,,N,6634.0,3748.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,
9615.0,1.0,,A,,,,CHEMBL618508,,BAO_0000218,,50588.0,In vivo,,N,6635.0,2713.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL618509,,BAO_0000218,,50588.0,In vivo,,N,6636.0,6512.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL618510,,BAO_0000218,,50588.0,In vivo,,N,6637.0,6679.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,
9615.0,1.0,,A,,,,CHEMBL618511,,BAO_0000218,,50588.0,In vivo,,N,6638.0,3749.0,1.0,,Intermediate,Canis lupus familiaris,The compound was tested for bioavailability in dogs,
9615.0,1.0,,A,,,,CHEMBL618512,,BAO_0000218,,50588.0,In vivo,,N,6639.0,3749.0,1.0,,Intermediate,Canis lupus familiaris,The compound was tested for oral bioavailability in dogs,
9615.0,1.0,,A,,,,CHEMBL618513,,BAO_0000218,,50588.0,In vivo,,N,6640.0,6742.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog,
9615.0,1.0,,A,,,,CHEMBL618514,,BAO_0000218,,50588.0,,,N,6641.0,6227.0,1.0,,Intermediate,Canis lupus familiaris,Compound was tested for percent protein binding (PB) in dog,
9615.0,1.0,,A,,,,CHEMBL620052,,BAO_0000218,,50588.0,,,N,6642.0,6874.0,1.0,,Intermediate,Canis lupus familiaris,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,
9615.0,1.0,,A,,,1969.0,CHEMBL620053,,BAO_0000218,,50588.0,In vivo,,N,6643.0,2877.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for plasma clearance.,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL620054,,BAO_0000218,,50588.0,In vivo,,N,6644.0,12500.0,1.0,,Intermediate,Canis lupus familiaris,The compound was tested for plasma clearance in dog,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL620055,,BAO_0000218,,50588.0,In vivo,,N,6645.0,12500.0,1.0,,Intermediate,Canis lupus familiaris,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,Plasma
9615.0,1.0,,A,,,,CHEMBL620056,,BAO_0000218,,50588.0,,,N,6646.0,4709.0,1.0,,Intermediate,Canis lupus familiaris,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,
9615.0,1.0,,A,,,2107.0,CHEMBL620057,,BAO_0000218,,50588.0,,,N,6647.0,5542.0,1.0,,Intermediate,Canis lupus familiaris,In vitro relative rate of metabolism was determined in dog liver microsomes,Liver
9615.0,1.0,,A,,,,CHEMBL618939,,BAO_0000218,,50588.0,In vivo,,N,6648.0,17594.0,1.0,,Intermediate,Canis lupus familiaris,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,
9615.0,1.0,,A,,,,CHEMBL618940,,BAO_0000218,,50588.0,In vivo,,N,6649.0,2652.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,
9615.0,1.0,,A,,,,CHEMBL618941,,BAO_0000218,,50588.0,In vivo,,N,6650.0,17764.0,1.0,,Intermediate,Canis lupus familiaris,Half life after intravenous administration in dogs at 1.2 uM/kg,
10090.0,1.0,,A,,,2048.0,CHEMBL624473,,BAO_0000218,CCRF S-180,50594.0,,,N,6651.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL624474,,BAO_0000218,CCRF S-180,50594.0,,,N,6652.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL624475,,BAO_0000218,CCRF S-180,50594.0,,,N,6653.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,Lung
10090.0,1.0,,A,,,,CHEMBL624476,,BAO_0000218,CCRF S-180,50594.0,,,N,6654.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,
10090.0,1.0,,A,,,,CHEMBL623478,,BAO_0000218,CCRF S-180,50594.0,,,N,6655.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,
10090.0,1.0,,A,,,,CHEMBL623479,,BAO_0000218,CCRF S-180,50594.0,,,N,6656.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,
10090.0,1.0,,A,,,,CHEMBL623480,,BAO_0000218,CCRF S-180,50594.0,,,N,6657.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,
10090.0,1.0,,A,,,,CHEMBL623481,,BAO_0000218,CCRF S-180,50594.0,,,N,6658.0,6599.0,1.0,42.0,Intermediate,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,
10090.0,1.0,,A,,,955.0,CHEMBL623482,,BAO_0000218,,50594.0,,,N,6659.0,17641.0,1.0,,Intermediate,Mus musculus,C2 in brain of mice at the oral dose of 50 mg/kg,Brain
10090.0,1.0,,A,,,2113.0,CHEMBL623483,,BAO_0000218,,50594.0,,,N,6660.0,17641.0,1.0,,Intermediate,Mus musculus,C2 in kidney of mice at the oral dose of 50 mg/kg,Kidney
10090.0,1.0,,A,,,2107.0,CHEMBL623484,,BAO_0000218,,50594.0,,,N,6661.0,17641.0,1.0,,Intermediate,Mus musculus,C2 in liver of mice at the oral dose of 50 mg/kg,Liver
10090.0,1.0,,A,,,2048.0,CHEMBL623485,,BAO_0000218,,50594.0,,,N,6662.0,17641.0,1.0,,Intermediate,Mus musculus,C2 in lungs of mice at the oral dose of 50 mg/kg,Lung
10090.0,1.0,,A,,,2106.0,CHEMBL623486,,BAO_0000218,,50594.0,,,N,6663.0,17641.0,1.0,,Intermediate,Mus musculus,C2 in spleen of mice at the oral dose of 50 mg/kg,Spleen
10090.0,1.0,,A,,,,CHEMBL623487,,BAO_0000218,,50594.0,In vivo,,N,6664.0,17852.0,1.0,,Intermediate,Mus musculus,Plasma clearance in mouse,
10090.0,1.0,,A,,,,CHEMBL623488,,BAO_0000218,,50594.0,In vivo,,N,6665.0,17764.0,1.0,,Intermediate,Mus musculus,Clearance of compound after intravenous administration in mice at 24 uM/kg,
10090.0,1.0,,A,,,,CHEMBL623489,,BAO_0000218,,50594.0,In vivo,,N,6666.0,17837.0,1.0,,Intermediate,Mus musculus,Clearance from mouse blood following i.v. administration of 10 mg/kg,
10090.0,1.0,,A,,,,CHEMBL875157,,BAO_0000218,,50594.0,In vivo,,N,6667.0,2675.0,1.0,,Intermediate,Mus musculus,Clearance was evaluated in mice after intravenous administration,
10090.0,1.0,,A,,,,CHEMBL623490,,BAO_0000218,,50594.0,In vivo,,N,6668.0,2675.0,1.0,,Intermediate,Mus musculus,Clearance was evaluated in mice after oral administration,
10090.0,1.0,,A,,,,CHEMBL623491,,BAO_0000218,,50594.0,In vivo,,N,6669.0,4239.0,1.0,,Intermediate,Mus musculus,Pharmacokinetic property (Plasma clearance) was measured in mouse,
10090.0,1.0,,A,,,,CHEMBL623492,,BAO_0000218,,50594.0,In vivo,,N,6670.0,17753.0,1.0,,Intermediate,Mus musculus,Plasma clearance of compound was determined at 40 mg/Kg,
10090.0,1.0,,A,,,,CHEMBL623493,,BAO_0000218,,50594.0,In vivo,,N,6671.0,17753.0,1.0,,Intermediate,Mus musculus,Plasma clearance of at 24 mg/Kg,
10090.0,1.0,,A,,,,CHEMBL623494,,BAO_0000218,,50594.0,In vivo,,N,6672.0,17753.0,1.0,,Intermediate,Mus musculus,Plasma clearance at 24 mg/Kg,
10090.0,1.0,,A,,,,CHEMBL623495,,BAO_0000218,,50594.0,In vivo,,N,6673.0,17753.0,1.0,,Intermediate,Mus musculus,Plasma clearance at 5 mg/Kg,
10090.0,1.0,,A,,,,CHEMBL623496,,BAO_0000218,,50594.0,In vivo,,N,6674.0,5727.0,1.0,,Intermediate,Mus musculus,Plasma clearance in mice,
10090.0,1.0,,A,,,,CHEMBL623497,,BAO_0000218,,50594.0,In vivo,,N,6675.0,2862.0,1.0,,Intermediate,Mus musculus,Plasma clearance value upon iv administration in mouse,
10090.0,1.0,,A,,,1969.0,CHEMBL623498,,BAO_0000218,,50594.0,In vivo,,N,6676.0,5980.0,1.0,,Intermediate,Mus musculus,Total plasma clearance in mice,Plasma
10090.0,1.0,,A,,,,CHEMBL623499,,BAO_0000218,,50594.0,In vivo,,N,6677.0,17592.0,1.0,,Intermediate,Mus musculus,Clearance in mouse,
10090.0,1.0,,A,,,,CHEMBL623500,,BAO_0000218,,50594.0,In vivo,,N,6678.0,17718.0,1.0,,Intermediate,Mus musculus,Clearance value was determined,
10090.0,1.0,,A,,,,CHEMBL623501,,BAO_0000218,,50594.0,In vivo,,N,6679.0,16597.0,1.0,,Intermediate,Mus musculus,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,
,0.0,,P,,,,CHEMBL875158,,BAO_0000100,,22229.0,,,U,6680.0,17384.0,1.0,,Intermediate,,Calculated partition coefficient (clogP),
10090.0,1.0,,A,,,,CHEMBL623502,,BAO_0000218,,50594.0,In vivo,,N,6681.0,6062.0,1.0,,Intermediate,Mus musculus,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,
10090.0,1.0,,A,,,,CHEMBL623503,,BAO_0000218,,50594.0,In vivo,,N,6682.0,17734.0,1.0,,Intermediate,Mus musculus,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,
10090.0,1.0,,A,,,,CHEMBL623504,,BAO_0000218,,50594.0,In vivo,,N,6683.0,6348.0,1.0,,Intermediate,Mus musculus,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,
10090.0,1.0,,A,,,,CHEMBL623505,,BAO_0000218,,50594.0,In vivo,,N,6684.0,5969.0,1.0,,Intermediate,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,
10090.0,1.0,,A,,,,CHEMBL623506,,BAO_0000218,,50594.0,In vivo,,N,6685.0,5969.0,1.0,,Intermediate,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,
10090.0,1.0,,A,,,,CHEMBL623507,,BAO_0000218,,50594.0,In vivo,,N,6686.0,5969.0,1.0,,Intermediate,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,
10090.0,1.0,,A,,,,CHEMBL623508,,BAO_0000218,,50594.0,In vivo,,N,6687.0,16597.0,1.0,,Intermediate,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,
10090.0,1.0,,A,,,,CHEMBL623509,,BAO_0000218,,50594.0,In vivo,,N,6688.0,5781.0,1.0,,Intermediate,Mus musculus,Cmax after oral administration at 30 mg/kg in ICR mouse,
10090.0,1.0,,A,,,,CHEMBL875159,,BAO_0000218,,50594.0,In vivo,,N,6689.0,17764.0,1.0,,Intermediate,Mus musculus,Cmax after peroral administration in mice at 2.4 uM/kg,
10090.0,1.0,,A,,,955.0,CHEMBL623510,,BAO_0000218,,50594.0,In vivo,,N,6690.0,17641.0,1.0,,Intermediate,Mus musculus,Cmax in brain of mice at the oral dose of 50 mg/kg,Brain
10090.0,1.0,,A,,,2113.0,CHEMBL623511,,BAO_0000218,,50594.0,In vivo,,N,6691.0,17641.0,1.0,,Intermediate,Mus musculus,Cmax in kidney of mice at the oral dose of 50 mg/kg,Kidney
10090.0,1.0,,A,,,2107.0,CHEMBL623512,,BAO_0000218,,50594.0,In vivo,,N,6692.0,17641.0,1.0,,Intermediate,Mus musculus,Cmax in liver of mice at the oral dose of 50 mg/kg,Liver
10090.0,1.0,,A,,,2048.0,CHEMBL623513,,BAO_0000218,,50594.0,In vivo,,N,6693.0,17641.0,1.0,,Intermediate,Mus musculus,Cmax in lungs of mice at the oral dose of 50 mg/kg,Lung
10090.0,1.0,,F,,,,CHEMBL623514,,BAO_0000218,,50594.0,In vivo,,N,6694.0,17764.0,1.0,,Intermediate,Mus musculus,Cmax in mice at 18 uM/kg i.p. administration,
10090.0,1.0,,F,,,,CHEMBL622609,,BAO_0000218,,50594.0,In vivo,,N,6695.0,17764.0,1.0,,Intermediate,Mus musculus,Cmax in mice at 23 uM/kg i.v. administration,
10090.0,1.0,,F,,,,CHEMBL622610,,BAO_0000218,,50594.0,In vivo,,N,6696.0,17764.0,1.0,,Intermediate,Mus musculus,Cmax in mice at 24 uM/kg i.p. administration,
10090.0,1.0,,F,,,,CHEMBL621823,,BAO_0000218,,50594.0,In vivo,,N,6697.0,17764.0,1.0,,Intermediate,Mus musculus,Cmax in mice at 25 uM/kg i.p. administration,
10090.0,1.0,,F,,,,CHEMBL621824,,BAO_0000218,,50594.0,In vivo,,N,6698.0,17764.0,1.0,,Intermediate,Mus musculus,Cmax in mice at 26 uM/kg i.p. administration,
10090.0,1.0,,A,,,2106.0,CHEMBL621825,,BAO_0000218,,50594.0,In vivo,,N,6699.0,17641.0,1.0,,Intermediate,Mus musculus,Cmax in spleen of mice at the oral dose of 50 mg/kg,Spleen
10090.0,1.0,,A,,,,CHEMBL621826,,BAO_0000218,,50594.0,In vivo,,N,6700.0,16597.0,1.0,,Intermediate,Mus musculus,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,
10090.0,1.0,,A,,,,CHEMBL621827,,BAO_0000218,,50594.0,In vivo,,N,6701.0,16597.0,1.0,,Intermediate,Mus musculus,Cmax value at a dose of 10 mg/kg peroral administration in mice.,
10090.0,1.0,,A,,,,CHEMBL621828,,BAO_0000218,,50594.0,In vivo,,N,6702.0,5727.0,1.0,,Intermediate,Mus musculus,Cmax value was determined,
10090.0,1.0,,A,,,,CHEMBL621829,,BAO_0000218,,50594.0,In vivo,,N,6703.0,5951.0,1.0,,Intermediate,Mus musculus,Cmax value in IRC mice,
10090.0,1.0,,A,,,,CHEMBL621830,,BAO_0000218,,50594.0,In vivo,,N,6704.0,5506.0,1.0,,Intermediate,Mus musculus,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,
10090.0,1.0,,A,,,,CHEMBL621831,,BAO_0000218,,50594.0,In vivo,,N,6705.0,5506.0,1.0,,Intermediate,Mus musculus,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,
10090.0,1.0,,A,,,1969.0,CHEMBL621832,,BAO_0000218,,50594.0,In vivo,,N,6706.0,14239.0,1.0,,Intermediate,Mus musculus,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL624579,,BAO_0000218,,50594.0,In vivo,,N,6707.0,4890.0,1.0,,Intermediate,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",Plasma
10090.0,1.0,,A,,,,CHEMBL624580,,BAO_0000218,,50594.0,In vivo,,N,6708.0,429.0,1.0,,Intermediate,Mus musculus,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,
6277.0,1.0,,F,,,,CHEMBL624581,,BAO_0000218,,50535.0,,,N,6709.0,10986.0,1.0,,Intermediate,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,
6277.0,1.0,,F,,,,CHEMBL624582,,BAO_0000218,,50535.0,,,N,6710.0,10986.0,1.0,,Intermediate,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,
6277.0,1.0,,F,,,,CHEMBL624583,,BAO_0000218,,50535.0,,,N,6711.0,10986.0,1.0,,Intermediate,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,
9606.0,1.0,,F,,,,CHEMBL624584,,BAO_0000219,A-375,80018.0,,,N,6712.0,13227.0,1.0,455.0,Intermediate,Homo sapiens,Inhibitory activity against human tumor cell line A0375 melanoma.,
10116.0,9.0,,B,,,,CHEMBL624585,,BAO_0000249,,12512.0,,Brain membranes,D,6713.0,4481.0,1.0,,Expert,Rattus norvegicus,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,
9606.0,9.0,,F,,,,CHEMBL875165,,BAO_0000019,,114.0,,,D,6714.0,16931.0,1.0,,Expert,Homo sapiens,Forskolin-induced cAMP production at human A1 adenosine receptor,
,8.0,,F,,,,CHEMBL619490,,BAO_0000219,CHO,114.0,,,H,6715.0,3850.0,1.0,449.0,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,
,8.0,,F,,,,CHEMBL619491,,BAO_0000219,CHO,114.0,,,H,6716.0,3850.0,1.0,449.0,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,
,8.0,,F,,,,CHEMBL619492,,BAO_0000219,CHO,114.0,,,H,6717.0,3850.0,1.0,449.0,Expert,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,
,8.0,,F,,,,CHEMBL619493,,BAO_0000219,CHO,114.0,,,H,6718.0,3850.0,1.0,449.0,Expert,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,
,8.0,,F,,,,CHEMBL619494,,BAO_0000219,CHO,114.0,,,H,6719.0,3850.0,1.0,449.0,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,
,8.0,,F,,,,CHEMBL619495,,BAO_0000219,CHO,114.0,,,H,6720.0,3850.0,1.0,449.0,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,
,8.0,,F,,,,CHEMBL619496,,BAO_0000219,CHO,114.0,,,H,6721.0,3850.0,1.0,449.0,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,
9606.0,9.0,,F,,,,CHEMBL619497,,BAO_0000219,CHO,114.0,,,D,6722.0,3850.0,1.0,449.0,Expert,Homo sapiens,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,
,8.0,,F,,,,CHEMBL619498,,BAO_0000219,CHO,114.0,,,H,6723.0,3850.0,1.0,449.0,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,
,8.0,,F,,,,CHEMBL619499,,BAO_0000219,CHO,114.0,,,H,6724.0,3850.0,1.0,449.0,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,
,8.0,,F,,,,CHEMBL619500,,BAO_0000219,CHO,114.0,,,H,6725.0,3850.0,1.0,449.0,Expert,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,
,8.0,,F,,,,CHEMBL619501,,BAO_0000219,CHO,114.0,,,H,6726.0,3850.0,1.0,449.0,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,
,8.0,,F,,,,CHEMBL619502,,BAO_0000219,CHO,114.0,,,H,6727.0,3850.0,1.0,449.0,Expert,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,
,8.0,,F,,,,CHEMBL619503,,BAO_0000219,CHO,114.0,,,H,6728.0,3850.0,1.0,449.0,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,
,8.0,,F,,,,CHEMBL619504,,BAO_0000219,CHO,114.0,,,H,6729.0,3850.0,1.0,449.0,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,
,8.0,,F,,,,CHEMBL621298,,BAO_0000219,CHO,114.0,,,H,6730.0,3850.0,1.0,449.0,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,
,8.0,,F,,,,CHEMBL621299,,BAO_0000219,CHO,114.0,,,H,6731.0,3850.0,1.0,449.0,Expert,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,
,8.0,,F,,,,CHEMBL621300,,BAO_0000219,CHO,114.0,,,H,6732.0,3850.0,1.0,449.0,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,
,8.0,,F,,,,CHEMBL621301,,BAO_0000219,CHO,114.0,,,H,6733.0,3850.0,1.0,449.0,Autocuration,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,
,8.0,,F,,,,CHEMBL621302,,BAO_0000219,CHO,114.0,,,H,6734.0,3850.0,1.0,449.0,Expert,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,
9986.0,1.0,,F,,,,CHEMBL621303,,BAO_0000219,A10,80013.0,,,N,6735.0,12680.0,1.0,164.0,Intermediate,Oryctolagus cuniculus,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,
10116.0,0.0,,F,,,,CHEMBL621304,,BAO_0000219,A10,22226.0,,,U,6736.0,1313.0,1.0,164.0,Autocuration,Rattus norvegicus,In vitro potassium channel opening activity in A10 (smooth muscle) cells,
10116.0,0.0,,F,,,,CHEMBL621305,,BAO_0000219,A10,22226.0,,,U,6737.0,1313.0,1.0,164.0,Autocuration,Rattus norvegicus,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,
10116.0,1.0,,F,,,,CHEMBL621306,,BAO_0000219,A10,80013.0,,,N,6738.0,17567.0,1.0,164.0,Intermediate,Rattus norvegicus,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,
10116.0,1.0,,F,,,,CHEMBL618444,,BAO_0000219,A10,80013.0,,,N,6739.0,17567.0,1.0,164.0,Intermediate,Rattus norvegicus,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,
10116.0,1.0,,F,,,,CHEMBL618445,,BAO_0000219,A10,80013.0,,,N,6740.0,11819.0,1.0,164.0,Intermediate,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,
10029.0,1.0,,F,,,,CHEMBL618446,,BAO_0000219,CHO-AA8,80089.0,,,N,6741.0,13436.0,1.0,185.0,Intermediate,Cricetulus griseus,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,
10029.0,1.0,,F,,,,CHEMBL618447,,BAO_0000219,CHO-AA8,80089.0,,,N,6742.0,12687.0,1.0,185.0,Intermediate,Cricetulus griseus,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,
10029.0,1.0,,F,,,,CHEMBL618448,,BAO_0000219,CHO-AA8,80089.0,,,N,6743.0,12651.0,1.0,185.0,Intermediate,Cricetulus griseus,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,
10029.0,1.0,,F,,,,CHEMBL618449,,BAO_0000219,CHO-AA8,80089.0,,,N,6744.0,13300.0,1.0,185.0,Intermediate,Cricetulus griseus,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,
10029.0,1.0,,F,,,,CHEMBL618637,,BAO_0000219,CHO-AA8,80089.0,,,N,6745.0,15296.0,1.0,185.0,Intermediate,Cricetulus griseus,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,
10029.0,1.0,,F,,,,CHEMBL618638,,BAO_0000219,CHO-AA8,80089.0,,,N,6746.0,15328.0,1.0,185.0,Intermediate,Cricetulus griseus,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",
10029.0,1.0,,F,,,,CHEMBL618639,,BAO_0000219,CHO-AA8,80089.0,,,N,6747.0,13302.0,1.0,185.0,Intermediate,Cricetulus griseus,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),
10029.0,1.0,,F,,,,CHEMBL618640,,BAO_0000219,CHO-AA8,80089.0,,,N,6748.0,14367.0,1.0,185.0,Expert,Cricetulus griseus,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",
10029.0,1.0,,F,,,,CHEMBL618641,,BAO_0000219,CHO-AA8,80089.0,,,N,6749.0,17002.0,1.0,185.0,Expert,Cricetulus griseus,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,
10029.0,1.0,,F,,,,CHEMBL618642,,BAO_0000219,CHO-AA8,80089.0,,,N,6750.0,13436.0,1.0,185.0,Intermediate,Cricetulus griseus,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,
10029.0,1.0,,F,,,,CHEMBL618643,,BAO_0000219,CHO-AA8,80089.0,,,N,6751.0,13435.0,1.0,185.0,Intermediate,Cricetulus griseus,Inhibitory activity against aerobic growth of AA8 cells.,
10029.0,1.0,,A,,,,CHEMBL884013,,BAO_0000219,CHO-AA8,80089.0,,,N,6752.0,10503.0,1.0,185.0,Intermediate,Cricetulus griseus,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,
10029.0,1.0,,F,,,,CHEMBL622723,,BAO_0000219,CHO-AA8,80089.0,,,N,6753.0,10503.0,1.0,185.0,Expert,Cricetulus griseus,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,
10029.0,1.0,,F,,,,CHEMBL622724,,BAO_0000219,CHO-AA8,80089.0,,,N,6754.0,10503.0,1.0,185.0,Intermediate,Cricetulus griseus,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,
10029.0,1.0,,F,,,,CHEMBL622725,,BAO_0000219,CHO-AA8,80089.0,,,N,6755.0,15090.0,1.0,185.0,Expert,Cricetulus griseus,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,
10029.0,1.0,,F,,,,CHEMBL622726,,BAO_0000219,CHO-AA8,80089.0,,,N,6756.0,10368.0,1.0,185.0,Expert,Cricetulus griseus,Cytotoxicity against AA8 cell line,
10029.0,1.0,,F,,,,CHEMBL622727,,BAO_0000219,CHO-AA8,80089.0,,,N,6757.0,12651.0,1.0,185.0,Intermediate,Cricetulus griseus,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),
10029.0,1.0,,A,,,,CHEMBL622728,,BAO_0000219,CHO-AA8,80089.0,,,N,6758.0,12687.0,1.0,185.0,Intermediate,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),
10029.0,1.0,,F,,,,CHEMBL622729,,BAO_0000219,CHO-AA8,80089.0,,,N,6759.0,12687.0,1.0,185.0,Intermediate,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),
10029.0,1.0,,A,,,,CHEMBL622730,,BAO_0000219,CHO-AA8,80089.0,,,N,6760.0,12687.0,1.0,185.0,Intermediate,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),
10029.0,1.0,,F,,,,CHEMBL622731,,BAO_0000219,CHO-AA8,80089.0,,,N,6761.0,1890.0,1.0,185.0,Intermediate,Cricetulus griseus,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,
10029.0,1.0,,F,,,,CHEMBL622732,,BAO_0000219,CHO-AA8,80089.0,,,N,6762.0,10747.0,1.0,185.0,Intermediate,Cricetulus griseus,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,
10029.0,1.0,,F,,,,CHEMBL622733,,BAO_0000219,CHO-AA8,80089.0,,,N,6763.0,10747.0,1.0,185.0,Intermediate,Cricetulus griseus,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,
10029.0,0.0,,F,,,,CHEMBL622734,,BAO_0000218,,22224.0,,,U,6764.0,11616.0,1.0,,Autocuration,Cricetulus griseus,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),
10029.0,1.0,,F,,,,CHEMBL622735,,BAO_0000219,CHO-AA8,80089.0,,,N,6765.0,11616.0,1.0,185.0,Expert,Cricetulus griseus,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,
10029.0,0.0,,F,,,,CHEMBL618746,,BAO_0000219,CHO-AA8,22224.0,,,U,6766.0,3471.0,1.0,185.0,Autocuration,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,
10029.0,0.0,,F,,,,CHEMBL618747,,BAO_0000219,CHO-AA8,22224.0,,,U,6767.0,3471.0,1.0,185.0,Autocuration,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,
10029.0,0.0,,F,,,,CHEMBL620540,,BAO_0000219,CHO-AA8,22224.0,,,U,6768.0,3471.0,1.0,185.0,Autocuration,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,
10029.0,0.0,,F,,,,CHEMBL620541,,BAO_0000219,CHO-AA8,22224.0,,,U,6769.0,3471.0,1.0,185.0,Autocuration,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,
10029.0,0.0,,F,,,,CHEMBL620542,,BAO_0000219,CHO-AA8,22224.0,,,U,6770.0,3471.0,1.0,185.0,Autocuration,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,
10029.0,0.0,,F,,,,CHEMBL620543,,BAO_0000219,CHO-AA8,22224.0,,,U,6771.0,3471.0,1.0,185.0,Autocuration,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,
10029.0,0.0,,F,,,,CHEMBL618832,,BAO_0000219,CHO-AA8,22224.0,,,U,6772.0,3471.0,1.0,185.0,Autocuration,Cricetulus griseus,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,
10029.0,1.0,,F,,,,CHEMBL618833,,BAO_0000219,CHO-AA8,80089.0,,,N,6773.0,11616.0,1.0,185.0,Expert,Cricetulus griseus,Concentration required to reduce AA8 cell survival by 10%,
10029.0,0.0,,F,,,,CHEMBL618834,,BAO_0000219,CHO-AA8,22224.0,,,U,6774.0,2656.0,1.0,185.0,Autocuration,Cricetulus griseus,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",
10029.0,0.0,,F,,,,CHEMBL618835,,BAO_0000219,CHO-AA8,22224.0,,,U,6775.0,10518.0,1.0,185.0,Autocuration,Cricetulus griseus,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,
10029.0,0.0,,F,,,,CHEMBL618836,,BAO_0000219,CHO-AA8,22224.0,,,U,6776.0,10518.0,1.0,185.0,Autocuration,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,
10029.0,0.0,,F,,,,CHEMBL618837,,BAO_0000219,CHO-AA8,22224.0,,,U,6777.0,10518.0,1.0,185.0,Autocuration,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,
10029.0,0.0,,F,,,,CHEMBL618838,,BAO_0000219,CHO-AA8,22224.0,,,U,6778.0,10518.0,1.0,185.0,Autocuration,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,
10029.0,0.0,,F,,,,CHEMBL618839,,BAO_0000219,CHO-AA8,22224.0,,,U,6779.0,16156.0,1.0,185.0,Autocuration,Cricetulus griseus,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,
10029.0,0.0,,F,,,,CHEMBL618840,,BAO_0000219,CHO-AA8,22224.0,,,U,6780.0,2656.0,1.0,185.0,Autocuration,Cricetulus griseus,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,
10029.0,0.0,,F,,,,CHEMBL618841,,BAO_0000019,,22224.0,,,U,6781.0,11005.0,1.0,,Autocuration,Cricetulus griseus,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",
10029.0,0.0,,F,,,,CHEMBL618842,,BAO_0000219,CHO-AA8,22224.0,,,U,6782.0,11942.0,1.0,185.0,Autocuration,Cricetulus griseus,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,
10029.0,0.0,,F,,,,CHEMBL618843,,BAO_0000219,CHO-AA8,22224.0,,,U,6783.0,2128.0,1.0,185.0,Autocuration,Cricetulus griseus,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,
9615.0,1.0,,A,,,,CHEMBL618844,,BAO_0000218,,50588.0,In vivo,,N,6784.0,16907.0,1.0,,Intermediate,Canis lupus familiaris,Half life period after 15 mg/kg iv dose in Dogs,
9615.0,1.0,,A,,,,CHEMBL618845,,BAO_0000218,,50588.0,In vivo,,N,6785.0,16907.0,1.0,,Intermediate,Canis lupus familiaris,Half life period after 30 mg/kg po dose in Dogs,
9615.0,1.0,,A,,,,CHEMBL618846,,BAO_0000218,,50588.0,In vivo,,N,6786.0,9579.0,1.0,,Intermediate,Canis lupus familiaris,Half life was measured after oral 2b administration (tested in 6 dogs),
9615.0,1.0,,A,,,,CHEMBL618847,,BAO_0000218,,50588.0,In vivo,,N,6787.0,9579.0,1.0,,Intermediate,Canis lupus familiaris,Half life was measured in dog after oral 17b administration,
9615.0,1.0,,A,,,,CHEMBL618848,,BAO_0000218,,50588.0,In vivo,,N,6788.0,9579.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,
9615.0,1.0,,A,,,,CHEMBL618849,,BAO_0000218,,50588.0,In vivo,,N,6789.0,9579.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,
9615.0,1.0,,A,,,,CHEMBL618850,,BAO_0000218,,50588.0,In vivo,,N,6790.0,16907.0,1.0,,Intermediate,Canis lupus familiaris,Tmax value after 15 mg/kg iv dose in Dogs,
9615.0,1.0,,A,,,,CHEMBL618851,,BAO_0000218,,50588.0,In vivo,,N,6791.0,16907.0,1.0,,Intermediate,Canis lupus familiaris,Tmax value after 30 mg/kg po dose in Dogs,
9615.0,1.0,,A,,,,CHEMBL873815,,BAO_0000218,,50588.0,In vivo,,N,6792.0,3184.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for its half life when administered intravenously in dog,
9615.0,1.0,,A,,,1969.0,CHEMBL618852,,BAO_0000218,,50588.0,In vivo,,N,6793.0,5017.0,1.0,,Intermediate,Canis lupus familiaris,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Plasma
9615.0,1.0,,A,,,,CHEMBL618853,,BAO_0000218,,50588.0,,,N,6794.0,6821.0,1.0,,Intermediate,Canis lupus familiaris,Elimination Half-life of compound was determined in dog,
9615.0,1.0,,A,,,,CHEMBL618854,,BAO_0000218,,50588.0,In vivo,,N,6795.0,17839.0,1.0,,Intermediate,Canis lupus familiaris,Half life of compound in dog following oral administration,
9615.0,1.0,,A,,,,CHEMBL618855,,BAO_0000218,,50588.0,,,N,6796.0,17267.0,1.0,,Intermediate,Canis lupus familiaris,Half life of compound was determined in dog,
9615.0,1.0,,A,,,178.0,CHEMBL618856,,BAO_0000218,,50588.0,,,N,6797.0,4727.0,1.0,,Intermediate,Canis lupus familiaris,Half life of compound was determined in dog blood,Blood
9615.0,1.0,,A,,,,CHEMBL875827,,BAO_0000218,,50588.0,In vivo,,N,6798.0,5238.0,1.0,,Intermediate,Canis lupus familiaris,Half life after oral and iv dosing in dogs,
9615.0,1.0,,A,,,,CHEMBL618857,,BAO_0000218,,50588.0,,,N,6799.0,4942.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dogs in hours,
9615.0,1.0,,A,,,,CHEMBL618858,,BAO_0000218,,50588.0,In vivo,,N,6800.0,6505.0,1.0,,Intermediate,Canis lupus familiaris,Half life on i.v. administration of 2 mg/kg was measured in dog,
9615.0,1.0,,A,,,,CHEMBL618859,,BAO_0000218,,50588.0,In vivo,,N,6801.0,5130.0,1.0,,Intermediate,Canis lupus familiaris,t1/2 in dog after oral dose (1 mg/kg),
9615.0,1.0,,A,,,,CHEMBL618860,,BAO_0000218,,50588.0,,,N,6802.0,1475.0,1.0,,Intermediate,Canis lupus familiaris,Half life was evaluated in dog,
9615.0,1.0,,A,,,,CHEMBL618861,,BAO_0000218,,50588.0,In vivo,,N,6803.0,17804.0,1.0,,Intermediate,Canis lupus familiaris,Half life period of compound was determined after intravenous administration at 2 mg/kg,
9615.0,1.0,,A,,,,CHEMBL622539,,BAO_0000218,,50588.0,In vivo,,N,6804.0,17804.0,1.0,,Intermediate,Canis lupus familiaris,Half life period of compound was determined after peroral administration at 2 mg/kg,
9615.0,1.0,,A,,,,CHEMBL622540,,BAO_0000218,,50588.0,In vivo,,N,6805.0,6084.0,1.0,,Intermediate,Canis lupus familiaris,Half life period (10 mg/kg) was determined in dog,
9615.0,1.0,,A,,,,CHEMBL873803,,BAO_0000218,,50588.0,In vivo,,N,6806.0,6084.0,1.0,,Intermediate,Canis lupus familiaris,Half life period (10 mg/kg) was determined in dog,
9615.0,1.0,,A,,,,CHEMBL873804,,BAO_0000218,,50588.0,In vivo,,N,6807.0,5542.0,1.0,,Intermediate,Canis lupus familiaris,Half life period by iv administration in dog at a dose of 0.3 mg/kg,
9615.0,1.0,,A,,,,CHEMBL624311,,BAO_0000218,,50588.0,In vivo,,N,6808.0,5542.0,1.0,,Intermediate,Canis lupus familiaris,Half life period by po administration in dog at a dose of 0.3 mg/kg,
9615.0,1.0,,A,,,,CHEMBL624312,,BAO_0000218,,50588.0,,,N,6809.0,6084.0,1.0,,Intermediate,Canis lupus familiaris,Half life period in dog,
9615.0,1.0,,A,,,,CHEMBL624313,,BAO_0000218,,50588.0,In vivo,,N,6810.0,6241.0,1.0,,Intermediate,Canis lupus familiaris,Half life period in dogs after oral administration at 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL624314,,BAO_0000218,,50588.0,In vivo,,N,6811.0,1916.0,1.0,,Intermediate,Canis lupus familiaris,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,
9615.0,1.0,,A,,,,CHEMBL624315,,BAO_0000218,,50588.0,,,N,6812.0,6621.0,1.0,,Intermediate,Canis lupus familiaris,Half-life of compound was determined in dogs,
9615.0,1.0,,A,,,1969.0,CHEMBL624316,,BAO_0000218,,50588.0,,,N,6813.0,1696.0,1.0,,Intermediate,Canis lupus familiaris,Half-life in dog plasma,Plasma
9615.0,1.0,,A,,,,CHEMBL624317,,BAO_0000218,,50588.0,,,N,6814.0,17800.0,1.0,,Intermediate,Canis lupus familiaris,Half-life in mongrel dogs was determined,
9615.0,1.0,,A,,,,CHEMBL624318,,BAO_0000218,,50588.0,In vivo,,N,6815.0,17657.0,1.0,,Intermediate,Canis lupus familiaris,Half-life in dog upon oral administration,
9615.0,1.0,,A,,,,CHEMBL624319,,BAO_0000218,,50588.0,In vivo,,N,6816.0,17657.0,1.0,,Intermediate,Canis lupus familiaris,Half-life in dog upon oral administration; Unable to calculate,
9615.0,1.0,,A,,,,CHEMBL624496,,BAO_0000218,,50588.0,,,N,6817.0,4239.0,1.0,,Intermediate,Canis lupus familiaris,Half-life was measured in dog,
9615.0,1.0,,A,,,,CHEMBL624497,,BAO_0000218,,50588.0,,,N,6818.0,5985.0,1.0,,Intermediate,Canis lupus familiaris,Half-life was measured in dog,
9615.0,1.0,,A,,,,CHEMBL624498,,BAO_0000218,,50588.0,,,N,6819.0,9932.0,1.0,,Intermediate,Canis lupus familiaris,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,
9615.0,1.0,,A,,,,CHEMBL624499,,BAO_0000218,,50588.0,In vivo,,N,6820.0,5199.0,1.0,,Intermediate,Canis lupus familiaris,Oral half life was determined,
9615.0,1.0,,A,,,1969.0,CHEMBL624500,,BAO_0000218,,50588.0,In vivo,,N,6821.0,5199.0,1.0,,Intermediate,Canis lupus familiaris,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL624501,,BAO_0000218,,50588.0,,,N,6822.0,1475.0,1.0,,Intermediate,Canis lupus familiaris,Plasma half life was evaluated,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL623666,,BAO_0000218,,50588.0,,,N,6823.0,1475.0,1.0,,Intermediate,Canis lupus familiaris,Plasma half life was evaluated in Dog,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL623667,,BAO_0000218,,50588.0,,,N,6824.0,1475.0,1.0,,Intermediate,Canis lupus familiaris,Plasma half life was evaluated in dog,Plasma
9615.0,1.0,,A,,,,CHEMBL623668,,BAO_0000218,,50588.0,In vivo,,N,6825.0,6316.0,1.0,,Intermediate,Canis lupus familiaris,T1/2 (Half-life) was after oral administration at 5 mg/kg,
9615.0,1.0,,A,,,,CHEMBL623669,,BAO_0000218,,50588.0,,,N,6826.0,4883.0,1.0,,Intermediate,Canis lupus familiaris,Tested for the half life value in dog,
9615.0,1.0,,A,,,,CHEMBL623670,,BAO_0000218,,50588.0,In vivo,,N,6827.0,4727.0,1.0,,Intermediate,Canis lupus familiaris,Maximum time at the dose of 2 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL623671,,BAO_0000218,,50588.0,In vivo,,N,6828.0,1916.0,1.0,,Intermediate,Canis lupus familiaris,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,
9615.0,1.0,,A,,,178.0,CHEMBL875945,,BAO_0000218,,50588.0,In vivo,,N,6829.0,1337.0,1.0,,Intermediate,Canis lupus familiaris,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Blood
9615.0,1.0,,A,,,178.0,CHEMBL623672,,BAO_0000218,,50588.0,In vivo,,N,6830.0,1337.0,1.0,,Intermediate,Canis lupus familiaris,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Blood
9615.0,1.0,,A,,,,CHEMBL623673,,BAO_0000218,,50588.0,In vivo,,N,6831.0,6265.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL623674,,BAO_0000218,,50588.0,In vivo,,N,6832.0,4809.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),
9615.0,1.0,,A,,,,CHEMBL623675,,BAO_0000218,,50588.0,In vivo,,N,6833.0,5983.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,
9615.0,1.0,,A,,,,CHEMBL872526,,BAO_0000218,,50588.0,,,N,6834.0,5313.0,1.0,,Intermediate,Canis lupus familiaris,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",
9615.0,1.0,,A,,,,CHEMBL623676,,BAO_0000218,,50588.0,In vivo,,N,6835.0,5313.0,1.0,,Intermediate,Canis lupus familiaris,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",
9615.0,1.0,,A,,,1969.0,CHEMBL623677,,BAO_0000218,,50588.0,In vivo,,N,6836.0,17650.0,1.0,,Intermediate,Canis lupus familiaris,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL623678,,BAO_0000218,,50588.0,In vivo,,N,6837.0,5199.0,1.0,,Intermediate,Canis lupus familiaris,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL623679,,BAO_0000218,,50588.0,,,N,6838.0,933.0,1.0,,Intermediate,Canis lupus familiaris,Time taken for maximum plasma concentration in dog,Plasma
9615.0,1.0,,A,,,,CHEMBL623680,,BAO_0000218,,50588.0,In vivo,,N,6839.0,16367.0,1.0,,Intermediate,Canis lupus familiaris,Time to reach Cmax after oral administration to dogs,
9615.0,1.0,,A,,,1969.0,CHEMBL623681,,BAO_0000218,,50588.0,In vivo,,N,6840.0,6348.0,1.0,,Intermediate,Canis lupus familiaris,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Plasma
9615.0,1.0,,A,,,,CHEMBL623682,,BAO_0000218,,50588.0,In vivo,,N,6841.0,6316.0,1.0,,Intermediate,Canis lupus familiaris,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,
9615.0,1.0,,A,,,,CHEMBL623683,,BAO_0000218,,50588.0,In vivo,,N,6842.0,6215.0,1.0,,Intermediate,Canis lupus familiaris,Tmax after peroral administration (1 mg/kg) was determined in dog,
9615.0,1.0,,A,,,,CHEMBL623684,,BAO_0000218,,50588.0,In vivo,,N,6843.0,3598.0,1.0,,Expert,Canis lupus familiaris,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,
9615.0,1.0,,A,,,,CHEMBL622745,,BAO_0000218,,50588.0,In vivo,,N,6844.0,4527.0,1.0,,Intermediate,Canis lupus familiaris,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,
9615.0,1.0,,A,,,,CHEMBL622746,,BAO_0000218,,50588.0,In vivo,,N,6845.0,17764.0,1.0,,Intermediate,Canis lupus familiaris,Tmax after peroral administration in dogs at 2.4 uM/kg,
10090.0,1.0,,A,,,,CHEMBL622747,,BAO_0000218,,50594.0,In vivo,,N,6846.0,5969.0,1.0,,Intermediate,Mus musculus,In vivo Cmax in mice at dose of 100 mg/kg,
10090.0,1.0,,A,,,,CHEMBL622748,,BAO_0000218,,50594.0,In vivo,,N,6847.0,5969.0,1.0,,Intermediate,Mus musculus,In vivo Cmax in mice at dose of 50 mg/kg,
10090.0,1.0,,A,,,,CHEMBL622749,,BAO_0000218,,50594.0,In vivo,,N,6848.0,4573.0,1.0,,Intermediate,Mus musculus,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,
10090.0,1.0,,A,,,1969.0,CHEMBL622750,,BAO_0000218,,50594.0,In vivo,,N,6849.0,3277.0,1.0,,Intermediate,Mus musculus,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL623411,,BAO_0000218,,50594.0,In vivo,,N,6850.0,17734.0,1.0,,Intermediate,Mus musculus,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL875946,,BAO_0000218,,50594.0,In vivo,,N,6851.0,3132.0,1.0,,Intermediate,Mus musculus,Maximum concentration obtained in mouse plasma was determined,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL623412,,BAO_0000218,,50594.0,In vivo,,N,6852.0,3132.0,1.0,,Intermediate,Mus musculus,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL623413,,BAO_0000218,,50594.0,In vivo,,N,6853.0,6348.0,1.0,,Intermediate,Mus musculus,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL623414,,BAO_0000218,,50594.0,In vivo,,N,6854.0,17729.0,1.0,,Intermediate,Mus musculus,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL623415,,BAO_0000218,,50594.0,In vivo,,N,6855.0,17729.0,1.0,,Intermediate,Mus musculus,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL623416,,BAO_0000218,,50594.0,In vivo,,N,6856.0,17729.0,1.0,,Intermediate,Mus musculus,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL623417,,BAO_0000218,,50594.0,In vivo,,N,6857.0,17728.0,1.0,,Intermediate,Mus musculus,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL623418,,BAO_0000218,,50594.0,In vivo,,N,6858.0,17728.0,1.0,,Intermediate,Mus musculus,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL623419,,BAO_0000218,,50594.0,In vivo,,N,6859.0,17728.0,1.0,,Intermediate,Mus musculus,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,Plasma
10090.0,1.0,,A,,,,CHEMBL622816,,BAO_0000218,,50594.0,In vivo,,N,6860.0,4066.0,1.0,,Intermediate,Mus musculus,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,
10090.0,1.0,,A,,,,CHEMBL623313,,BAO_0000218,,50594.0,In vivo,,N,6861.0,6178.0,1.0,,Intermediate,Mus musculus,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,
10090.0,1.0,,A,,,,CHEMBL623314,,BAO_0000218,,50594.0,In vivo,,N,6862.0,6178.0,1.0,,Intermediate,Mus musculus,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,
10090.0,1.0,,A,,,,CHEMBL876788,,BAO_0000218,,50594.0,In vivo,,N,6863.0,3760.0,1.0,,Intermediate,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,
10090.0,1.0,,A,,,,CHEMBL623315,,BAO_0000218,,50594.0,In vivo,,N,6864.0,3760.0,1.0,,Intermediate,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,
10090.0,1.0,,A,,,,CHEMBL623316,,BAO_0000218,,50594.0,In vivo,,N,6865.0,3760.0,1.0,,Intermediate,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,
10090.0,1.0,,A,,,,CHEMBL623317,,BAO_0000218,,50594.0,In vivo,,N,6866.0,3760.0,1.0,,Intermediate,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,
10090.0,1.0,,A,,,,CHEMBL623319,,BAO_0000218,,50594.0,In vivo,,N,6868.0,5961.0,1.0,,Intermediate,Mus musculus,Cmax in male mice after 2 mg/kg oral dose,
10090.0,1.0,,A,,,,CHEMBL623320,,BAO_0000218,,50594.0,In vivo,,N,6869.0,6137.0,1.0,,Intermediate,Mus musculus,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,
10090.0,1.0,,A,,,,CHEMBL623321,,BAO_0000218,,50594.0,In vivo,,N,6870.0,3802.0,1.0,,Intermediate,Mus musculus,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,
10090.0,1.0,,A,,,,CHEMBL623322,,BAO_0000218,,50594.0,,,N,6871.0,3535.0,1.0,,Intermediate,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,
10090.0,1.0,,A,,,,CHEMBL623323,,BAO_0000218,,50594.0,,,N,6872.0,3535.0,1.0,,Intermediate,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,
10090.0,1.0,,A,,,,CHEMBL623324,,BAO_0000218,,50594.0,,,N,6873.0,3535.0,1.0,,Intermediate,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,
10090.0,1.0,,A,,,,CHEMBL623325,,BAO_0000218,,50594.0,,,N,6874.0,3535.0,1.0,,Intermediate,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,
10090.0,1.0,,A,,,,CHEMBL623326,,BAO_0000218,,50594.0,,,N,6875.0,3535.0,1.0,,Intermediate,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,
10090.0,1.0,,A,,,,CHEMBL623327,,BAO_0000218,,50594.0,,,N,6876.0,3535.0,1.0,,Intermediate,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,
10090.0,1.0,,A,,,1969.0,CHEMBL623328,,BAO_0000218,,50594.0,,,N,6877.0,2862.0,1.0,,Intermediate,Mus musculus,Maximum concentration in plasma upon oral administration in mouse,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL623329,,BAO_0000218,,50594.0,,,N,6878.0,2675.0,1.0,,Intermediate,Mus musculus,Maximum plasma concentration was evaluated in mice after oral administration,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL623330,,BAO_0000218,,50594.0,In vivo,,N,6879.0,2675.0,1.0,,Intermediate,Mus musculus,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,Plasma
10090.0,1.0,,A,,,,CHEMBL876789,,BAO_0000218,,50594.0,,,N,6880.0,5399.0,1.0,,Intermediate,Mus musculus,Dose at which the compound induced fecal excretion in mice,
10116.0,1.0,,F,,,,CHEMBL623333,,BAO_0000219,A10,80013.0,,,N,6893.0,11819.0,1.0,164.0,Expert,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,
10116.0,1.0,,F,,,,CHEMBL623334,,BAO_0000219,A10,80013.0,,,N,6894.0,11819.0,1.0,164.0,Expert,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,
10116.0,1.0,,F,,,,CHEMBL627536,,BAO_0000219,A10,80013.0,,,N,6895.0,11819.0,1.0,164.0,Expert,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,
10116.0,1.0,,F,,,,CHEMBL627537,,BAO_0000219,A10,80013.0,,,N,6896.0,11819.0,1.0,164.0,Expert,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,
10116.0,1.0,,F,,,,CHEMBL627538,,BAO_0000219,A10,80013.0,,,N,6897.0,16361.0,1.0,164.0,Intermediate,Rattus norvegicus,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),
9606.0,1.0,,F,,,,CHEMBL884106,,BAO_0000219,A121,80655.0,,,N,6898.0,2288.0,1.0,393.0,Intermediate,Homo sapiens,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,
9606.0,1.0,,F,,,,CHEMBL625294,,BAO_0000219,A121,80655.0,,,N,6899.0,10404.0,1.0,393.0,Intermediate,Homo sapiens,Anticancer activity against human ovarian carcinoma A121 cells,
9606.0,1.0,,F,,,,CHEMBL625295,,BAO_0000219,A121,80655.0,,,N,6900.0,14790.0,1.0,393.0,Intermediate,Homo sapiens,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,
9606.0,1.0,,F,,,,CHEMBL625296,,BAO_0000219,A121,80655.0,,,N,6901.0,14790.0,1.0,393.0,Intermediate,Homo sapiens,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,
9606.0,1.0,,F,,,,CHEMBL625297,,BAO_0000219,A121,80655.0,,,N,6902.0,14253.0,1.0,393.0,Expert,Homo sapiens,Growth inhibition of human ovarian carcinoma (A121) cell line,
9606.0,1.0,,F,,,,CHEMBL625298,,BAO_0000219,A121,80655.0,,,N,6903.0,13617.0,1.0,393.0,Expert,Homo sapiens,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,
9606.0,1.0,,F,,,,CHEMBL625960,,BAO_0000219,A121,80655.0,,,N,6904.0,1003.0,1.0,393.0,Intermediate,Homo sapiens,Cytotoxicity against human A121 ovarian cells,
9606.0,1.0,,F,,,,CHEMBL625961,,BAO_0000219,A121,80655.0,,,N,6905.0,830.0,1.0,393.0,Intermediate,Homo sapiens,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL625962,,BAO_0000219,A121,80655.0,,,N,6906.0,12307.0,1.0,393.0,Intermediate,Homo sapiens,In vitro cytotoxicity against human ovarian carcinoma A21,
9606.0,1.0,,F,,,,CHEMBL624717,,BAO_0000219,A121,80655.0,,,N,6907.0,14254.0,1.0,393.0,Intermediate,Homo sapiens,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,
9606.0,1.0,,F,,,,CHEMBL624718,,BAO_0000219,A121,80655.0,,,N,6908.0,13370.0,1.0,393.0,Intermediate,Homo sapiens,Inhibitory activity of compound against human A121 ovarian cell line.,
9606.0,1.0,,F,,,,CHEMBL624719,,BAO_0000219,A121,80655.0,,,N,6909.0,14790.0,1.0,393.0,Intermediate,Homo sapiens,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,
9606.0,1.0,,F,,,,CHEMBL624720,,BAO_0000219,A121,80655.0,,,N,6910.0,3614.0,1.0,393.0,Intermediate,Homo sapiens,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,
9606.0,1.0,,F,,,,CHEMBL624721,,BAO_0000219,A 172,80012.0,,,N,6911.0,2664.0,1.0,622.0,Intermediate,Homo sapiens,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,
9606.0,1.0,,F,,,,CHEMBL624722,,BAO_0000219,A 172,80012.0,,,N,6912.0,2037.0,1.0,622.0,Expert,Homo sapiens,In vitro cytotoxicity against A172 human tumor cell lines.,
9606.0,1.0,,F,,,,CHEMBL877597,,BAO_0000219,A 172,80012.0,,,N,6913.0,14539.0,1.0,622.0,Intermediate,Homo sapiens,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,
9606.0,1.0,,F,,,,CHEMBL624723,,BAO_0000219,A 172,80012.0,,,N,6914.0,2836.0,1.0,622.0,Intermediate,Homo sapiens,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,
9606.0,1.0,,F,,,,CHEMBL624724,,BAO_0000219,A 172,80012.0,,,N,6915.0,10708.0,1.0,622.0,Intermediate,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,
9615.0,4.0,,B,,,,CHEMBL624725,,BAO_0000224,,104729.0,,,H,6916.0,8975.0,1.0,,Autocuration,Canis lupus familiaris,Association constant against A2 adenosine receptor,
,1.0,,F,,,,CHEMBL624726,,BAO_0000219,A2,80656.0,,,N,6917.0,7645.0,1.0,1085.0,Intermediate,fish,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,
10116.0,5.0,,B,,,,CHEMBL857535,,BAO_0000224,,104713.0,,,D,6918.0,11377.0,1.0,,Autocuration,Rattus norvegicus,Ratio of Ki for adenosine A2 and A1 receptor binding,
9606.0,1.0,,F,,,,CHEMBL624727,,BAO_0000219,A204,80014.0,,,N,6919.0,13528.0,1.0,623.0,Expert,Homo sapiens,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,
9606.0,1.0,,F,,,,CHEMBL624728,,BAO_0000219,A204,80014.0,,,N,6920.0,10160.0,1.0,623.0,Expert,Homo sapiens,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,
9606.0,1.0,,F,,,,CHEMBL624729,,BAO_0000219,A2058,80015.0,,,N,6921.0,15144.0,1.0,404.0,Intermediate,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL624730,,BAO_0000219,A253 cell line,80657.0,,,N,6922.0,13160.0,1.0,973.0,Intermediate,Homo sapiens,Growth inhibition against Human squamous cell line(A 253),
9606.0,1.0,,F,,,,CHEMBL624731,,BAO_0000219,A253 cell line,80657.0,,,N,6923.0,12898.0,1.0,973.0,Intermediate,Homo sapiens,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,
9606.0,1.0,,F,,,,CHEMBL624732,,BAO_0000219,A253 cell line,80657.0,,,N,6924.0,13069.0,1.0,973.0,Intermediate,Homo sapiens,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,
9606.0,1.0,,F,,,,CHEMBL883245,,BAO_0000219,A253 cell line,80657.0,,,N,6925.0,15984.0,1.0,973.0,Intermediate,Homo sapiens,Growth inhibition of A253 cell lines.,
9606.0,1.0,,F,,,,CHEMBL624733,,BAO_0000219,A253 cell line,80657.0,,,N,6926.0,15564.0,1.0,973.0,Intermediate,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),
9606.0,1.0,,F,,,,CHEMBL624734,,BAO_0000219,A253 cell line,80657.0,,,N,6927.0,15564.0,1.0,973.0,Intermediate,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,
9606.0,1.0,,F,,,,CHEMBL624735,,BAO_0000219,A253 cell line,80657.0,,,N,6928.0,15564.0,1.0,973.0,Intermediate,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,
9606.0,1.0,,F,,,,CHEMBL621780,,BAO_0000219,A2780,81034.0,,,N,6929.0,4720.0,1.0,478.0,Intermediate,Homo sapiens,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,
9606.0,1.0,,F,,,,CHEMBL877598,,BAO_0000219,A2780,81034.0,,,N,6930.0,16112.0,1.0,478.0,Intermediate,Homo sapiens,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,
9606.0,1.0,,F,,,,CHEMBL621781,,BAO_0000219,A2780,81034.0,,,N,6931.0,16597.0,1.0,478.0,Expert,Homo sapiens,Cytotoxic activity against A2780 human ovarian carcinoma cell line,
9606.0,1.0,,F,,,,CHEMBL621782,,BAO_0000219,A2780,81034.0,,,N,6932.0,16378.0,1.0,478.0,Intermediate,Homo sapiens,Cytotoxicity against human cancer cell lines A2780 (ovarian),
9606.0,1.0,,F,,,,CHEMBL621783,,BAO_0000219,A2780,81034.0,,,N,6933.0,16085.0,1.0,478.0,Expert,Homo sapiens,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,
9606.0,1.0,,F,,,,CHEMBL621784,,BAO_0000219,A2780,81034.0,,,N,6934.0,16317.0,1.0,478.0,Intermediate,Homo sapiens,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,
9606.0,1.0,,F,,,,CHEMBL621785,,BAO_0000219,A2780,81034.0,,,N,6935.0,15748.0,1.0,478.0,Intermediate,Homo sapiens,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),
9606.0,1.0,,F,,,,CHEMBL621968,,BAO_0000219,A2780,81034.0,,,N,6936.0,16597.0,1.0,478.0,Expert,Homo sapiens,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,
9606.0,1.0,,F,,,,CHEMBL621969,,BAO_0000219,A2780,81034.0,,,N,6937.0,16597.0,1.0,478.0,Expert,Homo sapiens,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,
9606.0,1.0,,F,,,,CHEMBL621970,,BAO_0000219,A2780,81034.0,,,N,6938.0,16597.0,1.0,478.0,Expert,Homo sapiens,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,
9606.0,1.0,,F,,,,CHEMBL621971,,BAO_0000219,A2780,81034.0,,,N,6939.0,15608.0,1.0,478.0,Intermediate,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,
9606.0,1.0,,F,,,,CHEMBL621972,,BAO_0000219,A2780,81034.0,,,N,6940.0,15608.0,1.0,478.0,Intermediate,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,
9606.0,1.0,,F,,,,CHEMBL884108,,BAO_0000219,A2780,81034.0,,,N,6941.0,15608.0,1.0,478.0,Intermediate,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,
10029.0,0.0,,F,,,,CHEMBL623826,,BAO_0000019,,22224.0,,,U,6942.0,15296.0,1.0,,Autocuration,Cricetulus griseus,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,
10029.0,0.0,,A,,,,CHEMBL623827,,BAO_0000219,CHO-AA8,22224.0,,,U,6943.0,10251.0,1.0,185.0,Autocuration,Cricetulus griseus,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,
10029.0,0.0,,F,,,,CHEMBL623828,,BAO_0000219,CHO-AA8,22224.0,,,U,6944.0,10251.0,1.0,185.0,Autocuration,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic conditions,
10029.0,0.0,,F,,,,CHEMBL623829,,BAO_0000219,CHO-AA8,22224.0,,,U,6945.0,10251.0,1.0,185.0,Autocuration,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,
10029.0,0.0,,F,,,,CHEMBL623830,,BAO_0000219,CHO-AA8,22224.0,,,U,6946.0,10251.0,1.0,185.0,Autocuration,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),
10029.0,0.0,,F,,,,CHEMBL623831,,BAO_0000019,,22224.0,,,U,6947.0,11858.0,1.0,,Autocuration,Cricetulus griseus,Growth inhibition against CHO-derived cell line AA8,
10029.0,0.0,,F,,,,CHEMBL623832,,BAO_0000219,CHO-AA8,22224.0,,,U,6948.0,11858.0,1.0,185.0,Autocuration,Cricetulus griseus,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],
36483.0,1.0,,F,,,,CHEMBL623833,,BAO_0000219,CHO-AA8,80089.0,,,N,6949.0,11616.0,1.0,185.0,Expert,hampster,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,
10029.0,1.0,,F,,,,CHEMBL623834,,BAO_0000219,CHO-AA8,80089.0,,,N,6950.0,11616.0,1.0,185.0,Expert,Cricetulus griseus,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,
10029.0,0.0,,F,,,,CHEMBL623835,,BAO_0000219,CHO-AA8,22224.0,,,U,6951.0,10518.0,1.0,185.0,Autocuration,Cricetulus griseus,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,
10029.0,0.0,,F,,,,CHEMBL623836,,BAO_0000219,CHO-AA8,22224.0,,,U,6952.0,11396.0,1.0,185.0,Autocuration,Cricetulus griseus,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,
10029.0,0.0,,F,,,,CHEMBL623837,,BAO_0000219,CHO-AA8,22224.0,,,U,6953.0,10518.0,1.0,185.0,Autocuration,Cricetulus griseus,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,
10029.0,1.0,,F,,,,CHEMBL623838,,BAO_0000219,CHO-AA8,80089.0,,,N,6954.0,11616.0,1.0,185.0,Expert,Cricetulus griseus,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,
,8.0,,F,,,,CHEMBL623839,,BAO_0000019,,12675.0,,,H,6955.0,14837.0,1.0,,Autocuration,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,
,8.0,,F,,,,CHEMBL623840,,BAO_0000019,,12675.0,,,H,6956.0,14837.0,1.0,,Autocuration,,Number of binding sites (n) of isolated serum protein AAG,
,3.0,,B,,,,CHEMBL623841,,BAO_0000225,,22222.0,,,M,6957.0,16037.0,1.0,,Intermediate,,Association constant for binding to AATT duplex,
9606.0,1.0,,F,,,,CHEMBL623842,,BAO_0000219,ABAE,100090.0,,,N,6958.0,16597.0,1.0,416.0,Expert,Homo sapiens,Inhibition of ABAE human fibroblast cell proliferation,
10090.0,1.0,,F,,,,CHEMBL623843,,BAO_0000218,AC755,80668.0,,,N,6959.0,8831.0,1.0,1064.0,Intermediate,Mus musculus,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",
9986.0,9.0,,F,,,,CHEMBL618669,,BAO_0000218,,102444.0,,,D,6960.0,13419.0,1.0,,Expert,Oryctolagus cuniculus,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,
9986.0,9.0,,F,,,,CHEMBL618670,,BAO_0000218,,102444.0,In vivo,,D,6961.0,13419.0,1.0,,Expert,Oryctolagus cuniculus,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,
,8.0,,B,,,,CHEMBL618671,,BAO_0000357,,69.0,,,H,6962.0,15778.0,1.0,,Autocuration,,Inhibitory activity against angiotensin-converting enzyme (ACE).,
,8.0,,B,,,,CHEMBL618672,,BAO_0000357,,69.0,,,H,6963.0,15778.0,1.0,,Autocuration,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,
9606.0,1.0,,F,,,,CHEMBL618673,,BAO_0000219,ACH-2 cell line,80669.0,,,N,6964.0,12988.0,1.0,978.0,Intermediate,Homo sapiens,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,
9606.0,1.0,,F,,,,CHEMBL618674,,BAO_0000219,ACH-2 cell line,80669.0,,,N,6965.0,12988.0,1.0,978.0,Intermediate,Homo sapiens,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),
11676.0,0.0,,F,,,,CHEMBL618675,,BAO_0000219,T cell line,22224.0,,,U,6966.0,12988.0,1.0,998.0,Autocuration,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,
11676.0,0.0,,F,,,,CHEMBL618676,,BAO_0000219,T cell line,22224.0,,,U,6967.0,12988.0,1.0,998.0,Autocuration,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),
11676.0,0.0,,F,,,,CHEMBL618677,,BAO_0000219,T cell line,22224.0,,,U,6968.0,12988.0,1.0,998.0,Autocuration,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),
9606.0,1.0,,F,,,,CHEMBL618678,,BAO_0000219,ACHN,80025.0,,,N,6969.0,11843.0,1.0,626.0,Intermediate,Homo sapiens,Inhibition of growth of renal cancer ACHN cell line,
9606.0,1.0,,F,,,,CHEMBL618679,,BAO_0000219,ACHN,80025.0,,,N,6970.0,16939.0,1.0,626.0,Intermediate,Homo sapiens,Inhibition of growth of ACHN renal cancer cell line,
9606.0,1.0,,F,,,,CHEMBL618680,,BAO_0000219,ACHN,80025.0,,,N,6971.0,4782.0,1.0,626.0,Intermediate,Homo sapiens,Inhibitory concentration required against ACHN renal cancer cell line,
9606.0,1.0,,F,,,,CHEMBL618681,,BAO_0000219,ACHN,80025.0,,,N,6972.0,6310.0,1.0,626.0,Expert,Homo sapiens,Concentration required to inhibit growth of human renal (ACHN) cell line,
9606.0,1.0,,F,,,,CHEMBL618682,,BAO_0000219,ACHN,80025.0,,,N,6973.0,6310.0,1.0,626.0,Intermediate,Homo sapiens,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,
9606.0,1.0,,F,,,,CHEMBL618683,,BAO_0000219,ACHN,80025.0,,,N,6974.0,12858.0,1.0,626.0,Intermediate,Homo sapiens,Cytotoxic activity against ACHN Renal cancer cell line,
9606.0,1.0,,F,,,,CHEMBL618684,,BAO_0000219,ACHN,80025.0,,,N,6975.0,17380.0,1.0,626.0,Intermediate,Homo sapiens,Cytotoxicity evaluation against ACHN renal cancer cells,
9606.0,1.0,,F,,,,CHEMBL618685,,BAO_0000219,ACHN,80025.0,,,N,6976.0,5858.0,1.0,626.0,Intermediate,Homo sapiens,In vitro antitumor activity against human renal ACHN cell line,
9606.0,1.0,,F,,,,CHEMBL876499,,BAO_0000219,ACHN,80025.0,,,N,6977.0,3838.0,1.0,626.0,Intermediate,Homo sapiens,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,
9606.0,1.0,,F,,,,CHEMBL618686,,BAO_0000219,ACHN,80025.0,,,N,6978.0,3838.0,1.0,626.0,Intermediate,Homo sapiens,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,
9606.0,1.0,,F,,,,CHEMBL618687,,BAO_0000219,ACHN,80025.0,,,N,6979.0,5406.0,1.0,626.0,Intermediate,Homo sapiens,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",
9606.0,1.0,,F,,,,CHEMBL618688,,BAO_0000219,ACHN,80025.0,,,N,6980.0,4071.0,1.0,626.0,Intermediate,Homo sapiens,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,
9606.0,1.0,,F,,,,CHEMBL618689,,BAO_0000219,ACHN,80025.0,,,N,6981.0,4071.0,1.0,626.0,Expert,Homo sapiens,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,
9606.0,1.0,,F,,,,CHEMBL618690,,BAO_0000219,ACHN,80025.0,,,N,6982.0,4071.0,1.0,626.0,Intermediate,Homo sapiens,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,
9606.0,1.0,,F,,,,CHEMBL618691,,BAO_0000219,ACHN,80025.0,,,N,6983.0,15002.0,1.0,626.0,Intermediate,Homo sapiens,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,
9606.0,1.0,,F,,,,CHEMBL619373,,BAO_0000219,ACHN,80025.0,,,N,6984.0,14769.0,1.0,626.0,Intermediate,Homo sapiens,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),
9606.0,1.0,,F,,,,CHEMBL884008,,BAO_0000219,ACHN,80025.0,,,N,6985.0,13958.0,1.0,626.0,Intermediate,Homo sapiens,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",
9606.0,1.0,,F,,,,CHEMBL619374,,BAO_0000219,ACHN,80025.0,,,N,6986.0,1665.0,1.0,626.0,Intermediate,Homo sapiens,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,
9606.0,1.0,,F,,,,CHEMBL619375,,BAO_0000219,ACHN,80025.0,,,N,6987.0,15354.0,1.0,626.0,Intermediate,Homo sapiens,Compound was tested for the growth inhibition of ACHN renal tumor cell line,
9606.0,1.0,,F,,,,CHEMBL619376,,BAO_0000219,ACHN,80025.0,,,N,6988.0,15354.0,1.0,626.0,Intermediate,Homo sapiens,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,
9606.0,1.0,,F,,,,CHEMBL619377,,BAO_0000219,ACHN,80025.0,,,N,6989.0,13978.0,1.0,626.0,Intermediate,Homo sapiens,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,
9606.0,1.0,,F,,,,CHEMBL619378,,BAO_0000219,ACHN,80025.0,,,N,6990.0,6798.0,1.0,626.0,Intermediate,Homo sapiens,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,
9615.0,1.0,,A,,,,CHEMBL872527,,BAO_0000218,,50588.0,In vivo,,N,6991.0,2959.0,1.0,,Intermediate,Canis lupus familiaris,Tmax value after administration of 4 mg/Kg oral dose in dog,
9615.0,1.0,,A,,,,CHEMBL876500,,BAO_0000218,,50588.0,,,N,6992.0,9932.0,1.0,,Intermediate,Canis lupus familiaris,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",
9615.0,1.0,,A,,,,CHEMBL619379,,BAO_0000218,,50588.0,,,N,6993.0,5546.0,1.0,,Intermediate,Canis lupus familiaris,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,
9615.0,1.0,,A,,,,CHEMBL619538,,BAO_0000218,,50588.0,In vivo,,N,6994.0,16907.0,1.0,,Intermediate,Canis lupus familiaris,Volume distribution after 15 mg/kg iv dose in Dogs,
9615.0,1.0,,A,,,,CHEMBL619539,,BAO_0000218,,50588.0,In vivo,,N,6995.0,16907.0,1.0,,Intermediate,Canis lupus familiaris,Volume distribution after 30 mg/kg po dose in Dogs,
9615.0,1.0,,A,,,,CHEMBL619540,,BAO_0000218,,50588.0,In vivo,,N,6996.0,4257.0,1.0,,Intermediate,Canis lupus familiaris,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,
9615.0,1.0,,A,,,,CHEMBL619541,,BAO_0000218,,50588.0,In vivo,,N,6997.0,4305.0,1.0,,Intermediate,Canis lupus familiaris,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL619542,,BAO_0000218,,50588.0,In vivo,,N,6998.0,5472.0,1.0,,Intermediate,Canis lupus familiaris,Volume of distribution was evaluated in dog,
9615.0,1.0,,A,,,,CHEMBL619543,,BAO_0000218,,50588.0,In vivo,,N,6999.0,6062.0,1.0,,Intermediate,Canis lupus familiaris,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL619544,,BAO_0000218,,50588.0,,,N,7000.0,3598.0,1.0,,Expert,Canis lupus familiaris,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,
9615.0,1.0,,A,,,,CHEMBL619545,,BAO_0000218,,50588.0,In vivo,,N,7001.0,12500.0,1.0,,Intermediate,Canis lupus familiaris,The compound was tested for volume of distribution in dog,
9615.0,1.0,,A,,,,CHEMBL619546,,BAO_0000218,,50588.0,In vivo,,N,7002.0,12500.0,1.0,,Intermediate,Canis lupus familiaris,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,
9615.0,1.0,,A,,,,CHEMBL619547,,BAO_0000218,,50588.0,In vivo,,N,7003.0,6227.0,1.0,,Intermediate,Canis lupus familiaris,Vd (1 mg/kg) was determined in dog (in vivo),
9615.0,1.0,,A,,,,CHEMBL619548,,BAO_0000218,,50588.0,In vivo,,N,7004.0,6227.0,1.0,,Intermediate,Canis lupus familiaris,Vd in dog,
9615.0,1.0,,A,,,,CHEMBL619549,,BAO_0000218,,50588.0,In vivo,,N,7005.0,4219.0,1.0,,Intermediate,Canis lupus familiaris,Volume distribution was determined,
9615.0,1.0,,A,,,,CHEMBL619550,,BAO_0000218,,50588.0,In vivo,,N,7006.0,1696.0,1.0,,Intermediate,Canis lupus familiaris,Volume of distribution in dog,
9615.0,1.0,,A,,,,CHEMBL876501,,BAO_0000218,,50588.0,In vivo,,N,7007.0,5542.0,1.0,,Intermediate,Canis lupus familiaris,Volume of distribution by as 4 fold increase by iv administration in dogs,
9615.0,1.0,,A,,,,CHEMBL619551,,BAO_0000218,,50588.0,In vivo,,N,7008.0,5199.0,1.0,,Intermediate,Canis lupus familiaris,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,
9615.0,1.0,,A,,,,CHEMBL619552,,BAO_0000218,,50588.0,In vivo,,N,7009.0,6348.0,1.0,,Intermediate,Canis lupus familiaris,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,
9615.0,1.0,,A,,,,CHEMBL619553,,BAO_0000218,,50588.0,In vivo,,N,7010.0,4727.0,1.0,,Intermediate,Canis lupus familiaris,Volume distribution at the dose of 2 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL618722,,BAO_0000218,,50588.0,In vivo,,N,7011.0,16367.0,1.0,,Intermediate,Canis lupus familiaris,Steady state volume of distribution was determined,
9615.0,1.0,,A,,,,CHEMBL618723,,BAO_0000218,,50588.0,In vivo,,N,7012.0,2652.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,
9615.0,1.0,,A,,,,CHEMBL618724,,BAO_0000218,,50588.0,In vivo,,N,7013.0,16452.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,
9615.0,1.0,,A,,,,CHEMBL618725,,BAO_0000218,,50588.0,In vivo,,N,7014.0,16452.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,
9615.0,1.0,,A,,,,CHEMBL618726,,BAO_0000218,,50588.0,In vivo,,N,7015.0,16452.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),
9615.0,1.0,,A,,,,CHEMBL618727,,BAO_0000218,,50588.0,In vivo,,N,7016.0,5334.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),
9615.0,1.0,,A,,,,CHEMBL624233,,BAO_0000218,,50588.0,In vivo,,N,7017.0,4239.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic property (vdss) was measured in dog,
9615.0,1.0,,A,,,,CHEMBL624234,,BAO_0000218,,50588.0,In vivo,,N,7018.0,4709.0,1.0,,Intermediate,Canis lupus familiaris,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL624235,,BAO_0000218,,50588.0,In vivo,,N,7019.0,5600.0,1.0,,Intermediate,Canis lupus familiaris,Vdss was determined after iv 0.1 mg/kg administration in dog,
9615.0,1.0,,A,,,,CHEMBL624236,,BAO_0000218,,50588.0,In vivo,,N,7020.0,6057.0,1.0,,Intermediate,Canis lupus familiaris,Volume displacement was calculated in dog,
9615.0,1.0,,A,,,,CHEMBL624237,,BAO_0000218,,50588.0,In vivo,,N,7021.0,5654.0,1.0,,Intermediate,Canis lupus familiaris,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL624238,,BAO_0000218,,50588.0,In vivo,,N,7022.0,5505.0,1.0,,Intermediate,Canis lupus familiaris,Volume distribution constant was determined,
9615.0,1.0,,A,,,,CHEMBL624239,,BAO_0000218,,50588.0,In vivo,,N,7023.0,4527.0,1.0,,Intermediate,Canis lupus familiaris,Volume distribution at a dose of 1 uM/kg in dog was determined,
9615.0,1.0,,A,,,,CHEMBL875829,,BAO_0000218,,50588.0,In vivo,,N,7024.0,4521.0,1.0,,Intermediate,Canis lupus familiaris,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,
9615.0,1.0,,A,,,,CHEMBL624240,,BAO_0000218,,50588.0,In vivo,,N,7025.0,4521.0,1.0,,Intermediate,Canis lupus familiaris,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,
9615.0,1.0,,A,,,,CHEMBL624241,,BAO_0000218,,50588.0,In vivo,,N,7026.0,15660.0,1.0,,Intermediate,Canis lupus familiaris,Volume distribution (Vdss) was measured in dog,
9615.0,1.0,,A,,,,CHEMBL624242,,BAO_0000218,,50588.0,In vivo,,N,7027.0,15660.0,1.0,,Intermediate,Canis lupus familiaris,Volume distribution (Vdss) was measured in dog,
9615.0,1.0,,A,,,,CHEMBL624243,,BAO_0000218,,50588.0,In vivo,,N,7028.0,6679.0,1.0,,Intermediate,Canis lupus familiaris,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,
9615.0,1.0,,A,,,,CHEMBL624244,,BAO_0000218,,50588.0,In vivo,,N,7029.0,5145.0,1.0,,Intermediate,Canis lupus familiaris,Volume of distribution in steady state was determined in dog,
9615.0,1.0,,A,,,,CHEMBL624245,,BAO_0000218,,50588.0,In vivo,,N,7030.0,6821.0,1.0,,Intermediate,Canis lupus familiaris,Volume of distribution of compound was determined in dog,
9615.0,1.0,,A,,,,CHEMBL624246,,BAO_0000218,,50588.0,In vivo,,N,7031.0,4137.0,1.0,,Intermediate,Canis lupus familiaris,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,
9615.0,1.0,,A,,,,CHEMBL624247,,BAO_0000218,,50588.0,In vivo,,N,7032.0,5334.0,1.0,,Intermediate,Canis lupus familiaris,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),
9615.0,1.0,,A,,,,CHEMBL624248,,BAO_0000218,,50588.0,In vivo,,N,7033.0,15660.0,1.0,,Intermediate,Canis lupus familiaris,Volume of distribution (Vdss) was measured in dog,
9615.0,1.0,,A,,,,CHEMBL624249,,BAO_0000218,,50588.0,In vivo,,N,7034.0,6642.0,1.0,,Intermediate,Canis lupus familiaris,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),
9615.0,1.0,,A,,,,CHEMBL624250,,BAO_0000218,,50588.0,In vivo,,N,7035.0,6641.0,1.0,,Intermediate,Canis lupus familiaris,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),
9615.0,1.0,,A,,,,CHEMBL624251,,BAO_0000218,,50588.0,In vivo,,N,7036.0,6642.0,1.0,,Intermediate,Canis lupus familiaris,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),
9615.0,1.0,,A,,,,CHEMBL624252,,BAO_0000218,,50588.0,,,N,7037.0,11659.0,1.0,,Intermediate,Canis lupus familiaris,Maximum rate of depolarization of the upstroke of the action potential,
9615.0,1.0,,A,,,,CHEMBL624253,,BAO_0000218,,50588.0,In vivo,,N,7038.0,6448.0,1.0,,Intermediate,Canis lupus familiaris,Steady state volume distribution in dog,
9615.0,1.0,,A,,,,CHEMBL624950,,BAO_0000218,,50588.0,In vivo,,N,7039.0,5474.0,1.0,,Intermediate,Canis lupus familiaris,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,
9615.0,1.0,,A,,,,CHEMBL624951,,BAO_0000218,,50588.0,In vivo,,N,7040.0,1466.0,1.0,,Intermediate,Canis lupus familiaris,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,
9615.0,1.0,,A,,,,CHEMBL875830,,BAO_0000218,,50588.0,In vivo,,N,7041.0,6535.0,1.0,,Intermediate,Canis lupus familiaris,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,
9615.0,1.0,,A,,,,CHEMBL624952,,BAO_0000218,,50588.0,In vivo,,N,7042.0,6535.0,1.0,,Intermediate,Canis lupus familiaris,Volume distribution in dog after administration of 1 mg/kg iv,
9615.0,1.0,,A,,,,CHEMBL624953,,BAO_0000218,,50588.0,In vivo,,N,7043.0,17764.0,1.0,,Intermediate,Canis lupus familiaris,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,
9615.0,1.0,,A,,,,CHEMBL624954,,BAO_0000218,,50588.0,In vivo,,N,7044.0,6215.0,1.0,,Intermediate,Canis lupus familiaris,Vss after intravenous administration (0.5 mg/kg) was determined in dog,
9615.0,1.0,,A,,,,CHEMBL624955,,BAO_0000218,,50588.0,In vivo,,N,7045.0,6505.0,1.0,,Intermediate,Canis lupus familiaris,Vss on i.v. administration of 2 mg/kg was measured in dog,
9615.0,1.0,,A,,,,CHEMBL624956,,BAO_0000218,,50588.0,,,N,7046.0,3639.0,1.0,,Intermediate,Canis lupus familiaris,Vss was determined,
9615.0,1.0,,A,,,,CHEMBL625129,,BAO_0000218,,50588.0,,,N,7047.0,3639.0,1.0,,Intermediate,Canis lupus familiaris,Vss in dog,
9615.0,1.0,,A,,,,CHEMBL625130,,BAO_0000218,,50588.0,In vivo,,N,7048.0,6062.0,1.0,,Intermediate,Canis lupus familiaris,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL625131,,BAO_0000218,,50588.0,In vivo,,N,7049.0,4942.0,1.0,,Intermediate,Canis lupus familiaris,Volume distribution in dogs,
9615.0,1.0,,A,,,,CHEMBL625132,,BAO_0000218,,50588.0,In vivo,,N,7050.0,17796.0,1.0,,Intermediate,Canis lupus familiaris,Volume of distribution in dog,
9615.0,1.0,,A,,,,CHEMBL872263,,BAO_0000218,,50588.0,In vivo,,N,7051.0,4883.0,1.0,,Intermediate,Canis lupus familiaris,Tested for the oral bioavailability in dog,
10090.0,1.0,,A,,,,CHEMBL624336,,BAO_0000218,,50594.0,In vivo,,N,7060.0,17837.0,1.0,,Intermediate,Mus musculus,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,
10090.0,1.0,,A,,,,CHEMBL624337,,BAO_0000218,,50594.0,In vivo,,N,7061.0,17729.0,1.0,,Intermediate,Mus musculus,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,
10090.0,1.0,,A,,,,CHEMBL624338,,BAO_0000218,,50594.0,In vivo,,N,7062.0,17729.0,1.0,,Intermediate,Mus musculus,Bioavailability after peroral administration of 50 mg/kg of dose in mice,
10090.0,1.0,,A,,,,CHEMBL624339,,BAO_0000218,,50594.0,In vivo,,N,7063.0,4239.0,1.0,,Intermediate,Mus musculus,Bioavailability was measured in mouse,
10090.0,1.0,,A,,,,CHEMBL624340,,BAO_0000218,,50594.0,In vivo,,N,7064.0,17592.0,1.0,,Intermediate,Mus musculus,Bioavailability in mouse,
10090.0,1.0,,A,,,,CHEMBL624341,,BAO_0000218,,50594.0,In vivo,,N,7065.0,6348.0,1.0,,Intermediate,Mus musculus,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,
10090.0,1.0,,A,,,,CHEMBL624342,,BAO_0000218,,50594.0,In vivo,,N,7066.0,2801.0,1.0,,Intermediate,Mus musculus,Bioavailability in mouse,
10090.0,1.0,,A,,,,CHEMBL624343,,BAO_0000218,,50594.0,In vivo,,N,7067.0,2801.0,1.0,,Intermediate,Mus musculus,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,
10090.0,1.0,,A,,,,CHEMBL624344,,BAO_0000218,,50594.0,In vivo,,N,7068.0,17718.0,1.0,,Intermediate,Mus musculus,Oral bioavailability in mouse,
10090.0,1.0,,A,,,,CHEMBL624345,,BAO_0000218,,50594.0,In vivo,,N,7069.0,5727.0,1.0,,Intermediate,Mus musculus,Oral availability at 50 mg/kg po in male mice,
10090.0,1.0,,A,,,,CHEMBL624346,,BAO_0000218,,50594.0,In vivo,,N,7070.0,5302.0,1.0,,Intermediate,Mus musculus,Oral bioavailability in mouse (dose 10 mg/kg),
10090.0,1.0,,A,,,,CHEMBL624347,,BAO_0000218,,50594.0,In vivo,,N,7071.0,3598.0,1.0,,Expert,Mus musculus,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,
10090.0,1.0,,A,,,,CHEMBL624348,,BAO_0000218,,50594.0,In vivo,,N,7072.0,5961.0,1.0,,Intermediate,Mus musculus,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",
10090.0,1.0,,A,,,,CHEMBL622754,,BAO_0000218,,50594.0,In vivo,,N,7074.0,6091.0,1.0,,Intermediate,Mus musculus,Oral bioavailability in mouse,
10090.0,1.0,,A,,,,CHEMBL622755,,BAO_0000218,,50594.0,In vivo,,N,7075.0,6091.0,1.0,,Intermediate,Mus musculus,Oral bioavailability in vivo in mice;ND=Not determined,
10090.0,1.0,,A,,,,CHEMBL622756,,BAO_0000218,,50594.0,In vivo,,N,7076.0,5711.0,1.0,,Intermediate,Mus musculus,Oral bioavailability in mouse at 10 mg/kg of the compound,
10090.0,1.0,,A,,,,CHEMBL622757,,BAO_0000218,,50594.0,In vivo,,N,7077.0,17728.0,1.0,,Intermediate,Mus musculus,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),
10090.0,1.0,,A,,,,CHEMBL622758,,BAO_0000218,,50594.0,In vivo,,N,7078.0,17728.0,1.0,,Intermediate,Mus musculus,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),
10090.0,1.0,,A,,,,CHEMBL622759,,BAO_0000218,,50594.0,In vivo,,N,7079.0,3802.0,1.0,,Intermediate,Mus musculus,Tested for bioavailability of the compound,
10090.0,1.0,,A,,,,CHEMBL622760,,BAO_0000218,,50594.0,In vivo,,N,7080.0,3802.0,1.0,,Intermediate,Mus musculus,Tested for half life at the dose of 10 mg/kg when administered intravenously,
10090.0,1.0,,A,,,1969.0,CHEMBL622761,,BAO_0000218,,50594.0,,,N,7081.0,14029.0,1.0,,Intermediate,Mus musculus,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL622762,,BAO_0000218,,50594.0,,,N,7082.0,14029.0,1.0,,Intermediate,Mus musculus,The plasma half life of compound was determined on heparin prepared by human plasma. ,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL622763,,BAO_0000218,,50594.0,,,N,7083.0,14029.0,1.0,,Intermediate,Mus musculus,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL622764,,BAO_0000218,,50594.0,,,N,7084.0,14029.0,1.0,,Intermediate,Mus musculus,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,Plasma
10090.0,1.0,,A,,,1969.0,CHEMBL622765,,BAO_0000218,,50594.0,,,N,7085.0,14029.0,1.0,,Intermediate,Mus musculus,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,Plasma
10090.0,1.0,,F,,,,CHEMBL622766,,BAO_0000218,,50594.0,,,N,7086.0,17753.0,1.0,,Intermediate,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,
10090.0,1.0,,A,,,,CHEMBL622767,,BAO_0000218,,50594.0,,,N,7087.0,17753.0,1.0,,Intermediate,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,
10090.0,1.0,,A,,,,CHEMBL622768,,BAO_0000218,,50594.0,,,N,7088.0,17753.0,1.0,,Intermediate,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,
10090.0,1.0,,A,,,178.0,CHEMBL875948,,BAO_0000218,,50594.0,In vivo,,N,7089.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Blood
10090.0,1.0,,A,,,178.0,CHEMBL622769,,BAO_0000218,,50594.0,In vivo,,N,7090.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Blood
10090.0,1.0,,A,,,178.0,CHEMBL622770,,BAO_0000218,,50594.0,In vivo,,N,7091.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Blood
10090.0,1.0,,A,,,178.0,CHEMBL622771,,BAO_0000218,,50594.0,In vivo,,N,7092.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Blood
10090.0,1.0,,A,,,178.0,CHEMBL622772,,BAO_0000218,,50594.0,In vivo,,N,7093.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Blood
10090.0,1.0,,A,,,178.0,CHEMBL622773,,BAO_0000218,,50594.0,In vivo,,N,7094.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Blood
10090.0,1.0,,A,,,178.0,CHEMBL622774,,BAO_0000218,,50594.0,In vivo,,N,7095.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Blood
10090.0,1.0,,A,,,10000001.0,CHEMBL621725,,BAO_0000218,,50594.0,In vivo,,N,7096.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Bone
10090.0,1.0,,A,,,10000001.0,CHEMBL621726,,BAO_0000218,,50594.0,In vivo,,N,7097.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Bone
9606.0,1.0,,F,,,,CHEMBL621727,,BAO_0000219,A2780,81034.0,,,N,7098.0,15608.0,1.0,478.0,Intermediate,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,
9606.0,1.0,,F,,,,CHEMBL622413,,BAO_0000219,A2780,81034.0,,,N,7099.0,3290.0,1.0,478.0,Expert,Homo sapiens,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,
9606.0,1.0,,F,,,,CHEMBL622414,,BAO_0000219,A2780,81034.0,,,N,7100.0,2859.0,1.0,478.0,Intermediate,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell line,
9606.0,1.0,,F,,,,CHEMBL622415,,BAO_0000219,A2780,81034.0,,,N,7101.0,15688.0,1.0,478.0,Expert,Homo sapiens,Inhibition of A2780 cell clonogenic assay,
9606.0,1.0,,F,,,,CHEMBL884001,,BAO_0000219,A2780,81034.0,,,N,7102.0,5642.0,1.0,478.0,Expert,Homo sapiens,Cytotoxic effect on ovarian cancer cell line (A2780),
9606.0,1.0,,F,,,,CHEMBL622416,,BAO_0000219,A2780,81034.0,,,N,7103.0,6633.0,1.0,478.0,Intermediate,Homo sapiens,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,
9606.0,1.0,,F,,,,CHEMBL622417,,BAO_0000219,A2780,81034.0,,,N,7104.0,3906.0,1.0,478.0,Intermediate,Homo sapiens,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",
9606.0,1.0,,F,,,,CHEMBL622590,,BAO_0000219,A2780,81034.0,,,N,7105.0,6788.0,1.0,478.0,Expert,Homo sapiens,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,
9606.0,1.0,,F,,,,CHEMBL622591,,BAO_0000219,A2780,81034.0,,,N,7106.0,17582.0,1.0,478.0,Expert,Homo sapiens,Antiproliferative activity against human A2780 cells,
9606.0,1.0,,F,,,,CHEMBL622592,,BAO_0000219,A2780,81034.0,,,N,7107.0,17764.0,1.0,478.0,Expert,Homo sapiens,Inhibition of human A2780 cell proliferation,
9606.0,1.0,,F,,,,CHEMBL622593,,BAO_0000219,A2780,81034.0,,,N,7108.0,17764.0,1.0,478.0,Expert,Homo sapiens,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,
9606.0,1.0,,F,,,,CHEMBL622594,,BAO_0000219,A2780,81034.0,,,N,7109.0,17764.0,1.0,478.0,Expert,Homo sapiens,Inhibition of human A2780 cell proliferation (No data),
9606.0,1.0,,F,,,,CHEMBL622595,,BAO_0000219,A2780,81034.0,,,N,7110.0,2815.0,1.0,478.0,Intermediate,Homo sapiens,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,
9606.0,1.0,,F,,,,CHEMBL622596,,BAO_0000219,A2780,81034.0,,,N,7111.0,16930.0,1.0,478.0,Intermediate,Homo sapiens,Compound was evaluated against human Ovarian carcinoma cell line A2780,
9606.0,1.0,,F,,,,CHEMBL622597,,BAO_0000219,A2780,81034.0,,,N,7112.0,17777.0,1.0,478.0,Expert,Homo sapiens,Growth inhibition against A2780 wild-type ovarian cell lines,
9606.0,1.0,,F,,,,CHEMBL622598,,BAO_0000219,A2780,81034.0,,,N,7113.0,17777.0,1.0,478.0,Intermediate,Homo sapiens,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,
9606.0,5.0,,F,,,,CHEMBL622599,,BAO_0000019,,104766.0,,,D,7114.0,16936.0,1.0,,Autocuration,Homo sapiens,Inhibition of tubulin polymerization in human ovarian cancer cell lines,
9606.0,1.0,,F,,,,CHEMBL622600,,BAO_0000219,A2780,81034.0,,,N,7115.0,13759.0,1.0,478.0,Intermediate,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,
9606.0,1.0,,F,,,,CHEMBL622601,,BAO_0000219,A2780,81034.0,,,N,7116.0,13759.0,1.0,478.0,Intermediate,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,
9606.0,1.0,,F,,,,CHEMBL622602,,BAO_0000219,A2780,81034.0,,,N,7117.0,13759.0,1.0,478.0,Intermediate,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,
9606.0,1.0,,F,,,,CHEMBL622603,,BAO_0000219,A2780,81034.0,,,N,7118.0,13759.0,1.0,478.0,Intermediate,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,
9606.0,1.0,,F,,,,CHEMBL622604,,BAO_0000219,A2780,81034.0,,,N,7119.0,15292.0,1.0,478.0,Intermediate,Homo sapiens,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,
9606.0,1.0,,F,,,,CHEMBL622605,,BAO_0000219,A2780,81034.0,,,N,7120.0,15292.0,1.0,478.0,Intermediate,Homo sapiens,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,
9606.0,1.0,,F,,,,CHEMBL622606,,BAO_0000219,A2780,81034.0,,,N,7121.0,15069.0,1.0,478.0,Expert,Homo sapiens,In vitro inhibition of human ovarian cell line A2780,
9606.0,1.0,,F,,,,CHEMBL619463,,BAO_0000219,A2780,81034.0,,,N,7122.0,15069.0,1.0,478.0,Expert,Homo sapiens,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",
9606.0,1.0,,F,,,,CHEMBL619464,,BAO_0000219,A2780,81034.0,,,N,7123.0,14073.0,1.0,478.0,Intermediate,Homo sapiens,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),
9606.0,1.0,,F,,,,CHEMBL619465,,BAO_0000219,A2780,81034.0,,,N,7124.0,14553.0,1.0,478.0,Expert,Homo sapiens,Concentration required to inhibit A2780-cell growth by 50%,
9606.0,1.0,,F,,,,CHEMBL619466,,BAO_0000219,A2780,81034.0,,,N,7125.0,13040.0,1.0,478.0,Expert,Homo sapiens,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,
9606.0,1.0,,F,,,,CHEMBL619467,,BAO_0000219,A2780,81034.0,,,N,7126.0,6891.0,1.0,478.0,Expert,Homo sapiens,Cytotoxic effect on human ovarian (A2780) cancer cell line,
9606.0,1.0,,F,,,,CHEMBL619468,,BAO_0000219,A2780,81034.0,,,N,7127.0,15569.0,1.0,478.0,Intermediate,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,
9606.0,1.0,,F,,,,CHEMBL619469,,BAO_0000219,A2780,81034.0,,,N,7128.0,14190.0,1.0,478.0,Expert,Homo sapiens,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,
9606.0,1.0,,F,,,,CHEMBL619470,,BAO_0000219,A2780,81034.0,,,N,7129.0,15014.0,1.0,478.0,Expert,Homo sapiens,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,
9606.0,1.0,,F,,,,CHEMBL619471,,BAO_0000219,A2780,81034.0,,,N,7130.0,15014.0,1.0,478.0,Intermediate,Homo sapiens,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,
9606.0,1.0,,F,,,,CHEMBL619472,,BAO_0000219,A2780,81034.0,,,N,7131.0,17496.0,1.0,478.0,Intermediate,Homo sapiens,Cytotoxicity against human ovarian carcinoma A2780 cell line,
9606.0,1.0,,F,,,,CHEMBL619473,,BAO_0000219,A2780,81034.0,,,N,7132.0,13617.0,1.0,478.0,Intermediate,Homo sapiens,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",
9606.0,1.0,,F,,,,CHEMBL874368,,BAO_0000219,A2780,81034.0,,,N,7133.0,13617.0,1.0,478.0,Intermediate,Homo sapiens,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",
9606.0,1.0,,F,,,,CHEMBL884003,,BAO_0000219,A2780,81034.0,,,N,7134.0,13617.0,1.0,478.0,Intermediate,Homo sapiens,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",
9606.0,1.0,,F,,,,CHEMBL622690,,BAO_0000219,A2780,81034.0,,,N,7135.0,13617.0,1.0,478.0,Intermediate,Homo sapiens,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",
9606.0,1.0,,F,,,,CHEMBL622691,,BAO_0000219,A2780,81034.0,,,N,7136.0,17672.0,1.0,478.0,Intermediate,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,
9606.0,1.0,,F,,,,CHEMBL622692,,BAO_0000219,A2780,81034.0,,,N,7137.0,4544.0,1.0,478.0,Intermediate,Homo sapiens,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,
9606.0,1.0,,F,,,,CHEMBL623406,,BAO_0000219,A2780,81034.0,,,N,7138.0,4544.0,1.0,478.0,Intermediate,Homo sapiens,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,
9606.0,1.0,,F,,,,CHEMBL884004,,BAO_0000219,A2780,81034.0,,,N,7139.0,16317.0,1.0,478.0,Intermediate,Homo sapiens,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",
9606.0,1.0,,F,,,,CHEMBL623407,,BAO_0000219,A2780,81034.0,,,N,7140.0,15099.0,1.0,478.0,Intermediate,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,
9606.0,1.0,,F,,,,CHEMBL623408,,BAO_0000219,A2780,81034.0,,,N,7141.0,13978.0,1.0,478.0,Intermediate,Homo sapiens,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,
9606.0,1.0,,F,,,,CHEMBL623409,,BAO_0000219,A2780,81034.0,,,N,7142.0,12989.0,1.0,478.0,Expert,Homo sapiens,In vitro antitumor activity against A2780 cell line.,
9606.0,1.0,,F,,,,CHEMBL623410,,BAO_0000219,A2780,81034.0,,,N,7143.0,5574.0,1.0,478.0,Intermediate,Homo sapiens,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,
9606.0,1.0,,F,,,,CHEMBL623576,,BAO_0000219,A2780,81034.0,,,N,7144.0,13528.0,1.0,478.0,Expert,Homo sapiens,In vitro cytotoxicity against A2780 human ovarian cancer cell line,
9606.0,1.0,,F,,,,CHEMBL623577,,BAO_0000219,ACHN,80025.0,,,N,7145.0,12782.0,1.0,626.0,Intermediate,Homo sapiens,Inhibitory activity against kidney A-CHN tumor cell growth in culture,
9606.0,1.0,,F,,,,CHEMBL623578,,BAO_0000219,ACHN,80025.0,,,N,7146.0,14255.0,1.0,626.0,Intermediate,Homo sapiens,The IC50 value was measured on ACHN cell line in renal tumor type.,
9606.0,1.0,,F,,,,CHEMBL623579,,BAO_0000219,ACHN,80025.0,,,N,7147.0,16364.0,1.0,626.0,Intermediate,Homo sapiens,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,
9606.0,1.0,,F,,,,CHEMBL623580,,BAO_0000219,ACHN,80025.0,,,N,7148.0,17376.0,1.0,626.0,Expert,Homo sapiens,In vitro lethal concentration against most sensitive ACHN cell line,
9606.0,1.0,,F,,,,CHEMBL623581,,BAO_0000219,ACHN,80025.0,,,N,7149.0,12016.0,1.0,626.0,Intermediate,Homo sapiens,Tested for cytotoxic activity against renal cancer ACHN cell line,
9606.0,1.0,,F,,,,CHEMBL857456,,BAO_0000219,ACHN,80025.0,,,N,7150.0,6058.0,1.0,626.0,Intermediate,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line ACHN,
9606.0,1.0,,F,,,,CHEMBL623582,,BAO_0000219,ACHN,80025.0,,,N,7151.0,17708.0,1.0,626.0,Intermediate,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,
9606.0,1.0,,F,,,,CHEMBL623583,,BAO_0000219,ACHN,80025.0,,,N,7152.0,15176.0,1.0,626.0,Intermediate,Homo sapiens,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,
9606.0,1.0,,F,,,,CHEMBL623584,,BAO_0000219,ACHN,80025.0,,,N,7153.0,2806.0,1.0,626.0,Intermediate,Homo sapiens,In vitro anticancer activity against ACHN renal cancer cell line,
9606.0,1.0,,F,,,,CHEMBL623585,,BAO_0000219,ACHN,80025.0,,,N,7154.0,15300.0,1.0,626.0,Intermediate,Homo sapiens,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,
9606.0,1.0,,F,,,,CHEMBL623586,,BAO_0000219,ACHN,80025.0,,,N,7155.0,16364.0,1.0,626.0,Intermediate,Homo sapiens,Percent selectivity was evaluated in renal ACHN cell lines,
9606.0,1.0,,F,,,,CHEMBL623587,,BAO_0000219,ACHN,80025.0,,,N,7156.0,13859.0,1.0,626.0,Intermediate,Homo sapiens,In vitro inhibitory activity against renal ACHN cancer cell line,
9606.0,1.0,,F,,,,CHEMBL875279,,BAO_0000219,ACHN,80025.0,,,N,7157.0,11970.0,1.0,626.0,Intermediate,Homo sapiens,Tested for cytotoxicity against ACHN cell lines in renal cancer,
9606.0,1.0,,F,,,,CHEMBL623588,,BAO_0000219,ACHN,80025.0,,,N,7158.0,2450.0,1.0,626.0,Intermediate,Homo sapiens,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,
9606.0,1.0,,F,,,,CHEMBL623589,,BAO_0000219,ACHN,80025.0,,,N,7159.0,12696.0,1.0,626.0,Intermediate,Homo sapiens,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,
9606.0,1.0,,F,,,,CHEMBL623590,,BAO_0000219,ACHN,80025.0,,,N,7160.0,12400.0,1.0,626.0,Intermediate,Homo sapiens,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,
9606.0,1.0,,F,,,,CHEMBL623591,,BAO_0000219,ACHN,80025.0,,,N,7161.0,12888.0,1.0,626.0,Expert,Homo sapiens,Cytotoxic effect on renal cancer line ACHN,
9606.0,1.0,,F,,,,CHEMBL623592,,BAO_0000219,ACHN,80025.0,,,N,7162.0,3156.0,1.0,626.0,Intermediate,Homo sapiens,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,
9606.0,1.0,,F,,,,CHEMBL623593,,BAO_0000219,ACHN,80025.0,,,N,7163.0,3381.0,1.0,626.0,Intermediate,Homo sapiens,In vitro inhibition of Renal Cancer ACHN cell lines,
9606.0,1.0,,F,,,,CHEMBL623594,,BAO_0000219,ACHN,80025.0,,,N,7164.0,16747.0,1.0,626.0,Intermediate,Homo sapiens,Antitumor activity against human renal adenocarcinoma ACHN cells,
9606.0,1.0,,F,,,,CHEMBL621833,,BAO_0000219,ACHN,80025.0,,,N,7165.0,16748.0,1.0,626.0,Expert,Homo sapiens,Antitumor activity against human renal adenocarcinoma ACHN cells.,
9606.0,1.0,,F,,,,CHEMBL621834,,BAO_0000219,ACHN,80025.0,,,N,7166.0,12062.0,1.0,626.0,Intermediate,Homo sapiens,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,
9606.0,1.0,,F,,,,CHEMBL621835,,BAO_0000219,ACHN,80025.0,,,N,7167.0,14769.0,1.0,626.0,Intermediate,Homo sapiens,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),
9606.0,1.0,,F,,,,CHEMBL621836,,BAO_0000219,ACHN,80025.0,,,N,7168.0,15895.0,1.0,626.0,Intermediate,Homo sapiens,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",
9606.0,1.0,,F,,,,CHEMBL621837,,BAO_0000219,ACHN,80025.0,,,N,7169.0,17376.0,1.0,626.0,Intermediate,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,
9606.0,1.0,,F,,,,CHEMBL875280,,BAO_0000219,ACHN,80025.0,,,N,7170.0,14882.0,1.0,626.0,Intermediate,Homo sapiens,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,
9606.0,1.0,,F,,,,CHEMBL621838,,BAO_0000219,ACHN,80025.0,,,N,7171.0,14882.0,1.0,626.0,Intermediate,Homo sapiens,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,
9606.0,1.0,,F,,,,CHEMBL621839,,BAO_0000219,ACHN,80025.0,,,N,7172.0,15661.0,1.0,626.0,Intermediate,Homo sapiens,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,
,0.0,,A,,,,CHEMBL621840,,BAO_0000019,,22224.0,,,U,7173.0,9680.0,1.0,,Autocuration,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,
,8.0,,F,,,,CHEMBL621841,,BAO_0000019,,10647.0,,,H,7174.0,14579.0,1.0,,Autocuration,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,
10358.0,1.0,,F,,,,CHEMBL622979,,BAO_0000218,HEL,50529.0,,,N,7175.0,17290.0,1.0,468.0,Expert,Cytomegalovirus,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,
10358.0,1.0,,F,,,,CHEMBL876595,,BAO_0000218,,50529.0,,,N,7176.0,17290.0,1.0,,Intermediate,Cytomegalovirus,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,
,8.0,,B,,,,CHEMBL620221,,BAO_0000357,,12159.0,,,H,7177.0,15891.0,1.0,,Autocuration,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),
,8.0,,B,,,,CHEMBL620222,,BAO_0000357,,12159.0,,,H,7178.0,15890.0,1.0,,Autocuration,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),
9913.0,1.0,,F,,,,CHEMBL620506,,BAO_0000219,ADDP cell line,80670.0,,,N,7179.0,3801.0,1.0,979.0,Intermediate,Bos taurus,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,
10090.0,1.0,,F,,,,CHEMBL620507,,BAO_0000219,ADJ/PC6,80671.0,,,N,7180.0,9222.0,1.0,980.0,Intermediate,Mus musculus,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,
10090.0,1.0,,F,,,,CHEMBL620508,,BAO_0000219,ADJ/PC6,80671.0,,,N,7181.0,9222.0,1.0,980.0,Intermediate,Mus musculus,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,
10090.0,1.0,,F,,,,CHEMBL620509,,BAO_0000219,ADJ/PC6,80671.0,,,N,7182.0,7257.0,1.0,980.0,Intermediate,Mus musculus,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",
10090.0,1.0,,F,,,,CHEMBL620510,,BAO_0000219,ADJ/PC6,80671.0,,,N,7183.0,7257.0,1.0,980.0,Intermediate,Mus musculus,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,
10090.0,1.0,,A,,,,CHEMBL620511,,BAO_0000219,ADJ/PC6,80671.0,,,N,7184.0,7257.0,1.0,980.0,Intermediate,Mus musculus,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,
10090.0,1.0,,F,,,,CHEMBL620512,,BAO_0000219,ADJ/PC6,80671.0,,,N,7185.0,8084.0,1.0,980.0,Intermediate,Mus musculus,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,
10090.0,0.0,,F,,,,CHEMBL620513,,BAO_0000019,,22224.0,,,U,7186.0,14943.0,1.0,,Autocuration,Mus musculus,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,
10090.0,0.0,,F,,,,CHEMBL620514,,BAO_0000019,,22224.0,,,U,7187.0,14943.0,1.0,,Autocuration,Mus musculus,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,
10090.0,0.0,,F,,,,CHEMBL620515,,BAO_0000019,,22224.0,,,U,7188.0,14943.0,1.0,,Autocuration,Mus musculus,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,
1423.0,0.0,,A,,,,CHEMBL620516,,BAO_0000218,,22224.0,In vivo,,U,7189.0,10524.0,1.0,,Autocuration,Bacillus subtilis,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),
9615.0,1.0,,A,,,1969.0,CHEMBL620517,,BAO_0000218,,50588.0,,,N,7190.0,3546.0,1.0,,Intermediate,Canis lupus familiaris,AUC value in dog after IV administration at a dose of 5 mg/kg,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL620518,,BAO_0000218,,50588.0,,,N,7191.0,3546.0,1.0,,Intermediate,Canis lupus familiaris,AUC value in dog after oral administration at a dose of 5 mg/kg,Plasma
9615.0,1.0,,A,,,,CHEMBL620519,,BAO_0000218,,50588.0,In vivo,,N,7192.0,3546.0,1.0,,Intermediate,Canis lupus familiaris,Cmax value in dog after oral administration at a dose of 5 mg/kg,
9615.0,1.0,,A,,,,CHEMBL621386,,BAO_0000218,,50588.0,In vivo,,N,7193.0,3546.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog after oral administration at a dose of 5 mg/kg,
9615.0,1.0,,A,,,,CHEMBL621387,,BAO_0000218,,50588.0,In vivo,,N,7194.0,3546.0,1.0,,Intermediate,Canis lupus familiaris,Tmax value in dog after oral administration at a dose of 5 mg/kg,
9615.0,1.0,,A,,,,CHEMBL621388,,BAO_0000218,,50588.0,In vivo,,N,7195.0,3184.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for its clearance when administered intravenously in dog,
9615.0,1.0,,A,,,,CHEMBL621389,,BAO_0000218,,50588.0,In vivo,,N,7196.0,16456.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,
9615.0,1.0,,A,,,,CHEMBL621390,,BAO_0000218,,50588.0,In vivo,,N,7197.0,4809.0,1.0,,Intermediate,Canis lupus familiaris,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),
,0.0,,P,,,,CHEMBL621391,,BAO_0000100,,22229.0,,,U,7198.0,4219.0,1.0,,Intermediate,,Calculated partition coefficient (clogP),
9615.0,1.0,,A,,,,CHEMBL621392,,BAO_0000218,,50588.0,,,N,7199.0,3748.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog,
9615.0,1.0,,A,,,,CHEMBL621393,,BAO_0000218,,50588.0,,,N,7200.0,3132.0,1.0,,Intermediate,Canis lupus familiaris,Time taken for EC90 was determined when tested in dog,
9615.0,1.0,,A,,,,CHEMBL621394,,BAO_0000218,,50588.0,,,N,7201.0,4219.0,1.0,,Intermediate,Canis lupus familiaris,Half life (iv) was determined,
9615.0,1.0,,A,,,2107.0,CHEMBL621395,,BAO_0000218,,50588.0,,,N,7202.0,16907.0,1.0,,Intermediate,Canis lupus familiaris,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Liver
9615.0,1.0,,A,,,,CHEMBL621396,,BAO_0000218,,50588.0,,,N,7203.0,6057.0,1.0,,Intermediate,Canis lupus familiaris,Area under the curve was calculated in dog after iv administration,
9615.0,1.0,,A,,,,CHEMBL621397,,BAO_0000218,,50588.0,,,N,7204.0,6057.0,1.0,,Intermediate,Canis lupus familiaris,Area under the curve was calculated in dog after peroral administration,
9615.0,1.0,,A,,,,CHEMBL621398,,BAO_0000218,,50588.0,,,N,7205.0,17853.0,1.0,,Intermediate,Canis lupus familiaris,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,
9615.0,1.0,,A,,,,CHEMBL618818,,BAO_0000218,,50588.0,,,N,7206.0,3639.0,1.0,,Intermediate,Canis lupus familiaris,pKa was evaluated in dog,
9615.0,1.0,,A,,,,CHEMBL618819,,BAO_0000218,,50588.0,,,N,7207.0,14541.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,
9615.0,1.0,,A,,,,CHEMBL618820,,BAO_0000218,,50588.0,In vivo,,N,7208.0,16456.0,1.0,,Intermediate,Canis lupus familiaris,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,
9615.0,1.0,,A,,,,CHEMBL873810,,BAO_0000218,,50588.0,In vivo,,N,7209.0,16456.0,1.0,,Intermediate,Canis lupus familiaris,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,
9615.0,1.0,,A,,,,CHEMBL876606,,BAO_0000218,,50588.0,In vivo,,N,7210.0,2652.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,
9615.0,1.0,,A,,,,CHEMBL618821,,BAO_0000218,,50588.0,,,N,7211.0,3624.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for the half-life (t 1/2) in hours,
9615.0,1.0,,A,,,178.0,CHEMBL618822,,BAO_0000218,,50588.0,In vivo,,N,7212.0,1337.0,1.0,,Intermediate,Canis lupus familiaris,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Blood
9615.0,1.0,,A,,,178.0,CHEMBL618823,,BAO_0000218,,50588.0,In vivo,,N,7213.0,1337.0,1.0,,Intermediate,Canis lupus familiaris,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Blood
9615.0,1.0,,A,,,,CHEMBL618824,,BAO_0000218,,50588.0,In vivo,,N,7214.0,4709.0,1.0,,Intermediate,Canis lupus familiaris,Half life after intravenous administration of 1 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL618825,,BAO_0000218,,50588.0,,,N,7215.0,15660.0,1.0,,Intermediate,Canis lupus familiaris,Half life was measured in dog,
9615.0,1.0,,A,,,,CHEMBL618826,,BAO_0000218,,50588.0,In vivo,,N,7216.0,5302.0,1.0,,Intermediate,Canis lupus familiaris,Half life period in dog after 5 mg/kg dose,
9615.0,1.0,,A,,,,CHEMBL618827,,BAO_0000218,,50588.0,,,N,7217.0,17791.0,1.0,,Intermediate,Canis lupus familiaris,Half life period was evaluated in dog; 4-4.8,
9615.0,1.0,,A,,,,CHEMBL618828,,BAO_0000218,,50588.0,In vivo,,N,7218.0,6348.0,1.0,,Intermediate,Canis lupus familiaris,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,
9615.0,1.0,,A,,,,CHEMBL618829,,BAO_0000218,,50588.0,In vivo,,N,7219.0,4257.0,1.0,,Intermediate,Canis lupus familiaris,Half-life was determined in dog after a3 mg/kg of iv dose,
9615.0,1.0,,A,,,,CHEMBL618830,,BAO_0000218,,50588.0,,,N,7220.0,3771.0,1.0,,Intermediate,Canis lupus familiaris,Half-life was determined,
9615.0,1.0,,A,,,,CHEMBL618831,,BAO_0000218,,50588.0,,,N,7221.0,6305.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dogs,
9615.0,1.0,,A,,,1969.0,CHEMBL619489,,BAO_0000218,,50588.0,In vivo,,N,7222.0,13501.0,1.0,,Intermediate,Canis lupus familiaris,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,Plasma
9615.0,1.0,,A,,,,CHEMBL619649,,BAO_0000218,,50588.0,In vivo,,N,7223.0,17594.0,1.0,,Intermediate,Canis lupus familiaris,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,
9615.0,1.0,,A,,,,CHEMBL876607,,BAO_0000218,,50588.0,In vivo,,N,7224.0,3045.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for the half life period after iv administration in Beagle dog.,
9615.0,1.0,,A,,,,CHEMBL619650,,BAO_0000218,,50588.0,In vivo,,N,7225.0,3043.0,1.0,,Intermediate,Canis lupus familiaris,Compound was evaluated for the half life period after oral administration in conscious dog.,
9615.0,1.0,,A,,,,CHEMBL619651,,BAO_0000218,,50588.0,,,N,7226.0,4839.0,1.0,,Intermediate,Canis lupus familiaris,Compound was tested for half life in dog,
9615.0,1.0,,A,,,,CHEMBL619652,,BAO_0000218,,50588.0,,,N,7227.0,4839.0,1.0,,Intermediate,Canis lupus familiaris,Compound was tested for its half life in dog,
9615.0,1.0,,A,,,,CHEMBL619653,,BAO_0000218,,50588.0,In vivo,,N,7228.0,5802.0,1.0,,Intermediate,Canis lupus familiaris,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,
9615.0,1.0,,A,,,,CHEMBL619654,,BAO_0000218,,50588.0,,,N,7229.0,17839.0,1.0,,Intermediate,Canis lupus familiaris,Half life of compound in dog was determined,
9615.0,1.0,,A,,,,CHEMBL619655,,BAO_0000218,,50588.0,In vivo,,N,7230.0,4219.0,1.0,,Intermediate,Canis lupus familiaris,Half life (iv) was determined,
9615.0,1.0,,A,,,178.0,CHEMBL619656,,BAO_0000218,,50588.0,,,N,7231.0,13966.0,1.0,,Intermediate,Canis lupus familiaris,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),Blood
9615.0,1.0,,A,,,1969.0,CHEMBL873812,,BAO_0000218,,50588.0,In vivo,,N,7232.0,3994.0,1.0,,Intermediate,Canis lupus familiaris,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Plasma
9615.0,1.0,,F,,,1969.0,CHEMBL621365,,BAO_0000218,,50588.0,In vivo,,N,7233.0,3994.0,1.0,,Intermediate,Canis lupus familiaris,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Plasma
9615.0,1.0,,A,,,,CHEMBL621366,,BAO_0000218,,50588.0,,,N,7234.0,4453.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog,
9615.0,1.0,,A,,,1969.0,CHEMBL621367,,BAO_0000218,,50588.0,,,N,7235.0,6535.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog plasma,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL621368,,BAO_0000218,,50588.0,In vivo,,N,7236.0,6535.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog plasma after administration of 0.25 mg/kg iv,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL621369,,BAO_0000218,,50588.0,In vivo,,N,7237.0,6535.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog plasma after administration of 1 mg/kg iv,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL621370,,BAO_0000218,,50588.0,In vivo,,N,7238.0,3132.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog plasma was determined at dose 10 mg/kg,Plasma
9615.0,1.0,,A,,,,CHEMBL621371,,BAO_0000218,,50588.0,,,N,7239.0,5374.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog was determined,
9615.0,1.0,,A,,,,CHEMBL621372,,BAO_0000218,,50588.0,In vivo,,N,7240.0,5007.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),
9615.0,1.0,,A,,,1969.0,CHEMBL621373,,BAO_0000218,,50588.0,,,N,7241.0,16907.0,1.0,,Intermediate,Canis lupus familiaris,Half life upon exposure to human plasma,Plasma
9615.0,1.0,,A,,,,CHEMBL621374,,BAO_0000218,,50588.0,,,N,7242.0,6057.0,1.0,,Intermediate,Canis lupus familiaris,Half life was calculated in dog,
9615.0,1.0,,A,,,,CHEMBL621375,,BAO_0000218,,50588.0,,,N,7243.0,5006.0,1.0,,Intermediate,Canis lupus familiaris,Half life was determined,
9615.0,1.0,,A,,,,CHEMBL621376,,BAO_0000218,,50588.0,,,N,7244.0,5473.0,1.0,,Intermediate,Canis lupus familiaris,Half life was determined,
9615.0,1.0,,A,,,,CHEMBL619624,,BAO_0000218,,50588.0,In vivo,,N,7245.0,4368.0,1.0,,Intermediate,Canis lupus familiaris,Half life by intravenous administration of 1.2 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL875840,,BAO_0000218,,50588.0,,,N,7246.0,6448.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog,
9615.0,1.0,,A,,,,CHEMBL619625,,BAO_0000218,,50588.0,,,N,7247.0,4353.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog after intra venous administration of the compound,
9615.0,1.0,,A,,,,CHEMBL619626,,BAO_0000218,,50588.0,,,N,7248.0,4353.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog after intra venous administration of the compound; ND means Not determined,
9615.0,1.0,,A,,,,CHEMBL619627,,BAO_0000218,,50588.0,In vivo,,N,7249.0,4353.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog after po administration of the compound,
9615.0,1.0,,A,,,,CHEMBL873817,,BAO_0000218,,50588.0,In vivo,,N,7250.0,4353.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog after po administration of the compound; ND means Not determined,
9615.0,1.0,,A,,,,CHEMBL619628,,BAO_0000218,,50588.0,In vivo,,N,7251.0,6265.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog at the single oral dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL619629,,BAO_0000218,,50588.0,,,N,7252.0,5006.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dogs,
9615.0,1.0,,A,,,,CHEMBL619630,,BAO_0000218,,50588.0,In vivo,,N,7253.0,5356.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,
9615.0,1.0,,A,,,,CHEMBL619631,,BAO_0000218,,50588.0,,,N,7254.0,405.0,1.0,,Intermediate,Canis lupus familiaris,Half life in rat,
9615.0,1.0,,A,,,,CHEMBL619632,,BAO_0000218,,50588.0,In vivo,,N,7255.0,6642.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),
10090.0,1.0,,A,,,10000001.0,CHEMBL619633,,BAO_0000218,,50594.0,In vivo,,N,7256.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Bone
10090.0,1.0,,A,,,10000001.0,CHEMBL875841,,BAO_0000218,,50594.0,In vivo,,N,7257.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Bone
10090.0,1.0,,A,,,10000001.0,CHEMBL619634,,BAO_0000218,,50594.0,In vivo,,N,7258.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Bone
10090.0,1.0,,A,,,10000001.0,CHEMBL619635,,BAO_0000218,,50594.0,In vivo,,N,7259.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Bone
10090.0,1.0,,A,,,10000001.0,CHEMBL619636,,BAO_0000218,,50594.0,In vivo,,N,7260.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Bone
10090.0,1.0,,A,,,10000004.0,CHEMBL619637,,BAO_0000218,,50594.0,In vivo,,N,7261.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Gut
10090.0,1.0,,A,,,10000004.0,CHEMBL619638,,BAO_0000218,,50594.0,In vivo,,N,7262.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Gut
10090.0,1.0,,A,,,10000004.0,CHEMBL619639,,BAO_0000218,,50594.0,In vivo,,N,7263.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Gut
10090.0,1.0,,A,,,10000004.0,CHEMBL619640,,BAO_0000218,,50594.0,In vivo,,N,7264.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Gut
10090.0,1.0,,A,,,10000004.0,CHEMBL619641,,BAO_0000218,,50594.0,In vivo,,N,7265.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Gut
10090.0,1.0,,A,,,10000004.0,CHEMBL619642,,BAO_0000218,,50594.0,In vivo,,N,7266.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Gut
10090.0,1.0,,A,,,10000004.0,CHEMBL619643,,BAO_0000218,,50594.0,In vivo,,N,7267.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Gut
10090.0,1.0,,A,,,948.0,CHEMBL619644,,BAO_0000218,,50594.0,In vivo,,N,7268.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Heart
10090.0,1.0,,A,,,948.0,CHEMBL621112,,BAO_0000218,,50594.0,In vivo,,N,7269.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Heart
10090.0,1.0,,A,,,948.0,CHEMBL621113,,BAO_0000218,,50594.0,In vivo,,N,7270.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Heart
10090.0,1.0,,A,,,948.0,CHEMBL621114,,BAO_0000218,,50594.0,In vivo,,N,7271.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Heart
10090.0,1.0,,A,,,948.0,CHEMBL621115,,BAO_0000218,,50594.0,In vivo,,N,7272.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Heart
10090.0,1.0,,A,,,948.0,CHEMBL621116,,BAO_0000218,,50594.0,In vivo,,N,7273.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Heart
10090.0,1.0,,A,,,948.0,CHEMBL621117,,BAO_0000218,,50594.0,In vivo,,N,7274.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Heart
10090.0,1.0,,A,,,2113.0,CHEMBL621118,,BAO_0000218,,50594.0,In vivo,,N,7275.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL621119,,BAO_0000218,,50594.0,In vivo,,N,7276.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL621120,,BAO_0000218,,50594.0,In vivo,,N,7277.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL621757,,BAO_0000218,,50594.0,In vivo,,N,7278.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL621758,,BAO_0000218,,50594.0,In vivo,,N,7279.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL621759,,BAO_0000218,,50594.0,In vivo,,N,7280.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Kidney
10090.0,1.0,,A,,,2113.0,CHEMBL621760,,BAO_0000218,,50594.0,In vivo,,N,7281.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Kidney
10090.0,1.0,,A,,,2107.0,CHEMBL621761,,BAO_0000218,,50594.0,In vivo,,N,7282.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL621762,,BAO_0000218,,50594.0,In vivo,,N,7283.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL621763,,BAO_0000218,,50594.0,In vivo,,N,7284.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL624502,,BAO_0000218,,50594.0,In vivo,,N,7285.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL624503,,BAO_0000218,,50594.0,In vivo,,N,7286.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL624504,,BAO_0000218,,50594.0,In vivo,,N,7287.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Liver
10090.0,1.0,,A,,,2107.0,CHEMBL624505,,BAO_0000218,,50594.0,In vivo,,N,7288.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Liver
10090.0,1.0,,A,,,2048.0,CHEMBL624506,,BAO_0000218,,50594.0,In vivo,,N,7289.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Lung
9606.0,1.0,,F,,,,CHEMBL624507,,BAO_0000219,A2780,81034.0,,,N,7290.0,5895.0,1.0,478.0,Intermediate,Homo sapiens,In vitro cytotoxicity against A2780 (human ovarian cancer),
9606.0,1.0,,F,,,,CHEMBL624508,,BAO_0000219,A2780,81034.0,,,N,7291.0,6338.0,1.0,478.0,Intermediate,Homo sapiens,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,
9606.0,1.0,,F,,,,CHEMBL624509,,BAO_0000219,A2780,81034.0,,,N,7292.0,15163.0,1.0,478.0,Intermediate,Homo sapiens,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,
9606.0,1.0,,F,,,,CHEMBL624510,,BAO_0000219,A2780,81034.0,,,N,7293.0,15163.0,1.0,478.0,Intermediate,Homo sapiens,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,
9606.0,1.0,,F,,,,CHEMBL875956,,BAO_0000219,A2780,81034.0,,,N,7294.0,15000.0,1.0,478.0,Expert,Homo sapiens,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,
9606.0,1.0,,F,,,,CHEMBL839885,,BAO_0000219,A2780,81034.0,,,N,7295.0,15000.0,1.0,478.0,Expert,Homo sapiens,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,
9606.0,1.0,,F,,,,CHEMBL624511,,BAO_0000219,A2780,81034.0,,,N,7296.0,14729.0,1.0,478.0,Expert,Homo sapiens,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,
9606.0,1.0,,F,,,,CHEMBL624512,,BAO_0000219,A2780,81034.0,,,N,7297.0,17270.0,1.0,478.0,Intermediate,Homo sapiens,In vitro cytotoxicity against A2780 cell line,
9606.0,1.0,,F,,,,CHEMBL624513,,BAO_0000219,A2780,81034.0,,,N,7298.0,5685.0,1.0,478.0,Intermediate,Homo sapiens,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,
9606.0,1.0,,F,,,,CHEMBL624514,,BAO_0000219,A2780,81034.0,,,N,7299.0,3563.0,1.0,478.0,Intermediate,Homo sapiens,In vitro inhibitory activity against human ovarian cancer A2780 cell line,
9606.0,1.0,,F,,,,CHEMBL618547,,BAO_0000218,A2780,81034.0,,,N,7300.0,17753.0,1.0,478.0,Intermediate,Homo sapiens,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,
9606.0,1.0,,F,,,,CHEMBL618548,,BAO_0000219,A2780,81034.0,,,N,7301.0,16317.0,1.0,478.0,Intermediate,Homo sapiens,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",
9606.0,1.0,,F,,,,CHEMBL618549,,BAO_0000219,A2780,81034.0,,,N,7302.0,16936.0,1.0,478.0,Intermediate,Homo sapiens,Inhibition of tubulin polymerization in analogy of ca.,
9606.0,1.0,,F,,,,CHEMBL618550,,BAO_0000219,A2780,81034.0,,,N,7303.0,3801.0,1.0,478.0,Intermediate,Homo sapiens,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,
9606.0,1.0,,F,,,,CHEMBL618551,,BAO_0000219,A2780,81034.0,,,N,7304.0,6181.0,1.0,478.0,Expert,Homo sapiens,Cytotoxic effect in ovarian cancer cell line (A2780),
9606.0,1.0,,F,,,,CHEMBL618552,,BAO_0000219,A2780,81034.0,,,N,7305.0,5318.0,1.0,478.0,Intermediate,Homo sapiens,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,
9606.0,1.0,,F,,,,CHEMBL618553,,BAO_0000219,A2780,81034.0,,,N,7306.0,4840.0,1.0,478.0,Intermediate,Homo sapiens,Tested for the cytotoxicity in A2780 ovarian cell line,
9606.0,1.0,,F,,,,CHEMBL618554,,BAO_0000219,A2780,81034.0,,,N,7307.0,15748.0,1.0,478.0,Intermediate,Homo sapiens,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),
9606.0,1.0,,F,,,,CHEMBL618555,,BAO_0000219,A2780,81034.0,,,N,7308.0,15748.0,1.0,478.0,Intermediate,Homo sapiens,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,
,1.0,,F,,,,CHEMBL618556,,BAO_0000219,A2780cisR,80017.0,,,N,7309.0,15748.0,1.0,481.0,Intermediate,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,
,1.0,,F,,,,CHEMBL618557,,BAO_0000219,A2780cisR,80017.0,,,N,7310.0,15748.0,1.0,481.0,Intermediate,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),
,1.0,,F,,,,CHEMBL618558,,BAO_0000219,A2780cisR,80017.0,,,N,7311.0,15748.0,1.0,481.0,Intermediate,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,
,1.0,,F,,,,CHEMBL618559,,BAO_0000219,A2780cisR,80017.0,,,N,7312.0,15748.0,1.0,481.0,Intermediate,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),
9606.0,1.0,,F,,,,CHEMBL618560,,BAO_0000218,A2780,81034.0,,,N,7313.0,17753.0,1.0,478.0,Intermediate,Homo sapiens,In vivo log of cells killed after administration of compound in A2780 cell line,
9606.0,1.0,,F,,,,CHEMBL618561,,BAO_0000218,A2780,81034.0,In vivo,,N,7314.0,17753.0,1.0,478.0,Intermediate,Homo sapiens,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,
9606.0,1.0,,F,,,,CHEMBL618562,,BAO_0000219,A2780,81034.0,,,N,7315.0,16936.0,1.0,478.0,Intermediate,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,
9606.0,1.0,,F,,,,CHEMBL618563,,BAO_0000219,A2780,81034.0,,,N,7316.0,16936.0,1.0,478.0,Intermediate,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,
9606.0,1.0,,F,,,,CHEMBL618564,,BAO_0000219,A2780,81034.0,,,N,7317.0,16936.0,1.0,478.0,Intermediate,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,
9606.0,1.0,,F,,,,CHEMBL618565,,BAO_0000219,A2780,81034.0,,,N,7318.0,16936.0,1.0,478.0,Intermediate,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,
9606.0,1.0,,F,,,,CHEMBL618566,,BAO_0000218,A2780,81034.0,,,N,7319.0,17528.0,1.0,478.0,Intermediate,Homo sapiens,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),
9606.0,1.0,,F,,,,CHEMBL618567,,BAO_0000219,A2780,81034.0,,,N,7320.0,6633.0,1.0,478.0,Intermediate,Homo sapiens,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,
9606.0,1.0,,F,,,,CHEMBL618568,,BAO_0000219,A2780,81034.0,,,N,7321.0,15000.0,1.0,478.0,Expert,Homo sapiens,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,
9606.0,1.0,,F,,,,CHEMBL618569,,BAO_0000219,A2780,81034.0,,,N,7322.0,17528.0,1.0,478.0,Expert,Homo sapiens,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,
9606.0,1.0,,F,,,,CHEMBL621857,,BAO_0000219,A2780,81034.0,,,N,7323.0,16936.0,1.0,478.0,Intermediate,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,
9606.0,1.0,,F,,,,CHEMBL621858,,BAO_0000219,A2780,81034.0,,,N,7324.0,16936.0,1.0,478.0,Intermediate,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,
9606.0,1.0,,F,,,,CHEMBL621859,,BAO_0000219,A2780,81034.0,,,N,7325.0,16936.0,1.0,478.0,Intermediate,Homo sapiens,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,
9606.0,1.0,,F,,,,CHEMBL621860,,BAO_0000219,A2780,81034.0,,,N,7326.0,16936.0,1.0,478.0,Intermediate,Homo sapiens,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",
9606.0,1.0,,F,,,,CHEMBL621861,,BAO_0000219,A2780,81034.0,,,N,7327.0,16936.0,1.0,478.0,Intermediate,Homo sapiens,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),
9606.0,1.0,,F,,,,CHEMBL621862,,BAO_0000219,A2780,81034.0,,,N,7328.0,16936.0,1.0,478.0,Expert,Homo sapiens,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",
9606.0,1.0,,F,,,,CHEMBL621863,,BAO_0000219,A2780,81034.0,,,N,7329.0,16936.0,1.0,478.0,Intermediate,Homo sapiens,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),
9606.0,1.0,,F,,,,CHEMBL621864,,BAO_0000219,A2780,81034.0,,,N,7330.0,16936.0,1.0,478.0,Intermediate,Homo sapiens,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),
9606.0,1.0,,F,,,,CHEMBL621865,,BAO_0000219,A2780,81034.0,,,N,7331.0,16936.0,1.0,478.0,Intermediate,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),
10090.0,1.0,,F,,,,CHEMBL621866,,BAO_0000219,A2780,81034.0,,,N,7332.0,17737.0,1.0,478.0,Intermediate,Mus musculus,In vitro antiproliferative activity against A2780 cell line,
10090.0,1.0,,F,,,,CHEMBL621867,,BAO_0000219,A2780,81034.0,,,N,7333.0,17764.0,1.0,478.0,Expert,Mus musculus,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,
9606.0,1.0,,F,,,,CHEMBL621868,,BAO_0000219,A2780,81034.0,,,N,7334.0,3830.0,1.0,478.0,Intermediate,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,
9606.0,1.0,,F,,,,CHEMBL875282,,BAO_0000219,A2780,81034.0,,,N,7335.0,3829.0,1.0,478.0,Intermediate,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,
9615.0,1.0,,A,,,,CHEMBL621869,,BAO_0000218,,50588.0,,,N,7336.0,3546.0,1.0,,Intermediate,Canis lupus familiaris,Vc value in dog after IV administration at a dose of 5 mg/kg,
9615.0,1.0,,A,,,,CHEMBL621870,,BAO_0000218,,50588.0,In vivo,,N,7337.0,3546.0,1.0,,Intermediate,Canis lupus familiaris,Half life period in dog after IV administration at a dose of 5 mg/kg,
9527.0,0.0,,A,,,,CHEMBL621871,,BAO_0000019,,22224.0,,,U,7338.0,5668.0,1.0,,Autocuration,Cercopithecidae,Area under curve was determine after peroral administration at 10 mpk in Rhesus,
9527.0,0.0,,A,,,1969.0,CHEMBL621243,,BAO_0000218,,22224.0,,,U,7339.0,3443.0,1.0,,Autocuration,Cercopithecidae,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Plasma
9527.0,0.0,,A,,,1969.0,CHEMBL621244,,BAO_0000218,,22224.0,,,U,7340.0,3443.0,1.0,,Autocuration,Cercopithecidae,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Plasma
9541.0,0.0,,A,,,,CHEMBL621245,,BAO_0000218,,22224.0,In vivo,,U,7341.0,4256.0,1.0,,Autocuration,Macaca fascicularis,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,
9541.0,0.0,,A,,,,CHEMBL621246,,BAO_0000218,,22224.0,In vivo,,U,7342.0,4256.0,1.0,,Autocuration,Macaca fascicularis,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,
9541.0,0.0,,A,,,,CHEMBL621247,,BAO_0000218,,22224.0,In vivo,,U,7343.0,4256.0,1.0,,Autocuration,Macaca fascicularis,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,
10116.0,0.0,,A,,,,CHEMBL618386,,BAO_0000218,,22224.0,In vivo,,U,7344.0,4256.0,1.0,,Autocuration,Rattus norvegicus,Oral Bioavailability in rat,
9527.0,0.0,,A,,,,CHEMBL618387,,BAO_0000218,,22224.0,,,U,7345.0,1916.0,1.0,,Autocuration,Cercopithecidae,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,
9527.0,0.0,,A,,,,CHEMBL618388,,BAO_0000218,,22224.0,,,U,7346.0,5302.0,1.0,,Autocuration,Cercopithecidae,Area under curve value in monkey at a dose of 5 mg/kg,
9527.0,0.0,,A,,,,CHEMBL618389,,BAO_0000218,,22224.0,,,U,7347.0,4257.0,1.0,,Autocuration,Cercopithecidae,Area under curve was determined in monkey after a 3 mg/kg of oral dose,
9527.0,0.0,,A,,,,CHEMBL618574,,BAO_0000019,,22224.0,,,U,7348.0,5355.0,1.0,,Autocuration,Cercopithecidae,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,
9527.0,0.0,,A,,,,CHEMBL618575,,BAO_0000019,,22224.0,,,U,7349.0,5355.0,1.0,,Autocuration,Cercopithecidae,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,
9527.0,0.0,,A,,,,CHEMBL618576,,BAO_0000019,,22224.0,,,U,7350.0,5355.0,1.0,,Autocuration,Cercopithecidae,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,
9527.0,0.0,,A,,,,CHEMBL618577,,BAO_0000218,,22224.0,,,U,7351.0,6078.0,1.0,,Autocuration,Cercopithecidae,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,
9527.0,0.0,,A,,,,CHEMBL876487,,BAO_0000218,,22224.0,,,U,7352.0,6078.0,1.0,,Autocuration,Cercopithecidae,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,
9527.0,0.0,,A,,,,CHEMBL618578,,BAO_0000218,,22224.0,,,U,7353.0,6062.0,1.0,,Autocuration,Cercopithecidae,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,
9527.0,0.0,,A,,,,CHEMBL618579,,BAO_0000218,,22224.0,,,U,7354.0,2661.0,1.0,,Autocuration,Cercopithecidae,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,
9527.0,0.0,,A,,,,CHEMBL618580,,BAO_0000019,,22224.0,,,U,7355.0,2661.0,1.0,,Autocuration,Cercopithecidae,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,
9527.0,0.0,,A,,,,CHEMBL618581,,BAO_0000218,,22224.0,,,U,7356.0,5394.0,1.0,,Autocuration,Cercopithecidae,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,
9527.0,0.0,,A,,,,CHEMBL618582,,BAO_0000218,,22224.0,,,U,7357.0,4397.0,1.0,,Autocuration,Cercopithecidae,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,
9527.0,0.0,,A,,,,CHEMBL618583,,BAO_0000218,,22224.0,,,U,7358.0,17509.0,1.0,,Autocuration,Cercopithecidae,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,
9527.0,0.0,,A,,,,CHEMBL618584,,BAO_0000218,,22224.0,,,U,7359.0,17509.0,1.0,,Autocuration,Cercopithecidae,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,
9527.0,0.0,,A,,,,CHEMBL618585,,BAO_0000218,,22224.0,In vivo,,U,7360.0,6641.0,1.0,,Autocuration,Cercopithecidae,Oral AUCN in monkey (dosed at 0.5 mpk iv ),
9527.0,0.0,,A,,,,CHEMBL618586,,BAO_0000218,,22224.0,,,U,7361.0,5355.0,1.0,,Autocuration,Cercopithecidae,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),
9527.0,0.0,,A,,,,CHEMBL618587,,BAO_0000218,,22224.0,In vivo,,U,7362.0,3443.0,1.0,,Autocuration,Cercopithecidae,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,
9527.0,0.0,,A,,,,CHEMBL618588,,BAO_0000218,,22224.0,In vivo,,U,7363.0,3443.0,1.0,,Autocuration,Cercopithecidae,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,
9527.0,0.0,,A,,,,CHEMBL618589,,BAO_0000019,,22224.0,,,U,7364.0,17409.0,1.0,,Autocuration,Cercopithecidae,Binding towards monkey plasma protein at 10 uM,
9527.0,0.0,,A,,,,CHEMBL618590,,BAO_0000019,,22224.0,,,U,7365.0,17409.0,1.0,,Autocuration,Cercopithecidae,Binding towards monkey plasma protein at 100 uM,
9527.0,0.0,,A,,,,CHEMBL872262,,BAO_0000218,,22224.0,In vivo,,U,7366.0,1052.0,1.0,,Autocuration,Cercopithecidae,Apparent bioavailability in squirrel monkey was determined,
9527.0,0.0,,A,,,,CHEMBL618591,,BAO_0000218,,22224.0,In vivo,,U,7367.0,13501.0,1.0,,Autocuration,Cercopithecidae,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,
9443.0,0.0,,A,,,,CHEMBL618592,,BAO_0000218,,22224.0,In vivo,,U,7368.0,17509.0,1.0,,Autocuration,monkey,Bioavailability in monkey (dose 2 mg/kg),
9527.0,0.0,,A,,,,CHEMBL876488,,BAO_0000218,,22224.0,In vivo,,U,7369.0,5394.0,1.0,,Autocuration,Cercopithecidae,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,
9527.0,0.0,,A,,,,CHEMBL618593,,BAO_0000218,,22224.0,In vivo,,U,7370.0,2661.0,1.0,,Autocuration,Cercopithecidae,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,
9443.0,0.0,,A,,,,CHEMBL618594,,BAO_0000218,,22224.0,In vivo,,U,7371.0,11219.0,1.0,,Autocuration,monkey,Bioavailability in monkey (i.d. dosing),
9527.0,0.0,,A,,,,CHEMBL618595,,BAO_0000218,,22224.0,In vivo,,U,7372.0,3045.0,1.0,,Autocuration,Cercopithecidae,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,
9527.0,0.0,,A,,,,CHEMBL621469,,BAO_0000019,,22224.0,,,U,7373.0,17796.0,1.0,,Autocuration,Cercopithecidae,Clearance of the drug was measured in cynomolgus,
9527.0,0.0,,A,,,,CHEMBL621470,,BAO_0000218,,22224.0,In vivo,,U,7374.0,1399.0,1.0,,Autocuration,Cercopithecidae,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,
9527.0,0.0,,A,,,,CHEMBL621471,,BAO_0000218,,22224.0,In vivo,,U,7375.0,2661.0,1.0,,Autocuration,Cercopithecidae,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,
9544.0,0.0,,A,,,1969.0,CHEMBL621472,,BAO_0000218,,22224.0,In vivo,,U,7376.0,5005.0,1.0,,Autocuration,Macaca mulatta,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Plasma
9527.0,0.0,,A,,,,CHEMBL621473,,BAO_0000218,,22224.0,In vivo,,U,7377.0,17267.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance in rhesus monkey was determined,
9527.0,0.0,,A,,,,CHEMBL621474,,BAO_0000218,,22224.0,In vivo,,U,7378.0,6535.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance in monkey after administration of 1 mg/kg iv,
9527.0,0.0,,A,,,,CHEMBL621475,,BAO_0000218,,22224.0,In vivo,,U,7379.0,5922.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance in cynomolgus monkey,
9527.0,0.0,,A,,,,CHEMBL621476,,BAO_0000218,,22224.0,In vivo,,U,7380.0,6221.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,
9527.0,0.0,,A,,,,CHEMBL624290,,BAO_0000218,,22224.0,In vivo,,U,7381.0,5668.0,1.0,,Autocuration,Cercopithecidae,Plasma clearance after peroral administration at 10 mpk in Rhesus,
9527.0,0.0,,A,,,,CHEMBL624291,,BAO_0000218,,22224.0,In vivo,,U,7382.0,5355.0,1.0,,Autocuration,Cercopithecidae,The total clearance was determined after intravenous administration in cynomolgus monkeys,
9527.0,0.0,,A,,,,CHEMBL624292,,BAO_0000218,,22224.0,In vivo,,U,7383.0,5355.0,1.0,,Autocuration,Cercopithecidae,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,
9527.0,0.0,,A,,,,CHEMBL624293,,BAO_0000218,,22224.0,In vivo,,U,7384.0,5355.0,1.0,,Autocuration,Cercopithecidae,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,
9527.0,0.0,,A,,,,CHEMBL624294,,BAO_0000218,,22224.0,In vivo,,U,7385.0,4578.0,1.0,,Autocuration,Cercopithecidae,Tested for Clearance upon iv administration to african green monkey,
9527.0,0.0,,A,,,,CHEMBL624295,,BAO_0000218,,22224.0,In vivo,,U,7386.0,17592.0,1.0,,Autocuration,Cercopithecidae,Clearance in monkey,
9615.0,1.0,,A,,,,CHEMBL624296,,BAO_0000218,,50588.0,In vivo,,N,7387.0,6641.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),
9615.0,1.0,,A,,,,CHEMBL624297,,BAO_0000218,,50588.0,In vivo,,N,7388.0,6642.0,1.0,,Intermediate,Canis lupus familiaris,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),
9615.0,1.0,,A,,,,CHEMBL624298,,BAO_0000218,,50588.0,In vivo,,N,7389.0,16367.0,1.0,,Intermediate,Canis lupus familiaris,Half life was evaluated after intravenous administration to dogs,
9615.0,1.0,,A,,,,CHEMBL624299,,BAO_0000218,,50588.0,,,N,7390.0,5472.0,1.0,,Intermediate,Canis lupus familiaris,Half life was evaluated in dog,
9615.0,1.0,,A,,,,CHEMBL624300,,BAO_0000218,,50588.0,,,N,7391.0,5474.0,1.0,,Intermediate,Canis lupus familiaris,Half life was evaluated in dog,
9615.0,1.0,,A,,,,CHEMBL624301,,BAO_0000218,,50588.0,In vivo,,N,7392.0,5654.0,1.0,,Intermediate,Canis lupus familiaris,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL624302,,BAO_0000218,,50588.0,In vivo,,N,7393.0,6227.0,1.0,,Intermediate,Canis lupus familiaris,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),
9615.0,1.0,,A,,,,CHEMBL876026,,BAO_0000218,,50588.0,In vivo,,N,7394.0,6227.0,1.0,,Intermediate,Canis lupus familiaris,Half life period after intravenous administration in dog,
9615.0,1.0,,A,,,,CHEMBL624303,,BAO_0000218,,50588.0,In vivo,,N,7395.0,6221.0,1.0,,Intermediate,Canis lupus familiaris,Half life period after oral administration (2.5 mg/kg) in dog was determined,
9615.0,1.0,,A,,,,CHEMBL624304,,BAO_0000218,,50588.0,,,N,7396.0,4527.0,1.0,,Intermediate,Canis lupus familiaris,Half life period at a dose of 1 uM/kg in dog was determined,
9615.0,1.0,,A,,,,CHEMBL624305,,BAO_0000218,,50588.0,In vivo,,N,7397.0,5668.0,1.0,,Intermediate,Canis lupus familiaris,Half life period was determine after peroral administration at 10 mpk in dog,
9615.0,1.0,,A,,,,CHEMBL624306,,BAO_0000218,,50588.0,In vivo,,N,7398.0,5668.0,1.0,,Intermediate,Canis lupus familiaris,Half life period was determine after peroral administration at 5 mpk in dog,
9615.0,1.0,,A,,,,CHEMBL624307,,BAO_0000218,,50588.0,,,N,7399.0,3854.0,1.0,,Intermediate,Canis lupus familiaris,Half life period was determined,
9615.0,1.0,,A,,,,CHEMBL624308,,BAO_0000218,,50588.0,,,N,7400.0,5505.0,1.0,,Intermediate,Canis lupus familiaris,Half life period was determined,
9615.0,1.0,,A,,,,CHEMBL624309,,BAO_0000218,,50588.0,In vivo,,N,7401.0,6251.0,1.0,,Intermediate,Canis lupus familiaris,Half life period by iv administration in dog at a dose of 6 mg/kg,
9615.0,1.0,,A,,,,CHEMBL624310,,BAO_0000218,,50588.0,,,N,7402.0,1918.0,1.0,,Intermediate,Canis lupus familiaris,Half life period was evaluated in dog,
9615.0,1.0,,A,,,,CHEMBL625003,,BAO_0000218,,50588.0,In vivo,,N,7403.0,5546.0,1.0,,Intermediate,Canis lupus familiaris,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,
9615.0,1.0,,A,,,,CHEMBL625004,,BAO_0000218,,50588.0,In vivo,,N,7404.0,4809.0,1.0,,Intermediate,Canis lupus familiaris,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),
9615.0,1.0,,A,,,,CHEMBL625005,,BAO_0000218,,50588.0,In vivo,,N,7405.0,6215.0,1.0,,Intermediate,Canis lupus familiaris,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,
9615.0,1.0,,A,,,,CHEMBL873813,,BAO_0000218,,50588.0,In vivo,,N,7406.0,4527.0,1.0,,Intermediate,Canis lupus familiaris,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,
9615.0,1.0,,A,,,,CHEMBL625006,,BAO_0000218,,50588.0,In vivo,,N,7407.0,17594.0,1.0,,Intermediate,Canis lupus familiaris,Half-life after oral dose of compound at 3 mg/kg in dogs,
9615.0,1.0,,A,,,,CHEMBL625007,,BAO_0000218,,50588.0,In vivo,,N,7408.0,17839.0,1.0,,Intermediate,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,
9615.0,1.0,,A,,,,CHEMBL876027,,BAO_0000218,,50588.0,In vivo,,N,7409.0,17839.0,1.0,,Intermediate,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,
9615.0,1.0,,A,,,,CHEMBL625008,,BAO_0000218,,50588.0,In vivo,,N,7410.0,17839.0,1.0,,Intermediate,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,
9615.0,1.0,,A,,,,CHEMBL625009,,BAO_0000218,,50588.0,In vivo,,N,7411.0,17839.0,1.0,,Intermediate,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 1 mg/kg,
9615.0,1.0,,A,,,1969.0,CHEMBL625010,,BAO_0000218,,50588.0,,,N,7412.0,5210.0,1.0,,Intermediate,Canis lupus familiaris,Half-life of compound in plasma of dog was determined,Plasma
9615.0,1.0,,A,,,,CHEMBL625011,,BAO_0000218,,50588.0,,,N,7413.0,5210.0,1.0,,Intermediate,Canis lupus familiaris,Half-life of compound was determined in dogs,
9615.0,1.0,,A,,,,CHEMBL621553,,BAO_0000218,,50588.0,In vivo,,N,7414.0,2959.0,1.0,,Intermediate,Canis lupus familiaris,Half-life after administration of 4 mg/Kg oral dose in dog,
9615.0,1.0,,A,,,,CHEMBL621554,,BAO_0000218,,50588.0,In vivo,,N,7415.0,4137.0,1.0,,Intermediate,Canis lupus familiaris,Half-life after intravenous administration of 1 mg/kg/h in dog,
9615.0,1.0,,A,,,,CHEMBL621555,,BAO_0000218,,50588.0,,,N,7416.0,5064.0,1.0,,Intermediate,Canis lupus familiaris,Half-life in Dog,
9615.0,1.0,,A,,,,CHEMBL621556,,BAO_0000218,,50588.0,,,N,7417.0,5147.0,1.0,,Intermediate,Canis lupus familiaris,Half-life in Dog,
9615.0,1.0,,A,,,,CHEMBL621557,,BAO_0000218,,50588.0,,,N,7418.0,5145.0,1.0,,Intermediate,Canis lupus familiaris,Half-life in dog,
9615.0,1.0,,A,,,,CHEMBL621558,,BAO_0000218,,50588.0,In vivo,,N,7419.0,6123.0,1.0,,Intermediate,Canis lupus familiaris,Half-life in dog after oral administration at 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL621559,,BAO_0000218,,50588.0,In vivo,,N,7420.0,6123.0,1.0,,Intermediate,Canis lupus familiaris,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,
9615.0,1.0,,A,,,,CHEMBL621560,,BAO_0000218,,50588.0,,,N,7421.0,4333.0,1.0,,Intermediate,Canis lupus familiaris,Half-life in dogs,
9615.0,1.0,,A,,,,CHEMBL876028,,BAO_0000218,,50588.0,,,N,7422.0,4333.0,1.0,,Intermediate,Canis lupus familiaris,Half-life in dogs; ND indicates not determined,
9615.0,1.0,,A,,,1969.0,CHEMBL621561,,BAO_0000218,,50588.0,,,N,7423.0,12500.0,1.0,,Intermediate,Canis lupus familiaris,Half-life in plasma of dog,Plasma
9615.0,1.0,,A,,,1969.0,CHEMBL621562,,BAO_0000218,,50588.0,,,N,7424.0,12500.0,1.0,,Intermediate,Canis lupus familiaris,Half-life in plasma of dog at dose of 3-10 mgkg,Plasma
9615.0,1.0,,A,,,,CHEMBL621563,,BAO_0000218,,50588.0,In vivo,,N,7425.0,6005.0,1.0,,Intermediate,Canis lupus familiaris,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL621564,,BAO_0000218,,50588.0,In vivo,,N,7426.0,6062.0,1.0,,Intermediate,Canis lupus familiaris,Half-life was measured in dog after an iv dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL621565,,BAO_0000218,,50588.0,In vivo,,N,7427.0,17650.0,1.0,,Intermediate,Canis lupus familiaris,Half-life was measured in dogs after an oral dose of 10 uM/kg,
9615.0,1.0,,A,,,,CHEMBL621566,,BAO_0000218,,50588.0,In vivo,,N,7428.0,5530.0,1.0,,Intermediate,Canis lupus familiaris,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,
9615.0,1.0,,A,,,,CHEMBL621567,,BAO_0000218,,50588.0,In vivo,,N,7429.0,5530.0,1.0,,Intermediate,Canis lupus familiaris,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,
9615.0,1.0,,A,,,,CHEMBL622978,,BAO_0000218,,50588.0,In vivo,,N,7430.0,5600.0,1.0,,Intermediate,Canis lupus familiaris,Half-life of the compound after 0.3 mg/kg po administration in dog,
9615.0,1.0,,A,,,,CHEMBL873814,,BAO_0000218,,50588.0,In vivo,,N,7431.0,6039.0,1.0,,Intermediate,Canis lupus familiaris,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,
9615.0,1.0,,A,,,,CHEMBL623219,,BAO_0000218,,50588.0,In vivo,,N,7432.0,6039.0,1.0,,Intermediate,Canis lupus familiaris,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,
9615.0,1.0,,A,,,,CHEMBL624477,,BAO_0000218,,50588.0,In vivo,,N,7433.0,6039.0,1.0,,Intermediate,Canis lupus familiaris,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,
9615.0,1.0,,A,,,,CHEMBL624478,,BAO_0000218,,50588.0,,,N,7434.0,6227.0,1.0,,Intermediate,Canis lupus familiaris,t1/2 in dog,
9615.0,1.0,,A,,,,CHEMBL624479,,BAO_0000218,,50588.0,,,N,7435.0,14541.0,1.0,,Intermediate,Canis lupus familiaris,Half-life period measured in dogs,
9615.0,1.0,,A,,,,CHEMBL624480,,BAO_0000218,,50588.0,In vivo,,N,7436.0,4521.0,1.0,,Intermediate,Canis lupus familiaris,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,
9615.0,1.0,,A,,,,CHEMBL623595,,BAO_0000218,,50588.0,In vivo,,N,7437.0,4521.0,1.0,,Intermediate,Canis lupus familiaris,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,
9615.0,1.0,,A,,,,CHEMBL623596,,BAO_0000218,,50588.0,In vivo,,N,7438.0,6679.0,1.0,,Intermediate,Canis lupus familiaris,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,
9615.0,1.0,,A,,,1969.0,CHEMBL623597,,BAO_0000218,,50588.0,In vitro,,N,7439.0,1116.0,1.0,,Intermediate,Canis lupus familiaris,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",Plasma
9615.0,1.0,,A,,,,CHEMBL623598,,BAO_0000218,,50588.0,In vivo,,N,7440.0,5444.0,1.0,,Intermediate,Canis lupus familiaris,In vivo half life period was calculated at 1 mg/kg in dog,
9615.0,1.0,,A,,,,CHEMBL623599,,BAO_0000218,,50588.0,In vivo,,N,7441.0,5444.0,1.0,,Intermediate,Canis lupus familiaris,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,
9615.0,1.0,,A,,,,CHEMBL623600,,BAO_0000218,,50588.0,In vivo,,N,7442.0,17853.0,1.0,,Intermediate,Canis lupus familiaris,Longer half-life in dog (i.v.) at 0.5 mpk,
9615.0,1.0,,A,,,,CHEMBL623601,,BAO_0000218,,50588.0,In vivo,,N,7443.0,4353.0,1.0,,Intermediate,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),
9615.0,1.0,,A,,,,CHEMBL623602,,BAO_0000218,,50588.0,In vivo,,N,7444.0,16452.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,
9615.0,1.0,,A,,,,CHEMBL623603,,BAO_0000218,,50588.0,In vivo,,N,7445.0,16452.0,1.0,,Intermediate,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,
9615.0,1.0,,A,,,,CHEMBL623604,,BAO_0000218,,50588.0,In vivo,,N,7446.0,16452.0,1.0,,Intermediate,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),
10090.0,1.0,,A,,,2048.0,CHEMBL623605,,BAO_0000218,,50594.0,In vivo,,N,7447.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL623606,,BAO_0000218,,50594.0,In vivo,,N,7448.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL623607,,BAO_0000218,,50594.0,In vivo,,N,7449.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL623608,,BAO_0000218,,50594.0,In vivo,,N,7450.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL623609,,BAO_0000218,,50594.0,In vivo,,N,7451.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Lung
10090.0,1.0,,A,,,2048.0,CHEMBL623610,,BAO_0000218,,50594.0,In vivo,,N,7452.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Lung
10090.0,1.0,,A,,,2385.0,CHEMBL623611,,BAO_0000218,,50594.0,In vivo,,N,7453.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Muscle tissue
10090.0,1.0,,A,,,2385.0,CHEMBL623612,,BAO_0000218,,50594.0,In vivo,,N,7454.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Muscle tissue
10090.0,1.0,,A,,,2385.0,CHEMBL623613,,BAO_0000218,,50594.0,In vivo,,N,7455.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Muscle tissue
10090.0,1.0,,A,,,2385.0,CHEMBL623614,,BAO_0000218,,50594.0,In vivo,,N,7456.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Muscle tissue
10090.0,1.0,,A,,,2385.0,CHEMBL623615,,BAO_0000218,,50594.0,In vivo,,N,7457.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Muscle tissue
10090.0,1.0,,A,,,2385.0,CHEMBL623616,,BAO_0000218,,50594.0,In vivo,,N,7458.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Muscle tissue
10090.0,1.0,,A,,,2385.0,CHEMBL623617,,BAO_0000218,,50594.0,In vivo,,N,7459.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Muscle tissue
10090.0,1.0,,A,,,14.0,CHEMBL875944,,BAO_0000218,,50594.0,In vivo,,N,7460.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Zone of skin
10090.0,1.0,,A,,,14.0,CHEMBL623618,,BAO_0000218,,50594.0,In vivo,,N,7461.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Zone of skin
10090.0,1.0,,A,,,14.0,CHEMBL623619,,BAO_0000218,,50594.0,In vivo,,N,7462.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Zone of skin
10090.0,1.0,,A,,,14.0,CHEMBL623620,,BAO_0000218,,50594.0,In vivo,,N,7463.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Zone of skin
10090.0,1.0,,A,,,14.0,CHEMBL623621,,BAO_0000218,,50594.0,In vivo,,N,7464.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Zone of skin
10090.0,1.0,,A,,,14.0,CHEMBL623622,,BAO_0000218,,50594.0,In vivo,,N,7465.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Zone of skin
10090.0,1.0,,A,,,14.0,CHEMBL623623,,BAO_0000218,,50594.0,In vivo,,N,7466.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Zone of skin
10090.0,1.0,,A,,,2106.0,CHEMBL623624,,BAO_0000218,,50594.0,In vivo,,N,7467.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Spleen
10090.0,1.0,,A,,,2106.0,CHEMBL618521,,BAO_0000218,,50594.0,In vivo,,N,7468.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Spleen
10090.0,1.0,,A,,,2106.0,CHEMBL618522,,BAO_0000218,,50594.0,In vivo,,N,7469.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Spleen
10090.0,1.0,,A,,,2106.0,CHEMBL618523,,BAO_0000218,,50594.0,In vivo,,N,7470.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Spleen
10090.0,1.0,,A,,,2106.0,CHEMBL618524,,BAO_0000218,,50594.0,In vivo,,N,7471.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Spleen
10090.0,1.0,,A,,,2106.0,CHEMBL618525,,BAO_0000218,,50594.0,In vivo,,N,7472.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Spleen
10090.0,1.0,,A,,,2106.0,CHEMBL624586,,BAO_0000218,,50594.0,In vivo,,N,7473.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Spleen
10090.0,1.0,,A,,,945.0,CHEMBL624587,,BAO_0000218,,50594.0,In vivo,,N,7474.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Stomach
10090.0,1.0,,A,,,945.0,CHEMBL624588,,BAO_0000218,,50594.0,In vivo,,N,7475.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Stomach
10090.0,1.0,,A,,,945.0,CHEMBL624589,,BAO_0000218,,50594.0,In vivo,,N,7476.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Stomach
10090.0,1.0,,A,,,945.0,CHEMBL624590,,BAO_0000218,,50594.0,In vivo,,N,7477.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Stomach
10090.0,1.0,,A,,,945.0,CHEMBL624591,,BAO_0000218,,50594.0,In vivo,,N,7478.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Stomach
10090.0,1.0,,A,,,945.0,CHEMBL624592,,BAO_0000218,,50594.0,In vivo,,N,7479.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Stomach
10090.0,1.0,,A,,,945.0,CHEMBL624593,,BAO_0000218,,50594.0,In vivo,,N,7480.0,10107.0,1.0,,Intermediate,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Stomach
10116.0,1.0,,A,,,,CHEMBL624594,,BAO_0000218,,50597.0,In vivo,,N,7481.0,4689.0,1.0,,Intermediate,Rattus norvegicus,Oral bioavailability in rat,
10116.0,1.0,,A,,,,CHEMBL624595,,BAO_0000218,,50597.0,In vivo,,N,7482.0,4950.0,1.0,,Intermediate,Rattus norvegicus,Tested for the bioavailability in rat,
10116.0,1.0,,A,,,,CHEMBL624596,,BAO_0000218,,50597.0,In vivo,,N,7483.0,5328.0,1.0,,Intermediate,Rattus norvegicus,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),
10116.0,1.0,,A,,,,CHEMBL624597,,BAO_0000218,,50597.0,In vivo,,N,7484.0,406.0,1.0,,Intermediate,Rattus norvegicus,Bioavailability in rat,
10116.0,1.0,,A,,,,CHEMBL624598,,BAO_0000218,,50597.0,In vivo,,N,7485.0,12500.0,1.0,,Intermediate,Rattus norvegicus,Bioavailability in rat,
10116.0,1.0,,A,,,,CHEMBL624599,,BAO_0000218,,50597.0,In vivo,,N,7486.0,12500.0,1.0,,Intermediate,Rattus norvegicus,Bioavailability in rat (dose 3-10 mg/kg),
10116.0,1.0,,A,,,,CHEMBL875166,,BAO_0000218,,50597.0,In vivo,,N,7487.0,5247.0,1.0,,Intermediate,Rattus norvegicus,Bioavailability in rat,
10116.0,1.0,,A,,,1969.0,CHEMBL624600,,BAO_0000218,,50597.0,In vivo,,N,7488.0,4186.0,1.0,,Intermediate,Rattus norvegicus,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Plasma
10116.0,1.0,,A,,,1969.0,CHEMBL624601,,BAO_0000218,,50597.0,In vivo,,N,7489.0,4186.0,1.0,,Intermediate,Rattus norvegicus,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Plasma
10116.0,1.0,,A,,,,CHEMBL624602,,BAO_0000218,,50597.0,In vivo,,N,7490.0,6647.0,1.0,,Intermediate,Rattus norvegicus,Half life after oral administration was determined in rats at 6 mg/kg,
10116.0,1.0,,A,,,,CHEMBL624603,,BAO_0000218,,50597.0,,,N,7491.0,6484.0,1.0,,Intermediate,Rattus norvegicus,Half life was determined,
10116.0,1.0,,A,,,,CHEMBL624604,,BAO_0000218,,50597.0,In vivo,,N,7492.0,3249.0,1.0,,Intermediate,Rattus norvegicus,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,
10116.0,1.0,,A,,,1969.0,CHEMBL624605,,BAO_0000218,,50597.0,In vivo,,N,7493.0,6281.0,1.0,,Intermediate,Rattus norvegicus,Plasma half life in rat at oral dose 2.8 mg/mk body weight,Plasma
10116.0,1.0,,A,,,,CHEMBL624606,,BAO_0000218,,50597.0,,,N,7494.0,3307.0,1.0,,Intermediate,Rattus norvegicus,Half life in rats,
10116.0,1.0,,A,,,178.0,CHEMBL624607,,BAO_0000218,,50597.0,In vivo,,N,7495.0,12058.0,1.0,,Intermediate,Rattus norvegicus,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,Blood
10116.0,1.0,,A,,,,CHEMBL624608,,BAO_0000218,,50597.0,,,N,7496.0,8833.0,1.0,,Intermediate,Rattus norvegicus,Hill coefficient of the compound,
10116.0,1.0,,A,,,178.0,CHEMBL624609,,BAO_0000218,,50597.0,,,N,7497.0,3193.0,1.0,,Intermediate,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,Blood
10116.0,1.0,,A,,,178.0,CHEMBL624610,,BAO_0000218,,50597.0,,,N,7498.0,3193.0,1.0,,Intermediate,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,Blood
10116.0,1.0,,A,,,178.0,CHEMBL624611,,BAO_0000218,,50597.0,,,N,7499.0,3193.0,1.0,,Intermediate,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,Blood
10116.0,1.0,,A,,,178.0,CHEMBL624612,,BAO_0000218,,50597.0,,,N,7500.0,3193.0,1.0,,Intermediate,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,Blood
10116.0,1.0,,A,,,178.0,CHEMBL875167,,BAO_0000218,,50597.0,,,N,7501.0,3193.0,1.0,,Intermediate,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,Blood
10116.0,1.0,,A,,,178.0,CHEMBL624613,,BAO_0000218,,50597.0,,,N,7502.0,3193.0,1.0,,Intermediate,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,Blood
10116.0,1.0,,A,,,178.0,CHEMBL624614,,BAO_0000218,,50597.0,,,N,7503.0,3193.0,1.0,,Intermediate,Rattus norvegicus,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",Blood
10116.0,1.0,,A,,,,CHEMBL624392,,BAO_0000218,,50597.0,,,N,7504.0,5960.0,1.0,,Intermediate,Rattus norvegicus,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,
10116.0,1.0,,A,,,955.0,CHEMBL624393,,BAO_0000218,,50597.0,In vivo,,N,7505.0,13950.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,Brain
10116.0,1.0,,A,,,955.0,CHEMBL624394,,BAO_0000218,,50597.0,In vivo,,N,7506.0,13950.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,Brain
10116.0,1.0,,A,,,955.0,CHEMBL624395,,BAO_0000218,,50597.0,In vivo,,N,7507.0,13950.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,Brain
10116.0,1.0,,A,,,955.0,CHEMBL624396,,BAO_0000218,,50597.0,In vivo,,N,7508.0,13950.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,Brain
10116.0,1.0,,A,,,955.0,CHEMBL624397,,BAO_0000218,,50597.0,In vivo,,N,7509.0,13950.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,Brain
10116.0,1.0,,A,,,2046.0,CHEMBL624398,,BAO_0000218,,50597.0,In vivo,,N,7510.0,13950.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,Thyroid gland
10116.0,1.0,,A,,,2046.0,CHEMBL624399,,BAO_0000218,,50597.0,In vivo,,N,7511.0,13950.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,Thyroid gland
10116.0,1.0,,A,,,2046.0,CHEMBL624400,,BAO_0000218,,50597.0,In vivo,,N,7512.0,13950.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,Thyroid gland
10116.0,1.0,,A,,,2046.0,CHEMBL624401,,BAO_0000218,,50597.0,In vivo,,N,7513.0,13950.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,Thyroid gland
10116.0,1.0,,A,,,2046.0,CHEMBL624402,,BAO_0000218,,50597.0,In vivo,,N,7514.0,13950.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,Thyroid gland
10116.0,1.0,,A,,,178.0,CHEMBL624403,,BAO_0000218,,50597.0,In vivo,,N,7515.0,9866.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Blood
10116.0,1.0,,A,,,178.0,CHEMBL624404,,BAO_0000218,,50597.0,In vivo,,N,7516.0,9866.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,Blood
10116.0,1.0,,A,,,178.0,CHEMBL624405,,BAO_0000218,,50597.0,In vivo,,N,7517.0,9866.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,Blood
10116.0,1.0,,A,,,10000001.0,CHEMBL624406,,BAO_0000218,,50597.0,In vivo,,N,7518.0,9866.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Bone
10116.0,1.0,,A,,,10000001.0,CHEMBL624407,,BAO_0000218,,50597.0,In vivo,,N,7519.0,9866.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,Bone
10116.0,1.0,,A,,,10000001.0,CHEMBL624408,,BAO_0000218,,50597.0,In vivo,,N,7520.0,9866.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,Bone
10116.0,1.0,,A,,,948.0,CHEMBL618644,,BAO_0000218,,50597.0,In vivo,,N,7521.0,9866.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Heart
10116.0,1.0,,A,,,948.0,CHEMBL618645,,BAO_0000218,,50597.0,In vivo,,N,7522.0,9866.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,Heart
10116.0,1.0,,A,,,948.0,CHEMBL618646,,BAO_0000218,,50597.0,In vivo,,N,7523.0,9866.0,1.0,,Intermediate,Rattus norvegicus,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,Heart
